Generic Name	Trade Name	Designation Date	Designation	Orphan Drug Status	FDA Approval Status	Approved Indication	Marketing Approval Date	Exclusivity End Date	Contact Company	Contact Address 1	Contact Address 2	Contact City	Contact State	Contact Zip	Contact Country
1-(2-Nitro-imidazolyl)-3-[18F]fluoro-2-propanol;1H-1-(3-[18F]fluoro-2-hydroxypropyl)-2-nitroimidazole	n/a	1/6/16	"As a diagnostic for clinical management of soft tissue sarcoma, including rhabdomyosarcoma."	Designated			N/A	N/A	"Advanced Imaging Projects, LLC"	7947 Brookside Ct.		Lake Worth	Florida	33467	USA
ascorbic acid	n/a	5/11/09	Treatment of Charcot-Marie-Tooth disease type 1A.	Designated			N/A	N/A	Murigenetics SAS	Faculte de Medecine Timone	13005 Marseille				France
budesonide	n/a	12/20/06	Treatment of patients with eosinophilic esophagitis	Designated			N/A	N/A	Shire ViroPharma Incorporated	300 Shire Way		Lexington	Massachusetts	2421	USA
S-nitrosoglutathione reductase inhibitor	n/a	1/13/16	Treatment of cystic fibrosis	Designated			N/A	N/A	"Nivalis Therapeutics, Inc."	3122 Sterling Circle	Suite 200	Boulder	Colorado	80301	USA
single chain urokinase plasminogen activator	n/a	9/11/14	Treatment of empyema (pleural)	Designated			N/A	N/A	"Lung Therapeutics, Inc."	P. O. Box 150183		Austin	Texas	78715	USA
"(+/-)-7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid"	n/a	3/31/03	Prevention of serious adverse events associated with vascular leak syndrome caused by Interleukin-2 therapy	Designated/Withdrawn			N/A	N/A	"Intarcia Therapeutics, Inc."	24650 Industrial Blvd		Hayward	California	94545	USA
"(+/-)-cis-3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2H-cromen-7-ol"	n/a	2/1/08	Treatment of Stage IIB through Stage IV malignant melanoma	Designated/Withdrawn			N/A	N/A	"Marshall Edwards, Inc."	11975 El Camino Real	Suite 101	San Diego	California	92130	USA
"(+/-)-cis-3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2H-cromen-7-ol"	n/a	1/10/08	Treatment of cholangiocarcinoma	Designated/Withdrawn			N/A	N/A	"Marshall Edwards, Inc."	11975 El Camino Real	Suite 101	San Diego	California	92130	USA
"(+/-)-cis-3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2H-cromen-7-ol"	n/a	1/10/08	Treatment of pancreatic cancer	Designated/Withdrawn			N/A	N/A	"Marshall Edwards, Inc."	11975 El Camino Real	Suite 101	San Diego	California	92130	USA
"(-)-(3aR,4S,7aR)-4-Hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester"	n/a	10/12/11	Treatment of Fragile X syndrome	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Jersey	7936	USA
"(1,3)--D-glucan synthesis inhibitor"	n/a	8/22/16	Treatment of invasive Aspergillus infections	Designated			N/A	N/A	"SCYNEXIS, Inc."	101 Hudson Street	Suite 3610	Jersey City	New Jersey	7302	USA
"(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-broethyl) diamidophosphate"	n/a	6/5/13	Treatment of pancreatic cancer	Designated			N/A	N/A	EMD Serono	One Technology Place		Rockland	Massachusetts	2370	USA
"(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate"	n/a	3/9/12	Treatment of soft tissue sarcoma	Designated			N/A	N/A	"Threshold Pharmaceuticals, Inc."	170 Harbor Way	Suite 300	South San Francisco	California	94080	USA
"(1OR)-7-amino-12-fluoro-2,10,16-trimethyl-15 oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile"	n/a	6/23/15	Treatment of anaplastic lymphoma kinase (ALK)-positive or ROS1-positive non-small cell lung cancer	Designated			N/A	N/A	"Pfizer, Inc."	235 East 42nd Street (M/S 219/9/30)		New York	New York	10017	USA
"(1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O-(sodium(2S)-3-cyclohexyl-propanoate-"	n/a	2/17/09	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	Designated			N/A	N/A	"Pfizer, Inc."	500 Arcola Road		Collegeville	Pennsylvania	19426	USA
"(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride"	n/a	1/29/04	Treatment of T-cell non-Hodgkin's lymphoma	Designated			N/A	N/A	Mundipharma Research Limited	Cambridge Science Park	Cambridge CB4 0GW	England			United Kingdom
"(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride"	n/a	8/13/04	Treatment of acute lymphoblastic leukemia	Designated			N/A	N/A	Mundipharma Research Limited	Cambridge Science Park	Cambridge CB4 0GW	England			United Kingdom
"(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride"	n/a	8/10/04	"Treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia"	Designated			N/A	N/A	Mundipharma Research Ltd.	Cambridge Science Park	Cambridge CB4 0GW				United Kingdom
"(1S, 2S, 3R, 4R)-3-(5-Fluoro-2-(3-methyl-4-(4-methylpiperazin-1-yl)-phenylamino)-pyrimidin-4-ylamino)bicycle[2.2.1]hept-5-ene-2-carboxamide benzoate"	n/a	1/19/10	Treatment of acute myeloid leukemia	Designated/Withdrawn			N/A	N/A	"EMD Serono, Inc."	1 Technology Place		Rockland	Massachusetts	2370	USA
"(1S,3S)-3-amino-4-(difluoromethylene)cyclopentanecarboxylic acid hydrochloride, (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride"	n/a	9/15/10	Treatment of infantile spasms.	Designated			N/A	N/A	"Catalyst Pharmaceuticals, Inc."	355 Alhambra Circle	Suite 1250	Coral Gables	Florida	33134	USA
"(2'R,3'S)-2'-hydroxy-N-carboxy-3'-amino-5'-methyl-hexanoic,N-tert-butyl ester, 13 ester 5B-20-epoxy-1B,2a,4a,7B,9a,10a,13a-heptahydroxy-4,10-diacetate-2-benzoate-(1""S)-7,9-acrolein acetal-11(15-1)-abeotaxane"	n/a	6/23/14	Treatment of progressive supranuclear palsy	Designated			N/A	N/A	"Cortice Biosciences, Inc."	50 W. 57th Street	15th Floor	New York	New York	10019	USA
"(2,2-diphenyl-tetrahydro-furan-3-yl-methyl)-dimethylamine hydrochloride"	n/a	5/18/16	Treatment of Rett Syndrome.	Designated			N/A	N/A	Anavex Life Sciences Corporation	51 West 52nd Street	7th Floor	New York	New York	10019	USA
(2-((2-chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide)	n/a	11/29/16	Treatment of multiple myeloma	Designated			N/A	N/A	"Acetylon Pharmaceuticals, Inc."	(Celgene Subsidiary)	86 Morris Avenue	Summit	New Jersey	7901	USA
"(2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1h-pyrazolo [4,3-c] pyridine-3,6(2h,5h)-dione)"	n/a	10/14/15	Treatment of systemic sclerosis.	Designated			N/A	N/A	Genkyotex Innovation SAS	18 Avenue Marie Curie		Archamps			France
"(2E, 4E, 6Z, 8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-l-yl) nona-2,4,6,8-tetraen-l-yl acetate"	n/a	12/2/10	Treatment of retinitis pigmentosa	Designated			N/A	N/A	QLT Inc.	887 Great Northern Way	"Vancouver, British Columbia V5T 4T5"				Canada
"(2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenyl acetate 9-cis-retinyl acetate (API)"	n/a	12/2/10	Treatment of Leber congential amaurosis (LCA) due to inherited mutations in RPE65 (encoding the protein retinal pigment epithelial protein 65) or LRAT (encoding the enzyme lecithin:retinol acyltransferase)genes.	Designated			N/A	N/A	"QLT, Inc."	887 Great Northern Way - Suite 250	"Vancouver, British Columbia"	V5T 4T5			Canada
"(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid"	n/a	10/31/12	Treatment of primary biliary cirrhosis	Designated			N/A	N/A	Albireo AB	Arvid Wallgrens Backe 20	S-413 46 Gothenburg				Sweden
"(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid"	n/a	10/31/12	Treatment of progressive familial intrahepatic cholestatis	Designated			N/A	N/A	Albireo AB	Arvid Wallgrens Backe 20	S-413 46 Gothenburg				USA
(2Z)-2-cyano-3-3hydroxy-N-[4-(trifluoromethly)phenyl]-2-hepten-6-ynamide	Fk778	1/10/05	"Prevention of acute rejection following kidney, heart, and liver transplantation"	Designated			N/A	N/A	"Fujisawa Healthcare, Inc."	Three Parkway North		Deerfield	Illinois	60015	USA
"(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide"	n/a	3/18/11	Treatment of chronic myelogenous leukemia.	Designated			N/A	N/A	NATCO Pharma Limited	Natco House		Hyderbad 500033			India
"(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide"	n/a	3/18/11	Treatment of pancreatic cancer	Designated			N/A	N/A	NATCO Pharma Limited	Natco House		Hyderabad 500033			India
"(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamideNRC-AN-019"	n/a	3/18/11	Treatment of Glioma	Designated			N/A	N/A	NATCO Pharma Limited	Natco House		Hyderbad 500033			India
"(3E,5E)-3,5-bis[(4-fluoro-3-nitrophenyl)methylidene]-1-(prop-2-enoyl)azepan-4-0ne"	n/a	4/30/14	Treatment of multiple myeloma	Designated			N/A	N/A	VivoLux AB	Uppsala Science Park	SE-751 83 Uppsala				Sweden
"(3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one"	n/a	12/9/15	Treatment of Fragile X Syndrome.	Designated			N/A	N/A	Centre National de la Recherche Scientifique (CNRS)	3 Rue Michel-Ange		Paris			France
"(3S)-1-azabicyclo[2.2.2]oct-3-yl {2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate"	n/a	9/11/14	Treatment of Gaucher disease	Designated			N/A	N/A	Genzyme	500 Kendall Street		Cambridge	Massachusetts	2142	USA
"(3S)-1-azabicylo[2.2.2]oct-3yl {2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate"	n/a	8/26/14	Treatment of Fabry's disease	Designated			N/A	N/A	Genzyme Corporation	500 Kendall Street		Cambridge	Massachusetts	1242	USA
"(3S)-3-(4-trifluoromethoxybenzyloxy)-6-nitro-2H-3,4-dihydroimidazo[2,1-b]oxazine"	n/a	7/5/07	Treatment of tuberculosis	Designated			N/A	N/A	Global Alliance for TB Drug Development	40 Wall Street	24th Floor	New York	New York	10005	USA
"(3S)-3-[(2S)-2-({N-[2-tert-butyl)phenyl]carbamoyl}carbonylamino) propanoylamino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy) pentanoci acid"	n/a	8/19/03	Treatment of patients undergoing solid organ transplantation.	Designated			N/A	N/A	Pfizer Global Research and Development	50 Pequot Avenue		New London	Connecticut	6320	USA
"(3S)-3-[({1-(2-Chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3yl}amino)carbonyl]amino-3-(4-methylphenyl)propanoic acid monosodium salt"	n/a	4/25/16	For mobilization of hematopoietic stem cells	Designated			N/A	N/A	"Aviara Pharmaceuticals, Inc/"	3331 Green Tree Park		Houston	Texas	77027	USA
"(3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (2R,3R)-2,3-dihydroxybutanedioate"	n/a	9/18/15	Treatment of pediatric (aged 0 through 16 years) juvenile idiopathic arthritis (JIA) ILAR categories excluding systemic JIA	Designated			N/A	N/A	"AbbVie, Inc."	1 North Waukegan Road		North Chicago	Illinois	60064	USA
"(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride"	n/a	9/4/13	Treatment of primary sclerosing cholangitis	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	300 Shire Way		Lexington	California	2421	USA
"(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride"	n/a	9/4/13	Treatment of alagille syndrome	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	300 Shire Way		Lexington	Massachusetts	2421	USA
"(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride"	n/a	9/4/13	Treatment of primary biliary cirrhosis	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	300 Shire Way		Lexington	Massachusetts	2421	USA
"(4S)-4-ethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1-H-pyrano[3?,4?:6,7]-indolizino-[1,2-b]-quinoline-11-carbaldehyde O-(tert-butyl)-(E)-oxime"	Gimatecan	11/29/02	Treatment malignant glioma	Designated/Withdrawn			N/A	N/A	"Sigma-Tau Research, Inc."	9841 Washingtonian Blvd	Suite 502	Gaithersburg	Maryland	20878	USA
"(5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, hydrochloride"	n/a	1/30/17	Treatment of erythromelalgia	Designated			N/A	N/A	Convergence Pharmaceuticals (Biogen Subsidiary)	225 Binney Street		Cambridge	Massachusetts	2142	USA
"(5R)-5-(4-{[2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, hydrochloride"	n/a	7/24/13	Treatment of trigeminal neuralgia	Designated			N/A	N/A	Convergence Pharmaceuticals Ltd.	Babraham Research Campus	Cambridge CB22 3AT				United Kingdom
"(5S,8S, 10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5] diazocine-8-carboxyamide"	n/a	4/14/16	Treatment of ovarian cancer	Designated			N/A	N/A	DebioPharm International SA	"Forum ""apres-demain"""	"Chemin Messidor, 5-7"	Lausanne			Switzerland
(6-maleimidocaproyl)hydrazone of doxorubicin	n/a	6/29/11	Treatment of soft tissue sarcoma	Designated			N/A	N/A	CytRx Corporation	11726 San Vicente Blvd.		Los Angeles	California	90049	USA
"(6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl] amino-L-glyceroB-L-manno-heptopyranosyl]amino-9H-purine)"	n/a	2/21/14	"Parenteral treatment of painful, chronic, chemotherapy-induced peripheral neuropathy that is refractory to conventional analgesics"	Designated			N/A	N/A	"DARA BioSciences, Inc."	8601 Six Forks Road	Suite 160	Raleigh	North Carolina	27615	USA
"(6aR, 10aR)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid"	n/a	10/13/15	Treatment of cystic fibrosis.	Designated			N/A	N/A	"Corbus Pharmaceuticals, Inc."	100 River Ridge Drive	Suite 103	Norwood	Massachusetts	2062	USA
"(6aR, 10aR)-3-(1,1-dimethylheptyl)-8-tetrahydro-cannabinol-9-carboxylic acid"	n/a	6/10/15	Treatment of systemic sclerosis	Designated			N/A	N/A	"Corbus Pharmaceuticals, Inc."	100 River Ridge Drive	Suite 103	Norwood	Massachusetts	2062	USA
"(6R,S)5,10-methylene-tetrahydrofolic acid"	Cofactor	8/13/04	For use in combination with 5-fluorouracil for the treatment of patients with pancreatic cancer	Designated			N/A	N/A	"Adventrx Pharmaceuticals, Inc."	6725 Mesa Ridge Road	Suite 100	San Diego	California	92121	USA
"(9-[N-(3-morpholinopropyl)-sulfonyl]-5,6-dihydro-5-oxo-11-H-indeno [1,2-c] isoquinoline methanesulfonic acid"	n/a	12/8/04	Prevention of post-operative complications of aortic anuerysm surgical repair	Designated			N/A	N/A	Inotek Pharmaceuticals Corporation	100 Cummings Center		Beverly	Massachusetts	1915	USA
(E)-N-(1-(5-Chloro-2-hydroxy phenyl)Ethylidene)-3-((4-Methyl Piperazin-1-yl) Sulfonyl) Benzohydrazide Mesylate	n/a	1/12/17	Treatment of Ewing's sarcoma.	Designated			N/A	N/A	Salarius Pharmaceuticals	2450 Holcombe Boulevard	Suite J-608	Houston	Texas	77021	USA
"(E, Z)-4,5,9-trithiadodeca-1, 6, 11-triene 9-oxide (Ajoene)"	n/a	4/21/16	Treatment of Pseudomonas aeruginosa pulmonary infections in cystic fibrosis patients	Designated			N/A	N/A	Neem Biotech Ltd.	Units G & H	Roseheyworth Business Park	Blaenau Gwent			United Kingdom
(monomethoxypolyethylene glycol) recombinant adenosine deaminase	n/a	3/19/15	Treatment of adenosine deaminase deficiency in patients with severe combined immunodeficiency	Designated			N/A	N/A	"Sigma-Tau Pharmaceuticals, Inc."	9841 Washingtonian Blvd	Suite 500	Gaithersburg	Maryland	20878	USA
"(N-[2,6-bis(1-methylethyl)-pheyl-N'-[[1-4-dimethyl-amino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt"	n/a	3/9/12	Treatment of adrenocortical carcinoma	Designated			N/A	N/A	"Atterocor, Inc."	301 North Main Street	Suite 100	Ann Arbor	Michigan	48104	USA
"(R)-1-(2,2-difluorobenzo [d][1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide"	n/a	4/24/14	Treatment of cystic fibrosis	Designated			N/A	N/A	Vertex Pharmaceuticals Inc.	50 Northern Avenue		Boston	Massachusetts	2210	USA
(R)-1-phenylethyl-5-(4-biphenyl-4-cyclopropanecarboxylic acid)-3-methylisoxazole-4-yl carbamate sodium salt	n/a	4/15/11	Treatment of idiopathic pulmonary fibrosis	Designated			N/A	N/A	Bristol-Myers Squibb Company	P. O. Box 4000		Princeton	New Jersey	8543	USA
"(R)-1-[1-(4-Acetoxy-3,3-dimethyl-2-oxo-butyl)-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-(3-methylamino-phenyl)-urea"	n/a	5/12/16	Treatment of gastric neuroendocrine tumors (gastric NETs).	Designated			N/A	N/A	Trio Medicines Ltd.	Pavillion View	Brighton BN1 1EY				United Kingdom
"(R)-2-(5-cyano-2-(6-(methoxycarbonyl)-7-methyl-3-oxo-8-(3-(trifluoromethyl)phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidin-5-yl)phenyl)-N,N,N-trimethylethanaminium methanesulfonate dehydrate"	n/a	1/25/17	Treatment of cystic fibrosis	Designated			N/A	N/A	Chiesi Farmaceutici S.p.A.	26A Via Palermo		Parma			Italy
"(R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole"	n/a	7/12/07	Treatment of pulmonary tuberculosis.	Designated			N/A	N/A	"Otsuka Pharmaceutical Company, Ltd"	2440 Research Blvd		Rockville	Maryland	20850	USA
"(R)-4-(3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enylmethyl]-piperazin-1-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride"	n/a	12/19/07	Treatment of small cell lung cancer.	Designated			N/A	N/A	"AbbVie, Inc"	1 North Waukegan Road	"Dept. PA77, Bldg. AP30-1"	North Chicago	Illinois	60064	USA
"(R)-4-(3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enylmethyl]-piperazin-1-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride"	n/a	5/5/08	Treatment of multiple myeloma	Designated/Withdrawn			N/A	N/A	"AbbVie, Inc."	1 N Waukegan Road	AP34/RA72	North Chicago	Illinois	60064	USA
"(R)-4-(3-morpholin-4-yl-l-phenylsulfanylmenthyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-enylmethyl]-piperazin-l-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride"	n/a	12/19/07	Treatment of chronic lymphocytic leukemia	Designated/Withdrawn			N/A	N/A	"AbbVie, Inc."	1 N Waukegan Road	AP34/RA72	North Chicago	Illinois	60064	USA
"(R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride"	n/a	11/19/15	Treatment of cholangiocarcinoma.	Designated			N/A	N/A	"ArQule, Inc."	One Wall Street		Burlington	Massachusetts	1803	USA
(R)-N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide	n/a	10/3/01	Treatment of circadian rhythm sleep disorders in blind people with no light perception	Designated			N/A	N/A	"Phase 2 Discovery, Inc."	"3130 Highland Avenue, Third Floor"		Cincinnati	Ohio	45219	USA
(R)-N-[2-(6-Chloro-methoxy-1H-indol-3yl)propyl]acetamide	n/a	7/3/03	Treatment of neuroleptic-induced tardive dyskinesia in schizophrenia patients	Designated			N/A	N/A	"Phase 2 Discovery, Inc."	3130 Highland Ave.	Third Floor	Cincinnati	Ohio	45219	USA
"(RS)-baclofen, naltrexone and D-sorbitol"	n/a	3/17/14	Treatment of Charcot-Marie-Tooth disease type 1A	Designated			N/A	N/A	Pharnext SA	"11, rue des Peupliers"	92130 Issey les Moulineaux				France
"(S)-1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine"	n/a	11/5/14	Treatment of acute myeloid leukemia	Designated			N/A	N/A	BerGenBio AS	Jonas Lies vei 91	N-5021 Bergen				Norway
"(S)-10-[(dimethylamino)methyl]-4-ethyl-9hydroxy-4-O-[a-(2"",4"",5"",7""-tetranitro-9""-fluorenylideneaminooxy)propionyl]- 1H-pyrano[3',4',6',7',] indolizino [1,2-B]-quinoline-3, 14-(4H, 12H)-dione, hydrochloride"	Lipotecan	10/6/10	Treatment of hepatocellular carcinoma	Designated			N/A	N/A	"TLC Biopharmaceuticals, Inc."	432 N Canal St	Suite 20	South San Francisco	California	94080	USA
"(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile"	n/a	1/26/15	Treatment of pemphigus vulgaris	Designated			N/A	N/A	Almirall S.A.	"Ronda General Mitre, 151"		Barcelona			Spain
"(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile"	n/a	1/5/17	Treatment of epidermolysis bullosa acquisita	Designated			N/A	N/A	"Almirall, S.A."	"Ctra. Laurea Miro, 408-410"	Sant Feliu de Llobregat	Barcelona			Spain
"(S)-3-((3-(1-((6-((3,4-dimethoxyphenyl)pryazin-2-yl)amino)ethyl)phenyl)carbamoyl)-5-methylpridin-1-ium"	n/a	11/17/14	Treatment of pulmonary arterial hypertension	Designated			N/A	N/A	"Pulmokine, Inc."	7 University Place	B127B	Rensselaer	New York	12144	USA
(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one	n/a	8/1/13	Treatment of follicular lymphoma	Designated			N/A	N/A	"Verastem, Inc."	117 Kendrick Street	Suite 500	Needham	Massachusetts	2494	USA
"(S)-4,5-dihydro-2[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiaxolecarboxylic acid"	n/a	2/4/09	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Designated			N/A	N/A	"Ferrokin BioSciences, Inc."	2729 Debbie Court		San Carlos	California	94070	USA
(S)-4-(5-chloro-2-(isopropylamino)pyridin-4-yl)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1H-pyrrole-2-carboxamide hydrochloride	n/a	6/24/13	Treatment of Stage IIb through Stage IV BRAF mutant melanoma	Designated			N/A	N/A	"BioMed Valley Discoveries, Inc."	4520 Main Street	16th Floor	Kansas City	Missouri	64111	USA
"(S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)-imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)-benzamide"	n/a	10/22/15	Treatment of Waldenstrom macroglobulinemia.	Designated			N/A	N/A	Acerta Pharma BV	Molenstraat 110	5342 CC Oss				Netherlands
"(S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)-imidazo[1,5-a]pyrazine-1-yl)-N-(pyridine-2-yl)-benzamide"	n/a	9/21/15	Treatment of mantle cell lymphoma.	Designated			N/A	N/A	Acerta Pharma BV	Molenstraat 110	5342 CC Oss				Netherlands
"(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride"	n/a	11/17/14	Treatment of inherited mitochondrial respiratory chain diseases	Designated			N/A	N/A	Khondrion BV	Philips van Leydenlaan 15	6525 Ex Nijmegen				Netherlands
"(S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one"	n/a	4/29/15	Treatment of Hodgkin lymphoma	Designated			N/A	N/A	Incyte Corporation	1801 Augustine Cut-Off		Wilmington	Delaware	19803	USA
"(S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydroprazolo[1,5-a]pyrimidine-3-carboxamide"	n/a	6/23/16	Treatment of mantle cell lymphoma.	Designated			N/A	N/A	"BeiGene USA, Inc."	2115 Linwood Avenue	4th Floor	Fort Lee	New Jersey	7024	USA
"(S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide"	n/a	6/29/16	Treatment of Waldenstrom's macroglobulinemia	Designated			N/A	N/A	"BeiGene USA, Inc."	2115 Linwood Avenue	4th Floor	Fort Lee	New Jersey	7024	USA
"(S)-7-(1acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide"	n/a	7/20/16	Treatment of chronic lymphocytic leukemia.	Designated			N/A	N/A	"BeiGene USA, Inc."	2115 Linwood Avenue	4th Floor	Fort Lee	New Jersey	7024	USA
"(S)-8-{2-Amino-6-[1-(5-chloro-biphenyl-2-yl)-(R)-2,2,2-trifluoro-ethoxy]-pyrimidin-4-yl}-2,8-diaza-spiro[4.5]decane-3-carboxylic acid ethyl ester"	n/a	10/6/15	Treatment of pulmonary arterial hypertension (PAH).	Designated			N/A	N/A	"KAROS Pharmaceuticals, Inc."	5 Science Park		New Haven	Connecticut	6511	USA
"(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate"	n/a	8/31/15	Treatment of soft tissue sarcoma.	Designated			N/A	N/A	"Loxo Oncology, Inc."	One Landmark Square	Suite 1122	Stamford	Connecticut	6901	USA
(S)-perillyl alcohol temozolomide	n/a	11/12/14	Treatment of glioma	Designated			N/A	N/A	"NeOnc Technologies, Inc."	"8335 Sunset Blvd., #240"		Los Angeles	California	90069	USA
(UDU-stereoisomer of c-UJUun UNU-terminal UkUnhibitor)	n/a	3/28/06	Treatment of acute sensorineural hearing loss	Designated			N/A	N/A	"Auris Medical, Inc."	444 North Michagan Ave.	Suite 1200	Chicago	Illinois	60611	USA
"(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide"	n/a	5/14/14	Treatment of diffuse large B-cell lymphoma	Designated			N/A	N/A	"Karyopharm Therapeutics, Inc."	2 Mercer Road		Natick	Massachusetts	1760	USA
1 8-(p[131I]-iodophenyl)octadecyl phosphocholine	n/a	12/3/14	Treatment of multiple myeloma	Designated			N/A	N/A	"Cellectar Biosciences, Inc."	3301 Agriculture Drive		Madison	Wisconsin	53716	USA
"1'-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3-f][1,3]benzodioxole-7,3'-indol]-2'(1'H)-one"	n/a	11/19/12	Treatment of erythromelalgia	Designated			N/A	N/A	Teva Pharmaceuticals	41 Moores Road	P. O. Box 4011	Frazer	Pennsylvania	19355	USA
"1,2:5,6-Dianhdrogalactitol, NSC-132313"	n/a	1/31/12	Treatment of malignant gliomas	Designated			N/A	N/A	"DelMar Pharmaceuticals, Inc."	3475 Edison Way	Suite R	Menlo Park	California	94025	USA
"1,2:5,6-dianhydrogalactitol"	n/a	4/19/16	Treatment of ovarian cancer.	Designated			N/A	N/A	"DelMar Pharmaceuticals, Inc. (Clinical Operations)"	3475 Edison Way	Suite R	Menlo Park	California	94025	USA
"1,2:5,6-dianhydrogalactitol"	n/a	3/10/16	Treatment of medulloblastoma.	Designated			N/A	N/A	"DelMar Pharmaceuticals, Inc."	3475 Edison Way	Suite R	Menlo Park	California	94025	USA
"1,5-(Butylimino)-1,5 dideoxy,D-glucitol"	n/a	5/12/98	Treatment of Fabry's disease.	Designated			N/A	N/A	Oxford GlycoSciences	"10, The Quadrant"	Abington Science Park	United Kingdom			United Kingdom
"1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine hydrogen methanesulfonate"	n/a	1/18/00	Treatment of hormone refractory prostate carcinoma.	Designated/Withdrawn			N/A	N/A	"Cell Therapeutics, Inc."	201 Elliott Avenue West	Suite 400	Seattle	Washington	98119	USA
"1-(2,8-Dimethyl-1-thia-3,8-diazaspiro[4.5]dec-3-yl)-3-(1H-indol-3-yl)propan-1-one"	n/a	4/6/16	Treatment of frontotemporal dementia.	Designated			N/A	N/A	Anavex Life Sciences Corp.	51 West 52nd Street	7th Floor	New York	New York	10019	USA
1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine	Sapacitabine	6/24/10	Treatment of acute myelogenous leukemia	Designated			N/A	N/A	Cyclacel Limited	1 James Linday Place	Dundee DD1 5JJ				United Kingdom
1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine	Sapacitabine	6/24/10	Treatment of myelodysplastic syndrome	Designated			N/A	N/A	Cyclacel Limited	1 James Linday Place	Dundee DD1 5JJ				United Kingdom
1-(2-chlorophenyl)-1-(S)-hydroxy-2-(S)-carbamoyloxy-propane	n/a	7/7/16	Treatment of status epilepticus	Designated			N/A	N/A	"Bio-Pharm Solutions Co., Ltd."	Advanced Institute of Convergence Technology	"6F, C Bldg"	Yeongtong Suwon			"Korea, Republic of"
1-(2-Nitro-imidazolyl)-3-[18F]fluoro-2-propanol; 1H-1-(3-[18F]fluoro-2-hydroxypropyl0-2-nitroimidazole (18F-Misonidazole)	n/a	4/6/16	Diagnostic for management of glioma.	Designated			N/A	N/A	"Advanced Imaging Projects, LLC"	7947 Brookside Ct.		Lake Worth	Florida	33467	USA
"1-(3-chloro-5-{[4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-l-yl)-1,3-thiazol-2-yl]carbamoyl}- 2-pyridyl) piperidine-4-caboxylic acid Monomaleate"	n/a	9/1/11	Treatment of idiopathic thrombocytopenic purpura	Designated			N/A	N/A	"Eisai, Inc."	300 Tice Blvd		Woodcliff Lake	New Jersey	7677	USA
"1-(4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide"	n/a	7/8/15	Treatment of multiple myeloma	Designated			N/A	N/A	"Cleave Biosciences, Inc."	866 Malcolm Road	Suite 100	Burlingame	California	94010	USA
"1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one"	n/a	9/26/13	Management of postherpetic neuralgia	Designated/Withdrawn			N/A	N/A	Zalicus Pharmaceuticals Ltd.	245 First Street		Cambridge	Massachusetts	2142	USA
"1-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridine-3-yl}phenyl)-3-(3-fluorophenyl)urea)"	n/a	7/28/11	Treatment of acute myelogenous leukemia	Designated/Withdrawn			N/A	N/A	"AbbVie, Inc."	1 N Waukegan Road	AP34/RA72	North Chicago	Illinois	60064	USA
1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid	n/a	3/31/15	Treatment of systemic sclerosis	Designated			N/A	N/A	Inventiva Pharma	50 rue de Dijon	Daix 21121				France
1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea	n/a	11/12/09	Treatment of acute myeloid leukemia	Designated			N/A	N/A	Astex Therapeutics Ltd	436 Cambridge Science Park	CB4 0QA				United Kingdom
"1-[(2-Chloro-4-methoxyphenoxy)methyl]-4-[(2,6-dichlorophenoxy) methyl]benzene"	n/a	1/9/12	Treatment of poliovirus infection.	Designated			N/A	N/A	"ViroDefense, Inc."	155 Gibbs Street	Suite 529	Rockville	Maryland	20850	USA
10 synthetic peptides targeting 5 tumor asociated antigens	n/a	1/23/13	Treatment of non-small cell lung cancer in patients expressing HLA-A2	Designated			N/A	N/A	Orphan Synergy Europe Pharma (OSE Pharma)	OSE Pharma Pepiniere Paris Sante Cochin	29 bis rue du faubourg Saint Jacques	Paris			France
111Indium pentetreotide	Somatother	6/10/99	Treatment of somatostatin receptor positive neuroendocrine tumors.	Designated			N/A	N/A	Louisiana State University Medical Center Foundation	1600 Canal St.	10th Floor	New Orleans	Louisiana	70112	USA
12-A-p21 RAS(5-21). 12-C-p21 RAS(5-21). 12-D-p21 RAS(5-21). 12-Rp21 RAS(5-21). 12-S-p21 RAS(5-21). 12-V-p21 RAS(5-21). 13-D-p21 RAS(5-21)	n/a	6/7/11	Treatment of pancreatic cancer	Designated			N/A	N/A	Oncos Therapeutics	Saukonpaadenranta 2		Helsinki			Finland
131-I-8H9 monoclonal antibody	n/a	8/29/16	Treatment of neuroblastoma	Designated			N/A	N/A	Memorial Sloan Kettering Cancer Center	1275 York Avenue		New York	New York	10065	USA
131I-BC8 monoclonal antibody (Anti-CD45 murine monoclonal antibody radiolabeled with 131I	n/a	3/28/16	Treatment of Acute Myeloid Leukemia (AML)	Designated			N/A	N/A	"Actinium Pharmaceuticals, Inc."	379 Thornall Avenue	6th Floor	Edison	New Jersey	8837	USA
14-amino acid peptide derived from wound growth factor	n/a	8/16/10	Treatment of delayed graft function in renal transplant recipients	Designated/Withdrawn			N/A	N/A	NephRx Corporation	4717 Campus Drive		Kalamazoo	Michigan	49008	USA
14-amino acid peptide derived from wound growth factor	n/a	8/5/10	Prevention of delayed graft function in renal transplant recipients	Designated/Withdrawn			N/A	N/A	NephRx Corporation	4717 Campus Drive		Kalamazoo	Michigan	49008	USA
17 amino acid peptide	n/a	1/29/10	Prevention of ischemia reperfusion injury in the lung during lung tranplantation	Designated			N/A	N/A	Apeptico Forschung und Entwicklung GmbH	Mariahilferstrabe 136	Top 1150	Vienna			Austria
17-a-hydroxyprogesterone caporate (oral formulation)	n/a	6/1/15	Prevention of preterm birth in women with a singleton pregnancy	Designated			N/A	N/A	"Lipocine, Inc."	675 Arapeen Drive	Suite 202	Salt Lake City	Utah	84108	USA
17-allylamino-17-demethoxygeldanamycin (17-AGG)	n/a	9/3/04	Treatment of chronic myelogenous leukemia	Designated			N/A	N/A	Bristol-Myers Squibb Company	Research & Development	5 Research Parkway	Wallingford	Connecticut	6492	USA
177-LU-DOTA-GlyGlyNle-CycMSHhex	n/a	4/16/15	Treatment of Stage IIB through IV malignant melanoma	Designated			N/A	N/A	"SolaranRx, Inc."	"5901 Indian School Road, NE"		Albuquerque	New Mexico	87110	USA
177Lu-tetraxetan-tetulomab	Betalutin	5/14/14	Treatment of Follicular Lymphoma	Designated			N/A	N/A	Nordic Nanovector AS	Anniken Hagen	"Kjelsasveien 168B, NO-0884"	Oslo			Norway
18-(p-[124I]-iodophenyl)octadecyl phosphocholine	n/a	4/30/14	Diagnostic for the management of glioma	Designated			N/A	N/A	"Cellectar Biosciences, Inc."	3301 Agriculture Drive		Madison	Wisconsin	53716	USA
18Fluorine-N-3-Fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl) Nortropane	n/a	1/26/15	Diagnostic to be used in the management of multiple system atrophy (MSA)	Designated			N/A	N/A	"Advanced Imaging Projects, LLC"	7947 Brookside Ct.		Lake Worth	Florida	33467	USA
"1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione or [(1E, 4Z,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one]"	n/a	2/17/16	Treatment of spinal and bulbar muscular atrophy	Designated			N/A	N/A	Allianz Pharmascience Ltd.	8630 Fenton Street	Suite 724	Silver Spring	Maryland	20910	USA
2 dimethylbutyrate	n/a	6/18/08	Treatment of beta thalassemia	Designated			N/A	N/A	"HemaQuest Pharmaceuticals, Inc."	1001 Fourth Avenue	Suite 3317	Seattle	Washington	98154	USA
"2',3',5'-tri-o-acetyluridine"	n/a	1/13/03	Treatment of mitochondrial disease	Designated/Withdrawn			N/A	N/A	Repligen Corporation	41 Seyon Street	"Building 1, Suite 100"	Waltham	Massachusetts	2453	USA
2'-3'-dideoxyadenosine	n/a	7/21/87	Treatment of aquired immunodeficiency syndrome.	Designated/Withdrawn			N/A	N/A	"National Cancer Institute, Dct"	"NIH, Exec. Plaza N., Room 7-18"		Bethesda	Maryland	20892	USA
2'-deoxycytidine	n/a	9/9/96	As a host-protective agent in the treatment of acute myelogenous leukemia.	Designated			N/A	N/A	"Grant, Steven M.D."	"Massey Cancer Center, VCU"	P.O. Box 980230	Richmond	Virginia	23298	USA
2'-O-(2-methoxyethyl)phosphorothioate antisense oligonucleotide	n/a	5/10/16	Treatment of acromegaly	Designated			N/A	N/A	Antisense Therapeutics Limited	6 Wallace Avenue	TOORAK VIC 3142	Trevose			Australia
2'-O-methyl phosphorothioate 5'-GCUAGGUUUACGGGACCUCU-3'	n/a	10/31/12	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	LifeSplice Pharma LLC	1 Great Valley Parkway	Suite 20	Malvern	Pennsylvania	19355	USA
"2,2'-{2-[1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid (ixazomib citrate)"	n/a	3/9/12	Treatment of systemic light chain (AL) amyloidosis.	Designated			N/A	N/A	"Millennium Pharmaceuticals, Inc."	40 Landsdowne Street		Cambridge	Massachusetts	2139	USA
"2,5-dimethyl-3-[2-methyl-4-(methyloxy)phenyl]-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-"	n/a	1/15/15	Treatment of congenital adrenal hyperplasia (CAH)	Designated			N/A	N/A	"Neurocrine Biosciences, Inc."	12780 El Camino Real		San Diego	California	92130	USA
2-(2-chlorobenzylidene)hydrazinecarboximidamide acetate	n/a	9/10/15	Treatment of Charcot-Marie Tooth disease.	Designated			N/A	N/A	InFlectis BioScience	21 rue de la Noue Bras de Fer	44200 Nantes				France
"2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione"	n/a	9/21/10	Treatment of idiopathic pulmonary fibrosis.	Designated			N/A	N/A	GenKyoTex S.A.	14 Chemin des Aulx		Geneva			Switzerland
2-(2-phenylvinyl)-4-[-methylpiperazin-l-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	1/29/10	Treatment of acute myeloid leukemia.	Designated			N/A	N/A	"EntreMed, Inc."	Research Triangle Park Center	Suite 400	Durham	North Carolina	27703	USA
2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	7/1/14	Treatment of hepatocellular carcinoma	Designated			N/A	N/A	"CASI Pharmaceuticals, Inc."	9620 Medical Center Drive	Suite 300	Rockville	Maryland	20850	USA
2-(2-phenylvinyl)-4-[4-methylpiperazin-l-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	12/22/08	Treatment of multiple myeloma.	Designated			N/A	N/A	"EntreMed, Inc."	Research Triangle Park Center	Suite 400	Durham	North Carolina	27703	USA
2-(2-phenylvinyl)-4-[4-methylpiperazin-l-yl)]-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidine L(+) tartrate salt	n/a	3/18/09	Treatment of ovarian carcinoma	Designated			N/A	N/A	"EntreMed, Inc."	Research Triangle Park Center	Suite 400	Durham	North Carolina	27703	USA
"2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-l-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-yl)azetidin-3-yl)acetonitrile adipate"	n/a	1/26/15	Treatment of pancreatic cancer	Designated			N/A	N/A	Incyte Corporation	1801 Augustine Cut-Off		Wilmington	Delaware	19803	USA
"2-(3-diethylaminopropyl)-8,8-dipropyl-2-azaspiro [4,5] decan dimaleate"	Atiprimod	12/2/03	Treatment of mulitple myeloma and associated bone resorption	Designated			N/A	N/A	"Callisto Pharmaceuticals, Inc."	2 Executive Drive	Suite 450	Somerset	New Jersey	8873	USA
"2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5] decane dimaleate"	Atiprimod	9/18/06	Treatment of carcinoid tumors	Designated			N/A	N/A	"Callisto Pharmaceuticals, Inc."	420 Lexington Avenue		New York	New York	10170	USA
"2-(5-fluoro-2-methyl-1H-indol-3-yl)-1H-imidazo[4,5-f][1,10] phenanthroline"	n/a	6/1/15	Treatment of acute myeloid leukemia	Designated			N/A	N/A	"Aptose Biosciences, Inc."	5955 Airport Road	Suite 228	"Mississauga, Ontario L4V"			Canada
2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl)acetamide	n/a	5/13/15	Treatment of cystic fibrosis	Designated			N/A	N/A	Flatley Discovery Lab	529 Main Street	Suite 115	Charlestown	Massachusetts	2129	USA
"2-0-Butyryl-1-0-octyl-myo-inositol 3,4,5,6-tetrakisphosphate"	n/a	8/15/03	Treatment of cystic fibrosis	Designated			N/A	N/A	"Inologic, Inc."	"101 Elliott Ave., West"		Seattle	Washington	98119	USA
2-0-desulfated heparin	Aeropin	9/17/93	Treatment of cystic fibrosis.	Designated			N/A	N/A	"Kennedy & Hoidal, M.D.'s"	University of Utah Health Sciences Center	"50 North Medical Drive, Room 4R240"	Salt Lake City	Utah	84132	USA
"2-amino-2-[2-[2-chloro-4-[[3-(phenylmethoxy) phenyl] thio]phenyl]ethyl]1,3-propanediol hydrochloride"	n/a	10/6/15	Prevention of graft versus host disease.	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
2-amino-3-[3-[[4-(2-pyridyloxymethyl)phenyl]methyl]isoxazol-5-yl]pyridin-1-ium-1-yl]methyl hydrogen phosphate	n/a	10/26/16	Treatment of invasive aspergillosis	Designated			N/A	N/A	"Amplyx Pharmaceuticals, Inc."	12730 High Bluff Drive	Suite 160	San Diego	California	92130	USA
2-amino-3-[3-[[4-(2-pyridyloxymethyl)phenyl]methyl]isoxazol-5-yl]pyridin-1-ium-1-yl]methyl hydrogen phosphate	n/a	11/3/16	Treatment of coccidioidomycosis	Designated			N/A	N/A	"Amplyx Pharmaceuticals, Inc."	12730 High Bluff Drive	Suite 160	San Diego	California	92130	USA
2-amino-3-[3-[[4-(2-pyridyloxymethyl)phenyl]methyl]isoxazol-5-yl]pyridin-1-ium-1-yl]methyl hydrogen phosphate	n/a	11/2/16	"Treatment of invasive rare mold infections caused by scedosporium spp., fusarium spp., and mucorales fungi (including mucor spp., and rhizopus spp.)"	Designated			N/A	N/A	"Amplyx Pharmaceuticals, Inc."	12730 High Bluff Drive	Suite 160	San Diego	California	92130	USA
2-amino-3-[3-[[4-(2-pyridyloxymethyl)phenyl]methyl]isoxazol-5-yl]pyridin-1-ium-1-yl]methyl hydrogen phosphate	n/a	10/19/16	Treatment of invasive candidiasis	Designated			N/A	N/A	"Amplyx Pharmaceuticals, Inc."	12730 High Bluff Drive	Suite 160	San Diego	California	92130	USA
"2-Amino-4-[11C]methylsulfanyl-butanoic acid, l-[S methyl[11C]methionine"	n/a	1/17/17	Diagnostic agent for the Clinical Management of Medulloblastoma	Designated			N/A	N/A	"Advanced Imaging Projects, LLC"	7947 Brookside Ct.		Lake Worth	Florida	33467	USA
2-amino-N-({methyl-[(6-trifluoromethoxy-benzothiazol-2-ylcarbamoyl)-methyl]-carbamoyl}-methyl)-acetamide monohydrochloride	n/a	5/18/16	Treatment of spinocerebellar ataxia.	Designated			N/A	N/A	"Biohaven Pharmaceuticals, Inc."	234 Church Street	Suite 304	New Haven	Connecticut	6510	USA
2-Chloro-N6--(3-iodobenzyl)adenosine-5'-N-methyluronamide	n/a	2/17/12	Treatment of hepatocellular carcinoma	Designated			N/A	N/A	Can-Fite BioPharma Ltd.	10 Bareket Street	P. O. Box 7537	Petah-Tikva			Israel
2-chloroethyl-3-sarcosinamide-1-nitrosourea	n/a	8/3/01	Treatment for malignant gliomas	Designated			N/A	N/A	"Lawrence Panasci, MD"	"Professor of Medicine, McGill University"	3755 Cote Ste Catherine				USA
2-chloroethyl-3-sarcosinamide-1-nitrosourea	Sarmustine	11/15/01	Treatment for malignant glioma	Designated			N/A	N/A	Pangene Corporation	5500 Stewart Avenue		Fremont	California	94538	USA
"2-Ethylbutyl (2S)-2-{[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate"	n/a	9/18/15	Treatment of Ebola virus disease	Designated			N/A	N/A	"Gilead Sciences, Inc."	333 Lakeside Drive		Foster City	California	94404	USA
2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl) methoxy)benzaldehyde	n/a	12/29/15	Treatment of sickle cell disease (SCD).	Designated			N/A	N/A	"Global Blood Therapeutics, Inc."	400 East Jamie Court	Suite 101	South San Francisco	California	94080	USA
2-hydroxypropyl-B-cyclodextrin	Kleptose	2/18/13	"Treatment of Niemann Pick disease, type C."	Designated			N/A	N/A	"Vtesse, Inc."	700 Technology Square	Third Floor	Cambridge	Massachusetts	2139	USA
2-iminobiotin	n/a	2/24/09	Treatment of perinatal asphyxia.	Designated			N/A	N/A	Neurophyxia B.V.	Onderwijsboulevard 219					Netherlands
2-methoxyestradiol	Panzem	7/10/01	Treatment of multiple myeloma	Designated/Withdrawn			N/A	N/A	"EntreMed, Inc."	Research Triangle Park Center	Suite 400	Durham	North Carolina	27703	USA
2-methoxyestradiol	Panzem	6/16/06	Treatment of multiforme glioblastoma	Designated/Withdrawn			N/A	N/A	"EntreMed, Inc."	4819 Emperor Blvd	Suite 400	Durham	North Carolina	27703	USA
2-methoxyestradiol	Panzem Ncd	4/4/05	Treatment of ovarian cancer	Designated/Withdrawn			N/A	N/A	"EntreMed, Inc."	4819 Emperor Blvd	Suite 400	Durham	North Carolina	27703	USA
2-methoxyestradiol	Pulmolar	4/11/05	Treatment of pulmonary arterial hypertension	Designated			N/A	N/A	"PR Pharmaceuticals, Inc."	1716 Heath Parkway		Fort Collins	Colorado	80524	USA
"2-Pyrazinecarbonitrile, 5-[[5-2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino] monomesylate monohydrate"	n/a	4/9/15	Treatment of anal cancer	Designated			N/A	N/A	Eli Lilly and Company	Lilly Corporate Center		Indianapolis	Indiana	46285	USA
"2-[(3-methyl-4-(2,2,2-trifluoroethoxy) pyridin-2-yl)methylsulfinyl] -1H-benzoimidazole"	Prevonco (Tm)	8/27/08	Treatment of hepatocellular carcinoma.	Designated			N/A	N/A	"BioQuant, Inc."	6330 Nancy Ridge Drive		San Diego	California	92121	USA
"2-[(4S)-6-(4-chlorophenyl)-1,7,8-trimethylthiophenol[3,2-f]1,2,4-triazolo[4,3-a]1,4-diazepin-4-yl]-N-[3-(4-methylpiperazinyl)propyl]acetamide"	n/a	9/29/15	Treatment of nuclear protein in testis (NUT) midline carcinoma.	Designated			N/A	N/A	"Genentech, Inc (a Roche Group Member)"	1 DNA Way	M/S# 35-5e	South San Francisco	California	94080	USA
"2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thienol[3,2,-f]-[1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)-acetamide dihydrate"	n/a	7/16/14	Treatment of acute myeloid leukemia	Designated			N/A	N/A	OncoEthix SA	Avenue do l'Elysee 32	CH-1006 Lausanne				Switzerland
2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimadazole-4-carboxamide	n/a	12/18/07	Treatment of malignant melanoma stages IIb through IV.	Designated			N/A	N/A	"AbbVie, Inc."	1 N. Waukegan Road		North Chicago	Illinois	60064	USA
2-[4-(1-Methyl-4-pyridin-4-yl-lH-pyrazol-3-yl)-phenoxymethyl]-quinoline succinic acid	n/a	6/2/14	Treatment of Huntington's disease.	Designated			N/A	N/A	Pfizer Inc.	445 Eastern Point Road		Groton	Connecticut	6340	USA
2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indian-2-carboxylic acid	n/a	5/14/13	Treatment of patients with systemic sclerosis	Designated			N/A	N/A	"Sanofi U. S., Inc."	55 Corporate Drive		Bridgewater	New Jersey	8807	USA
2-[4-[[(2-R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate	n/a	4/15/15	Treatment of patients with Frederickson Type I or V hyperlipoproteinemia	Designated			N/A	N/A	"CymaBay Therapeutics, Inc."	7999 Gateway Blvd	Suite 130	Newark	California	94560	USA
2-[4-[[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate	n/a	11/7/16	Treatment of primary biliary cholangitis	Designated			N/A	N/A	CymaBay Therapeutics	7999 Gateway Boulevard	Suite 130	Newark	California	94560	USA
2-[4-[[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate	n/a	3/18/15	Treatment of homozygous familial hypercholesterolemia (HoFH)	Designated			N/A	N/A	"CymaBay Therapeutics, Inc."	7999 Gateway Blvd	Suite 130	Newark	California	94560	USA
2-[[3-({4-[(5-{2-[(3-Fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}propyl](ethyl)amino]ethyl dihydrogen phosphate trihydrate	n/a	1/19/10	Treatment of acute myeloid leukemia	Designated			N/A	N/A	AstraZeneca Pharmaceuticals LP	1800 Concord Pike	P. O. Box 8355	Wilmington	Delaware	19803	USA
"2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid"	n/a	6/16/15	Treatment of ovarian cancer.	Designated			N/A	N/A	"Rgenix, Inc."	310 East 67th St.	Suite 1-12	New York	New York	10065	USA
"2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid"	n/a	6/16/15	Treatment of glioblastoma multiforme.	Designated			N/A	N/A	"Rgenix, Inc."	310 East 67th St.	Suite 1-12	New York	New York	10065	USA
"2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid"	n/a	6/23/15	Treatment of malignant melanoma stages IIB to IV.	Designated			N/A	N/A	"Rgenix, Inc."	310 East 67th St.	Suite 1-12	New York	New York	10065	USA
"2-{[(1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexy]methoxy} acetic acid"	n/a	8/28/14	Treatment of pulmonary arterial hypertension	Designated			N/A	N/A	"Arena Pharmaceuticals, Inc."	6154 Nancy Ridge Drive		San Diego	California	92121	USA
20-mer complementary to Akt mRNA	n/a	12/10/04	Treatment of stomach cancer	Designated			N/A	N/A	Rexahn Corporation	9620 Medical Center Drive		Rockville	Maryland	20850	USA
20-mer oligonucleotide complementary to Akt mRNA	n/a	12/1/04	Treatment of renal cell carcinoma	Designated			N/A	N/A	Rexahn Corporation	9620 Medical Center Drive		Rockville	Maryland	20850	USA
20-mer oligonucleotide complementary to Akt mRNA	n/a	12/8/04	Treatment of pancreatic cancer	Designated			N/A	N/A	Rexahn Corporation	9620 Medical Center Drive		Rockville	Maryland	20850	USA
20-mer oligonucleotide complementary to Akt mRNA	n/a	12/1/04	Treatment of ovarian cancer	Designated			N/A	N/A	Rexahn Corporation	9620 Medical Center Drive		Rockville	Maryland	20850	USA
20-mer oligonucleotide complementary to Akt mRNA	n/a	12/8/04	Treatment of glioblastoma	Designated			N/A	N/A	Rexahn Corporation	9620 Medical Center Drive		Rockville	Maryland	20850	USA
225Ac-lintuzumab	n/a	11/25/14	Treatment of acute myelogenous leukemia	Designated			N/A	N/A	"Actinium Pharmaceuticals, Inc."	379 Thornall Avenue	6th Floor	Edison	New Jersey	8837	USA
"24,25 dihydroxycholecalciferol"	n/a	2/27/87	Treatment of uremic osteodystrophy.	Designated			N/A	N/A	Lemmon Company	1510 Delp Drive		Kulpsville	Pennsylvania	19443	USA
"2S,4R ketoconazole"	n/a	3/9/12	Treatment of endogenous Cushing's syndrome	Designated			N/A	N/A	Cortendo AB (HQ address)	Box 47	SE-433 21 Partille				Sweden
"3'-azido-2',3'dideoxyuridine"	Azdu	11/20/89	Treatment of acquired immunodeficiency syndrome.	Designated/Withdrawn			N/A	N/A	"Berlex Laboratories, Inc."	1401 Harbor Bay Parkway		Alameda	California	94501	USA
"3,4 diaminopyridine and choline bitartrate"	n/a	4/30/10	Treatment of Lambert-Eaton myasthenic syndrome	Designated			N/A	N/A	MS Therapeutics Limited	Beechy House	Berkshire RG45 7AW				United Kingdom
"3,4-diaminopyridine"	n/a	12/18/90	Treatment of Lambert-Eaton myasthenic syndrome.	Designated			N/A	N/A	Jacobus Pharmaceutical Company	37 Cleveland Avenue	P.O. Box 5290	Princeton	New Jersey	8540	USA
"3,5,3'-triiodothyroacetate"	n/a	9/20/00	"Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid gland."	Designated			N/A	N/A	"Elliot Danforth, Jr., M.D."	University of Vermont	84 Beartown Road	Underhill	Vermont	5489	USA
"3,5-diiodothyropropionic acid"	n/a	5/14/13	Treatment of Allan-Herndon-Dudley syndrome	Designated			N/A	N/A	Zarion Pharmaceuticals P/L	8 Grandview Grove	Sassafras 3787	Victoria			Australia
"3-(3,5-dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one"	n/a	9/11/98	Treatment of Kaposi's sarcoma.	Designated			N/A	N/A	"Sugen, Inc."	230 East Grand Ave.		South San Francisco	California	94080	USA
"3-(3,5-Dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one"	n/a	3/23/00	Treatment of von Hippel-Lindau disease.	Designated			N/A	N/A	"Sugen, Inc."	230 East Grand Ave.		South San Francisco	California	94080	USA
"3-(4-(1,5-Napthrydine)-Imidazole[1,2-a]pyridine-7-(1-phenyl-4-(1-(4-methyl piperazine)"	n/a	7/14/15	Treatment of fibrodysplasia ossificans progressiva.	Designated			N/A	N/A	"La Jolla Pharmaceutical Company, Inc."	10182 Telesis Court	Suite 600	San Diego	California	92121	USA
"3-(4-(8-fluoroquinoline)-Imidazole[1,2-a]pyridine-7-(1-phenyl-4-(1-(4-methyl piperazine)"	n/a	7/14/15	Treatment of fibrodysplasia ossificans progressiva.	Designated			N/A	N/A	"La Jolla Pharmaceutical Company, Inc."	10182 Telesis Court	Suite 600	San Diego	California	92121	USA
"3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride"	n/a	9/19/16	Treatment of diffuse large B-cell lymphoma	Designated			N/A	N/A	Celgene Corporation	400 Connell Drive	Suite 7000	Berkeley Heights	New Jersey	7922	USA
"3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-pyrrole-2,5-dione"	n/a	3/29/16	Treatment of glioblastoma	Designated			N/A	N/A	Actuate Therapeutics	1401 Foch Street	Suite 140	Fort Worth	Texas	76107	USA
"3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxyl-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid"	n/a	3/2/10	Treatment of cystic fibrosis	Designated			N/A	N/A	Vertex Pharmaceuticals Inc.	130 Waverly Street		Cambridge	Massachusetts	2139	USA
3-aminopropyl-butyl phosphinic acid	n/a	12/13/16	Treatment of succinic semialdehyde dehydrogenase deficiency.	Designated			N/A	N/A	"Speragen, Inc."	13492 Research Boulevard	Suite 120-475	Austin	Texas	78750	USA
3-bromopyruvate	n/a	3/5/13	Treatment of liver and intrahepatic bile duct cancer	Designated			N/A	N/A	"Primocure Pharma, Inc."	1521 Concord Pike	#303	New Castle	Delaware	19803	USA
3-bromopyruvate	n/a	4/29/14	Treatment of pancreatic cancer	Designated			N/A	N/A	"PreScience Labs, LLC"	9500 Reach Road		Potomac	Maryland	20854	USA
3-chloro-4-fluorophenyl-[4-fluoro-4-[[(5-methylpyrimidin-2-ylmethyl)amino]methyl]piperidin-1yl]methanone	n/a	10/25/13	Treatment of Rett syndrome	Designated			N/A	N/A	"Neurolixis, Inc."	3210 Merryfield Row		San Diego	California	92121	USA
3-fluoro-5-[5-(2-menthyl-thiazol-4-ylethylnyl)-pyridin-2-yl]-benzonitrile dihydrochloride	n/a	7/28/08	Treatment of behavioral abnormalities associated with fragile X syndrome.	Designated			N/A	N/A	Seaside Therapeutics	840 Memorial Drive		Cambridge	Massachusetts	2139	USA
3-pentylbenzenacetic acid sodium salt	n/a	2/11/15	Treatment of idiopathic pulmonary fibrosis.	Designated			N/A	N/A	"ProMetic Life Sciences, Inc."	440 Blvd Armand Frappier	"Laval, Quebec, H7V 4B4"				Canada
3-[2-(4-carbamimidoyl-phenylcarbamoyl)-5-methoxy-4-vinyl-phenyl]-6-(cyclopropylmethyl-carbamoyl)-pyridine-2-carboxylic acid	n/a	12/23/14	Prevention of acute attacks of angioedema in individuals with hereditary angioedema	Designated			N/A	N/A	"BioCryst Pharmaceuticals, Inc."	4505 Emperor Blvd	Suite 200200	Durham	North Carolina	27703	USA
3-[3-(6-guanidino-1-oxoisoindolin-2yl) propanamido]-3-(pyridine-3yl) propanoic acid dihydrochloride	Ocurin	1/17/17	Treatment of retinopathy of prematurity	Designated			N/A	N/A	"Advanced Imaging Projects, LLC"	7947 Brookside Ct.		Lake Worth	Florida	33467	USA
3-[4-(lH-imidazol-l-ylmethyl)phenyl]-5-(2-methylpropyl) thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt	n/a	1/25/17	Treatment of idiopathic pulmonary fibrosis	Designated			N/A	N/A	Vicore Pharma	c/o AstraZeneca	Pepparedsleden 1	Mlndal			Sweden
"3-{3-[4-(1-aminocyclobutyl)phenyl]-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl}cpyridin-2-amine bis-mesylate"	n/a	11/9/15	Treatment of Proteus Syndrome.	Designated			N/A	N/A	"ArQule, Inc."	One Wall Street		Burlington	Massachusetts	1803	USA
"4, 5 dibromorhodamine methyl ester"	Theralux Photodynamic Therapy	10/30/08	Treatment of diffuse large B-cell lymphoma	Designated			N/A	N/A	"Kiadis Pharma Canada, Inc."	2525 Marie Curie					Canada
"4, 5 dibromorhodamine methyl ester"	Theralux Photodynamic Therapy	10/30/08	Treatment of follicular lymphoma	Designated			N/A	N/A	"Kiadis Pharma Canada, Inc."	2525 Marie Curie					Canada
"4,5 dibromorhodamine methyl ester"	Theralux Photodynamic Therapy	10/23/07	For immune reconstitution and prevention of graft versus host disease following allogeneic hematopoietic stem cell transplantation.	Designated			N/A	N/A	Kiadis Pharma Netherlands B.V.	Entrada 231 - 234					Netherlands
"4,5,6,7-tetrachloro-2',4',5',7'-tetraiodofluorescein disodium salt"	n/a	4/18/11	Treatment of hepatocellular carcinoma.	Designated			N/A	N/A	"Provectus Pharmaceuticals, Inc."	7327 Oak Ridge Highway		Knoxville	Tennessee	37931	USA
"4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol"	n/a	9/6/16	Treatment of Angelman syndrome.	Designated			N/A	N/A	Ovid Therapeutics	1460 Broadway		New York	New York	10036	USA
"4,5-dibromorhodamine 123"	Theralux Irradiation Device	4/10/03	Treatment of chronic myelogenous leukemia	Designated/Withdrawn			N/A	N/A	"Kiadis Pharma Canada, Inc."	2525 Marie-Curie	Saint-Laurent (Quebec) H4S 2E1				Canada
"4,6,8-trihydroxy-10-(3,7,11-trimethyldodeca-2,6,10-trienyl)-5,10-dihydrodibenzo b,e][1,4]diazepin-11-one"	n/a	4/27/09	Treatment of malignant glioma.	Designated/Withdrawn			N/A	N/A	"Thallion Pharmaceuticals, Inc."	7150 Alexander-Fleming					Canada
4-(2-fluorophenyl)-6-methyl-2-(1-piperzinyl)	n/a	10/11/06	Treatment of Chronic Functional Vomiting to include functional vomiting and cyclic vomiting syndrome.	Designated			N/A	N/A	"Dynogen Pharmaceuticals, Inc."	52 Second Avenue		Waltham	Massachusetts	2451	USA
4-(3-Methanesulfonyl-phenyl)-1-propylpiperidine HCl	n/a	12/12/05	Treatment of Huntington's disease.	Designated			N/A	N/A	Teva Branded Pharmaceutical Products R&D	41 Moores Road		Frazer	Pennsylvania	19355	USA
4-(4-Methoxy-phenylamino)-6-methylcarbamyl-quinoline-3-carboxylic acid	n/a	3/24/15	Prevention of scarring post ab externo glaucoma surgery	Designated			N/A	N/A	Clanotech AB	"Fogdevreten 2, Solna S-171 65"					Sweden
"4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide"	n/a	3/27/14	Treatment of diffuse large B-cell lymphoma.	Designated			N/A	N/A	AbbVie	Research and Development	1 North Waukegan Road	North Chicago	Illinois	60064	USA
"4-(6-(4-(piperazin-1-yl)phenyl_pyrazolo[1,5-a]pyrimidin-3-yl)quinoline hydrochloride"	n/a	4/15/13	Treatment of fibrodysplasia ossificans progressiva	Designated			N/A	N/A	"La Jolla Pharmaceutical Company, Inc."	"10182 Telesis Court, Suite 600"		San Diego	California	92121	USA
"4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one"	n/a	5/4/15	Treatment of congenital long QT syndrome	Designated			N/A	N/A	"Gilead Sciences, Inc."	333 Lakeside Drive		Foster City	California	94404	USA
"4-amino-1-[(1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl) cyclopent-2-en-1-yl] pyrimidin-2-one"	n/a	9/23/14	Treatment of pancreatic cancer.	Designated			N/A	N/A	"Rexahn Pharmaceuticals, Inc."	15245 Shady Grove Road		Rockville	Maryland	20850	USA
"4-Amino-1-[5-O-[(2R, 4S)-2-oxido-4-(4-pyridinyl)-1, 3, 2-dioxaphosphorinan-2-yl]-b-D-arabinofuranosyl]-2(1H)-pyrimidinone"	n/a	8/22/07	Treatment of hepatocellular carcinoma.	Designated			N/A	N/A	"Ligand Pharmaceuticals, Inc."	11085 N. Torrey Pines Road	Suite 300	LaJolla	California	92037	USA
4-Aminopyridine	n/a	12/14/05	Treatment chronic functional motor and sensory deficits from Guillain-Barre syndrome	Designated			N/A	N/A	"Acorda Therapeutics, Inc."	420 Saw Mill River Road		Ardsley	New York	10502	USA
4-aminosalicylic acid	"Pamisyl (P-D), Rezipas (Squibb)"	12/13/89	Treatment of mild to moderate ulcerative colitis in patients intolerant to sulfasalazine.	Designated			N/A	N/A	"Beeken, Warren M.D."	University Of Vermont	Given C-317	Burlington	Vermont	5405	USA
4-aminosalicylic acid	Paser Granules	4/26/06	Treatment of acute flares in pediatric patients with ileo-cecal Crohn's disease	Designated			N/A	N/A	"Jacobus Pharmaceutical Co., Inc."	37 Cleveland Lane		Princeton	New Jersey	8540	USA
"4-benzyl-2-(a-naphtyl)-1,2,4-thiadiazolidine-3,5-dione"	n/a	10/13/09	Treatment of progressive supranuclear palsy	Designated/Withdrawn			N/A	N/A	"NOSCIRA, S.A."	"Avda. de la Industria, 52"		Madrid			Spain
"4-cholest-en-3-one, oxime"	n/a	12/1/05	Treatment of amyotrophic lateral sclerosis	Designated/Withdrawn			N/A	N/A	Trophos SA	"Parc scientifique de Lumigny, Case 931"	1322 Marseille cedex				France
4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide monohydrochloride	n/a	7/20/06	Treatment of acute myeloid leukemia	Designated			N/A	N/A	"Johnson & Johnson Pharmaceutical Research & Dev,"	920 U S Highway 202	P.O. Box 300	Raritan	New Jersey	8869	USA
"4-Hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl"	n/a	9/29/15	Treatment of cerebral cavernous malformation.	Designated			N/A	N/A	"REcursion Pharmaceuticals, LLC"	383 S. Colorow Drive		Salt Lake City	Utah	84108	USA
4-methylpiperazine-1-carboxylic acid [1-(3-benzenesufonyl-1-phenethylallyl-carbamoyl)-2-phenylethyl] amide	n/a	1/11/17	Treatment of Chagas disease.	Designated			N/A	N/A	Center for Discovery & Innovation in Parasitic Diseases	"University of CA, San Francisco"	9500 Gilman Drive	LaJolla	California	92093	USA
4-pyridinylmethyl 3(4-chlorophenyl)adamantine carboxamide	n/a	11/2/10	Treatment of pancreatic cancer.	Designated			N/A	N/A	Apogee Biotechnology Corporation	Hershey Center for Applied Research	Suite 1016	Hummelstown	Pennsylvania	17036	USA
"4-[(2E)-1-Oxo-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-propen-1-yl]-1-piperazinecarboxamide"	n/a	2/8/16	Treatment of retinitis pigmentosa	Designated			N/A	N/A	"Shire HGT, Inc."	300 Shire Way		Lexington	Massachusetts	2421	USA
"4-[(7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl]benzoic acid, hemifumarate"	n/a	11/18/15	Treatment of patients with Duchenne Muscular Dystrophy.	Designated			N/A	N/A	"ARMGO Pharma, Inc."	777 Old Saw Mill River Road		Tarrytown	New York	10591	USA
4-[131I]iodo-L-phenylalanine	n/a	1/4/11	Treatment of glioma.	Designated			N/A	N/A	Therapeia GmbH & Co KG	Veilchenweg 38	D-01326 Dresden				Germany
"4-[1]benzofuro[3,2-d]pyrimidin-4-yl-N-(1,3-benzodioxol-5-ylmethyl)piperazine-1-carbothioamide"	n/a	7/30/08	"Treatment, in combination with radiotherapy and temozolomide chemotherapy, of patients with glioblastoma multiforme."	Designated			N/A	N/A	"SuperGen, Inc."	4140 Dublin Blvd		Dublin	California	94568	USA
"4-[2-(3-Propyl-[1,2,4]0xadiazol-5-yl)-vinyl]-benzene-1,2-diol"	n/a	10/4/11	Treatment of chronic myeloid leukemia	Designated			N/A	N/A	Piramal Enterprises Limited	1 Nirlon Complex	"Goregaon (East) 400063, Maharashtra"	Mumbai			India
"4-[4-[[[[3-(1,1-dimethylethyl)-1-(6-quinolinyl)-1H-pyrazol-5-yl]amino]carbonyl]-amino]-3-fluorophenoxyl]-N-methyl-2-pyridinecarboxamide, p-toluenesulfonate salt"	n/a	9/3/09	Treatment of Philadelphia chromosome positive chronic myeloid leukemia	Designated			N/A	N/A	"Deciphera Pharmaceuticals, LLC"	643 Massachusetts	Suite 200	Lawrence	Kansas	66044	USA
"4-[[9-(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol"	n/a	9/23/11	Treatment of idiopathic pulmonary fibrosis	Designated			N/A	N/A	Celgene Corporation	33 Technology Drive		Warren	New Jersey	7059	USA
4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]-methyl] tetrahydro-N-hydroxy-2H-pyran-4-carboxamide	n/a	6/18/08	Prophylaxis of organ rejection in patients receiving allogeneic liver transplants	Designated/Withdrawn			N/A	N/A	"Conatus Pharmaceuticals, Inc."	4365 Executive Drive		San Diego	California	92121	USA
"4-{[(2R,3S,4R,5S)-4-(4-Chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid"	n/a	5/19/14	Treatment of Acute Myeloid Leukemia	Designated			N/A	N/A	Roche Genentech	F. Hoffmann-La Roche Ltd.	430 East 29th Street	New York	New York	10016	USA
40K PEGylated recombinant factor IX	n/a	3/18/13	Routine prophylactic administration for prevention of bleeding in patients with hemophilia B (Christmas disease)	Designated			N/A	N/A	"Novo Nordisk, Inc."	100 College Road West		Princeton		8540	USA
5'-CTATCTGUC*G1TTCTCTGU-3'.17 Na+	n/a	3/31/15	Treatment of diffuse large B-cell lymphoma.	Designated			N/A	N/A	"Idera Pharmaceuticals, Inc."	167 Sidney Street		Cambridge	Massachusetts	2139	USA
5'-GCCATGGTTTTTTCTCAGG-3'	n/a	10/31/12	Prophylaxis for patients following documented or suspected exposure to ebolavirus	Designated			N/A	N/A	"Sarepta Therapeutics, Inc."	215 First Street	Suite 415	Cambridge	Massachusetts	2142	USA
"5'-O-(trans-9""-octadecenoyl)-1-beta-D-2'deoxy-2',2'-difluorocytidine"	n/a	12/7/09	Treatment of pancreatic cancer	Designated/Withdrawn			N/A	N/A	"Clovis Oncology, Inc."	5500 Flatiron Parkway	Suite 100	Boulder	Colorado	80301	USA
5(S)-(2'-hydroxy ethoxy)-20(S)-Camptothecin	n/a	6/15/07	Treatment of osteosarcoma (bone cancer)	Designated			N/A	N/A	"Dr. Reddy's Laboratories, Inc."	200 Somerset Corporate Blvd	"Building II, 7th Floor"	Bridgewater	New Jersey	8807	USA
"5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(phenylmethyl)-a-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S,10S)- (9CI)"	n/a	10/11/06	Treatment of malignant gliomas	Designated/Withdrawn			N/A	N/A	"Reata Pharmaceuticals, Inc."	1950 N. Stemmons Freeway		Dallas	Texas	75207	USA
"5,5',5""-[Phosphinothioylidyne-tris(imino-2,1-ethanediyl)]tris[5-methylchelidoninium]trihydroide hexahydrochloride"	n/a	8/20/03	Treatment of pancreatic cancer	Designated			N/A	N/A	Now Pharm AG	"241, route d'Arlon"	L-1150				
"5,6-dihydro-5-azacytidine"	n/a	5/11/92	Treatment of malignant mesothelioma.	Designated			N/A	N/A	"ILEX Oncology, Inc."	4545 Horizon Hill Blvd.		San Antonio	Texas	78229	USA
"5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline hydrochloride"	n/a	9/4/14	Treatment of Huntington's disease	Designated			N/A	N/A	Prana Biotechnology Limited	"Level 2, 369 Royal Parade"	Parkville	Victoria 3052			Australia
"5,7-dihydroxy-3-(4-hydroxyphenyl)-chromen-4-one"	n/a	6/18/07	Prevention of acute radiation syndrome	Designated			N/A	N/A	Humanetics Corporation	1550 Utica Avenue South	Suite 770	Eden Prairie	Minnesota	55416	USA
"5-((4-(6-chlorothieno[2,3-d]pyrimidine-4-ylamino)piperidin-1-yl)methyl)-2-fluorobenzonitrile monofumurate"	n/a	10/21/10	Treatment of pulmonary arterial hypertension	Designated/Withdrawn			N/A	N/A	"Forest Laboratories, Inc."	Harborside Financial Center	Plaza V	Jersey City	New Jersey	7311	USA
"5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride"	n/a	4/18/11	Treatment of progressive supranuclear palsy.	Designated			N/A	N/A	"Mithridion, Inc."	505 Science Drive		Madison	Wisconsin	53711	USA
"5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)-pyridin-2-amine"	n/a	11/21/16	Treatment of primary central nervous system lymphoma.	Designated			N/A	N/A	PIQUR Therapeutics AG	Hochbergerstrasse 60C	CH-4057 Basel				Switzerland
"5-(4-Cyclopropyl-1H-imidazol-l-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide"	n/a	1/15/15	Treatment pulmonary arterial hypertension	Designated			N/A	N/A	"Gilead Sciences, Inc."	333 Lakeside Drive		Foster City	California	94404	USA
5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzp[d]oxazole	n/a	11/22/11	Treatment of Duchenne Muscular Dystrophy	Designated			N/A	N/A	Summit Corporation plc	91 Milton Park	Oxfordshire OX14 4RY				United Kingdom
5-aminolevulinic acid	Gliolan	1/15/13	Visualization of malignant tissue during surgery for malignant glioma (WHO garde III and IV)	Designated			N/A	N/A	NX Development Corporation	1827 South Bayshore Lane		Miami	Florida	33133	USA
5-aza-2'-deoxycytidine	n/a	8/3/87	Treatment of acute leukemia.	Designated			N/A	N/A	"SuperGen, Inc."	4140 Dublin Blvd.	Suite 200	Dublin	California	94568	USA
5-hydroxymethyl-2-furfuraldehyde	n/a	5/26/06	Treatment of sickle cell disease	Designated			N/A	N/A	"Baxalta US, Inc."	ONe Baxter Way		Westlake Village	California	91362	USA
5-imino-13-deoxydoxorubicin HCl	n/a	12/31/15	Treatment of soft tissue sarcoma	Designated			N/A	N/A	"Gem Pharmaceuticals, LLC"	941 Lake Forest Circle		Birmingham	Alabama	35244	USA
5-iodo-2-pytimidinone-2'-deoxyribose	n/a	5/26/06	Treatment of malginant glioma	Designated			N/A	N/A	"Hana Biosciences, Inc."	7000 Shoreline Court	Suite 370	South San Francisco	California	94080	USA
"5-[(E)-2-(4-hydroxyphenyl)-ethenyl] benzene-1,3 diol"	Resveratrol	3/13/08	Treatment of MELAS syndrome	Designated			N/A	N/A	"Sirtris Pharmaceuticals, Inc."	200 Technology Square		Cambridge	Massachusetts	2139	USA
"5-[1-(2,6-Dichlorobenzyl)-piperidin-4-yl]methoxyquinazoline-2,4-diamine"	n/a	8/25/09	Treatment of spinal muscular atrophy	Designated			N/A	N/A	CureSMA	925 Busse Avenue		Elk Grove Village	Illinois	60007	USA
5-[8-methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6yl]-2-pyrimidinamine	n/a	2/10/15	Treatment of malignant mesothelioma	Designated/Withdrawn			N/A	N/A	"Verastem, Inc."	117 Kendrick Street	Suite 500	Needham	Massachusetts	2494	USA
"5-{[(3R,4R)-1-(4-chloro-2,6-difluorophenyl)-3,4-dihydroxypiperidin-4-yl]methoxy}-8-fluoro-3,4-dihydroquinolin-2(1H)-one"	n/a	12/5/16	Treatment of active tuberculosis	Designated			N/A	N/A	"Otsuka Pharmaceutical Company, Ltd"	2440 Research Blvd		Rockville	Maryland	20850	USA
"5a8, monoclonal antibody to CD4"	n/a	12/20/93	For use in post-exposure prophylaxis for occupational exposure to human immunodeficiency virus.	Designated/Withdrawn			N/A	N/A	"Biogen, Inc."	14 Cambridge Center		Cambridge	Massachusetts	2142	USA
"5""-GAATATTAACAIACTGACAAGTC-3"""	n/a	10/31/12	Prophylaxis following documented or suspected exposure to marburg virus	Designated			N/A	N/A	"Sarepta Therapeutics, Inc."	215 First Street	Suite 415	Cambridge	Massachusetts	2142	USA
"6'-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)- paromamine sulfate"	n/a	11/3/16	Treatment of Rett syndrome	Designated			N/A	N/A	"Eloxx Pharmaceuticals, Ltd."	Weizmann Science Park	7 Golda Meir Street	Ness Ziona			Israel
"6,8-bis-benzylsulfanyl-octanoic acid"	n/a	2/6/06	Treatment of pancreatic cancer	Designated			N/A	N/A	"Cornerstone Pharmaceuticals, Inc."	25 Health Science Drive		Stony Brook	New York	11790	USA
"6,8-bis-benzylsulfanyl-octanoic acid"	n/a	9/26/13	Treatment of myelodysplastic syndrome	Designated			N/A	N/A	"Cornerstone Pharmaceuticals, Inc."	25 Health Science Drive		Stony Brook	New Mexico	11790	USA
"6,8-bis-benzylsulfanyl-octanoic acid"	n/a	8/22/11	Treatment of acute myeloid leukemia.	Designated			N/A	N/A	"Cornerstone Pharmaceuticals, Inc."	25 Health Science Drive		Stony Brook	New Mexico	11790	USA
"6-((3S,4S)-4-Methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl-1-(tetrahydro-pyran-4-yl)-1,5-dihydro-pryazolo[3,4-d]pyrimidin-4-one"	n/a	9/4/14	Treatment of sickle cell disease	Designated			N/A	N/A	"Pfizer, Inc."	500 Arcola Road		Collegeville	Pennsylvania	19426	USA
"6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo-[1,2-alpha]pyrazin-8-amine bis-methanesulfonate"	n/a	4/14/14	Treatment of chronic lymphocytic leukemia	Designated			N/A	N/A	"Gilead Sciences, Inc."	333 Lakeside Drive		Foster City	California	94404	USA
"6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo[b][1,4]oxazin-3(4H)-one hydrochloride"	n/a	11/9/16	Treatment of pulmonary arterial hypertension (WHO Group 1)	Designated			N/A	N/A	"Reviva Pharmaceuticals, Inc."	3900 Freedom Circle	Suite 101	Santa Clara	California	95054	USA
"6-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)- paromamine sulfate"	n/a	10/18/16	Treatment of mucopolysaccharidosis type 1 (MPS I)	Designated			N/A	N/A	"Eloxx Pharmaceuticals, Ltd."	Weizmann Science Park	7 Golda Meir Street	Ness Ziona			Israel
6-alpha-ethylchenodeoxycholic acid	n/a	4/9/08	Treatment of primary sclerosing cholangitis	Designated			N/A	N/A	"Intercept Pharmaceuticals, Inc."	18 Desbrosses Street		New York	New York	10013	USA
6-amino-5-chloro-N-[1R)-1-[5-[[[5-hloro-4-(trifluoromethyl)-2pyridinyl]amino]carbonyl]-2-thiazoyl]ethyl]-4-pyrimdinecarboxamide	n/a	10/15/13	Treatment of stage IIb-IV melanoma	Designated			N/A	N/A	"Millennium Pharmaceuticals, Inc."	40 Landsdowne Street		Cambridge	Massachusetts	2139	USA
"6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-bensoxazin-4-one"	n/a	6/18/15	Treatment of Netherton syndrome	Designated			N/A	N/A	Sixera Pharma AB	Erik Dahlbergsgaten 11a2t	Vastra Gotaland 41126				Sweden
"6-fluoro-(18F)-L-3,4-dihydroxyphenylalanine"	n/a	9/7/16	A diagnostic for management of patients with Lesch-Nyhan syndrome	Designated			N/A	N/A	"Advanced Imaging Projects, LLC"	7947 Brookside Ct.		Lake Worth	Florida	33467	USA
6-hydroxymethylacylfulvene	n/a	4/6/99	Treatment of histologically confirmed advanced or metastatic pancreatic cancer.	Designated/Withdrawn			N/A	N/A	"Eisai, Inc."	300 Tice Blvd		Woodcliff Lake	New Jersey	7677	USA
6-mercaptopurine oral liquid	n/a	12/7/09	Treatment of acute lymphoblastic leukemia in the pediatric population	Designated			N/A	N/A	Orbona Pharma Ltd	Old Chambers	"Farnham, England"	Surrey			United Kingdom
"6-methoxy-3-(3',4',5'-trimethoxybenzoyl) indole"	n/a	5/11/16	Treatment of cholangiocarcinoma	Designated			N/A	N/A	SynCore Biotechnology Co. Ltd.	"4F, 69 Dongxing Road"	XinYi Dist				Taiwan
"6-[(3S,4S-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imadazo[1,5-a]pyrazin-8-one"	n/a	1/31/17	Treatment of sickle cell disease (SCD)	Designated			N/A	N/A	Imara Inc.	700 Technology Square	3rd Floor	Cambridge	Massachusetts	2139	USA
"6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glycero-B-L-manno-heptopyranosyl]amino-9H-purine"	n/a	6/12/14	Treatment of multiple myeloma	Designated			N/A	N/A	"DARA BioSciences, Inc."	8601 Six Forks Road	Suite 160	Raleigh	North Carolina	27615	USA
"6-{4-[l-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide"	n/a	2/11/16	Treatment of glioblastoma multiforme (GBM).	Designated			N/A	N/A	"Upsher-Smith Laboratories, Inc."	6701 Evenstad Drive		Maple Grove	Minnesota	55369	USA
"6-{[(1S)-1-phenylethyl]amino}-3-(propan-2-yl)-1,2,3,4 tetrahydropyrimidine-2,4-dione"	n/a	4/27/16	Treatment of symptomatic obstructive hypertrophic cardiomyopathy	Designated			N/A	N/A	"MyoKardia, Inc."	333 Allerton Avenue		South San Francisco	California	94080	USA
"68G-OPS202, small somatostatin analog labeled with 68Gallium"	n/a	9/24/14	Management of gastroenteropancreatic neuroendocrine tumors.	Designated			N/A	N/A	"Ipsen Biosciences, Inc."	650 East Kendall Street		Cambridge	Massachusetts	2142	USA
7-B-Hydroxy Cholesteryl-3-B-Oleate-Ester	n/a	6/15/11	Treatment of gliomas.	Designated			N/A	N/A	Intsel Chimos SA	1 rue Royale	91123 Saint-Cloud Cedex				France
"7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one*2HCl"	n/a	6/23/16	Treatment of glioblastoma.	Designated			N/A	N/A	"Oncoceutics, Inc."	3624 Market Street	Suite 5E	Philadelphia	Pennsylvania	19104	USA
7-ethyl-10-hydroxycamptothecin (EHC)	n/a	4/13/16	Treatment of small cell lung cancer.	Designated			N/A	N/A	"Nippon Kayaku Co., Ltd."	"1-1, Marunouchi 2-chome"		Chiyoda			Japan
"8 Cyclopentyl 1,3-dipropylxanthine"	n/a	3/24/97	Treatment of cystic fibrosis.	Designated/Withdrawn			N/A	N/A	"SciClone Pharmaceuticals, Inc."	901 Mariner's Island Boulevard		San Mateo	California	94404	USA
8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo[c]chromen-6-one	n/a	1/21/15	Treatment of glioblastoma multiforme	Designated			N/A	N/A	"Diffusion Pharmaceuticals, Inc."	2020 Avon Court	Suite 4	Charlottesville	Virginia	22902	USA
8-methoxsalen	Uvadex	6/22/93	For use in conjunction with the UVAR photopheresis to treat diffuse systemic sclerosis.	Designated			N/A	N/A	"Therakos, Inc."	Oaklands Corporate Center	437 Creamery Way	Exton	Pennsylvania	19341	USA
"8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naph-thyrin-3(2H)-one mono-hydrochloride"	n/a	9/3/09	Treatment of ovarian cancer.	Designated			N/A	N/A	Merck Sharp & Dohme Corp.	P. O. Box 1000	UG-2C50	North Wales	Pennsylvania	19454	USA
"9,10-dimethoxy-5,6-dihydro-[1,3] dioxolo[4,5-g]isoquinolino[3,2-alpha]isoquinolin-7-ium(R)-4-((3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyhexadecahydro-1H-cyclopenta[alpha]"	n/a	8/29/16	Treatment of primary sclerosing cholangitis	Designated			N/A	N/A	HighTide Biopharma Pty. Ltd.	1 Melissa Street		Mount Waverley			Australia
"9-cis, 12-cis-11,11-d2-linoleic acid ethyl ester"	n/a	5/23/16	Treatment of Friedreich's Ataxia	Designated			N/A	N/A	"Retroitope, Inc."	4300 El Camino Real	Suite 201	Los Altos	California	94022	USA
9-cis-retinoic acid	n/a	1/2/97	Prevention of retinal detachment due to proliferative vitreoretinopathy.	Designated/Withdrawn			N/A	N/A	"Allergan, Inc."	2525 Dupont Drive	P.O. Box 19534	Irvine	California	92623	USA
9-nitro-20-(S)-camptothecin	Camvirex	5/15/01	Treatment of pediatric HIV infection/AIDS	Designated			N/A	N/A	"NovoMed Pharmaceuticals, Inc."	P.O. Box 900		Germantown	Maryland	20875	USA
9-nitro-20-(S)-camptothecin	n/a	9/16/96	Treatment of pancreatic cancer.	Designated			N/A	N/A	"SuperGen, Inc."	"Two Annabel Lane, Suite 220"		San Ramon	California	94583	USA
90Y-DOTA-tyr3-Octreotide	n/a	1/20/16	Treatment of neuroendocrine tumors	Designated			N/A	N/A	"M. Sue O'Dorisio, MD, PhD"	"2519 JPP, 200 Hawkins Drive"		Iowa City	Iowa	52242	USA
90Y-hPAMA4	Pan-Cide	1/29/04	Treatment of pancreatic cancer	Designated/Withdrawn			N/A	N/A	"Immunomedics, Inc."	300 American Road		Morris Plains	New Jersey	7950	USA
a live attenuated bioengineered Listeria monocytogenes cancer immunotherapy	n/a	4/29/14	Treatment of Stage II to IV invasive cervical carcinoma	Designated			N/A	N/A	"Advaxis, Inc."	305 College Road East		Princeton	New Jersey	8540	USA
A-dmDT390-bisFv(UCHT1)	Resimmune	10/9/14	Treatment of cutaneous T-cell lymphoma	Designated			N/A	N/A	"Angimmune, LLC"	American Red Cross Holland Laboratory	15601 Crabbs Branch Way	Rockville	Maryland	20855	USA
a-Galactosidase A	Plant-Produced Human A-Glactosidase A	1/21/03	Treatment of Fabry's disease	Designated			N/A	N/A	"iBio, Inc."	9 Innovation Way	Suite 100	Newark	Delaware	19711	USA
A10 & AS2-1 Antineoplaston	n/a	9/3/04	Treatment for patients with brain stem glioma	Designated			N/A	N/A	"Burzynski Research Institute, Inc."	9432 Old Katy Road		Houston	Texas	77055	USA
"aadeno-associated viral vector, serotype 2, containing the human choroideremia gene encoding human Rab escort protein 1"	n/a	9/12/13	Treatment of choroideremia due to mutations in the human choroideremia gene (CHM)	Designated			N/A	N/A	"Sparks Therapeutics, Inc."	3737 Market Street	Suite 1300	Philadelphia	Pennsylvania	19104	USA
AAV-G6Pase vector	n/a	3/11/13	Treatment of glycogen storage disease type Ia	Designated			N/A	N/A	"GlyGenix Therapeutics, Inc."	15 Research Drive		Woodbridge	Connecticut	6443	USA
abagovomab	n/a	11/25/03	Treatment of epithelial ovarian cancer	Designated/Withdrawn			N/A	N/A	Menarini Ricerche S.p.A.	Via Tito Speri 10	Pomezia Roma				Italy
abatacept	Orencia	5/30/13	Treatment of type 1 diabetes mellitus patients with residual beta cell function	Designated			N/A	N/A	Orban Biotech LLC	64 Aspinwall Avenue		Brookline	Massachusetts	2446	USA
ABCA4 DNA nanoparticles	n/a	10/28/15	Treatment of Stargardt Macular Degeneration	Designated			N/A	N/A	"Copernicus Therapeutics, Inc."	11000 Cedar Avenue		Cleveland	Ohio	44106	USA
abeotaxane inhibitor of microtubules	n/a	4/18/11	Treatment of pediatric neuroblastoma.	Designated			N/A	N/A	Cortice Biosciences	50 W 57th Street	15th Floor	New York	New York	10019	USA
abeotaxane inhibitor of microtubules	n/a	10/7/11	Treatment of gliomas	Designated			N/A	N/A	Cortice Biosciences	50 W 57th Street	15th Floor	New York	New York	10019	USA
Abetimus	n/a	7/28/00	Treatment of lupus nephritis.	Designated			N/A	N/A	La Jolla Pharmaceutical Co.	6455 Nancy Ridge Dr.		San Diego	California	92121	USA
Ac-Ile-Cys-Val-Trp(1-Me)-Gln-Asp-Trp-Gly-Ala-His-Arg-Cys-Thr-AEEA-Lys-PEG 40KDa-Lys-AEEA-Thr-Cys-Arg-His-ALa-Gly-Trp-Asp-Gln-(1-Me)Trp-Val-Cys-Ile-Ac	n/a	4/20/14	Treatment of paroxysmal nocturnal hemoglobinuria	Designated			N/A	N/A	"Apellis Pharmaceuticals, Inc."	6400 Westwind Way	Suite A	Crestwood	Kentucky	40014	USA
acadesine	n/a	5/4/11	Treatment of multiple myeloma	Designated			N/A	N/A	Advancell-Advanced In Vitro Cell Technologies S.A.	"Via Augusta 59, 3rd floor, door 313"		Barcelona			Spain
acadesine	n/a	3/3/11	Treatment of chronic lymphocytic leukemia	Designated			N/A	N/A	"Avanced In Vitro Cell Technologies, S.L."	(Advancell)	08028 Barcelona				Spain
acamprosate	n/a	3/25/13	Treatment of fragile X syndrome	Designated			N/A	N/A	"Confluence Pharmaceuticals, LLC"	Box 528	351 West 10th Street	Indianapolis	Indiana	46202	USA
aceneuramic acid	n/a	9/23/11	Treatment of hereditary inclusion body myopathy	Designated			N/A	N/A	"Ultragenyx Pharmaceutical, Inc."	60 Leveroni Court	Suite 200	Novato	California	94949	USA
acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-cysteinyl-D-glutaminyl-D-cystenyl-D-arginyl-D-arginyl-D-lysyl-D-asparaginylmaide disulfide	n/a	11/24/15	Treatment of acute myeloid leukemia.	Designated			N/A	N/A	"Genus Oncology, LLC"	2458 N. Racine Avenue		Chicago	Illinois	60614	USA
acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-cysteinyl-D-glutaminyl-D-cysteinyl-D-arginyl-D-arginyl-D-lysyl-Dasparaginylamide disulfide	n/a	2/18/11	Treatment of pancreatic cancer.	Designated/Withdrawn			N/A	N/A	"Genus Oncology, LLC"	2458 N. Racine Avenue		Chicago	Illinois	60614	USA
acetyl-l-carnitine	n/a	7/24/12	Treatment of Fragile X syndrome	Designated			N/A	N/A	Sigma Tau Industrie Farmaceutiche Riunite S.p.A.	Via Pontina	km 30.400 - 00071	Rome			Italy
acetyl-l-carnitine (ALC)	n/a	3/18/11	Treatment of Rett syndrome	Designated			N/A	N/A	Sigma Tau Industrie Farmaceutiche Riunite S.p.A.	Via Pontina	km 30.400 - 00071	Rome			Italy
Acetylcysteine	Mucomyst/Mucomyst 10 Iv	8/13/87	Intravenous treatment of patients presenting with moderate to severe acetaminophen overdose.	Designated			N/A	N/A	Bristol-Myers Squibb Company	P.O. Box 4500		Princeton	New Jersey	8543	USA
acetylcysteine	Acetadote	10/19/01	For the intravenous treatment of moderate to severe acetaminophen overdose	Designated/Approved	Approved for Orphan Indication	"For the use of Acetadote(registered TM) Injection, administered intravenously within 8 to 10 hours after ingestion of a potentially heptotoxic quantity of acetaminophen, to prevent or lessen hepatic injur"	01/23/2004	01/23/2011	"Cumberland Pharmaceuticals, Inc."	209 10th Street South	Suite 332	Nashville	Tennessee	37203	USA
acetylcysteine effervescent tablets for oral solution	Cetylev	2/24/15	Preventing hepatic injury from acetaminophin overdose	Designated/Approved	Approved for Orphan Indication	Indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion	01/29/2016	N/A	"Arbor Pharmaceuticals, Inc."	6 Concourse Parkway	Suite 1800	Atlanta	Georgia	30328	USA
Aconiazide	n/a	6/20/88	Treatment of tuberculosis.	Designated/Withdrawn			N/A	N/A	Lincoln Diagnostics	P.O. Box 1128		Decatur	Illinois	62525	USA
ActRIIB-IgG1)	n/a	8/16/10	Treatment of Duchenne muscular dystrophy	Designated			N/A	N/A	"Acceleron Pharma, Inc."	128 Sidney St.		Cambridge	Massachusetts	2139	USA
acyclovir	n/a	9/16/10	Treatment of herpetic keratitis	Designated/Withdrawn			N/A	N/A	GlaxoSmithKline	One Franklin Plaza		Philadelphia	Pennsylvania	19101	USA
acyclovir	n/a	5/3/16	Treatment of herpetic keratitis.	Designated			N/A	N/A	Cumulus Pharmaceuticals LLC	1712 Pioneer Avenue	Suite 1377	Cheyenne	Wyoming	82001	USA
acyclovir	n/a	12/13/10	Treatment of acute herpetic keratitis caused by Herpes Simplex Virus type 1 and 2	Designated			N/A	N/A	Fera Pharmaceuticals	134 Birch Hill Road		Locust Valley	New York	11560	USA
Ad5/3-D24-granulocyte-macrophage colony stimulating factor (GMCSF)-encoding oncolytic adenovirus	n/a	3/17/14	Treatment of ovarian cancer	Designated			N/A	N/A	Oncos Therapeutics	Saukonpaadenranta 2		Helsinki			Finland
adalimumab	Humira	3/21/05	Treatment of juvenile rheumatoid arthritis	Designated/Approved	Approved for Orphan Indication	Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older.	02/21/2008	02/21/2015	AbbVie Inc.	1 North Waukegan Road		North Chicago	Illinois	60064	USA
adalimumab	Humira	10/19/06	Treatment of pediatric Crohn's disease.	Designated/Approved	Approved for Orphan Indication	"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate. (Orphan approval for patients from 6 through 16 years of age.)"	09/23/2014	09/23/2021	"AbbVie, Inc."	1 N. Waukegan Road	"Bldg AP30, Dept. PA77"	North Chicago	Illinois	60064	USA
adalimumab	Humira	3/21/05	Treatment of juvenile rheumatoid arthritis	Designated/Approved	Approved for Orphan Indication	Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years to 4 years of age.	09/30/2014	09/30/2021	AbbVie Inc.	1 North Waukegan Road		North Chicago	Illinois	60064	USA
adalimumab	Humira	5/11/11	Treatment of pediatric patients with ulcerative colitis	Designated			N/A	N/A	"AbbVie, Inc."	1 N. Waukegan Road		North Chicago	Illinois	60064	USA
adalimumab	n/a	7/10/14	Treatment of Behcet's disease	Designated			N/A	N/A	Mucora	32b Eisenberg St	Rehovot 7628810				Israel
adalimumab	Humira	5/13/14	"Treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis"	Designated/Approved	Approved for Orphan Indication	"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients"	06/30/2016	06/30/2023	"AbbVie, Inc."	1 North Waukegan Road		North Chicago	Illinois	60064	USA
adalimumab	Humira	5/13/15	Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)	Designated/Approved	Approved for Orphan Indication	Treatment of moderate to severe hidradenitis suppurativa	09/09/2015	09/09/2022	"AbbVie, Inc."	1 North Waukegan Road		North Chicago	Illinois	60064	USA
aden-associated virus vector serotype 9 expressing human a-L-iduronidase	n/a	9/29/15	Treatment of mucopolysaccharidosis Type I (MSP I).	Designated			N/A	N/A	"REGENXBIO, Inc."	9712 Medical Center Drive	Suite 100	Rockville	Maryland	20850	USA
adeno associated viral vector containing human ARSB gene	n/a	3/17/11	Treatment of mucopolysaccharidosis type VI (MPS VI; Maroteaux-Lamy syndrome)	Designated			N/A	N/A	Fondazione Telethon	Via Varese 16 - 00185 Roma					Italy
adeno associated viral vector serotype rh.10 carrying the human SGSH and SUMF1 cDNAs	n/a	5/6/13	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo type A syndrome)	Designated			N/A	N/A	Lysogene	52 rue La Boetie		Paris			France
adeno associated virus with modified transthyretin and sequence encoding factor IX variant gene	n/a	3/14/14	Treatment of hemophilia B	Designated			N/A	N/A	"Baxalta US, Inc."	One Baxter Way		Westlake Village	California	91362	USA
Adeno-associated vector expressing the human lipoprotein lipase protein	n/a	5/21/07	Treatment of lipoprotein lipase deficiency	Designated			N/A	N/A	uniQure B.V.	Meibergdreef 61	1100 DA	Amsterdam			Netherlands
adeno-associated viral (AAV) vector serotype rh. 10 encoding the human N-sulfoglycosamine sulphohydrolase cDNA (SGSH)	n/a	11/18/15	Treatment of mucopolysaccharidosis type IIIA or Sanfilippo type A syndrome	Designated			N/A	N/A	LYSOGENE	20 Rue Jacques Dulud		Neuilly-sur-Seine			France
adeno-associated viral serotype 2 vector under the regulatory control of a CMV promoter encoding the human tripeptidyl peptidase-1 (hTPP1) cDNA	n/a	3/16/16	Treatment of CLN2 disease (neuronal ceroid lipofuscinosis (NCL)) caused by TPP1 deficiency.	Designated			N/A	N/A	"Spark Therapeutics, Inc."	3737 Market Street	Suite 1300	Philadelphia	Pennsylvania	19104	USA
adeno-associated viral vector composed of a bioengineered AAV capsid and a codon-optimized expression cassette encoding a high-specific activity variant of human coagulation factor IX	n/a	9/21/15	Treatment of hemophilia B.	Designated			N/A	N/A	"Spark Therapeutics, Inc."	3737 Market Street	Suite 1300	Philadelphia	Pennsylvania	19104	USA
adeno-associated viral vector containing DNA encoding an RNAi targeting rhodopsin in combination with an adeno-associated viral vector containing DNA encoding a rhodopsin gene	n/a	12/13/12	treatment of retinitis pigmentosa	Designated			N/A	N/A	Genable Technologies Limited	Smurfit Institute of Genetics	Trinity College	Dublin 2			Ireland
adeno-associated viral vector containing modified U11 snRNA	n/a	9/15/10	Treatment of Duchenne muscular dystrophy.	Designated			N/A	N/A	uniQure B.V.	Meibergdreef 61	1100 DA	Amsterdam			Netherlands
Adeno-associated viral vector containing the gene for human coagulation factor IX	Coagulin-B	6/13/01	Intrahepatic treatment of patients with moderate to severe hemophilia	Designated			N/A	N/A	"Avigen, Inc."	1301 Harbor Bay Parkway		Alameda	California	94502	USA
Adeno-associated viral vector containing the gene for human coagulation factor IX	Coagulin-B	6/13/01	Intramuscular treatment of patients with moderate to severe hemophilia	Designated			N/A	N/A	"Avigen, Inc."	1301 Harbor Bay Parkway		Alameda	California	94502	USA
adeno-associated viral vector containing the human NADH Dehydrogenase 4 Gene	n/a	11/20/13	Treatment of Leber Hereditary Optic Neuropathy	Designated			N/A	N/A	Gen Sight Biologics						
Adeno-associated viral vector differentially expressing microdystrophin 5 gene via the muscle-specific promoter CK8.	n/a	8/31/16	Treatment of Duchenne muscular dystrophy.	Designated			N/A	N/A	"Solid GT, LLC"	161 First Street	Suite 3A	Cambridge	Massachusetts	2142	USA
Adeno-associated viral vector expressing human acid alpha glucosidase gene	n/a	3/20/07	Treatment of Pompe disease	Designated			N/A	N/A	"Audentes Therapeutics, Inc."	"101 Montgomery St., #2650"		San Francisco	California	94104	USA
adeno-associated viral vector expressing human retinoschisin-1 gene	n/a	5/21/07	Treatment of X-linked juvenile retinoschisis (XLRS).	Designated			N/A	N/A	Applied Genetic Technologies Corporation	11801 Research Drive		Alachua	Florida	32615	USA
Adeno-Associated Viral Vector Expressing Low-Density Lipoprotein Receptor	n/a	1/31/12	Treatment of homozygous familial hypercholesterolemia	Designated			N/A	N/A	ReGenX Biosciences LLC	"750 17th Street, NW"	Suite 1100	Washington	District of Columbia	20006	USA
adeno-associated viral vector expressing the human vascular endothelial growth factor gene	n/a	12/31/15	"Treatment of critical limb ischemia in no-option patients where other procedures, grafts, or angioplasty are not indicated"	Designated			N/A	N/A	"Integene International Holding, LLC"	1951 NW 7th Avenue	Suite 300	Miami	Florida	33136	USA
adeno-associated viral vector serotype 2 containing the human Rab escort protein 1 gene	n/a	11/5/14	Treatment of choroideremia	Designated			N/A	N/A	NightstaRx Ltd.	215 Euston Road	NW1 2BE	London			United Kingdom
adeno-associated viral vector serotype 2.7m8 containing the chrimsonR-tdTomato gene	n/a	1/25/17	Treatment of retinitis pigmentosa	Designated			N/A	N/A	GenSight Biologics	74 Rue du Faubourg Saint-Antoine		Paris			France
Adeno-associated viral vector serotype 5 containing human ABCA4 gene	n/a	9/30/08	Treatment of Stargardt's disease.	Designated/Withdrawn			N/A	N/A	Fondazione Telethon	Via Varese 16 - 00185 Roma					Italy
adeno-associated viral vector serotype 9 containing human N-acetylglucosaminidase alpha gene	n/a	12/27/12	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome)	Designated			N/A	N/A	"Laboratorios del Dr. Esteve, S.A."	"Av. Marie de Deu de Montserrat, 221"		Barcelona			Spain
adeno-associated viral vector serotype 9 containing the human cardiac calsequestrin gene	Calmarythm	10/2/14	Treatment of catecholaminergic polymorphic ventricular tachycardia	Designated			N/A	N/A	"Audentes Therapeutics, Inc."	"101 Montgomery St., #2650"		San Francisco	California	94104	USA
adeno-associated viral vector type 2 expressing human recombinant retinal pigment epithelial 65KDa protein gene	n/a	3/18/15	Treatment of inherited retinal dystrophy due to biallelic RPE65 gene mutations	Designated			N/A	N/A	"Spark Therapeutics, Inc."	3737 Market Street	Suite 1300	Philadelphia	Pennsylvania	19104	USA
Adeno-associated viral-based vector cystic fibrosis gene therapy	n/a	2/15/95	Treatment of cystic fibrosis.	Designated/Withdrawn			N/A	N/A	Targeted Genetics Corporation	"1100 Olive Way, Suite 100"		Seattle	Washington	98101	USA
adeno-associated virus (AAV) serotype rh.10 expressing beta-galactosidase	n/a	1/30/17	Treatment of GM1 gangliosidosis	Designated			N/A	N/A	"Lysogene, Inc."	245 First Street	18th Floor	Cambridge	Massachusetts	2142	USA
Adeno-associated virus delivered transgene of follistatin	n/a	9/19/16	Treatment of inclusion body myositis	Designated			N/A	N/A	Milo Biotechnology	2322 Delaware Drive		Cleveland Heights	Ohio	44106	USA
Adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and human factor 9 gene (SB-FIX)	n/a	9/1/16	Treatment of hemophilia B	Designated			N/A	N/A	"Sangamo BioSciences, Inc."	Point Richmond Tech Center	501 Canal Boulevard	Richmond	California	94804	USA
adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and the human alpha-L-iduronidase (hIDUA) gene	n/a	1/9/17	Treatment of mucopolysaccharidosis type I (MPS I)	Designated			N/A	N/A	"Sangamo BioSciences, Inc."	Point Richmond Tech Center	501 Canal Boulevard	Richmond	California	94804	USA
adeno-associated virus serotype 9 expressing the human Survival Motor Neuron gene	n/a	9/30/14	Treatment of spinal muscular atrophy	Designated			N/A	N/A	"AveXis, Inc."	One Energy Square	Suite 604	Dallas	Texas	75206	USA
adeno-associated virus serotype 9 vector containing human Iduronate-2-sulfatase transgene	n/a	7/16/15	Treatment of mucopolysaccharidosis type II (Hunter syndrome).	Designated			N/A	N/A	"Laboratorios del Dr. Esteve, S.A."	"Av. Marie de Deu de Montserrat, 221"		Barcelona			Spain
Adeno-associated virus serotype rh10 vector encoding the human factor IX gene	n/a	8/25/15	Treatment of hemophilia B.	Designated			N/A	N/A	Dimension Therapeutics	840 Memorial Drive		Cambridge	Massachusetts	2139	USA
adeno-associated virus transgene of follistatin	n/a	11/19/12	Treatment of Duchennes and Becker's muscular dystrophy	Designated			N/A	N/A	Milo Biotechnology	2322 Delaware Drive		Cleveland Heights	Ohio	44106	USA
adeno-associated virus type 8 delivering a vector genome with human retinoschisin promoter (RS/IRBP) and the human retinoschisin cDNA (hRS)	n/a	11/16/15	Treatment of X-linked retinoschisis	Designated			N/A	N/A	"Paul A. Sievig, MD, PhD, National Eye Institute, NIH"	31 Center Drive	"Bldg 31, Room 6A03"	Bethesda	Maryland	20892	USA
adeno-associated virus vector encoding the SQ variant of human blood clotting factor VIII	n/a	2/29/16	Treatment of Hemophilia A.	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	105 Digital Drive		Novato	California	94949	USA
adeno-associated virus vector serotype 9 expressing human sulfamidase	n/a	6/1/11	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A Syndrome).	Designated			N/A	N/A	"Laboratorios del Dr. Esteve, S.A."	"Av. Marie de Deu de Montserrat, 221"		Barcelona			Spain
Adenoassociated virus vector (AAV) carrying a modified AAV serotype 2 backbone and coding sequence of human thymidine phosphorylase preceded by a human thyroxin-binding globulin promoter	n/a	9/4/14	For the treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)	Designated			N/A	N/A	Columbia University Medical Center	Department of Neurology	"630 West 168th Street, P&S 4-423"	New York	New York	10032	USA
Adenosine	n/a	8/1/89	For use in conjunction with BCNU in the treatment of brain tumors.	Designated/Withdrawn			N/A	N/A	"Medco Research, Inc."	8455 Beverly Boulevard	Suite 308	Los Angeles	California	90048	USA
Adenosine triphosphate type 1 competitive inhibitor of JAK2 V617F tyrosine kinase	n/a	3/3/11	"Treatment of myeloproliferative disorders (polycythemia vera, essential throbocythemia, and myelofibrosis)"	Designated			N/A	N/A	Eli Lilly and Company	Lilly Corporate Center		Indianapolis	Indiana	46285	USA
Adenoviral vector expressing Herpes simplex virus thymidine kinase gene	n/a	6/17/05	Treatment of malignant brain tumors	Designated			N/A	N/A	"Advantagene, Inc."	160 Paulson Road		Waban	Massachusetts	2468	USA
adenoviral vector expressing the E.coli purine nucleoside phosphorylase gene and fludarabine	n/a	6/8/15	"Intratumoral treatment of anatomically accessible oral and pharyngeal cancers (lip, tongue, gum, floor of mouth, salivary gland, and other oral cavity)"	Designated			N/A	N/A	"PNP Therapeutics, Inc."	15 Richard Arrington Jr. Blvd North		Birmingham	Alabama	35203	USA
Adenoviral vector-RheoSwitch Therapeutic System-human interleukin 12 + veledimex	n/a	7/23/15	Treatment of malignant glioma.	Designated			N/A	N/A	"Ziopharm Oncology, Inc."	One First Avenue	Navy Yard Plaza	Boston	Maryland	2129	USA
adenovirus associated viral vector serotype 5 containing the human RPE65 gene	n/a	3/10/16	Treatment of Leber congenital amaurosis	Designated			N/A	N/A	MeiraGTx Limited	450 East 29th Street	15th Floor	New York	New York	10016	USA
adenovirus associated viral vector serotype 5 containing the RPGR gene	n/a	11/29/16	Treatment of retinitis pigmentosa	Designated			N/A	N/A	MeiraGTx Limited	450 East 29th Street	15th Floor	New York	New York	10016	USA
adenovirus associated viral vector serotype 8 containing the human CNGB3 gene	n/a	3/10/16	Treatment of achromatopsia due to mutations in the CNGB3 gene.	Designated			N/A	N/A	MeiraGTx Limited	450 East 29th Street	15th Floor	New York	New York	10016	USA
adenovirus containing a human FAS-c gene	n/a	4/2/12	Treatment of malignant glioma	Designated			N/A	N/A	Vascular Biogenics Ltd	6 Jonathan Netanyahu St		Or Yehuda			Israel
"adenovirus delta 24-RGD, an oncolytic adenovirus genetically modified for treatment of glioma"	n/a	10/1/14	Treatment of glioma	Designated			N/A	N/A	"DNAtrix, Inc."	3210 Merryfield Row		San Diego	California	92121	USA
Adenovirus encoding the recombinant CD40 ligand	n/a	4/19/16	Treatment of stage IIb through IV melanoma.	Designated			N/A	N/A	Memgen LLC	12 Greenway Plaza	Suite 1100	Houston	Texas	77046	USA
"Adenovirus serotype-5 (Ad5) vector that contains a modified non-oncogenic fused early 6 (E6) and early 7 (E7) gene of the human papillomavirus (HPV); (Ad5 [E1-, E2b-]-E6/E7)"	n/a	9/4/14	Treatment of human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC)	Designated			N/A	N/A	Etubics Corporation	410 West Harrison Street	Suite 100	Seattle	Washington	98119	USA
adenovirus vaccine encoding reduced expression in immortalized cell protein	n/a	7/14/15	Treatment of mesothelioma	Designated			N/A	N/A	MTG Biotherapeutics	8195 Run of the Knolls Court		San Diego	California	92127	USA
adenovirus-associated viral vector serotype 5 containing the human pde6B gene	n/a	7/5/16	Treatment of retinitis pigmentosa due to pde6B gene mutations	Designated			N/A	N/A	"HORAMA, SAS"	9 Rue de l'peron		Paris			France
Adenovirus-based vector Factor VIII complementary DNA to somatic cells	Miniadfviii	12/15/99	Treatment of hemophilia A.	Designated			N/A	N/A	GenStar Therapeutics Corporation	10835 Altman Row	Suite 150	San Diego	California	92121	USA
ADF-APO-CCN-GUC-K67-MET-MMP-MUC-RGS; HLA class I/II binding tumor associated peptides	n/a	9/28/12	Treatment of renal cell carcinoma in HLA-A*2 positive patients	Designated/Withdrawn			N/A	N/A	Immatics Biotechnologies GmbH	Paul-Ehrlich-Strasse 15	72072 Tubingen				Germany
adult adherent bone marrow-derived multipotent stem cells	Multistem	7/6/12	"Treatment of MPS-1, including Hurler syndrome"	Designated			N/A	N/A	"Athersys, Inc."	3201 Carnegie Avenue		Cleveland	Ohio	44115	USA
adult hemogenic endothelial cells	n/a	5/27/15	Treatment of aplastic anemia	Designated			N/A	N/A	HemoGenyx LLC	640 Elliott Street	Suite 108	Buffalo	New York	14203	USA
ADXS11-001	n/a	8/12/13	Treatment of HPV-positive associated anal cancer	Designated			N/A	N/A	"Advaxis, Inc."	305 College Road East		Princeton	New Jersey	8540	USA
aerosolized beractant	n/a	3/11/13	Treatment of respiratory distress syndrome	Designated			N/A	N/A	"Beena G. Sood, MD, MS"	Wayne State University School of Medicine	Children's Hospital fo MI	Detroit	Michigan	48201	USA
Aerosolized pooled immune globulin	n/a	1/3/89	Treatment of respiratory syncytial virus lower respiratory tract disease.	Designated/Withdrawn			N/A	N/A	"Pediatric Pharmaceuticals, Inc."	718 Bradford Avenue		Westfield	New Jersey	7090	USA
AEZS-108 (LHRH-agonist linked to doxorubicin)	n/a	4/30/10	Treatment of ovarian cancer	Designated			N/A	N/A	Aeterna Zentaris	"100 Marketplace, Suite 203"	25 Mountainview Blvd	Basking Ridge	New Jersey	7920	USA
afamelanotide	n/a	7/17/08	Treatment of erythropoietic porphyrias	Designated			N/A	N/A	Clinuvel Inc.	40 Worth Street	Suite 1053	New York	New York	10013	USA
afamelanotide	n/a	12/11/09	Treatment of solar urticaria	Designated			N/A	N/A	"Clinuvel, Inc."	P. O. Box 2176		Blue Bell	Pennsylvania	19422	USA
afamelanotide	n/a	5/14/14	Treatment of familial benign chronic pemphigus (Hailey-Hailey disease)	Designated			N/A	N/A	"Clinuvel, Inc."	40 Worth Street	10th Floor - Suite 1053	New York	New York	10013	USA
afamelanotide	n/a	2/4/16	Treatment of cutaneous variants of porphyria (which includes treatment and prevention of cutaneous manifestations of disease)	Designated			N/A	N/A	Clinuvel Inc.	40 Worth Street	Suite 1053	New York	New York	10013	USA
afatinib	Gilotrif(R)	6/4/14	Treatment of malignant brain and central nervous system tumors	Designated			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc."	900 Ridgebury Road	P. O. Box 368	Ridgefield	Connecticut	6877	USA
afatinib	Gilotrif(R)	8/3/15	Treatment of non-small cell lung cancer with squamous histology.	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with metastatic, squamous, non-small cell lung cancer progressing after platinum-based chemotherapy"	04/15/2016	04/15/2023	"Boehringer Ingelheim Pharmaceuticals, Inc."	900 Ridgebury Road	P. O. Box 368	Ridgefield	Connecticut	6877	USA
afatinib	Gilotrif	12/3/12	Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).	Designated/Approved	Approved for Orphan Indication	First-line treatment of patients with metastatic non-small cell lung cancer (NSCLS) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.	07/12/2013	07/12/2020	"Boehringer Ingelheim Pharmaceuticals, Inc."	P. O. Box 368	900 Ridgebury Road	Ridgefield	Connecticut	6877	USA
aganirsen	n/a	11/7/16	Prevention of corneal graft rejection.	Designated			N/A	N/A	Gene Signal International SA	Route Cantonale		Lausanne			Switzerland
AI-RSA	n/a	10/8/92	Treatment of autoimmune uveitis.	Designated/Withdrawn			N/A	N/A	"AutoImmune, Inc."	128 Spring Street		Lexington	Massachusetts	2173	USA
Albendazole	Albenza	1/18/96	"Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis."	Designated/Approved	Approved for Orphan Indication	"Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium."	06/11/1996	06/11/2003	Amedra Pharmaceuticals LLC	2 Walnut Grove Drive	Suite 190	Horsham	Pennsylvania	19044	USA
Albendazole	Albenza	1/17/96	Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).	Designated/Approved	Approved for Orphan Indication	"Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus."	06/11/1996	06/11/2003	Amedra Pharmaceuticals LLC	2 Walnut Grove Drive	Suite 190	Horsham	Pennsylvania	19044	USA
Albuterol	n/a	3/12/02	Prevention of paralysis due to spinal cord injury	Designated			N/A	N/A	"MotoGen, Inc."	3 Pine View Road		Mount Kisco	New York	10549	USA
Aldesleukin	Proleukin	9/14/88	Treatment of metastatic renal cell carcinoma.	Designated/Approved	Approved for Orphan Indication	Treatment of adults (>18 years old) with metastatic renal cell carcinoma.	05/05/1992	05/05/1999	Chiron Corporation	4560 Horton St.		Emeryville	California	94608	USA
Aldesleukin	Proleukin	9/10/96	Treatment of metastatic melanoma.	Designated/Approved	Approved for Orphan Indication	Treatment of adults with metastatic melanoma.	01/09/1998	01/09/2005	Chiron Corporation	4560 Horton St.		Emeryville	California	94608	USA
Aldesleukin	Proleukin	3/22/89	Treatment of primary immunodeficiency disease associated with T-cell defects.	Designated			N/A	N/A	"Prometheus Laboratories, Inc."	9410 Carroll Park Drive		San Diego	California	92121	USA
Aldesleukin	Proleukin	7/31/98	Treatment of acute myelogenous leukemia.	Designated/Withdrawn			N/A	N/A	Chiron Corporation	4560 Horton St.		Emeryville	California	94608	USA
Aldesleukin	Proleukin	11/24/98	For the treatment non-Hodgkin's lymphoma.	Designated			N/A	N/A	"Prometheus Laboratories, Inc."	9410 Carroll Park Drive		San Diego	California	92121	USA
aldoxorubicin	n/a	9/24/14	Treatment of small cell lung cancer	Designated			N/A	N/A	CytRx Corporation	11726 San Vicente Blvd - Suite 650		Los Angeles	California	90049	USA
aldoxorubicin	n/a	9/24/14	Treatment of ovarian cancer	Designated			N/A	N/A	CytRx Corporation	11726 San Vicente Blvd - Suite 650		Los Angeles	California	90049	USA
aldoxorubicin	n/a	9/24/14	Treatment of glioblastoma multiforme	Designated			N/A	N/A	CytRx Corporation	11726 San Vicente Blvd	Suite 650	Los Angeles	California	90049	USA
alectinib	Alecensa	1/27/15	Treatment of ALK-positive non-small cell lung cancer	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), who have progressed on or are intolerant to crizotinib"	12/11/2015	12/11/2022	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
Alefacept	Amevive	12/19/07	For use as prophylaxis of rejection in patients receiving allogenic solid organ transplants.	Designated/Withdrawn			N/A	N/A	"Astellas Pharma Global Development, Inc."	Three Parkway North		Deerfield	Illinois	60015	USA
alemtuzumab	Campath	10/20/97	Treatment of chronic lymphocytic leukemia.	Designated/Approved	Approved for Orphan Indication	The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy.	05/07/2001	05/07/2008	Genzyme Corporation	4545 Horizon Hill Blvd.		San Antonio	Texas	78229	USA
alendronate	Fosamax	3/31/03	Treatment of osteogenesis imperfecta in pediatric patients 4 years of age and older	Designated/Withdrawn			N/A	N/A	"Merck, Sharpe & Dohme Corp."	126 East Lincoln Ave.	RY 33-212	Rahway	New Jersey	7065	USA
Alendronate disodium	Fosamax	2/13/01	Treatment of the bone manifestations of Gaucher disease	Designated			N/A	N/A	"Richard J. Wenstrup, M.D."	Division of Human Genetics	Children's Hospital Research Foundation	Cincinnati	Ohio	45229	USA
Alfentanil	n/a	8/9/05	Treatment of painful HIV-associated neuropathy	Designated			N/A	N/A	"Cinergen, LLC"	146 Medinah Drive		Blue Bell	Pennsylvania	19422	USA
Alfentanil	n/a	7/8/05	Management of postherpetic neuralgia	Designated			N/A	N/A	"Cinergen, LLC"	146 Medinah Drive		Blue Bell	Pennsylvania	19422	USA
alfimeprase	n/a	9/20/12	Treatment of ST-elevation myocardial infarcted patients who are undergoing primary percutaneous coronary intervention	Designated			N/A	N/A	"Niche Therapeutics, LLC"	2009 Morton Avenue		Ann Arbor	Michigan	48104	USA
algenpantucel-L	Hyperacute(R)-Pancreatic Cance	10/21/10	Treatment of pancreatic cancer.	Designated			N/A	N/A	NewLink Genetics Corporation	2503 S. Loop Drive		Ames	Iowa	50010	USA
Alglucerase injection	Ceredase	7/21/95	Replacement therapy in patients with Type II and III Gaucher's disease.	Designated			N/A	N/A	Genzyme Corporation	One Kendall Square		Cambridge	Massachusetts	2139	USA
Alglucerase injection	Ceredase	3/11/85	For replacement therapy in patients with Gaucher's disease type I.	Designated/Approved	Approved for Orphan Indication	"Long-term enzyme replacement therapy for children, adolescents and adult patients with a confirmed diagnosis of Type I Gaucher disease who exhibit signs and symptoms that are severe enough to result in one or more of the following conditions: a) moderate-to-severe anemia; b) thrombocytopenia with bleeding tendency; c) bone disease; d) significant hepatomegaly or splenomegaly."	04/05/1991	04/05/1998	Genzyme Corporation	One Kendall Square		Cambridge	Massachusetts	2139	USA
alicaforsen	n/a	6/24/08	Treatment of pouchitis.	Designated			N/A	N/A	Atlantic Healthcare Limited	Maple House	"Halsted, Essex CO9 4BB"				United Kingdom
alisertib	n/a	5/14/12	Treatment of peripheral T-cell lymphoma	Designated/Withdrawn			N/A	N/A	"Millennium Pharmaceuticals, Inc."	40 Landsdowne Street		Cambridge	Massachusetts	2139	USA
alisertib	n/a	7/12/13	Treatment of small cell lung cancer	Designated			N/A	N/A	"Millennium Pharmaceuticals, Inc."	40 Landsdowne Street		Cambridge	Massachusetts	2139	USA
Alitretinoin	Panretin	3/24/98	Treatment of AIDS-related Kaposi's sarcoma.	Designated/Approved	Approved for Orphan Indication	Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.	02/02/1999	02/02/2006	"Eisai, Inc"	300 Tice Blvd		Woodcliff Lake	New Jersey	7677	USA
Alitretinoin	Panretin	4/10/92	Treatment of acute promyelocytic leukemia	Designated			N/A	N/A	"Ligand Pharmaceuticals, Inc."	10275 Science Center Dr.		San Diego	California	92121	USA
"all-cis-docosa-4,7,10,13,16,19-hexaenoic acid"	Retriacyl	5/21/14	Treatment of retinitis pigmentosa	Designated			N/A	N/A	"Natac Pharma, S.L."	C/ Faraday 7	28049	Madrid			Spain
allantoin	Alwextin	11/21/02	Treatment of skin blistering and erosions associated with inherited epidermolysis bullosa	Designated			N/A	N/A	"Scioderm, Inc."	1007 Slater Road	Suite 170	Durham	North Carolina	27703	USA
allogeneic cardiosphere-derived cells	n/a	4/21/15	Treatment of Duchenne Muscular Dystrophy	Designated			N/A	N/A	"Capricor, Inc."	8840 Wilshire Blvd.	2nd Floor	Beverly HIlls	California	90211	USA
"allogeneic cord blood cells, ex vivo modulated with 16,16 dimethyl prostaglandin E2 (dmPGE2)"	n/a	12/2/10	"Enhancement of stem cell engraftment through ex vivo treatment of human allogeneic hematopoietic stem cells (treatment of neuropenia, thrombocytopenia, lymphopenia, and anemia)."	Designated			N/A	N/A	"Fate Therapeutics, Inc."	3535 General Atomics Court		San Diego	California	92121	USA
allogeneic Epstein-Barr virus cytotoxic T lymphocytes	n/a	2/4/16	Treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disorders.	Designated			N/A	N/A	"ATARA Biotherapeutics, Inc."	4360 Park Terrace Drive	Suite 100	Westlake Village	California	91361	USA
allogeneic ex vivo expanded umbilical cord blood cells	Stemex	2/1/10	For use as hematopoietic support in patients with chronic myeloid leukemia	Designated/Withdrawn			N/A	N/A	Gamida Cell - Teva Joint Venture	PO Box 34670					Israel
allogeneic ex vivo expanded unbilical cord blood cells	Stemex	2/1/10	For use as hematopoietic support in patients with myelodysplastic syndromes	Designated/Withdrawn			N/A	N/A	Gamida Cell - Teva Joint Venture	PO Box 34670					Israel
allogeneic ex-vivo expanded placental adherent stromal cells	n/a	8/22/11	Treatment of thromboangiitis obliterans (Buerger's disease)	Designated			N/A	N/A	"Pluristem Therapeutics, Inc."	MATAM Advanced Technology Park	Building #20	Haifa			Israel
allogeneic ex-vivo expanded placental adherent stromal cells	n/a	12/29/15	For the treatment of severe preeclampsia	Designated			N/A	N/A	"Pluristem Therapeutics, Inc"	MATAM Advanced Technology Park	Building # 5	Haifa			Israel
allogeneic ex-vivo expanded placental adherent stromal cells	n/a	2/18/13	Treatment of Aplastic Anemia	Designated			N/A	N/A	"Pluristem Therapeutics, Inc."	MATAM Advanced Technology Park	Building #20	Haifa			Israel
allogeneic ex-vivo generated CD56+CD3-natural killer cells from CD34+ umbilical cord blood progenitor cells	n/a	4/20/16	Treatment of acute myeloid leukemia	Designated			N/A	N/A	IPD-Therapeutics BV	(Trading as Glycostem-Therapeutics)	Molenstraat 110 5342 CC Oss				Netherlands
allogeneic hematopoietic stem cell	Atir	2/2/10	"Prevention (reduction) of transplant related mortality (TRM, which is caused by graft versus host disease and/or infections) following mismatched (haploidentical) allogeneic hematopoietic stem cell transplantation."	Designated			N/A	N/A	Kiadis Pharma Netherlands B.V.	Entrada 231 - 234					Netherlands
Allogeneic human aortic endothelial cells cultured in a porcine gelatin matrix	Vascugel (R)	4/3/09	Prevention of arteriovenous fistula or arteriovenous graft failure in patients with end satge renal disease receiving hemodialysis or preparing for hemodialysis	Designated			N/A	N/A	Shire	300 Shire Way		Lexington	Massachusetts	2421	USA
Allogeneic human retinal pigment epithelial cells on gelatin microcarriers	Spheramine	7/18/97	Treatment of Hoehn and Yahr stage 3 and 4 Parkinson's disease.	Designated/Withdrawn			N/A	N/A	"Bayer Healthcare Pharmaceuticals, Inc."	100 Bayer Boulevard		Whippany	New Jersey	7981	USA
Allogeneic motor neuron progenitor cells derived from human embryonic stem cells	Motorgraft (Tm)	1/17/14	Treatment of Amyotrophic Lateral Sclerosis	Designated			N/A	N/A	Caladrius Biosciences	106 Allen Road	4th Floor	Basking Ridge	New Jersey	7920	USA
Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture	Cytoimplant	6/13/97	Treatment of pancreatic cancer	Designated			N/A	N/A	"Applied Immunotherapeutics, LLC"	14132 E. Firestone Boulevard		Santa Fe Springs	California	90670	USA
Allogeneic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor	n/a	9/1/04	Treatment of retinitis pigmentosa	Designated			N/A	N/A	"Neurotech USA, Inc."	6 Blackstone Valley Place		Lincoln	Rhode Island	2865	USA
"Allogeneic T-cells cultured with anti-CD3 and IL-2; transduced with retroviral vector (SFCMM-3), expressing herpes simplex 1 virus-thymidine kinase (HSV-TK) and truncated low affinity nerve growth factor receptor; selected with anti-low affinity nerve gro"	n/a	1/28/05	Immunotherapy for acceleration of T-cell reconstitution in patients undergoing allogeneic hematopoietic stem cell transplantation	Designated			N/A	N/A	MolMed S.p.A.	Via Olgettina 58		Milan			Italy
allogenic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor	n/a	7/24/12	Treatment of macular telangiectasia type 2 (MacTel)	Designated			N/A	N/A	"Neurotech USA, Inc."	701 George Washington Highway		Lincoln	Rhode Island	2865	USA
allopregnanolone	n/a	4/20/14	Treatment of status epilepticus	Designated			N/A	N/A	Sage Therapeutics	215 First Street	Suite 220	Cambridge	Massachusetts	2142	USA
allopregnanolone	n/a	7/12/13	"Treatment of Neimann-Pick disease, type C"	Designated			N/A	N/A	"La Jolla Pharmaceutical Company, Inc."	4660 La Jolla Village Drive	Suite 400	San Diego	California	92122	USA
Allopurinol riboside	n/a	12/4/85	1. Treatment of Chagas' disease 2. Treatment of cutaneous and visceral leishmaniasis	Designated/Withdrawn			N/A	N/A	Burroughs Wellcome Company	3030 Cornwallis Road	P.O. Box 12700	Research Triangle Park	North Carolina	27709	USA
Allopurinol sodium	Aloprim For Injection	10/16/92	"Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy."	Designated/Approved	Approved for Orphan Indication	"Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy."	05/17/1996	05/17/2003	"Catalytica Pharmaceuticals, Inc"	PO Box 1887		Greenville	North Carolina	27835	USA
Allopurinol sodium	n/a	11/9/87	Ex-vivo preservation of cadaveric kidneys for transplantation	Designated/Withdrawn			N/A	N/A	Burroughs Wellcome Company	3030 Cornwallis Road	P.O. Box 12700	Research Triangle Pk	North Carolina	27709	USA
allosteric activator of the red blood cell-specific form of pyruvate kinase	n/a	3/24/15	Treatment of pyruvate kinase deficiency	Designated			N/A	N/A	"Agios Pharmaceuticals, Inc."	88 Sidney Street		Cambridge	Massachusetts	2139	USA
alpha melanotropin	n/a	9/2/10	Treatment of chronic beryllium disease	Designated			N/A	N/A	mondoBIOTECH Laboratories AG	Herrengasse 21	Furstentum Liechtenstein				Germany
alpha-1 proteinase inhibitor (human)	Glassia	7/28/11	Treatment of patients with recent onset (	Designated			N/A	N/A	"Kamada, Ltd."	"Kiryat Weizmann, Science Park"	Ness-Ziona 74036				Israel
alpha-1 proteinase inhibitor (human)	Glassia	10/23/14	Treatment of graft versus host disease	Designated			N/A	N/A	Kamada Ltd.	Kiryat Weizmann	7 Sapir Street	Ness-Ziona			Israel
Alpha-1-acid glycoprotein	n/a	3/5/04	Treatment of cocaine overdose	Designated/Withdrawn			N/A	N/A	Bio Products Laboratory	"Dagger Lane, Elstree, Hertfordshire"	WD6 3BX				United Kingdom
Alpha-1-acid glycoprotein	n/a	3/17/04	Treatment of tricyclic antidepressant poisoning	Designated/Withdrawn			N/A	N/A	Bio Products Laboratory	"Dagger Lane, Elstree, Hertfordshire"	WD6 3BX				United Kingdom
Alpha-1-antitrypsin (recombinant DNA Origin)	n/a	1/1/84	As supplementation therapy for alpha-1-antitrypsin deficiency in the ZZ phenotype population.	Designated/Withdrawn			N/A	N/A	Chiron Corporation	4560 Horton Street		Emeryville	California	94608	USA
Alpha-galactosidase A	Cc-Galactosidase	6/17/91	Treatment of alpha-galactosidase A deficiency (Fabry's disease).	Designated			N/A	N/A	"David Calhoun, Ph.D."	Department of Chemistry	Convent Avenue & 138th Street	New York	New York	10031	USA
Alpha-galactosidase A	Fabrase	7/20/90	Treatment of Fabry's disease.	Designated			N/A	N/A	"Desnick, Robert J. M.D."	The Mount Sinai School Of Medicine	"Fifth Avenue at 100th Street, Box 1203"	New York	New York	10029	USA
Alpha-galactosidase A	Replagal	6/22/98	Long-term enzyme replacement therapy for the treatment of Fabry disease	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	700 Main Street		Cambridge	Massachusetts	2139	USA
Alpha-melanocyte stimulating hormone	n/a	8/19/97	Prevention and treatment of intrinsic acute renal failure due to ischemia.	Designated			N/A	N/A	"National Institute of Diabetes, and Digestive and Kidney Diseases"	"National Institutes of Health, 31 Center Drive MSC"	"Building 31, Room 9N-222"	Bethesda	Maryland	20892	USA
Alpha-tocopherol quinone	n/a	3/28/06	Treatment of inherited mitochondrial respiratory chain diseases	Designated			N/A	N/A	Penwest Pharmaceuticals Company	39 Old Ridgebury Road	Suite 11	Danbury	Connecticut	6810	USA
alpha-tocotrienol quinone	n/a	10/21/10	Treatment of inherited mitochondrial respiratory chain diseases.	Designated			N/A	N/A	"Edison pharmaceuticals, Inc."	350 N. Bernardo Ave.		Mountain View	California	94043	USA
alpha1 proteinase inhibitor (human)	n/a	1/29/10	Treatment of emphysema secondary to congenital alpha1-antitrypsin deficiency.	Designated			N/A	N/A	"Grifols Therapeutics, Inc."	79 TW Alexander Drive		Research Triangle Park	North Carolina	27709	USA
Alpha1-antitrypsin(human)	n/a	4/3/08	Treatment of bronchiectasis	Designated			N/A	N/A	Kamada Ltd.	7 Sapir Street		Ness Ziona			Israel
alpha1-proteinase inhibitor (human)	n/a	4/6/12	Treatment of cystic fibrosis	Designated			N/A	N/A	"Grifols Therapeutics, Inc."	8368 US 70 BUS Hwy W.		Clayton	North Carolina	27520	USA
Alpha1-proteinase inhibitor (human)	Prolastin	12/7/84	For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.	Designated/Approved	Approved for Orphan Indication	For chronic replacement therapy of individuals having congenital deficiency of alpha1- proteinase inhibitor with clinically demonstrable panacinar emphysema.	12/02/1987	12/02/1994	Bayer Corporation	"Pharmaceutical Division, Biological Products"	400 Morgan Lane	New Haven	Connecticut	6516	USA
Alpha1-proteinase inhibitor (human)	n/a	11/24/99	For slowing the progression of emphysema in alpha1-antitrypsin deficient patients.	Designated/Withdrawn			N/A	N/A	CSL Behring L.L.C.	1020 First Ave.	PO Box 61501	King of Prussia	Pennsylvania	19406	USA
alpha1-proteinase inhibitor (human)	n/a	2/20/09	Treatment of cystic fibrosis	Designated			N/A	N/A	CSL Behring LLC	1020 First Avenue	P. O. Box 61501	King of Prussia	Pennsylvania	19406	USA
alpha1-proteinase inhibitor (human)	Prolastin(R)-C	3/3/15	Treatment of Type 1 diabetes mellitus patients with residual beta-cell function.	Designated			N/A	N/A	"Grifols Therapeutics, Inc."	8368 US Business Hwy 70 West		Clayton	North Carolina	27520	USA
Alpha1-Proteinase Inhibitor (Human)	n/a	12/22/04	Inhalation therapy for the treatment of congential deficiency of alpha1-proteinase inhibitor.	Designated			N/A	N/A	Kamada Ltd.	7 Sapir Street		Ness Ziona			Israel
Alpha1-Proteinase Inhibitor (Human)	Arc-Api	9/1/04	Treatment of cystic fibrosis	Designated			N/A	N/A	Kamada Ltd.	7 Sapir Street		Ness Ziona			Israel
Alprostadil	n/a	10/20/93	"Treatment of severe peripheral arterial occlusive disease (critical limb ischemia) in patients where other procedures, grafts or angioplasty, are not indicated."	Designated/Withdrawn			N/A	N/A	"Schwarz Pharma, Inc."	P.O. Box 2038		Milwaukee	Wisconsin	53201	USA
alteplase	Activase	1/27/03	Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage	Designated			N/A	N/A	"Daniel F. Hanley, MD"	Johns Hopkins University	"600 N. Wolfe St., Jefferson 1-109"	Baltimore	Maryland	21287	USA
altiratinib	n/a	8/19/14	Treatment of glioblastoma multiforme.	Designated			N/A	N/A	"Deciphera Pharmaceuticals, LLC"	643 Massachusetts	Suite 200	Lawrence	Kansas	66044	USA
Altretamine	Hexalen	2/9/84	Treatment of advanced adenocarcinoma of the ovary.	Designated/Approved	Approved for Orphan Indication	Single agent palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent based combination.	12/26/1990	12/26/1997	"Medimmune Oncology, Inc."	One Tower Bridge	"100 Front St., Suite 400"	West Conshohocken	Pennsylvania	19428	USA
alvocidib	n/a	4/21/14	Treatment of acute myeloid leukemia	Designated			N/A	N/A	"Tolero Pharmaceuticals, Inc."	2975 West Executive Parkway	Suite 320	Lehi	Utah	84043	USA
Alvocidib	n/a	4/13/07	Teatment of B-cell chronic lymphocytic leukemia (B-CLL) or prolymphocytic leukemia arising from CLL.	Designated			N/A	N/A	"Tolero Pharmaceuticals, Inc."	2975 West Executive Parkway	Suite 320	Lehi	Utah	84043	USA
Amantadine HCl	n/a	7/20/15	Treatment of levodopa-induced dyskinesia	Designated			N/A	N/A	Osmotica Pharmaceutical Corporation	"Regulatory, Clinical Operations & Legal"	"Lumina Station #2, Suite 209-A"	Wilmington	North Carolina	28403	USA
Amantadine hydrochloride	Nurelin	4/9/15	Treatment of levodopa-induced dyskinesia	Designated			N/A	N/A	"Adamas Pharmaceuticals, Inc."	1900 Powell Street	Suite 750	Emeryville	California	94608	USA
amatuximab	n/a	9/28/12	Treatment of mesothelioma	Designated			N/A	N/A	"Morphotek, Inc."	210 Welsh Pool Road		Exton	Pennsylvania	19341	USA
ambrisentan	Letairis	7/16/04	Treatment of pulmonary arterial hypertension	Designated/Approved	Approved for Orphan Indication	Treatment of pulmonary arterial hypertension (WHO group I) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening	06/15/2007	06/15/2014	Gilead Colorado	7575 West 103rd Avenue	Suite 102	Westminister	Colorado	80021	USA
ambrisentan	Letairis	12/23/09	Treatment of idiopathic pulmonary fibrosis	Designated/Withdrawn			N/A	N/A	"Gilead Sciences, Inc."	199 East Blaine Street		Seattle	Washington	98102	USA
ambrisentan/tadalafil fixed combination	n/a	8/22/16	Treatment of pulmonary arterial hypertension	Designated			N/A	N/A	"Gilead Sciences, Inc."	333 Lakeside Drive		Foster City	California	94404	USA
ambroxol	n/a	6/29/11	Treatment of Gaucher disease	Designated			N/A	N/A	"Belrose Pharma, Inc."	500 College Road E	Suite 205	Princeton	New Jersey	8540	USA
amifampridine phosphate	n/a	3/3/15	Treatment of congenital myasthenic syndromes	Designated			N/A	N/A	Catalyst Pharmaceuticals	"(dba Catalyst Pharmaceutical Partner, Inc)"	Suite 1500	Coral Gables	Florida	33134	USA
amifampridine phosphate	n/a	11/12/09	Treatment of Lambert-Eaton Myasthenic Syndrome	Designated			N/A	N/A	"Catalyst Pharmaceuticals, Inc."	355 Alhambra Circle	Suite 1250	Coral Gables	Florida	33134	USA
amifampridine phosphate	n/a	8/31/16	Treatment of myasthenia gravis	Designated			N/A	N/A	"Catalyst Pharmaceuticals, Inc."	355 Alhambra Circle	Suite 1250	Coral Gables	Florida	33134	USA
Amifostine	Ethyol	11/24/98	For the reduction of the incidence and severity of toxicities associated with cisplatin administration.	Designated			N/A	N/A	Clinigen Group plc	"Pitcairn House, Crown Square"	DE14 2WW				United Kingdom
Amifostine	Ethyol	5/30/90	For use as a chemoprotective agent for cisplatin in the treatment of advanced ovarian carcinoma.	Designated/Approved	Approved for Orphan Indication	To reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer.	12/08/1995	12/08/2002	"Medimmune Oncology, Inc."	One Tower Bridge	"100 Front St., Suite 400"	West Conshohocken	Pennsylvania	19428	USA
Amifostine	Ethyol	10/4/99	Treatment of myelodysplastic syndromes.	Designated			N/A	N/A	Clinigen Group plc	"Pitcairn House, Crown Square"	DE14 2WW				United Kingdom
Amifostine	Ethyol	5/30/90	For use as a chemoprotective agent for cyclophosphamide in the treatment of advanced ovarian carcinoma.	Designated			N/A	N/A	Clinigen Group plc	"Pitcairn House, Crown Square"	DE14 2WW				United Kingdom
Amifostine	Ethyol	5/12/98	Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.	Designated/Approved	Approved for Orphan Indication	"Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands."	06/24/1999	06/24/2006	"Medimmune Oncology, Inc."	One Tower Bridge	"100 Front St., Suite 400"	West Conshohocken	Pennsylvania	19428	USA
Amifostine	Ethyol	5/30/90	For use as a chemoprotective agent for cisplatin in the treatment of metastatic melanoma.	Designated			N/A	N/A	Clinigen Group plc	"Pitcairn House, Crown Square"	DE14 2WW				United Kingdom
amikacin sulfate	n/a	1/5/15	Management of cystic fibrosis patients with Pseudomonas aeruginosa lung infections	Designated			N/A	N/A	PlumeStars s.r.l.	Via Lago Scuro11	43124 Parma				Italy
Amiloride HCl solution for inhalation	n/a	7/18/90	Treatment of cystic fibrosis.	Designated/Withdrawn			N/A	N/A	Glaxo Wellcome Research and Development	5 Moore Drive	PO Box 13398	Research Triangle Park	North Carolina	27709	USA
Aminocaproic acid	Caprogel	1/6/95	For the topical treatment of traumatic hyphema of the eye.	Designated			N/A	N/A	Eastern Virginia Medical School	Department of Ophthalomology	"880 Kempsville Road, Suite 2500"	Norfolk	Virginia	23502	USA
aminolevulinic acid hydrochloride	Levulan	3/20/07	Treatment of esophageal dysplasia	Designated			N/A	N/A	"DUSA Pharmaceuticals, Inc."	25 Upton Place		Wilmington	Massachusetts	1887	USA
Aminosalicylate sodium	n/a	4/6/93	Treatment of Crohn's disease.	Designated/Withdrawn			N/A	N/A	"Syncom Pharmaceuticals, Inc."	66 Hanover Road		Florham Park	New Jersey	7932	USA
Aminosalicylic acid	Paser Granules	2/19/92	Treatment of tuberculosis infections	Designated/Approved	Approved for Orphan Indication	Treatment of tuberculosis	06/30/1994	06/30/2001	Jacobus Pharmaceutical Company	37 Cleveland Avenue	P.O. Box 5290	Princeton	New Jersey	8540	USA
Aminosidine	Paromomycin	9/9/94	Treatment of visceral leishmaniasis (kala-azar).	Designated			N/A	N/A	"Kanyok, Thomas P. Pharm.D."	University of Illinois at Chicago College of Pharm	833 South Wood Street (m/c886) Rm. 176	Chicago	Illinois	60612	USA
Aminosidine	Gabbromicina	11/15/93	Treatment of Mycobacterium avium complex.	Designated			N/A	N/A	"Kanyok, Thomas P. Pharm.D."	University Of Illinois At Chicago College of Pharm	833 South Wood Street (m/c886) Rm. 176	Chicago	Illinois	60612	USA
Aminosidine	Gabbromicina	5/14/93	Treatment of tuberculosis.	Designated			N/A	N/A	"Kanyok, Thomas P. Pharm.D."	University Of Illinois At Chicago College of Pharm	833 South Wood Street (m/c886) Rm. 176	Chicago	Illinois	60612	USA
aminosidine	Paromomycin	3/29/05	Treatment of visceral leishmaniasis	Designated			N/A	N/A	The Institute for One World Health	50 California Street	Suite 500	San Francisco	California	94111	USA
Amiodarone	Amio-Aqueous	8/17/93	Treatment of incessant ventricular tachycardia.	Designated			N/A	N/A	"Academic Pharmaceuticals, Inc."	21 N. Skokie Highway		Lake Bluff	Illinois	60044	USA
Amiodarone HCl	Cordarone	3/16/94	For the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation.	Designated/Approved	Approved for Orphan Indication	For initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy.	08/03/1995	08/03/2002	Wyeth-Ayerst Laboratories	P.O. Box 8299		Philadelphia	Pennsylvania	19101	USA
amitriptyline and ketamine	Amiket(Tm)	1/19/10	Treatment of postherpetic neuralgia	Designated			N/A	N/A	"Immune Pharmaceuicals, Inc."	Alexandria Center for LIfe Sciences	430 E. 29th St.	New York	New York	10016	USA
ammonium 21-tungsto-9-antimoniate	n/a	7/17/85	Treatment of acquired immunodeficiency syndrome.	Designated/Withdrawn			N/A	N/A	Rhone-Poulenc Rorer Pharm.	500 Arcola Road		Collegeville	Pennsylvania	19426	USA
ammonium tetrathiomolybdate	n/a	5/5/08	Treatment of idiopathic pulmonary fibrosis	Designated			N/A	N/A	"Pipex Pharmaceuticals, Inc."	3930 Varsity Drive		Ann Arbor	Michigan	48108	USA
Ammonium tetrathiomolybdate	Coprexa	1/31/94	Treatment of Wilson's disease.	Designated			N/A	N/A	"Pipex Pharmaceuticals, Inc."	3930 Varsity Drive		Ann Arbor	Michigan	48108	USA
"Ammonium trichloro [dioxoethylene-O,O') tellurium (IV)"	n/a	11/9/87	Treatment of acquired immunodeficiency syndrome.	Designated/Withdrawn			N/A	N/A	"NPDC-AS101, Inc."	783 Jersey Avenue		New Brunswick	New Jersey	8901	USA
Amonafide L-malate	Xanafide	12/20/06	Treatment of acute myeloid leukemia	Designated/Withdrawn			N/A	N/A	"Xanthus Pharmaceuticals, Inc."	An Antisoma Group Company	300 Technology Square	Cambridge	Massachusetts	2139	USA
amphotericin B	n/a	9/15/10	Treatment of visceral leishmaniasis.	Designated			N/A	N/A	iCo Therapeutics Inc.	760-777 Hornby Street		"Vancouver, BC V6Z 1S4"			Canada
Amphotericin B inhalation powder	n/a	12/15/05	"Prevention of pulmonary fungal infections in patients at risk for aspergillosis due to immunosuppressive therapy including those receiving organ or stem cell transplants, or treated with chemotherapy or radiation for hematologic malignancies"	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	150 Industrial Road		San Carlos	California	94070	USA
Amphotericin B lipid complex	Abelcet	5/6/96	Treatment of invasive coccidioidomycosis.	Designated/Withdrawn			N/A	N/A	"The Liposome Company, Inc."	One Research Way		Princeton	New Jersey	8540	USA
Amphotericin B lipid complex	Abelcet	6/27/96	Treatment of invasive candidiasis.	Designated/Withdrawn			N/A	N/A	"The Liposome Company, Inc."	One Research Way		Princeton	New Jersey	8540	USA
Amphotericin B lipid complex	Abelcet	9/23/96	Treatment of invasive sporotrichosis.	Designated/Withdrawn			N/A	N/A	"The Liposome Company, Inc."	One Research Way		Princeton	New Jersey	8540	USA
Amphotericin B lipid complex	Abelcet	12/5/91	Treatment of invasive fungal infections.	Designated/Approved	Approved for Orphan Indication	Treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy.	10/18/1996	10/18/2003	"Liposome Company, Inc."	One Research Way		Princeton	New Jersey	8540	USA
Amphotericin B lipid complex	Abelcet	5/6/96	Treatment of invasive zygomycosis.	Designated/Withdrawn			N/A	N/A	"The Liposome Company, Inc."	One Research Way		Princeton	New Jersey	8540	USA
Amphotericin B lipid complex	Abelcet	8/21/96	Treatment of invasive protothecosis.	Designated/Withdrawn			N/A	N/A	"The Liposome Company, Inc."	One Research Way		Princeton	New Jersey	8540	USA
amrubicin	n/a	3/10/08	Treatment of small cell lung cancer	Designated/Withdrawn			N/A	N/A	Celgene Corporation	9900 W. 109th Street	Suite 300	Overland Park	Kansas	66210	USA
Amsacrine	Amsidyl	12/7/84	Treatment of acute adult leukemia.	Designated/Withdrawn			N/A	N/A	Warner-Lambert Company	2800 Plymouth Road		Ann Arbor	Michigan	48106	USA
"Amyl nitrite, sodium nitrite, sodium thiosulfate"	Cyanide Antidote Kit	12/18/06	Treatment of cyanide poisoning	Designated			N/A	N/A	"Akorn, Inc."	2500 Millbrook Drive		Buffalo Grove	Illinois	60089	USA
amylopectin	n/a	3/24/15	Treatment of glycogen storage disease types Ia and Ib	Designated			N/A	N/A	"Michael K. Davis, MD, MBA"	University of Florida Health	7046 SW Archer Road	Gainesville	Florida	32608	USA
an adeno-associated viral vector containing a codon-optimised human factor IX gene (AAV5-hFIXco)	n/a	12/22/11	Treatment of hemophilia B	Designated			N/A	N/A	"uniQure, B.V."	Meiberdreef 61	1100 DA	Amsterdam			Netherlands
ANA-conjugated dactunomycin nanoemulsion	n/a	7/7/15	Treatment of Ewing sarcoma	Designated			N/A	N/A	"NanoSmart Pharmaceuticals, Inc."	27071 Cabot Road	Suite 104	Laguna Hills	California	92653	USA
Anagrelide	Agrylin	6/11/85	Treatment of polycythemia vera.	Designated			N/A	N/A	Roberts Pharmaceutical Corp.	Meridian Center II	Four Industrial Way West	Eatontown	New Jersey	7724	USA
Anagrelide	Agrylin	1/27/88	Treatment of essential thrombocythemia.	Designated/Approved	Approved for Orphan Indication	Treatment of patients with essential thrombocythemia to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms.	03/14/1997	03/14/2004	Roberts Pharmaceutical Corp.	Meridian Center III	6 Industrial Way West	Eatontown	New Jersey	7724	USA
Anagrelide	Agrylin	7/14/86	Treatment of thrombocytosis in chronic myelogenous leukemia.	Designated			N/A	N/A	Roberts Pharmaceutical Corp.	Meridian Center II	Four Industrial Way West	Eatontown	New Jersey	7724	USA
anakinra	Kineret	8/19/10	Treatment of cryopyrin-associated periodic syndromes	Designated/Approved	Approved for Orphan Indication	Treatment of neonatal-onset multisystem inflammatory disease (NOMID)	12/21/2012	12/21/2019	Swedish Orphan Biovitrum AB (publ)	SE-011276		Stockholm			Sweden
"Ananain, comosain"	Vianain	1/21/92	For the enzymatic debridement of severe burns.	Designated			N/A	N/A	Genzyme Corporation	One Kendall Square		Cambridge	Massachusetts	2139	USA
Anaritide acetate	Auriculin	4/10/92	Improvement of early renal allograft function following renal transplantation.	Designated/Withdrawn			N/A	N/A	"Scios, Inc."	2450 Bayshore Parkway		Mountain View	California	94043	USA
Anaritide acetate	Auriculin	8/27/92	Treatment of patients with acute renal failure.	Designated/Withdrawn			N/A	N/A	"Scios, Inc."	2450 Bayshore Parkway		Mountain View	California	94043	USA
Anatibant	n/a	4/15/05	Treatment of patients having experienced a severe traumatic brain injury (Glasgow Coma Scale 3 to 8) in order to decrease early mortality and improve long-term functional and neurological outcome	Designated			N/A	N/A	"Xytis, Inc."	400 South El Camino Real	Suite 1200	San Mateo	California	94402	USA
Ancestim	Stemgen	7/5/95	For use in combination with filgrastim to decrease the number of phereses required to collect peripheral blood progenitor cells capable of providing rapid multi-lineage hematopoietic reconstitution following myelosuppressive or myeloablative therapy.	Designated/Withdrawn			N/A	N/A	"Amgen, Inc."	One Amgen Center Drive		Thousand Oaks	California	91320	USA
Ancrod	Viprinex	10/20/89	To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.	Designated			N/A	N/A	Knoll Pharmaceutical Company	"3000 Continental Dr., North"		Mt. Olive	New Jersey	7828	USA
andexanet alfa	n/a	2/23/15	For reversing the anticoagulant effect of direct or indirect factor Xa inhibitors in patients experiencing a serious uncontrolled bleeding event or who require urgent or emergent surgery	Designated			N/A	N/A	Portola Pharmaceuticals	270 East Grand Avenue		South San Francisco	California	94080	USA
anfibatide	n/a	3/10/16	Treatment of thrombotic thrombocytopenic purpura.	Designated			N/A	N/A	Lee's Pharmaceutical (Hong Kong) Limited	"Unit 110-11, Bio-Informatics Centre"	"Hong Kong Science Park, Shatin, Hong Kong"				China
Angiotensin (1-7)	n/a	11/26/13	Treatment of limb-girdle muscular dystrophy	Designated			N/A	N/A	"US Biotest, Inc."	231 Bonetti Drive	Suite 240	San Luis Obispo	California	93401	USA
angiotensin (1-7)	n/a	8/30/13	Treatment of patients requiring stem cell transplantation to accelerate the mobilization of hematopoietic stem cells (CD34+) from the bone marrow to the peripheral blood when combined with a granulocyte colony-stimulating factor	Designated			N/A	N/A	"US Biotest, Inc."	"231 Bonetti Dr.,"	Suite 240	San Luis Obispo	California	93401	USA
Angiotensin (1-7)	n/a	2/8/16	Treatment of LAMA2-related muscular dystrophy	Designated			N/A	N/A	"Tarix Orphan, LLC"	12 Bow Street		Cambridge	Massachusetts	2138	USA
Angiotensin (1-7)	n/a	9/1/16	Treatment of recessive dystrophic epidermolysis bullosa (RDEB).	Designated			N/A	N/A	"Tarix Orphan, LLC"	12 Bow Street		Cambridge	Massachusetts	2138	USA
angiotensin (1-7)[A(1-7)]	n/a	7/25/13	Treatment of Duchenne muscular dystrophy	Designated			N/A	N/A	"US Biotest, Inc."	"231 Bonetti Dr.,"	Suite 240	San Luis Obispo	California	93401	USA
angiotensin 1-7	n/a	6/17/10	"To accelerate engraftment of hematopoietic cells (treatment of neutropenia, thrombocytopenia, lymphoma, and aneima)in hematopoietic stem cell transplants."	Designated			N/A	N/A	"US Biotest, Inc."	"231 Bonetti Dr.,"	Suite 240	San Luis Obispo	California	93401	USA
Angiotensin 1-7	Marstem	8/3/01	Treatment of myelodysplastic syndrome	Designated			N/A	N/A	Maret Pharmaceutical Corporation	"4041 MacArthur Boulevard, Suite 375"		Newport Beach	California	92660	USA
Angiotensin 1-7	n/a	2/16/00	Treatment of neutropenia associated with autologous bone marrow transplantation.	Designated			N/A	N/A	Maret Pharmaceuticals	4041 MacArthur Blvd.	Suite 375	Newport Beach	California	92660	USA
angiotensin 1-7	n/a	1/29/10	Treatment of sarcoma.	Designated			N/A	N/A	"W. Jeffrey Petty, MD"	Wake Forest University Health Sciences		Winston-Salem	North Carolina	27157	USA
Angiotensin-(1-7)	n/a	9/13/11	Treatment of pulmonary arterial hypertension.	Designated			N/A	N/A	"US Biotest, Inc."	231 Bonetti Drive	Suite 240	San Luis Obispo	California	93401	USA
anisina	n/a	7/14/15	Treatment of neuroblastoma.	Designated			N/A	N/A	Novogen Ltd	16-20 Edgeworth David Avenue	"Hornsbsy, NSW 2077"				Australia
anlotinib hydrochloride	n/a	12/31/15	Treatment of ovarian cancer	Designated			N/A	N/A	"Advenchen Laboratories, LLC"	887 Patriot Drive	Suite A	Moorpark	California	93021	USA
antagonist of the complement 5a receptor	n/a	11/17/14	Treatment of atypical hemolytic uremic syndrome	Designated			N/A	N/A	"ChemoCentryx, Inc."	850 Maude Avenue		Mountain View	California	94043	USA
antagonist of the complement 5a receptor	n/a	6/2/14	"Treatment of anti-neutrophil cytoplasmic autoantibodies associated vasculitides (granulomatosis with polyangiitis or Wegener's granulomatosis), microscopic polyangiitis, and Churg-Strauss syndrome."	Designated			N/A	N/A	"ChemoCentryx, Inc."	850 Maude Avenue		Mountain View	California	94043	USA
"antagonist of the endosomal Toll-like receptors (TLRs) 7, 8, and 9"	n/a	12/23/14	Treatment of Waldenstrom's macroglobulinemia	Designated			N/A	N/A	"Idera Pharmaceuticals, Inc."	167 Sidney Street		Cambridge	Massachusetts	2139	USA
anthrax immune globulin	n/a	9/3/09	Treatment of inhalation anthrax disease	Designated/Withdrawn			N/A	N/A	"Emergent Biosolutions, Inc."	300 Professional Drive		Gaithersburg	Maryland	20879	USA
anthrax immune globulin (human)	n/a	7/29/08	Treatment of inhalational anthrax	Designated/Approved	Approved for Orphan Indication	Treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs	03/24/2015	03/24/2022	Cangene Corp. - Emergent Biosolutions	155 Innovation Drive	R3T 5Y3	"Winnipeg, MB"			Canada
Anthrax Vaccine Adsorbed	Biothrax	4/11/14	For post-exposure prophylaxis of anthrax disease resulting from suspected or confirmed Bacillus anthracis exposure	Designated/Approved	Approved for Orphan Indication	"For post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs."	11/23/2015	11/23/2022	Emergent BioDefense Operations Lansing LLC	300 Proessional Drive		Gaithersburg	Maryland	20879	USA
anti human Nogo-A human monoclonal antibody	n/a	10/20/08	Treatment of acute spinal cord injury	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
Anti pan T lymphocyte monoclonal antibody	Anti-T Lymphocyte Immunotoxin Xmmly-H65-Rta	1/29/86	1. For ex-vivo treatment to eliminate mature T cells from potential bone marrow grafts 2. For in-vivo treatment of bone marrow recipients to prevent graft rejection and graft versus host disease.	Designated/Withdrawn			N/A	N/A	Xoma Corporation	2910 Seventh Street		Berkeley	California	94710	USA
Anti-Beta1 integrin monoclonal antibody	n/a	8/7/14	Treatment of glioblastoma	Designated			N/A	N/A	"OncoSynergy, Inc."	409 Illinois Street	Room 3044	San Francisco	California	94158	USA
anti-Beta1 integrin monoclonal antibody	n/a	1/13/15	Treatment of ovarian cancer	Designated			N/A	N/A	"OncoSynergy, Inc."	409 Illinois Street	Room 3044	San Francisco	California	94158	USA
"anti-CD23 IgG1, kappa monoclonal antibody"	n/a	2/12/03	Treatment of chronic lymphocytic leukemia	Designated/Withdrawn			N/A	N/A	"Biogen IDEC, Inc."		5200 Research Place	San Diego	California	92122	USA
anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein and anti-CD7 mAb (WT1)-ricin A chain fusion protein	n/a	9/13/13	Treatment of graft versus host disease	Designated			N/A	N/A	Xenikos BV	Molenveldlaan 152A	6523RN	NIJMEGEN			Netherlands
anti-CD30 Fc engineered humanized monoclonal antibody	n/a	12/2/08	Treatment of Hodgkin lymphoma	Designated			N/A	N/A	"Xencor, Inc."	111 W. Lemon Avenue		Monrovia	California	91016	USA
Anti-CD45 monoclonal antibodies	n/a	9/10/90	Prevention of acute graft rejection of human organ transplants.	Designated/Withdrawn			N/A	N/A	Baxter Healthcare Corporation	1620 Waukegan Road		Mcgaw Park	Illinois	60085	USA
Anti-CEA Sheep-human chimeric monoclonal antibody labeled w/iodine-131 (KAb201)	n/a	5/21/03	Treatment of pancreatic cancer	Designated/Withdrawn			N/A	N/A	Avaant Pharmaceuticals India Ltd.	"3rd Floor, Neelkanth Commercial Centre"	Mumbai - 400 099				India
Anti-cytomegalovirus monoclonal antibodies	n/a	5/3/90	1. Treatment of human cytomegalovirus infection in patients diagnosed with AIDS 2. Prevention of human cytomegalovirus infection in patients diagnosed with AIDS	Designated/Withdrawn			N/A	N/A	Biomedical Research Institute	345 North Smith Avenue		St. Paul	Minnesota	55102	USA
Anti-cytomegalovirus monoclonal antibodies	n/a	5/2/90	1. Treatment of human cytomegalovirus infection in bone marrow and organ transplant patients 2. Prevention of human cytomegalovirus infection in bone marrow and organ transplant patients	Designated/Withdrawn			N/A	N/A	Biomedical Research Institute	345 North Smith Avenue		St. Paul	Minnesota	55102	USA
Anti-EphA1 monoclonal antibody conjugated to mcMMAF	n/a	7/27/09	Treatment of ovarian cancer	Designated/Withdrawn			N/A	N/A	"MedImmune, LLC"	One MedImmune Way		Gaithersburg	Maryland	20878	USA
Anti-eTau Humanized IgG4 Monoclonal Antibody	n/a	5/13/15	Treatment of Progressive Supranuclear Palsy	Designated			N/A	N/A	Britol-Myers Squibb Company	P. O. Box 4000		Princeton	New Jersey	8543	USA
anti-HER2 bispecific antibody	n/a	5/18/16	Treatment of ovarian cancer	Designated			N/A	N/A	Zymeworks Inc.	18 West Mercer Street	Suite 370	Seattle	Washington	98119	USA
anti-HER2 bispecific antibody drug conjugate	n/a	7/6/16	Treatment of ovarian cancer	Designated			N/A	N/A	Zymeworks Inc.	18 West Mercer Street	Suite 370	Seattle	Washington	98119	USA
anti-inhibitor coagulant complex	Feiba	4/12/13	Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors	Designated/Approved	Approved for Orphan Indication	Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors	12/16/2013	12/16/2020	"Baxalta US, Inc."	One Baxter Way		West Lake Village	California	91362	USA
anti-interferon-gamma Fab from goats	n/a	11/18/03	For the treatment of immunologic corneal allograft rejection	Designated			N/A	N/A	"Advanced Biotherapy, Inc."	6355 Topanga Canyon Blvd.	Suite 510	Woodland Hills	California	91367	USA
anti-interleukin 21 (NNC0114-0006) in combination with liraglutide	n/a	1/12/17	Treatment of Type I Diabetes Mellitus with residual beta cell function.	Designated			N/A	N/A	"Novo Nordisk, Inc."	800 Scudders Mill Road	P. O. Box 846		New Jersey	8536	USA
anti-Lewis Y humanized monoclonal antibody	n/a	3/9/12	Treament of ovarian cancer	Designated			N/A	N/A	Recepta Biopharma S.A.	"Rua Tabapua, 1123 cj.36"	04533-014				Brazil
anti-nogo-A monoclonal antibody	n/a	7/7/09	Treatment of amyotrophic lateral sclerosis	Designated/Withdrawn			N/A	N/A	GlaxoSmithKline	Glaxo Wellcome House	"Greenford, Middlesex, UK UB6 0NN"				United Kingdom
anti-sense oligonucleotide consisting of 2_0-Me RNA with a phosphorothioate backbone	n/a	9/23/13	Treatment of cystic fibrosis	Designated			N/A	N/A	ProQR Therapeutics III B.V.	"Zernikedreef 9, 2333 CK Leiden"	The Netherlands				Netherlands
anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single domain antibody	n/a	8/29/16	Treatment of pancreatic cancer	Designated			N/A	N/A	"Singh Biotechnology, LLC"	4708 Rue Bordeaux		Lutz	Florida	33558	USA
Anti-T cell receptor murine monoclonal antibody	n/a	4/3/09	Prophylaxis of acute rejection of solid organ transplantation	Designated			N/A	N/A	"Tolera Therapeutics, Inc."	4717 Campus Drive #800		Kalamazoo	Michigan	49008	USA
"anti-T-lymphocyte immune globulin, rabbit"	Atg-Fresenius(R)	3/26/10	Prevention of graft versus host disease (GVHD)	Designated			N/A	N/A	"Neovii Biotech NA, Inc."	430 Bedford Street	Suite 195	Lexington	Massachusetts	2420	USA
"anti-T-lymphocyte immune globulin, rabbit"	n/a	9/12/08	Prophylaxis of acute allograft rejection in adult recipients in solid organ transplantation	Designated			N/A	N/A	"Neovii Biotech NA, Inc."	430 Bedford Street	Suite 195	Lexington	Massachusetts	2420	USA
Anti-tap-72 immunotoxin	Xomazyme-791	3/6/87	Treatment of metastatic colorectal adenocarcinoma.	Designated/Withdrawn			N/A	N/A	Xoma Corporation	2910 Seventh Street		Berkeley	California	94710	USA
"anti-TCR murine monoclonal antibody (MAb, type IgM)"	n/a	6/7/10	Treatment of patients 16 years of age and younger with immune-mediated T1DM and preserved pancreatic beta cell function	Designated			N/A	N/A	"Tolera Therapeutics, Inc."	350 E. Michigan Avenue		Kalamazoo	Michigan	49001	USA
"anti-TCR murine monoclonal antibody (MAB, type IgM)"	n/a	1/12/11	Treatment of pediatric multiple sclerosis in patients less than or equal to 16 years of age	Designated			N/A	N/A	"Tolera Therapeutics, Inc."	350 E. Michigan Ave.		Kalamazoo	Michigan	49008	USA
Anti-tenascin 81C6 monoclonal antibody labeled w/ I 131	Neuradiab	10/4/05	Treatment of primary malignant brain tumors	Designated			N/A	N/A	"Bradmer Pharmaceuticals, Inc."	9900 Corporate Campus Drive	Suite 3000	Louisville	Kentucky	40223	USA
anti-thymocyte Globulin (rabbit)	Thymoglobulin	9/6/00	Treatment of myelodysplastic syndrome	Designated/Withdrawn			N/A	N/A	Genzyme Corporation	A Sanofi Company	500 Kendall Street	Cambridge	Massachusetts	2142	USA
anti-thymocyte globulin [rabbit]	Thymoglobulin	5/25/10	Prophylaxis of acute organ rejection in patients receiving renal transplants	Designated			N/A	N/A	Genzyme Corporation	500 Kendall Street		Cambridge	Massachusetts	2142	USA
Anti-thymocyte serum	Nashville Rabbit Anti-Thymocyte Serum	6/2/93	"Treatment of allograft rejection, including solid organ (kidney, liver, heart, lung, and pancreas) and bone marrow transplantation."	Designated			N/A	N/A	Applied Medical Research	1600 Hayes Street		Nashville	Tennessee	37203	USA
anti-tumor necrosis factor (TNF) polyclonal antibody (bovine)	n/a	11/17/14	Treatment of pediatric ulcerative colitis (0 through 16 years of age)	Designated			N/A	N/A	"Avaxia Biologics, Incorporated"	"128 Spring St., Suite 620"		Lexington	Massachusetts	2421	USA
Anti-von Willebrand Aptamer	n/a	4/9/08	Treatment of thrombotic thrombocytopenic purpura	Designated/Withdrawn			N/A	N/A	Archemix Corporation	300 Third Street		Cambridge	Massachusetts	2142	USA
antiangiogenic components extracted from marine cartilage	Neovastat (Ae-941)	10/16/02	Treatment of renal cell carcinoma	Designated			N/A	N/A	"AEterna Zentaris, Inc."	Dr. Claude Hariton	"Chief Medical Officer, VP, Cli"	"Quebec G1P 4P5, Canada"			Canada
Antibody drug conjugate consisting of a humanized IgG1 anti-NaPi2b monoclonal antibody and monomethyl auristatin E	n/a	7/29/14	Treatment of ovarian cancer	Designated/Withdrawn			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
antibody drug conjugate consisting of fully human anti-guanylyl cyclase C monoclonal antibody linked to the cytotoxic drug monomethyl auristatin E	n/a	7/21/14	Treatment of gastric cancer	Designated/Withdrawn			N/A	N/A	"Millennium Pharmaceuticals, Inc."	40 Landsdowne Street		Cambridge	Massachusetts	2139	USA
Antiepilepsirine	n/a	3/23/89	Treatment of drug resistant generalized tonic-clonic epilepsy in children and adults.	Designated			N/A	N/A	Children's Hospital	700 Children's Drive		Columbus	Ohio	43205	USA
Antihemophilic factor (human)	Alphanate	1/5/96	Treatment of von Willebrand's disease	Designated/Approved	Approved for Orphan Indication	For surgical and/or invasive procedures in patients with von Willebrand Disease (VWD) in whom desmopressin is either ineffective or contraindicated. It is not indicated for patients with severe VWD (Type 3) undergoing major surgery	01/31/2007	01/31/2014	Grifols Biologicals Inc.	5555 Valley Boulevard		Los Angeles	California	90032	USA
Antihemophilic factor (recombinant)	"Refacto, Xyntha"	2/8/96	For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).	Designated/Approved	Approved for Orphan Indication		03/06/2000	N/A	"Wyeth Pharmaceuticals, Inc."	P. O. Box 8299		Philadelphia	Pennsylvania	19101	USA
Antihemophilic factor (recombinant)	Kogenate	9/25/89	Prophylaxis and treatment of bleeding in individuals with hemophilia A or for prophylaxis when surgery is required in individuals with hemophilia A.	Designated/Approved	Approved for Orphan Indication	Treatment and prophylaxis of bleeding in patients with hemophilia A (not von Willebrand's disease)	02/25/1993	02/25/2000	Bayer Corporation	1884 Miles Avenue		Elkhart	Indiana	46515	USA
Antihemophilic factor (recombinant) formulated with sucrose reconstituted with liposome diluent	Kogenate Fs/Liposomal Diluent	4/29/09	Treatment of hemophilia A	Designated/Withdrawn			N/A	N/A	Bayer HealthCare LLC	555 Whiteplains Road		Tarrytown	New York	10591	USA
"antihemophilic factor (recombinant), Fc fusion protein"	Eloctate	11/23/10	Treatment of hemophilia A	Designated/Approved	Approved for Orphan Indication	"Treatment of adults and children with Hemophilia A (congenital Factor VIII deficiency) for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes."	06/06/2014	06/06/2021	Biogen Idec Inc.	14 Cambridge Center		Cambridge	Massachusetts	2142	USA
"antihemophilic factor (recombinant), porcine sequence"	Obizur	3/16/04	Treatment and prevention of episodic bleeding in patients with inhibitor antibodies to human coagulation factor VIII	Designated/Approved	Approved for Orphan Indication	Treatment of bleeding episodes in adults with acquired hemophilia A.	10/23/2014	10/23/2021	"Baxalta US, Inc."	1 Baxter Way	Mail Box Number 1A-3	Westlake Village	California	91362	USA
"Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized"	Humate-P	10/16/92	Treatment of patients with von Willebrand's disease	Designated/Approved	Approved for Orphan Indication	"(1) In adult patients for treatment and prevention of bleeding in hemophilia A (classic hemophilia) and (2) in adult and pediatric patients for treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease, and in mild and moderate von Willebrand disease where use of desmopressin is known or suspected to be inadequate."	04/01/1999	04/01/2006	CSL Behring	1020 First Avenue	PO Box 61501	King Of Prussia	Pennsylvania	19406	USA
Antimelanoma Antibody XMMME-001-DTPA 111 Indium	Antimelanoma Antibody Xmmme-001-Dtpa 111 Indium	11/14/84	Diagnostic use in imaging systemic and nodal melanoma metastasis.	Designated/Withdrawn			N/A	N/A	Xoma Corporation	2910 Seventh Street		Berkeley	California	94710	USA
Antimelanoma Antibody XMMME-001-RTA	Antimelanoma Antibody Xmmme-001-Rta	11/14/84	Treatment of stage III melanoma not amenable to surgical resection.	Designated/Withdrawn			N/A	N/A	Xoma Corporation	2910 Seventh Street		Berkeley	California	94710	USA
antimesothelin-ADC (antibody drug conjugate)	n/a	7/5/12	Treatment of mesothelioma	Designated			N/A	N/A	"Bayer HealthCare Pharmaceuticals, Inc."	340 Changebridge Road		Pine Brook	New Jersey	7058	USA
"antineoplaston A10, antineoplaston AS2-1"	n/a	11/21/08	Treatment of gliomas	Designated			N/A	N/A	"Burzynski Research Institute, Inc."	9432 Old Katy Road		Houston	Texas	77055	USA
antinuclear antibody conjugated liposomal doxorubicin	n/a	2/3/15	Treatment of Ewing's sarcoma.	Designated			N/A	N/A	"NanoSmart Pharmaceuticals, Inc."	27071 Cabot Road	Suite 104	Laguna Hills	California	92653	USA
Antipyrine Test	n/a	2/21/85	For use as an index of hepatic drug-metabolizing capacity.	Designated/Withdrawn			N/A	N/A	"Upsher-Smith Laboratories, Inc"	4905 23rd Avenue North		Minneapolis	Minnesota	55447	USA
Antisense 20-mer oligonucleotide complementary to R2 component of ribonucleotide reductase mRNA	n/a	4/15/05	Treatment of acute myeloid leukemia	Designated			N/A	N/A	"Lorus Therapeutics, Inc."	2 Meridan Road		M9W 4Z7			Canada
antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA]	Gti-2040	3/12/03	Treatment for renal cell carcinoma	Designated			N/A	N/A	"Lorus Therapeutics, Inc"	2 Meridan Road	M9W427				Canada
antisense oligonucleotide complementary to the exonic splicer enhancer sequence at intron 26 of the centrosomal protein 290 pre-mRNA	n/a	5/25/16	Treatment of Leber's congenital amaurosis.	Designated			N/A	N/A	ProQR Therapeutics IV B.V.	"Zernikedreef 9, 2333 CK Leiden"		Leiden			Netherlands
Antisense oligonucleotide directed against connexin43	Nexagon	4/27/09	Treatment of persistent corneal epithelial defects	Designated			N/A	N/A	"CoDa Therapeutics, Inc."	10505 Sorrento Valley Road		San Diego	California	92121	USA
antisense oligonucleotide inhibitor of the expression of superoxide dismutase 1 gene	n/a	9/19/16	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	Biogen	225 Binney Street		Cambridge	Massachusetts	2142	USA
antisense oligonucleotide targeted to human transthyretin (TTR) mRNA	n/a	7/24/12	Treatment of familial amyloid polyneuropathy	Designated			N/A	N/A	"Isis Pharmaceuticals, Inc."	2855 Gazelle Court		Carlsbad	California	92010	USA
Antisense oligonucleotide targeted to the huntingtin protein	n/a	12/29/15	Treatment of Huntington's disease	Designated			N/A	N/A	"Isis Pharmaceuticals, Inc."	2855 Gazelle Court		Carlsbad	California	92010	USA
antisense oligonucleotide targeting the U isoform of SNP rs362307	n/a	6/16/16	Treatment of Huntington's disease (prodromal stage Huntington's disease and diagnosed Huntington's disease)	Designated			N/A	N/A	Wave LIfe Sciences	733 Concord Avenue		Cambridge	Massachusetts	2138	USA
Antithrombin III (human)	Atnativ	2/8/85	For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.	Designated/Approved	Approved for Orphan Indication		12/13/1989	12/13/1996	Pharmacia & Upjohn AB	Lindhagensgatan 133	Stockholm				Sweden
Antithrombin III (human)	Thrombate Iii	11/26/84	For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.	Designated/Approved	Approved for Orphan Indication		12/30/1991	12/30/1998	Bayer Corporation	"Pharmaceutical Division, Biological Products"	400 Morgan Lane	New Haven	Connecticut	6516	USA
Antithrombin III (human) concentrate IV	Kybernin P	7/2/85	For prophylaxis and treatment of thromboembolic episodes in patients with genetic AT-III deficiency.	Designated/Withdrawn			N/A	N/A	CSL Behring	1020 First Ave.	PO Box 61501	King of Prussia	Pennsylvania	19406	USA
Antithrombin III human	Antithrombin Iii Human	1/2/86	Preventing or arresting episodes of thrombosis in patients with congenital AT-III deficiency and/or to prevent the occurrence of thrombosis in patients with AT-III deficiency who have undergone trauma or who are about to undergo surgery or parturition.	Designated			N/A	N/A	American National Red Cross	9312 Old Georgetown Road		Bethesda	Maryland	20814	USA
Antivenin crotaline (pit-viper) equine immune F(ab)2)	Anavip	1/29/04	Treatment of envenomation by Crotaline snakes	Designated/Approved	Approved for Orphan Indication	Management of adult and pediatric patients with North American rattlesnake envenomation	05/06/2015	N/A	"Rare Disease Therapeutics, Inc."	2550 Meridian Blvd	Suite 150	Franklin	Tennessee	37067	USA
"Antivenin, crotalidae polyvalent immune Fab (ovine)"	Crofab	1/12/94	Treatment of envenomations inflicted by North American crotalid snakes.	Designated/Approved	Approved for Orphan Indication	Treatment of minimal and moderate North American Crotalidae envenomation	10/02/2000	10/02/2007	"Protherics, Inc."	"1207 17th Ave. S., Suite 103"		Nashville	Tennessee	37212	USA
Antivenom (crotalidae) purified (avian)	n/a	2/12/91	Treatment of envenomation by poisonous snakes belonging to the Crotalidae family.	Designated			N/A	N/A	"Ophidian Pharmaceuticals, Inc."	5445 East Cheryl Parkway		Madison	Wisconsin	53711	USA
antroquinonol	n/a	1/21/15	Treatment of pancreatic cancer	Designated			N/A	N/A	Golden Biotechnology Corp.	"10F., No. 9, Ln 3"	"Tamsui Dist., New Taipei City 251"				Taiwan
antroquinonol	Hocena(R)	4/30/15	Treatment of acute myeloid leukemia	Designated			N/A	N/A	Golden Biotechnology Corporation	"10F, No. 9, Ln. 3, Sec. 1, Zhong-Zheng E. Rd"	New Taipei City 251				Taiwan
antroquinonol	n/a	7/23/15	Treatment of hepatocellular carcinoma	Designated			N/A	N/A	Golden Biotechnology Corporation	"10F, No. 9, Ln. 3"	"Tamsui Dist., New Taipei City 251"				Taiwan
aphidicolin	n/a	4/20/16	Treatment of Ebola virus infection	Designated			N/A	N/A	Biospherics.net LLC	Department of Pharmaceutical Sciences	University of Kentucky	Nicholasville	Kentucky	40356	USA
apolipoprotein E mimetic peptide	n/a	12/3/12	Treatment of homozygous familial hypercholesterolemia	Designated			N/A	N/A	"LipimetiX Development, LLC"	5 Commonwealth Road	Suite 2A	Natick	Massachusetts	1760	USA
Apomorphine	n/a	10/20/97	For use as rescue treatment for early morning motor dysfunction in late-stage Parkinson's disease.	Designated/Withdrawn			N/A	N/A	Scherer DDS	Frankland Road	Swindon SN5 8RU	Wiltshire			United Kingdom
Apomorphine	n/a	7/17/95	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	Designated			N/A	N/A	"Pentech Pharmaceuticals, Inc."	1110 Lake Cook Rd.	Suite 257	Buffalo Grove	Illinois	60089	USA
Apomorphine HCl	Apokyn	4/22/93	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	Designated/Approved	Approved for Orphan Indication	"For the acute, intermittent treatment of hypomobility, ""off"" episodes (""end-of-dose-wearing-off"" and unpredictable :on/off"" episodes) associated with advanced Parkinson's disease"	04/20/2004	04/20/2011	"US WorldMeds, LLC"	4010 Dupont Circle	Suite L-07	Louisville	Kentucky	40207	USA
Apomorphine hydrochloride	n/a	5/23/06	For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous)	Designated			N/A	N/A	"NeuroHealing Pharmaceuticals, Inc."	50 Undine Road		Newton	Massachusetts	2135	USA
apremilast	n/a	1/17/13	Treatment of Behcet's disease	Designated			N/A	N/A	Celgene Corporation	86 Morris Avenue		Summit	New Jersey	7901	USA
Aprotinin	Trasylol	11/17/93	"For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary coronary artery bypass graft surgery where the risk of bleeding is especially high (impaired hemostasis) or where transfusion is unavailable or unacceptable."	Designated/Approved	Approved for Orphan Indication		12/29/1993	12/29/2000	Bayer Corporation	Pharmaceutical Division	400 Morgan Lane	West Haven	Connecticut	6516	USA
AQ-13 (4-aminoquinoline analog)	n/a	9/12/08	Treatment of malaria	Designated			N/A	N/A	"Immtech Pharmaceuticals, Inc."	150 Fairway Drive		Vernon Hills	Illinois	60061	USA
Arcitumomab	99m Tc-Labeled Cea-Scan	5/10/96	"Diagnosis and localization of primary, residual, recurrent and metastatic medullary thyroid carcinoma."	Designated/Withdrawn			N/A	N/A	"Immunomedics, Inc."	300 American Road		Morris Plains	New Jersey	7950	USA
Arenegyr	n/a	8/22/08	Treatment of malignant pleural mesothelioma	Designated			N/A	N/A	MolMed S.p.A.	Via Olgettina 58		Milan			Italy
Arginine butyrate	n/a	5/25/94	Treatment of sickle cell disease and beta thalassemia.	Designated/Withdrawn			N/A	N/A	Vertex Pharmaceuticals Inc.	130 Waverly Street		Cambridge	Massachusetts	2139	USA
Arginine butyrate	n/a	4/7/92	Treatment of beta-hemoglobinopathies and beta-thalassemia.	Designated			N/A	N/A	"Perrine, Susan P., M.D."	Boston University	Cancer Research Center	Boston	Massachusetts	2118	USA
arimoclomol	n/a	3/29/05	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	Orphazyme ApS	3 Ole Maales Vej		Copenhagen			Denmark
arimoclomol citrate	n/a	1/13/15	"Treatment of Neimann-Pick disease, type C"	Designated			N/A	N/A	Orphazyme ApS	Ole Maaloes Vej 3	2200 Copenhagen				Denmark
aripiprazole	Abilify	1/25/06	Treatment of Tourette's syndrome	Designated/Approved	Approved for Orphan Indication	Treatment of pediatric patients with Tourette's	12/12/2014	12/12/2021	Otsuka Pharmaceutical Development	and Commercialization	1st Floor	Princeton	New Jersey	8540	USA
arsenic	Trisenox	11/2/01	"Treatment of acute myelocytic leukemia subtypes M0, M1, M2, M4, M5, M6 and M7"	Designated			N/A	N/A	"Teva Branded Pharmaceutical Products R&D, Inc."	41 Moores Road	P. O. Box 4011	Frazer	Pennsylvania	19355	USA
Arsenic trioxide	Trisenox	5/13/03	Treatment of chronic lymphocytic leukemia	Designated			N/A	N/A	"Teva Branded Pharmaceutical Products R&D, Inc."	41 Moores Road	P.O. Box 4011	Frazer	Pennsylvania	19355	USA
Arsenic trioxide	Trisenox	3/3/98	Treatment of acute promyelocytic leukemia.	Designated/Approved	Approved for Orphan Indication	"For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation of PML/RAR-alpha gene expression."	09/25/2000	09/25/2007	Cephalon	41 Moores Road	PO Box 4011	Frazer	Pennsylvania	19355	USA
arsenic trioxide	Trisenox	7/17/00	Treatment of myelodysplastic syndrome.	Designated			N/A	N/A	"Teva Branded Pharmaceutical Products R&D, Inc."	41 Moores Road	P.O. Box 4011	Frazer	Pennsylvania	19355	USA
Arsenic trioxide	Trisenox	4/28/00	Treatment of multiple myeloma.	Designated			N/A	N/A	"TEVA Branded Pharmaceutical Products R & D, Inc."	41 Moores Road		Frazer	Pennsylvania	19355	USA
arsenic trioxide	Trisenox	6/13/03	Treatment of liver cancer	Designated			N/A	N/A	"Teva Branded Pharmaceutical Products R&D, Inc."	41 Moores Road	P. O. Box 4011	Frazer	Pennsylvania	19355	USA
Arsenic trioxide	Trisenox	3/4/05	Treatment of malignant glioma	Designated			N/A	N/A	"Teva Branded Pharmaceutical Products R&D, Inc."	41 Moores Road	P. O. Box 4011	Frazer	Pennsylvania	19355	USA
arsenic trioxide	Trisenox	10/18/01	Treatment of chronic myeloid leukemia	Designated			N/A	N/A	"Teva Branded Pharmaceutical Products R*D, Inc."	41 Moores Road		Frazer	Pennsylvania	19355	USA
arsenic trioxide capsule (oral)	n/a	11/2/15	Treatment of acute promyelocytic leukemia.	Designated			N/A	N/A	Orsenix Holdings BV	1105 North Market Street	Suite 1800	Wilmington	Delaware	19801	USA
artemether/lumefantrine	Coartem	8/31/07	For the treatment of infections due to Plasmodium falciparum or mixed infections including P. falciparum.	Designated/Approved	Approved for Orphan Indication	"Treatment of malaria in patients of 5 kg bodyweight or above with acute, uncomplicated malaria due to Plasmodium falciparum or mixed infections including P. falciparum"	04/07/2009	04/07/2016	Novartis Pharmaceuticals	Bldg 405/4051	One Health Plaza	East Hanover	New Jersey	7936	USA
Artesunate	n/a	7/19/99	Treatment of malaria.	Designated			N/A	N/A	World Health Organization	Special Programme for Research and Training in Tro	"Via Appia , Geneva 27"				Switzerland
Artesunate	n/a	3/28/06	Immediate treatment of malaria	Designated			N/A	N/A	US Army Medical Materiel Development Activity	Office of the Surgeon General	622 Neiman Street	Ft. Detrick	Maryland	21702	USA
arylsulfatase A (rhASA)	n/a	2/27/08	Treatment of metachromatic leukodystrophy	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	300 Shire Way		Lexington	Massachusetts	2421	USA
Ascorbic acid	Ascor L 500	8/31/07	Treatment of scurvy	Designated			N/A	N/A	McGuff Pharmaceuticals Inc.	2921 W. McArthur Blvd.	Suite 141	Santa Ana	California	92704	USA
Asfotase alfa	Strensiq	9/12/08	Treatment of hypophosphatasia	Designated/Approved	Approved for Orphan Indication	For the treatment of patients with perinatal/infantile-and juvenile-onset hypophosphatasia (HPP)	10/23/2015	10/23/2022	"Alexion Pharmaceuticals, Inc."	352 Knotter Drive		Cheshire	Connecticut	6410	USA
astuprotimut-R	n/a	5/29/09	Treatment of MAGE-A3 positive non-small cell lung cancer	Designated			N/A	N/A	"GlaxoSmithKline Biologicals, S.A."	Rue de I'Institut 89	B-1330 Rixensart				Belgium
astuprotimut-R	n/a	5/29/09	Treatment of MAGE-A3 positive stages IIb to IV malignant melanoma	Designated/Withdrawn			N/A	N/A	"GlaxoSmithKline Biologicals, S.A."	Rue de l'Institut 89					Belgium
ataluren	n/a	1/10/05	Treatment of Muscular Dystrophy resulting from premature stop mutations in the dystrohin gene	Designated			N/A	N/A	"PTC Therapeutics, Inc."	100 Corporate Court		South Plainfield	New Jersey	7080	USA
ataluren	n/a	3/10/08	Treatment of spinal muscular atrophy	Designated			N/A	N/A	"PTC Therapeutics, Inc."	100 Corporate Court		South Plainfield	New Jersey	7080	USA
ataluren	Translarna	12/10/14	Treatment of mucopolysaccharidosis type I	Designated			N/A	N/A	"PTC Therapeutics, Inc."	100 Corporate Court		South Plainfield	New Jersey	7080	USA
ataluren	n/a	9/1/04	For use in the treatment of cystic fibrosis resulting fron a nonsense (premature stopcodon) mutation in the cystic bibrosis transmembrane conductance regulatory gene	Designated			N/A	N/A	"PTC Therapeutics, Inc."	100 Corporate Court		South Plainfield	New Jersey	7080	USA
ataluren	n/a	9/1/15	Treatment of aniridia	Designated			N/A	N/A	"PTC Therapeutics, Inc."	100 Corporate Court		South Plainfield	New Jersey	7080	USA
Atezolizumab	n/a	10/13/16	Treatment of small cell lung cancer (SCLC)	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
Atomoxetine hydrochloride	Strattera	8/26/03	Treatment of Tourette's Syndrome	Designated/Withdrawn			N/A	N/A	Eli Lilly & Company	Lilly Corporate Center		Indianapolis	Indiana	46285	USA
Atovaquone	Mepron	8/14/91	"Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3."	Designated/Approved	Approved for Orphan Indication	Prevention of PCP in patients who are intolerant to trimethoprim-sulfamethoxazole.	01/05/1999	01/05/2006	Glaxo Wellcome Research and Development	5 Moore Drive	PO Box 13398	Research Triangle Park	North Carolina	27709	USA
Atovaquone	Mepron	3/16/93	Treatment and suppression of Toxoplasma gondii encephalitis.	Designated/Withdrawn			N/A	N/A	"GlaxoSmithKline, Inc."	5 Moore Drive	PO Box 13398	Research Triangle Park	North Carolina	27709	USA
Atovaquone	Mepron	9/10/90	Treatment of AIDS associated Pneumocystis Carinii Pneumonia.	Designated/Approved	Approved for Orphan Indication	For the acute oral treatment of mild to moderate Pneumocystis carinii pneumonia in patients who are intolerant to trimethoprim-sulfamethoxazole.	11/25/1992	11/25/1999	Glaxo Wellcome Inc.	5 Moore Drive		Research Triangle Park	North Carolina	27709	USA
Atovaquone	Mepron	3/16/93	Primary prophylaxis of HIV-infected persons at high risk for developing Toxoplasma gondii encephalitis.	Designated/Withdrawn			N/A	N/A	"GlaxoSmithKline, Inc."	5 Moore Drive	PO Box 13398	Research Triangle Park	North Carolina	27709	USA
Atrasentan	n/a	9/29/16	Treatment of pediatric nephrotic syndrome	Designated			N/A	N/A	AbbVie Inc.	Regulatory Affairs	1 North Waukegan Road	North Chicago	Illinois	60044	USA
Attenuated autologous cancer cells and granulocyte macrophage colony stimulating factor in combination with activated autologous blood derived T-cells	n/a	4/27/07	Treatment of primary central nervous system malignancies	Designated			N/A	N/A	"TVAX Biomedical, LLC"	8006 Reeder Street		Lenexa	Kansas	66214	USA
auranofin	Ridaura	4/30/10	Treatment of amebiasis	Designated			N/A	N/A	Ctr for Discovery & Innovation in Parasitic Diseas	"U. of CA, San Francisco"	"QB3, Byers Hall 508B"	San Francisco	California	94158	USA
autologous adipose derived mesenchymal stromal cells	n/a	10/22/14	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	Mayo Clinic	200 First Street SW		Rochester	Minnesota	55905	USA
autologous adipose tissue derived mesenchymal stem cells	n/a	5/4/16	Treatment of Buerger's disease (thromboangiitis obliterans).	Designated			N/A	N/A	Biostar Stem Cell Research Institute	"305 Lotte IT Castle 2,"	550-1 Gasan-dong	Seoul			"Korea, Republic of"
autologous antigen presenting cells pulsed with autologous tumor Ig idiotype	Mylovenge	4/18/02	Treatment of multiple myeloma	Designated/Withdrawn			N/A	N/A	Dendreon Corporation	3005 First Avenue		Seattle	Washington	98121	USA
"autologous bone marrow CD34+ cells transduced ex vivo with a self activating HIV-1 -based lentiviral vector, EFS-ADA"	n/a	10/21/14	Treatment of adenosine deaminase deficient severe combined immunodeficiency	Designated			N/A	N/A	"Donald B. Kohn, MD - Professor, UC-UCLA"	"Microbiology, Immunology & Molecular Genetics"	"610 Charles E. Yound Drive, East"	Los Angeles	California	90095	USA
Autologous CD3+ T cells transduced with retroviral vector containing a chimeric antigen receptor directed against CD19 (Autologous CD3+ T cells containing CD19 chimeric antigen receptor)	n/a	11/13/14	Treatment of acute lymphoblastic leukemia (ALL)	Designated			N/A	N/A	"Juno Therapeutics, Inc."	"307 Westlake Ave. N., St. 300"		Seattle	Washington	98109	USA
autologous CD34+ bone marrow derived stem cells transduced with a self-inactivating gammaretroviral vector encoding the human IL2RG (yc)	n/a	1/15/15	Treatment of severe combined immune deficiency-X1	Designated			N/A	N/A	Boston Children's Hospital	Div. of Hematology/Oncology	Karp 08215	Boston	Massachusetts	2115	USA
Autologous CD34+ cells transfected with lentiviral vector containing the human WAS cDNA (Telethon 003)	n/a	4/30/10	Treatment of Wiskott Aldrich syndrome	Designated			N/A	N/A	GlaxoSmithKline Intellectual Property Development	980 Great West Road	TW8 9GS England				United Kingdom
autologous CD34+ hematopoietic stem cells tranduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA	n/a	4/19/12	Treatment of andrenoleukodystrophy	Designated			N/A	N/A	"bluebird bio, Inc."	840 Memorial Drive		Cambridge	Massachusetts	2139	USA
autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene	n/a	3/18/13	Treatment of B-thalassemia major and intermedia	Designated			N/A	N/A	"bluebird bio, Inc."	150 second Street		Cambridge	Massachusetts	2141	USA
autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene	n/a	2/26/14	For the treatment of Sickle Cell Disease	Designated			N/A	N/A	bluebird bio Inc.	840 Memorial Dr.	4th Floor	Cambridge	Massachusetts	2139	USA
autologous CD4+/CD8+ T cells expressing a CD19 chimeric antigen receptor (CAR) and a truncated epidermal growth factor receptor.	n/a	10/4/16	Treatment of chronic lymphocytic leukemia	Designated			N/A	N/A	"Juno Therapeutics, Inc."	307 Westlake Avenue	Suite 300	Seattle	Washington	98109	USA
autologous CD4+/CD8+ T cells expressing a CD19 chimeric antigen receptor and a truncated epidermal growth factor receptor	n/a	9/7/16	Treatment of acute lymphoblastic leukemia	Designated			N/A	N/A	"Juno Therapeutics, Inc."	307 Westlake Avenue	Suite 300	Seattle	Washington	98109	USA
autologous CD4+/CD8+ T cells expressing a CD19 chimeric antigen receptor and truncated epidermal growth factor receptor	n/a	4/27/16	Treatment of diffuse large B-cell lymphoma	Designated			N/A	N/A	"Juno Therapeutics, Inc."	307 Westlake Avenue	Suite 300	Seattle	Washington	98109	USA
autologous CD4+/CD8+ T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19	n/a	11/6/14	Treatment of acute lymphoblastic leukemia (inclusive of B-cell acute lymphoblastic leukemia)	Designated			N/A	N/A	"Juno Therapeutics, Inc."	"307 Westlake Avenue, North"	Suite 300	Seattle	Washington	98109	USA
Autologous CD4+/CD8+ T cells transduced with lentiviral vector directed against the NY-ESO-1 protein	n/a	3/28/16	Treatment of soft tissue sarcoma.	Designated			N/A	N/A	"Adaptimmune, LLC"	Two Commerce Square	2001 Market Street	Philadelphia	Pennsylvania	19103	USA
autologous CD4+CD25hiFoxP3+regulatory T cells	n/a	11/19/13	Prevention of graft rejection following solid organ transplantation	Designated			N/A	N/A	iREG Medical AB	"Tallmov 2A,"		Uppsala			Sweden
Autologous cultured endothelial cells on a donor human corneal disk	n/a	6/1/07	"Treatment of Fuch's dystrophy, pseudophakic bullous keratopathy, and bullous keratopathy"	Designated			N/A	N/A	"Cellular Bioengineering, Inc."	1946 Young Street		Honolulu	Hawaii	96826	USA
Autologous dendritic cell/tumor antigens	n/a	9/27/16	Treatment of glioblastoma multiforme (GBM)	Designated			N/A	N/A	China Medical University Hospital	"No. 2, Yude Road, North District"					Taiwan
autologous dendritic cells pulsed with allogeneic tumor cell lysate	n/a	5/6/14	Treatment of malignant mesothelioma	Designated			N/A	N/A	Amphera BV	Onderwijs Blvd 219	5223 DE's-Hertogenbosch				Netherlands
Autologous dendritic cells pulsed with autologous antigens from primay malignant brain tumor cells	Dcvax-Brain	11/29/02	Treatment of primary brain malignant cancer	Designated			N/A	N/A	"Northwest Biotherapeutics, Inc."	22322 20th Avenue SE	Suite 150	Bothell	Washington	98021	USA
Autologous dendritic cells pulsed with recombinant human fusion protein (mucin1- glutathione S transferase) coupled to oxidized polymannose	Cvac(Tm)	9/13/10	Treatment of ovarian cancer.	Designated			N/A	N/A	Prima Biomed Ltd.	1233 High Street	Suite 1	"Armadale, Victoria 3143"			Australia
Autologous DNP-conjugated tumor vaccine	M-Vax	2/23/99	For adjuvant therapy in melanoma patients with surgically resectable lymph node metastasis (Stage III and limited Stage IV disease).	Designated			N/A	N/A	"Avax Technologies, Inc."	9200 Indian Creek Parkway	"Building 9, Suite 200"	Overland Park	Kansas	66210	USA
Autologous Engineered Skin Substitute	Permaderm	6/1/12	Treatment of hospitalized patients with deep partial and full thickness burns requiring grafting.	Designated			N/A	N/A	"Amarantus BioScience Holdings, Inc."	655 Montgomery St.	Suite 900	San Francisco	California	94111	USA
autologous Epstein-Barr virus specific T-cells	n/a	3/9/15	Treatment of Epstein-Barr virus positive non-Hodgkin lymphomas.	Designated			N/A	N/A	"Cell Medica, Inc."	"7505 Fannin Street, Suite 200"		Houston	Texas	77054	USA
autologous ex vivo expanded CD4+-enriched leukocytes treated with the de-methylating agent 5-aza-2-deoxycytidine	Alecsat	9/13/13	Treatment of glioblastoma multiforme	Designated			N/A	N/A	CytoVac A/S	Science & Technology Park Scion DTU	DK-2970	Horsholm			Denmark
autologous ex vivo expanded polyclonal CD4+CD25+CD1271o/-FOXP3+ Regulatory T cells	n/a	5/10/16	Treatment of type 1 diabetes mellitus with residual beta cell function	Designated			N/A	N/A	Caladrius Biosciences	18301 Von Karman	Suite 130	Irvine	California	92612	USA
autologous genetically modified human dermal fibroblasts	n/a	6/10/14	Treatment of dystrophic epidermolysis bullosa.	Designated			N/A	N/A	"Fibrocell Technologies, Inc."	405 Eagleview Blvd		Exton	Pennsylvania	19341	USA
Autologous incubated macrophage	n/a	9/3/04	Therapy to improve the motor and sensory neurological outcome in acute cases of spinal cord injury	Designated			N/A	N/A	"Proneuron Biotechnologies, Inc."	2029 Century Park East	Sixth Floor	Los Angeles	California	90067	USA
"autologous lymphocytes depleted ex vivo of immunoreactive T cells using 4,5"	Theralux Photodynamic Therapy	4/3/08	Treatment of chronic graft versus host disease	Designated			N/A	N/A	"Kiadis Pharma Canada, Inc."	2525 Marie Curie					Canada
Autologous lymphoma-derived immunoglobulin idiotype antigen vaccine conjugated to keyhole limpet hemocyanin	Biovaxid	10/18/11	Treatment of Waldenstrom's macroglobulinemia	Designated			N/A	N/A	"Biovest International, Inc."	324 S. Hyde Park Avenue	Suite 350	Tampa	Florida	33606	USA
autologous neo-uninary conduit	n/a	6/7/11	Treatment of bladder dysfunction requiring incontinent urinary diversion.	Designated			N/A	N/A	"Tengion, Inc."	2900 Potshop Lane		East Norriton	Pennsylvania	19403	USA
Autologous olfactory neural progenitors	Rhinocytes	2/1/08	"Treatment of spinal cord injury patients with ASIA Impairment grades A, B, or C"	Designated			N/A	N/A	"RhinoCyte, Inc."	201 E. Jefferson Street		Louisville	Kentucky	40202	USA
autologous olfactory neural progenitors	Rhinocytes	12/31/08	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	"RhinoCyte, Inc."	201 E. Jefferson Street		Louisville	Kentucky	40202	USA
Autologous or allogeneic limbal epithelial stem cells expanded ex vivo on human amniotic membrane	n/a	7/14/05	Treatment of ocular surface diseases that are characterized by total limbal stem cell deficiency	Designated			N/A	N/A	"TissueTech, Inc."	7000 SW 97th Avenue		Miami	Florida	33173	USA
autologous osteogenic cells cultured from adipose tissue derived stem cells embedded in extracellular matrix with demineralized bone matrix.	n/a	6/30/16	Treatment of congenital pseudarthrosis of the tibia	Designated			N/A	N/A	Novadip Biosciences	11 Granbonpr		Mont-Saint-Guibert			Belgium
autologous peripheral blood T lymphocytes transduced with retroviral vector containing anti CD19 CD28/CD3 zeta chimeric antigen receptor	n/a	3/27/14	Treatment of diffuse large B-cell lymphoma.	Designated			N/A	N/A	"Kite Pharma, Inc."	2225 Colorado Avenue		Santa Monica	California	90404	USA
Autologous stromal vascular cell fraction from adipose tissue (central facitily processed)	Eccs-50	11/9/16	Treatment of impaired hand function due to systemic sclerosis	Designated			N/A	N/A	"Cytori Therapuetics, Inc."	3020 Callan Road		San Diego	California	92121	USA
autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19	n/a	3/14/14	Treatment of chronic lymphocytic leukemia	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19	n/a	1/31/14	For the treatment of Acute Lymphoblastic Leukemia	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor	n/a	4/20/16	Treatment of primary mediastinal B-cell lymphoma.	Designated			N/A	N/A	"Kite Pharma, Inc."	2225 Colorado Avenue		Santa Monica	California	90404	USA
autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor	n/a	4/28/16	Treatment of mantle cell lymphoma.	Designated			N/A	N/A	"Kite Pharma, Inc."	2225 Colorado Avenue		Santa Monica	California	90404	USA
autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor	n/a	4/25/16	Treatment of follicular lymphoma.	Designated			N/A	N/A	"Kite Pharma, Inc."	2225 Colorado Avenue		Santa Monica	California	90404	USA
autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor	n/a	4/20/16	Treatment of chronic lymphocytic leukemia.	Designated			N/A	N/A	"Kite Pharma, Inc."	2225 Colorado Avenue		Santa Monica	California	90404	USA
Autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor	n/a	4/20/16	Treatment of acute lymphoblastic leukemia. (ALL).	Designated			N/A	N/A	"Kite Pharma, Inc."	2225 Colorado Avenue		Santa Monica	California	90404	USA
autologous T-lymphocytes transduced with anti-BCMA02 CAR lentiviral vector encoding a chimeric antigen receptor (CAR) specific for the human B cell maturation antigen	n/a	5/11/16	Treatment of multiple myeloma	Designated			N/A	N/A	"bluebird bio, Inc."	150 second Street		Cambridge	Massachusetts	2141	USA
"autologous tumor cells fused with polyethylene glycol to human allogeneic FO-1, DNA plasmid transfected tumor cell line"	n/a	5/6/15	Treatment of glioblastoma	Designated			N/A	N/A	"Sebastiano Gattoni-Celli, MD"	Med. University of SC- Dept of Radiation Oncology	114 Doughty St.	Charleston	South Carolina	29403	USA
autologous tumor-derived gp96 heat shock protein-peptide complex	Oncophage	5/10/02	Treatment of renal cell carcinoma	Designated			N/A	N/A	"Agenus, Inc."	3 Forbes Rd.		Lexington	Massachusetts	2421	USA
autologous tumor-derived gp96 heat shock protein-peptide complex	Oncophage	7/11/02	Treatment of metastatic melanoma	Designated			N/A	N/A	"Agenus, Inc."	3 Forbes Rd.		l	Massachusetts	2421	USA
autologous umbilical cord blood	n/a	7/24/12	Treatment of pediatric (0-16 yrs old inclusive) cerebral palsy due to acquired brain injury	Designated			N/A	N/A	Duke University	2301 Erwin Road		Durham	North Carolina	27710	USA
autologus CD34+ cells transfected with retroviral vector containing adenosine deaminase gene	n/a	8/26/09	Treatment of severe combined immunodeficiency due to adenosine deaminase deficiency.	Designated			N/A	N/A	Glaxo Group Limited	I-3 Iron Bridge Road	Stockley Park West				United Kingdom
Autolymphocyte therapy	n/a	7/12/94	Treatment of renal cell carcinoma.	Designated			N/A	N/A	Cytogen Corporation	600 College Road East	CN 5308	Princeton	New Jersey	8540	USA
avicin d	n/a	3/24/15	Treatment of multiple myeloma	Designated			N/A	N/A	Avicin Therapeutics Ltd.	Westpark Corporate Center	4634 S. Alston Avenue	Durham	North Carolina	27713	USA
aviptadil	n/a	2/22/05	Treatment of pulmonary arterial hypertension	Designated			N/A	N/A	Mondobiotech Laboratories AG	Herrengasse 21	Furstentum Liechtenstein				Switzerland
axitinib	n/a	5/31/07	Treatment of pancreatic cancer	Designated/Withdrawn			N/A	N/A	"Pfizer, Inc."	10646 Science Center Drive		San Diego	California	92121	USA
azacitidine	Vidaza	12/3/01	Treatament of myelodysplastic syndromes	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia and requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia"	05/19/2004	05/19/2011	Celgene Corporation	9900 W. 109th Street	Suite 300	Overland Park	Kansas	66210	USA
Azacitidine	Vidaza	6/18/08	Treatment of acute myeloid leukemia	Designated			N/A	N/A	Celgene Corporation	9900 W. 109th Street	Suite 300	Overland Park	Kansas	66210	USA
Azathioprine	Imuran	9/14/99	Treatment of oral manifestations of graft-versus-host disease.	Designated			N/A	N/A	"Oral Solutions, Inc."	"787 Seventh Ave., 48th Floor"		New York	New York	10019	USA
aztreonam	n/a	5/15/09	Improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.	Designated/Withdrawn			N/A	N/A	"Gilead Sciences, Inc."	2025 1st Avenue		Seattle	Washington	98121	USA
aztreonam	Cayston	3/12/02	Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis	Designated/Approved	Approved for Orphan Indication	To improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa	02/22/2010	02/22/2017	Gilead Sciences (formerly Corus Pharma)	199 East Blaine St		Seattle	Washington	98102	USA
Azurin-p28	n/a	12/2/15	Treatment of glioma	Designated			N/A	N/A	"CDG Therapeutics, Inc."	840 South Wood Street	M/C 820	Chicago	Illinois	60612	USA
B Lymphocyte Stimulator	Blys	2/21/01	Treatment of common variable immunodeficiency (CVID)	Designated/Withdrawn			N/A	N/A	"Human Genome Sciences, Inc."	9410 Key West Avenue		Rockville	Maryland	20850	USA
Bacillus Calmette-Guerin vaccine	n/a	8/9/06	Treatment of stage IIb through IV metastatic melanoma	Designated			N/A	N/A	OncoVac Corporation	P. O. Box 970		Pacific Palisades	California	90272	USA
Bacillus subtilis oxalate decarboxylase	n/a	2/29/16	Treatment of pediatric hyperoxaluria	Designated			N/A	N/A	Allena Pharmaceuticals	1 Executive Park Drive	Suite 202	Newton	Massachusetts	2462	USA
Bacitracin	Altracin	3/13/84	Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.	Designated			N/A	N/A	"A. L. Laboratories, Inc."	One Executive Drive	P.O. Box 1399	Fort Lee	New Jersey	7024	USA
Baclofen	Lioresal Intrathecal	9/26/94	Treatment of spasticity associated with cerebral palsy.	Designated			N/A	N/A	"Medtronic, Inc."	800 53rd Avenue N.E.	P.O. 1250	Minneapolis	Minnesota	55440	USA
baclofen	n/a	12/2/03	Treatment of dystonia	Designated			N/A	N/A	Medtronic Neurological	710 Medtronic Parkway NE		Minneapolis	Minnesota	55432	USA
baclofen	n/a	12/16/91	Treatment of intractable spasticity due to multiple sclerosis or spinal cord injury.	Designated			N/A	N/A	"Metacel Pharmaceuticals, LLC"	137 N. Broad Street	Suite E	Winder	Georgia	30680	USA
baclofen	Gablofen	10/28/15	Treatment of complex regional pain syndrome.	Designated			N/A	N/A	"Mallinckrodt, Inc."	675 McDonnell Blvd.		St. Louis	Missouri	63134	USA
baclofen	Lioresal Intrathecal	11/10/87	"Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy)."	Designated/Approved	Approved for Orphan Indication	Management of severe spasticity of spinal cord origin in patients who are unresponsive to oral baclofen therapy or experience intolerable CNS side effects at effective doses.	06/25/1992	06/25/1999	"Medtronic, Inc."	800 53rd Avenue N.E.		Minneapolis	Minnesota	55432	USA
bacterium Bacteroides thetaiotaomicron	n/a	9/26/13	Treatment of active Crohn's disease in the pediatric population	Designated			N/A	N/A	4D Pharma Research Ltd	Life Sciences Innovation Bldg.	Cornhill Rd.				United Kingdom
Balsalazide disodium	Colazal	8/12/05	Treatment of pediatric patients with ulcerative colitis	Designated/Approved	Approved for Orphan Indication	Treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Safety and Effectiveness of Colazal beyond 8 weeks in children (ages 5-17) and 12 weeks in adults have not been established.	12/20/2006	12/20/2013	"Salix Pharmaceuticals, Inc."	400 Somerset Corporate Blvd		Bridgewater	New Jersey	8807	USA
bardoxolone	n/a	3/30/15	Treatment of pulmonary arterial hypertension	Designated			N/A	N/A	"Reata Pharmaceuticals, Inc."	2801 Gateway Drive	Suite 150	Irving	Texas	75063	USA
Bardoxolone	n/a	8/6/08	Treatment of pancreatic cancer	Designated			N/A	N/A	"Reata Pharmaceuticals, Inc."	2801 Gateway Drive		Irving	Texas	75063	USA
Basiliximab	Simulect	12/12/97	Prophylaxis of solid organ rejection.	Designated/Approved	Approved for Orphan Indication	Prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.	05/12/1998	05/12/2005	Novartis Pharmaceuticals Corporation	59 Route 10		East Hanover	New Jersey	7936	USA
basimglurant	n/a	3/9/12	Treatment of Fragile X Syndrome	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA
BCL-005 (fused (hybrid) melanoma-dendritic cells)	n/a	10/21/10	Treatment of stage IIb to IV melanoma in HLA-A2 positive patients	Designated/Withdrawn			N/A	N/A	Brucells SA	Rue de Ransbeekstraat 310		Brussel			Belgium
beclomethasone	n/a	3/4/09	Treatment of pediatriac patients with ulcerative colitis	Designated			N/A	N/A	"Aptalis Pharma US, Inc."	100 Somerset corporate Blvd		Bridgewater	New Jersey	8807	USA
"beclomethasone 17,21-dipropionate"	Bec	8/28/01	Prevention of gastrointestinal graft-versus-host disease	Designated			N/A	N/A	"Soligenix, Inc."	29 Emmons Drive		Princeton	New Jersey	8540	USA
"beclomethasone 17,21-dipropionate"	n/a	11/19/12	Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster	Designated			N/A	N/A	"Soligenix, Inc"	"29 Emmons Drive, Suite C-10"		Princeton	New Jersey	8540	USA
"beclomethasone 17,21-dipropionate"	Orbec(R)	7/24/09	Treatment of gastrointestinal symptoms with chronic graft versed host disease in patients undergoing allogenic hematopoietic cell transplantation	Designated			N/A	N/A	"Soligenix, Inc."	29 Emmons Drive		Princeton	New Jersey	8540	USA
"beclomethasone 17,21-diproprionate"	n/a	12/18/07	Treatment of pediatric patients with Crohn disease.	Designated			N/A	N/A	"Soligenix, Inc."	29 Emmons Drive	Suite C-10	Princeton	New Jersey	8540	USA
Beclomethasone dipropionate	n/a	3/27/98	For oral administration in the treatment of intestinal graft-versus-host disease.	Designated			N/A	N/A	"Soligenix, Inc."	29 Emmons Drive		Princeton	New Jersey	8540	USA
"bedaquiline; (1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol"	Sirturo	1/10/05	Treatment of active tuberculosis	Designated/Approved	Approved for Orphan Indication	Part of combination therapy in adults (greater than or equal to 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB).	12/28/2012	12/28/2019	"Janssen Research & Development, LLC"	920 Route 202 South		Raritan	New Jersey	8869	USA
belatacept	Nulojix	2/20/08	Prophylaxis of organ rejection in renal allograft recipients	Designated/Approved	Approved for Orphan Indication	Prophylaxis of organ rejection in adult patients receiving kidney transplants	06/15/2011	06/15/2018	Bristol-Myers Squibb Company	P. O. Box 4000		Princeton	New Jersey	8543	USA
Belinostat	Beleodaq	9/3/09	Treatment of peripheral T-cell lymphoma (PTCL).	Designated/Approved	Approved for Orphan Indication	Treatment of patients with relapsed or refractory peripheral T-cell lymphoma	07/03/2014	07/03/2021	"Spectrum Pharmaceuticals, Inc."	157 Technology Drive		Irvine	California	92618	USA
beloranib	n/a	1/15/13	Treatment of Prader-Willi syndrome	Designated/Withdrawn			N/A	N/A	"Zafgen, Inc."	175 Portland Street	4th Floor	Boston	Massachusetts	2114	USA
bendamustine for 50 ml admixture	Bendeka	7/2/14	Treatment of chronic lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of patients with CLL and treatment of patients with indolent B-cell NHL	12/07/2015	N/A	"Eagle Pharmaceuticals, INc."	50 Tice Blvd	Suite 315	Woodcliff Lake	New Jersey	7677	USA
bendamustine for 50ml admixture	Bendeka	7/2/14	"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)"	Designated/Approved	Approved for Orphan Indication	Treatment of patients with CLL and treatment of patients with indolent B-cell NHL	12/07/2015	N/A	"Eagle Pharmaceuticals, Inc."	50 Tice Blvd	Suite 315	Woodcliff Lake	New Jersey	7677	USA
bendamustine hydrochloride	Treanda	11/26/13	"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)"	Designated/Approved	Approved for Orphan Indication	Treatment of Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.	10/31/2008	10/31/2015	"Cephalon, Inc."	A wholly owned subsidiary of Teva Pharmaceuticals	PO Box 4011	Frazer	Pennsylvania	19355	USA
Bendamustine hydrochloride	Treanda	8/17/07	Treatment of chronic lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of patients with chronic lymphocytic leukemia	03/20/2008	03/20/2015	"Cephalon, Inc."	41 Moores Road		Frazer	Pennsylvania	19355	USA
bendamustine hydrochloride with betadex sulfobutyl ether sodium	n/a	9/10/13	Treatment of chronic lymphocytic leukemia	Designated			N/A	N/A	"Supratek Pharma, Inc."	6100 Royalmount Avenue	H4P 2R2	Quebec			Canada
Bendamustine oral doseage formulation	n/a	11/5/15	Treatment of chronic lymphocytic leukemia	Designated			N/A	N/A	Exinda Theapeutics LLC	8430 Rovana Circle	Suite B	Sacramento	California	95828	USA
benznidazole	n/a	4/14/14	Treatment of Chagas disease	Designated			N/A	N/A	"Chemo Research, S.L."		"Edificio Nectar, c/Quintanapalla, 2, 3 planta"	Madrid			Spain
benzoate	Naben	7/6/12	Treatment of pediatric schizophrenia	Designated			N/A	N/A	SyneuRx International (Taiwan) Corp.	1380 S. Marengo Ave		Pasadena	California	91106	USA
Benzoate and phenylacetate	Ucephan	1/21/86	"For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency."	Designated/Approved	Approved for Orphan Indication		12/23/1987	12/23/1994	ImmunexImmunex	2525 McGaw Avenue	P.O. Box 19791	Irvine	California	92623	USA
benzoate/phenylacetate	Ammonul	11/22/93	Treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.	Designated/Approved	Approved for Orphan Indication	Adjunctive therapy in the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.	02/17/2005	02/17/2012	Medicis Pharmaceutical Corp.	8125 N. Hayden Road		Scottsdale	Arizona	85258	USA
"Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide"	Total Block Vl Spf 75	8/13/01	For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy	Designated			N/A	N/A	Fallien Cosmeceuticals Ltd.	677 W. Dekalb Pike		King of Prussia	Pennsylvania	19406	USA
Benzydamine hydrochloride	Tantum	5/18/98	Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.	Designated			N/A	N/A	"Angelini Pharmaceuticals, Inc."	70 Grand Avenue		River Edge	New Jersey	7661	USA
"Benzylpenicillin, benzylpenicilloic, benzylpenilloic acid"	Pre-Pen/Mdm	9/28/87	Assessing the risk of administrating penicillin when it is the preferred drug of choice in adult patients who have previously received penicillin and have a history of clinical sensitivity.	Designated			N/A	N/A	AllerQuest LLC	836 Farmington Avenue	Suite 207	West Hanford	Connecticut	6119	USA
Beractant	Survanta Intratracheal Suspension	2/5/86	Treatment of neonatal respiratory distress syndrome	Designated/Approved	Approved for Orphan Indication	"Treatment of (""rescue"") of premature infants with RDS confirmed by x-ray and requiring mechanical ventilation"	07/01/1991	07/01/1998	Ross Laboratories	625 Cleveland Avenue		Columbus	Ohio	43215	USA
Beractant	Survanta Intratracheal Suspension	2/5/86	Treatment of neonatal respiratory distress syndrome	Designated/Approved	Approved for Orphan Indication	Prevention of RDS (hyaline membrane disease) in premature infants less than 1250 grams birthweight or with evidence of surfactant deficiency	07/02/1991	07/02/1998	Ross Laboratories	625 Cleveland Avenue		Columbus	Ohio	43215	USA
Beractant	Survanta Intratracheal Suspension	12/20/93	"Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis."	Designated			N/A	N/A	Ross Laboratories	625 Cleveland Avenue		Columbus	Ohio	43215	USA
Beraprost	n/a	4/29/99	"Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV)."	Designated			N/A	N/A	"LungRx, Inc."	1040 Spring Street		Silver Spring	Maryland	20910	USA
beraprost sodium 314d	n/a	12/22/11	Treatment of pulmonary arterial hypertension	Designated			N/A	N/A	"Lung Rx, Inc."	1040 Spring Street		Silver Spring	Maryland	20910	USA
Beta alethine	Betathine	3/24/97	Treatment of metastatic melanoma.	Designated			N/A	N/A	"Dovetail Technologies, Inc."	"Bldg. 337, Paint Branch Drive"		College Park	Maryland	20742	USA
Beta alethine	Betathine	3/24/97	Treatment of multiple myeloma.	Designated			N/A	N/A	"Dovetail Technologies, Inc."	"Bldg. 337, Paint Branch Drive"		College Park	Maryland	20742	USA
Betahistine dihydrochloride	n/a	11/8/07	Treatment of obesity associated with Prader Willi syndrome	Designated			N/A	N/A	"Floyd R. Sallee, M.D., Ph.D."	University of Cincinnati School of Medicine	ML 0559	Cincinnati	Ohio	45267	USA
Betaine	Cystadane	5/16/94	Treatment of homocystinuria.	Designated/Approved	Approved for Orphan Indication	Treatment of homocystinuria to decrease elevated homocysteine blood levels.	10/25/1996	10/25/2003	Jazz Pharmaceuticals	3180 Porter Drive		Palo Alto	California	94304	USA
betamethasone	n/a	10/7/15	Treatment of Ataxia Telangiectasia.	Designated			N/A	N/A	"Grace Therapeutics, LLC"	675 U.S. 1		North Brunswick Township	New Jersey	8902	USA
Bethanidine sulfate	n/a	9/20/88	Treatment of primary ventricular fibrillation.	Designated/Withdrawn			N/A	N/A	"Medco Research, Inc."	8455 Beverly Blvd.	Suite 308	Los Angeles	California	90048	USA
Bethanidine sulfate	n/a	11/24/89	Prevention of recurrence of primary ventricular fibrillation.	Designated/Withdrawn			N/A	N/A	"Medco Research, Inc."	8455 Beverly Blvd.	Suite 308	Los Angeles	California	90048	USA
Betulinic acid	n/a	8/9/07	Topical treatment of metastatic melanoma	Designated			N/A	N/A	"Advanced Life Sciences, Inc. (ALS)"	1440 Davey Road		Woodridge	Illinois	60517	USA
bevacizumab	Avastin	11/6/03	Treatment of renal cell carcinoma	Designated/Approved	Approved for Orphan Indication	Treatment of renal cell carcinoma in combination with interferon alfa	07/31/2009	07/31/2016	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
bevacizumab	n/a	10/21/10	Treatment of hereditary hemorrhagic telangiectasia	Designated			N/A	N/A	"Terence M. Davidson, MD"	UCSD Medical Center		San Diego	California	92103	USA
bevacizumab	Avastin	2/9/06	Therapeutic treatment of patients with ovarian cancer	Designated/Approved	Approved for Orphan Indication	"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens"	11/14/2014	11/14/2021	"Genentech, Inc"	1 DNA Way	M/S# 355E	South San Francisco	California	94080	USA
bevacizumab	Avastin	11/23/10	Treatment of fallopian tube carcinoma	Designated/Approved	Approved for Orphan Indication	"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer."	12/06/2016	12/06/2023	"Genentech, Inc"	1 DNA Way	M/S# 355E	South San Francisco	California	94080	USA
bevacizumab	Avastin	11/20/09	In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
bevacizumab	Avastin	10/20/04	Treatment of pancreatic cancer	Designated			N/A	N/A	"Genentech, Inc."	"1 DNA Way, MS #242"		South San Francisco	California	94080	USA
bevacizumab	Avastin	2/9/06	Therapeutic treatment of patients with ovarian cancer	Designated/Approved	Approved for Orphan Indication	"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer."	12/06/2016	12/06/2023	"Genentech, Inc"	1 DNA Way	M/S# 355E	South San Francisco	California	94080	USA
bevacizumab	Avastin	10/13/09	Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
bevacizumab	n/a	3/10/16	Treatment of Coat's disease	Designated			N/A	N/A	"MicroSert, Ltd."	Bar Yehuda Street		Nesher			Israel
bevacizumab	Avastin	5/26/06	Treatment of malignant glioma	Designated/Approved	Approved for Orphan Indication	Treatment of glioblastoma with progressive disease following prior therapy	05/05/2009	05/05/2016	"Genentech, Inc."	"1 DNA Way, MS 241B"		South San Francisco	California	94080	USA
bevacizumab	Avastin	11/2/10	Treatment of primary peritoneal carcinoma.	Designated/Approved	Approved for Orphan Indication	"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer."	12/06/2016	12/06/2023	"Genentech, Inc"	1 DNA Way	M/S# 355E	South San Francisco	California	94080	USA
bevacizumab	Avastin	11/2/10	Treatment of primary peritoneal carcinoma.	Designated/Approved	Approved for Orphan Indication	"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens"	11/14/2014	11/14/2021	"Genentech, Inc"	1 DNA Way	M/S# 355E	South San Francisco	California	94080	USA
bevacizumab	Avastin	1/27/16	Treatment of mesothelioma	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
bevacizumab	Avastin	11/23/10	Treatment of fallopian tube carcinoma	Designated/Approved	Approved for Orphan Indication	"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens."	11/14/2014	11/14/2021	"Genentech, Inc"	1 DNA Way	M/S# 355E	South San Francisco	California	94080	USA
Bexarotene	Targretin	6/18/99	Treatment of cutaneous T-cell lymphoma.	Designated/Approved	Approved for Orphan Indication	Treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.	12/29/1999	12/29/2006	"Eisai, Inc."	300 Tice Blvd		Woodcliff Lake	New Jersey	7677	USA
bezafibrate	Bezalip	7/24/13	For therapeutic treatment of Barth syndrome	Designated			N/A	N/A	"Barth Sydrome Foundation, Inc."	P. O. Box 618		Larchmont	New York	10538	USA
BF2.649 (Pitolisant)	n/a	5/17/10	Treatment of narcolepsy	Designated			N/A	N/A	Bioprojet Pharma	"9, rue Rameau"		Paris			France
bi-shRNA furin and GMCSF Autologous Tumor Cell Vaccine	Fang	10/22/14	Treatment of Ewing's sarcoma	Designated			N/A	N/A	"Gradalis, Inc."	2545 Golden Bear Drive	Suite 110	Carrollton	Texas	75006	USA
bi-shRNAfurin and granulocyte macrophage colony stimulating factor augmented autologus tumor cell vaccine	Fang	2/17/12	Treatment of stage IIB to IV melanoma	Designated			N/A	N/A	"Gradalis, Inc."	2545 Golden Bear Drive	Suite 110	Carrollton	Texas	75006	USA
bi-shRNAfurin and granulocyte macrophage colony stimulating factor augmented autologus tumor cell vaccine	Fang	4/18/11	Treatment of ovarian cancer	Designated			N/A	N/A	"Gradalis, Inc."	2545 Golden Bear Drive		Carrollton	Texas	75006	USA
bifidobacterium infantis 35624	n/a	3/24/08	Treatment of pediatric ulcerative colitis	Designated			N/A	N/A	Alimentary Health Limited	"Cork Airport Business Park, Building 2800"	Cork				Ireland
bifidobacterium longum infantis 35624	n/a	1/16/03	Treatment of pediatric Crohn's disease	Designated			N/A	N/A	Alimentary Health Limited	"Guardwell, Kinsale"		County Cork			Ireland
"bilayer, engineered collagen hydrogel-based skin graft composed of autologous keratinocytes and fibroblasts"	Primeskin	9/6/16	Treatment of partial deep dermal and full thickness burn wounds	Designated			N/A	N/A	University Children's Hospital Zurich	Tissue Biology Research Unit	7 August-Forel-Strasse	Zrich			Switzerland
Bindarit	n/a	2/3/98	Treatment of lupus nephritis.	Designated			N/A	N/A	"Angelini Pharmaceuticals, Inc."	70 Grand Avenue	Suite 109	River Edge	New Jersey	7661	USA
binimetinib	n/a	11/19/13	Treatment Stage IIB-IV melanoma.	Designated			N/A	N/A	"Array BioPharma, Inc."	125 Cambridge Park Drive	Suite 301	Cambridge	Massachusetts	2140	USA
binimetinib	n/a	7/31/14	Treatment of ovarian cancer	Designated			N/A	N/A	"Array Biopharma, Inc."	3200 Walnut Street		Boulder	Colorado	80301	USA
Bio-engineered oral mucosal tissue	n/a	4/27/06	For use as a graft for restoring a cornea-like epithelial phenotype to substitute for the normal corneal epithelium that is lost in patients due to total limbal stem cell deficiency	Designated			N/A	N/A	"TissueTech, Inc."	7000 SW 97th Avenue		Miami	Florida	33173	USA
Bioartificial liver system utilizing xenogenic hepatocytes in a hollow fiber bioreactor cartridge (BAL)	n/a	2/11/02	Treatment of patients with acute liver failure presenting with encephalopathy deteriorating beyond Parson's grade 2	Designated			N/A	N/A	"Excorp Medical, Inc."	Suite 235	7200 Hudson Blvd.	Oakdale	Minnesota	55128	USA
biocarbonate infusate	Normocarb Hf	8/9/05	Use in the management of patients undergoing continuous renal replacement therapy with hemofiltration	Designated/Approved	Approved for Orphan Indication	Use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace water and to correct electrolytes and acid-base imbalances in adults and children	07/26/2006	07/26/2013	"Dialysis Solutions, Inc."	14 Emmett Place	"Whitby, Ontario L1R 2B4"				Canada
Bis(4-fluorophenyl)phenylacetamide	n/a	3/2/00	Treatment of sickle cell disease.	Designated			N/A	N/A	ICAgen Inc.	Ion Channel Advances	PO Box 14487	Durham	North Carolina	27709	USA
bisantrene HCl	n/a	2/14/14	Treatment of acute myeloid leukemia	Designated			N/A	N/A	"Update Pharma, Inc."	1701 Jackson Street	Suite 102	San Francisco	California	94109	USA
bispecific antibody (monoclonal antibody)	n/a	8/8/13	Treatment of HER2-expressing advanced adenocarcinoma of the stomach and gastroesophageal junction	Designated			N/A	N/A	"Merrimack Pharmaceuticals, inc."	One Kendall Square	Suite B7201	Cambridge	Massachusetts	2139	USA
bispecific antibody (monoclonmal antibody)	n/a	8/8/13	Treatment of HER2-expressing adenocarcinoma of the esophagus	Designated			N/A	N/A	"Merrimack Pharmaceuticals, Inc."	1 Kendall Square	Suite B7201	Cambridge	Massachusetts	2139	USA
Bispecific antibody 520c9x22	n/a	10/5/93	For in vivo serotherapy of patients with ovarian cancer.	Designated/Withdrawn			N/A	N/A	"Medarex, Inc."	519 Route 173 West		Bloomsbury	New Jersey	8804	USA
bispecific antibody targeting interleukin 4 (IL-4) and interleukin 13 (IL-13)	n/a	9/14/11	Treatment of idiopathic pulmonary fibrosis.	Designated			N/A	N/A	"Sanofi-Aventis US, Inc."	200 Crossing Blvd		Bridgewater	New Jersey	8807	USA
bivalent anti-human myostatin adnectin-IgG1	n/a	2/10/15	Treatment of duchenne muscular dystrophy	Designated			N/A	N/A	Bristol-Myers Squibb Co.	5 Research Parkway		Wallingford	Connecticut	6492	USA
bivalirudin	Angiomax	11/2/05	For use as an anticoagulant in patients with or at risk of heparin-induced thrombocytopenia/heparin-induced thrombocytopenia thrombosis syndrome	Designated			N/A	N/A	The Medicines Company	8 Sylvan Way		Parsippany	New Jersey	7054	USA
Bleomycin	n/a	12/20/10	Treatment of pancreatic cancer.	Designated			N/A	N/A	CIRJ Company Ltd.	1800 Loma Vista St.		Pasadena	California	91004	USA
Bleomycin	Blenoxane	2/9/99	Treatment of pancreatic cancer.	Designated			N/A	N/A	"Genetronics, Inc."	11199 Sorrento Valley Rd.		San Diego	California	92121	USA
Bleomycin sulfate	Blenoxane	9/17/93	Treatment of malignant pleural effusion.	Designated/Approved	Approved for Orphan Indication	Treatment of malignant pleural effusion.	02/20/1996	02/20/2003	Bristol-Myers Squibb Pharmaceutical Research Institute	P.O. Box 4000		Princeton	New Jersey	8543	USA
blinatumomab	n/a	5/16/08	Treatment for hairy cell leukemia.	Designated			N/A	N/A	"Amgen, Inc."	One Amgen Center Drive		Thousand Oaks	California		
blinatumomab	n/a	5/16/08	Treatment of prolymphocytic leukemia	Designated			N/A	N/A	"Amgen, Inc."	One Amgen Center Drive		Thousand Oaks	California		
blinatumomab	Blincyto	5/16/08	Treatment of acute lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).	12/03/2014	12/03/2021	"Amgen, Inc."	One Amgen Center Dr.	Mail Stop 17-2-A	Thousand Oaks	California	91320	USA
blinatumomab	n/a	2/6/06	"Treatment of indolent B-cell lymphoma, excluding CLL and NHL with CNS involvement"	Designated			N/A	N/A	"Amgen, Inc."	One Amgen Center Drive		Thousand Oaks	California		
Blinatumomab	n/a	5/16/08	Treatment of chronic lymphocytic leukemia	Designated			N/A	N/A	"Amgen, Inc."	One Amgen Center Drive		Thousand Oaks	California		
Bone marrow-derived mononuclear cells	n/a	5/17/10	Treatment of thromboangiitis obliterans (Buerger's disease)	Designated			N/A	N/A	t2cure GmbH	Kennedyallee 93	60596 Frankfurt am Main				Germany
bortezomib	Velcade	5/30/12	Treatment of mantle cell lymphoma.	Designated/Approved	Approved for Orphan Indication	Treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.	12/08/2006	12/08/2013	"Millennium Pharmaceuticals, Inc."	40 Landsdowne Street		Cambridge	Massachusetts	2139	USA
bortezomib	Velcade	2/3/15	Treatment of acute lymphoblastic leukemia	Designated			N/A	N/A	"Millennium Pharmaceuticals, Inc."	40 Landsdowne Street		Cambridge	Massachusetts	2139	USA
bortezomib	n/a	7/5/16	Treatment of neurofibromatosis type 2 (NF2)	Designated			N/A	N/A	BioXcel Corporation	780 East Main Street	Suite 2	Branford	Connecticut	6405	USA
bortezomib	Velcade	5/30/12	Treatment of mantle cell lymphoma.	Designated/Approved	Approved for Orphan Indication	Treatment of patients with mantle cell lymphoma who have not received at least 1 prior therapy	10/08/2014	10/08/2021	"Millennium Pharmaceuticals, Inc."	40 Landsdowne Street		Cambridge	Massachusetts	2139	USA
bortezomib	Velcade	1/15/03	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	Treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy	05/13/2003	05/13/2010	"Millennium Pharmaceuticals, Inc."	40 Landsdowne Street		Cambridge	Massachusetts	2139	USA
bortezomib	Velcade	1/4/11	Treatment of follicular non-Hodgkin lymphoma	Designated			N/A	N/A	"Millennium Pharmaceuticals, Inc."	40 Landsdowne Street		Cambridge	Massachusetts	2139	USA
bortezomib	Velcade	1/15/03	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	First-line therapy of multiple myeloma.	06/20/2008	06/20/2015	"Millennium Pharmaceuticals, Inc."	40 Landsdowne Street		Cambridge	Massachusetts	2139	USA
bortezomib	Velcade	1/15/03	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	Treatment of multiple myeloma patients who have received at least one prior therapy	03/25/2005	03/25/2012	"Millennium Pharmaceuticals, Inc."	40 Landsdowne Street		Cambridge	Massachusetts	2139	USA
bosentan	Tracleer(R)	6/7/10	Reduction of the number (treatment) of new digital ulcers in patients with systemic sclerosis	Designated/Withdrawn			N/A	N/A	Actelion Ltd.	Gewerbestrasse 16	CH-4123				Switzerland
bosentan	Tracleer	9/30/08	Treatment of idiopathic pulmonary fibrosis	Designated/Withdrawn			N/A	N/A	Actelion Pharmaceuticals Ltd	Gewerbestrasse 16	CH-4123				Switzerland
Bosentan	Tracleer	10/6/00	Treatment of pulmonary arterial hypertension.	Designated/Approved	Approved for Orphan Indication	Treatment of pulmonary arterial hypertension.	11/20/2001	11/20/2008	Actelion Life Sciences Ltd.	1840 Gateway Dr.	2nd Floor	San Mateo	California	94404	USA
bosutinib	Bosulf	2/24/09	Treatment of chronic myelogenous leukemia	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy"	09/04/2012	09/04/2019	"Wyeth Pharmaceuticals, Inc."	"Subsidiary of Pfizer, Inc."	Eastern Point Road	Groton	Connecticut	6340	USA
Botulinum toxin type A	Botox	12/6/91	Treatment of dynamic muscle contracture in pediatric cerebral palsy patients.	Designated			N/A	N/A	"Allergan, Inc."	2525 Dupont Drive	P.O. Box 19534	Irvine	California	92623	USA
Botulinum toxin type A	Botox	3/22/84	Treatment of strabismus and blepharospasms	Designated/Approved	Approved for Orphan Indication	Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above)	12/29/1989	12/29/1996	"Allergan, Inc."	2525 Dupont Drive	P.O. Box 19534	Irvine	California	92713	USA
Botulinum toxin type A	Dysport	10/20/99	Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.	Designated/Approved	Approved for Orphan Indication	Treatment of lower limb spasticity in pediatric cerebral patients 2 years of age and older	07/29/2016	07/29/2023	Ipsen Limited	"1 Bath Rd., Maidenhead"		Berkshire SL6 4UH			United Kingdom
Botulinum toxin type A	n/a	9/15/92	Treatment of synkinetic closure of the eyelid associated with VII cranial nerve aberrant regeneration.	Designated			N/A	N/A	"Botulinum Toxin Research Associates, Inc."	1261 Furnace Brook Parkway		Quincy	Massachusetts	2169	USA
Botulinum toxin type A	Botox	3/22/84	Treatment of strabismus and blepharospasms	Designated/Approved	Approved for Orphan Indication	Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above)	12/30/1989	12/30/1996	"Allergan, Inc."	2525 Dupont Drive	P.O. Box 19534	Irvine	California	92713	USA
Botulinum toxin type A	Dysport	3/23/89	Treatment of essential blepharospasm.	Designated			N/A	N/A	"Porton International, Inc."	"1155 15th Street, N.W., #315"		Washington	District of Columbia	20005	USA
Botulinum toxin type A	Botox	8/20/86	Treatment of cervical dystonia.	Designated/Approved	Approved for Orphan Indication	Treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia.	12/21/2000	12/21/2007	"Allergan, Inc."	2525 Dupont Drive	P.O. Box 19534	Irvine	California	92623	USA
Botulinum toxin type A	Dysport	8/12/98	Treatment of spasmodic torticollis (cervical dystonia).	Designated			N/A	N/A	Ipsen Biopharm Limited	1 Bath Road	Maidenhead	"Berkshire, SL6 4UH"			United Kingdom
Botulinum toxin type B	Myobloc	1/16/92	Treatment of cervical dystonia.	Designated/Approved	Approved for Orphan Indication	Treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.	12/08/2000	12/08/2007	"Soltice Neurosciences, LLC"	4010 Dupont Circle	Suite L-07	Louisville	Kentucky	40207	USA
Botulinum toxin type F	n/a	10/24/91	Treatment of spasmodic torticollis (cervical dystonia).	Designated			N/A	N/A	Ipsen Limited	27 Maple Street		Milford	Massachusetts	1757	USA
"botulism antitoxin heptavalent (A, B, C, D, E, F, G) (Equine)"	n/a	6/29/11	Treatment of botulism.	Designated/Approved	Approved for Orphan Indication	"Treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients"	03/22/2013	03/22/2020	Cangene Corporation	155 Innovation Drive	"Winnipeg, Manitoba R3T5Y3"				Canada
Botulism immune globulin	Babybig	1/31/89	Treatment of infant botulism.	Designated/Approved	Approved for Orphan Indication	Indicated for treatment of infant botulism caused by type A or type B Clostridium botulinum.	10/23/2003	10/23/2010	California Department of Health Services	2151 Berkeley Way		Berkeley	California	94704	USA
Bovine colostrum	n/a	11/19/90	Treatment of AIDS-related diarrhea.	Designated			N/A	N/A	"Hastings, Donald DVM"	1030 North Parkview Drive		Bismarck	North Dakota	58501	USA
"Bovine immunoglobulin concentrate, Cryptosporidium parvum"	Sporidin-G	3/1/94	Treatment and symptomatic relief of Cryptosporidium parvum infection of the gastrointestinal tract in immunocompromised patients.	Designated			N/A	N/A	"GalaGen, Inc."	4001 Lexington Avenue North		Arden Hills	Minnesota	55126	USA
bovine lactoferrin	n/a	2/19/15	Prevention of late-onset sepsis in very low birth weight infants	Designated			N/A	N/A	"Metrodora Therapeutics, LLC"	2502 Avenue I		Brooklyn	New York	11210	USA
bovine lactoferrin	n/a	2/23/15	Prevention of necrotizing enterocolitis in very low birth weight infants (birth weight less than or equal to 1500 grams)	Designated			N/A	N/A	"Metrodora Therapeutics, LLC"	2502 Avenue I		Brooklyn	New York	11210	USA
Bovine whey protein concentrate	Immuno-C	9/30/93	Treatment of cryptosporidiosis caused by the presence of Cryptosporidium parvum in the gastrointestinal tract of patients who are immunodeficient/immunocompromised or immunocompetent.	Designated			N/A	N/A	"Biomune Systems, Inc."	"540 Arapeen Drive, Suite 202"		Salt Lake City	Utah	84108	USA
Branched chain amino acids	n/a	12/23/88	Treatment of amyotrophic lateral sclerosis.	Designated			N/A	N/A	Mount Sinai Medical Center	One Gustave L. Levy Place		New York	New York	10029	USA
brentuximab vedotin	Adcetris	10/23/08	Treatment of anaplastic large cell lymphoma	Designated/Approved	Approved for Orphan Indication	The treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen	08/19/2011	08/19/2018	"Seattle Genetics, Inc."	21823 30th Drive Southeast		Bothell	Washington	98021	USA
brentuximab vedotin	Adcetris	4/15/13	"Treatment of patients with peripheral T-cell lymphoma, not otherwise specified"	Designated			N/A	N/A	"Seattle Genetics, Inc."	21823 30th Drive Southeast		Bothell	Washington	98021	USA
brentuximab vedotin	Adcetris	1/30/07	Treatment of Hodgkin's lymphoma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT).	08/17/2015	08/17/2022	"Seattle Genetics, Inc."	21823 30th Drive Southeast		Bothell	Washington	98021	USA
brentuximab vedotin	Adcetris	7/7/16	Treatment of enteropathy-associated T-cell lymphoma.	Designated			N/A	N/A	"Seattle Genetics, Inc."	21823 30th Drive Southeast		Bothell	Washington	98021	USA
brentuximab vedotin	Adcetris(R)	1/31/14	Treatment of patients with diffuse large B-cell lymphoma.	Designated			N/A	N/A	"Seattle Genetics, Inc."	21823 30th Drive Southeast		Bothell	Washington	98021	USA
brentuximab vedotin	Adcetris	1/30/07	Treatment of Hodgkin's lymphoma	Designated/Approved	Approved for Orphan Indication	The treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates	08/19/2011	08/19/2018	"Seattle Genetics, Inc."	21823 30th Drive Southeast		Bothell	Washington	98021	USA
brentuximab vedotin	Adcetris	11/19/12	Treatment of mycosis fungoides	Designated			N/A	N/A	"Seattle Genetics, Inc."	21823 30th Drive Southeast		Bothell	Washington	98021	USA
brentuximab vedotin	Adcetris	9/13/13	Treatment of patients with angioimmunoblastic T-cell lymphoma	Designated			N/A	N/A	"Seattle Genetics, Inc."	21823 30th Drive Southeast		Bothell	Washington	98021	USA
Brentuximab vedotin	Adcetris	9/7/16	Treatment of primary cutaneous CD30-positive T-cell lymphoproliferative disorders	Designated			N/A	N/A	"Seattle Genetics, Inc."	21823 30th Drive Southeast		Bothell	Washington	98021	USA
brentuximab vedotin	n/a	5/23/16	Treatment of adult T-cell leukemia/lymphoma	Designated			N/A	N/A	"Seattle Genetics, Inc."	21823 30th Drive Southeast		Bothell	Washington	98021	USA
brigatinib	n/a	4/28/16	"Treatment of anaplastic lymphoma kinase-positive (ALK+), c-ros 1 oncogene positive (ROS1+), or epidermal growth factor receptor positive (EGFR+) non-small cell lung cancer (NSCLC)."	Designated			N/A	N/A	"ARIAD Pharmaceuticals, Inc."	26 Landsdowne Street		Cambridge	Massachusetts	2139	USA
brilliant blue G	Brilliant Peel	12/16/09	For use in ophthalmic surgery to aid in the removal of the inner limiting membrane of the eye.	Designated			N/A	N/A	Fluron GmbH - Subsidiary of Geuder AG	Biberkopfweg 1					Germany
Brilliant Blue G	Dorc Ilm-Blue	7/31/12	"To selectively stain the thickened internal limiting membrane, which has formed onto the inner side of the retina in vitreo-retinal disorders"	Designated			N/A	N/A	Dutch Opthalmic Research Center	"Scheijdelveweg 2, 3214 VN"		Zuidland			Netherlands
Brimonidine	Alphagan	2/7/00	Treatment of anterior ischemic optic neuropathy.	Designated			N/A	N/A	"Allergan, Inc."	2525 Dupont Dr.		Irvine	California	92612	USA
brivanib alaninate	n/a	3/18/11	Treatment of hepatocellular carcinoma	Designated/Withdrawn			N/A	N/A	Bristol-Myers Squibb	P. O. Box 4000		Princeton	New Jersey	8543	USA
Brivaracetam	n/a	10/5/05	Treatment of symtomatic myoclonus	Designated			N/A	N/A	"UCB Pharma, Inc."	1950 Lake Park Drive		Smyra	Georgia	30080	USA
Brivudin	n/a	11/15/07	Adjunct treatment of pancreatic cancer	Designated/Withdrawn			N/A	N/A	"SciClone Pharmaceuticals, Inc."	901 Mariner's Island Blvd.		San Mateo	California	94404	USA
Bromhexine	Bisolvon	5/15/89	Treatment of mild to moderate keratoconjunctivitis sicca in patients with Sjogren's syndrome.	Designated/Withdrawn			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc."	"900 Ridgebury Road, Box 368"		Ridgefield	Connecticut	6877	USA
Broxuridine	Broxine/Neomark	9/18/95	Radiation sensitizer in the treatment of primary brain tumors.	Designated			N/A	N/A	"NeoPharm, Inc."	"225 East Deerpath, Suite 250"		Lake Forest	Illinois	60045	USA
Bruton's Tyrosine Kinase (Btk) Inhibitor	n/a	5/13/15	Treatment of chronic lymphocytic leukemia (CLL).	Designated			N/A	N/A	Acerta Pharma BV	Molenstraat 110	5342 CC Oss				Netherlands
Bruton's tyrosine kinase inhibitor	n/a	2/10/14	Treatment of chronic lymphocytic leukemia	Designated/Withdrawn			N/A	N/A	Celgene Corporation	400 Connell Drive	Suite 700	Berkeley Heights	New Jersey	7922	USA
bryostatin 1	n/a	3/31/15	Treatment of Fragile X Syndrome.	Designated			N/A	N/A	"Neurotrope BioScience, Inc."	50 Park Place	Suite 1401	Newark	New Jersey	7102	USA
bryostatin-1	n/a	12/3/01	For use in combination with paclitaxel in the treatment of esophageal cancer	Designated			N/A	N/A	"GPC Biotech, Inc."	610 Lincoln Street		Waltham	Massachusetts	2451	USA
Bucillamine	n/a	10/22/15	Treatment of cystinuria	Designated			N/A	N/A	"Revive Therapeutics, Ltd."	5 Director Court	Suite 105	Vaughan	Ontario		Canada
budesonide	Uceris	5/6/13	Treat of ulcerative colitis in pediatric patients aged 0 through 16 years.	Designated			N/A	N/A	"Santarus, Inc."	"3611 Valley Centre Drive, Suite 400"		San Diego	California	92130	USA
budesonide	Nefecon	5/17/10	To slow the progression of immunoglobulin A nephropathy & delay kidney failure in patients affected by the disease.	Designated			N/A	N/A	Pharmalink AB	Engelbrekts kyrkogata 7b		Stockholm			Sweden
Buffered intrathecal electrolyte/dextrose injection	Elliotts B Solution	8/24/94	For use as a diluent in the intrathecal administration of methotrexate and cytarabine for the prevention or treatment meningeal leukemia and lymphocytic lymphoma	Designated/Approved	Approved for Orphan Indication	For the intrathecal administration of methotrexate and cytarabine for the prevention or treatment of meningeal leukemia and lymphocytic lymphoma.	09/27/1996	09/27/2003	"Lukare Medical, LLC"	4 Julia Court	P. O. Box 782	Scotch Plains	New Jersey	7076	USA
Buffered Ursodeoxycholic Acid	Ursocarb	9/3/04	Treatment of pruritus in patients with Alagille Syndrome	Designated			N/A	N/A	"Digestive Care, Inc."	1120 Win Drive		Bethlehem	Pennsylvania	18017	USA
bupivacaine	Transdur	6/18/08	Relief of persistent pain associated with postherpetic neuralgia	Designated			N/A	N/A	"Impax Laboratories, Inc."	30831 Huntwood Avenue		Hayward	California	94544	USA
bupivacaine hydrochloride	n/a	5/31/16	treatment of pain associated with postherpetic neuralgia.	Designated			N/A	N/A	"Grace Therapeutics, LLC"	675 U.S. 1		North Brunswick Township	New Jersey	8902	USA
Buprenorphine hydrochloride	Subutex	6/15/94	Treatment of opiate addiction in opiate users.	Designated/Approved	Approved for Orphan Indication	Treatment of opioid dependence in patients 16 years of age or older	10/08/2002	10/08/2009	"Reckitt Benckiser Pharmaceuticals, Inc."	1901 Huguenot Road		Richmond	Virginia	23235	USA
buprenorphine in combination with naloxone	Suboxone	10/27/94	Treatment of opiate addiction in opiate users	Designated/Approved	Approved for Orphan Indication	Treatment of opioid dependence in patients 16 years of age or older	10/08/2002	10/08/2009	"Reckitt Benckiser Pharmaceuticals, Inc."	1901 Huguenot Road		Richmond	Virginia	23235	USA
Busulfan	Busulfex	7/28/94	As preparative therapy in the treatment of malignancies with bone marrow transplantation.	Designated/Approved	Approved for Orphan Indication	For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia.	02/04/1999	02/04/2006	Otsuka Pharmaceutical Company		Tokyo				Japan
Busulfan	Spartaject	4/21/94	For use as preparative therapy for malignancies treated with bone marrow transplantation.	Designated			N/A	N/A	"Sparta Pharmaceuticals, Inc."	111 Rock Road		Horsham	Pennsylvania	19044	USA
busulfan	Partaject	11/25/02	Preparative therapy for pediatric patients undergoing bone marrow transplantation	Designated			N/A	N/A	"SuperGen, Inc."	4140 Dublin Blvd.	Suite 200	Dublin	California	94568	USA
Busulfan	Spartaject	7/7/97	Treatment of primary brain malignancies.	Designated			N/A	N/A	"SuperGen, Inc."	"Two Annabel Lane, Suite 220"		San Ramon	California	94583	USA
Busulfan	Spartajet-Busulfan	3/5/01	Intrathecal therapy for neoplastic meningitis	Designated/Withdrawn			N/A	N/A	"SuperGen, Inc."	4140 Dublin Boulevard		Dublin	California	94568	USA
Buthionine sulfoxamine	n/a	10/5/05	Use as a modulator of chemotherapy for the treatment of pediatric patients with primary malignant brain tumors	Designated			N/A	N/A	USC-CHLA Institute for Pediatric Clinical Research	Childrens Hospital of Los Angeles	"4650 Sunset Blvd, MS 55"	Los Angeles	California	90027	USA
Buthionine sulfoxamine	n/a	10/5/05	For use in children as a modulator of chemotherapy for the treatment of pediatric patients with neuroblastoma	Designated			N/A	N/A	USC-CHLA Institute for Pediatric Clinical Research	Childrens Hospital of Los Angeles	"4650 Sunset Blvd, MS 55"	Los Angeles	California	90027	USA
butylidenephthalide	n/a	8/5/15	Treatment of Malignant Glioma	Designated			N/A	N/A	"Everfront Biotech, Inc."	"11F., No. 31, Ln. 169, Kangning St."	New Taipei City 221				Taiwan
Butyrylcholinesterase	n/a	9/30/92	Treatment of post-surgical apnea.	Designated			N/A	N/A	Shire Laboratories Inc.	1550 East Gude Drive		Rockville	Maryland	20850	USA
Butyrylcholinesterase	n/a	3/25/92	For the reduction and clearance of toxic blood levels of cocaine encountered during a drug overdose.	Designated			N/A	N/A	Shire Laboratories Inc.	1550 East Gude Drive		Rockville	Maryland	20850	USA
c-myb antisense oligodeoxynucleotide	n/a	2/22/05	Treatment of chronic myelogenous leukemia	Designated/Withdrawn			N/A	N/A	"Genta, Inc."	Two Conell Drive		Berkeley Heights	New Jersey	7922	USA
C1 esterase inhibitor (human)	Cinryze(R)	7/16/04	Treatment of angioedema	Designated/Approved	Approved for Orphan Indication	Routine prophylaxis against angioedema attacks in patients with Hereditary Angioedema (HAE)	10/10/2008	10/10/2015	Shire	300 Shire Way		Lexington	Massachusetts	2421	USA
C1 esterase inhibitor (human)	n/a	8/21/96	Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.	Designated			N/A	N/A	Alpha Therapeutic Corporation	5555 Valley Boulevard		Los Angeles	California	90032	USA
C1 esterase inhibitor (Human)	Cinryze	11/30/16	Treatment of acute antibody mediated rejection following kidney transplantation	Designated			N/A	N/A	"Shire ViroPharma, Inc."	300 Shire Way		Lexington	Massachusetts	2421	USA
C1-esterase inhibitor (recombinant)	Ruconest	2/23/99	Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Designated/Approved	Approved for Orphan Indication	Treatment of acute attacks of hereditary angioedema (HAE) in adult and adolescent patients.	07/16/2014	07/16/2021	Pharming Americas B.V.	Darwinweg 24	Leiden 2333 CR				Netherlands
"C1-esterase-inhibitor, human, pasteurized"	Berinert	10/16/92	Prevention and/or treatment of acute attacks of hereditary angioedema.	Designated/Approved	Approved for Orphan Indication	Treatment of acute attacks of hereditary angioedema.	10/08/2009	10/08/2016	CSL Behring LLC	1020 First Ave.	PO Box 61501	King of Prussia	Pennsylvania	19406	USA
C1-inhibitor	"C1-Inhibitor (Human) Vapor Heated, Immuno"	8/30/90	Treatment of acute attacks of angioedema.	Designated/Withdrawn			N/A	N/A	Baxter Healthcare Corp.	One Baxter Way		Westlake Village	California	91362	USA
C1-inhibitor	"C1-Inhibitor (Human) Vapor Heated, Immuno"	8/30/90	"Prevention of acute attacks of angioedema, including short-term prophylaxis for patients requiring dental or other surgical procedures."	Designated/Withdrawn			N/A	N/A	Baxter Healthcare Corp.	One Baxter Way		Westlake Village	California	91362	USA
C20-D3-retinyl acetate	n/a	9/16/10	Treatment of Stargardt's disease	Designated			N/A	N/A	"Alkeus pharmaceuticals, Inc."	2103 Massachusetts Avenue		Cambridge	Massachusetts	2140	USA
C21H27O10P	Minnelide	3/30/15	Treatment of gastric cancer.	Designated			N/A	N/A	"Minneamrita Therapeutics, LLC"	6 Hickory Court		Rock Island	Illinois	61201	USA
C24H28N8O7S2	n/a	4/2/15	Treatment of diffuse large B-cell lymphoma (DLBCL).	Designated			N/A	N/A	"Curis, Inc."	4 Maguire Road		Lexington	Massachusetts	2421	USA
C66H100N6O27	n/a	3/11/13	Treatment of of hepatocellular carcinoma	Designated			N/A	N/A	"GenSpera, Inc."	2511 North Loop 1604 W	Suite 204	San Antonio	Texas	78258	USA
cabozantinib	Cometriq	11/29/10	"Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer."	Designated/Approved	Approved for Orphan Indication	"Treatment of progressive, metastatic medullary thyroid cancer (MTC)."	11/29/2012	11/29/2019	"Exelixis, Inc."	210 East Grand Avenue		South San Francisco	California	94083	USA
Caffeine	Cafcit	9/20/88	Treatment of apnea of prematurity.	Designated/Approved	Approved for Orphan Indication	Short term treatment of apnea of prematurity in infants between 28 and less than 33 weeks gestational age.	09/21/1999	09/21/2006	"O.P.R. Development, L.P."	1501 Wakarusa Drive		Lawrence	Kansas	66047	USA
caffeine and sodium benzoate	n/a	8/22/12	Treatment of seizure prolongation in patients undergoing electroconvulsive therapy	Designated			N/A	N/A	"Luitpold Pharmaceuticals, Inc."	"800 Adams Ave., Suite 100"		Norristown	Pennsylvania	19403	USA
Calcitonin salmon nasal spray	Miacalcin Nasal Spray	10/29/90	Treatment of symptomatic Paget's disease (osteitis deformans).	Designated/Withdrawn			N/A	N/A	Sandoz Pharmaceuticals Corp.	59 Route 10		East Hanover	New Jersey	7936	USA
Calcitonin-human for injection	Cibacalcin	1/20/87	Treatment of symptomatic Paget's disease (osteitis deformans).	Designated/Approved	Approved for Orphan Indication		10/31/1986	10/31/1993	Novartis Pharmaceutical Corporation	59 Route 10		East Hanover	New Jersey	7936	USA
Calcium acetate	n/a	6/27/89	Treatment of hyperphosphatemia in end stage renal disease.	Designated			N/A	N/A	Pharmedic Company	"28101 Ballard Road, Suite F"		Lake Forest	Illinois	60045	USA
Calcium acetate	Phos-Lo	12/22/88	Treatment of hyperphosphatemia in end stage renal failure.	Designated/Approved	Approved for Orphan Indication		12/10/1990	12/10/1997	Fresenius Medical Care North America	920 Winter Street		Waltham	Massachusetts	2451	USA
calcium benzoate and risperidone	n/a	12/20/10	Treatment of pediatric patients with schizophrenia	Designated			N/A	N/A	"University of California, Los Angeles"	Dept. of Psychiarty	"HH212, 1000 W. Carson Street"	Torrance	California	90509	USA
Calcium carbonate	R & D Calcium Carbonate/600	6/6/90	Treatment of hyperphosphatemia in patients with end stage renal disease.	Designated			N/A	N/A	"R & D Laboratories, Inc."	4204 Glencoe Avenue		Marina Del Rey	California	90292	USA
Calcium gluconate	Calgonate	11/20/97	For use as a wash for hydrofluoric acid spills on human skin.	Designated			N/A	N/A	Calgonate Corp.	3310 South Ocean Blvd	Unit 132	Highland Beach	Florida	33487	USA
Calcium gluconate gel	H-F Gel	5/21/91	For use in the emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Designated			N/A	N/A	Calgonate Corporation	3310 South Ocean Blvd	Unit 132	Highland Beach	Florida	33487	USA
Calcium gluconate gel 2.5%	n/a	9/10/90	Emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Designated			N/A	N/A	"Paddock Laboratories, Inc."	3940 Quebec Avenue North		Minneapolis	Minnesota	55427	USA
calfactant	Infasurf	9/5/00	Treatment of acute respiratory distress syndrome (ARDS)	Designated			N/A	N/A	"ONY, Inc."	Baird Research Park	Suite 114	Amherst	New York	14228	USA
calfactant	Infasurf	6/7/85	Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.	Designated/Approved	Approved for Orphan Indication	Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.	07/01/1998	N/A	"ONY, Inc."	1576 Sweet Home Road		Amherst	New York	14228	USA
camostat	n/a	5/18/11	Treatment of chronic pancreatitis	Designated			N/A	N/A	NIXS Corporation	"Nichi-Iko Pharmaceutical Co., Ltd."	7th Floor - NOF Nihonbashi Honcho Bldg	Tokyo			Japan
canakinumab	Ilaris	12/5/13	Treatment of familial mediterranean fever	Designated/Approved	Approved for Orphan Indication	Indicated for Familial Mediterranean Fever (FMF) in adult and pediatric patients	09/23/2016	09/23/2023	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
canakinumab	Ilaris	9/4/12	Treatment of TNF-receptor associated periodic syndrome (TRAPS)	Designated/Approved	Approved for Orphan Indication	Indicated for Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients	09/23/2016	09/23/2023	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
canakinumab	Ilaris	12/5/13	Treatment of hyperimmunoglobulinemia D and periodic fever syndrome	Designated/Approved	Approved for Orphan Indication	Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients	09/23/2016	09/23/2023	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
canakinumab	Ilaris	12/18/07	Treatment of cryopyrin-associated periodic syndromes	Designated/Approved	Approved for Orphan Indication	"Treatment of cryopyrin-associated periodic syndromes (CAPS), in adults and children 4 years of age and older."	06/17/2009	06/17/2016	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
canakinumab	Ilaris	9/30/08	Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.	Designated/Approved	Approved for Orphan Indication	Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 through 16 years.	05/09/2013	05/09/2020	Novartis Pharmaceuticals Corporation	One Health Plaza	Bldg 135-566G	East Hanover	New Jersey	7936	USA
cannabidiol	n/a	4/19/16	Treatment of tuberous sclerosis complex.	Designated			N/A	N/A	GW Pharma Ltd.	15 T.W. Alexander Drive	P. O. Box 13547	Research Triangle Park	North Carolina	27709	USA
cannabidiol	n/a	9/24/14	Treatment of glioma	Designated			N/A	N/A	"Insys Development Company, Inc."	1333 S. Spectrum Blvd	Suite 100	Chandler	Arizona	85286	USA
cannabidiol	n/a	8/20/14	Treatment of glioblastoma multiforme	Designated			N/A	N/A	"Insys Development Company, Inc."	1333 S. Spectrum Blvd	Suite 100	Chandler	Arizona	85286	USA
cannabidiol	n/a	6/23/14	Treatment of Lennox-Gastaut syndrome	Designated			N/A	N/A	"Insys Development Company, Inc."	1333 S. Spectrum Blvd	Suite 100	Chandler	Arizona	85286	USA
cannabidiol	n/a	6/13/16	Treatment of infantile spasms	Designated			N/A	N/A	GW Research Ltd.	"Sovereign House, Vision Park"	Chivers Way	Histon			United Kingdom
cannabidiol	n/a	7/23/15	Treatment of infantile spasms	Designated			N/A	N/A	"Insys Development Company, Inc."	1333 South Spectrum Boulevard	Suite 100	Chandler	Arizona	85286	USA
cannabidiol	n/a	2/23/16	Treatment of Fragile X syndrome	Designated			N/A	N/A	"Zynerba Pharmaceuticals, Inc."	80 West Lancaster Avenue	Suite 300	Devon	Pennsylvania	19333	USA
cannabidiol	n/a	11/17/14	Treatment of pediatric schizophrenia (pediatrics is defined as 0 through 16 years of age)	Designated			N/A	N/A	"Insys Development Company, Inc."	1333 S. Spectrum Blvd	Suite 100	Chandler	Arizona	85286	USA
cannabidiol	n/a	7/14/15	Prevention of Graft versus Host Disease (GVHD).	Designated			N/A	N/A	Talent biotechs Ltd.	14 - 18 Baruch Hirsch St.	Bnei Brak 5120206				Israel
cannabidiol	n/a	7/1/14	Treatment of Dravet syndrome	Designated			N/A	N/A	"Insys Development Company, Inc."	1333 S. Spectrum Blvd	Suite 100	Chandler	Arizona	85286	USA
cannabidiol	n/a	11/14/13	Treatment of Dravet syndrome.	Designated			N/A	N/A	GW Pharma Ltd.	Porton Down Science Park	"Salisbury, Wiltshire SP4 0JQ"				United Kingdom
cannabidiol	n/a	4/22/15	Treatment of neonatal hypoxic ischemic encephalopathy	Designated			N/A	N/A	GW Pharma Ltd.	15 T.W. Alexander Drive	P. O. Box 13547	Research Triangle Park	North Carolina	27709	USA
cannabidiol	n/a	11/29/16	Treatment of Graft versus Host Disease	Designated			N/A	N/A	Talent biotechs Ltd.	14-18 Baruch Hirsch Street		Bnei Brak			Israel
cannabidiol;	n/a	2/27/14	Treatment of Lennox-Gastaut syndrome	Designated			N/A	N/A	GW Pharma Ltd.	Porton Down Science Park	"Salisbury, Wiltshire SP4 OJQ"				United Kingdom
cannabidivarin	n/a	11/30/16	Treatment of Rett syndrome	Designated			N/A	N/A	GW Research Ltd.	"Sovereign House, Histon"		Cambridge			United Kingdom
cantharidin	n/a	7/24/12	"Treatment of perforating diseases, including Kyrle's disease, reactive perforating collangenosis, perforating folliculitis and elastosis perforans serpiginosa"	Designated			N/A	N/A	"Orenova Group, LLC"	10 New King Street	Suite 106	White Plains	New York	10604	USA
cantrixil	n/a	4/20/15	Treatment of ovarian cancer	Designated			N/A	N/A	"CanTx, Inc."	5 Science Park	3rd Floor	New Haven	Connecticut	6511	USA
Caplacizumab	n/a	4/14/09	Treatment of thrombotic thrombocytopenic purpura	Designated			N/A	N/A	Ablynx NV	Technologiepark 21	B-9052	Zwijnaarde			Belgium
caprine hyperimmune serum against HIV lysate	n/a	2/14/14	Treatment of systemic sclerosis	Designated			N/A	N/A	Daval International Limited	"4a Gildredge Road,"	"East Sussex, BN21 4RL"	East Sussex			United Kingdom
caprine hyperimmune serum against HIV lysate	n/a	10/28/09	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	Daval International Limited	50 Lady Somerset Road					United Kingdom
capsaicin	n/a	10/23/02	Treatment of erythromelalgia	Designated			N/A	N/A	"Acorda Therapeutics, Inc."	420 Saw Mill River Road		Ardsley	New York	10502	USA
capsaicin	Qutenza	5/2/03	Treatment of painful HIV-associated neuropathy	Designated			N/A	N/A	"Acorda Therapeutics, Inc."	420 Saw Mill River Road		Ardsley	New York	10502	USA
Capsaicin	n/a	9/29/06	Treatment of intermetatarsal neuroma (Morton's Neuroma) that does not respond to conservative treatment and requires either neurectomy or neurolysis	Designated			N/A	N/A	Centrexion Corporation	509 S. Exeter Street	Suite 202	Baltimore	Maryland	21202	USA
Capsaicin	n/a	8/3/05	Treatment of postherpetic neuralgia.	Designated			N/A	N/A	"TheraQuest Biosciences, LLC"	146 Medinah Drive		Blue Bell	Pennsylvania	19422	USA
capsaicin	Qutenza	5/22/09	Management of neuropathic pain in patients with postherpetic neuralgia	Designated/Approved	Approved for Orphan Indication	Management of neuropathic pain associated with postherpetic neuralgia	11/16/2009	11/16/2016	"Acorda Therapeutics, Inc."	420 Saw Mill River Road		Ardsley	New York	10502	USA
"carbamic acid, [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methyl-ethyl]phenoxy]methyl]phenyl]methoxy]-phenyl]iminomethyl]-,ethyl ester"	n/a	1/15/02	Management of cystic fibrosis	Designated/Withdrawn			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc"	900 Ridgebury Road	P.O. Box 368	Ridgefield	Connecticut	6877	USA
carbenoxolone	n/a	7/2/14	Treatment of Huntington's Disease	Designated			N/A	N/A	"Oxalys Pharmaceuticals, Inc."	4 Mollard Road		"Toronto, ON M1S 2L4"			Canada
carbetocin (nasal spray)	n/a	4/11/14	Treatment of Prader Willi syndrome	Designated			N/A	N/A	"Ferring Pharmaceuticals, Inc."	4 Gatehall Drive	3rd Floor	Parsippany	New Jersey	7054	USA
carbon dioxide	n/a	12/17/15	Treatment of trigeminal neuralgia	Designated			N/A	N/A	"Capnia, Inc."	3 Twin Dolphin Drive	Suite 160	Redwood City	California	94065	USA
carbon monoxide	Covox	6/24/08	For use in the reduction of the incidence and severity of delayed graft function in patients undergoing solid organ transplanation.	Designated/Withdrawn			N/A	N/A	INO Therapeutics	Perryville III Corporate Park	P. O. Box 9001	Hampton	New Jersey	8827	USA
carbon monoxide	n/a	8/16/16	Treatment of idiopathic pulmonary fibrosis (IPF).	Designated			N/A	N/A	"Proterris, Inc."	197 West Springfield Street		Boston	Massachusetts	2118	USA
carbon monoxide	n/a	9/28/12	Treatment of sickle cell disease	Designated			N/A	N/A	"Hillhurst Biopharmaceuticals, Inc."	2029 Verdugo Blvd	Suite 125	Montrose	California	91020	USA
Carbovir	n/a	12/13/89	Treatment of persons with AIDS and in patients with symptomatic HIV infection and a CD4 count less than 200/mm3.	Designated/Withdrawn			N/A	N/A	Glaxo Wellcome Inc.	5 Moore Drive		Research Triangle Park	North Carolina	27709	USA
carboxy pyrrolidine hexanoyl pyrrolidine carboxylate	n/a	2/10/15	Treatment of AL amyloidosis	Designated			N/A	N/A	"Glaxo Group Limited, England d/b/a GlaxoSmithKline"	980 Great West Road	"Middlesex, TW8 9GS"				United Kingdom
cardiotrophin-1	n/a	6/24/08	To protect the liver from ischemia-reperfusion injury inherent to the procedure of transplantation.	Designated			N/A	N/A	"Digna Biotech, S.L."	Avenids Carlos III de Noble	Pamplona (Navarra)				Spain
cardiotrophin-1	n/a	10/16/14	Prevention of ischemia-reperfusion injury in kidney transplant recipients	Designated			N/A	N/A	"Digna Biotech, S.L."	Avenida Pio XII 22	Pamplona (Navarra)				Spain
cardiotrophin-1	n/a	9/13/11	Treatment of acute liver failure	Designated			N/A	N/A	Digna Biotech S.L.	C/Boix y Morer 6-8	28003 Madrid				Spain
carfilzomib	Kyprolis	1/18/08	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.	07/20/2012	07/20/2019	"Onyx Therapeutics, Inc."	249 East Grand Avenue		South San Francisco	California	94080	USA
carglumic acid	Carbaglu	6/17/14	Treatment of organic acidemias	Designated			N/A	N/A	Orphan Europe SARL	Immeuble Le Wilson	70 avenue du General de Gaulle	92800 Puteaux			France
carglumic acid	Carbaglu	1/20/98	Treatment of N-acetylglutamate synthetase deficiency.	Designated/Approved	Approved for Orphan Indication	As an adjunctive therapy for the treatment of acute hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS) and as manitenance therapy for chronic hyperammonemia due to NAGS deficiency	03/18/2010	03/18/2017	Orphan Europe SARL	Immeuble Le Wilson	70 avenue du General de Gaulle	92800 Puteaux			France
carisbamate	n/a	3/16/12	Management of patients with infantile spasms	Designated			N/A	N/A	"SK Life Science, Inc."	22-10 Route 208 South		Fair Lawn	New Jersey	7410	USA
carlumab	n/a	10/24/06	Treatment of pancreatic cancer	Designated			N/A	N/A	"Centocor, Inc."	200 Great Valley PArkway		Malvern	Pennsylvania	19355	USA
carlumab	n/a	11/8/07	Treatment of idiopathic pulmonary fibrosis	Designated/Withdrawn			N/A	N/A	"Janssen Biotech, Inc."	Welsh & McKean Roads	P.O. Box 776	Spring House	Pennsylvania	19477	USA
Carmustine	n/a	7/3/00	Treatment of intracranial malignancies.	Designated			N/A	N/A	"Direct Therapeutics, Inc."	460 Seaport Court	Suite 220	Redwood	California	94063	USA
Cascara sagrada fluid extract	n/a	3/21/89	Treatment of oral drug overdosage to speed lower bowel evacuation.	Designated			N/A	N/A	Intramed Corporation	102 Tremont Way		Augusta	Georgia	30907	USA
CaspaCIDe System (combination product) consisting of allogeneic T Cell genetically modified to contain an inducible caspase 9 gene and Rimiducid	n/a	2/18/16	Replacement T-cell therapy for the treatment of immunodeficiency and graft versus host disease after allogeneic hematopoietic stem cell transplant	Designated			N/A	N/A	"Bellicum Pharmaceuticals, Inc."	2130 West Holcombe Boulevard		Houston	Texas	77030	USA
catumaxomab	n/a	7/1/09	Treatment of gastric cancer	Designated			N/A	N/A	"Neoviibiotech North America, Inc."	920 Winter Street		Waltham	Massachusetts	2451	USA
Catumaxomab	Removab	6/9/06	Treatment of ovarian cancer	Designated			N/A	N/A	"Neoviibiotech North America, Inc."	920 Winter Street		Waltham	Massachusetts	2451	USA
CD123 x CD3 dual affinity re-targeting (DART) protein	n/a	12/22/16	Treatment of acute myeloid leukemia (AML)	Designated			N/A	N/A	"MacroGenics, Inc."	9704 Medical Center Drive		Rockville	Maryland	20850	USA
CD4 human truncated 369 AA polypeptide	Soluble T4	11/21/89	Treatment of acquired immunodeficiency syndrome.	Designated/Withdrawn			N/A	N/A	SmithKline Beecham	"Route 23 & Woodmont Ave., P.O. Box 1510"		King Of Prussia	Pennsylvania	19406	USA
CD40/CD80/CD86 modified autologous dendritic cell therapy	n/a	12/20/13	Treatment Type 1 diabetes mellitus patients with residual beta cell function	Designated			N/A	N/A	"DiaVacs, Inc."	410 Tower Drive		Edgewater	New Jersey	7020	USA
CD5-T lymphocyte immunotoxin	Xomazyme-H65	8/27/87	Treatment of graft versus host disease and/or rejection in patients who have received bone marrow transplants.	Designated/Withdrawn			N/A	N/A	Xoma Corporation	2910 Seventh Street		Berkeley	California	94710	USA
cediranib	n/a	12/13/10	Treatment of glioblastoma	Designated			N/A	N/A	National Institutes of Health	National Cancer Institute	9609 Medical Center Dr.	Bethesda	Maryland	20892	USA
Ceftriaxone sodium	Rocephin	3/28/06	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	Mass General Hospital	"Merit E. Cudkowicz, MD, MSc"	"Building 149 13th Street, Room 2274"	Charlestown	Massachusetts	2129	USA
Celecoxib oral liquid suspension	Nu-Celecoxib	1/5/17	Treatment of pediatric juvenile idiopathic arthritis	Designated			N/A	N/A	"NuBioPharma, LLC"	111 Dennis Drive	Suite 121	Sanford	North Carolina	27330	USA
celiprolol	n/a	1/5/15	Treatment of Ehlers-Danlos syndrome	Designated			N/A	N/A	"Acer Therapeutics, Inc."	222 Third Street	Suite 2240	Cambridge	Massachusetts	2142	USA
cell based therapeutic composed of allogeneic donor apoptotic cells	Apocell	3/18/13	Prevention of graft versus host disease	Designated			N/A	N/A	Enlivex Therapeutics Ltd.	POB 12167	Hadassah Ein Kerem	Jerusalem			Israel
Cells produced using the AastromReplicelle System and SC-I Therapy Kit	n/a	7/10/02	For use in patients receiving high dose chemotherapy who are unable to generate an acceptable dose of peripheral blood stem cells and who have a sufficient bone marrow aspirate without morphological evidence of tumor	Designated			N/A	N/A	Aastrom Biosciences Incorporated	P.O. Box 376		Ann Arbor	Michigan	48106	USA
cellspan esophageal implant	n/a	11/29/16	"Restore the structure and function of the esophagus subsequent to esophageal damage due to cancer, injury, or congenital abnormality"	Designated			N/A	N/A	"Biostage, Inc."	84 October Hill Road	Suite 11	Holliston	Massachusetts	1746	USA
cenersen	Aezea	2/27/08	Treatment of chronic lymphocytic leukemia	Designated			N/A	N/A	"Eleos, Inc."	1001 Twelve Oaks Center Drive	Suite 1002	Wayzata	Minnesota	55391	USA
cenersen	Aezea	6/18/08	Treatment of stage IIB through IV melanoma	Designated			N/A	N/A	"Eleos, Inc."	1001 Twelve Oaks Center Drive	Suite 1002	Wayzata	Minnesota	55391	USA
cenersen	n/a	5/8/06	Treatment of acute myeloid leukemia	Designated			N/A	N/A	"Eleos, Inc."	1001 Twelve Oaks Center Drive	Suite 1002	Wayzata	Minnesota	55391	USA
Centruroides immune F(ab)2	Anascorp	6/12/00	Treatment of scorpion envenomations requiring medical attention.	Designated/Approved	Approved for Orphan Indication	Treatment of clinical signs of scorpion envenomation	08/04/2011	08/04/2018	"Rare Disease Therapeutics, Inc."	9550 Cuyamaca Street	Suite 203	Santee	California	92701	USA
ceramide	n/a	8/8/16	Treatment of liver cancer	Designated			N/A	N/A	"Keystone Nano, Inc."	1981 Pine Hall Road		State College	Pennsylvania	16801	USA
Ceramide trihexosidase/alpha-galactosidase A	Fabrazyme	1/19/88	Treatment of Fabry's disease.	Designated/Approved	Approved for Orphan Indication	For use in patients with Fabry disease to reduce globotriaosylceramide (GL-3) deposition in capillary endothelium of the kidney and certain other cell types	04/24/2003	04/24/2010	Genzyme Corporation	One Kendall Square		Cambridge	Massachusetts	2139	USA
cerebrolysin	n/a	4/5/16	"Treatment of frontotemporal dementia, including all subvariants"	Designated			N/A	N/A	EVER Neuro Pharma GmbH	3 Oberburgau	4866 Unterach				Austria
ceritinib	Zykadia	9/27/13	Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive	Designated/Approved	Approved for Orphan Indication	Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.	04/29/2014	04/29/2021	Novartis Pharmaceuticals Corp.	"One Health Plaza, 315/5450A"		East Hanover	New Jersey	7936	USA
cerliponase alfa	n/a	4/1/13	Treatment of neuronal ceroid lipofuscinosis type 2	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	105 Digital Drive		Novato	California	94949	USA
cethromycin	Restanza(Tm)	9/9/09	Prophylactic treatment of plague due to Yersinia pestis	Designated			N/A	N/A	"Advanced Life Sciences, Inc."	1440 Davey Road		Woodridge	Illinois	60517	USA
cethromycin	n/a	2/28/07	Prophylactic treatment of patients exposed to inhalation anthrax.	Designated			N/A	N/A	"Advanced LIfe Sciences, Inc."	1440 Davey Road		Woodridge	Illinois	60517	USA
cethromycin	Restanza(Tm)	9/9/09	Prophylactic treatment of tularemia due to Francisella tularensis.	Designated			N/A	N/A	"Advanced Life Sciences, Inc."	1440 Davey Road		Woodridge	Illinois	60517	USA
Cetiedil citrate injection	n/a	12/22/88	Treatment of sickle cell disease crisis.	Designated/Withdrawn			N/A	N/A	"Baker Cummins Pharmaceuticals, Inc."						
cetuximab	Erbitux	7/3/00	Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor	Designated/Approved	Approved for Orphan Indication	"For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed"	03/01/2006	03/01/2013	ImClone Systems Incorporated	33 ImClone Drive		Branchburg	New Jersey	8876	USA
cetuximab	Erbitux	6/15/07	Treatment of pancreatic cancer	Designated/Withdrawn			N/A	N/A	ImClone Systems Incorporated	33 ImClone Drive		Branchburg	New Jersey	8876	USA
Chelating agent delivering Holmium-166	n/a	2/10/99	Treatment of multiple myeloma.	Designated			N/A	N/A	NeoRx Corporation	410 W. Harrison Street		Seattle	Washington	98119	USA
chelmab-y or chelamusab-Y	Oncorad Ov103	4/24/90	Treatment of ovarian cancer.	Designated			N/A	N/A	Cytogen Corporation	600 College Road East		Princeton	New Jersey	8540	USA
chenodeoxycholic acid	n/a	2/12/07	Treatment of cerebrotendinous xanthomatosis	Designated			N/A	N/A	"Baxalta US, Inc."	650 Kendall Street		Cambridge	Massachusetts	2142	USA
Chenodeoxycholic acid	Chenofalk	1/29/04	Treatment of cerebrotendinous xanthomatosis	Designated			N/A	N/A	Dr. Falk Pharma GmbH	Leinenweberstrasse 5	"9041 Freiburg, GERMANY"				Germany
chenodiol	Chenadal	3/22/10	Treatment of cerebrotendinous xanthomatosis	Designated			N/A	N/A	"Retrophin, Inc."	"777 Third Avenue, 22nd Floor"		New York	New York	10017	USA
chenodiol	Chenix	9/21/84	"For patients with radiolucent stones in well opacifying gallbladders, in whom elective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age"	Designated/Approved	Approved for Orphan Indication		07/28/1983	07/28/1990	Solvay	901 Sawyer Road		Marietta	Georgia	30062	USA
Chimeric (human-murine) G250 IgG monoclonal antibody	n/a	7/24/00	Treatment of renal cell carcinoma.	Designated/Withdrawn			N/A	N/A	Wilex Biotechnology GmbH	Grillparzerstrasse 10B	81675 Munich				Germany
chimeric antigen receptor directed against the target protein CD4 lentivirally transfected T cells	n/a	7/28/16	Treatment of peripheral T-cell lymphoma	Designated			N/A	N/A	iCell Gene Therapeutics	25 Health Sciences Drive	Suite 118	Stony Brook	New York	11793	USA
chimeric fusion protein of recombinant human alpha-N-acetylglucosaminidase and human insulin-like growth factor 2	n/a	11/25/14	"Treatment of mucopolysaccharidosis III Type B (MPS IIIB, Sanfilippo Syndrome Type B)"	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	105 Digital Drive		Novato	California	94949	USA
Chimeric M-T412 (human-murine) IgG monoclonal anti-CD4	n/a	6/5/91	Treatment of multiple sclerosis.	Designated/Withdrawn			N/A	N/A	"Centocor, Inc."	244 Great Valley Parkway		Malvern	Pennsylvania	19355	USA
"Chimeric monoclonal antibodies, c-alphaStx2"	n/a	10/4/05	For treatment of shiga-toxin producing bacterial infection	Designated			N/A	N/A	"Thallion Pharmaceuticals, Inc."	275 Armand Frappier Blvd	"Laval, Quebec, H7V 4A7"				Canada
chimeric monoclonal antibody against Claudin 6	n/a	3/18/13	Treatment of ovarian cancer	Designated			N/A	N/A	Ganymed Pharmaceuticals AG	"Freiligrathstr. 12,"	Mainz				Germany
chimeric monoclonal antibody against claudin-18 splice variant 2	n/a	9/26/13	Treatment of pancreatic cancer	Designated			N/A	N/A	Ganymed Pharmaceuticals AG	"Freiligrathstr. 12,"	Mainz				Germany
Chimeric monoclonal antibody to CD30 (anti-CD30 antibody)	n/a	2/18/04	Treatment of CD30 positive T-cell lymphomas	Designated/Withdrawn			N/A	N/A	"Seattle Genetics, Inc."	21823 30th Drive Southeast		Bothell	Washington	98021	USA
Chimeric monoclonal antibody to CD30 (anti-CD30 antibody)	n/a	7/18/03	Treatment of Hodgkin's disease	Designated/Withdrawn			N/A	N/A	"Seattle Genetics, Inc"	"21823 30th Drive, Southeast"		Bothell	Washington	98021	USA
chimeric monoclonal antibody to claudin 18 splice variant 2	n/a	11/20/12	Treatment of gastric cancer	Designated			N/A	N/A	GANYMED Pharmaceuticals AG	"Freiligrathstr.12, D-155131 Mainz"					Germany
Chimeric monoclonal antibody to mesothelin	n/a	10/31/06	Treatment of pancreatic cancer	Designated			N/A	N/A	"Morphotek, Inc."	210 Welsh Pool Road		Exton	Pennsylvania	19341	USA
chimeric murine/human IgG1 monoclonal antibody to human interleukin-3 receptor alpha chain	n/a	4/3/09	Treatment of acute myeloid leukemia	Designated/Withdrawn			N/A	N/A	CSl Limited	45 Poplar Road					Australia
"Chimeric, humanized monoclonal antibody to staphylococcus"	n/a	8/3/00	Prophylaxis of Staphylococcus epidermidis sepsis in low birth weight (1500 grams or less) infants.	Designated			N/A	N/A	"Biosynexus, Inc."	9298 Gaither Road		Rockville	Maryland	20877	USA
Chlorhexidine gluconate mouthrinse	Peridex	8/18/86	For use in the amelioration of oral mucositis associated with cytoreductive therapy used in conditioning patients for bone marrow transplantation therapy.	Designated			N/A	N/A	Procter & Gamble Company	Sharon Wood Technical Center	11370 Reed Hartman Highway	Cincinnati	Ohio	45241	USA
chlorobutanol/propylene glycol/hydrochloric acid	Patul-End	2/18/97	Treatment of patulous eustachian tube	Designated			N/A	N/A	Ear Foundation	"2420 Castillo Street, Suite 100"		Santa Barbara	California	93105	USA
chloropyramine	n/a	10/22/10	Treatment of pancreatic cancer	Designated			N/A	N/A	"CurFAKtor Pharmaceuticals, LLC"	14 Rock Dove Lane		Orchard Park	New York	14127	USA
chloroquine	n/a	5/20/15	Treatment of glioblastoma multiforme.	Designated			N/A	N/A	"DualTpharma B.,V."	Boschstraat 111-D01	6211 A W Maastricht				Netherlands
Chlorotoxin	n/a	12/18/07	Treatment of malignant glioma	Designated			N/A	N/A	"Morphotek, Inc."	210 Welsh Pool Road		Exon	Pennsylvania	19341	USA
chlorotoxin	n/a	12/2/08	"Treatment of stage IIb, IIc, III & IV melanoma"	Designated			N/A	N/A	"Morphotek, Inc."	210 Welsh Pool Road		Exon	Pennsylvania	19341	USA
chlorotoxin conjugated to indocyanine green dye	n/a	6/23/15	Diagnostic for the management of malignant brain tumors	Designated			N/A	N/A	"Blaze Bioscience, Inc."	"530 Fairview Avenue, North"	Suite 1400	Seattle	Washington	98109	USA
"cholest-4-en-3-one, oxime"	n/a	2/17/09	Treatment of spinal muscular atrophy.	Designated			N/A	N/A	"Genentech, Inc."	A Roche Group Member	1 DNA Way	South San Francisco	California	94080	USA
cholic acid	Cholbam	7/18/03	Treatment of inborn errors of cholesterol and bile acid synthesis and metabolism	Designated/Approved	Approved for Orphan Indication	Treatment of bile acid synthesis disorders due to single enzyme defects	03/17/2015	03/17/2022	"Retrophin, Inc."	777 Third Avenue	22nd Floor	New York	New York	10017	USA
Choline chloride	Intrachol	7/20/06	Prevention and/or treatment of choline deficiency in patients on long-term parenteral nutrition	Designated			N/A	N/A	"Alan L. Buchman, MD, MSPH"	959 Oak Drive		Glencoe	Illinois	60022	USA
Choline chloride	Intrachol	2/10/94	"Treatment of choline deficiency, specifically the choline deficiency, hepatic steatosis, and cholestasis, associated with long-term parenteral nutrition."	Designated			N/A	N/A	"Alan L. Buchman, MD, MSPH"	959 Oak Drive		Glencoe	Illinois	60022	USA
choline tetrathiomolybdate	n/a	8/25/11	Treatment of Wilson's disease.	Designated			N/A	N/A	Wilson Therapeutics AB	Strandvagen 5b	"114 51 Stockholm, Sweden"				USA
Chondrocyte-alginate gel suspension	n/a	12/1/97	For use in correcting vesicoureteral reflux in the pediatric population.	Designated			N/A	N/A	"Curis, Inc."	61 Moulton Street		Cambridge	Massachusetts	2138	USA
Chondroitinase	n/a	2/9/95	Treatment of patients undergoing vitrectomy.	Designated/Withdrawn			N/A	N/A	"Bausch & Lomb Pharmaceuticals, Inc."	8500 Hidden River Pkwy.		Tampa	Florida	33637	USA
chromium picolinate and chromium histidinate	n/a	12/22/14	Treatment of pediatic polycystic ovary syndrome (0 through 16 years of age)	Designated			N/A	N/A	"JDS Therapeutics, LLC"	3 Manhattanville Rd	Suite 201	Purchase	New York	10577	USA
cicletanine hydrochloride	n/a	6/24/08	Treatment for pulmonary arterial hypertension.	Designated/Withdrawn			N/A	N/A	"Gilead Sciences, Inc."	333 Lakeside Drive		Foster City	California	94404	USA
cilengitide	n/a	5/27/05	Treatment of malignant glioma	Designated/Withdrawn			N/A	N/A	"EMD Serono, Inc."	One Technology Place		Rockland	Massachusetts	2370	USA
Ciliary neurotrophic factor	n/a	1/30/92	Treatment of amyotrophic lateral sclerosis.	Designated			N/A	N/A	Regeneron Pharmaceuticals Inc	777 Old Saw Mill River Road		Tarrytown	New York	10591	USA
"Ciliary neurotrophic factor, recombinant human"	n/a	5/8/92	"Treatment of motor neuron disease (including amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and primary lateral sclerosis)."	Designated/Withdrawn			N/A	N/A	Syntex-Synergen Neuroscience	3200 Walnut Street		Boulder	Colorado	80301	USA
"Ciliary neurotrophic factor, recombinant human"	n/a	4/2/92	Treatment of spinal muscular atrophies.	Designated/Withdrawn			N/A	N/A	Syntex-Synergen Neuroscience	3200 Walnut Street		Boulder	Colorado	80301	USA
cinacalcet	Sensipar	5/12/03	Treatment of hypercalcemia in patients with parathyroid carcinoma	Designated/Approved	Approved for Orphan Indication	Treatment of hypercalcemia in patients with parathyroid carcinoma	03/08/2004	03/08/2011	"Amgen, Inc."		One Amgen Center Drive	Thousand Oaks	California	91320	USA
cinacalcet	Sensipar	4/30/10	"Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery"	Designated/Approved	Approved for Orphan Indication	"Treatment of hypercalcemia in adult patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy."	11/21/2014	11/21/2021	"Amgen, Inc."	One Amgen Center Drive	"Bldg 17, 1A-4-4, Mail Stop 17-1-B"	Thousand Oaks	California	91320	USA
cinacalcet	Sensipar	4/30/10	"Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery"	Designated/Approved	Approved for Orphan Indication	Treatment of severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy	02/25/2011	02/25/2018	"Amgen, Inc."	One Amgen Center Drive	"Bldg 17, 1A-4-4, Mail Stop 17-1-B"	Thousand Oaks	California	91320	USA
cinacalcet	Sensipar	9/7/16	Treatment of secondary hyperparathyroidism (HPT) in pediatric patients with chronic kidney disease receiving dialysis	Designated			N/A	N/A	"Amgen, Inc."	One Amgen Center Drive	"Bldg 17, 1A-4-4, Mail Stop 17-1-B"	Thousand Oaks	California	91320	USA
Cintredekin Besudotox	n/a	4/30/10	Treatment of idiopathic pulmonary fibrosis	Designated			N/A	N/A	"Insys Development Company, Inc."	"1333 South Sprectum Blvd, Suite 100"		Chandler	Arizona	85286	USA
ciprofloxacin	n/a	6/1/11	The management of bronchiectasis	Designated			N/A	N/A	Aradigm Corporation	3929 Point Eden Way		Hayward	California	94545	USA
ciprofloxacin DPI	Ciprofloxacin Pulmosphere(R)	2/2/10	Management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis patients	Designated			N/A	N/A	"Bayer HealthCare Pharmaceuticals, Inc."	100 Bayer Blvd	P. O. Box 915	Whippany	New Jersey	7981	USA
ciprofloxacin dry powder inhaler	n/a	4/17/14	Treatment of non-cystic fibrosis bronchiectasis	Designated			N/A	N/A	"Bayer HealthCare Pharmaceuticals, Inc."	P. O. Box 1000		Montville	New Jersey	7045	USA
"cis-adamantane-2-spiro-3'-8'-[4'-[2'-(4'-morpholinyl)ethoxy]phenyl]-1',2,'4'-trioxaspiro[4.5] decane mesylate"	n/a	1/19/10	"Treatment of malaria caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, or Plasmodium malariae"	Designated			N/A	N/A	Medicines for Malaria Venture (MMV)	International Centre Cointrin	P. O. Box 1826	CH-1215 Geneva 15			Switzerland
Cisplatin	n/a	9/6/16	Treatment of anal cancer	Designated			N/A	N/A	Privo Technologies	13 Bristol Street	Unit #1	Cambridge	Massachusetts	2141	USA
Cisplatin ChemoThin Wafer	n/a	11/3/15	"Treatment of anatomically accessible oral cancers (lip, tongue, gum, floor of mouth, salivary gland, and other oral cavity)"	Designated			N/A	N/A	Privo Technologies	13 Bristol Street	Unit #1	Cambridge	Massachusetts	2141	USA
Cisplatin in liposomal formulation	Slit Cisplatin For Inhalation	3/20/07	Treatment of osteosarcoma	Designated			N/A	N/A	Eleison Pharmaceuticals LLC	263 13th Avenue	Suite 375	St. Petersburg	Florida	33701	USA
Cisplatin/epinephrine	Intradose	4/3/00	Treatment of squamous cell carcinoma of the head and neck.	Designated			N/A	N/A	"Matrix Pharmaceutical, Inc."	34700 Campus Drive		Fremont	California	94555	USA
Cisplatin/epinephrine	Intradose	9/7/00	Treatment of metastatic malignant melanoma.	Designated			N/A	N/A	"Matrix Pharmaceutical, Inc."	34700 Campus Drive		Fremont	California	94555	USA
"Citric acid, glucono-delta-lactone and magnesium carbonate"	Renacidin Irrigation	8/28/89	Treatment of renal and bladder calculi of the apatite or struvite variety.	Designated/Approved	Approved for Orphan Indication		10/02/1990	10/02/1997	"United-Guardian, Inc."	P.O. Box 2500		Smithtown	New York	11787	USA
civamide	n/a	2/17/09	Treatment of postherpetic neuralgia.	Designated			N/A	N/A	"Winston Laboratories, Inc."	100 Fairway Drive		Vernon Hills	Illinois	60061	USA
civamide	Zucapsaicin	12/9/02	Treatment of postherpetic neuralgia of the trigeminal nerve	Designated			N/A	N/A	"Winston Laboratories, Inc."	100 Fairway Drive	Suite 134	Vernon Hills	Illinois	60061	USA
Cladribine	Mylinax	4/19/94	Treatment of the chronic progressive form of multiple sclerosis.	Designated			N/A	N/A	"Johnson & Johnson Pharmaceutical R & D, LLC"	920 Route 202	PO Box 300	Raritan	New Jersey	8869	USA
Cladribine	Leustatin Injection	11/15/90	Treatment of hairy cell leukemia.	Designated/Approved	Approved for Orphan Indication		02/26/1993	02/26/2000	R. W. Johnson Pharmaceutical Research Institute	"Route 202, P.O. Box 300"		Raritan	New Jersey	8869	USA
Cladribine	Leustatin	7/20/90	Treatment of acute myeloid leukemia.	Designated/Withdrawn			N/A	N/A	"Janssen Research & Development, LLC"	920 US Highway 202		Raritan	New Jersey	8869	USA
cladribine	n/a	3/19/15	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	Designated			N/A	N/A	Chord Therapeutics S.a.r.l.	c/o Eclosion	CH-1228 Plan-les-Ouates				Switzerland
Cladribine	Leustatin Injection	4/19/93	Treatment of non-Hodgkin's lymphoma.	Designated/Withdrawn			N/A	N/A	"Janssen Research & Development, LLC"	920 US Highway 202		Raritan	New Jersey	8869	USA
cladribine	n/a	12/31/90	Treatment of chronic lymphocytic leukemia	Designated/Withdrawn			N/A	N/A	"Janssen Research & Development, LLC"	Global Regulatory Affairs	920 US Route 202	Raritan	New Jersey	8869	USA
"clarithromycin, rifabutin, clofazimine"	n/a	4/26/11	Treatment of pediatric Crohn's disease.	Designated			N/A	N/A	RedHill Biopharma Ltd.	42 Givati St.					Israel
Clazosentan	Erajet	2/16/06	Treatment of cerebral vasospasm following subarachnoid hemorrhage	Designated			N/A	N/A	Actelion Pharmaceuticals Ltd.	Gewerbestrasse 16					Switzerland
Clenbuterol	n/a	1/9/17	Treatment of Pompe disease (glycogen storage disease type II)	Designated			N/A	N/A	"Dwight D. Koeberl, MD, PhD"	Duke University Medical Center	"Pediatrics Dept., Div. of Genetics"	Durham	North Carolina	27710	USA
clenbuterol	"Spiropent, Ventipulmin"	10/27/14	Adjunctive therapy with enzyme replacement therapy in the treatment of Pompe disease	Designated			N/A	N/A	Duke University Medical Center	Box 103856		Durham	North Carolina	27710	USA
Clindamycin	Cleocin	10/28/88	Prevention of Pneumocystis carinii pneumonia in AIDS patients.	Designated			N/A	N/A	Pfizer Inc.	235 East 42nd Street		New York	New York	10017	USA
Clindamycin	Cleocin	10/28/88	Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.	Designated			N/A	N/A	Pharmacia & Upjohn	7000 Portage Road	Unit 0633-298-113	Kalamazoo	Michigan	49001	USA
Clindamycin hydrochloride	n/a	8/9/06	Treatment of sarcoidosis	Designated			N/A	N/A	Autoimmunity Research Foundation	3423 Hill Canyon Avenue		Thousand Oaks	California	91360	USA
clobazam	Onfi	12/18/07	Treatment of Lennox-Gastaut Syndrome	Designated/Approved	Approved for Orphan Indication	Adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome inpatients 2 years of age or older	10/21/2011	10/21/2018	"Lundbeck, Inc."	Four Parkway North		Deerfield	Illinois	60015	USA
clofarabine	Clolar	2/7/02	Treatment of acute lymphoblastic leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens	12/28/2004	12/28/2011	Genzyme Corporation	4545 Horizon Hill Blvd.		San Antonio	Texas	78229	USA
clofarabine	Clofarex	3/14/02	Treatment of acute myelogenous leukemia	Designated			N/A	N/A	"Genzyme Corp (Ilex Products, Inc.)"	4545 Horizon Hill Blvd.		San Antonio	Texas	78229	USA
Clofazimine	Lamprene	6/11/84	"Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum."	Designated/Approved	Approved for Orphan Indication		12/15/1986	12/15/1993	Novartis Pharmaceutical Corporation	59 Route 10		East Hanover	New Jersey	7936	USA
clofazimine	Lamprene	6/25/14	Treatment of active tuberculosis	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	One Health Plaza	Bldg 135/409	East Hanover	New Jersey	7936	USA
Clonazepam	Klonopin	8/4/94	Treatment of hyperekplexia (startle disease).	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA
Clonazepam Intranasal Spray	n/a	12/19/07	Treatment of recurrent acute repetitive seizures	Designated			N/A	N/A	"Jazz Pharmaceuticals, Inc."	3180 Porter Drive		Palo Alto	California	94304	USA
Clonidine	Duraclon	1/24/89	"For continous epidural administration as adjunctive therapy with intraspinal opiates for the treatment of pain in cancer patients tolerant to, or unresponsive to, intraspinal opiates."	Designated/Approved	Approved for Orphan Indication	In combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone.	10/02/1996	10/02/2003	"Roxane Laboratories, Inc."	PO Box 16532		Columbus	Ohio	43216	USA
Clotrimazole	n/a	6/14/05	Topical treatment of children and adults with pouchitis	Designated			N/A	N/A	"AesRx, LLC"	275 Grove Street	Suite 2-400	Newton	Massachusetts	2466	USA
Clotrimazole	n/a	4/24/95	Treatment of sickle cell disease.	Designated			N/A	N/A	"Brugnara, Carlo M.D."	The Children's Hospital	"300 Longwood Avenue, Bader 760"	Boston	Massachusetts	2115	USA
Clotrimazole	n/a	3/13/06	Treatment of Huntington's disease	Designated			N/A	N/A	"EnVivo Pharmaceuticals, Inc."	480 Arsenal Street		Watertown	Massachusetts	2472	USA
clotrimazole otic solution	n/a	5/10/16	Treatment of fungal otitis externa (otomycosis).	Designated			N/A	N/A	Laboratorios SALVAT S.A.	"C/ Gall, 30-36"	Esplugues de Llobregat	Barcelona			Spain
CNDO-109-activated allogeneic natural killer cells	n/a	6/18/12	Treatment of acute myeloid leukemia	Designated			N/A	N/A	"Coronado Biosciences, Inc."	15 New England Executive Park		Burlington	Massachusetts	1803	USA
Coagulation factor IX	Mononine	6/27/89	Replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia B.	Designated/Approved	Approved for Orphan Indication	"Prevention and control of bleeding in factor IX deficiency, also known as hemophilia B or Christmas disease."	08/20/1992	08/20/1999	Armour Pharmaceutical Company	"500 Arcola Road, P.O. Box 1200"		Collegeville	Pennsylvania	19426	USA
Coagulation Factor IX (human)	Alphanine	7/5/90	"For use as replacement therapy in patients with hemophilia B for the prevention and control of bleeding episodes, and during surgery to correct defective hemostasis."	Designated/Approved	Approved for Orphan Indication		12/31/1990	12/31/1997	Alpha Therapeutic Corporation	5555 Valley Boulevard		Los Angeles	California	90032	USA
Coagulation Factor IX (recombinant)	Benefix	10/3/94	Treatment of hemophilia B.	Designated/Approved	Approved for Orphan Indication	"For the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency and Christmas disease), including control and prevention of bleeding in surgical settings."	02/11/1997	02/11/2004	"Genetics Institute, Inc."	87 Cambridge Park Drive		Cambridge	Massachusetts	2140	USA
coagulation factor IX (recombinant)	Rixubis	10/31/12	Prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (routine prophylaxis in patients where there is no evidence or suspicion of bleeding)	Designated/Approved	Approved for Orphan Indication	Adults with Hemophilia B for routine prophylaxis to prevent or reduce the frequency of bleeding episodes.	06/26/2013	06/26/2020	"Baxalta US, Inc."	One Baxter Way		Westlake Village	California	91362	USA
"Coagulation factor IX (recombinant), Fc fusion protein"	Alprolix	10/30/08	Control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease)	Designated/Approved	Approved for Orphan Indication	"Adults and children with Hemophilia B for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes."	03/28/2014	03/28/2021	Biogen Idec Inc.	14 Cambridge Center		Cambridge	Massachusetts	2142	USA
Coagulation factor VIIa (recombinant)	Novoseven	6/18/04	"Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors"	Designated/Approved	Approved for Orphan Indication	Prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX	08/12/2005	08/12/2012	"Novo Nordisk, Inc."	100 College Road West		Princeton	New Jersey	8540	USA
Coagulation factor VIIa (recombinant)	Novoseven	6/18/04	Prevention of bleeding episodes in Glanzmann's thrombasthenia	Designated			N/A	N/A	"Novo Nordisk, Inc."	100 College Road West		Princeton	New Jersey	8540	USA
coagulation factor VIIa (recombinant)	Novoseven Rt	6/18/04	Treatment of bleeding episodes in Glanzmann's thrombasthenia	Designated/Approved	Approved for Orphan Indication	"Treatment of bleeding episodes and peri-operative management in adults and children with Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets."	07/02/2014	07/02/2021	Novo Nordisk Inc.	800 Scudders Mill Rd.		Plainsboro	New Jersey	8536	USA
Coagulation Factor VIIa (Recombinant)	Novoseven	7/16/04	Treatment of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Designated/Approved	Approved for Orphan Indication	Treatment of bleeding episodes in surgical interventions or invasive procedures in patients with acquired hemophilia	10/13/2006	10/13/2013	"Novo Nordisk, Inc."	100 College Road West		Princeton	New Jersey	8540	USA
Coagulation factor VIIa (recombinant)	Novoseven	7/21/04	Prevention of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Designated/Approved	Approved for Orphan Indication	Prevention of bleeding in surgical interventions or invasive procedures in patients with acquired hemophilia	10/13/2006	10/13/2013	"Novo Nordisk, Inc."	100 College Road West		Princeton	New Jersey	8540	USA
Coagulation factor VIIa (recombinant)	Novoseven	9/10/04	Treatment of bleeding episodes in patients with congenital factor VII deficiency	Designated/Approved	Approved for Orphan Indication	Treatment of bleeding episodes in patients with Factor VII Deficiency	07/11/2005	07/11/2012	"Novo Nordisk, Inc."	100 College Road West		Princeton	New Jersey	8540	USA
Coagulation factor VIIa (recombinant)	Novoseven	6/6/88	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Designated/Approved	Approved for Orphan Indication	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	03/25/1999	03/25/2006	"Novo Nordisk, Inc."	100 College Road West		Princeton	New Jersey	8540	USA
Coagulation factor VIIa (recombinant)	Novoseven	9/10/04	Prevention of bleeding episodes in patients with congenital Factor VII deficiency	Designated/Approved	Approved for Orphan Indication	Prevention of bleeding in surgical interventions or invasive procedures in patients with congenital F VII deficiency	07/11/2005	07/11/2012	"Novo Nordisk, Inc."	100 College Road West		Princeton	New Jersey	8540	USA
Coagulation Factor VIIa (Recombinant)	Novoseven	10/3/06	Treatment of bleeding in patients experiencing intracranial hemorrhage.	Designated/Withdrawn			N/A	N/A	"Novo Nordisk, Inc."	P. O. Box 846		Plainsboro	New Jersey	8536	USA
coagulation factor XIII A-subunit (recombinant)	Tretten	11/6/03	Prophylaxis of bleeding associated with congential factor XIII deficiency	Designated/Approved	Approved for Orphan Indication	Routine prophylaxis of bleeding in patients with congenital Factor XIII A-subunit deficiency.	12/23/2013	12/23/2020	"Novo Nordisk, Inc."	800 Scudders Mill Rd.		Plainsboro	New Jersey	8536	USA
cobimetinib	n/a	1/31/14	"Treatment of stage IIb, IIc, III, and IV melanoma with BRAFV600 mutation"	Designated/Approved	Approved for Orphan Indication	"For the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation, in combination with vemurafenib. COTELLIC is not indicated for treatment of patients with wild-type BRAF melanoma"	11/10/2015	11/10/2022	"Genentech, Inc."	"1 DNA Way, MS 241A"		South San Francisco	California	94080	USA
cobiprostone	n/a	11/14/02	Treatment of cystic fibrosis	Designated/Withdrawn			N/A	N/A	"Sucampo Pharma Americas, LLC."	4520 East-West Highway	Suite 300	Bethesda	Maryland	20814	USA
coccidioidin SD Skin Test Antigen	n/a	12/19/07	For the diagnosis of Coccidioidomycosis	Designated/Approved	Approved for Orphan Indication	"For the detection of delayed type hypersensitivity to C. immitis in individuals, 18-64 years of age, with a history of pulmonary coccidioidomy-cosis"	07/29/2011	N/A	"Allermed Labortories, Inc."	7203 Convoy Court		San Diego	California	92111	USA
Coenzyme Q10	n/a	3/5/01	Treatment of Huntington's disease	Designated			N/A	N/A	"Integrative Therapeutics, Inc."	825 Challenger Drive		Green Bay	Wisconsin	54311	USA
coenzyme Q10 and d-alpha-tocopherol	n/a	3/14/11	Treatment of Friedreich's Ataxia.	Designated			N/A	N/A	"NBI Pharmaceuticals, Inc."	c/o Neil & Co CPAs	"1184 N. 15th Ave., Suite 1"	Bozeman	Montana	59715	USA
Colchicine	n/a	12/9/85	For arresting the progression of neurologic disability caused by chronic progressive multiple sclerosis.	Designated/Withdrawn			N/A	N/A	Pharmacontrol Corporation	"661 Palisade Ave., P.O. Box 931"		Englewood Cliffs	New Jersey	7632	USA
Colchicine	n/a	9/25/07	Treatment of Behcet's Syndrome	Designated			N/A	N/A	"AR Scientific, Inc."	1100 Orthodox Street		Philadelphia	Pennsylvania	19124	USA
colchicine	Colcrys	9/25/07	Treatment of familial Mediterranean fever	Designated/Approved	Approved for Orphan Indication	Treatment of familial Mediterranean fever	07/29/2009	07/29/2016	"AR Holding Company, Inc."	1100 Orthodox Street		Philadelphia	Pennsylvania	19124	USA
"Colfosceril palmitate, cetyl alcohol, tyloxapol"	Exosurf	1/11/93	Treatment of adult respiratory distress syndrome.	Designated/Withdrawn			N/A	N/A	GlaxoSmithKline	5 Moore Drive	P.O. Box 13398	Research Triangle Park	North Carolina	27709	USA
"Colfosceril palmitate, cetyl alcohol, tyloxapol"	Exosurf Neonatal For Intratracheal Suspension	10/20/89	"1. Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less 2. prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32 weeks gestation or less and in the treatment of established HMO at all gestational ages."	Designated/Approved	Approved for Orphan Indication	"Prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32 weeks gestation or less and in the treatment of established HMO at all gestational ages"	08/02/1990	08/02/1997	Glaxo Wellcome Inc.	5 Moore Drive		Research Triangle Park	North Carolina	27709	USA
collagenase clostridium histolyticum	Xiaflex	3/12/96	Treatment of Peyronie's disease.	Designated/Approved	Approved for Orphan Indication	Treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.	12/06/2013	12/06/2020	"Auxilium Pharmaceuticals, Inc."	640 Lee Road		Chesterbrook	Pennsylvania	19087	USA
collagenase clostridium histolyticum	Xiaflex	5/23/96	Treatment of advanced (involutional or residual stage) Dupuytren's disease.	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with Dupuytren's contracture with a palpable cord	02/02/2010	02/02/2017	"Auxilium Pharmaceuticals, Inc."	40 Valley Stream Parkway		Malvern	Pennsylvania	19335	USA
"Combination of an inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium)"	n/a	10/13/16	Treatment of hepatocellular carcinoma	Designated			N/A	N/A	"Yisheng US Biopharma, Inc."	11 Firstfield Road	Suite A	Gaithersburg	Maryland	20878	USA
combination of disulfiram and copper gluconate	n/a	5/18/16	Treatment of glioblastoma multiforme.	Designated			N/A	N/A	"Cantex Pharmaceuticals, Inc."	1792 Bell Tower Lane		Weston	Florida	33326	USA
Combination of nivolumab and ipilimumab	n/a	10/9/14	Treatment of Stage IIb to Stage IV melanoma	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with BRAF V600 wild-type, unresectable or metastatic melanoma"	09/30/2015	09/30/2022	Bristol-Myers Squibb Company	5 Research Parkway		Wallingford	Connecticut	6492	USA
combinatorial regimen of LV305 (lentiviral vector encoding NY-ESO-1 gene) and G305 (NY-ESO-1 recombinant protein plus GLA-SE)	n/a	5/2/16	Treatment of soft tissue sarcoma	Designated			N/A	N/A	Immune Design Corp.	1616 Eastlake Ave. E	Suite 310	Seattle	Washington	98102	USA
combretastatin A 1 diphosphate	n/a	11/19/12	Treatment of acute myelogenous leukemia	Designated			N/A	N/A	"Mateon Therapeutics, Inc."	701 Gateway Blvd	Suite 210	South San Francisco	California	94080	USA
Combretastatin A4 Phosphate	n/a	7/23/03	"Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer"	Designated			N/A	N/A	"Mateon Therapeutics, Inc."	701 Gateway Boulevard	Suite 210	South San Francisco	California	94080	USA
Combretastatin A4 phosphate	n/a	5/8/06	Treatment of ovarian cancer	Designated			N/A	N/A	"Mateon Therapeutics, Inc."	701 Gateway Blvd	Suite 210	South San Francisco	California	94080	USA
competetive small molecule inhibitor of the enzyme O-GlcNAcase	n/a	3/10/16	Treatment of progressive supranuclear palsy.	Designated			N/A	N/A	"Merck & Company, Inc."	126 East Lincoln Avenue	P. O. Box 2000	Rahway	New Jersey	7065	USA
complement factor H	n/a	12/7/09	Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system	Designated/Withdrawn			N/A	N/A	LFB Biotechnologies S.A.	"3, avenue des Tropiques"	91943 Courtaboeuf Cedex				France
Conjugate of a dengue virus specific small chemical ligand and an amphiphilic PEG based polymer	n/a	8/6/13	Treatment of dengue fever (includes dengue hemorrhagic fever and dengue shock syndrome)	Designated			N/A	N/A	NanoViricides Incorporated	"135 Wood Street, Suite 205"		West Haven	Connecticut	6516	USA
conjugate of human transferrin and a mutant diphtheria toxin (CRM 107)	Transmid	12/3/01	Treatment of malignant tumors of the central nervous system	Designated			N/A	N/A	Xenova Biomedix Limited	957 Budkingham Avenue	Slough				United Kingdom
conjugated bile acids	Cobartin	7/18/03	Treatment of steatorrhea in patients with short bowel syndrome	Designated			N/A	N/A	"Jarrow Formulas, Inc."	1824 S. Robertson Blvd.		Los Angeles	California	90035	USA
Contulakin-G	n/a	7/7/05	Intrathecal treatment of neuropathic pain associated with spinal cord injury	Designated			N/A	N/A	"Cognetix, Inc."	421 Wakara Way		Salt Lake City	Utah	84108	USA
copanlisib	n/a	2/5/15	Treatment of follicular lymphoma	Designated			N/A	N/A	"Bayer HealthCare Pharmaceuticals, Inc."	100 Bayer Blvd	P. O. Box 915	Whippany	New Jersey	7981	USA
Copper 64-DOTA-TATE	Netmedix (Tm)	5/18/16	Diagnostic for the management of neuroendocrine tumors.	Designated			N/A	N/A	"RadioMedix, Inc."	9701 Richmond Avenue	Suite 222	Houston	Texas	77042	USA
copper histidine	n/a	5/14/12	Treatment of Menkes disease	Designated			N/A	N/A	"Stephen G. Kaler, M.D."	"Head, Unit on Human Copper Metabolism"	"10 Center Drive-Rm 10N313, MSC 1853"	Bethesda	Maryland	20892	USA
Cordycepin	n/a	7/5/07	Treatment of TdT-positive acute lymphocytic leukemia	Designated			N/A	N/A	"OncoVista, Inc."	14785 Omicron Drive		San Antonio	Texas	78245	USA
corifungin	n/a	7/6/11	Treatment of visceral leishmaniasis	Designated			N/A	N/A	Sandler Center for Drug Discovery	"University of CA, San Francisco"	1700 4th Street	San Francisco	California	94158	USA
corifungin	n/a	8/22/11	Treatment of amebic meningoencephalitis.	Designated			N/A	N/A	Ctr for Discovery & Innovation in Parasitic Diseas	"University of CA, San Francisco"	"Byers Hall Room 508B, QB3"	San Francisco	California	94158	USA
Corticorelin ovine triflutate	Acthrel	11/24/89	For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushings syndrome.	Designated/Approved	Approved for Orphan Indication	To differentiate between pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome.	05/23/1996	05/23/2003	"Ferring Laboratories, Inc."	"400 Rella Boulevard, Suite 201"		Suffern	New York	10901	USA
"Corticotropin-releasing factor, human"	Xerecept	4/6/98	Treatment of peritumoral brain edema.	Designated			N/A	N/A	"Neurobiological Technologies, Inc."	1387 Marina Way South		Richmond	California	94804	USA
Coumarin	Onkolox	12/22/94	Treatment of renal cell carcinoma.	Designated			N/A	N/A	Drossapharm LTD	4002 Basel					Switzerland
coversin; rEV675	n/a	9/8/16	Treatment of paroxysmal nocturnal hemoglobinuria	Designated			N/A	N/A	Akari Therapeutics Plc	24 West 40th Street	8th Floor	New York	New York	10018	USA
Coxsackievirus A21	Cavatak	12/15/05	"Treatment of stage II (T4), stage III, and stage IV melanoma"	Designated			N/A	N/A	Viralytics Limited	P. O. Box 1045	"Unit 8/33 Ryde Road, Pymble, NSW 22073"				Australia
Creatine	Creapure	10/11/05	Treatment of Huntington's disease	Designated			N/A	N/A	"Marathon Pharmaceuticals, LLC"	1033 Skokie Blvd	Suite 600	Northbrook	Illinois	60062	USA
creatine	Creapure	2/12/02	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	"Avicena Group, Inc."	580 California St.	Suite 1600	San Francisco	California	94104	USA
crenolanib	n/a	3/18/11	Treatment of soft tissue sarcoma	Designated			N/A	N/A	"AROG Pharmaceuticals, LLC"	12400 Coit Road	Suite 570	Dallas	Texas	75251	USA
crenolanib	n/a	10/31/12	Treatment of acute myelogenous leukemia	Designated			N/A	N/A	"AROG Pharmaceuticals, LLC"	12400 Coit Road	Suite 570	Dallas	Texas	75251	USA
crenolanib besylate	n/a	12/20/10	Treatment of malignant glioma	Designated			N/A	N/A	"AROG Pharmaceuticals, LLC"	Two Lincoln Centre	Suite 410	Dallas	Texas	75240	USA
cridanimod	n/a	1/12/11	Treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy.	Designated			N/A	N/A	"Xenetic Biosciences, Inc."	99 Hayden Avenue	Suite 230	Lexington	Massachusetts	2421	USA
crizotinib	Xalkori	10/31/12	Treatment of neuroblastoma	Designated			N/A	N/A	"Pfizer, Inc."	10646 Science Center Drive		San Diego	California	92121	USA
crizotinib	Xalkori	9/28/12	Treatment of anaplastic large cell lymphoma	Designated			N/A	N/A	"Pfizer, Inc."	10646 Science Center Drive		San Diego	California	92121	USA
crizotinib	Xalkori	9/13/10	"Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer"	Designated/Approved	Approved for Orphan Indication	Treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDAapproved test	08/26/2011	08/26/2018	"Pfizer, Inc."	10646 Science Center Drive		San Diego	California	92121	USA
Cromolyn sodium	Gastrocrom	3/8/84	Treatment of mastocytosis.	Designated/Approved	Approved for Orphan Indication		12/22/1989	12/22/1996	Fisons Corporation	"755 Jefferson Rd., P.O. Box 1710"		Rochester	New York	14603	USA
Cromolyn sodium 4% ophthalmic solution	Opticrom 4% Ophthalmic Solution	7/24/85	Treatment of vernal keratoconjunctivitis.	Designated/Approved	Approved for Orphan Indication		10/03/1984	10/03/1991	Fisons Corporation	755 Jefferson Rd.	P.O. Box 1710	Rochester	New York	14603	USA
cromolyn sodium for inhalation	n/a	12/9/15	Treatment of mastocytosis.	Designated			N/A	N/A	"Patara Pharma, LLC"	11455 El Camino Real	Suite 460	San Diego	California	92130	USA
Cryptosporidium hyperimmune bovine colostrum IgG concentrate	n/a	12/30/91	Treatment of diarrhea in AIDS patients caused by infection with Cryptosporidium parvum.	Designated			N/A	N/A	ImmuCell Corporation	56 Evergreen Drive		Portland	Maine	4103	USA
CT-2584 mesylate	n/a	4/16/99	Treatment of malignant mesothelioma.	Designated/Withdrawn			N/A	N/A	"Cell Therapeutics, Inc."	"501 Elliott Avenue West, #400"		Seattle	Washington	98119	USA
CT-2584 Mesylate	n/a	4/16/99	Treatment of adult soft tissue sarcoma.	Designated/Withdrawn			N/A	N/A	"Cell Therapeutics, Inc."	"501 Elliott Avenue West, #400"		Seattle	Washington	98119	USA
cultured skin substitute (CSS)	Novaderm	8/22/16	Treatment of burns requiring skin grafting.	Designated			N/A	N/A	Regenicin Inc.	10 High Court		Little Falls	New Jersey	7424	USA
"cultured, partially T-Cell depleted, allogenic thymic tissue for transplantation"	n/a	8/15/03	As a therapy for primary immune deficiency resulting from athymia associated with complete DiGeorge Syndrome	Designated			N/A	N/A	Duke University Medical Center	Division of Pediatric Allergy & Immunology	Erwin Road	Durham	North Carolina	27710	USA
cyclic pyranopterin monophosphate (cPMP)	n/a	11/5/09	Treatment of molybdenum cofactor deficiency type A (MoCD)	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	100 College Street		New Haven	Connecticut	6510	USA
"Cyclo {{(E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl}-L-2-aminobytyrl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl}"	n/a	12/20/06	"Treatment and chronic control of non-infectious posterior, intermediate and pan-uveitis"	Designated			N/A	N/A	"Lux Biosciences, Inc."	Hoarborside Financial Center	"Plaza 10, 14th Floor"	Jersey City	New Jersey	7302	USA
"cyclo(-y-aminobutyryl-L-phenylalanyl-L-tryptophanyl-D-tryptophanyl-L-lysyl-L-threonly-L-phenylalanyl-N-3-carboxypropyl)-glycine amide, acetate salt"	n/a	6/24/13	Treatment of acromegaly	Designated			N/A	N/A	Aspireo Pharmaceuticals Limited	P. O. Box 880		Ra'annana			Israel
cyclocreatine	n/a	6/18/12	Treatment of creatine transporter deficiency	Designated			N/A	N/A	Lumos Pharma	4200 Marathon Blvd.	Suite 200	Austin	Texas	78756	USA
cyclophosphamide	Cyrevia(Tm)	6/7/11	Treatment of systemic sclerosis.	Designated			N/A	N/A	"Accentia Biopharmaceuticals, Inc."	"324 South Hyde Avenue, Suite 350"		Tampa	Florida	33606	USA
cyclophosphamide	Cyrevia(Tm)	6/17/11	Prevention of graft versus host disease following allogeneic hematopoietic stem cell transplant	Designated			N/A	N/A	"Accentia Biopharmaceuticals, Inc."	324 S. Hyde Park Avenue		Tampa	Florida	33606	USA
Cyclosporin A	Mitogard	10/29/04	Treatment of amyotrophic lateral sclerosis and its variants	Designated			N/A	N/A	"Maas Biolab,LLC"	Tecnology Ventures Corporation Technopolis	"1155 University Blvd., SE"	Albuquerque	New Mexico	87106	USA
Cyclosporine	n/a	11/25/03	Prophylaxis of organ rejection in patients receiving allogeneic lung transplant	Designated			N/A	N/A	"APT Pharmaceuticals, Inc."	700 Airport Blvd.	Suite 350	Burlingame	California	94010	USA
Cyclosporine	Pluminiq	11/25/03	Treatment of acute rejection in patients requiring allogenic lung transplants	Designated			N/A	N/A	"APT Pharmaceuticals, Inc."	700 Airport Blvd.	Suite 350	Burlingame	California	94010	USA
cyclosporine	n/a	2/17/09	Treatment of graft-versus-host disease	Designated			N/A	N/A	Sigmoid Pharma Limited	Dublin City University					Ireland
cyclosporine	n/a	2/17/09	Prophylaxis of graft-versus-host disease	Designated			N/A	N/A	Sigmoid Pharma Limited	Dublin City University					Ireland
Cyclosporine 2% ophthalmic ointment	n/a	8/1/91	Treatment of patients at high risk of graft rejection following penetrating keratoplasty	Designated			N/A	N/A	"Allergan, Inc."	2525 Dupont Drive	P. O. Box 19534	Irvine	California	92612	USA
cyclosporine 2% ophthalmic ointment	n/a	8/1/91	"For use in corneal melting syndromes of known or presumed immunologic etiopathogenesis, including Mooren's ulcer"	Designated			N/A	N/A	"Allergan, Inc."	2525 Dupont Drive	Mail Code AND-150B	Irvine	California	92612	USA
cyclosporine A	Nova22007	4/9/08	Treatment of herpes simplex virus stromal keratitis	Designated			N/A	N/A	Santen SAS	1 rue Pierre Fontaine	91058 Evry cedex				France
Cyclosporine A	n/a	5/4/07	Treatment of vernal keratoconjunctivitis	Designated			N/A	N/A	Santen SAS	Batiment Genavenir IV	F-91058-Evry cedex				France
cyclosporine A	n/a	9/30/08	Prevention of corneal graft rejection	Designated			N/A	N/A	Santen SAS	Batiment Genavenir IV	F-91058-Evry cedex				France
Cyclosporine A implant	n/a	1/8/07	For the prevention of acute rejection in cornea transplant patients	Designated/Withdrawn			N/A	N/A	"Lux Biosciences, Inc."	Harborside Financial Center	"Plaza 10, 14th Floor"	Jersey City	New Jersey	7302	USA
Cyclosporine in combination with omega-3 polyunsaturated fatty acids	n/a	12/6/00	Prevention of solid organ graft rejection.	Designated			N/A	N/A	RTP Pharma Corporation	200 Westpark Corporate Center	4364 South Alston Avenue	Durham	North Carolina	27713	USA
Cyclosporine ophthalmic	Optimmune	11/9/88	Treatment of severe keratoconjunctivitis sicca associated with Sjogren's syndrome.	Designated			N/A	N/A	University Of Georgia	College Of Veterinary Medicine	Department of Small Animal Medicine	Athens	Georgia	30602	USA
cyclosporine; ciclosporin	Neurostat(R)/Ciclomulsion(R)	11/23/10	Treatment of moderate to severe traumatic brain injury.	Designated			N/A	N/A	NeuroVive Pharmaceutical AB	Medicon Village	SE-223 81	Lund			Sweden
Cyclo{-Asn-Leu-d-Phe-Al[(N5-acetyl-N5-hydroxy-Orn)-(N5-acetyl-N5-hydroxy-Orn)-(N5-hydroxy-Orn)]-} . Al(III)	n/a	12/29/15	Treatment of invasive aspergillosis.	Designated			N/A	N/A	Vical Incorporated	10390 Pacific Center Court		San Diego	California	92121	USA
Cyproterone acetate	Androcur	10/26/84	Treatment of severe hirsutism.	Designated/Withdrawn			N/A	N/A	"Berlex Laboratories, Inc."	300 Fairfield Road		Wayne	New Jersey	7470	USA
Cys-His-Ala-Val-Cys	n/a	2/14/08	"For use in conjunction with melphalen for the treatment of malignant melanoma, AJCC stages IIB, IIC, III and IV"	Designated			N/A	N/A	"Adherex Technologies, Inc."	4620 Creekstone Drive		Durham	North Carolina	27703	USA
Cysteamine	Cystagon	1/25/91	Treatment of nephropathic cystinosis.	Designated/Approved	Approved for Orphan Indication	Treatment of nephropathic cystinosis in adults and children.	08/15/1994	08/15/2001	"Mylan Laboratories, Inc."	781 Chestnut Ridge Road	P.O. Box 4310	Morgantown	West Virginia	26504	USA
cysteamine	n/a	5/9/08	Treatment of Huntington's disease	Designated			N/A	N/A	Horizon Orphan LLC	7 Hamilton Landing	Suite 100	Novato	California	94949	USA
cysteamine	n/a	8/6/08	Treatment of neuronal ceroid lipofuscinoses (Batten disease)	Designated			N/A	N/A	"Raptor Pharmaceuticals, Inc."	9 Commercial Blvd.	Suite 200	Novato	California	94949	USA
Cysteamine	Lynovex	9/11/14	Treatment of cystic fibrosis	Designated			N/A	N/A	NovaBiotics Ltd.	Cruickshank Building	Craibstone	Aberdeen AB21 9TR			United Kingdom
Cysteamine	n/a	5/1/86	Treatment of nephropathic cystinosis.	Designated			N/A	N/A	"Thoene, Jess G., M.D."	University of Michigan Medical School	"300 NIB, 1192 SE"	Ann Arbor	Michigan	48109	USA
cysteamine	n/a	9/11/13	Treatment of pancreatic cancer	Designated			N/A	N/A	Horizon Orphan LLC	7 Hamilton Landing	Suite 100	Novato	California	94949	USA
cysteamine enteric coated	Procysbi	10/24/06	Treatment of cystinosis	Designated/Approved	Approved for Orphan Indication	For management of nephropathic cystinosis in adults and children ages 6 years and older	04/30/2013	04/30/2020	Horizon Orphan LLC	7 Hamilton Landing	Suite 100	Novato	California	94949	USA
cysteamine enteric coated	Procysbi	10/24/06	Treatment of cystinosis	Designated/Approved	Approved for Orphan Indication	To expand the indication to pediatric patients 2-6 years of age with nephropathic cystinosis	08/14/2015	08/14/2022	Horizon Orphan LLC	7 Hamilton Landing	Suite 100	Novato	California	94949	USA
Cysteamine hydrochloride	Cystaran	8/19/97	Treatment of corneal cystine crystal accumulation in cystinosis patients.	Designated/Approved	Approved for Orphan Indication	Treatment of corneal cystine crystal accumulation in patients with cystinosis	10/02/2012	10/02/2019	"Sigma-Tau Pharmaceuticals, Inc."	9841 Washingtonian Blvd	Suite 500	Gaithersburg	Maryland	20878	USA
Cystic fibrosis gene therapy	n/a	6/30/92	Treatment of cystic fibrosis.	Designated/Withdrawn			N/A	N/A	Genzyme Corporation	One Mountain Rd.	P.O. Box 9322	Framingham	Massachusetts	1701	USA
Cystic fibrosis Tr gene therapy (recombinant adenovirus)	Adgvcftr.10	3/9/95	Treatment of cystic fibrosis.	Designated			N/A	N/A	"GenVec, Inc."	12111 Parklawn Drive		Rockville	Maryland	20852	USA
Cystic fibrosis transmembrane conductance regulator	n/a	1/14/92	For cystic fibrosis transmembrane conductance regulator protein replacement therapy in cystic fibrosis patients.	Designated/Withdrawn			N/A	N/A	Genzyme Corporation	One Mountain Road	P.O. Box 9322	Framingham	Massachusetts	1701	USA
Cystic fibrosis transmembrane conductance regulator gene	n/a	1/8/93	Treatment of cystic fibrosis.	Designated			N/A	N/A	"Genetic Therapy, Inc."	938 Clopper Road		Gaithersburg	Maryland	20878	USA
Cytarabine liposomal	Depocyt	6/2/93	Treatment of neoplastic meningitis.	Designated/Approved	Approved for Orphan Indication	Intrathecal treatment of lymphomatous meningitis.	04/01/1999	04/01/2006	"Pacira Pharmaceuticals, Inc."	10450 Science Center Drive		San Diego	California	92121	USA
cytarabine liposome	Depocyt	1/30/07	Treatment of gliomas	Designated			N/A	N/A	"Bruce Frankel, MD"	Medical University of South Carolina	"96 Jonathan Lucas Street, Suite 428 CSB"	Charleston	South Carolina	29425	USA
Cytarabine:daunorubicin liposome injection	n/a	8/22/08	Treatment of acute myeloid leukemia	Designated			N/A	N/A	"Celator Pharmaceuticals, Inc."	200 Princeton South Corporate Center	Suite 180	Ewing	New Jersey	8628	USA
"cytochrome C, flavin mononucleotide and thiamin diphosphate"	n/a	6/17/11	Treatment of mitochondrial disorders	Designated			N/A	N/A	"NBI Pharmaceuticals, Inc."	c/o Neil & Co CPAs	"1184 N. 15th Ave., Suite 1"	Bozeman	Montana	59715	USA
cytochrome P450 isoform 2B1 gene transfected human embryonic kidney 293 cells encapsulated in polymeric cellulose sulphate	n/a	12/17/14	Treatment of pancreatic cancer in combination with ifosfamide	Designated			N/A	N/A	"PharmaCyte Biotech, Inc."	23046 Avenida de la Carlota	Suite 600	Laguna Hills	California	92652	USA
Cytomegalovirus DNA Vaccine w/Copolymer/Benzalkonium Chloride	n/a	9/23/06	"For use in prevention of clinically significant CMV viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant and solid organ transplant populations"	Designated			N/A	N/A	Vical Inc.	10390 Pacific Center Court		San Diego	California	92121	USA
Cytomegalovirus DNA vaccine with plasmids expressing pp65 and gB genes	n/a	6/3/05	"Prevention of clinically significant cytomegalovirus (CMV) viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant and solid transplant populations"	Designated			N/A	N/A	"Astellas Pharma Global Development, Inc."	1 Astellas Way		Northbrook	Illinois	60062	USA
Cytomegalovirus immune globulin (human)	Cytogam	8/3/87	Prevention or attenuation of primary cytomegalovirus disease in immunosuppressed recipients of organ transplants.	Designated/Approved	Approved for Orphan Indication	"#1) Attenuation of primary CMV disease associated with kidney transplant recipients who are seronegative for CMV and who receive a kidney from a CMV seropositve donor; #2) Prophylaxis of CMV disease associated transplantation of kidney (all other), lung, liver, pancreas and heart."	12/04/1998	12/04/2005	CSL Behring LLC	1020 First Avenue	P. O. Box 61501	King of Prussia	Pennsylvania	19406	USA
Cytomegalovirus immune globulin intravenous (human)	n/a	1/28/91	For use in conjunction with ganciclovir sodium for the treatment of cytomegalovirus pneumonia in bone marrow transplant patients.	Designated			N/A	N/A	Bayer Corporation	"Pharmaceutical Division, Biological Products"	400 Morgan Lane	New Haven	Connecticut	6516	USA
cytomegalovirus specific cytotoxic T lymphocytes	n/a	1/5/17	Treatment of cytomegalovirus infection in severely immunocompromised patients	Designated			N/A	N/A	"ViraCyte, LLC"	"33 - 5th Avenue, NW"	Suite 700	New Brighton	Minnesota	55112	USA
D-mannitol and L-proline	Prodarsan	4/20/09	Treatment of Cockayne syndrome	Designated			N/A	N/A	DNage B.V.	Darwinweg 24					Netherlands
d-methadone	n/a	6/2/16	Treatment of postherpetic neuralgia	Designated			N/A	N/A	"Relmada Therapeutics, Inc."	"275 Madison Avenue, Suite 702"		New York	New York	10016	USA
D-peptide	Nerofe	2/4/11	Treatment of acute myelogenous leukemia	Designated			N/A	N/A	"Immune System Key, Ltd"	POB 23365		Jerusalem 91233			Israel
D-peptide of the sequence AKRHHGYKRKFH - NH2	Pulmadex	10/23/02	Treatment of cystic fibrosis	Designated			N/A	N/A	"Demegen, Inc."	100 Technology Drive	Suite 440 B	Pittsburgh	Pennsylvania	15219	USA
D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-Nh2 (disulfide bridge: 2-6) acetate	n/a	3/19/09	"Treatment of melanoma, stages IIb through IV"	Designated/Withdrawn			N/A	N/A	"Thallion Pharmaceuticals, Inc."	7150 Alexander-Fleming					Canada
D-tagatose	n/a	1/19/17	Treatment of Prader-Willi Syndrome	Designated			N/A	N/A	Biospherics.net LLC	Department of Pharmaceutical Sciences	University of Kentucky	Nicholasville	Kentucky	40356	USA
"d6-tetrabenazine, deutetrabenazine"	n/a	11/5/14	Treatment of Huntington's Disease	Designated			N/A	N/A	"Teva Branded Pharmaceutical Products R&D, Inc."	3366 N. Torrey Pines Court	Suite 225	La Jolla	California	92037	USA
D9-ivacaftor	n/a	1/18/17	Treatment of cystic fibrosis (CF)	Designated			N/A	N/A	"Concert Pharmaceuticals, Inc."	99 Hayden Avenue	Suite 500	Lexington	Massachusetts	2421	USA
dabrafenib	Tafinlar	2/8/16	Treatment of malignant glioma with BRAF V600 mutation	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	1 Health Plaza	Bldg 337	East Hanover	New Jersey	7936	USA
dabrafenib	Tafinler	10/20/14	Treatment of patients with BRAF mutation positive non-small cell lung cancer	Designated			N/A	N/A	Novartis Pharmaceuticals Corp	1 Health Plaza		East Hanover	New Jersey	7936	USA
dabrafenib	Tafinlar	1/12/11	Treatment BRAF V600 mutation positive Stage IIB through IV melanoma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA approved test.	05/29/2013	05/29/2020	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Jersey	7936	USA
dabrafenib and trametinib	Tafinlar(R) Capsules A Nd Mekinist(R) Tablets	9/1/16	Treatment of patients with anaplastic thyroid cancer and locally advanced or metastatic papillary thyroid cancer whose tumors harbor a BRAF V600 mutation.	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Jersey	7936	USA
dabrafenib and trametinib	n/a	10/29/15	Treatment of patients with BRAF mutation positive non-small cell lung cancer.	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	One Health Plaza	Bldg 337	East Hanover	New Jersey	7936	USA
dacetuzumab	n/a	8/13/04	Treatment of multiple myeloma.	Designated			N/A	N/A	"Seattle Genetics, Inc."	21823 30th Drive Southeast		Bothell	Washington	98021	USA
dacetuzumab	n/a	10/6/05	Treatment of chronic lymphocytic leukemia	Designated			N/A	N/A	"Seattle Genetics, Inc."	21823 30th Drive Southeast		Bothell	Washington	98021	USA
Daclizumab	Zenapax	3/5/93	Prevention of acute renal allograft rejection.	Designated/Approved	Approved for Orphan Indication	"Prophylaxis of acute organ rejection in patients receiving renal transplants, to be used as a part of an immunosuppressive regimen that includes cyclosporine and corticosteroids."	12/10/1997	12/10/2004	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA
dacomitinib	n/a	3/3/15	"Treatment of non-small cell lung cancer with EGFR, HER2, HER4, or DDR2 mutations."	Designated			N/A	N/A	"Pfizer, Inc."	235 East 42nd Street		New York	New York	10017	USA
dalbavancin	Dalvance	3/30/15	Treatment of acute osteomyelitis in children (0 through 16 years of age)	Designated			N/A	N/A	Durata Therapeutics International B.V.	"Spaces Zuidas II, Kantoor 4.03"	"1083HN, Amsterdam"				Netherlands
dalfampridine	Ampyra	6/2/87	Relief of symptoms of multiple sclerosis	Designated/Approved	Approved for Orphan Indication	Treatment to improve walking in patients with multiple sclerosis	01/22/2010	01/22/2017	Acorda Therapeutics	15 Skyline Dr.		Hawthorne	New York	10532	USA
Dantrolene sodium	Dantrium	12/14/87	Treatment of the neuroleptic malignant syndrome.	Designated/Withdrawn			N/A	N/A	Norwich Eaton Pharmaceuticals	P.O. Box 191		Norwich	New York	13815	USA
dantrolene sodium	n/a	9/25/12	Treatment of heat stroke	Designated			N/A	N/A	"Eagle Pharmaceuticals, Inc."	50 Tice Blvd	Suite 315	Woodcliff Lake	New Jersey	7677	USA
dantrolene sodium	n/a	2/17/16	Treatment of Wolfram Syndrome	Designated			N/A	N/A	Washington University in St. Louis	660 S. Euclid Avenue	Campus Box 8127	St. Louis	Missouri	63110	USA
dantrolene sodium suspension for injection	Ryanodex	8/16/13	Treatment of malignant hyperthermia syndrome	Designated/Approved	Approved for Orphan Indication	Treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk.	07/22/2014	07/22/2021	"Eagle Pharmaceuticals, Inc."	50 Tice Blvd	Suite 315	Woodcliff Lake	New Jersey	7677	USA
Dapsone	n/a	11/7/94	Prophylaxis of toxoplasmosis in severely immunocompromised patients with CD4 counts below 100.	Designated			N/A	N/A	"Jacobus Pharmaceutical Company, Inc."	37 Cleveland Lane	P.O. Box 5290	Princeton	New Jersey	8540	USA
Dapsone USP	Dapsone	1/8/92	For the combination treatment of Pneumocystis carinii pneumonia in conjunction with trimethoprim.	Designated			N/A	N/A	Jacobus Pharmaceutical Company	37 Cleveland Avenue	P.O. Box 5290	Princeton	New Jersey	8540	USA
Dapsone USP	Dapsone	12/24/91	Prophylaxis for Pneumocystis carinii pneumonia.	Designated			N/A	N/A	Jacobus Pharmaceutical Company	37 Cleveland Avenue	P.O. Box 5290	Princeton	New Jersey	8540	USA
daratumumab	Darzalex	5/6/13	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent	11/16/2015	11/16/2022	"Janssen Biotech, Inc."	920 Route 202 South	PO Box 300	Raritan	New Jersey	8869	USA
daratumumab	Humax (R) - Cd38	11/9/15	Treatment of diffuse large B-cell lymphoma.	Designated			N/A	N/A	"Janssen Research and Development, LLC"	1400 McKean Road	P. O. Box 776	Spring hOuse	Pennsylvania	19477	USA
daratumumab	Darzalex	5/6/13	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	"DARZALEX in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy."	11/21/2016	11/21/2023	"Janssen Biotech, Inc."	920 Route 202 South	PO Box 300	Raritan	New Jersey	8869	USA
daratumumab	n/a	8/20/15	Treatment of mantle cell lymphoma.	Designated			N/A	N/A	"Janssen Research & Development, LLC"	1400 McKean Road	P. O. Box 776	Spring House	Pennsylvania	19477	USA
daratumumab	n/a	8/6/15	Treatment of follicular lymphoma	Designated			N/A	N/A	"Janssen Research & Development, LLC"	1400 McKean Road	P. O. Box 776	Spring House	Pennsylvania	19477	USA
Darinaparsin	n/a	9/13/10	Treatment of peripheral T-cell lymphoma.	Designated			N/A	N/A	Solasia Pharma K.K.	"3F, Shiodome Building"	Toyko 105-0022				Japan
Dasatinib	Sprycel	11/18/05	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy	06/28/2006	06/28/2013	Bristol-Myers Squibb Company	5 Research Parkway		Wallingford	Connecticut	6492	USA
Dasatinib	Sprycel	11/28/05	Treatment of chronic myelogenous leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of adults with chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib	06/28/2006	06/28/2013	Bristol-Myers Squibb Company	5 Research Parkway		Wallingford	Connecticut	6492	USA
dasiprotimut-T	Biovax Id	6/17/10	Treatment of mantle cell lymphoma	Designated			N/A	N/A	"Biovest International, Inc."	324 S. Hyde Park Ave.		Tampa	Florida	33606	USA
dasiprotimut-T	Biovaxid	10/28/09	Treatment of follicular lymphoma	Designated			N/A	N/A	"Biovest International, Inc."	324 S. Hyde Park Avenue		Tampa	Florida	33606	USA
daunorubicin citrate liposome	Daunoxome	4/15/13	Treatment of acute myeloid leukemia	Designated/Withdrawn			N/A	N/A	Galen Limited	Seagoe Industrial Estate	"Graigavon, BT63 5UA"				United Kingdom
Daunorubicin citrate liposome injection	Daunoxome	5/14/93	Treatment of patients with advanced HIV-associated Kaposi's sarcoma.	Designated/Approved	Approved for Orphan Indication	"First line cytotoxic therapy for advanced, HIV related Kaposi's sarcoma."	04/08/1996	04/08/2003	"NeXstar Pharmaceuticals, Inc."	650 Cliffside Drive		San Dimas	California	91773	USA
Daunorubicin liposomal	n/a	9/5/08	Treatment of acute myeloid leukemia	Designated			N/A	N/A	"Diatos USA, LLC"	15310 Amberly Drive		Tampa	Florida	33647	USA
davunetide	n/a	12/7/09	Treatment of progressive supranuclear palsy.	Designated			N/A	N/A	"Allon Therapeutics, Inc."	506-1168 Hamilton Street	"Vancouver, BC V6B 2S2"				Canada
DCVAC OvCa	n/a	5/14/13	Treatment of ovarian cancer	Designated			N/A	N/A	SOTIOS a.s.	Jankovcova 1518/2	170 00 Praha 7				Czech Republic
DEAE-rebeccamycin	n/a	3/1/04	Treatment of bile duct tumors	Designated			N/A	N/A	Helsinn Healthcare SA	"Via Pian Scairolo, 6912 Pazzallo"	Lugano				Switzerland
debrase	Debridase	8/20/03	"Debridement of acute, deep dermal burns in hospitalized patients"	Designated			N/A	N/A	"MediWound, Ltd."	42 Hayarkon Street	Industrial Zone				Israel
decitabine	Dacogen	8/4/06	Treatment of acute myeloid leukemia	Designated/Withdrawn			N/A	N/A	Otsuka Pharmaceutical Development &	"Commercialization, Inc."	508 Carnegie Center Drive	Princeton	New Jersey	8540	USA
decitabine	n/a	3/8/99	Treatment of chronic myelogenous leukemia.	Designated/Withdrawn			N/A	N/A	Otsuka Pharmaceutical Development &	"Commercialization, Inc."	508 Carnegie Center Drive	Princeton	New Jersey	8540	USA
decitabine	Dacogen	3/8/99	Treatment of myelodysplastic syndromes.	Designated/Approved	Approved for Orphan Indication	"for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups"	05/02/2006	05/02/2013	Otsuka Pharmaceutical Development	"and Commercialization, Inc."	508 Carnegie Center Drive	Princeton	New Jersey	8540	USA
decitabine	n/a	9/9/02	Treatment of sickle cell anemia	Designated/Withdrawn			N/A	N/A	Otsuka Pharmaceutical Development &	"Commercialization, Inc."	508 Carnegie Center Drive	Princeton	New Jersey	8540	USA
decitabine and tetrahydrouridine	n/a	9/19/16	Treatment of sickle cell disease	Designated			N/A	N/A	EpiDestiny Inc.	7536 Royal Portrush Drive		Solon	Ohio	44139	USA
defactinib	n/a	2/12/15	Treatment of ovarian cancer	Designated			N/A	N/A	"Verastem, Inc."	117 Kendrick Street	Suite 500	Needham	Massachusetts	2494	USA
Deferasirox	Exjade	11/21/02	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Designated/Approved	Approved for Orphan Indication	Treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age or older	11/02/2005	11/02/2012	Novartis Pharmaceuticals Corporation	59 Route 10		East Hanover	New Jersey	7936	USA
deferasirox	Exjade	2/24/15	Treatment of chronic iron overload in alpha-thalassemia	Designated/Approved	Approved for Orphan Indication	Treatment of chronic iron overload in patients 10 years of age and older with non-transfusion dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and serum ferritin greater than 300 mcg/L.	01/23/2013	01/23/2020	Novartis Pharmaceuticals Corporation	One Health Plaza	Building 105/W112	East Hanover	New Jersey	7936	USA
deferiprone	n/a	7/31/08	Treatment of Friedreich's ataxia	Designated			N/A	N/A	"ApoPharma, Inc."	200 Barmac Drive	M9L 2Z7				Canada
deferiprone	Ferriprox	12/12/01	Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy	Designated/Approved	Approved for Orphan Indication	Treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate	10/14/2011	10/14/2018	"ApoPharma, Inc. A Division of"	Apotex Research Inc.	"Toronto, Canada M9L 1T9"				Canada
deferiprone	n/a	9/1/11	Treatment of superficial siderosis	Designated			N/A	N/A	"ApoPharma, Inc."	200 Barmac Drive					Canada
Deferitrin	n/a	4/14/04	Treatment of iron overload	Designated/Withdrawn			N/A	N/A	Genzyme Corporation	153 Second Avenue		Waltham	Massachusetts	2451	USA
deferoxamine starch conjugate	n/a	1/28/05	Treatment of acute iron poisoning	Designated			N/A	N/A	"Biomedical Frontiers, Inc."	"1087 10th Avenue, SE"		Minneapolis	Minnesota	55414	USA
deferoxamine starch conjugate	n/a	12/21/98	Treatment of chronic iron overload resulting from conventional transfusional treatment of beta-thalassemia major and sickle cell anemia.	Designated			N/A	N/A	"Biomedical Frontiers, Inc."	"108710th Ave., S.E."		Minneapolis	Minnesota	55414	USA
defibrotide	Defitelio	5/21/03	For the treatment of hepatic veno-occlusive disease	Designated/Approved	Approved for Orphan Indication	"For the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT)."	03/30/2016	03/30/2023	"Jazz Pharmaceuticals, Inc."	3180 Porter Dr.		Palo Alto	California	94304	USA
defibrotide	n/a	1/8/07	For the prevention of hepatic veno-occlusive disease.	Designated			N/A	N/A	"Jazz Pharmaceuticals, Inc."	3180 Porter Drive		Palo Alto	California	94304	USA
Defibrotide	n/a	7/5/85	Treatment of thrombotic thrombocytopenic purpura.	Designated			N/A	N/A	Crinos International	Via Belvedere 1		"Villa Guardia, Italy"		22079	USA
deflazacort	Calcort	9/16/10	Treatment of Duchenne muscular dystrophy	Designated			N/A	N/A	University of Rochester Medical Center	1351 Mt. Hope Avenue	Suite 203	Rochester	New York	14620	USA
deflazacort	n/a	8/16/13	Treatment of Duchenne muscular dystrophy	Designated			N/A	N/A	"Marathon Pharmaceuticals, LLC"	"1033 Skokie Blvd.,"	Suite 600	Northbrook	Illinois	60062	USA
deflazacort	n/a	10/22/15	Treatment of pediatric (0 through 16 years of age) juvenile idiopathis arthritis (JIA) International League of Associations for Rheumatology (ILAR) categories excluding systemic JIA.	Designated			N/A	N/A	"Marathon Pharmaceuticals, LLC"	1033 Skokie Blvd	Suite 600	Northbrook	Illinois	60062	USA
dehydrated alcohol	n/a	3/16/12	Treatment of trigeminal neuralgia	Designated			N/A	N/A	"Luitpold Pharmaceuticals, Inc."	One Luitpold Drive	P. O. Box 9001	Shirley	New York	11967	USA
dehydrated alcohol	Ablysinol	9/11/13	Treatment of hypertrophic obstructive cardiomyopathy	Designated			N/A	N/A	"Belcher Pharmaceuticals, LLC"	6911 Bryan Dairy Road		Largo	Florida	33777	USA
Dehydroepiandrosterone	n/a	7/13/94	Treatment of systemic lupus erythematosus (SLE) and the reduction in the use of steroids in steroid-dependent SLE patients.	Designated/Withdrawn			N/A	N/A	GlaxoSmithKline	P. O. Box 13398	Five Moore Drive	Research Triangle Park	North Carolina	27709	USA
Dehydroepiandrosterone (DHEA)	Fidelin	8/19/03	Replacement therapy in individuals with adrenal insufficiency	Designated			N/A	N/A	"Paladin Labs, Inc."	"6111 Royalmount Avenue, Suite 102"	Montreal	Quebec H4P 2T4			Canada
Dehydroepiandrosterone sulfate sodium	n/a	1/28/97	To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.	Designated			N/A	N/A	"Pharmadigm, Inc."	2401 Foothill Drive		Salt Lake City	Utah	84109	USA
Dehydroepiandrosterone sulfate sodium	n/a	1/29/97	Treatment of serious burns requiring hospitalization.	Designated			N/A	N/A	"Pharmadigm, Inc."	2401 Foothill Drive		Salt Lake City	Utah	84109	USA
delta-9-tetrahydrocannibinol and cannabidiol	n/a	12/3/15	Treatment of glioma.	Designated			N/A	N/A	GW Research Ltd.	"Sovereign House, Vision Park"	Chivers Way	Histon			United Kingdom
demcizumab	n/a	4/30/14	Treatment of pancreatic cancer	Designated			N/A	N/A	"OncoMed Pharmaceuticals, Inc."	800 Chesapeake Drive		Redwood City	California	94063	USA
Dendritic cell/tumor cell fusion vaccine + recombinant human interleukin 12	n/a	1/25/17	Treatment of malignant glioma	Designated			N/A	N/A	CyTIX Inc.	"7F Terada Bldg, 2-3-3 Shibakoen"		Minato-ku			Japan
"dendritic cells pulsed with synthetic peptides derived from antigens MAGE1, HER-2, AIM-2,TRP-2, gp100 and interleukin-13 receptor alpha"	n/a	6/7/10	Treatment of glioblastoma or brain stem glioma	Designated			N/A	N/A	ImmunoCellular Therapeutics Ltd.	21900 Burbank Blvd		Woodland Hills	California	91367	USA
dendritic hybrid cell vaccine	Neuroblaxin	9/23/11	Treatment of neuroblastoma	Designated			N/A	N/A	"Orbis Health Solutions, LLC"	111 Smith Hines Road	Suite E & F	Greenville	South Carolina	29607	USA
"dendritic-cell targeting, lentiviral vector encoding the NY-ESO-1 gene"	n/a	1/6/16	Treatment of soft tissue sarcoma.	Designated			N/A	N/A	Immune Design Corp.	1616 Eastlake Ave. E	Suite 310	Seattle	Washington	98102	USA
denileukin diftitox	Ontak	4/30/10	Treatment of peripheral T-cell lymphoma	Designated			N/A	N/A	"Eisai, Inc."	300 Tice Boulevard		Woodcliff Lake	New Jersey	7677	USA
denileukin diftitox	Ontak	8/21/96	Treatment of patients with cutaneous T-cell lymphoma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.	02/05/1999	02/05/2006	"Eisai, Inc."	300 Tice Boulevard		Woodcliff Lake	New Jersey	7677	USA
denileukin diftitox	n/a	6/29/11	Treatment of peripheral T-cell lymphoma (PTCL)	Designated			N/A	N/A	"Eisai, Inc."	155 Tice Blvd.		Woodcliff Lake	New Jersey	5271	USA
denileukin diftitox	n/a	7/12/13	Treatment of cutaneous T-cell lymphoma	Designated			N/A	N/A	Eisai Inc.	155 Tice Blvd		Woodcliff Lake	New Jersey	7677	USA
denosumab	Xgeva	9/11/13	Treatment of hypercalcemia in malignancy	Designated/Approved	Approved for Orphan Indication	To treat hypercalcemia of malignancy refractory to biphosphonate therapy.	12/05/2014	12/05/2021	"Amgen, Inc."	One Amgen Center Drive	MS 17-2-C	Thousand Oaks	California	91320	USA
denosumab	Xgeva	12/20/10	Treatment of patients with giant cell tumor of bone	Designated/Approved	Approved for Orphan Indication	Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.	06/13/2013	06/13/2020	"Amgen, Inc."	One Amgen Center Drive		Thousand Oaks	California	91320	USA
deoxythymidine monophosphate and deoxycytidine monophosphate	n/a	7/7/16	Treatment of thymidine kinase 2 deficiency.	Designated			N/A	N/A	Columbia University Medical Center	Department of Neurology	"630 West 168th Street, P&S 4-423"	New York	New York	10032	USA
Dermagraft	n/a	12/13/10	Treatment of epidermolysis bullosa	Designated			N/A	N/A	"Shire Regenerative Medicine, Inc."	11095 Torreyana Road	subsidiary of Shire Pharmaceuticals.	San Diego	California	92121	USA
Deslorelin	Somagard	11/5/87	Treatment of central precocious puberty.	Designated			N/A	N/A	Roberts Pharmaceutical Corp.	Meridian Center II	Four Industrial Way West	Eatontown	New Jersey	7724	USA
Desmoglein 3 synthetic peptide (PI-0824)	n/a	10/26/04	Treatment of pemphigus vulgaris	Designated			N/A	N/A	"Peptimmune, Inc."	64 Sidney Street		Cambridge	Massachusetts	2139	USA
Desmopressin acetate	n/a	1/22/91	Treatment of mild hemophilia A and von Willebrand's disease.	Designated/Approved	Approved for Orphan Indication	Treatment of patients with hemophilia A or von Willebrand's disease (type I) whose factor VIII coagulant activity level is greater than 5%.	03/07/1994	03/07/2001	Aventis Behring L.L.C.	1020 First Avenue	PO Box 61501	King of Prussia	Pennsylvania	19406	USA
deutetrabenazine	n/a	1/13/15	Treatment of Tourette syndrome in the pediatric population (defined as 0 through 16 years of age)	Designated			N/A	N/A	TEVA Pharmaceuticals	3366 North Torrey Pines Court	Suite 225	LaJolla	California	92037	USA
dexamethasone intravitreal implant	Ozurdex	9/11/98	"Treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate, posterior, and panuveitis"	Designated/Approved	Approved for Orphan Indication	For treatment of non-infectious uveitis affecting the posterior segment of the eye	09/24/2010	09/24/2017	Allergan	2525 Dupont Drive		Irvine	California	92623	USA
dexamethasone phosphate	n/a	12/2/08	Treatment of corneal graft rejection.	Designated			N/A	N/A	"EyeGate Pharmaceuticals, Inc."	100 Beaver Street		Waltham	Massachusetts	2453	USA
dexamethasone sodium phosphate encapsulated in autologous erythrocytes	n/a	7/24/12	Treatment of ataxia-telangiectasia	Designated			N/A	N/A	EryDel S.p.A.	Via Sasso 36	61029 Urbino (PU)				Italy
dexanabinol	n/a	8/11/04	For the attenuation or amelioration of the long-term neurological sequelae associated with moderate and severe traumatic brain injury	Designated			N/A	N/A	Pharmos Corporation	99 Wood Avenue	Suite 311	Iselin	New Jersey	8830	USA
dexpramipexole	n/a	10/11/07	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	Knopp Biosciences LLC	2100 Wharton Street	Suite 615	Pittsburgh	Pennsylvania	15203	USA
Dexrazoxane	Zinecard	12/17/91	For the prevention of cardiomyopathy associated with doxorubicin administration.	Designated/Approved	Approved for Orphan Indication	Cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative dose of 300mg/m2.	05/26/1995	05/26/2002	Pharmacia & Upjohn	7000 Portage Road		Kalamazoo	Michigan	49001	USA
dexrazoxane	Totect(R)	3/25/04	Treatment of anthracycline extravasation during chemotherapy	Designated/Approved	Approved for Orphan Indication	Treatment of extravasation resulting from IV anthracycline chemotherapy	09/06/2007	09/06/2014	Clinigen Healthcare Ltd.	"Pitcairn House, First Avenue"	Burton on Trent	Staffordshire			United Kingdom
dexrazoxane hydrochloride	n/a	8/19/14	Prevention of cardiomyopathy for chilren and adolescents 0 through 16 years of age treated with anthracyclines	Designated			N/A	N/A	"Satiscor, LLC"	45 Marine Road		Boston	Massachusetts	2127	USA
dextran 1	n/a	3/21/03	Treatment of cystic fibrosis	Designated			N/A	N/A	BCY LifeSciences Inc.	160 Eglinton Ave. East	Suite 600	"Toronto, Ontario M4P 3B"			Canada
Dextran 70	Dehydrex	3/5/90	Treatment of recurrent corneal erosion unresponsive to conventional therapy.	Designated			N/A	N/A	"Holles Laboratories, Inc."	30 Forest Notch		Cohasset	Massachusetts	2025	USA
Dextran and deferoxamine	Bio-Rescue	3/8/91	Treatment of acute iron poisoning.	Designated			N/A	N/A	"Biomedical Frontiers, Inc."	1095 10th Avenue S.E.		Minneapolis	Minnesota	55414	USA
"Dextran sulfate (inhaled, aerosolized)"	Uendex	10/5/90	For use as an adjunct to the treatment of cystic fibrosis.	Designated			N/A	N/A	"Kennedy & Hoidal, M.D.'s"	University of Utah Health Sciences Center	"50 North Medical Drive, Room 4R240"	Salt Lake City	Utah	84132	USA
Dextran sulfate sodium	n/a	11/19/87	Treatment of aquired immunodeficiency syndrome.	Designated			N/A	N/A	"Ueno Fine Chemicals Industry, Ltd."	"2-31 Koraibashi, Higashi-ku"		Osaka 541			Japan
DHA-paclitaxel	Taxoprexin	10/10/02	Treatment of metastatic malignant melanoma	Designated/Withdrawn			N/A	N/A	"Luitpold Pharmaceuticals, Inc."	One Luitpold Drive	P. O. Box 9001	Shirley	New York	11967	USA
DHA-paclitaxel	Taxoprexin	9/25/01	Treatment of pancreatic cancer	Designated/Withdrawn			N/A	N/A	"Luitpold Pharmaceuticals, Inc."	One Luitpold Drive		Shirley	New York	11976	USA
DHA-paclitaxel	Taxoprexin	5/1/03	Treatment of adenocarcinoma of the stomach or lower esophagus	Designated/Withdrawn			N/A	N/A	"Luitpold Pharmaceuticals, Inc."	One Luitpold Drive	P. O. Box 9001	Shirley	New York	11967	USA
diacerein	n/a	10/15/14	Treatment of epidermolysis bullosa	Designated			N/A	N/A	Castle Creek Pharmaceuticals	1033 Skokie Blvd	Suite 600	Northbrook	Illinois	60062	USA
Dianeal peritoneal dialysis solution with 1.1% amino acids	Nutrineal (Peritoneal Dialysis Solution With 1.1% Amino Acid	6/11/92	For use as a nutritional supplement for the treatment of malnourishment in patients undergoing continuous ambulatory peritoneal dialysis.	Designated			N/A	N/A	Baxter Healthcare Corporation	1620 Waukegan Road		McGaw Park	Illinois	60085	USA
diannexin	n/a	10/28/09	Prevention of ischemia-reperfusion injury in solid organ transplants	Designated			N/A	N/A	"Astellas Pharma Global Development, Inc."	Three Parkway North		Deerfield	Illinois	60015	USA
diazepam (intranasal)	n/a	11/16/15	Management of acute repetitive seizures.	Designated			N/A	N/A	"Neurelis Pharmaceuticals, Inc."	1042-B N. El Camino Real	Suite 430	Encinitas	California	92024	USA
diazepam (intranasal)	n/a	7/31/12	Management of patients with acute repetitive seizures	Designated			N/A	N/A	"Acorda Therapeutics, Inc."	420 Saw Mill River Road		Ardsley	New York	10502	USA
diazepam auto-injector	n/a	5/30/13	"Management of selected, refractory patients with epilepsy on stable regimens of antiepileptic drugs, who require intermittent use of diazepam to control bouts of increased seizure activity"	Designated			N/A	N/A	Meridian Medical Technologies-a Pfizer subsidiary	445 Eastern Point Road		Groton	Connecticut	6340	USA
Diazepam buccal soluble film	n/a	11/10/16	"Treatment of selected, refractory patients with epilepsy who are on stable regimens of antiepileptic drugs (AED) and who require intermittent use of diazepam to control bouts of increased seizure activity (acute repetitive seizures)"	Designated			N/A	N/A	"MonoSol Rx, LLC"	30 Technology Drive		Warren	New Jersey	7059	USA
diazepam subcutaneous injection	Diazepen(Tm)	5/26/16	Treatment of acute repetitive seizures.	Designated			N/A	N/A	"Xeris Pharmaceuticals, Inc."	3208 Red River Street	Suite 300	Austin	Texas	78705	USA
Diazepam viscous solution for rectal administration	n/a	2/25/92	"For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity."	Designated/Approved	Approved for Orphan Indication		07/29/1997	07/29/2004	Valeant Pharmaceuticals	3300 Hyland Avenue		Costa Mesa	California	92626	USA
Diaziquone	n/a	11/10/83	Treatment of primary brain malignancies (grade III and IV astrocytomas).	Designated/Withdrawn			N/A	N/A	Warner-Lambert Company	"2800 Plymouth Rd., P.O. Box 1047"		Ann Arbor	Michigan	48106	USA
diazoxide	n/a	12/3/12	Treatment of Prader Willi Syndrome	Designated			N/A	N/A	"Sedogen, LLC"	1701 East Lake Avenue	Suite260	Glenview	Illinois	60025	USA
diazoxide choline	n/a	5/13/14	Treatment of Prader-Willi Syndrome	Designated			N/A	N/A	"Essentialis, Inc."	7915 Corte Cardo		Carlsbad	California	92009	USA
dichlorphenamide	n/a	9/2/10	Treatment of primary periodic paralyses	Designated/Approved	Approved for Orphan Indication	"Treatment of primary hyperkalemic periodic paralysis, primary hypokalemic period paralysis, and related variants"	08/07/2015	08/07/2022	Strongbridge US Inc.	900 Northbrook Drives	Suite 200	trevose	Pennsylvania	19053	USA
Dideoxyinosine	n/a	6/22/88	Treatment of acquired immunodeficiency syndrome.	Designated/Withdrawn			N/A	N/A	Bristol-Myers Squibb	2400 West Lloyd Expressway		Evansville	Indiana	47721	USA
Diethyldithiocarbamate	Imuthiol	4/3/86	Treatment of AIDS.	Designated			N/A	N/A	Connaught Laboratories	"Route 611, P.O. Box 187"		Swiftwater	Pennsylvania	18370	USA
diethylenetriaminepentaacetate (DPTA)	n/a	4/14/04	"For treatment of patients with known or suspected internal contamination with plutonium, americium or curium to increase the rates of elimination."	Designated			N/A	N/A	CIS-US	10 DeAngelo Drive		Bedford	Massachusetts	1730	USA
Diethylenetriaminepentaacetic acid (DTPA)	n/a	4/28/04	"Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination."	Designated/Approved	Approved for Orphan Indication	"Treatment of internal contamination with plutonium, americium or curium"	08/11/2004	08/11/2011	Hameln Pharmaceuticals gmbh	Langes Feld 13		Hameln			Germany
Diethylnorspermine (DENSPM)	n/a	5/25/04	Treatment for hepatocellular carcinoma	Designated/Withdrawn			N/A	N/A	Genzyme Corporation	153 Second Avenue		Waltham	Massachusetts	2451	USA
diferuloylmethane	n/a	6/13/03	Treatment of cystic fibrosis	Designated			N/A	N/A	"Allertein Therapeutics, LLC"	640 Sasco Hill Road		Fairfield	Connecticut	6824	USA
difluprednate	Durezol	9/30/08	Treatment of endogenous and traumatic anterior uveitis and panuveitis.	Designated/Approved	Approved for Orphan Indication	Treatment of endogenous anterior uveitis	06/13/2012	06/13/2019	Alcon Pharmaceuticals. Ltd.	Route Des Arsenaux 41	1701 Fribourg (P.O. Box 61)				Switzerland
digitoxin	n/a	5/27/05	Treatment of cystic fibrosis	Designated			N/A	N/A	Silver Pharmaceuticals	350 Seven Locks Road	Suite 211	Rockville	Maryland	20854	USA
digitoxin	n/a	10/18/01	Treatment of soft tissue sarcomas	Designated			N/A	N/A	SimRx Advisors LLC	247 West 87th Street	Suite 7G	New York	New York	10024	USA
digitoxin	n/a	11/2/01	Treatment of ovarian cancer	Designated			N/A	N/A	SimRx Advisors LLC	247 West 87th Street	Suite 7G	New York	New York	10024	USA
digoxin immune fab (ovine)	n/a	2/3/12	Treatment of severe preeclampsia and eclampsia	Designated			N/A	N/A	"Velo Bio, LLC"	90001 Aerial Center Parkway	Suite 110	Morrisville	North Carolina	27560	USA
Digoxin immune FAB (Ovine)	Digibind	11/1/84	Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.	Designated/Approved	Approved for Orphan Indication		04/22/1986	04/22/1993	Glaxo Wellcome Inc.	5 Moore Drive		Research Triangle Park	North Carolina	27709	USA
Digoxin immune fab(ovine)	Digidote	3/11/85	"Treatment of life-threatening acute cardiac glycoside intoxication manifested by conduction disorders, ectopic ventricular activity and (in some cases) hyperkalemia."	Designated			N/A	N/A	Boehringer Mannheim Corp.	1301 Piccard Drive		Rockville	Maryland	20850	USA
dihydroartemisinin and piperaquine	Eurartesim	1/8/07	"Treatment of uncomplicated malaria caused by ""Plasmodium falciparum,"" Plasmodium vivax,"" Plasmodium malariae,"" or ""Plasmodium ovale."""	Designated			N/A	N/A	Sigma Tau Industrie Farmaceutiche Riunite S.p.A.	Via Pontina	km 30.400 - 00071	Rome			Italy
Dihydrotestosterone	Androgel -Dht	2/5/96	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Designated			N/A	N/A	"Besins Internaitonal, US Inc."	610 Herndon Parkway	Suite 750	Herndon	Virginia	20170	USA
dimebon	n/a	5/12/09	Treatment of Huntington's Disease.	Designated			N/A	N/A	"Medivation, Inc."	201 Spear Street		San Francisco	California	94105	USA
Dimerizing drug that binds to mutated Fas protein/drug-binding domain fusion protein (FKBP)	n/a	11/24/99	Treatment of acute graft-versus-host disease in patients undergoing bone marrow transplantation.	Designated			N/A	N/A	"Bellicum Pharmaceuticals, Inc."	6400 Fannin Street	Suite 2300	Houston	Texas	77030	USA
dimethyl fumarate	n/a	9/11/13	Treatment of Friedreich's Ataxia	Designated			N/A	N/A	Forward Pharma FA ApS	"Ostergade 24A, 1"		Copenhagen			Denmark
dimethyl sulfoxide	n/a	5/9/08	For use in combination with antimicrobial drugs for the treatment of drug resistant tuberculosis	Designated			N/A	N/A	"Abela Pharmaceuticals, Inc."	21581 Midcrest Drive		Lake Forest	California	92630	USA
Dimethyl sulfoxide	n/a	6/6/86	Treatment of cutaneous manifestations of scleroderma.	Designated/Withdrawn			N/A	N/A	Research Industries Corp.						
Dimethyl sulfoxide	n/a	11/22/94	"Treatment of increased intracranial pressure in patients with severe, closed-head injury, also known as traumatic brain coma, for whom no other effective treatment is available."	Designated			N/A	N/A	"Abela Pharmaceuticals, Inc."	21581 Midcrest Drive		Lake Forest	California	92630	USA
Dimethylsulfoxide	n/a	4/15/97	Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.	Designated			N/A	N/A	"Cancer Technologies, Inc."	7301 East 22nd Street	Suite 10E	Tucson	Arizona	85710	USA
Dimethylsulfoxide	n/a	4/6/98	Treatment of palmar-plantar erythrodysethesia syndrome.	Designated			N/A	N/A	"Cancer Technologies, Inc."	7301 East 22nd Street	Suite 10E	Tucson	Arizona	85710	USA
dinaciclib	n/a	8/25/11	Treatment of chronic lymphocytic leukemia.	Designated			N/A	N/A	Merck Sharp & Dohme Ltd.	"Hertford Road, Hoddesdon"	Hertfordshire EN11 9BU				United Kingdom
dinutuximab	Unituxin	12/20/10	Treatment of neuroblastoma	Designated/Approved	Approved for Orphan Indication	"For use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy"	03/10/2015	03/10/2022	United Therapeutics Corporation	55 TW Alexander Drive		Research Triangle Park	North Carolina	27709	USA
Dipalmitoylphosphatidylcholine /phosphatidylglycerol	Alec	7/28/88	Prevention and treatment of neonatal respiratory distress syndrome.	Designated			N/A	N/A	"Forum Products, Inc."	33 Flying Point Road		Southampton	New York	11968	USA
diphenylcyclopenone	n/a	6/13/03	Treatment of chronic severe forms of alopecia areata (Alopecia Totalis [AT]/Alopecia Universalis [AU])	Designated			N/A	N/A	"Lloyd E. King, Jr."	1900 Patterson Street	Suite 104	Nashville	Tennessee	37203	USA
Diphenylcyclopropenone gel	Samcyprone (Tm)	4/15/15	Treatment of malignant melanoma stage IIB to IV	Designated			N/A	N/A	RXi Pharmaceuticals Corp.	257 Simarano Drive	Suite 101	Marlborough	Massachusetts	1752	USA
dipraglurant	n/a	12/29/15	Treatment of levodopa-induced dyskinesias	Designated			N/A	N/A	Addex Pharma SA	Chemin des Aulx 14	1228 Plan-Les-Ouates	Geneva			Switzerland
Disaccharide tripeptide glycerol dipalmitoyl	Immther	3/1/90	Treatment of pulmonary and hepatic metastases in patients with colorectal adenocarcinoma.	Designated			N/A	N/A	"ImmunoTherapeutics, Inc."	3505 Riverview Circle		Moorhead	Minnesota	56560	USA
Disodium clodronate	n/a	6/16/93	Treatment of hypercalcemia of malignancy.	Designated			N/A	N/A	"Discovery Experimental & Development, Inc."	29949 S.R. 54 West		Wesley Chapel	Florida	33543	USA
Disodium clodronate tetrahydrate	Bonefos	3/5/90	Treatment of increased bone resorption due to malignancy.	Designated			N/A	N/A	"Anthra Pharmaceuticals, Inc."	"103 Carnegie Center, Suite 102"		Princeton	New Jersey	8540	USA
Disodium silibinin dihemisuccinate	Legalon	7/10/86	Treatment of hepatic intoxication by Amanita phalloides (mushroom poisoning).	Designated/Withdrawn			N/A	N/A	Pharmaquest Corporation	4470 Redwood Highway		San Rafael	California	94903	USA
Disufenton sodium	n/a	8/22/16	Treatment of glioblastoma multiforme.	Designated			N/A	N/A	"Oblato, Inc."	116 Village Boulevard		Princeton	New Jersey	8540	USA
"disulfide-stabilized single-chain variable region fragment of the anti-EGFR wild type/EGFRvIII dual specificity monoclonal antibody with variable fragments fused to a truncated version of the Pseudomonas exotoxin A, PE38, and KDEL"	n/a	9/19/16	Treatment of glioma.	Designated			N/A	N/A	"Darell D. Bigner, MD, PhD"	Duke University Medical Center	Oreuss Laboratory -Brain Tumor Research	Durham	North Carolina	27710	USA
DNA plasmid encoding the acetylcholine receptor	n/a	4/18/11	Treatment of myasthenia gravis.	Designated/Withdrawn			N/A	N/A	Bayhill Therapeutics	1804 Embarcadero Rd.	Suite 201	Palo Alto	California	94303	USA
DNA plasmid expressing diphtheria toxin triggered by the presence of oncofetal gen H19	n/a	8/20/09	Treatment of ovarian cancer	Designated			N/A	N/A	BioCancell Therapeutics Ltd.	8 Harton Street	Jerusalem 97775				Israel
DNA plasmid vector (pCK-HGFX7) expressing human hepatocyte growth factor	n/a	2/6/14	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	"ViroMed Co., Ltd."	"2221 Peachtree RD, NE"	Suite D258	Atlanta	Georgia	30309	USA
DNA plasmid vector expressing eIF5Ak50	n/a	12/13/10	Treatment of multiple myeloma.	Designated			N/A	N/A	"Senesco Technologies, Inc."	303 George Street		New Brunswick	New Jersey	8901	USA
"DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the nastive eIF5A mRNA, and PEI (polyethyleneimine)"	n/a	7/24/12	Treatment of diffuse large B cell lymphoma	Designated			N/A	N/A	"Senesco Technologies, Inc."	721 Route 202/206	Suite 130	Bridgewater	New Jersey	8807	USA
"DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the native eIF5A mRNA, and PEI (polyethyleneimine)"	n/a	7/24/12	Treatment of mantle cell lymphoma	Designated			N/A	N/A	"Senesco Technologies, Inc."	721 Route 202/206	Suite 130	Bridgewater	New Jersey	8807	USA
DNA plasmid vector expressing human IL-12 gene	n/a	4/4/05	Treatment of ovarian cancer.	Designated			N/A	N/A	Celsion Corporation	997 Lenox Drive	Suite 100	Lawrenceville	New Jersey	8068	USA
"DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2"	Leuvectin	4/28/00	Treatment of renal cell carcinoma.	Designated			N/A	N/A	Vical Incorporated	9373 Towne Center Dr.	Suite 100	San Diego	California	92121	USA
DNP-Modified autologous tumor vaccine	O-Vax	9/21/00	Adjuvant therapy for the treatment of ovarian cancer	Designated			N/A	N/A	"AVAX Technologies, Inc."	9200 Indian Creek Parkway	"Building 9, Suite 200"	Overland Park	Kansas	66210	USA
docosahexaenoic acid	n/a	6/1/15	Treatment of short bowel syndrome	Designated			N/A	N/A	"Sancilio and Company, Inc."	3874 Fiscal Court	Suite 200	Riviera Beach	Florida	33404	USA
docosahexaenoic acid	n/a	4/27/15	Treatment of sickle cell disease	Designated			N/A	N/A	"Sancilio & Company, Inc."	"3874 Fiscal Ct., #100"		Riviera Beach	Florida	33404	USA
"docosahexaenoic acid, DHA"	n/a	12/17/14	Treatment of primary sclerosing cholangitis	Designated			N/A	N/A	"Sancilio and Company, Inc."	3874 Fiscal Ct.	Suite 100	Riviera Beach	Florida	33404	USA
docosahexanoic acid-paclitaxel	Taxoprexin	3/5/01	Treatment of hormone-refractory prostate cancer.	Designated/Withdrawn			N/A	N/A	"Luitpold Pharmaceuticals, Inc."	One Luitpold Drive		Shirley	New York	11976	USA
dodecafluoropentane emulsion	n/a	2/11/16	Treatment of sickle cell disease	Designated			N/A	N/A	NuvOx Pharma	1635 East 18th Street		Tucson	Arizona	85719	USA
dodecafluoropentane emulsion (DDFPe)	n/a	12/2/15	Radiosensitizer to be used during radiation treatment of glioblastoma multiforme (GBM).	Designated			N/A	N/A	NuvOx Pharma	1635 East 18th Street		Tucson	Arizona	85719	USA
domperidone	n/a	9/2/11	"Treatment of hypoprolactinemia in breastfeeding mothers, and in some hypoprolactinemic conditions following the use of cabergoline or bromocriptine in mothers who wish to initiate or return to breastfeeding"	Designated			N/A	N/A	"Thomas W. Hale, RPh, PhD"	Texas Tech University Health Sciences Ctr.	1400 Coulter Suite 1400	Amarillo	Texas	79106	USA
Doripenem	n/a	7/16/04	Treatment of bronchopulmonary infection in patients with cystic fibrosis who are colonized with Pseudomonas aeruginosa or Burkholderia cepacia.	Designated			N/A	N/A	"Shionogi, Inc."	300 Campus Drive	Suite 300	Florham Park	New Jersey	7932	USA
Dornase alfa	Pulmozyme	1/16/91	To reduce mucous viscosity and enable the clearance of airway secretions in patients with cystic fibrosis.	Designated/Approved	Approved for Orphan Indication	In conjunction with standard therapies in the management of cystic fibrosis patients to reduce the frequency of respiratory infections requiring parenteral antibiotics and to improve pulmonary function.	12/30/1993	12/30/2000	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
double stranded oligomer AD00370 RNA interference-based liver targeted therapeutic	n/a	6/9/15	Treatment of Alpha-1 Antitrypsin deficiency	Designated			N/A	N/A	Arrowhead Research Corporation	225 South Lake Avenue	Suite 1050	Pasadena	California	91101	USA
double stranded RNA which targets the mutated KRAS oncogene	n/a	1/26/15	Treatment of pancreatic cancer	Designated			N/A	N/A	Silenseed Ltd	Goldyne Savad Institute of Gene Therapy	"Jerusalem, 9112001"				Israel
Double-stranded DNA plasmid carrying the gene for the diphtheria toxin A (DT-A) chain	n/a	8/6/10	Treatment of pancreatic cancer	Designated			N/A	N/A	BioCancell Therapeutics Israel Ltd.	8 Hartom Street		Jerusalem			Israel
dovitinib	n/a	9/26/13	Treatment of adenoid cystic carcinoma	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
Dovitinib	n/a	10/3/06	Treatment of multiple myeloma	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
DOXO-EMCH	n/a	4/18/11	Treatment of adenocarcinoma of the pancreas.	Designated			N/A	N/A	CytRx Corporation	11726 San Vicente Blvd.		Los Angeles	California	90049	USA
doxofylline	n/a	2/14/14	Treatment of bronchiectasis	Designated			N/A	N/A	"Alitair Pharmaceuticals, Inc."	55 Madison Avenue	Suite 400	Morristown	New Jersey	7960	USA
doxorubicin	n/a	4/6/15	Treatment of cutaneous T-cell lymphoma	Designated			N/A	N/A	"Louis D. Falo, Jr."	"University of Pittsburgh, Dep. of Dermatology"	3500 Fifth Avenue	Pittsburgh	Pennsylvania	15213	USA
doxorubicin	n/a	8/25/09	Treatment of hepatocellular carcinoma.	Designated			N/A	N/A	"Delcath Systems, Inc."	810 Seventh Avenue	35th Floor	New York	New York	10019	USA
doxorubicin HCL liposome injection	Doxil	12/29/04	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	For use in combination with bortezomib for the treatment of patients with multiple myeloma who have not previously received bortezomib and have at least one prior therapy.	05/17/2007	05/17/2014	Johnson & Johnson Pharmaceutical Research & Dev.	"920 US Highway 202, P. O. Box 300"		Raritan		8869	USA
Doxorubicin HCl with pluronic L-61 and pluronic F-127	n/a	10/7/05	Treatment of esophageal carcinoma	Designated			N/A	N/A	Supratek Pharma Inc.	6100 Royalmount Avenue	Montreal	Quebec H4P 2R2			Canada
Doxorubicin liposome	Doxil	11/4/98	Treatment of ovarian cancer.	Designated/Approved	Approved for Orphan Indication	"Treatment of metastatic carcinoma of the ovary in patients with disease that is refractory to both paclitaxel- and platinium-based chemotherapy regimens. Refractory disease is defined as disease that has progressed while on treatment, or within 6 months of completing treatment."	06/28/1999	06/28/2006	Alza Corporation	1550 Plymouth St.	PO Box 7210	Mountain View	California	94039	USA
doxorubicin PIHCA nanoparticles	Doxorubicin Transdrug	3/14/05	Treatment of hepatocellular carcinoma	Designated			N/A	N/A	BioAlliance Pharma	"59, Bd Gal Martial Valin - 75015"		Paris			France
doxorubicin with pluronics F-127 and L-61	n/a	2/20/08	Treatment of gastric cancer	Designated			N/A	N/A	"Supratek Pharma, Inc."	6100 Royalmount Avenue	Montreal	Quebec H4P 2R2			Canada
DPX-Survivac	n/a	7/14/15	Treatment of ovarian cancer.	Designated			N/A	N/A	"Immunovaccine Technologies, Inc."	1344 Summer Street	"Halifax, Nova Scotia B3H"				Canada
Dronabinol	Marinol	1/15/91	For the stimulation of appetite and prevention of weight loss in patients with a confirmed diagnosis of AIDS.	Designated/Approved	Approved for Orphan Indication	Treatment of anorexia associated with weight loss in patients with AIDS.	12/22/1992	12/22/1999	"Unimed Pharmaceuticals, Inc."	901 Sawyer Rd.		Marietta	Georgia	30062	USA
droxidopa	Northera	1/17/07	"Treatment of neurogenic symptomatic orthostatic hypotension in patients with primary autonomic failure, dopamine-beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy."	Designated/Approved	Approved for Orphan Indication	"Treatment of orthostatic dizziness, lightheadedness, or the ""feeling that you are about to black out"" in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy."	02/18/2014	02/18/2021	Lundbeck LLC	Four Parkway North		Deerfield	Illinois	60015	USA
dry extract from Betulae Cortex (birch bark)	n/a	8/7/14	Treatment of epidermolysis bullosa	Designated			N/A	N/A	Birken AG	Streiflingsweg 11		Niefern-Oeschelbronn			Germany
"Dual antibody including HBV-Ab 17, libivirumab, and HBV-Ab 19, exbivirumab"	Hepex-B	7/15/03	For the prevention of hepatitis B virus (HBV) reinfection in patients who have received a liver transplantation	Designated/Withdrawn			N/A	N/A	Cubist Pharmaceuticals	65 Hayden Avenue		Lexington	Massachusetts	2421	USA
Duramycin	n/a	12/11/97	Treatment of cystic fibrosis.	Designated			N/A	N/A	"Lantibio, Inc."	100 Europa Drive	Suite 421	Chapel Hill	North Carolina	27517	USA
dusquetide	n/a	8/10/16	Treatment of macrophage activation syndrome	Designated			N/A	N/A	"Soligenix, Inc."	29 Emmons Drive	Suite C-10	Princeton	New Jersey	8540	USA
duvelisib	n/a	4/15/13	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	Designated			N/A	N/A	Infinity Pharmaceuticals	780 Memorial Drive		Cambridge	Massachusetts	2139	USA
duvoglustat hydrochloride	n/a	6/18/07	Treatment of Pompe disease	Designated			N/A	N/A	"Amicus Therapeutics, Inc"	1 Cedarbrook Drive		Cranbury	New Jersey	8512	USA
Dynamine	n/a	2/5/90	Treatment of Lambert Eaton myasthenic syndrome.	Designated			N/A	N/A	Mayo Foundation	200 First Street Southwest		Rochester	Minnesota	55905	USA
Dynamine	n/a	10/16/91	Treatment of hereditary motor and sensory neuropathy type I (Charcot-Marie-Tooth disease).	Designated			N/A	N/A	Mayo Foundation	200 First Street Southwest		Rochester	Minnesota	55905	USA
E-selectin antagonist	n/a	5/13/15	Treatment of acute myeloid leukemia (AML)	Designated			N/A	N/A	"GlycoMimetics, Inc."	401 Professional Drive	Suite 250	Gaithersburg	Maryland	20879	USA
ecallantide	Kalbitor	2/4/03	Treatment of angioedema	Designated/Approved	Approved for Orphan Indication	Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older	03/28/2014	03/28/2021	Dyax Corp.	55 Network Dr.		Burlington	Massachusetts	1803	USA
ecallantide	Kalbitor	2/4/03	Treatment of angioedema	Designated/Approved	Approved for Orphan Indication	Treatment of acute attacks of hereditary angioedema in patients 16 years of age and older	12/01/2009	12/01/2016	Dyax Corp.	55 Network Dr.		Burlington	Massachusetts	1803	USA
"Echinocandin B,1-[(4R,5R)-4-hydroxy-N2-[[4-(pentyloxy)[1,1:4,1-terphenyl]-4-yl]carbonyl]-5-[2-(trimethylammonio)ethoxy]-L-ornithine]-4-[(4S)-4-hydroxy-4-(4-hydroxyphenyl)-L-allothreonine]"	n/a	2/8/16	Treatment of candidemia and invasive candidiasis infections caused by susceptible Candida spp.	Designated			N/A	N/A	"Cidara Therapeutics, Inc."	6310 Nancy Ridge Drive	Suite 101	San Diego	California	92121	USA
echinomycin	n/a	5/21/15	Treatment of acute myeloid leukemia.	Designated			N/A	N/A	"OncoImmune, Inc."	"502 E. Street, NE"		Washington	District of Columbia	20002	USA
echinomycin	n/a	1/5/17	Treatment of graft-versus-host disease (GVHD)	Designated			N/A	N/A	"OncoImmune, Inc."	"502 E. Street, NE"		Washington	District of Columbia	20002	USA
echothiophate iodide	n/a	6/2/14	Treatment of Stargardt's disease	Designated			N/A	N/A	"Makindus, Inc."	3805 Old Easton Road		Doylestown	Pennsylvania	18902	USA
ecopipam hydrochloride	n/a	9/29/10	Treatment of Tourette's syndrome in children 0-16 years old.	Designated			N/A	N/A	"Psyadon Pharmaceuticals, Inc."	20451 Seneca Meadows Parkway		Germantown	Maryland	20876	USA
ecopipam hydrochloride	n/a	7/21/09	Symptomatic treatment of self injurious behaviors in patients with Lesch-Nyhan disease.	Designated			N/A	N/A	"Psyadon Pharmaceuticals, Inc."	20451 Seneca Meadows Parkway		Germantown	Maryland	20876	USA
Eculizumab	n/a	9/21/00	Treatment of dermatomyositis	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	352 Knotter Drive		Cheshire	Connecticut	6410	USA
eculizumab	Soliris	6/24/13	Treatment of neuromyelitis optica	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	352 Knotter Drive		Cheshire	Connecticut	6410	USA
eculizumab	Soliris	1/10/14	Prevention of delayed graft function after renal transplantation	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	352 Knotter Drive		Cheshire	Connecticut	6410	USA
eculizumab	Soliris	8/20/03	Treatment of paroxysmal nocturnal hemoglobinuria	Designated/Approved	Approved for Orphan Indication	Treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis	03/16/2007	03/16/2014	"Alexion Pharmaceuticals, Inc."	352 Knotter Drive		Cheshire	Connecticut	6410	USA
eculizumab	Soliris	4/29/09	Treatment of atypical hemolytic uremic syndrome	Designated/Approved	Approved for Orphan Indication	For the treatment of atypical Hemolytic Uremic Syndrome (aHUS)	09/23/2011	09/23/2018	"Alexion Pharmaceuticals, Inc."	352 Knotter Drive		Cheshire	Connecticut	6410	USA
eculizumab	n/a	6/12/14	Treatment of Myasthenia Gravis.	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	100 College Steet		New Haven	Connecticut	6510	USA
eculizumab	n/a	3/5/01	Treatment of idiopathic membranous glomerular nephropathy	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	352 Knotter Drive		Cheshire	Connecticut	6410	USA
eculizumab	Soliris	10/18/11	Treatment of Shiga-Toxin producing escherichia coli hemolytic uremic syndrome	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	352 Knotter Drive		Cheshire	Connecticut	6410	USA
edaravone	n/a	3/12/15	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	Treeway B.V.	Sevillaweg 142	3047 AL Rotterdam				Netherlands
edaravone	n/a	5/12/15	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	Mitsubishi Tanabe Pharma Corporation	"17-10, Nihonbashi-Koamicho"	"Chuo-ku, Tokyo 103-8405"				Japan
Edotreotide	Onalta(Tm)	7/28/05	Treatment of somatostatin receptor-positive neuroendocrine gastroenteropancreatic tumors	Designated			N/A	N/A	"Molecular Insight Pharmaceuticals, Inc. (Progenics Subsidiary)"	777 Old Saw Mill River Road		Tarrytown	New York	10591	USA
efaproxiral	n/a	7/28/04	Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancer	Designated			N/A	N/A	"Allos Therapeutics, Inc."	11080 CirclePoint Road	Suite 200	Westminster	Colorado	80020	USA
Efdispo (tm)	Efdispo (Tm)	1/15/13	Treatment of Ewings Sarcoma.	Designated			N/A	N/A	"TDP Biotherapeutics, Inc."	113 Summer Walk Drive		Gaithersburg	Maryland	20878	USA
Eflornithine	n/a	9/29/06	Treatment of anaplastic glioma	Designated			N/A	N/A	"Orbus Therapeutics, Inc."	1043 Via Tornasol		Aptos	California	95003	USA
eflornithine	n/a	2/4/11	Treatment of Familial Adenomatous Polyposis	Designated			N/A	N/A	Cancer Prevention Pharmaceuticals	1760 E. River Road #250		Tucson	Arizona	85718	USA
eflornithine	n/a	11/23/10	Treatment of neuroblastoma	Designated			N/A	N/A	"Cancer Prevention Pharmaceutical, Inc."	1760 East River Road		Tucson	Arizona	85718	USA
eflornithine	n/a	12/14/16	Treatment of pancreatic cancer.	Designated			N/A	N/A	"Cancer Prevention Pharmaceutical, Inc."	1760 East River Road	Suite 250	Tucson	Arizona	85718	USA
Eflornithine HCl	Ornidyl	4/18/86	Treatment of Pneumocystis carinii pneumonia in AIDS patients.	Designated/Withdrawn			N/A	N/A	"Marion Merrell Dow, Inc."	P.O. Box 9627		Kansas City	Missouri	64134	USA
eflornithine HCL	n/a	4/7/15	Treatment of gastric cancer	Designated			N/A	N/A	"Cancer Prevention Pharmaceuticals, Inc."	1760 East River Road	Suite 250	Tucson	Arizona	85718	USA
Eflornithine HCl	Ornidyl	4/23/86	Treatment of Trypanosoma brucei gambiense infection (sleeping sickness).	Designated/Approved	Approved for Orphan Indication		11/28/1990	11/28/1997	Hoechst Marion Roussel	P.O. Box 9627		Kansas City	Missouri	64134	USA
eflornithine plus sulindac	n/a	1/22/13	Treatment of familial adenomatous polyposis	Designated			N/A	N/A	"Cancer Prevention Pharmaceuticals, Inc."	1760 East River Road	Suite 250	Tucson	Arizona	85718	USA
eicosapentaenoic acid	n/a	3/8/11	Treatment of familial adenomatous polyposis	Designated			N/A	N/A	S.L.A. Pharma Ltd. (UK)	Elite House	"Leavesden, Watford WD25 7SA"				United Kingdom
elacytarabine	n/a	6/18/08	Treatment of acute myeloid leukemia (AML)	Designated			N/A	N/A	Clavis Pharma ASA	Parkveien 53 B					Norway
Elcatonin	n/a	9/25/95	Intrathecal treatment of intractable pain.	Designated			N/A	N/A	"Innapharma, Inc."	10 Mountainview Road		Upper Saddle River	New Jersey	7458	USA
Elesclomol	n/a	12/18/07	Treatment of metastatic melanoma in combination with paclitaxel	Designated			N/A	N/A	Synta Pharmaceuticals Corporation	45 Hartwell Ave.		Lexington	Massachusetts	2421	USA
eliglustat	Cerdelga	9/17/08	Treatment of Type I Gaucher disease	Designated/Approved	Approved for Orphan Indication	"Long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test."	08/19/2014	08/19/2021	Genzyme Corporation	500 Kendall Street		Cambridge	Massachusetts	2142	USA
elosulfase alfa	Vimizim	5/15/09	Use in the treatment of mucopolysaccharidosis (MPS) Type IV A (Morquio A syndrome)	Designated/Approved	Approved for Orphan Indication	Patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome)	02/14/2014	02/14/2021	BioMarin Pharmaceutical Inc.	105 Digital Drive		Novato	California	94949	USA
elotuzumab	Empliciti	9/1/11	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies	11/30/2015	11/30/2022	Bristol-Myers Squibb Co.	Route 206 & Province Line Road		Princeton	New Jersey	8540	USA
eltoprazine HCl	n/a	2/8/16	Treatment of levodopa-induced dyskinesia associated with Parkinson's disease.	Designated			N/A	N/A	"Amarantus BioScience Holdings, Inc."	655 Montgomery St.	Suite 900	San Francisco	California	94111	USA
eltrombopag	Promacta	11/8/13	Treatment of aplastic anemia	Designated/Approved	Approved for Orphan Indication	Treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.	08/26/2014	08/26/2021	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Jersey	7936	USA
eltrombopag	Promacta	5/5/08	Treatment of idiopathic thrombocytopenia purpura	Designated/Approved	Approved for Orphan Indication	"Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy"	11/20/2008	11/20/2015	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Jersey	7936	USA
emixustat	n/a	1/4/17	Treatment of Stargardt disease (STGD)	Designated			N/A	N/A	Acucela Inc.	1301 2nd Avenue	Suite 4200	Seattle	Washington	98101	USA
emodepside	n/a	9/13/16	"Treatment of onchocerhiasis (""river blindness"") caused by the filarial nematode onchocerca volvulus"	Designated			N/A	N/A	"Bayer HealthCare Pharmaceuticals, Inc."	100 Bayer Boulevard	P. O. Box 915	Whippany	New Jersey	7981	USA
emricasan	n/a	11/20/13	Treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end stage liver disease	Designated			N/A	N/A	Conatus Pharmaceuticals Inc.	4365 Executive Drive	Suite 200	San diego	California	92121	USA
Enadoline hydrochloride	n/a	1/28/97	Treatment of severe head injury.	Designated			N/A	N/A	Warner-Lambert Company	Parke-Davis Pharmaceutical Research Division	2800 Plymouth Road	Ann Arbor	Michigan	48105	USA
enalapril maleate (powder for oral solution)	Epaned	1/30/13	Treatment of hypertension in pediatric patients	Designated/Withdrawn by OPD			N/A	N/A	"Silvergate Pharmaceuticals, Inc."	5371 Gordon Way		Dublin	Ohio	43017	USA
Encapsulated porcine islet preparation	Betarx	7/5/95	Treatment of type I diabetic patients who are already on immunosuppression.	Designated			N/A	N/A	VivoRx	2825 Santa Monica Blvd.	2nd Floor	Santa Monica	California	90404	USA
encapsulated spores from fecal microbiota	n/a	8/19/15	Treatment of recurrent Clostridium difficile infection (CDI)	Designated			N/A	N/A	"Seres Health, Inc."	161 First Street		Cambridge	Massachusetts	2142	USA
enchochleate amphotericin B	n/a	1/10/14	Treatment of visceral leishmaniasis	Designated			N/A	N/A	"Aquarius Biotechnologies, Inc."	2037 West Carroll Avenue		Chicago	Illinois	60612	USA
encochleated amikacin	n/a	3/3/16	Treatment of non-tuberculous mycobacteria (NTM) infections	Designated			N/A	N/A	"Aquarius Biotechnologies, Inc."	1545 U.S. 206		Bedminster Township	New Jersey	7921	USA
encorafenib	n/a	11/19/13	Treatment of Stage IIB-IV melanoma positive for BRAF mutation	Designated			N/A	N/A	"Array BioPharmas, Inc."	3200 Walnut Street		Boulder	Colorado	80301	USA
encorafenib + binimetinib	n/a	11/19/13	Treatment in Stage IIB-IV melanoma positive for the BRAF mutation.	Designated			N/A	N/A	"Array BioPharma, Inc."	125 Cambridge Park Drive	Suite 301	Cambridge	Massachusetts	2140	USA
Endothelin receptor B antagonist	n/a	1/21/16	Treatment of malignant melanoma Stages IIB to IV.	Designated			N/A	N/A	"ENB Therapeutics, LLC"	166 5th Avenue	2nd Floor	New York	New York	10010	USA
"enfumafungin derivative B-(1,3)-D-glucan synthestis inhibitor"	n/a	5/10/16	"Treatment of invasive Candida infections, including candidemia"	Designated			N/A	N/A	"SCYNEXIS, Inc."	101 Hudson Street	Suite 3610	Jersey City	New Jersey	7302	USA
Engineered variant of recombinant human fibroblast growth factor 19	n/a	2/6/14	Treatment of primary biliary cirrhosis	Designated			N/A	N/A	"NGM Biopharmaceuticals, Inc."	630 Gateway Blvd		South San Francisco	California	94080	USA
eniluracil	n/a	12/15/05	Treatment of hepatocellular carcinoma.	Designated			N/A	N/A	"Adherex Technologies, Inc."	501 Eastowne Drive	Suite 140	Chapel Hill	North Carolina	27514	USA
enisoprost	n/a	10/20/89	1. For use with cyclosporine in organ transplant recipients to reduce acute transplant rejection 2. For use in organ transplant patients to diminish the nephrotoxicity induced by cyclosporine.	Designated/Withdrawn			N/A	N/A	G.D. Searle & Company	4901 Searle Parkway		Skokie	Illinois	60077	USA
ensituximab	n/a	10/21/10	Treatment of pancreatic cancer.	Designated			N/A	N/A	"Neogenix Oncology, Inc."	9700 Great Seneca Highway		Rockville	Maryland	20850	USA
"entrectinib;N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide"	n/a	12/22/14	Treatment of neuroblastoma	Designated			N/A	N/A	"Ignyta, Inc."	11111 Flintkote Avenue		San Diego	California	92121	USA
Enzastaurin	n/a	9/19/05	Treatment of glioblastoma multiforme	Designated			N/A	N/A	Denovo Biopharma LLC	6331 Nancy Ridge Drive		San Diego	California	92121	USA
enzastaurin	n/a	3/4/09	Treatment of diffuse large B-cell lymphoma	Designated			N/A	N/A	Denovo Biopharma LLC	6331 Nancy Ridge Drive		San Diego	California	92121	USA
epacadostat	n/a	2/11/16	Treatment of stage IIB-IV melanoma.	Designated			N/A	N/A	Incyte Corporation	1801 Augustine Cut-Off		Wilmington	Delaware	19803	USA
Epidermal growth factor (human)	n/a	3/6/85	For promotion of cutaneous wound healing in extreme burn treatment protocols.	Designated/Withdrawn			N/A	N/A	"Ethicon, Inc."	P.O. Box 151		Somerville	New Jersey	8876	USA
Epidermal growth factor (human)	n/a	10/5/87	For acceleration of corneal epithelial regeneration and the healing of stromal tissue in the condition of non-healing corneal defects.	Designated			N/A	N/A	Chiron Vision	500 Iolab Drive		Claremont	California	91711	USA
Epirubicin	Ellence	9/14/99	Treatment of breast cancer.	Designated/Approved	Approved for Orphan Indication	Component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.	09/15/1999	09/15/2006	Pharmacia & Upjohn Company	0634-298-113	7000 Portage Rd.	Kalamazoo	Michigan	49001	USA
Epitalon	n/a	9/2/10	Treatment of retinitis pigmentosa	Designated/Withdrawn			N/A	N/A	BioDiem Ltd	"Level 10, South Tower"	Victoria 3000	Melbourne			Australia
Epoetin alfa	Epogen	4/10/86	Treatment of anemia associated with end stage renal disease.	Designated/Approved	Approved for Orphan Indication		06/01/1989	06/01/1996	"Amgen, Inc."	1840 Dehavilland Drive		Thousand Oaks	California	91320	USA
Epoetin alfa	Epogen	7/1/91	Treatment of anemia associated with HIV infection or HIV treatment.	Designated/Approved	Approved for Orphan Indication	Treatment of AZT-induced anemia in HIV infected patients.	12/31/1990	12/31/1997	"Amgen, Inc."	1840 Dehavilland Drive		Thousand Oaks	California	91320	USA
Epoetin alfa	n/a	12/20/93	Treatment of myelodysplastic syndrome.	Designated			N/A	N/A	"Johnson & Johnson Pharmaceutical Research & Dev.,"	920 U.S. Highway	"Route 202, P.O. Box 300"	Raritan	New Jersey	8869	USA
Epoetin alpha	Procrit	7/21/88	Treatment of anemia of prematurity in preterm infants.	Designated/Withdrawn			N/A	N/A	"Janssen Research & Development, LLC"	1400 McKean Road	P. O. Box 776	Spring House	Pennsylvania	19477	USA
Epoetin alpha	Procrit	8/27/87	Treatment of anemia associated with end stage renal disease.	Designated			N/A	N/A	R. W. Johnson Pharmaceutical Research Institute	Route 202 South	P.O. Box 300	Raritan	New Jersey	8869	USA
Epoetin alpha	Procrit	3/7/89	Treatment of HIV associated anemia related to HIV infection or HIV treatment.	Designated			N/A	N/A	R. W. Johnson Pharmaceutical Research Institute	"Route 202, P.O. Box 300"		Raritan	New Jersey	8869	USA
Epoetin beta	Marogen	10/22/87	Treatment of anemia associated with end stage renal disease.	Designated			N/A	N/A	"Chugai-USA, Inc."	3780 Hawthorn Court		Waukegan	Illinois	60087	USA
Epoprostenol	Cycloprostin	10/29/84	Replacement of heparin in patients requiring hemodialysis and who are at increased risk of hemorrhage.	Designated/Withdrawn			N/A	N/A	Upjohn Company	301 Henrietta Street		Kalamazoo	Michigan	49001	USA
Epoprostenol	Flolan	3/29/84	Replacement of heparin in patients requiring hemodialysis and who are at risk of hemmorrage	Designated/Withdrawn			N/A	N/A	Glaxo Wellcome Inc.	5 Moore Drive		Research Triangle Park	North Carolina	27709	USA
Epoprostenol	Flolan	9/25/85	Treatment of primary pulmonary hypertension.	Designated/Approved	Approved for Orphan Indication	Long-term intravenous treatment of primary pulmonary hypertension in NYHA Class III and Class IV patients.	09/20/1995	09/20/2002	Glaxo Wellcome Inc.	5 Moore Drive		Research Triangle Park	North Carolina	27709	USA
epoprostenol	Flolan	3/22/99	Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.	Designated/Approved	Approved for Orphan Indication	treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases.	04/14/2000	04/14/2007	GlaxoSmithKline	2301 Renaissance Blvd	P. O. Box 61540	King of Prussia	Pennsylvania	19406	USA
epratuzumab	Lymphocide	7/13/98	Treatment of non-Hodgkin's lymphoma	Designated			N/A	N/A	"Immunomedics, Inc."	300 The American Road		Morris Plains	New Jersey	7950	USA
epratuzumab	n/a	9/30/08	Treatment of acute lymphoblastic leukemia	Designated			N/A	N/A	"Immunomedics, Inc."	300 The American Road		Morris Plains	New Jersey	7950	USA
Eprodisate	Kiacta(Tm)	4/6/99	Treatment of secondary amyloidosis	Designated			N/A	N/A	"C. T. Development America, Inc."	663 Fifth Avenue	7th Floor	New York	New York	10022	USA
Epstein Barr Virus specific cytotoxic T lymphocytes	n/a	12/27/06	Prevention and treatment of EBV-post transplant lymphoproliferative disease after hematopoietic stem cell transplant or solid organ transplant.	Designated/Withdrawn			N/A	N/A	Center for Cell and Gene Therapy	Feigin Center	Suite 1120	Houston	Texas	77030	USA
Epstein-Barr virus-specific autologous cytotoxic T lymphocytes	n/a	6/12/14	Treatment of Epstein-Barr virus positive head and neck cancers (which includes nasopharyngeal carcinoma)	Designated			N/A	N/A	FFCanVac Pte Ltd	3 Rodyk Street #10-15	238213				Singapore
eptifibatide and iloprost	n/a	4/20/12	Treatment of purpura fulminans	Designated			N/A	N/A	Thrombologic	COBIS/Ole Maaloesvej 3	2200 Copenhagen				Denmark
erdosteine	n/a	12/20/13	Treatment of bronchiectasis.	Designated			N/A	N/A	"Alitair Pharmaceuticals, Inc."	55 Madison Avenue	Suite 400	Morristown	New Jersey	7960	USA
eribulin mesylate	Halaven	5/14/12	Treatment of soft tissue sarcoma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen	01/28/2016	01/28/2023	Eisai Inc.	155 Tice Blvd		Woodcliff Lake	New Jersey	7677	USA
Erlotinib Hydrochloride	Tarceva	7/18/03	Treatment of malignant gliomas	Designated			N/A	N/A	"Genentech, Inc"	1 DNA Way		South San Francisco	California	94080	USA
Erwinia L-asparaginase	n/a	1/25/85	For use as an alternative to E. coli asparaginase in those situations where repeat courses of asparaginase therapy for acute lymphoblastic leukemia are required or where allergic reactions force the discontinuance of the E. coli preparation.	Designated/Withdrawn			N/A	N/A	"Lyphomed, Inc."						
Erwinia L-asparaginase	Erwinase	7/30/86	Treatment of acute lymphocytic leukemia.	Designated/Approved	Approved for Orphan Indication	Treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.	11/18/2011	11/18/2018	"Jazz Pharmaceuticals, Inc."	3180 Porter Drive		Palo Alto	California	94304	USA
"Erythropoietin (human, recombinant)"	n/a	11/19/87	Treatment of anemia associated with end stage renal disease.	Designated/Withdrawn			N/A	N/A	Organon Teknika Corporation						
Erythropoietin (recombinant human)	n/a	8/19/87	Treatment of anemia associated with end stage renal disease.	Designated			N/A	N/A	McDonnell Douglas Corp	"P.O. Box 516, 107/2 MS10"		St. Louis	Missouri	63166	USA
estradiol Gel	n/a	10/31/06	Estrogen replacement therapy in females with Turner syndrome	Designated			N/A	N/A	"Ascend Therapeutics US, LLC"	607 Herndon Parkway	Suite 110	Herndon	Virginia	21070	USA
etanercept	Enbrel	10/27/98	Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.	Designated/Approved	Approved for Orphan Indication	Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older	05/27/1999	05/27/2006	Immunex Corporation	One Amgen Center Drive		Thousand Oaks	California	91320	USA
Etanercept	Enbrel	4/6/99	Treatment of Wegener's granulomatosis.	Designated/Withdrawn			N/A	N/A	Immunex Corporation	51 University Street		Seattle	Washington	98101	USA
etaracizumab	Abegrin	4/14/04	"For the treatment of of stage IIb, stage IIc, stage III and stage IV melanoma"	Designated/Withdrawn			N/A	N/A	"MedImmune, LLC"	One MedImmune Way		Gaithersburg	Maryland	20878	USA
etarfolatide	n/a	2/16/00	For the identification of ovarian carcinomas	Designated			N/A	N/A	"Endocyte, Inc."	3000 Kent Ave.	Suite A1-100	West Lafayette	Indiana	47906	USA
eteplirsen	Exondys 51	10/23/07	Treatment of Duchenne Muscular Dystrophy.	Designated/Approved	Approved for Orphan Indication	Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping	09/19/2016	09/19/2023	"Sarepta Therapeutics, Inc."	215 First Street	Suite 415	Cambridge	Massachusetts	2142	USA
Ethanol gel	n/a	3/29/06	Treatment of congenital venous malformations	Designated/Withdrawn			N/A	N/A	Orfagen	CRDPF - LANGLADE	31035 Toulouse Cedex				France
Ethanol gel	n/a	3/13/06	Treatment of congenital lymphatic malformations	Designated/Withdrawn			N/A	N/A	Orfagen	CRDPF - LANGLADE	31035 Toulouse Cedex				France
ethanolamine	Ethamolin	1/17/14	Prophylactic use in pediatric patients (age 0 through 16 years) with esophageal varices that are at risk of bleeding to obliterate varices and to prevent bleeding	Designated			N/A	N/A	"QOL Medical, LLC"	"4445 North Highway A1A, 241"		Vero Beach	Florida	32963	USA
Ethanolamine oleate	Ethamolin	3/22/84	"Treatment of patients with esophageal varices that have recently bled, to prevent rebleeding."	Designated/Approved	Approved for Orphan Indication		12/22/1988	12/22/1995	QOL Medical	"4445 North Highway A1A, 241"		Vero Beach	Florida	32963	USA
"Ethinyl Estradiol, USP"	n/a	6/22/88	Treatment of Turner's syndrome.	Designated/Withdrawn			N/A	N/A	Bio-Technology General Corp.	"70 Wood Avenue, South"		Iselin	New Jersey	8830	USA
ethiodized oil injection	Lipiodol	9/26/13	Management of patients with known hepatocellular carcinoma (HCC)	Designated/Approved	Approved for Orphan Indication	Selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC)	04/04/2014	04/04/2021	Guerbet LLC	"120 West 7th St., Suite 108"		Bloomington	Indiana	47404	USA
Ethiofos	n/a	8/1/89	Use as a chemoprotective agent for cisplatin and cyclophosphamide in the treatment of ovarian cancer.	Designated/Withdrawn			N/A	N/A	U.S. Bioscience	100 Front Street		West Conshohocken	Pennsylvania	19428	USA
"Ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate"	n/a	5/13/98	Treatment of Crohn's disease.	Designated/Withdrawn			N/A	N/A	Tap Holdings Inc.	2355 Waukegan Road		Deerfield	Illinois	60015	USA
Ethyl eicosapentaenoate	n/a	4/6/00	Treatment of Huntington's disease.	Designated			N/A	N/A	Laxdale Ltd.	"Kings Park House, Laurelhill Business Park"	"Polmaise Road, Stirling FK7 9JQ"				United Kingdom
Etidronate disodium	Didronel	3/21/86	Treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.	Designated/Approved	Approved for Orphan Indication		04/21/1987	04/21/1994	"MGI Pharma, Inc."	5775 West Old Shakopee Rd.	Suite 100	Bloomington	Minnesota	55437	USA
Etidronate disodium	Didronel Iv Infusion	5/2/91	Treatment of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition.	Designated/Withdrawn			N/A	N/A	"MGI Pharma, Inc."	6300 West Old Shakoppe Rd.	Suite 110	Bloomington	Minnesota	55438	USA
Etidronate disodium	Didronel Iv Infusion	5/2/91	Prevention of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition.	Designated/Withdrawn			N/A	N/A	"MGI Pharma, Inc."	6300 West Old Shakoppe Rd.	Suite 110	Bloomington	Minnesota	55438	USA
Etiocholanedione	n/a	11/3/95	Treatment of aplastic anemia.	Designated			N/A	N/A	"SuperGen, Inc."	4140 Dublin Blvd.	Suite 200	Dublin	California	94568	USA
Etiocholanedione	n/a	5/7/96	Treatment of Prader-Willi syndrome.	Designated			N/A	N/A	"SuperGen, Inc."	4140 Dublin Blvd.	Suite 200	Dublin	California	94568	USA
etirinotecan pegol	n/a	4/18/11	Treatment of ovarian cancer.	Designated			N/A	N/A	Nektar Therapeutics	"455 Mission Bay Blvd, South"		San Francisco	California	94158	USA
etrolizumab	n/a	8/22/16	Treatment of pediatric patients with ulcerative colitis	Designated			N/A	N/A	"Genentech, Inc."	1 Dna Way		South San Francisco	California	94080	USA
everolimus	n/a	6/2/14	Treatment of diffuse large B-cell lymphoma	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Jersey	7936	USA
everolimus	Afinitor	2/14/08	Treatment of neuroendocrine tumors	Designated/Approved	Approved for Orphan Indication	"Treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease"	05/05/2011	05/05/2018	Novartis Pharmaceuticals Corporation	One Health Plaza	"Build 337, A14.5D"	East Hanover	New Jersey	7936	USA
everolimus	Afinitor	9/16/10	Treatment of Waldenstrom macroglobulinemia (also known as lymphoplasmacytic lymphoma)	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
everolimus	Afinitor	2/14/08	Treatment of neuroendocrine tumors	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with progressive, well-differentiated, non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin, (excluding pancreatic) with unresectable, locally advanced or metastatic disease."	02/26/2016	02/26/2023	Novartis Pharmaceuticals Corporation	One Health Plaza	"Build 337, A14.5D"	East Hanover	New Jersey	7936	USA
everolimus	Afinitor	5/24/11	Treatment of gastric cancer	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
everolimus	Afinitor	6/8/09	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	Designated/Approved	Approved for Orphan Indication	Treatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery.	04/26/2012	04/26/2019	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
everolimus	Afinitor	6/8/09	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	Designated/Approved	Approved for Orphan Indication	Treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical resection	10/29/2010	10/29/2017	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
everolimus	Afinitor	7/23/12	Treatment of hepatocellular carcinoma	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
everolimus ointment	n/a	9/10/15	Topical treatment of Tuberous Sclerosis Complex-related skin lesions	Designated			N/A	N/A	"Aucta Pharmaceuticals, LLC"	675 US Highway One		North Brunswick	New Jersey	8902	USA
evinacumab	n/a	2/8/16	Treat of homozygous familial hypercholesterolemia.	Designated			N/A	N/A	"Regeneron Pharmaceuticals, Inc."	777 Old Saw Mill River Road		Tarrytown	New York	10591	USA
evolocumab	Repatha	9/12/13	Treatment of homozygous familial hypercholesterolemia	Designated/Approved	Approved for Orphan Indication	"As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C."	08/27/2015	08/27/2022	Amgen Inc.	One Amgen Center Drive	M/S 17 2 B	Thousand Oaks	California	91320	USA
Ex vivo cultured adult human mesenchymal stem cells	Prochymal(R)	12/14/05	Treatment of acute graft versus host disease	Designated			N/A	N/A	"Mesoblast, Inc."	505 Fifth Avenue	Third Floor	New York	New York	10017	USA
ex vivo cultured human mesenchymal stromal cells	n/a	5/8/14	Prevention of graft rejection following solid organ transplantation	Designated			N/A	N/A	iCell Science AB	Tallmov. 2A	756 45 Uppsala				Sweden
ex-vivo cultered adult human mesenchymal stem cells	Prochymal(R)	4/30/10	Treatment of Type 1 diabetes patients with residual beta cell function	Designated			N/A	N/A	"Mesoblast, Inc."	505 Fifth Avenue	Third Floor	New York	New York	10017	USA
ex-vivo expanded autologous bone marrow-derived mesenchymal stem cells	n/a	12/20/10	Treatment of Amyotrophic Lateral Sclerosis	Designated			N/A	N/A	"TCA Cellular Therapy, LLC"	101 Judge Tanner Blvd.		Covington	Louisiana	70433	USA
Exemestane	Aromasin	9/19/91	Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.	Designated/Approved	Approved for Orphan Indication	Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.	10/21/1999	10/21/2006	Pharmacia & Upjohn	7000 Portage Road	Mail Stop: 0636-298-113	Kalamazoo	Michigan	49001	USA
Exendin 9-39 (Competitive antagonist of glucagon-like peptide-1)	n/a	12/8/16	Treatment of hyperinsulinemic hypoglycemia	Designated			N/A	N/A	"Eiger BioPharmaceuticals, Inc."	350 Cambridge Avenue	Suite 350	Palo Alto	California	94306	USA
exendin-(9-39)	n/a	6/1/11	Treatment of congential hyperinsulinenic hypoglycemia and other causes of hyperinsulinemic hypoglycemia in adults and children	Designated			N/A	N/A	The Children's Hospital of Philadelphia	Children's Hospital of Phil. Research Institute	Abramson Research Center	Philadelphia	Pennsylvania	19104	USA
Exisulind	n/a	2/14/94	For the suppression and control of colonic adenomatous polyps in the inherited disease adenomatous polyposis coli.	Designated			N/A	N/A	"OSI Pharmaceuticals, Inc."	41 Pinelawn Road		Melville	New York	11747	USA
Exon 44 specific phosphorothioate oligonucleotide	n/a	11/5/09	Treatment of Duchenne Muscular Dystrophy in patients who have a mutation correctable by skipping of exon 44of the dystrophin gene.	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	105 Digital Drive		Novato	California	94949	USA
Exon 45 specific phosphorothioate oligonucleotide	n/a	1/23/13	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 45	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	105 Digital Drive		Novato	California	94949	USA
Exon 46 specific phosphorothioate oligonucleotide	n/a	11/18/05	Treatment of Duchenne muscular dystrophy	Designated/Withdrawn			N/A	N/A	Prosensa Therapuetics BV	"J. H. Oortweg, 2333 CH"		Leiden			Netherlands
Exon 51 specific phosphorothioate oligonucleotide	n/a	8/25/09	Treatment of Duchenne Muscular Dystrophy.	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	105 Digital Drive		Novato	California	94949	USA
Exon 52 specific phosphorothiate oligonucleotide	n/a	1/23/13	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 52	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	105 Digital Drive		Novato	California	94949	USA
Exon 53 specific antisense morpholino oligonucleotide.	n/a	1/12/17	Treatment of Duchenne Muscular Dystrophy	Designated			N/A	N/A	"NS Pharma, Inc."	140 East Ridgewood Avenue	Suite 280S	Paramus	New Jersey	7652	USA
exon 53 specific phosphorothioate oligonucleotide	n/a	1/23/13	treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 53	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	105 Digital Drive		Novato	California	94949	USA
Exon 55 specific phosphorothioate oligonucleotide	n/a	1/23/13	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 55	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	105 Digital Drive		Novato	California	94949	USA
expanded allogeneic human dermal fibroblasts in hypothermosol(r)-FRS	n/a	8/20/09	Treatment of Dystrophic Epidermolysis Bullosa.	Designated			N/A	N/A	Intercytex Ltd.	St. John's Innovation Centre	Cambridge CB4 0WS				United Kingdom
expanded human allogeneic neural retinal progenitor cells extracted from neural retina	n/a	8/22/13	Treatment of retinitis pigmentosa	Designated			N/A	N/A	ReNeuron Ltd	Pencod Business Park	"Pencod, Bridgend"				United Kingdom
"Extract of sea cucumber, sea sponge, shark fin, sea urchin, and sargassum grass"	n/a	5/14/12	Treatment of multiple myeloma	Designated			N/A	N/A	Unicorn Pacific Corporation	No. 1 Monmount Road	Bellevue Estate	Port Vila			Vanuatu
extract of sorghum bicolor extract	n/a	11/19/12	Treatment of sickle cell disease	Designated			N/A	N/A	"Invenux, LLC"	1550 Main Street	Suite A3	Windsor	Colorado	80550	USA
ezatiostat hydrochloride	Telintra	1/9/13	Treatment of myelodysplastic syndrome	Designated			N/A	N/A	"Telik, Inc."	700 Hansen Way		Palo Alto	California	94304	USA
Facilitated DNA Plasmid Vaccine	n/a	3/8/95	Treatment of cutaneous T cell lymphoma.	Designated			N/A	N/A	Wyeth-Lederle Vaccines and Pediatrics	211 Bailey Rd.		West Henrietta	New York	14586	USA
factor VIII mimetic bispecific antibody	n/a	1/10/14	Treatment of hemophilia A	Designated			N/A	N/A	Genentech	1 DNA Way		South San Francisco	California	94080	USA
factor XIII concentrate (human)	Corifact	1/16/85	Treatment of congenital factor XIII deficiency	Designated/Approved	Approved for Orphan Indication	For the routine prophylactic treatment of congenital factor XIII deficiency	02/17/2011	02/17/2018	CSL Behring LLC	1020 First Ave.	PO Box 61501	King of Prussia	Pennsylvania	19406	USA
factor XIII concentrate (human)	Corifact	1/16/85	Treatment of congenital factor XIII deficiency	Designated/Approved	Approved for Orphan Indication	Peri-operative management of surgical bleeding in adult and pediatric patients with congenital Factor XIII deficiency.	01/24/2013	01/24/2020	CSL Behring LLC	1020 First Ave.	PO Box 61501	King of Prussia	Pennsylvania	19406	USA
"Factor XIII [A2] homodimer, recombinant DNA origin"	n/a	5/21/03	Treatment of congenital FXIII deficiency	Designated			N/A	N/A	"Novo Nordisk Pharmaceuticals, INc."	100 College Road West		Princeton	New Jersey	8540	USA
"Factor XIII, recombinant"	n/a	4/22/93	Treatment of congenital factor XIII deficiency.	Designated/Withdrawn			N/A	N/A	"Zymogenetics, Inc."	4225 Roosevelt Way		Seattle	Washington	98105	USA
Fampridine	Neurelan	6/2/97	"Treatment of chronic, incomplete spinal cord injury."	Designated			N/A	N/A	"Acorda Therapeutics, Inc."	15 Skyline Dr.		Hawthorne	New York	10532	USA
Fancalen (lentiviral vector containing the Fanconi anemia-A (FANCA) gene	n/a	5/2/16	Treatment of Fanconi anemia type A patients.	Designated			N/A	N/A	Centro de Investigacion Biomedica en Red (CIBER)	Montforte de Lemos	3-5 Pabellon 11	Madrid			Spain
farletuzumab	n/a	6/16/06	Treatment of ovarian cancer	Designated			N/A	N/A	"Morphotek, Inc."	210 Welsh Pool Road		Exton	Pennsylvania	19341	USA
fecal microbiota	n/a	3/10/14	Treatment of recurrent Clostridium difficile infection (Clostridium difficile gastrointestinal disease)	Designated			N/A	N/A	"Rebiotx, Inc."	2660 Patton Road		Roseville	Minnesota	55113	USA
Felbamate	Felbatol	1/24/89	Treatment of Lennox-Gastaut syndrome.	Designated/Approved	Approved for Orphan Indication	As adjunctive therapy in the treatment of partial and generalized seizures associated with the Lennox-Gastaut syndrome in children.	07/29/1993	07/29/2000	Wallace Laboratories	301B College Road East		Princeton	New Jersey	8540	USA
fenfluramine HCI	Brabafen	12/20/13	For the Treatment of Dravet Syndrome	Designated			N/A	N/A	"Zogenix, Inc."	"5858 Horton Street, Suite 455"	RG9 2LT	Emeryville	California		United Kingdom
Fenobam hydrochloride	n/a	11/20/06	Treatment of fragile X syndrome	Designated			N/A	N/A	"Neuropharm, Ltd."	87 Church Street	"Crowthorne, Berkshire"				United Kingdom
fenretinide	n/a	9/4/13	Treatment of cutaneous T-cell lymphoma	Designated			N/A	N/A	"CerRx, Inc."	Reese Technology Center	"9801 Reese Blvd, Suite 104"	Lubbock	Texas	79416	USA
Fenretinide	n/a	10/5/05	Treatment of neuroblastoma	Designated			N/A	N/A	USC-CHLA Institute for Pediatric Clinical Research	Childrens Hospital of Los Angeles	"4650 Sunset Blvd, MS 55"	Los Angeles	California	90027	USA
fenretinide	n/a	2/1/07	Treatment of Ewing's sarcoma family of tumors.	Designated			N/A	N/A	Cancer Research UK	61 Lincoln's Inn Fields	London WC2A 3PX				United Kingdom
Fenretinide	n/a	4/7/10	Treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis patients	Designated			N/A	N/A	McGill University	McGill University	"Montreal, Quebec, H3A 2T5"				Canada
fenretinide	n/a	9/4/13	Treatment of peripheral T-cell lymphoma	Designated			N/A	N/A	"CerRx, Inc."	Reese Technology Center	"9801 Reese Blvd, Suite 104"	Lubbock	Texas	79416	USA
"ferric hexacyanoferrate (II) ""Prussian Blue"""	n/a	6/26/03	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Designated			N/A	N/A	Degussa AG	Weissfrauenstr.9	D-60287	Frankfurt			Germany
ferumoxytol	n/a	10/7/11	For use in magnetic resonance imaging in brain metastases	Designated			N/A	N/A	Oregon Health & Science University	3181 SW Sam Jackson Pk Road	Mailcode L603	Portland	Oregon	97239	USA
ferumoxytol	Feraheme	4/29/11	For use in MR imaging for the mangement of brain tumors	Designated			N/A	N/A	"Edward A. Neuwelt, MD"	Oregon Health & Science University	3181 SW Sam Jackson Park Road - Mail Code L603	Portland	Oregon	97239	USA
ferumoxytol	n/a	4/6/12	"For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)"	Designated			N/A	N/A	"ArsNova Partners, LLC"	38 Frederick Street		Newton	Massachusetts	2460	USA
fexinidazole	n/a	4/4/16	Treatment of human African trypanosomiasis (HAT) or sleeping sickness	Designated			N/A	N/A	"Sanofi US Services, Inc."	55 Corporate Drive	Mail Code 55D-225A	Bridgewater	New Jersey	8807	USA
fialuridine	n/a	7/24/92	Adjunctive treatment of chronic active hepatitis B.	Designated			N/A	N/A	"Oclassen Pharmaceuticals, Inc."	100 Pelican Way		San Rafael	California	94901	USA
Fibrin-based agent containing a N-terminally modified parathyroid hormone fragment TGplPTH1-34	n/a	2/1/07	Treatment of solitary (unicameral) bone cysts	Designated			N/A	N/A	Kuros Biosurgery AG	Technoparkstrasse 1		Zurich			Switzerland
Fibrinogen (human)	n/a	8/23/95	For the control of bleeding and prophylactic treatment of patients deficient in fibrinogen.	Designated			N/A	N/A	Alpha Therapeutic Corporation	5555 Valley Boulevard		Los Angeles	California	90032	USA
Fibronectin (human plasma derived)	n/a	9/5/88	Treatment of non-healing corneal ulcers or epithelial defects which have been unresponsive to conventional therapy and the underlying cause has been eliminated.	Designated			N/A	N/A	"Melville Biologics, Inc."	310 East 67th Street		New York	New York	10021	USA
Fibronectin (plasma derived)	n/a	12/5/88	Treatment of non-healing corneal ulcers or epithelial defects which are unresponsive to conventional therapy and for which any infectious cause of the defect has been eliminated.	Designated/Withdrawn			N/A	N/A	Chiron Vision	9342 Jeronimo Road		Irvine	California	92718	USA
Fibronectin Peptide	n/a	6/29/11	"Prevention of burn injury progression of acute, deep dermal burns in hospitalized patients."	Designated			N/A	N/A	"NeoMatrix Therapeutics, Inc."	Long Island High Tech Incubator	25 Health Sciences Drive	Stony Brook	New York	11790	USA
fidaxomicin	Dificid	12/13/10	Treatment of pediatric Clostridium difficile infection	Designated			N/A	N/A	"Optimer Pharmaceuticals, Inc."	10110 Sorrento Valley Road		San Diego	California	92121	USA
filanesib	n/a	5/6/14	Treatment of multiple myeloma.	Designated			N/A	N/A	"Array BioPharma, Inc."	3200 Walnut Street		Boulder	Colorado	80301	USA
Filgrastim	Neupogen	8/30/90	Treatment of myelodysplastic syndrome	Designated/Withdrawn			N/A	N/A	"Amgen, Inc."	1840 Dehavilland Drive		Thousand Oaks	California	91320	USA
filgrastim	Neupogen	11/20/13	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	Designated/Approved	Approved for Orphan Indication	To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).	03/30/2015	03/30/2022	"Amgen, Inc."	One Amgen Center Drive	M/S 17-1-C	Thousand Oaks	California	91320	USA
Filgrastim	Neupogen	9/3/91	"Treatment of patients with AIDS who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir"	Designated/Withdrawn			N/A	N/A	"Amgen, Inc."	One Amgen Center Dr.		Thousand Oaks	California	91320	USA
Filgrastim	Neupogen	7/17/95	For use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy.	Designated/Approved	Approved for Orphan Indication	For use in the mobilization of hematopoietic progenitor cells into the peripheral blood collection by leukapheresis.	12/28/1995	12/28/2002	"Amgen, Inc."	1840 Dehavilland Drive		Thousand Oaks	California	91320	USA
Filgrastim	Neupogen	10/1/90	Treatment of neutropenia associated with bone marrow transplants.	Designated/Approved	Approved for Orphan Indication	Reduce the duration of neutropenia and neutropenia sequelae in patients with non-myeloid malignancies undergoing ablative chemotherapy followed by BMT.	06/15/1994	06/15/2001	"Amgen, Inc."	1840 Dehavilland Drive		Thousand Oaks	California	91320	USA
Filgrastim	Neupogen	11/7/90	Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).	Designated/Approved	Approved for Orphan Indication	Treatment of patients with severe chronic neutropenia.	12/19/1994	12/19/2001	"Amgen, Inc."	1840 Dehavilland Drive		Thousand Oaks	California	91320	USA
filgrastim	n/a	1/27/15	Treatment of amyotrophic lateral sclerosis (ALS)	Designated			N/A	N/A	Neurovision Pharma GmbH	Emil-Geis Str. 4		Grunwald			Germany
Filgrastim	Neupogen	11/7/96	"Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia."	Designated/Approved	Approved for Orphan Indication	"Reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with acute myeloid leukemia."	04/02/1998	04/02/2005	"Amgen, Inc."	One Amgen Center Dr.		Thousand Oaks	California	91320	USA
filociclovir	n/a	11/29/10	Treatment of active cytomegalovirus infections	Designated			N/A	N/A	"Microbiotix, Inc."	One Innovation Drive		Worcester	Massachusetts	1605	USA
fingolimod	n/a	4/30/10	Treatment of chronic inflammatory demyelinating polyneuropathy	Designated			N/A	N/A	Novartis Pharmaceutical Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
firtecan pegol	n/a	4/18/11	Treatment of neuroblastoma.	Designated			N/A	N/A	"Enzon Pharmaceuticals, Inc."	20 Kingsbridge Road		Piscataway	New Jersey	8854	USA
fixed dose combination formulation of macitentan and tadalafil	n/a	10/19/16	Treatment of pulmonary arterial hypertension	Designated			N/A	N/A	"Actelion Clinical Research, Inc."	1820 Chapel Avenue West	Suite 300	Cherry Hill	New Jersey	8002	USA
fixed dose combination of modafinil and flecainide	n/a	9/19/16	Treatment of narcolepsy	Designated			N/A	N/A	Theranexus S.A	86 Rue de Paris		Orsay			France
FliC Flagellin Deletion Variant TLR5 Agonist	n/a	11/23/10	Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster	Designated			N/A	N/A	"Cleveland BioLabs, Inc."	73 High Street		Buffalo	New York	14203	USA
florilglutamic acid	n/a	5/11/16	Diagnostic for the management of glioma	Designated			N/A	N/A	Piramal Imaging S.A.	13 Route de l'Ecole		Matran			Switzerland
"Floxuridine, FUDR"	n/a	12/22/04	Intraperitoneal treatment of gastric cancer.	Designated			N/A	N/A	"Franco Muggia, M.D."	160 East 34th Street		New York	New York	10016	USA
flubendazole	n/a	1/23/14	"Treatment of lymphatic filariasis caused by nematodes of the family Filariodidea, in children and adults."	Designated			N/A	N/A	"Janssen Research and Development, LLC"	920 Route 202 South		Raritan	New Jersey	8869	USA
flubendazole	n/a	10/25/13	Treatment of onchocerciasis caused by Onchocerca volvulus	Designated			N/A	N/A	"Janssen Research & Development, LLC"	920 Route 202 South		Raritan	New Jersey	8869	USA
"fluciclovine (18F)(anti-1-amino-3-fluorocyclobutane-1-carboxylic acid, labelled with Fluorine-18)"	n/a	4/7/15	For the diagnosis of glioma	Designated			N/A	N/A	Blue Earth Diagnostics Ltd.	215 Euston Rd	"London, NW1 2BE"				United Kingdom
Fludarabine phosphate	Fludara	4/18/89	Treatment and management of patients with non-Hodgkins lymphoma.	Designated			N/A	N/A	"Berlex Laboratories, Inc."	15049 San Pablo Avenue	P.O. Box 4099	Richmond	California	94804	USA
Fludarabine phosphate	Fludara	4/18/89	"Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL."	Designated/Approved	Approved for Orphan Indication		04/18/1991	04/18/1998	"Berlex Laboratories, Inc."	"15049 San Pablo Avenue, P.O. Box 4099"		Richmond	California	94804	USA
Fludarabine phosphate oral tablets	n/a	12/18/07	Treatment of B-cell chronic lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not responded to or has progressed during or after treatment with at least one standard alkylating-agent containing regimen	12/18/2008	12/18/2015	"Sanofi-Aventis U.S., Inc."	55 Corproate Drive	P. O. Box 5925	Bridgewater	New Jersey	8807	USA
Flumecinol	Zixoryn	1/15/85	Treatment of hyperbilirubinemia in newborn infants unresponsive to phototherapy.	Designated/Withdrawn			N/A	N/A	"Farmacon, Inc."	"Post House, Suite 213"	1720 Post Road East	Westport	Connecticut	6880	USA
flunarizine	Sibelium	1/6/86	Treatment of alternating hemiplegia.	Designated			N/A	N/A	Janssen Research Foundation		P.O. Box 200	Titusville	New Jersey	8560	USA
flunarizine	n/a	7/20/16	Treatment of hemiplegic migraine	Designated			N/A	N/A	"Xenon Pharmaceuticals, Inc."	3650 Gilmore Way		Burnaby	British Columbia		Canada
flunarizine	n/a	6/24/13	Treatment of alternating hemiplegia	Designated			N/A	N/A	"Marathon Pharmaceuticals, LLC"	1033 Skokie Blvd.	Suite 600	Northbrook	Illinois	60062	USA
Fluocinolone	Retisert	7/31/00	Treatment uveitis involving the posterior segment of the eye.	Designated/Approved	Approved for Orphan Indication	Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye	04/08/2005	04/08/2012	"Bausch & Lomb Pharmaceuticals, Inc."	8500 Hidden River Parkway		Tampa	Florida	33637	USA
Fluorouracil	n/a	4/18/90	"For use in combination with interferon alpha-2a, recombinant, for the treatment of advanced colorectal carcinoma."	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA
Fluorouracil	n/a	10/27/89	"For use in combination with interferon alpha-2a, recombinant, for the treatment of esophageal carcinoma."	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA
Fluorouracil	n/a	6/29/00	Treatment of glioblastoma multiforme.	Designated			N/A	N/A	Ethypharm SA	194 Bureaux de la Colline - Batiment D	92213 Saint-Cloud Cedex				USA
Fluorouracil	Adrucil	2/6/89	For use in combination with leucovorin for therapy of metastatic adenocarcinoma of the colon and rectum.	Designated/Withdrawn			N/A	N/A	Lederle Laboratories	Division of American Cyanamid Company	401 N. Middletown Road	Pearl River	New York	10965	USA
Fluoxetine	Prozac	4/30/99	Treatment of autism.	Designated			N/A	N/A	"Neuropharm, Ltd."	Felcham Park House	Surrey KT229HD				United Kingdom
Fluoxetine	Prozac	4/14/04	Treatment of body dysmorphic disorder in children and adolescents	Designated			N/A	N/A	"Hollander, Eric MD"	The Mount Sinai School of Medicine	One Gustave L. Levy Place	New York	New York	10029	USA
fluticasone propionate	n/a	1/19/11	Treatment of pediatric and adult eosinophilic esophagitis	Designated			N/A	N/A	"Adare Pharmaceuticals, Inc."	845 Center Drive		Vandalia	Ohio	45377	USA
fluticasone propionate	n/a	12/29/15	Treatment of eosinophilic esophagitis	Designated			N/A	N/A	"Banner Life Sciences, LLC"	4125 Premier Drive		High Point	North Carolina	27265	USA
folate binding protein peptide: Glu-Ile-Trp-Thr-His-Ser-Tyr-Lys-Val	n/a	6/8/16	Treatment (including prevention of recurrence) of ovarian cancer	Designated			N/A	N/A	"Galena Biopharma, Inc."	Crow Canyon Place	Suite 380	San Ramon	California	94583	USA
Folate Binding Protein Peptide: Glu-Ile-Trp-Thr-Phe-Ser-Thr-Lys-Val	n/a	6/8/16	Treatment (including prevention of recurrence) of ovarian cancer	Designated			N/A	N/A	"Galena Biopharma, Inc."	Crow Canyon Place	Suite 380	San Ramon	California	94583	USA
"Follitropin alfa, recombinant"	Gonal-F	12/21/98	"For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism. AMENDED indication 6/27/00: For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure."	Designated/Approved	Approved for Orphan Indication	For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.	05/24/2000	05/24/2007	"EMD Serono, Inc."	One Technology Place		Rockland	Massachusetts	2370	USA
Fomepizole	Antizole	12/22/88	Treatment of methanol or ethylene glycol poisoning.	Designated/Approved	Approved for Orphan Indication	"Use for suspected or confirmed methanol poisoning, either alone or in combination with hemodialysis"	12/08/2000	12/08/2007	Jazz Pharmaceuticals	3180 Porter Drive		Palo Alto	California	94304	USA
Fomepizole	Antizole	12/22/88	Treatment of methanol or ethylene glycol poisoning.	Designated/Approved	Approved for Orphan Indication	"As an antidote to ethylene glycol (antifreeze) poisoning, or for use in suspected ethylene glycol ingestion."	12/04/1997	12/04/2004	Jazz Pharmaceuticals	3180 Porter Drive		Palo Alto	California	94304	USA
fosbretabulin tromethamine	n/a	12/29/15	Treatment of neuroendocrine tumors	Designated			N/A	N/A	"Mateon Therapeutics, Inc."	701 Gateway Blvd	Suite 210	South San Francisco	California	94080	USA
fosbretabulin tromethamine	n/a	6/8/16	Treatment of glioma	Designated			N/A	N/A	"Mateon Therapeutics, Inc."	701 Gateway Boulevard	Suite 210	South San Francisco	California	94080	USA
fosfomycin/tobramycin	n/a	11/28/08	Treatment of pulmonary infections associated with cystic fibrosis	Designated			N/A	N/A	"CURx Pharmaceuticals, Inc."	3210 Merryfield Row		San Diego	California	92121	USA
Fosphenytoin	Cerebyx	6/4/91	For the acute treatment of patients with status epilepticus of the grand mal type.	Designated/Approved	Approved for Orphan Indication	For the control of generalized convulsive status epilepticus.	08/05/1996	08/05/2003	Warner-Lambert Company	2800 Plymouth Road		Ann Arbor	Michigan	48106	USA
fostamatinib disodium	n/a	8/25/15	Treatment of immune thrombocytopenic purpura	Designated			N/A	N/A	"Rigel Pharmaceuticals, INc."	1180 Veterans Blvd		South San Francisco	California	94080	USA
fresolimumab	n/a	10/21/10	Treatment of primary focal segmental glomerulosclerosis	Designated/Withdrawn			N/A	N/A	"Genzyme, a Sanofi Company"	200 Crossing Boulevard		Framingham	Massachusetts	1702	USA
"Fructose-1,6-diphosphate"	Cordox	5/29/98	Treatment of painful vaso-occlusive episodes associated with sickle cell disease.	Designated/Withdrawn			N/A	N/A	"Questcor Pharmaceuticals, Inc."	3260 Whipple Road		Union City	California	94587	USA
FTV1+GDP-fucose	n/a	3/18/11	To improve homing to bone (treatment of myeloablation) in patients receiving hematopoietic stem cell transplantation.	Designated			N/A	N/A	"America Stem Cell, Inc."	11014 Bar X Trail		Helotes	Texas	78023	USA
Full Phosphorothioate Antisense Oligonucleotide against EWS-Fli-1 nanoparticles	n/a	9/22/08	Treatment of Ewing's sarcoma	Designated			N/A	N/A	The Cure Our Children Foundation	1730 Michael Lane		Pacific Palisades	California	90272	USA
Fully human anti-interferon gamma monoclonal antibody	Ni-0501	3/26/10	Treatment of hemophagocytic lymphohistiocytosis	Designated			N/A	N/A	NovImmune S.A.	14 chemin des Aulx					Switzerland
fully human IgG2 monoclonal antibody that binds insulin receptors	n/a	6/9/15	Treatment of congenital hyperinsulinism	Designated			N/A	N/A	XOMA (US) LLC	2910 Seventh St.		Berkeley	California	94710	USA
fusion protein analog with recombinant human growth hormone (rhGH) at once-a-month dosing	n/a	10/16/13	Treatment of growth hormone deficiency	Designated			N/A	N/A	"Versartis, Inc."	275 Shoreline Drive	Suite 450	Redwood City		94065	USA
Fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1	n/a	1/11/06	Treatment of X-linked hypohidrotic ectodermal dysplasia	Designated			N/A	N/A	"Edimer Pharmaceuticals, Inc."	1 Broadway	8th Floor	Cambridge	Massachusetts	2142	USA
G17DT Immunogen	Gastrimmune(Tm)	7/10/02	Treatment of adenocarcinoma of the pancreas	Designated			N/A	N/A	"Cancer Advances, Inc."	Westpark Corporate Center	Suite 210	Durham	North Carolina	27713	USA
G17DT Immunogen	Gastrimmune(Tm)	7/18/02	Treatment of gastric cancer	Designated			N/A	N/A	"Cancer Advances, Inc."	Westpark Corporate Center	Suite 210	Durham	North Carolina	27713	USA
gabapentin	Neurontin	7/5/95	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	Warner-Lambert Company	Parke-Davis Pharmaceutical Research Division	2800 Plymouth Road	Ann Arbor	Michigan	48105	USA
gabapentin	Gralise	11/8/10	Management of postherpetic neuralgia	Designated/Approved	Approved for Orphan Indication	For the management of postherpetic neuralgia	01/28/2011	01/28/2018	"Depomed, Inc."	1360 O'Brien Drive		Menlo Park	California	94025	USA
gabapentin enacarbil	Horizant	6/7/11	Treatment of postherpetic neuralgia	Designated/Approved	Approved for Orphan Indication	Management of postherpetic neuralgia in adults.	06/06/2012	06/06/2019	"Arbor Pharmaceuticals, LLC"	6 Concourse Parkway	Suite 1800	Atlanta	Georgia	30328	USA
Gallium (68Ga) edotreotide	Somakit Toc	7/1/15	Diagnostic for the clinical management of neuroendocrine tumors.	Designated			N/A	N/A	"Advanced Accelerator Applications, USA"	350 Fifth Avenue	Suite 6902	New York	New York	10118	USA
Gallium nitrate injection	Ganite	12/5/88	Treatment of hypercalcemia of malignancy.	Designated/Approved/Withdrawn			N/A	01/17/1998	Solopak Pharmaceutical Co.	1845 Tonne Road		Elk Grove Village	Illinois	60007	USA
"Gallium [Ga-68]-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic(2-7)disulfide"	Netspot	12/31/13	Diagnostic for the clinical management of neuroendocrine tumors	Designated/Approved	Approved for Orphan Indication	"For use after radiolabeling with Ga 68, with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients."	06/01/2016	06/01/2023	"Advanced Accelerator Applications, USA"	350 Fifth Avenue	Suite 6902	New York	New York	10118	USA
Gallium-68 (DOTA0-Phel-Tyr3)octreotide	n/a	10/25/13	The management of neuroendocrine tumors	Designated			N/A	N/A	University of Iowa Hospital & Clinics	Department of Radiology/PET Imaging Center	200 Hawkins Drive	Iowa City	Iowa	52242	USA
Gamma hydroxybutyrate	n/a	12/3/87	"Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations and automatic behavior."	Designated			N/A	N/A	"Biocraft Laboratories, Inc."	18-01 River Road		Fair Lawn	New Jersey	7410	USA
Gamma-hydroxybutyric acid	n/a	1/22/85	"Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations, and automatic behavior."	Designated/Withdrawn			N/A	N/A	Sigma Chemical Company						
Gammalinolenic acid	n/a	7/27/94	Treatment of juvenile rheumatoid arthritis.	Designated			N/A	N/A	"Zurier, Robert B. M.D."	University of Massachusetts Medical Center	55 Lake Avenue	Worcester	Massachusetts	1655	USA
Ganaxolone	n/a	5/25/94	Treatment of infantile spasms.	Designated			N/A	N/A	"Marinus Pharmaceuticals, Inc."	21 Business Park Drive		Branford	Connecticut	6405	USA
ganaxolone	n/a	4/14/16	Treatment of status epilepticus.	Designated			N/A	N/A	"Marinus Pharmaceuticals, Inc."	Three Radnor Corporate Center	100 Matsonford Road	Radnor	Pennsylvania	19087	USA
ganaxolone	n/a	12/28/16	Treatment of Fragile X Syndrome	Designated			N/A	N/A	Marinus Pharmaceuticals	170 North Radnor Chester Road	Suite 250	Radnor	Pennsylvania	19087	USA
ganaxolone	n/a	3/24/15	Treatment of Protocadherin 19 (PCDH19) female epilepsy.	Designated			N/A	N/A	"Marinus Pharmaceuticals, Inc."	3 Radnor Corporate Center	Suite 304	Radnor	Pennsylvania	19087	USA
ganciclovir	Zirgan	3/22/07	Treatment of acute herpetic keratitis (dendritic and geographic ulcers)	Designated/Approved	Approved for Orphan Indication	Treatment of acute herpetic keratitis (dendritic ulcers)	09/15/2009	09/15/2016	"Sirion Therapeutics, Inc."	9314 East Broadway Avenue		Tampa	Florida	33619	USA
Ganciclovir intravitreal implant	Vitrasert Implant	6/7/95	Treatment of cytomegalovirus retinitis.	Designated/Approved	Approved for Orphan Indication	Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome.	03/04/1996	03/04/2003	"Bausch & Lomb Surgical, Chiron Vision Products"	9342 Jeronimo Road		Irvine	California	92718	USA
Ganciclovir sodium	Cytovene	10/31/85	Treatment of cytomegalovirus retinitis in immunocompromised patients with AIDS.	Designated/Approved/Withdrawn			N/A	06/23/1996	"Syntex (USA), Inc."	3401 Hillview Avenue		Palo Alto	California	94304	USA
Gancyclovir	n/a	6/7/85	Treatment of severe human cytomegalovirus infections in specific immunosuppressed patient populations.	Designated/Withdrawn			N/A	N/A	Burroughs Wellcome Company	3030 Cornwallis Road	P.O. Box 12700	Research Triangle Park	North Carolina	27709	USA
Gangliosides as sodium salts	Cronassial	11/17/88	Treatment of retinitis pigmentosa.	Designated/Withdrawn			N/A	N/A	Fidia Pharmaceutical Corp.	"1401 Eye Street, N.W. Suite 900"		Washington	District of Columbia	20005	USA
ganitumab	n/a	11/23/10	Treatment of pancreatic cancer.	Designated			N/A	N/A	Nantcell	9920 Jefferson Blvd		Culver City	California	90232	USA
Gastrin 17C Diphtheria Toxoid Immunogen	n/a	7/7/09	Treatment of pancreatic cancer	Designated			N/A	N/A	Astrimmune Ltd.	Mansfield i-cente	Hamilton Way	Mansfield			United Kingdom
Gavilimomab	n/a	11/20/00	Acute graft-versus-host disease (aGVHD)	Designated/Withdrawn			N/A	N/A	Amgen	One Amgen Center Drive	Mail Stop 17-2-A	Thousand Oaks	California	91320	USA
gefitinib	Iressa	8/26/14	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer	Designated/Approved	Approved for Orphan Indication	For the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test	07/13/2015	07/13/2022	AstraZeneca Pharmaceuticals LP	1800 Concord Pike	P. O. Box 8355	Wilmington	Delaware	19803	USA
gemcabene	n/a	2/6/14	Treatment of homozygous familial hypercholesterolemia	Designated			N/A	N/A	"Gemphire Therapeutics, Inc."	43334 Seven Mile Rd	Suite 1000	Northville	Michigan	48167	USA
gemcitabine	n/a	12/30/15	Treatment of upper tract urothelial carcinoma	Designated			N/A	N/A	TARIS Biomedical LLC	113 Hartwell Avenue		Lexington	Massachusetts	2421	USA
gemcitabine	n/a	1/11/16	Treatment of cholangiocarcinoma.	Designated			N/A	N/A	"InnoPharmax, Inc."	"9F, No. 22, Lane 478"	Rueiguang Road	Taipei			Taiwan
gemcitabine ready-to-use	n/a	6/24/15	Treatment of pancreatic cancer	Designated			N/A	N/A	Sun Pharmaceutical Industries Ltd.	Acme Plaza	"Andheri (East), Mumbai 400059"				India
gemcitabine ready-to-use	n/a	6/24/15	Treatment of ovarian cancer	Designated			N/A	N/A	Sun Pharmaceutical Industries Ltd.	Acme Plaza	"Andheri (East), Mumbai 400059"				India
Gemtuzumab ozogamicin	Mylotarg	11/24/99	Treatment of acute myeloid leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy	05/17/2000	05/17/2007	"Wyeth Pharmaceuticals, Inc., a Pfizer Company"	10646 Science Center Drive		San Diego	California	92121	USA
gene encoding chimeric CD40 ligand	n/a	2/4/09	Treatment of chronic lymphocytic leukemia	Designated			N/A	N/A	"Memgen, LLC"	402 W. Broadway	Suite 400	San Diego	California	92101	USA
genetically engineered herpes simplex virus (G207)	n/a	4/29/02	Treatment of malignant glioma	Designated			N/A	N/A	"Aettis, Inc."	128 Penarth Road		Bala Cynwyd	Pennsylvania	19004	USA
Genetically engineered human recombinant IgG4 monoclonal antibody directed against human TNF alpha	n/a	12/11/97	Treatment of Crohn's disease.	Designated			N/A	N/A	Celltech Chiroscience Limited	216 Bath Road	Berkshire				United Kingdom
Geneticin	n/a	6/6/05	Treatment of amoebiasis.	Designated			N/A	N/A	"ProcesScience, Inc (PSI)"	117 Woodberry Lane		Fayetteville	New York	13066	USA
gentamicin C2 congener	n/a	3/29/16	Treatment of cystic fibrosis	Designated			N/A	N/A	La Jolla Pharmaceuticals Company	10182 Telesis Court	Suite 600	San Diego	California	92121	USA
Gentamicin impregnated PMMA beads on surgical wire	Septopal	1/31/91	"Treatment of chronic osteomyelitis of post-traumatic, postoperative, or hematogenous origin."	Designated			N/A	N/A	"Lipha Pharmaceuticals, Inc."	9 West 57th Street	Suite 3825	New York	New York	10019	USA
Gentamicin liposome injection	Maitec	7/10/90	Treatment of disseminated Mycobacterium avium-intracellulare infection.	Designated			N/A	N/A	"Liposome Company, Inc."	One Research Way		Princeton	New Jersey	8540	USA
gevokizumab	n/a	2/21/14	Treatment of pyoderma gangrenosum	Designated			N/A	N/A	XOMA (US) LLC	2910 Seventh St.		Berkeley	California	94710	USA
gevokizumab	n/a	7/27/10	Treatment of Behcet's disease	Designated			N/A	N/A	XOMA (US) LLC	2910 Seventh St.		Berkeley	California	94710	USA
gevokizumab	n/a	8/20/12	"Treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis"	Designated			N/A	N/A	XOMA (US) LLC	2910 Seventh St.		Berkeley	California	94710	USA
Girentuximab	Rencarex	3/22/01	Treatment of renal cell carcinoma.	Designated			N/A	N/A	Wilex Biotechnology GmbH	Grillparzerstrasse 10B	81675 Munich				Germany
givinostat	n/a	4/12/13	Treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy	Designated			N/A	N/A	Italfarmaco SpA	"Via dei Lavoratori, 54"	20092 Cinisello Balsamo				Italy
Glatiramer acetate	Copaxone	11/9/87	Treatment of multiple sclerosis.	Designated/Approved	Approved for Orphan Indication	For reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis.	12/20/1996	12/20/2003	Teva Pharmaceuticals USA	1510 Delp Drive		Kulpsville	Pennsylvania	19443	USA
glatiramer acetate	Copaxone	11/14/07	Treatment of amyotrophic lateral sclerosis (ALS).	Designated			N/A	N/A	"Teva Neurosciences, Inc."	P. O. Box 1005		Horsham	Pennsylvania	19044	USA
Glatiramer acetate for injection	Copaxone	6/5/01	Treatment of primary-progressive multiple sclerosis	Designated			N/A	N/A	Teva Pharmaceuticals USA	1090 Horsham Road		North Wales	Pennsylvania	19454	USA
glecaprevir and pibrentasvir	n/a	1/9/17	Treatment of pediatric patients with chronic hepatitis C virus infection	Designated			N/A	N/A	"AbbVie, Inc."	1 Waukegan Road		North Chicago	Illinois	60044	USA
glibentek (glibenclamide oral suspension)	n/a	6/8/16	Treatment of neonatal diabetes (monogenic forms of diabetes that present in infancy)	Designated			N/A	N/A	AMMTeK	15 Rue Branger		Paris			France
glioma derived cell lysates and irradiated cells	n/a	1/12/11	Treatment of glioma.	Designated			N/A	N/A	Epitopoietic Research Corp.	1055 E. Colorado Blvd		Pasadena	California	91160	USA
glucagon	n/a	12/5/12	Prevention of hypoglycemia in the congenital hyperinsulinism population	Designated			N/A	N/A	"Biodel, Inc."	100 Saw Mill Road		Danbury	Connecticut	6810	USA
glucagon infusion	G-Pump (Tm)	9/25/14	"Prevention of chronic, severe hypoglycemia related to congential hyperinsulinism"	Designated			N/A	N/A	"Xeris Pharmaceuticals, Inc."	3208 Red River Street	Suite 300	Austin	Texas	78705	USA
glucarpidase	Voraxaze	8/19/03	Treatment of patients at risk of methotrexate toxicity	Designated/Approved	Approved for Orphan Indication	Treatment of toxic (>1 micromole/liter) plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function.	01/17/2012	01/17/2019	BTG International Inc.	5214 Maryland Way	Suite 405	Brentwood	Tennessee	37027	USA
glufosfamide	n/a	9/18/06	For treatment of pancreatic cancer.	Designated			N/A	N/A	Eleison Pharmaceuticals LLC	263 13th Avenue	Suite 375	St. Petersburg	Florida	33701	USA
Glutamine	Nutrestore	3/6/95	For use with human growth hormone in the treatment of short bowel syndrome (nutrient malabsorption from the gastrointestinal tract resulting from an inadequate absorptive surface).	Designated/Approved	Approved for Orphan Indication	Treatment of short bowel syndrome in patients receiving specialized nutritional support when used in conjunction with a recombinant human growth hormone that is approved for this indication.	06/10/2004	06/10/2011	"Emmaus Medical, Inc."	20725 S. Western Avenue	Suite 136	Torrence	California	90501	USA
glutathione	Arina-1	12/12/16	Treatment of lung dysfunction following lung transplant	Designated			N/A	N/A	"Renovion, Inc."	2 Briar Bridge Lane		Chapel Hill	North Carolina	27516	USA
Glutathione pegylated liposomal doxorubicin hydrochloride	n/a	8/16/10	Treatment of glioma	Designated			N/A	N/A	to-BBB technologies BV	"Niels Bohrweg 11, 2333 CA Leiden"					Netherlands
glyburide	n/a	2/8/16	Treatment of acute subarachnoid hemorrhage	Designated			N/A	N/A	"Remedy Pharmaceuticals, Inc."	"233 Broadway, Suite 1750"		New York	New York	10279	USA
Glyburide	Cirara	1/12/17	Treatment of severe cerebral edema in patients with acute ischemic stroke	Designated			N/A	N/A	"Remedy Pharmaceuticals, Inc."	"233 Broadway, Suite 1750"		New York	New York	10279	USA
glyburide	n/a	9/29/15	Treatment of acute spinal cord injury	Designated			N/A	N/A	"Remedy Pharmaceuticals, Inc."	"233 Broadway, Suite 1750"		New York	New York	10279	USA
glycafilin	n/a	8/22/08	Prevention of delayed graft function after solid organ transplantation	Designated			N/A	N/A	ProtAffin Biotechnologie AG	Impulszentrum Graz - West	A-8020 Graz				Austria
Glyceol	n/a	2/22/90	To decrease intracranial hypertension and/or alleviate cerebral edema in patients who may benefit from osmotherapy.	Designated/Withdrawn			N/A	N/A	"Chugai Pharmaceutical Co., Ltd."						
glycerol phenylbutyrate	Ravicti	4/27/09	Maintenance treatment of patients with deficiencies in enzymes of the urea cycle	Designated/Approved	Approved for Orphan Indication	"Use as a nitrogen-binding adjunctive therapy for chronic management of adult and pediatric patients at least 2 years of age with urea cycle disorders (UCDs) that cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (eg, essential amino acids, arginine, citrulline, protein-free calorie supplements)."	02/01/2013	02/01/2020	"Horizon Pharma, Inc."	150 S. Saunders Road	Suite 400	Lake Forest	Illinois	60045	USA
Glyceryl tri (4-phenylbutyrate)	n/a	5/24/05	Treatment of spinal muscular atrophy	Designated			N/A	N/A	"Ucyclyd Pharma, Inc"	Subsidiary of Medicis Pharmaceutical Corporation	7720 N. Dobson Road	Scottsdale	Arizona	85256	USA
Glyceryl trioleate and glyceryl trierucate	n/a	2/14/95	Treatment of adrenoleukodystrophy.	Designated			N/A	N/A	"Moser, Hugo W. M.D."	Johns Hopkins University	"Kennedy Krieger Institute, 707 North Broadway"	Baltimore	Maryland	21205	USA
glycopyrrolate	Cuvposa	6/9/06	Treatment of pathologic (chronic moderate to severe) drooling in pediatric patients	Designated/Approved	Approved for Orphan Indication	To reduce chronic drooling in patients aged 3 - 16 with neurologic conditions associated with problem drooling (e.g. cerebral palsy)	07/28/2010	07/28/2017	"Shionogi, Inc."	300 Campus Drive		Florham	New Jersey	7932	USA
glycopyrrolate 2%	n/a	6/17/10	Treatment of Frey's syndrome	Designated			N/A	N/A	"Wellesley Therapeutics, Inc."	"200 Gerrard St., East"	"Toronto, Ontario M5A 2E6"				Canada
glycosylated recombinant human interleukin-7	n/a	9/27/12	Treatment of progressive multifocal leukoencephalopathy	Designated			N/A	N/A	"Cytheris, Inc."	1700 Rockville Pike	Suite 230	Rockville	Maryland	20852	USA
glycyl-L-2-methylprolyl-L-glutamic Acid	n/a	10/23/13	Treatment of Fragile X Syndrome	Designated			N/A	N/A	"Neuren Pharmaceuticals, Ltd."	"Level 1, 57 Wellington Street"	Auckland 1011				New Zealand
glycyl-L-2-methylpropyl-L-glutamic acid	n/a	2/11/15	Treatment of Rett syndrome	Designated			N/A	N/A	"Neuren Pharmaceuticals, Ltd."	"Level 1, 57 Wellington Street"	Auckland 1011				New Zealand
Glyeraldehyde-3-phosphate dehydrogenase	Proenzy	4/30/10	Treatment of pediatric multiple sclerosis	Designated			N/A	N/A	"BPT Pharmaceuticals, Inc."	743 North Sweetzer Avenue #103		Los Angeles	California	90069	USA
GNE Lipoplex	n/a	11/13/08	Treatment of hereditary inclusion body myopathy-2	Designated			N/A	N/A	"Gradalis, Inc."	2545 Golden Bear Drive		Carrollton	Texas	75006	USA
GNE plasmid(H001)	n/a	3/26/10	Treatment of hereditary inclusion body myopathy type 2	Designated			N/A	N/A	HIBM Research Group	18341 Sherman Way #201A		Reseda	California	91335	USA
golimumab	Simponi	3/16/12	Treatment of pediatric ulcerative colitis	Designated			N/A	N/A	"Janssen Biotech, Inc."	800 & 850 Ridgeview Drive		Horsham	Pennsylvania	19044	USA
golimumab	Simponi Aria	4/2/15	Treatment of polyarticular juvenile idiopathic arthritis in patients 0 through 18 years of age.	Designated			N/A	N/A	"Janssen Research & Development, LLC"	Welsh & McKean Roads	P. O. Box 776	Spring House	Pennsylvania	19477	USA
golimumab	Simponi Aria	5/21/12	Treatment of sarcoidosis	Designated/Withdrawn			N/A	N/A	"Janssen Biotech, Inc."	Welsh & McKean Roads	P.O. Box 776	Spring House	Pennsylvania	19477	USA
golimumab	n/a	11/2/04	Treatment of chronic sarcoidosis	Designated/Withdrawn			N/A	N/A	"Centocor, Inc."	200 Great Valley Parkway		Malvern	Pennsylvania	19355	USA
golnerminogene pradenovec	Tnferade(Tm) Biologic	10/28/09	Treatment of pancreatic cancer.	Designated			N/A	N/A	"GenVec, Inc."	65 West Watkins Mill Road		Gaithersburg	Maryland	20878	USA
Gonadorelin acetate	Lutrepulse	4/22/87	For induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion.	Designated/Approved	Approved for Orphan Indication		10/10/1989	10/10/1996	"Ferring Laboratories, Inc."	"400 Rella Boulevard, Suite 201"		Suffern	New York	10901	USA
Gossypol	n/a	10/22/90	Treatment of cancer of the adrenal cortex.	Designated			N/A	N/A	"Reidenberg, Marcus M. M.D."	The New York Hospital - Cornell Medical Center	"525 East 68th Street, Box 70"	New York	New York	10021	USA
Gp100 adenoviral gene therapy	n/a	3/25/97	Treatment of metastatic melanoma.	Designated			N/A	N/A	Genzyme Corporation	500 Kendall Street		Cambridge	Massachusetts	2142	USA
granulocyte macrophage colony stimuling factor	n/a	8/27/08	Treatment of cystic fibrosis	Designated			N/A	N/A	Savara Inc.	900 S. Capital Texas Highway	Suite 150	Austin	Texas	78746	USA
Granulocyte macrophage-colony stimulating factor	Leucomax	12/12/89	Treatment of neutropenia associated with bone marrow transplants.	Designated/Withdrawn			N/A	N/A	Schering Corporation	2000 Galloping Hill Road		Kenilworth	New Jersey	7033	USA
Granulocyte macrophage-colony stimulating factor	Leucomax	5/4/90	Treatment of chronic lymphocytic leukemia to increase granulocyte count.	Designated/Withdrawn			N/A	N/A	Schering Corporation	2000 Galloping Hill Road		Kenilworth	New Jersey	7033	USA
Granulocyte macrophage-colony stimulating factor	Leucomax	5/3/90	Treatment of neutropenia due to hairy cell leukemia.	Designated/Withdrawn			N/A	N/A	Schering Corporation	2000 Galloping Hill Road		Kenilworth	New Jersey	7033	USA
Granulocyte macrophage-colony stimulating factor	Leucomax	6/6/89	Treatment of severe thermal injuries in patients with greater than 40% full or partial thickness burns.	Designated/Withdrawn			N/A	N/A	Schering Corporation	2000 Galloping Hill Road		Kenilworth	New Jersey	7033	USA
Granulocyte macrophage-colony stimulating factor	Leucomax	8/7/89	Treatment of myelodysplastic syndrome.	Designated/Withdrawn			N/A	N/A	Schering Corporation	2000 Galloping Hill Road		Kenilworth	New Jersey	7033	USA
"granulocyte-macrophage colony stimulating factor-coding oncolytic adenovirus, Ad5/3-D24-GMCSF"	n/a	7/24/13	Treatment of soft tissue sarcoma	Designated			N/A	N/A	Oncos Therapeutics	Saukonpaadenranta 2		Helsinki			Finland
Group B streptococcus immune globulin	n/a	5/8/90	Treatment of neonates for disseminated group B streptococcal infection.	Designated/Withdrawn			N/A	N/A	"North American Biologicals, Inc."	12280 Wilkins Avenue		Rockville	Maryland	20852	USA
Growth hormone releasing factor	n/a	8/7/89	For the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Designated			N/A	N/A	Valeant Pharmaceuticals North America	700 Route 202/206		Bridgewater	New Jersey	8807	USA
"growth hormone releasing hormone, 1-44 human amide"	n/a	2/23/16	Treatment of growth hormone deficiency	Designated			N/A	N/A	"Hollenbeck Pharmaceuticals, Inc."	P. O. Box 429		Falls Village	Connecticut	6031	USA
guadecitabine	n/a	9/29/15	Treatment of acute myeloid leukemia.	Designated			N/A	N/A	"Astex Pharmaceuticals, Inc."	4420 Rosewood Drive	Suite 200	Pleasanton	California	94588	USA
Guanethidine monosulfate	Ismelin	1/6/86	Treatment of moderate to severe reflex sympathetic dystrophy and causalgia.	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceuticals Corporation	59 Route 10		East Hanover	New Jersey	7936	USA
guanfacine	Tenex	8/5/99	Treatment of fragile X syndrome.	Designated			N/A	N/A	"Watson Laboratories, Inc."	311 Bonnie Circle	P.O. Box 1900	Corona	California	91718	USA
guanfacine and amphetamine	n/a	3/17/16	Treatment of pediatric patients with Tourette's syndrome (0 through 16 years of age)	Designated			N/A	N/A	"Genco Sciences, LLC"	1011 Greenwood Avenue		Willmette	Illinois	60091	USA
Gusperimus	Spanidin	6/27/96	Treatment of acute renal graft rejection episodes.	Designated/Withdrawn			N/A	N/A	Bristol-Myers Squibb Pharmaceutical Research Institute	5 Research Parkway	P.O. Box 5100	Wallingford	Connecticut	6492	USA
gusperimus trihydrochloride	n/a	6/29/11	Treatment of Wegener's granulomatosis	Designated			N/A	N/A	Nordic Group B.V.	Siriusdreef 22	2132 WT Hoofdorp				Netherlands
GVAX melanoma	n/a	12/23/10	Treatment of stage IIb to IV melanoma	Designated			N/A	N/A	"Aduro BioTech, Inc."	740 Heinz Avenue		Berkeley	California	94710	USA
gylceryl tri (4-pheynlybutyrate)	n/a	9/3/09	For intermittent or chronic treatment of patients with cirrhosis and any grade hepatic encephalopathy.	Designated			N/A	N/A	"Horizon Therapeutics, Inc."	520 Lake Cook Road	Suite 520	Deerfield	Illinois	60015	USA
H-(4-amino-3-iodo)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2	n/a	11/3/16	Treatment of acromegaly	Designated			N/A	N/A	Amryt Research Ltd.	18 Fitzwilliam Place		Dublin			Ireland
H-(D)p-Benzoylphenylalanyl-(D)seryl-(D)tryptophanyl-(D)seryl-(D)pentafluorophenylalanyl-(D)cyclohexylalanyl-(D)arginyl-(D)arginyl-(D)arginyl-(D)glutaminyl-(D)arginyl-(D)arginine acetate salt	n/a	12/22/11	For use in combination with cisplatin and pemetrexed for the treatment of patients with mesothelioma	Designated			N/A	N/A	"CanBas Company, Ltd."	2-2-1 Otemachi		"Numazu City, Shizuoka"			Japan
H-Leu-Pro-Pro-Ser-Arg-OH	n/a	9/20/12	Treatment of Kaposi sarcoma	Designated			N/A	N/A	"Immuno Tech, Inc."	"6329 256th Street, NE"		Arlington	Washington	98223	USA
H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-alys-aleu-Ser-Ser-Ile-Glu-Ser-Asp-Val-OH	n/a	5/14/13	Treatment of subarachnoid hemorrhage	Designated			N/A	N/A	"NoNO, Inc."	399 Bathurst Street	Toronto M5T 2S8	Ontario			Canada
H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-Glu- Ser-Asp-Val-OH	n/a	4/11/14	Treatment of acute ischemic stroke patients presenting within 3 hours of symptom onset	Designated			N/A	N/A	"NoNO, Inc."	399 Bathurst Street	Suite 4W-435	Toronto			Canada
Halofantrine	Halfan	11/4/91	Treatment of mild to moderate acute malaria caused by susceptible strains of P. falciparum and P. vivax.	Designated/Approved	Approved for Orphan Indication	Treatment of adults who can tolerate oral medication and who have mild to moderate malaria caused by Plasmodium falciparum or Plasmodium vivax.	07/24/1992	07/24/1999	SmithKline Beecham Pharmaceuticals	One Franklin Plaza	P.O. Box 7929	Philadelphia	Pennsylvania	19101	USA
Halofuginone	Stenorol	2/7/00	Treatment of systemic sclerosis.	Designated			N/A	N/A	Collgard Biopharmaceuticals Ltd.	"Textile House, 2 Koifman St."	Tel-Aviv 68012				Israel
halofuginone hydrobromide	n/a	10/13/11	Treatment of Duchenne Muscular Dystrophy	Designated			N/A	N/A	"Halo Theraeputics, LLC"	Riverside Center	Suite 2-400	Newton	Massachusetts	2466	USA
Hanferon	Hanferon	3/9/12	Treatment of Behcet's disease	Designated			N/A	N/A	"HanAll BioPharma Co., Ltd."	Jamsil I-Space Building 6F	138 420	Seoul			"Korea, Republic of"
Hantaan virus and Puumala virus DNA vaccines	n/a	11/13/12	Prevention of hemorrhagic fever with renal syndrome caused by Hantaan virus and Puumala virus	Designated			N/A	N/A	Surgeon General of the U. S. Army	1430 Veterans Drive	ATTN: USAMR and MC	Fort Detrick	Maryland	21702	USA
HDF-LV-RTS-MMP1 (human dermal fibroblasts genetically modified with LV-RTS-MMP1) and Veledimex	n/a	4/19/16	Treatment of localized scleroderma.	Designated			N/A	N/A	"Fibrocell Technologies, Inc."	405 Eagleview Blvd		Exton	Pennsylvania	19341	USA
heat killed mycobacterium w immunomodulator	Cadi Mw	11/21/02	Adjuvant to multi-drug therapy in the management of multibacillary leprosy	Designated			N/A	N/A	"CPL, Inc."	16020 Swingley Ridge Road	Suite 145	Chesterfield	Missouri	63017	USA
heat killed Mycobacterium w immunomodulator	Cadi Mw	9/3/04	Active tuberculosis	Designated			N/A	N/A	"Cadila Pharmaceuticals Limited, Inc."	9801 Washingtonian Blvd	Suite 220	Gaithersburg	Maryland	20878	USA
heat killed mycobacterium w immunomodulator	Cadi-Mw	7/31/12	Treatment of non-small cell lung cancers that express desmocollin-3	Designated			N/A	N/A	Cadila Pharmaceuticals Limited	"Sarkhej-Dholka Road, Bhat"	Ahmedabad - 382210	Gujarat			India
heat killed whole cell mycobacterium obuense	n/a	9/23/14	Treatment of pancreatic cancer	Designated			N/A	N/A	Immodulon Therapeutics Limited	22 Devonshire Place	"B2, London W1G 6JA"				United Kingdom
Heat Shock Protein (hsp60) antigen	Diapep277	5/21/12	For use in type 1 diabetic mellitus patients with residual beta-cell function	Designated/Withdrawn			N/A	N/A	"AndromedA Biotech, LTD"	42 Hayarkon St.		Yavne 81227			Israel
Heat Shock Protein 70	n/a	3/18/11	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	"ALS Biopharma, LLC"	3805 Old Easton Rd		Doylestown	Pennsylvania	18902	USA
hematopoietic stem and progenitor cells expanded ex-vivo with a low molecular weight aryl hydrocarbon receptor (AHR) antagonist	n/a	8/27/14	Hematopoietic support in patients with acute lymphoblastic leukemia (ALL)	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
hematopoietic stem cells modified with a lentiviral vector containing the CD18 (Integrin Beta 2) gene	Ladilen	11/9/16	Treatment of leukocyte adhesion deficiency Type I	Designated			N/A	N/A	Centro de Investigacion Biomedica en Red (CIBER)	Montforte de Lemos	3-5 Pabellon 11	Madrid			Spain
Heme arginate	Normosang	3/1/94	Treatment of myelodysplastic syndromes.	Designated			N/A	N/A	Orphan Europe	Immeuble Le Wilson	"70 avenue du General de Gaulle,"	92800 Puteaux			France
Heme arginate	Normosang	3/10/88	Treatment of symptomatic stage of acute porphyria.	Designated			N/A	N/A	Orphan Europe SARL	Immeuble Le Wilson	70 avenue du General de Gaulle	92800 Puteaux			France
Hemin	Panhematin	3/16/84	"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria."	Designated/Approved	Approved for Orphan Indication		07/20/1983	07/20/1990	Abbott Laboratories	Diagnostics Division		Abbott Park	Illinois	60064	USA
Hemin and zinc mesoporphyrin	Hemex	12/20/93	Treatment of acute porphyric syndromes.	Designated			N/A	N/A	"Bonkovsky, Herbert L. M.D."	University Of Massachusetts Medical Center	55 Lake Avenue North	Worcester	Massachusetts	1655	USA
Hemoximer (pyridoxalated hemoglobin polyoxyethylene)	n/a	12/18/07	Treatment of cardiogenic shock	Designated			N/A	N/A	"Apex Bioscience, Inc."	109 Conner Drive	`	Chapel Hill	North Carolina	27514	USA
heparan sulfate mimetic	n/a	5/29/14	Treatment of pancreatic cancer	Designated			N/A	N/A	"Momenta Pharmaceuticals, Inc."	675 West Kendall Street		Cambridge	Massachusetts	2142	USA
Heparin	n/a	11/3/05	Treatment of cystic fibrosis	Designated/Withdrawn			N/A	N/A	"Vectura Group, Inc."	1 Prospect West	Wiltshire SN14 6FH				United Kingdom
heparin activated recombinant human fibroblast growth factor 1 (FGF1)in combination with a surgically implanted biodegradable device	n/a	10/24/11	Treatment of patients with a confirmed traumatic complete spinal cord injury where no motor or sensory function is preserved below the injury(Scale A)	Designated			N/A	N/A	BioArctic Neuroscience AB	"Warfvinges vag 39, SE-112 51"		Stockholm			Sweden
Heparin sodium	n/a	6/29/06	Treatment of cystic fibrosis	Designated			N/A	N/A	Ockham Biotech Limited	Manor Farm	"Swanwick, Hampshire SO31 7HA"				United Kingdom
Heparin-binding epidermal growth factor-like growth factor	n/a	9/18/06	"Prevention and treatment of necrotizing enterocolitis (NEC) in preterm infants with birth weight less than 1,500 grams"	Designated			N/A	N/A	"Trillium Therapeutics, Inc."	96 Skyway Avenue	M9W 4Y4				Canada
hepatitis B immune globulin (human)	Hepagam	3/24/08	Prevention of hepatitis B recurrence following orthotopic liver transplant	Designated/Approved	Approved for Orphan Indication	Prevention of hepatitis B recurrence following liver transplantation in HBsAG-positive liver transplant patients	04/06/2007	04/06/2014	Cangene Corporation	155 Innovation Drive					Canada
Hepatitis B immune globulin intravenous (human)	Nabi-Hb	3/8/95	Prophylaxis against hepatitis B virus reinfection in liver transplant patients.	Designated			N/A	N/A	Biotest Pharmaceuticals Corporation	"5800 Park of Commerce Blvd., NW"		Boca Raton	Florida	33487	USA
hepatitis B virus neutralizing human monoclonal antibody	Hepabig Gene	5/6/13	Prevention of hepatitis B recurrence following liver transplantation	Designated			N/A	N/A	Green Cross Corp.	"303, Bojeong-Dong, Giheung-Gu"	"Gyunggi-Do, 446-770"				"Korea, Republic of"
Hepatitis C virus immune globulin (human)	Civacir(Tm)	11/14/02	Prophylaxis of hepatitis C infection in liver transplant recipients.	Designated			N/A	N/A	Biotest Pharmaceuticals Corporation	"5800 Park of Commerce Blvd, NW"		Boca Raton	Florida	33487	USA
hepcortespenlisimut-L	n/a	12/17/14	Treatment of hepatocellular carcinoma	Designated			N/A	N/A	"Immunitor, Inc."	365-2906 West Broadway	"Vancouver, BC, V6K 2G8"				Canada
herpes simplex type 1 virus containing cellular B-myb gene as tumor-specific promoter	n/a	12/23/14	Treatment of pancreatic cancer	Designated			N/A	N/A	Karcinolys S.A.S.	"16, rue des Pervenches"	92500 Rueil-Mamaison				France
Herpes simplex virus gene	n/a	10/16/92	Treatment of primary and metastatic brain tumors.	Designated			N/A	N/A	"Genetic Therapy, Inc."	938 Clopper Road		Gaithersburg	Maryland	20878	USA
heterologous human adult liver derived progenitor cells (HHALPC)	n/a	1/13/12	Treatment of urea cycle disorders	Designated			N/A	N/A	Promethera Biosciences	Watson & Crick Hill	B-1435 Mont-Saint-Guibert				Belgium
heterologous human liver derived progenitor cells	n/a	3/9/12	Treatment of Crigler-Najjar syndrome	Designated			N/A	N/A	Promethera Biosciences	Watson & Crick Hill	B-1435 Mont-Saint-Guibert				Belgium
hexasodium phytate	n/a	12/2/12	Treatment of calciphylaxis	Designated			N/A	N/A	"Laboratoris Sanifit, S.L."	Parc Bit - Building Disset - Office D3	07121 Palma de Mallorca				Spain
"high molecular weight multimer of E3-Fc, an endostatin C-terminus and IgG1-Fc fusion protein"	n/a	6/27/16	Treatment of systemic sclerosis	Designated			N/A	N/A	"iBio, Inc."	600 Madison Avenue	Suite 1601	New York	New York	10022	USA
HIRMAb-IDS	n/a	5/15/13	Treatment of mucopolysaccharidosis Type II (Hunter Syndrome)	Designated			N/A	N/A	"ArmaGen Technologies, Inc."	914 Colorado Avenue		Santa Monica	California	90401	USA
His-D-Trp-Ala-Trp-D-Phe-Lys NH2	n/a	5/23/90	For the long term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Designated/Withdrawn			N/A	N/A	SmithKline Beecham Pharmaceuticals	One Franklin Plaza		Philadelphia	Pennsylvania	19101	USA
His-His- Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr-NH2	n/a	1/13/16	Treatment of retinal detachment	Designated			N/A	N/A	"ONL Therapeutics, Inc"	1600 Huron Parkway	Second Floor	Ann Arbor	Michigan	48109	USA
His-His-Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr	n/a	3/11/13	Treatment of retinal detachment	Designated			N/A	N/A	"ONL Therapeutics, Inc"	1600 Huron Parkway	Second Floor	Ann Arbor	Michigan	48109	USA
Histamine	Maxamine	2/1/00	For use as an adjunct to cytokine therapy in the treatment of malignant melanoma.	Designated			N/A	N/A	EpiCept Corporation	777 Old Saw Mill River Road		Tarrytown	New York	10591	USA
Histamine	Ceplene	12/15/99	Adjunct to cytokine therapy in the treatment of acute myeloid leukemia.	Designated			N/A	N/A	EpiCept Corporation	777 Old Saw Mill River Road		Tarrytown	New York	10591	USA
Histrelin	n/a	5/3/91	"Treatment of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria."	Designated			N/A	N/A	"Anderson, Karl E., M.D."	University of Texas Medical Branch at Galveston	"Route J-09, 700 The Strand"	Galveston	Texas	77550	USA
Histrelin	Supprelin La	11/18/05	Treatment of central precocious puberty	Designated/Approved	Approved for Orphan Indication	Treatment of central precocious puberty	05/03/2007	05/03/2014	"Endo Pharmaceuticals Solutions, Inc."	100 Endo Blvd		Chadds Ford	Pennsylvania	19317	USA
Histrelin acetate	Supprelin Injection	8/10/88	Treatment of central precocious puberty.	Designated/Approved	Approved for Orphan Indication	Treatment of central precocious puberty.	12/24/1991	12/24/1998	Roberts Pharmaceutical Corp.	Meridian Center III	6 Industrial Way West	Eatontown	New Jersey	7724	USA
HIV neutralizing antibodies	Immupath	3/24/92	Treatment of acquired immunodeficiency syndrome.	Designated/Withdrawn			N/A	N/A	Hemacare Corporation	4954 Van Nuys Boulevard		Sherman Oaks	California	91403	USA
HLA-A2-selective gp100-specific T cell redirector	n/a	1/21/16	Treatment of uveal melanoma.	Designated			N/A	N/A	Immunocore Ltd	Milton Park	90 Park Drive	Milton			United Kingdom
HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex	Allovectin-7	9/30/99	"Treatment of invasive and metastatic melanoma (Stages II, III, and IV)."	Designated			N/A	N/A	Vical Incorporated	"9373 Towne Centre Dr., Suite 100"		San Diego	California	92121	USA
homoharringtonine	n/a	2/8/02	Treatment for chronic myelogenous leukemia	Designated			N/A	N/A	"American BioScience, Inc."	2730 Wilshire Blvd. #110		Santa Monica	California	90403	USA
HPV-16 cancer therapeutic trojan peptide vaccine	n/a	1/12/09	Treatment of HPV-16 expressing head and neck squamous cell carcinoma.	Designated			N/A	N/A	"Gliknik, Inc."	801 W. Baltimore Street		Baltimore	Maryland	21201	USA
HPV16 E6/E7 synthetic long peptides vaccine	n/a	9/1/11	Treatment of epithelial neoplasias of the vulva positive for human papilloma virus type 16.	Designated			N/A	N/A	ISA Therapeutics BV	J.H. Oortweg 19	2333 CH Leiden				Netherlands
"Hu1D10, humanized monoclonal antibody"	Remitogen	11/28/01	For use in the treatment of 1D10+ B cell non-Hodgkin's lymphoma	Designated			N/A	N/A	"PDL BioPharma, Inc."	34801 Campus Drive		Fremont	California	94555	USA
"Human acid precursor alpha-glucosidase, recombinant"	n/a	9/10/96	Treatment of glycogen storage disease type II.	Designated/Withdrawn			N/A	N/A	Pharming/Genzyme LLC	c/o Genzyme Corporation	1 Mountain Rd.	Framingham	Massachusetts	1701	USA
human allogeneic bone marrow derived osteoblastic cells	Allob	1/10/14	Treatment of osteonecrosis	Designated			N/A	N/A	Bone Therapeutics SA	"8, rue Adrienne Bolland"	6041 Gosselies				Belgium
human allogeneic bone marrow derived osteoblastic cells	n/a	11/9/15	Treatment of osteogenesis imperfecta.	Designated			N/A	N/A	Bone Therapeutics SA	"37, Rue Auguste Piccard"	Gosselies	Gosselies			Belgium
"Human Allogeneic HLA-matched, Umbilical Cord Blood Hematopoietic Progenitor Cells Ex Vivo Expanded on Allogeneic Mesenchymal Precursor Cells"	n/a	9/12/08	Treatment of insufficient hematopoietic stem cell production in patients with hematologic malignancies who have failed treatment with conventional chemotherapy.	Designated			N/A	N/A	"Mesoblast, Inc."	275 Madison Avenue	4th Floor	New York	New York	10016	USA
"Human alpha 2,6 sialyltransferase adenoviral gene therapy"	n/a	4/4/05	"Treatment of patients with invasive (malignant) brain and central nervous system tumors lacking alpha 2,6 sialyltransferase."	Designated			N/A	N/A	Falk Center for Molecular Therapeutics	1801 Maple Avenue	Suite 4300	Evanston	Illinois	60201	USA
Human anti-CD30 monoclonal antibody	n/a	9/27/04	Treatment of Hodgkin's disease	Designated			N/A	N/A	"Bristol-Myers Squibb, Inc."	519 Route 173 West		Bloomsbury	New Jersey	8804	USA
human anti-CD4 monoclonal antibody	Humax-Cd4	8/13/04	Treatment of mycosis fungoides	Designated			N/A	N/A	"Emergent Product Development Seattle, LLC"		2401 Fourth Avenue	Seattle	Washington	98121	USA
human anti-cellular adhesion molecule-1 monoclonal antibody	n/a	7/29/08	Treatment of multiple myeloma	Designated			N/A	N/A	BioInvent International AB	Solvegatan 41					Sweden
Human anti-integrin receptor av monoclonal antibody	n/a	5/5/05	Treatment of patients with angiosarcoma	Designated/Withdrawn			N/A	N/A	"Janssen Research & Development, LLC"	920 Route 202 South		Raritan	New Jersey	8869	USA
human anti-integrin receptor avb3/avb5 monoclonal antibody	n/a	12/1/04	"Treatment of patients with high-risk stage II, stage III, and stage IV malignant melanoma"	Designated/Withdrawn			N/A	N/A	"Janssen Research & Development, LLC"	920 Route 202 South		Raritan	New Jersey	8869	USA
human anti-transforming growth factor beta 1 monoclonal antibody	n/a	1/11/02	Treatment of systemic sclerosis	Designated/Withdrawn			N/A	N/A	Genzyme Corporation	One Kendall Square		Cambridge	Massachusetts	2139	USA
"human anti-transforming growth factor-B1,2,3"	n/a	7/9/04	Treatment of idiopathic pulmonary fibrosis	Designated/Withdrawn			N/A	N/A	Genzyme Corporation	500 Kendall Street		Cambridge	Massachusetts	2142	USA
Human Anti-tumor Necrosis factor alpha monoclonal antibody	n/a	1/16/03	"Treatment of uveitis of the posterior segment of non-infectious etiology, and uveitis of the anterior segment of non-infectious etiology and refractory to conventional therapy"	Designated/Withdrawn			N/A	N/A	"Centocor, Inc."	200 Great Valley Parkway		Malvern	Pennsylvania	19355	USA
Human autologous bone-forming cell derived from bone marrow stem cells	n/a	3/24/08	Treatment of osteonecrosis	Designated			N/A	N/A	Bone Therapeutics S.A.	"Rue Auguste Piccard, 37"		Gosselies			Belgium
human coagulation factor VIII	Octanate	12/3/12	Immune tolerance induction in hemophilia A patients with inhibitors	Designated			N/A	N/A	"OCTAPHARMA USA, Inc."	121 River Street	12th Floor	Hoboken	New Jersey	7030	USA
human coagulation factor XI	Hemoleven	11/8/07	Treatment of severe congential Factor XI deficiency.	Designated/Withdrawn			N/A	N/A	Laboratoire francais du Fractionnement et des Biot	3 Avenue des Tropiques	91985 Courtaboeuf Cedex				France
human cystic fibrosis transmembrane conductance regulator (hCFTR) messenger RNA (mRNA) complexed with branched polyethyleneimine (bPEI)	n/a	11/3/15	Treatment of patients with cystic fibrosis.	Designated			N/A	N/A	Shire	300 Shire Way		Lexington	Massachusetts	2421	USA
Human cytomegalovirus immunoglobulin	n/a	12/20/06	Prevention of congenital cytomegalovirus (CMV) infection following primary CMV infection in pregnant women	Designated			N/A	N/A	Biotest Pharmaceuticals Corporation	"5800 Park of Commerce Blvd, NW"		Boca Raton	Florida	33487	USA
human donor hematopoietic stem and progenitor cells (HSPC) that have been treated ex vivo with TBX-4000	n/a	6/2/16	Enhancement of cell engraftment in patients receiving hematopoietic stem cell transplant.	Designated			N/A	N/A	"Taiga Biotechnologies, Inc."	12635 Montview Boulevard	Fitzsimmons BBioscience Park Center	Aurora	Colorado	80045	USA
Human factor X	Coagadex	11/8/07	Treatment of hereditary factor X deficiency	Designated/Approved	Approved for Orphan Indication	Treatment of patients with hereditary Factor X Deficiency	10/20/2015	10/20/2022	Bio Products Laboratory	Dagger Lane	"Hertfordshire, WD6 3BX"				United Kingdom
"human fibrinogen concentrate, pasteurized"	Riastap	3/13/08	Treatment of fibrinogen deficient patients.	Designated/Approved	Approved for Orphan Indication	Treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia)	01/16/2009	01/16/2016	"CSL Behring, LLC"	1020 First Avenue	P.O. Box 61501	King of Prussia	Pennsylvania	19406	USA
human fully IgG1 antibody specific for CD33	n/a	6/19/14	Treatment of acute myeloid leukemia	Designated			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc."	900 Ridgebury Road	P. O. Box 368	Ridgefield	Connecticut	6877	USA
human gammaglobulin	Oralgam	9/16/02	"Treatment of gastrointestinal disturbances (to include constipation, diarrhea, and abdominal pain) associated with regression-onset autism in pediatric patients."	Designated			N/A	N/A	"Latona Life Sciences, Inc."	10 Village St.		Mills	Massachusetts	2054	USA
human gammaglobulin	Oralgam	5/25/01	Treatment for juvenile rheumatoid arthritis	Designated			N/A	N/A	"Latona Life Sciences, Inc."	10 Village St.		Mills	Massachusetts	2054	USA
human gammaglobulin	Oralgam	11/14/03	Treatment of idiopathic inflammatory myopathies	Designated			N/A	N/A	"Latona Life Sciences, Inc."	10 Village St.		Mills	Massachusetts	2054	USA
human glial restricted progenitor cells and their progeny	Q-Cells	9/11/13	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	"Q Therapeutics, Inc."	615 Arapeen Drive	Suite 102	Salt Lake City	Utah	84108	USA
human haptoglobin	n/a	11/19/13	Treatment of sickle cell disease	Designated			N/A	N/A	BioProducts Laboratory Limited	"Dagger Lane, Elstree"	WD6 3BX				United Kingdom
Human Hemin	n/a	8/6/13	Prevention of ischemia reperfusion injury in patients undergoing solid organ transplantation	Designated			N/A	N/A	Borders Technology Management Ltd	2 Broomlee Mains Court	"Peeblesshire, EH467JG"	Scotland			United Kingdom
human Hepatocarcinoma-Intestine-pancreas/pancreatitis associated protein	n/a	5/11/11	Treatment of acute liver failure	Designated			N/A	N/A	Alfact Innovation SAS	"320, rue Saint Honore"					France
human heterologous liver cells	n/a	2/14/11	Treatment of urea cycle disorders	Designated			N/A	N/A	Promethera Biosciences S.A./N.V.	rue Granbonpre 11	Watson & Crick Hill				Belgium
human IgG1k monoclonal antibody	n/a	10/16/13	Treatment of systemic sclerosis	Designated			N/A	N/A	MedImmune	One MedImmune Way		Gaithersburg	Maryland	20878	USA
Human IgM monoclonal antibody (C-58) To CMV	Centovir	8/7/89	Prophylaxis of cytomegalovirus infections in bone marrow transplant patients.	Designated/Withdrawn			N/A	N/A	"Centocor, Inc."	200 Great Valley Parkway		Malvern	Pennsylvania	19355	USA
Human IgM monoclonal antibody (C-58) To CMV	Centovir	8/7/89	Treatment of cytomegalovirus infections in allogenic bone marrow transplant patients.	Designated/Withdrawn			N/A	N/A	"Centocor, Inc."	200 Great Valley Parkway		Malvern	Pennsylvania	19355	USA
Human immune globulin	Flebogamma(R) 5% Dif	3/29/06	Treatment of post-polio syndrome	Designated			N/A	N/A	"Instituto Grifols, S.A."	"Can Guasch, 2"	08150 Parets del Valles	Barcelona			Spain
Human immunodeficiency virus immune globulin	n/a	11/21/89	Treatment of AIDS.	Designated/Withdrawn			N/A	N/A	NABI	"5800 Park of Commerce Blvd., NW"		Boca Raton	Florida	33487	USA
Human immunodeficiency virus immune globulin	n/a	3/25/92	Treatment of HIV-infected pregnant women and infants of HIV-infected mothers.	Designated/Withdrawn			N/A	N/A	NABI	"5800 Park of Commerce Blvd., NW"		Boca Raton	Florida	33487	USA
Human immunodeficiency virus immune globulin	Hivig	1/4/95	Treatment of HIV-infected pediatric patients.	Designated/Withdrawn			N/A	N/A	NABI	"5800 Park of Commerce Blvd., NW"		Boca Raton	Florida	33487	USA
Human immunoglobin anti-CD30 monoclonal antibody	n/a	1/10/06	Treatment of CD30+ T-cell lymphoma	Designated			N/A	N/A	Bristol-Myers Squibb	519 Route 173 West		Bloombury	New Jersey	8804	USA
human insulin (rDNA)	n/a	4/6/15	Treatment of short bowel syndrome (SBS).	Designated			N/A	N/A	"Nutrinia, Ltd."	"15 Abba Hillel Silver Rd, 7th Floor"	Ramat-Gan 5252208				Israel
human insulin beta chain peptide with incomplete Freund's adjuvant vaccine	n/a	2/11/13	Treatment of Type 1 diabetes patients with residual beta cell function	Designated			N/A	N/A	"Orban Biotech, LLC"	64 Aspinwall Avenue		Brookline	Massachusetts	2446	USA
human interleukin-3 genetically conjugated to diphtheria toxin protein	n/a	2/18/11	Treatment of acute myeloid leukemia.	Designated			N/A	N/A	"Stemline Therapeutics, Inc."	1675 York Avenue		New York	New York	10128	USA
human interleukin-3 genetically conjugated to diphtheria toxin protein	n/a	6/6/13	Treatment of blastic plasmacytoid dendritic cell neoplasm	Designated			N/A	N/A	"Stemline Therapeutics, Inc."	750 Lexington Avenue	11 th Floor	New York	New York	10022	USA
human laminin-111	n/a	9/23/11	Treatment of merosin (laminin-alpha2) deficient congential muscular dystrophy type 1A.	Designated			N/A	N/A	"Prothelia, Inc."	30 Haven Street		Milford	Massachusetts	1757	USA
human leukocyte antigen-A2 restricted peptides	n/a	1/26/15	Treatment of glioma.	Designated			N/A	N/A	"Stemline Therapeutics, Inc."	750 Lexington Avenue	11 th Floor	New York	New York	10022	USA
human leukocyte-derived cytokine mixture	n/a	7/7/05	Neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck	Designated			N/A	N/A	"IRX Therapeutics, Inc."	140 West 57th Street		New York City	New York	10019	USA
human MHC non-restricted cytotoxic T-cell line	n/a	7/6/12	Treatment of ovarian cancer	Designated			N/A	N/A	Galileo Research srl	Via Paradiso 6	56019 Migliarino Pisano	Pisa			Italy
human monoclonal anti-PA antibody	Yervoy	10/21/10	For post-exposure prophylaxis and treatment of inhalation anthrax.	Designated/Approved	Approved for Orphan Indication			N/A	"Emergent Product Development Gaithersburg, Inc."	300 Professional Drive		Gaithersburg	Maryland	20879	USA
Human Monoclonal Antibody against Epidermal Growth Factor Receptor Linked to Monomethylauristatin F	n/a	5/29/14	Treatment of glioblastoma multiforme	Designated			N/A	N/A	"AbbVie, Inc."	1 N. Waukegan Road		North Chicago	Illinois	60064	USA
Human monoclonal antibody against platelet-derived growth factor D	n/a	11/2/04	To slow the progression of IgA nephropathy and delay kidney failure in patients affected by the disease.	Designated			N/A	N/A	CuraGen Corporation	322 East Main Street		Branford	Connecticut	6405	USA
human monoclonal antibody againt human interleukin 13 (IL-13)	n/a	10/15/13	Treatment of eosinophilic esophagitis	Designated			N/A	N/A	Novartis Pharmaceuticals Corporaton	One Health Plaza		East Hanover	New Jersey	7936	USA
human monoclonal antibody directed against active plasma kallikrein	n/a	11/26/13	Treatment of hereditary angioedema (HAE)	Designated			N/A	N/A	Dyax Corporation	55 Network Drive		Burlington	Massachusetts	1803	USA
Human monoclonal antibody directed against human Activin A	n/a	1/19/17	Treatment of fibrodysplasia ossificans progressiva	Designated			N/A	N/A	"Regeneron Pharmaceuticals, Inc."	777 Old Saw Mill River Road		Tarrytown	New York	10591	USA
Human monoclonal antibody directed against serotype 011 Pseudomonas aeruginosa	Aerumab 11	9/18/06	Treatment of hospital acquired pneumonia caused by serotype 011 positive Pseudomonas aeruginosa	Designated			N/A	N/A	Kenta Biotech Limited	Rehhagstrsase					Switzerland
human monoclonal antibody directed against serotype O1 Pseudomonas aeruginosa	n/a	1/6/10	Treatment of pneumonia caused by serotype O1 positive Pseudomonas aeruginosa	Designated			N/A	N/A	Kenta Biotech Limited	Rehhagstrasase 79					Switzerland
human monoclonal antibody directed against tissue factor pathway inhibitor	n/a	5/18/16	"Treatment of hemophilia A and hemophilia B patients with or without inhibitors, which includes routine prophylaxis to prevent or reduce the frequency of bleeding in hemophilia A and hemophilia B patients."	Designated			N/A	N/A	"Pfizer, Inc."	500 Arcola Road		Collegeville	Pennsylvania	19426	USA
Human monoclonal antibody inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2)	n/a	12/16/13	Prevention (inhibition) of complement-mediated thrombotic microangiopathy	Designated			N/A	N/A	Omeros Corporation	201 Elliott Avenue West		Seattle	Washington	98119	USA
Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)	n/a	4/30/10	Treatment of ovarian cancer	Designated			N/A	N/A	Ortho Biotech	200 Great Valley Parkway		Malvern	Pennsylvania	19355	USA
human monoclonal antibody targeting human sclerostin	n/a	2/29/16	Treatment of osteogenesis imperfecta.	Designated			N/A	N/A	Mereo Biopharma 3 Limited	1 Cavendish Place	4th Floor	London			United Kingdom
Human plasma coagulation Factor VIII and human plasma von Willebrand Factor	Wilate	4/18/07	Treatment of von Willebrand disease except for surgical and/or invasive procedures in patients with von Willebrand disease in whom desmopressin is either ineffective or contraindicated	Designated/Approved	Approved for Orphan Indication	Treatment of spontaneous or trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD) as well as patients with mild or moderate VWD in whom the use of desmopressin is known or suspected to be ineffective or contraindicated	12/04/2009	N/A	"Octapharma USA, Inc."	121 River Street	12th Floor	Hoboken	New Jersey	7030	USA
Human plasma derived conagulation protein-Factor XI	n/a	4/30/14	For the treatment of congenital Factor XI deficiency	Designated			N/A	N/A	Cambryn Biologics	600Tallevast Rd	Unit 201	Sarasota	Florida	34243	USA
human plasminogen	n/a	6/7/10	Treatment of ligneous conjunctivitis	Designated			N/A	N/A	"Kedrion, S.p.A."	Loc. ai Conti	Barga (Lucca)				Italy
human platelet antigen-1a immunoglobulin (anti-HPA-1a)	Tromplate	6/27/13	Prevention of fetal and neonatal alloimmune thrombocytopenia	Designated			N/A	N/A	Prophylix Pharma AS	Forskningsparken	9292	Tromso			Norway
Human prothrombin complex concentrate	Octaplex	2/1/08	Reversal of anticoagulation therapy in patients needing treatment of serious or life threatening bleeding and/or needing urgent surgery or invasive procedures	Designated			N/A	N/A	"Octapharma USA, Inc."	121 River Street	12th Floor	Hoboken	New Jersey	7030	USA
human recombinant bone morphogenetic protein 4	n/a	5/4/16	Treatment of glioblastoma multiforme.	Designated			N/A	N/A	"HyperStem Therapeutics, Inc."	13223-1 Black Mountain Road		San Diego	California	92129	USA
"human recombinant DNA-derived, IgG1 kappa monoclonal anti-body to connective growth factor"	n/a	7/6/12	Treatment of idiopathic pulmonary fibrosis	Designated			N/A	N/A	"FibroGen, Inc."	409 Illinois Street		San Francisco	California	94158	USA
human recombinant dual-variable domain immunoglobulin G1 monoclonal antibody that selectively neutralizes tumor necrosis factor-alpha and interkeukin-17A	n/a	2/4/16	Treatment of pediatric patients 0 to	Designated			N/A	N/A	"AbbVie, Inc."	1 North Waukegan Road		North Chicago	Illinois	60064	USA
"human recombinant mesencephalic, astrocyte derived neurotrophic factor"	n/a	12/22/14	Treatment of retinitis pigmentosa	Designated			N/A	N/A	"Amarantus BioScience Holdings, Inc."	655 Montgomery Street	Suite 900	San Francisco	California	94111	USA
human retinal progenitor cells	n/a	7/23/12	Treatment of retinitis pigmentosa	Designated			N/A	N/A	"jCyte, Inc."	42 Whitman Court		Irvine	California	92617	USA
human single domain antibody-like protein inhibitor of the chemokine receptor type 4	n/a	1/11/17	Treatment of idiopathic pulmonary fibrosis	Designated			N/A	N/A	AdAlta Limited	15/2 Park Drive		Bundoora			Australia
human soluble receptor-Fc fusion protein that targets human activin A	n/a	10/14/15	Treatment of ovarian cancer.	Designated			N/A	N/A	Atara Biotherapeutics	4360 Park Terrace Drive	Suite 100	Westlake Village	California	91361	USA
human spinal cord derived neural stem cells	n/a	2/4/11	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	"Neuralstem, Inc."	20271 Goldenrod LAne		Germantown	Maryland	20876	USA
Human T-lymphotropic virus type III Gp160 antigens	Vaxsyn Hiv-1	11/20/89	Treatment of AIDS.	Designated			N/A	N/A	"MicroGeneSys, Inc."	1000 Research Parkway		Meriden	Connecticut	6450	USA
Human telomerase reverse transcriptase peptide vaccine	n/a	7/20/06	Treatment of pancreatic cancer	Designated			N/A	N/A	GemVax A/S	Froyas Gate 1	0273 Oslo				Norway
"human trtravalent, bi-specific monoclonal antibody that binds and co-inhibits two growth factor receptors; insulin-like growth factor receptor 1 (IGF-1R) and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (ErbB3)"	n/a	10/22/14	Treatment of pancreatic cancer	Designated			N/A	N/A	"Merrimack Pharmaceuticals, Inc."	1 Kendall Square	Suite B7201	Cambridge	Massachusetts	2139	USA
human tumor necrosis factor coupled to the C terminus of CNGRCG peptide	n/a	10/1/09	Treatment of liver cancer	Designated			N/A	N/A	Molecular Medicine S.p.A. (Molmed)	Via Olgettina 58					Italy
human umbilical cord blood-derived mesenchymal stem cells	Pneumostem	11/26/13	Prevention of bronchopulmonary dysplasia	Designated			N/A	N/A	"MEDIPOST America, Inc."	9601 Medical Center Drive		Rockville		20850	USA
human umbilical tissue derived cells (hUTC)	n/a	5/10/11	Treatment of amyotrophic lateral sclerosis	Designated/Withdrawn			N/A	N/A	"Janssen Research & Development, LLC"	1400 McKean Road	P. O. Box 776	Spring House	Pennsylvania	19477	USA
Human umbilical tissue-derived cells	n/a	3/13/06	Treatment of retinitis pigmentosa	Designated/Withdrawn			N/A	N/A	"Janssen Research and Development, LLC"	1400 McKean Road	P. O. Box 776	Spring House	Pennsylvania	19477	USA
Human Wilms tumor protein 1 peptides	n/a	12/23/15	Treatment of acute myeloid leukemia	Designated			N/A	N/A	SELLAS Life Sciences Group	75 Baarerstrasse		Zug			Switzerland
Human wilms tumor protein 1 peptides	n/a	2/23/16	treatment of mesothelioma.	Designated			N/A	N/A	SELLAS Life Sciences Group	75 Baarerstrasse		Zug			Switzerland
Human/Murine Chimeric Monoclonal antibody to Endoglin	n/a	1/20/16	Treatment of soft tissue sarcoma.	Designated			N/A	N/A	"Tracon Pharmaceuticals, Inc."	8910 University Center Lane	Suite 700	San Diego	California	92122	USA
Humanized 3F8-IgG1 monoclonal antibody	n/a	6/24/13	Treatment of neuroblastoma	Designated			N/A	N/A	Memorial Sloan-Kettering Cancer Center	1275 York Avenue		New York	New York	10065	USA
"humanized affinity-optimized, afucosylated immunoglobulin G1 kappa monoclonal antibody against CD19"	n/a	2/10/16	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders	Designated			N/A	N/A	"MedImmune, LLC"	1 Medimmune Way		Gaithersburg	Maryland	20878	USA
Humanized anti-CD2 monoclonal antibody	n/a	11/13/98	Treatment of graft-versus-host disease.	Designated/Withdrawn			N/A	N/A	"MedImmune, Inc."	35 West Watkins Mill Rd.		Gaithersburg	Maryland	20878	USA
Humanized anti-CD3 monoclonal antibody	n/a	9/29/06	Treatment of recent-onset Type I diabetes	Designated			N/A	N/A	"MacroGenics, Inc."	9640 Medical Center Drive		Rockville	Maryland	20850	USA
humanized anti-human CD16 monoclonal antibody	n/a	3/21/05	Treatment of adult idiopathic thrombocytopenic purpura	Designated/Withdrawn			N/A	N/A	Genzyme Corporation	500 Kendall Street		Cambridge	Massachusetts	2142	USA
Humanized anti-human CD2 MAb	Medi-507	9/17/98	"For the induction of donor-specific immunologic unresponsiveness resulting in prophylaxis of organ rejection without the need for chronic immunosuppressive therapy, in patients receiving allogeneic renal transplants."	Designated/Withdrawn			N/A	N/A	"Biotransplant, Inc."	"Building 75, 3rd. Ave."	Charlestown Navy Yard	Charlestown	Massachusetts	2129	USA
humanized anti-IL-6R receptor neutralizing IgG2 monoclonal antibody	n/a	6/30/14	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	Designated			N/A	N/A	"Chugai Pharma USA, LLC"	300 Connell Drive	Suite 3100	Berkeley Heights	New Jersey	7922	USA
Humanized anti-tac	Zenapax	3/5/93	Prevention of acute graft-vs-host disease following bone marrow transplantation.	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA
humanized Fc engineered monoclonal antibody against CD19	n/a	4/29/14	Treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma	Designated			N/A	N/A	MorphoSys AG	Lena-Christ-Str. 48	82152 Martinsried/Planegg				Germany
humanized Fc engineered monoclonal antibody against CD19	n/a	12/1/14	Treatment of diffuse large B-cell lymphoma.	Designated			N/A	N/A	MorphoSys AG	Lena-Christ-Str. 48	82152 Martinsried/Plannegg				Germany
humanized IgG1 anti-serum amyloid A monoclonal antibody	n/a	2/17/12	Treatment of AA amyloidosis and AL amyloidosis	Designated			N/A	N/A	Prothena Therapeutics Limited	Treasury Building	Lower Grand Canal Street	Dublin 2			Ireland
humanized IgG1 monoclonal anti-CD20 antibody	n/a	5/26/11	Treatment of follicular lymphoma	Designated			N/A	N/A	"MENTRIK Biotech, LLC"	12400 Coit Rd		Dallas	Texas	75251	USA
humanized IgG2 antibody	n/a	7/22/08	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	Designated			N/A	N/A	Selexys Pharmaceuticals Corp.	800 Research Parkway	Suite 338	Oklahoma	Oklahoma	73104	USA
humanized IgG4 monoclonal antibody	n/a	12/12/11	Prevention of ischemia/reperfusion injury associated with solid organ tranplantation	Designated			N/A	N/A	Opsona Theraeputics	Trinity Centre for Health sciences	St. James's Hospital	Dublin 8			Ireland
"humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s (C1s)"	n/a	7/27/16	Treatment of autoimmune hemolytic anemia (AIHA)	Designated			N/A	N/A	"True North Therapeutics, Inc."	951 Gateway Boulevard		South San Francisco	California	94080	USA
humanized IgG4 monoclonal antibody binding to human C1q	n/a	1/19/17	Treatment of Guillain-Barre Syndrome	Designated			N/A	N/A	Annexon Biosciences	280 Utah Avenue	Suite 110	South San Francisco	California	94080	USA
humanized IgG4 monoclonal antibody that binds to the SEMA4D antigen	n/a	8/16/16	Treatment of Huntington's disease	Designated			N/A	N/A	"Vaccinex, Inc."	1895 Mount Hope Avenue		Rochester	New York	14620	USA
humanized IgG4 monoclonal antibody to Toll-Like Receptor 2 (TLR2)	n/a	8/30/16	Treatment of myelodysplastic syndrome	Designated			N/A	N/A	Opsona Therapeutics Ltd.	2nd Floor Ashford House	Dublin 2				Ireland
humanized immunoglobulin monoclonal antibody against CD38	n/a	5/22/14	Treatment of multiple myeloma.	Designated			N/A	N/A	"Sanofi U.S. Services, Inc."	500 Kendall Street		Cambridge	Massachusetts	2142	USA
Humanized MAb (IDEC-131) to CD40L	n/a	2/9/99	Treatment of systemic lupus erythematosus.	Designated/Withdrawn			N/A	N/A	Biogen IdecInc.	3030 Callan Rd.		San Diego	California	92121	USA
humanized monoclonal antibodies hu1B7 and hu11E6	n/a	9/11/14	Treatment of Bordetella pertussis	Designated			N/A	N/A	"Synthetic Biologics, Inc."	155 Gibbs Street	Suite 412	Rockville	Maryland	20850	USA
humanized monoclonal antibody against human integrin alphaVbeta6	n/a	8/5/10	Treatment of idiopathic pulmonary fibrosis	Designated			N/A	N/A	"Biogen Idec, Inc."	14 Cambridge Center		Cambridge	Massachusetts	2142	USA
humanized monoclonal antibody against Shiga-like toxin II	n/a	9/12/01	To prevent the development of or to decrease the incidence and severity of hemolytic uremic syndrome and associated sequelae of Shiga-like toxin-producing E. coli.	Designated/Withdrawn			N/A	N/A	"Teijin America, Inc."	600 Alexander Park	Suite 304	Princeton	New Jersey	8540	USA
humanized monoclonal antibody of the IgG4 kappa isotype targeting CD47	n/a	8/20/15	Treatment of acute myeloid (myelogenous) leukemia.	Designated			N/A	N/A	"Forty Seven, Inc."	1490 O'Brien Drive	Suit A	Menlo Park	California	94025	USA
humanized monoclonal antibody that blocks activity of complement component C5	n/a	1/4/17	Treatment of paroxysmal nocturnal hemoglobinuria	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	55 Cambridge Parkway	Suite 800	Cambridge	Massachusetts	2142	USA
humanized monoclonal antibody that targets the a-subunit of the human IL-3 receptor also known as the CD123 antigen; (JNJ-56022473)	n/a	5/5/15	Treatment of acute myeloid leukemia	Designated			N/A	N/A	"Janssen Research & Development, LLC"	920 Route 202	Box 300	Raritan	New Jersey	8869	USA
humanized monoclonal antibody to tissue factor	n/a	4/26/11	Treatment of pancreatic cancer.	Designated			N/A	N/A	"Morphotek, Inc."	210 Welsh Pool Road		Exton	Pennsylvania	19341	USA
Humanized monoclonal antibody to TumorEndothelial Marker-1	n/a	4/29/11	Treatment of soft tissue sarcoma	Designated			N/A	N/A	Morphotek	210 Welsh Pool Rd		Exton	Pennsylvania	19341	USA
humanized monocloncal antibody against human integrin alphaVbeta6	n/a	6/18/08	Treatment of fibrosis-associated chronic allograft nephropathy in kidney transplant patients.	Designated			N/A	N/A	"Stromedix, Inc."	14 Cambridge Center	BIO 7-2	Cambridge	Massachusetts	2142	USA
humanized single chain monoclonal antibody(scFV: IgG1 hinge: IgG1 CH2 and CH3 domains)	n/a	11/17/11	Treatment of chronic lymphocytic leukemia	Designated			N/A	N/A	"Aptevo Therapeutics, Inc."	2401 Fourth Avenue	Suite 1050	Seattle	Washington	98121	USA
"humanized, afucosylated IgG1 kappa monoclonal antibody"	n/a	12/3/09	Treatment of scleroderma	Designated			N/A	N/A	MedImmune	One MedImmune Way		Gaithersburg	Maryland	20878	USA
hyaluronic acid	n/a	3/19/02	Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency	Designated			N/A	N/A	CoTherix	5000 Shoreline Court	Suite 101	South San Francisco	California	94080	USA
hyaluronic acid	n/a	1/18/17	Treatment of emphysema due to alpha1-antitrypsin deficiency.	Designated			N/A	N/A	"Gerard M. Turino, MD"	"Division of Pulmonary, Critical Care & Sleep Medicine"	Mt. Sinai Roosevelt Hospital Center	New York	New York	10019	USA
Hydralazine	n/a	4/9/04	Treatment of severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure greater than or equal to 160) associated with severe preeclampsia/eclampsia of pregnancy	Designated			N/A	N/A	Bioniche Pharma USA LLC	272 E. Deerpath Road	Suite 304	Lake Forest	Illinois	60045	USA
hydralazine - magnesium valproate	Transkrip(R)	3/17/11	Treatment of cutaneous T-cell lymphoma.	Designated			N/A	N/A	Neolpharma S.A.DE C.V.	Boulevard de los Ferrocarriles 277	Azcapotzalco	Mexico City			Mexico
hydralazine - magnesium valproate	Transkrip(R)	3/17/11	Treatment of myelodysplastic syndrome	Designated			N/A	N/A	Neolpharma S.A.DE C.V.	Boulevard de los Ferrocarriles 277	Azcapotzalco	Mexico City			Mexico
hydrocinnamate-[Orn-Pro-dCha-Trp-Arg](CH3COO)	n/a	3/9/15	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	Alsonex Pty Ltd	210 Alice Street	"OLD, 4000"	Brisbane			Australia
hydrocortisone modified release capsules	Chronocort	3/18/15	Treatment of congenital adrenal hyperpasia	Designated			N/A	N/A	Diurnal Limited	Cardiff Medicentre	Cardiff CF14 4UJ				United Kingdom
hydrocortisone modified release capsules	Chronocort(R)	9/3/15	Treatment of adrenal insufficiency.	Designated			N/A	N/A	Diurnal Ltd.	Cardiff Medicentre	Heath Park				United Kingdom
hydrocortisone modified release tabs	Duocort	6/18/08	Treatment of adrenal insufficiency	Designated			N/A	N/A	"Shire ViroPharma, Inc."	300 Shire Way		Lexington	Massachusetts	2421	USA
hydrocortisone oral granules	Infacort(R)	5/13/15	Treatment of pediatric adrenal insufficiency (0 through 16 years of age).	Designated			N/A	N/A	Diurnal Limited	Cardiff Medicentre	Cardiff CF14 4UJ				United Kingdom
hydromorphone hydrochloride (intrathecal infusion)	n/a	6/16/16	Treatment of complex regional pain syndrome	Designated			N/A	N/A	Mallinckrodt Inc.	675 McDonnell Boulevard		Hazelwood	Missouri	63042	USA
Hydroxocobalamin	n/a	9/22/00	Treatment of acute cyanide poisoning	Designated			N/A	N/A	Jazz Pharmaceuticals	3180 Porter Drive		Palo Alto	California	94304	USA
Hydroxocobalamin	Cyanokit	11/25/03	Treatment of acute cyanide poisoning	Designated/Approved	Approved for Orphan Indication	Treatment on known or suspected cyanide poisoning	12/15/2006	12/15/2013	"SERB, S.A."	480 Avenue Louise		Brussels			Belgium
Hydroxy-Propyl-Beta-Cyclodextrin	Trappsol	5/17/10	"Treatment of Niemann Pick Disease, Type C"	Designated			N/A	N/A	"Sphingo Biotech, LLC"	14120 NW 126th Terrace		Alachua	Florida	32615	USA
hydroxycarbamide (hydroxyurea)	Siklos	7/24/13	Treatment of sickle cell disease in patients under 18 years of age	Designated			N/A	N/A	addmedica Laboratories	101 rue Saint Lazare		Paris			France
Hydroxycobalamin/sodium thiosulfate	n/a	10/4/85	Treatment of severe acute cyanide poisoning.	Designated/Withdrawn			N/A	N/A	"Hall, Alan H., M.D."	Mile 5.0 Pass Creek Road	PO Box 24	Elk Mountain	Wyoming	82324	USA
hydroxypioglitazone	n/a	1/30/17	Treatment of X-linked adrenoleukodystrophy	Designated			N/A	N/A	Minoryx Therapeutics S.L.	TecnoCampus Mataro-Maresme. TCM3 602	"Av. Ernest Lluch, 32."	Matar			Spain
hydroxyprogesterone caproate	Makena	1/25/07	Prevention of preterm birth in singleton pregnancies	Designated/Approved	Approved for Orphan Indication	To reduce the risk of preterm birth in women with singleton pregnancy who have a history of singleton spontaneous preterm birth	02/03/2011	02/03/2018	KV Pharmaceutical Company	One Corporate Woods Drive		Bridgeton	Missouri	63044	USA
Hydroxyurea	Droxia	10/1/90	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Designated/Approved	Approved for Orphan Indication	To reduce the frequency of painful crises and to reduce the need for blood transfusions in adult patients with sickle cell anemia with recurrent moderate to severe painful crises (generally at least 3 during the preceding 12 months).	02/25/1998	02/25/2005	Bristol-Myers Squibb Pharmaceutical Research Institute	P.O. Box 4000		Princeton	New Jersey	8543	USA
hydroxyurea	Pedroxa	3/16/15	"Treatment of symptomatic sickle cell disease in pediatric patients, less than 17 years of age."	Designated			N/A	N/A	Ebelle D'Ebelle Pharmaceuticals LLC	5 Witherwood Drive		Hamburg	New Jersey	7419	USA
hydroxyurea	n/a	4/15/05	Treatment of pediatric patients with sickle cell anemia.	Designated			N/A	N/A	"UPM Pharmaceuticals, Inc."	6200 Seaforth Street		Baltimore	Maryland	21224	USA
Hypericin	n/a	2/7/00	Treatment of cutaneous T-cell lymphoma.	Designated			N/A	N/A	"Soligenix, Inc."	29 Emmons Drive	Suite C-10	Princeton	New Jersey	8540	USA
Hypericin	n/a	8/3/00	Treatment of glioblastoma multiforme.	Designated			N/A	N/A	"HyBiopharma, Inc."	2500 York Road	Suite 100	Jamison	Pennsylvania	18929	USA
Hypothiocyanite and lactoferrin	Meveol	11/5/09	Treatment of cystic fibrosis	Designated			N/A	N/A	Alaxia Biotechnologies Sante	3-11 Rue de la Perlerie	F- 69120 Vaulx-en-velin				France
I(131)-TM-601 (chlorotoxin)	n/a	2/14/02	Treatment of malignant glioma	Designated			N/A	N/A	"Morphotek, Inc."	210 Welsh Pool Road		Exon	Pennsylvania	19341	USA
ibalizumab	n/a	10/20/14	Treatment of HIV-1 infection in treatment experienced adult patients with documented multi-antiretroviral class resistance and evidence of HIV-1 replication despite ongoing antiretroviral therapy	Designated			N/A	N/A	"TaiMed Biologics, Inc."	18201 Von Karman Avenue	Suite 470	Irvine	California	92612	USA
Iboctadekin	n/a	6/3/05	Treatment of renal cell carcinoma	Designated/Withdrawn			N/A	N/A	GlaxoSmithKline LLC	Corporation service Company	Suite 400	Wilmington	Delaware	19808	USA
ibritumomab tiuxetan	Zevalin	9/6/94	Treatment of B-cell non-Hodgkin's lymphoma.	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan?) refractory follicular non-Hodgkin?s lymphoma"	02/19/2002	02/19/2009	"Spectrum Pharmaceuticals, Inc."	157 Technology Drive		Irvine	California	92618	USA
ibrutinib	Imbruvica	4/6/12	Treatment of chronic lymphocytic leukemia (CLL)	Designated/Approved	Approved for Orphan Indication	Indicated for the treatment of patients with chronic lymphocytic leukemia without 17p deletion who have not received at least one prior therapy (first line therapy).	03/04/2016	03/04/2023	"Pharmacyclics, LLC"	995 E. Arques Avenue		Sunnyvale	California	94085	USA
ibrutinib	n/a	9/8/14	Treatment of follicular lymphoma	Designated			N/A	N/A	"Pharmacyclics, LLC"	995 E. Arques Avenue		Sunnyvale	California	94085	USA
ibrutinib	Imbruvica	2/5/15	Treatment of splenic marginal zone lymphoma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.	01/18/2017	TBD	"Pharmacyclics, LLC"	995 E. Arques Avenue		Sunnyvale	California	94085	USA
ibrutinib	n/a	3/27/12	Treatment of chronic lymphocytic leukemia (CLL).	Designated/Withdrawn			N/A	N/A	"Pharmacyclics, LLC"	995 E. Arques Avenue		Sunnyvale	California	94085	USA
ibrutinib	Imbruvica	2/5/15	Treatment of nodal marginal zone lymphoma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.	01/18/2017	TBD	"Pharmacyclics, LLC"	995 E. Arques Avenue		Sunnyvale	California	94085	USA
ibrutinib	Imbruvica	5/30/13	Treatment of small lymphocytic lymphoma	Designated/Approved	Approved for Orphan Indication	For treatment of patients with small lymphocytic lymphoma (SLL)	05/06/2016	05/06/2023	"Pharmacyclics, LLC"	995 E. Arques Avenue		Sunnyvale	California	94085	USA
ibrutinib	n/a	10/23/13	Treatment of diffuse large B-cell lymphoma	Designated			N/A	N/A	"Pharmacyclics, LLC"	995 E. Arques Avenue		Sunnyvale	California	94085	USA
ibrutinib	Imbruvica	4/6/12	Treatment of chronic lymphocytic leukemia (CLL)	Designated/Approved	Approved for Orphan Indication	Treatment of patients with chronic lymphocytic leukemia with 17p deletion who have not received at least one prior therapy	07/28/2014	07/28/2021	"Pharmacyclics, LLC"	995 E. Arques Avenue		Sunnyvale	California	94085	USA
ibrutinib	Imbruvica	2/2/16	Treatment of patients with extranodal marginal zone lymphoma (mucosa associated lymphoid tissue [MALT type] lymphoma)	Designated/Approved	Approved for Orphan Indication	Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.	01/18/2017	TBD	"Pharmacyclics, LLC"	995 E. Arques Avenue		Sunnyvale	California	94085	USA
ibrutinib	Imbruvica	4/6/12	Treatment of chronic lymphocytic leukemia (CLL)	Designated/Approved	Approved for Orphan Indication	Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy	02/12/2014	02/12/2021	"Pharmacyclics, LLC"	995 E. Arques Avenue		Sunnyvale	California	94085	USA
ibrutinib	Imbruvica	10/15/13	Treatment of Waldenstrom's macroglobulinemia	Designated/Approved	Approved for Orphan Indication	Treatment of patients with Waldenstrom's macroglobulinemia	01/29/2015	01/29/2022	"Pharmacyclics, LLC"	995 E. Arques Avenue		Sunnyvale	California	94085	USA
ibrutinib	Imbruvica	12/3/12	Treatment of mantle cell lymphoma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy	11/13/2013	11/13/2020	"Pharmacyclics, LLC"	995 E. Arques Avenue		Sunnyvale	California	94085	USA
ibrutinib	n/a	6/23/16	Treatment of chronic Graft versus Host disease.	Designated			N/A	N/A	"Pharmacyclics, LLC"	995 East Arques Avenue		Sunnyvale	California	94085	USA
ibrutinib	n/a	5/16/13	Treatment of multiple myeloma	Designated			N/A	N/A	"Pharmacyclics, LLC"	995 E. Arques Avenue		Sunnyvale	California	94085	USA
ibudilast	n/a	6/1/15	Treatment of Krabbe disease	Designated			N/A	N/A	"MediciNova, Inc."	4275 Executive Square	Suite 650	La Jolla	California	92037	USA
ibudilast	n/a	10/6/16	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	"MediciNova, Inc."	4275 Executive Square	Suite 650	La Jolla	California	92037	USA
Ibuprofen i.v. solution	Salprofen	10/29/96	Prevention of patent ductus arteriosus.	Designated			N/A	N/A	"Farmacon-IL, LLC"	1720 Post Road East	Suite 213	Westport	Connecticut	6880	USA
Ibuprofen lysine	Neoprofen	10/29/96	Treatment of patent ductus arteriosus	Designated/Approved	Approved for Orphan Indication	"For closure of a clinically significant patent ductus arteriosus in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective"	04/13/2006	04/13/2013	"Lundbeck, Inc."	Four Parkway North		Deerfield	Illinois	60015	USA
icatibant	Firazyr	11/25/03	Treatment of angioedema	Designated/Approved	Approved for Orphan Indication	Treatment of acute attacks of hereditary angioedema in adults 18 years of age and older	08/25/2011	08/25/2018	Shire Orphan Therapies	300 Shire Way		Lexington	Massachusetts	2421	USA
icatibant	n/a	5/5/04	Treatment of burn patients hospitalized with burn-induced edema	Designated/Withdrawn			N/A	N/A	Shire Human Genetic Therapies	700 Main Street		Cambridge	Massachusetts	2139	USA
Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution	Extraneal (With 7.5% Icodextrin) Peritoneal Dialysis Solutio	7/18/97	Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.	Designated/Approved	Approved for Orphan Indication	For use as a single daily exchange for the long (8-16 hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of chronic renal failure.	12/20/2002	12/20/2009	Baxter Healthcare Corporation	Renal Division	1620 Waukegan Road	McGaw Park	Illinois	60085	USA
Idarubicin	Idamycin	12/1/92	Treatment of myelodysplastic syndromes.	Designated/Withdrawn			N/A	N/A	Pharmacia & Upjohn	7000 Portage Road	Unit 0633-298-113	Kalamazoo	Michigan	49001	USA
Idarubicin	Idamycin	12/2/92	Treatment of chronic myelogenous leukemia.	Designated/Withdrawn			N/A	N/A	Pharmacia & Upjohn	7000 Portage Road	Unit 0633-298-113	Kalamazoo	Michigan	49001	USA
Idarubicin HCl for injection	Idamycin	7/25/88	"Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia."	Designated/Approved	Approved for Orphan Indication		09/27/1990	09/27/1997	"Adria Laboratories, Inc."	P.O. Box 16529		Columbus	Ohio	43216	USA
Idarubicin HCl for injection	Idamycin	2/12/91	Treatment of acute lymphoblastic leukemia in pediatric patients.	Designated/Withdrawn			N/A	N/A	"Pfizer, Inc."	235 East 42nd Street		New York	New York	10017	USA
idarucizumab	n/a	5/28/15	To reverse the anticoagulant effect of dabigatran due to uncontrolled life-threatening bleeding requiring urgent intervention or a need to undergo an emergency surgery/urgent invasive procedure	Designated/Approved	Approved for Orphan Indication	For use in patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding	10/16/2015	10/16/2022	"Boehringer Ingelheim Pharmaceuticals, Inc."	PO Box 368	900 Ridgebury Road	Ridgefield	Connecticut	6877	USA
idebenone	n/a	2/16/07	Treatment of Duchenne muscular dystrophy	Designated			N/A	N/A	Santhera Pharaceuticals Limited	Hammerstrasse 47					Switzerland
idebenone	n/a	10/31/06	Treatment of Leber's hereditary optic neuropathy.	Designated			N/A	N/A	Santhera Pharmaceuticals Limited	Hammerstrasse 47					Switzerland
idebenone	n/a	5/22/09	"Treatment of mitochondrial myopathy, encephalopathy, lactic acidosis with stroke-like episodes syndrome (MELAS)"	Designated			N/A	N/A	Santhera Pharmaceuticals Limited	Hammerstrasse 7	Liestal				Switzerland
idebenone	n/a	3/25/04	Treatment of Friedreich's ataxia	Designated			N/A	N/A	Santhera Pharmaceuticals LLC	Hammerstrasse 25	CH-4410 Liestal				Switzerland
idelalisib	n/a	9/26/13	Treatment of lymphoplasmacytic lymphoma with or without Walenstrom's macroglobulinemia	Designated			N/A	N/A	"Gilead Sciences, Inc."	199 E. Blaine St		Seattle	Washington	98102	USA
idelalisib	n/a	10/15/13	Treatment of splenic marginal zone lymphoma	Designated			N/A	N/A	"Gilead Sciences, Inc."	199 E. Blaine St		Seattle	Washington	98102	USA
idelalisib	n/a	8/25/11	Treatment of chronic lymphocytic leukemia	Designated			N/A	N/A	"Gilead Sciences, Inc."	199 E. Blaine St.		Seattle	Washington	98102	USA
idelalisib	Zydelig	10/15/13	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	Designated/Approved	Approved for Orphan Indication	"(1) Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; and (2) Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies."	07/23/2014	07/23/2021	"Gilead Sciences, Inc."	199 E. Blaine St		Seattle	Washington	98102	USA
idelalisib	n/a	10/15/13	Treatment of extranodal marginal zone lymphoma	Designated			N/A	N/A	"Gilead Sciences, Inc."	199 E. Blaine St		Seattle	Washington	98102	USA
idelalisib	n/a	10/15/13	Treatment of nodal marginal zone lymphoma.	Designated			N/A	N/A	"Gilead Sciences, Inc."	199 E. Blaine St		Seattle	Washington	98102	USA
idelalisib	Zydelig	9/26/13	Treatment of follicular lymphoma	Designated/Approved	Approved for Orphan Indication	Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies.	07/23/2014	07/23/2021	"Gilead Sciences, Inc."	199 E. Blaine St		Seattle	Washington	98102	USA
Idoxuridine	n/a	4/8/96	Treatment of nonparenchymatous sarcomas.	Designated			N/A	N/A	"NeoPharm, Inc."	"225 East Deerpath, Suite 250"		Lake Forest	Illinois	60045	USA
IDUA-HIRMAb fusion protein	n/a	1/10/08	Treatment of mucopolysaccharidosis Type 1 (MPS)	Designated			N/A	N/A	"ArmaGen Technologies, Inc."	914 Colorado Ave.		Santa Monica	California	90401	USA
idursulfase	Elaprase	11/28/01	Long term enzyme replacement therapy for patients with mucopolysaccharidosis II (Hunter Syndrome)	Designated/Approved	Approved for Orphan Indication	"Indicated for patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Idursulfase has been shown to improve walking capacity in these patients"	07/24/2006	07/24/2013	"Shire Human Genetic Therapies, Inc."	700 Main Street		Cambridge	Massachusetts	2139	USA
idursulfase beta	n/a	2/11/13	Treatment of Hunter Syndrome (mucopolysaccharidoses)	Designated			N/A	N/A	Green Cross Corp.	"303 Bojeong-dong, Giheung-gu"	446-770				"Korea, Republic of"
idursulfase IT	n/a	9/3/09	For treatment of neurocognitive symptoms associated with Hunter Syndrome	Designated			N/A	N/A	Shire Human Genetic Therapies	300 Shire Way		Lexington	Massachusetts	2421	USA
iduvec	n/a	1/21/11	Treatment of Mucopolysaccharidosis Type I	Designated			N/A	N/A	Zebraic Corporation	8837 Stratford Crossing		Brooklyn Park	Minnesota	55443	USA
iferanserin (S-MPEC)	n/a	12/13/10	For use in pulmonary arterial hypertension.	Designated			N/A	N/A	"Sam Amer & Company, Inc."	P. O. Box 5685		Montecito	California	93150	USA
Ifosfamide	Ifex	1/20/87	Treatment of testicular cancer.	Designated/Approved	Approved for Orphan Indication	"In combination with certain other approved antineoplastic agents, for third line chemotherapy in the treatment of germ cell testicular cancer."	12/30/1988	12/30/1995	Bristol-Myers Squibb Pharmaceutical Research Institute	"5 Research Parkway, P.O. Box 5100"		Wallingford	Connecticut	6492	USA
ifosfamide	n/a	8/7/85	Treatment of soft tissue and bone sarcomas	Designated			N/A	N/A	Bristol-Myers Squibb Company	P.O. Box 4000	Mail Stop D12-02	Princeton	New Jersey	8543	USA
IgG1 chimeric monoclonal antibody	n/a	6/22/11	Treatment of multiple myeloma.	Designated			N/A	N/A	Immune System Therapeutics Ltd	"Suite 1, Level 1"	"Ultimo, NW 2007"				Australia
IL-12 secreting dendritic cells loaded with autologous tumor lysate	n/a	6/24/13	Treatment of malignant glioma	Designated			N/A	N/A	Activartis Biotech GmbH	1090 Vienna	Zimmermannplatz 10				Austria
IL-4 Pseudomonas Toxin Fusion Protein (IL-4(38-37)-PE38KDEL)	n/a	4/6/00	Treatment of astrocytic glioma.	Designated			N/A	N/A	"Medicenna Therapeutics, Inc."	220-1075 West George Street	"Vancouver, British Columbia"				Canada
IL13-PE38QQR	n/a	11/2/01	Treatment of malignant glioma	Designated/Withdrawn			N/A	N/A	"Insys Development Company, Inc."	"1333 South Sprectum Blvd, Suite 100"		Chandler	Arizona	85286	USA
iloprost	n/a	4/6/12	Treatment of pulmonary arterial hypertension	Designated			N/A	N/A	"Algorithum Sciences, LLC"	World Trade Center Delaware	702 West Street	Wilmington	Delaware	19801	USA
Iloprost inhalation solution	Ventavis	8/17/04	Treatment of pulmonary arterial hypertension	Designated/Approved	Approved for Orphan Indication	Treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms	12/29/2004	12/29/2011	"CoTherix, Inc."	5000 Shoreline Court		South San Francisco	California	94080	USA
Iloprost solution for infusion	n/a	9/21/89	Treatment of Raynaud's phenomenon secondary to systemic sclerosis.	Designated/Withdrawn			N/A	N/A	"Berlex Laboratories, Inc."	300 Fairfield Road		Wayne	New Jersey	7470	USA
Iloprost solution for infusion	n/a	5/14/90	Treatment of heparin-associated thrombocytopenia.	Designated/Withdrawn			N/A	N/A	"Berlex Laboratories, Inc."	300 Fairfield Road		Wayne	New Jersey	7470	USA
ilorasertib	n/a	3/16/12	Treatment of ovarian cancer	Designated/Withdrawn			N/A	N/A	"AbbVie, Inc."	1 N. Waukegan Road		North Chicago	Illinois	60064	USA
imatinib	Gleevec	10/11/05	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL)	10/19/2006	10/19/2013	Novartis Pharmaceuticals Corporation	One Health Plaza	Mail Code 105/1E870D	East Hanover	New Jersey	7936	USA
Imatinib	Gleevec	1/31/01	Treatment of chronic myelogenous leukemia	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy"	05/10/2001	05/10/2008	Novartis Pharmaceuticals Corporation	59 Route 10		East Hanover	New Jersey	7936	USA
imatinib	Gleevec	10/11/05	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Designated/Approved	Approved for Orphan Indication	"Treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy, approved under NDA #21588/S-037"	01/25/2013	01/25/2020	Novartis Pharmaceuticals Corporation	One Health Plaza	Mail Code 105/1E870D	East Hanover	New Jersey	7936	USA
imatinib	n/a	4/7/10	Treatment of pulmonary arterial hypertension	Designated/Withdrawn			N/A	N/A	Novartis	One Health Plaza		East Hanover	New Jersey	7936	USA
Imatinib mesylate	Gleevec	9/9/05	Treatment of systemic mastocytosis without the D816V c-kit mutation	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with aggressive mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown	10/19/2006	10/19/2013	Novartis Pharmaceuticals Corporation	One Health Plaza	Mail Code 105/1E870D	East Hanover	New Jersey	7936	USA
Imatinib mesylate	Gleevec	8/25/05	Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with hypereosinophic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFR} fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFR} fusion kinase negative or unknown	10/19/2006	10/19/2013	Novartis Pharmaceuticals Corporation	One Health Plaza	Mail Code 105/1E870D	East Hanover	New Jersey	7936	USA
Imatinib mesylate	Gleevec	10/5/05	Treatment of myeloproliferative disorders/myelodysplastic syndromes associated with platelet-derived growth factor gene re-arrangements	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements	10/19/2006	10/19/2013	Novartis Pharmaceuticals Corporation	One Health Plaza	Mail Code 105/1E870D	East Hanover	New Jersey	7936	USA
imatinib mesylate	n/a	5/6/14	Treatment of progressive multifocal leukencephalopathy	Designated			N/A	N/A	"Inhibikase Therapeutics, Inc."	3350 Riverwood Parkway	Suite 1927	Atlanta	Georgia	30339	USA
imatinib mesylate	Gleevec	11/1/01	Treatment of gastrointestinal stromal tumors	Designated/Approved	Approved for Orphan Indication	Adjuvant treatment of adult patients following complete resection Kit (CD 117) positive gastrointestinal stromal tumors (GIST).	12/19/2008	12/19/2015	Novartis Pharmaceuticals Corp.	One Health Plaza	Mail Code 105/1E870D	East Hanover	New Jersey	7936	USA
imatinib mesylate	Gleevec	11/1/01	Treatment of gastrointestinal stromal tumors	Designated/Approved	Approved for Orphan Indication	Treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST)	02/01/2002	02/01/2009	Novartis Pharmaceuticals Corp.	One Health Plaza	Mail Code 105/1E870D	East Hanover	New Jersey	7936	USA
imatinib mesylate	Gleevec	12/19/05	Treatment of dermatofibrosarcoma protuberans	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP)"	10/19/2006	10/19/2013	Novartis Pharmaceuticals Corporation	One Health Plaza	Mail Code 105/1E870D	East Hanover	New Jersey	7936	USA
Imciromab pentetate	Myoscint	1/25/89	Detecting early necrosis as an indication of rejection of orthotopic cardiac transplants.	Designated			N/A	N/A	"Centocor, Inc."	244 Great Valley Parkway		Malvern	Pennsylvania	19355	USA
imetelstat	n/a	12/23/15	Treatment of myelodysplastic syndrome	Designated			N/A	N/A	"Janssen Research & Development, LLC"	920 U.S. 202		Raritan	New Jersey	8869	USA
imetelstat	n/a	6/11/15	Treatment of myelofibrosis	Designated			N/A	N/A	"Janssen Research & Development, LLC"	P. O. Box 300	920 US Route 202	Raritan	New Jersey	8869	USA
imexon	Amplimexon	8/12/05	Treatment of ovarian cancer.	Designated			N/A	N/A	AmpliMed Corporation	4380 N. Campbell Ave.		Tucson	Arizona	85718	USA
Imexon	n/a	11/1/03	Treatment of pancreatic adenocarcinoma	Designated/Withdrawn			N/A	N/A	AmpliMed Corporation	4380 North Campbell Avenue	Suite 205	Tucson	Arizona	85718	USA
Imexon	n/a	8/3/01	Treatment of metastatic malignant melanoma	Designated/Withdrawn			N/A	N/A	AmpliMed Corporation	2321 Camino La Zorrela		Tucson	Arizona	85718	USA
Imexon	n/a	11/8/96	Treatment of multiple myeloma.	Designated			N/A	N/A	AmpliMed Corporation	2321 Camino La Zorrela		Tucson	Arizona	85718	USA
Imiglucerase	Cerezyme	11/5/91	"Replacement therapy in patients with types I, II, and III Gaucher's disease."	Designated/Approved	Approved for Orphan Indication	Enzyme replacement therapy in patients with type I Gaucher's disease.	05/23/1994	05/23/2001	Genzyme Corporation	One Kendall Square		Cambridge	Massachusetts	2139	USA
Imiquimod	n/a	12/3/14	Treatment of carcinoma in situ (CIS) of the urinary bladder	Designated			N/A	N/A	UroGen Pharma Ltd	9 Ha'Ta'asiya Street	P. O. Box 2397	Ra'anana			Israel
Immortalized human liver cells found in the extracorporeal liver assist device	Elad	7/16/04	Treatment of fulminant hepatic failure (acute liver failure)	Designated			N/A	N/A	"Vital Therapies, Inc."	15222 Avenue of Science	Suite C	San Diego	California	92128	USA
immune globulin (human)	n/a	3/2/10	Treatment of Guillain-Barre syndrome	Designated			N/A	N/A	"Octapharma USA, Inc."	121 River Street	12th Floor	Hoboken	New Jersey	7030	USA
Immune Globulin (Human)	Gamunex(R)-C	7/27/04	Treatment of chronic inflammatory demyelinating polyneuropathy	Designated/Approved	Approved for Orphan Indication	Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse	09/12/2008	09/12/2015	"Grifols Therapeutics, Inc."	8368 US 70 Business Hwy West		Clayton	North Carolina	27520	USA
immune globulin (human)	Gamunex (R)-C	12/12/16	Treatment of Myasthenia Gravis	Designated			N/A	N/A	"Grifols Therapeutics, Inc."	79 TW Alexander Drive		Research Triangle Park	North Carolina	27709	USA
Immune Globulin (Human) containing high titers of West Nile virus antibodies	Omr-Igg-Am (Tm) 5% (Wnv)	3/17/04	Treatment of the West Nile virus infection	Designated			N/A	N/A	"OMRIX Biopharmaceuticals, Ltd."	Plasma Fractionation Institute	Ramat Gan 52621				Israel
immune globulin infusion (human)	Gammagard Liquid	7/20/06	Treatment of multifocal motor neuropathy	Designated/Approved	Approved for Orphan Indication	Maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN).	06/22/2012	06/22/2019	"Baxalta US, Inc."	One Baxter Way		Westlake Village	California	91362	USA
immune globulin infusion 10% (human) with recombinant human hyaluronidase)	n/a	3/31/16	Treatment of chronic inflammatory demyelinating polyneuropathy	Designated			N/A	N/A	"Baxalta US, Inc."	1 Baxter Way		Westlake Village	California	91362	USA
Immune Globulin Intravenous (human)	Carimune Nf	5/4/04	Treatment for Guillain Barre Syndrome	Designated			N/A	N/A	ZLB Bioplasma AG	Wankdorfstrasse 10	CH-3000 Bern 22				Switzerland
Immune globulin intravenous (human)	"Iveegam, Immuno"	10/13/92	Treatment of polymyositis/dermatomyositis.	Designated/Withdrawn			N/A	N/A	Immuno Clinical Research Corp.	155 East 56th Street		New York	New York	10022	USA
Immune globulin intravenous (human)	"Iveegam, Immuno"	12/16/92	Treatment of juvenile rheumatoid arthritis.	Designated/Withdrawn			N/A	N/A	Immuno Clinical Research Corp.	750 Lexington Avenue		New York	New York	10022	USA
Immune globulin intravenous (human)	"Immune Globulin Intravenous (Human) Immuno, Iveegam"	11/22/93	Treatment of patients with acute myocarditis.	Designated/Withdrawn			N/A	N/A	Immuno Clinical Research Corp.	750 Lexington Avenue		New York	New York	10022	USA
"Immune globulin intravenous, human"	Gamimune N	2/18/93	Infection prophylaxis in pediatric patients affected with the human immunodeficiency virus.	Designated/Approved	Approved for Orphan Indication	"For prophylaxis of children with clinical or immunologic evidence of human immunodeficiency virus to decrease the frequency of serious and minor bacterial infections and the frequency of hospitalization, and to increase the time free of serious bacterial infections."	12/27/1993	12/27/2000	Bayer Corporation	"Pharmaceutical Division, Biological Products"	400 Morgan Lane	New Haven	Connecticut	6516	USA
immune globulin intraveous (human)	Gammaplex	4/29/11	Treatment of idiopathic thrombocytopenic purpura (also known as primary immune thrombocytopenia)	Designated/Approved	Approved for Orphan Indication	Idiopathic thrombocytopenic purpura	03/08/2013	N/A	Bio Products Laboratory	Dagger Lane	"Hertfordshire, WD3BX,"	England			United Kingdom
Immune Globulin Subcutaneous (Human)	Vivaglobin P (Proposed)	9/22/04	Treatment of patients with primary immune deficiency (PID) that are intolerant to immune globulin intravenous (IGIV) due to severe adverse events or poor venous access	Designated/Withdrawn			N/A	N/A	CSL Behring	1020 First Avenue	P.O. Box 61501	King of Prussia	Pennsylvania	19406	USA
"Immune Globulin Subcutaneous (Human), 20% Liquid"	Hizentra	8/18/14	Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)	Designated			N/A	N/A	CSL Behring	P. O. Box 61501	1020 First Avenue	King of Prussia	Pennsylvania	19406	USA
immunoglobulin G degrading enzyme of Streptococcus pyogenes	n/a	9/10/15	Prevention of antibody mediated organ rejection in solid organ transplant patients.	Designated			N/A	N/A	Hansa Medical AB	P. O. Box 785	SE-220 07 Lund				Sweden
immunologically active synthetic peptides	n/a	6/1/15	Treatment of Hemophilia A	Designated			N/A	N/A	Apitope International NV	"Agoralaan, Building A-bis"	3590 Diepenbeek				Belgium
Immunotherapeutic vaccine consisting of (PAM)2-Lys-Ser-Ser-Gln-Tyr-Ile-Lys-Ala-Asn-Ser-Lys-Phe-Ile-Gly-Ile-Thr-Glu-Ala-Ala-Ala-Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-Val	n/a	3/16/94	Treatment of chronic active hepatitis B infection in HLA-A2 positive patients.	Designated			N/A	N/A	Cytel Corporation	3525 John Hopkins Court		San Diego	California	92121	USA
Implitapide	n/a	8/19/04	Treatment of patients with Fredrickson type I or V hyperlipoproteinemia	Designated/Withdrawn			N/A	N/A	Medical Research Laboratories International	2 Tesseneer Drive		Highland Heights	Kentucky	41076	USA
Implitapide	n/a	8/13/04	Treatment of homozygous familial hypercholesterolemia	Designated/Withdrawn			N/A	N/A	Medical Research Laboratories International	2 Tesseneer Drive		Highland Heights	Kentucky	41076	USA
"Imported fire ant venom, allergenic extract"	n/a	5/12/92	"For skin testing of victims of fire ant stings to confirm fire ant sensitivity and if positive, for use as immunotherapy for the prevention of IgE-mediated anaphylactic reactions."	Designated			N/A	N/A	"ALK Laboratories, Inc."	Research Center	27 Village Lane	Wallingford	Connecticut	6492	USA
"Inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium)"	n/a	12/29/16	Prevention of rabies virus infection including post-exposure prophylaxis (PEP) for rabies	Designated			N/A	N/A	"Yisheng US Biopharma, Inc."	11 Firstfield Road	Suite A	Gaithersburg	Maryland	20878	USA
Inalimarev and falimarev	n/a	1/10/06	Treatment of adenocarcinoma of the pancreas	Designated			N/A	N/A	Therion Biologics Corporation	76 Rogers Street		Cambridge	Massachusetts	2142	USA
inBreath airway transplant system	n/a	9/4/14	"To restore the structure and/or function of the trachea subsequent to tracheal damage due to cancer, injury or infection"	Designated			N/A	N/A	"Biostage, Inc."	84 October Hill Road	Suite 11	Holliston	Massachusetts	1746	USA
Indium In 111 murine monoclonal antibody FAB to myosin	Myoscint	8/7/89	To aid in the diagnosis of myocarditis.	Designated/Withdrawn			N/A	N/A	"Centocor, Inc."	244 Great Valley Parkway		Malvern	Pennsylvania	19355	USA
Indium In-111 altumomab pentetate	Hybri-Ceaker	2/6/90	Detection of suspected and previously unidentified tumor foci of recurrent colorectal carcinoma.	Designated/Withdrawn			N/A	N/A	"Hybritech, Inc."	11095 Torreyanna Road		San Diego	California	92196	USA
Indium-111 pentetreotide	Neuroendomedix	6/16/06	Treatment of neuroendocrine tumors	Designated			N/A	N/A	RadioIsotope Therapy of America (RITA) Foundation	9701 Richmond Avenue		Houston	Texas	77042	USA
Inecalcitol	n/a	5/14/14	Treatment of chronic lymphocytic leukemia	Designated			N/A	N/A	"Hybrigenics, S.A."	"3-5, impasse Reille"		Paris			France
inecalcitol	n/a	8/3/15	Treatment of acute myeloid leukemia.	Designated			N/A	N/A	"Hybrigenics, S.A."	"3-5, impasse Reille"		Paris			France
infliximab	Remicade	11/12/03	Treatment of pediatric (0 to 16 years of age) ulcerative colitis	Designated/Approved	Approved for Orphan Indication	For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy	09/23/2011	09/23/2018	Janssen Biotech Inc.	200 Great Valley Parkway		Malvern	Pennsylvania	19355	USA
Infliximab	Remicade	11/12/03	Treatment of pediatric (0 to 16 years of age) Crohn's Disease	Designated/Approved	Approved for Orphan Indication	For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy	05/19/2006	05/19/2013	"Centocor, Inc."	200 Great Valley Parkway		Malvern	Pennsylvania	19355	USA
infliximab	Remicade	11/14/95	Treatment of Crohn's disease	Designated/Approved	Approved for Orphan Indication	"Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s)."	08/24/1998	08/24/2005	"Centocor, Inc."	200 Great Valley Parkway		Malvern	Pennsylvania	19355	USA
Infliximab	Remicade	5/21/03	Treatment of chronic sarcoidosis	Designated			N/A	N/A	"Centocor, Inc."	200 Great Valley Parkway		Malvern	Pennsylvania	19355	USA
infliximab	Remicade	10/23/02	Treatment of juvenile rheumatoid arthritis	Designated			N/A	N/A	"Centocor, Inc."		200 Great Valley Parkway	Malvern	Pennsylvania	19355	USA
infliximab	Remicade	5/6/03	Treatment of giant cell arteritis	Designated/Withdrawn			N/A	N/A	"Centocor, Inc."	200 Great Valley Parkway		Malvern	Pennsylvania	19355	USA
inhibitor of microRNA-451	n/a	2/4/11	Treatment of polycythemia vera	Designated/Withdrawn			N/A	N/A	"miRagen Therapeutics, Inc."	6200 Lookout Road		Boulder	Colorado	80301	USA
Inhibitor of primary and secondary KIT and PDGFR alpha kinase mutants found in GIST	n/a	10/2/14	Treatment of gastrointestinal stromal tumors (GIST)	Designated			N/A	N/A	"Deciphera Pharmaceuticals, LLC"	643 Massachusetts	Suite 200	Lawrence	Kansas	66044	USA
Inhibitor of Tissue Factor Pathway Inhibitor (TFPI)	n/a	1/29/10	Treatment of hemophilia A and hemophilia B.	Designated			N/A	N/A	"Baxter Healthcare Corporation, Baxter BioScience"	One Baxter Way		Westlake Village	California	91362	USA
inolimomab	Leukotac	10/23/02	Treatment of graft versus host disease	Designated			N/A	N/A	Jazz Pharmaceuticals	3180 Palo Alto Drive		Palo Alto	California	94304	USA
Inosine pranobex	Isoprinosine	9/20/88	Treatment of subacute sclerosing panencephalitis.	Designated			N/A	N/A	Newport Pharmaceuticals	897 West Sixteenth Street		Newport Beach	California	92663	USA
inotuzumab ozogamicin	n/a	3/25/13	Treatment of B-cell acute lymphoblastic leukemia	Designated			N/A	N/A	"Pfizer, Inc."	445 Eastern Point Road		Groton	Connecticut	6340	USA
insecticidal toxin derived from Bacillus thuringiensis	n/a	9/5/08	Treatment of soil transmitted helminth infection strongyloidiasis	Designated			N/A	N/A	"University of California, San Diego"	"Aroian Laboratory, Div. of Biological Sciences"	Department 0322	LaJolla	California	92093	USA
Interferon alfa-2a	Roferon A	6/6/89	Treatment of chronic myelogenous leukemia.	Designated/Approved	Approved for Orphan Indication	Treatment of chronic myelogenous leukemia.	10/19/1995	10/19/2002	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA
Interferon alfa-2a (recombinant)	Roferon-A	5/2/90	For the concomitant administration with Teceleukin for the treatment of metastatic renal cell carcinoma.	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7119	USA
Interferon alfa-2a (recombinant)	Roferon-A	5/11/90	For the treatment of metastatic malignant melanoma in combination with Teceleukin.	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7119	USA
Interferon alfa-2a (recombinant)	Roferon-A	5/14/90	For the concomitant administration with fluorouracil for the treatment of advanced colorectal cancer.	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA
Interferon alfa-2a (recombinant)	Roferon-A	4/18/88	Treatment of renal cell carcinoma.	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA
Interferon alfa-2a (recombinant)	Roferon-A	12/14/87	Treatment of AIDS related Kaposi's sarcoma.	Designated/Approved	Approved for Orphan Indication		11/21/1988	11/21/1995	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA
Interferon alfa-2a (recombinant)	Roferon-A	10/27/89	For use in combination with fluorouracil for the treatment of esophageal carcinoma.	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA
Interferon alfa-2b (recombinant)	Intron A	8/10/88	Treatment of carcinoma in situ of the urinary bladder.	Designated/Withdrawn			N/A	N/A	Schering Corporation	2000 Galloping Hill Road		Kenilworth	New Jersey	7033	USA
Interferon alfa-2b (recombinant)	Intron A	8/3/87	Treatment of ovarian carcinoma.	Designated/Withdrawn			N/A	N/A	Schering Corporation	2000 Galloping Hill Road		Kenilworth	New Jersey	7033	USA
Interferon alfa-2b (recombinant)	Intron A	6/24/87	Treatment of AIDS-related Kaposi's sarcoma.	Designated/Approved	Approved for Orphan Indication	Treatment of selected patients with AIDS-related Kaposi's sarcoma.	11/21/1988	11/21/1995	Schering Corporation	2000 Galloping Hill Road		Kenilworth	New Jersey	7033	USA
Interferon alfa-2b (recombinant)	Intron A	6/22/87	Treatment of metastatic renal cell carcinoma.	Designated/Withdrawn			N/A	N/A	Schering Corporation	2000 Galloping Hill Road		Kenilworth	New Jersey	7033	USA
Interferon alfa-2b (recombinant)	Intron A	5/13/88	Treatment of primary malignant brain tumors.	Designated/Withdrawn			N/A	N/A	Schering Corporation	2000 Galloping Hill Road		Kenilworth	New Jersey	7033	USA
Interferon alfa-2b (recombinant)	Intron A	5/4/90	Treatment of chronic delta hepatitis.	Designated/Withdrawn			N/A	N/A	Schering Corporation	2000 Galloping Hill Road		Kenilworth	New Jersey	7033	USA
Interferon alfa-2b (recombinant)	Intron A	11/17/88	Treatment of acute hepatitis B.	Designated/Withdrawn			N/A	N/A	Schering Corporation	2000 Galloping Hill Road		Kenilworth	New Jersey	7033	USA
Interferon alfa-2b (recombinant)	Intron A	8/17/88	Treatment of laryngeal (respiratory) papillomatosis.	Designated/Withdrawn			N/A	N/A	Schering Corporation	2000 Galloping Hill Road		Kenilworth	New Jersey	7033	USA
Interferon alfa-2b (recombinant)	Intron A	6/22/87	Treatment of chronic myelogenous leukemia.	Designated/Withdrawn			N/A	N/A	Schering Corporation	2000 Galloping Hill Road		Kenilworth	New Jersey	7033	USA
Interferon alfa-2b (recombinant)	Intron A	4/18/88	Treatment of invasive carcinoma of the cervix.	Designated/Withdrawn			N/A	N/A	Schering Corporation	2000 Galloping Hill Road		Kenilworth	New Jersey	7033	USA
Interferon alfa-nl	Wellferon	8/25/86	Treatment of AIDS related Kaposi's sarcoma.	Designated/Withdrawn			N/A	N/A	Burroughs Wellcome Company	3030 Cornwallis Road	P.O. Box 12700	Research Triangle Pk	North Carolina	27709	USA
Interferon alfa-nl	Wellferon	10/16/87	Treatment of human papillomavirus in patients with severe resistant/recurrent respiratory (laryngeal) papillomatosis.	Designated/Withdrawn			N/A	N/A	Glaxo Wellcome Inc.	5 Moore Drive		Research Triangle Park	North Carolina	27709	USA
Interferon beta (recombinant human)	Avonex	1/13/93	Treatment of primary brain tumors.	Designated/Withdrawn			N/A	N/A	"Biogen Idec, Inc."	14 Cambridge Center		Cambridge	Massachusetts	2142	USA
Interferon beta (recombinant)	R-Huifn-Beta	5/9/91	For the intralesional and/or systemic treatment of AIDS-related Kaposi's sarcoma.	Designated/Withdrawn			N/A	N/A	"Biogen, Inc."	14 Cambridge Center		Cambridge	Massachusetts	2142	USA
Interferon beta (recombinant)	R-Huifn-Beta	4/18/91	For the systemic treatment of cutaneous T-cell lymphoma.	Designated/Withdrawn			N/A	N/A	"Biogen, Inc."	14 Cambridge Center		Cambridge	Massachusetts	2142	USA
Interferon beta (recombinant)	R-Ifn-Beta	2/12/91	For the systemic treatment of metastatic renal cell carcinoma.	Designated/Withdrawn			N/A	N/A	"Biogen, Inc."	14 Cambridge Center		Cambridge	Massachusetts	2142	USA
"Interferon beta, recombinant human"	Betaseron	11/15/88	Treatment of acquired immunodeficiency syndrome.	Designated/Withdrawn			N/A	N/A	"Berlex Laboratories, Inc."	1401 Harbor Bay Parkway		Alameda	California	94501	USA
interferon Beta-1a	Avonex	10/14/98	Treatment of juvenile rheumatoid arthritis.	Designated/Withdrawn			N/A	N/A	"Biogen, Inc."	14 Cambridge Center		Cambridge	Massachusetts	2142	USA
Interferon beta-1a	Rebif	3/11/96	Treatment of patients with secondary progressive multiple sclerosis.	Designated			N/A	N/A	"EMD Serono, Inc."	One Technology Place		Rockland	Massachusetts	2370	USA
Interferon beta-1a	Avonex	12/16/91	Treatment of multiple sclerosis.	Designated/Approved	Approved for Orphan Indication	Treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations.	05/17/1996	05/17/2003	"Biogen, Inc."	14 Cambridge Center		Cambridge	Massachusetts	2142	USA
Interferon beta-1a (recombinant human)	n/a	7/24/92	"Treatment of acute non-A, non-B hepatitis."	Designated			N/A	N/A	"Biogen, Inc."	14 Cambridge Center		Cambridge	Massachusetts	2142	USA
Interferon beta-1a (recombinant human)	Avonex	1/7/99	Treatment of pulmonary fibrosis.	Designated/Withdrawn			N/A	N/A	"Biogen Idec, Inc."	14 Cambridge Center		Cambridge	Massachusetts	2142	USA
Interferon beta-1a (recombinant)	Rebif	12/2/92	Treatment of symptomatic patients with AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.	Designated			N/A	N/A	"EMD Serono, Inc."	One Technology Place		Roackland	Massachusetts	2370	USA
Interferon beta-1a (recombinant)	R-Huifn-Beta	4/3/91	For the systemic treatment of cutaneous malignant melanoma.	Designated/Withdrawn			N/A	N/A	"Biogen, Inc."	14 Cambridge Center		Cambridge	Massachusetts	2142	USA
Interferon beta-1b	Betaseron	11/17/88	Treatment of multiple sclerosis.	Designated/Approved	Approved for Orphan Indication	In ambulatory patients with relapsing-remitting multiple sclerosis to reduce the frequency of clinical exacerbations.	07/23/1993	07/23/2000	Chiron Corp. & Berlex Laboratories	4560 Horton Street		Emeryville	California	94608	USA
Interferon gamma	n/a	10/11/07	Treatment of idiopathic pulmonary fibrosis	Designated			N/A	N/A	mondoBIOTECH Laboratories AG	"Herrengasse 21, 9490 Vaduz"	Liechtenstein				Germany
interferon gamma	n/a	11/4/11	Treatment of Friedreich's ataxia	Designated			N/A	N/A	"Roberto Testi, MD"	School of Medicine	via Michelini-Tocci 82	Rome			Italy
Interferon gamma 1-b	Actimmune	9/30/88	Treatment of chronic granulomatous disease.	Designated/Approved	Approved for Orphan Indication		12/20/1990	12/20/1997	Horizon Pharma Ireland Limited	"Connaught House, 1st Floor"	Dublin 4				Ireland
Interferon gamma-1b	Actimmune	9/30/96	"Delaying time to disease progression in patients with severe, malignant osteopetrosis."	Designated/Approved	Approved for Orphan Indication	"Delaying time to disease progression in patients with severe, malignant osteopetrosis."	02/10/2000	02/10/2007	Horizon Pharma Ireland Limited	"Connaught House, 1st Floor"	1 Burlington Road	Dublin 4			Ireland
Interferon gamma-1b	Actimmune	12/4/95	Treatment of renal cell carcinoma.	Designated			N/A	N/A	Horizon Pharma Ireland Limited	"Connaught House, 1st Floor"	1 Burlington Road	Dublin 4			Ireland
interferon gamma-1b	Actimmune	9/12/02	Treatment of idiopathic pulmonary fibrosis	Designated/Withdrawn			N/A	N/A	"InterMune, Inc."	3280 Bayshore Boulevard		Brisbane	California	94005	USA
interferon gamma-1b	Actimmune	10/1/14	Treatment of Friedreich's Ataxia	Designated			N/A	N/A	Horizon Pharma Ireland Limited	"Connaught House, 1st Floor"	1 Burlington Road	Dublin 4			Ireland
Interferon-alfa-1b	n/a	4/17/01	Treatment of multiple myeloma	Designated			N/A	N/A	Ernest C.Borden	Center for Cancer Drud Discovery and Development	9500 Euclid Avenue	Clevland	Ohio	44195	USA
interferon-alpha secreting autologous micro-organ tissue converting into a biopump	Infradure Biopump	6/14/12	Treatment of chronic hepatitis D	Designated			N/A	N/A	"Medgenics, Inc."	555 California Street	Suite 365	San Francisco	California	94104	USA
"Interleukin-1 alpha, human recombinant"	n/a	6/17/91	For hematopoietic potentiation in aplastic anemia.	Designated/Withdrawn			N/A	N/A	Immunex Corporation	51 University Street		Seattle	Washington	98101	USA
"Interleukin-1 alpha, human recombinant"	n/a	6/17/91	For the promotion of early engraftment in bone marrow transplantation.	Designated/Withdrawn			N/A	N/A	Immunex Corporation	51 University Street		Seattle	Washington	98101	USA
interleukin-1 receptor antagonist anakinra	Kineret	9/15/15	Treatment of Still's disease including systemic juvenile idiopathic arithritis and adult-onset Still's disease.	Designated			N/A	N/A	Swedish Orphan Biovitrum AB	SE-112	75 Stockholm				Sweden
"Interleukin-1 receptor antagonist, human recombinant"	Antril	10/16/92	Prevention and treatment of graft versus host disease in transplant recipients.	Designated			N/A	N/A	Swedish Orphan Biovitrum AB (publ) (SOBI)	SE-112 76		Stockholm			Sweden
"Interleukin-1 receptor antagonist, human recombinant"	Antril	9/23/91	Treatment of juvenile rheumatoid arthritis.	Designated			N/A	N/A	Swedish Orphan Biovitrum AB (publ) (SOBI)	SE-112 76		Stockholm			Sweden
Interleukin-1 Trap	n/a	4/4/05	Treatment of Still's disease including juvenile rheumatoid arthritis and adult-onset Still's disease	Designated			N/A	N/A	"Regeneron Pharmaceuticals, Inc."	777 Old Saw Mill River Road		Tarrytown	New York	10591	USA
Interleukin-2	Teceleukin	5/3/90	In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7119	USA
Interleukin-2	Teceleukin	5/11/90	In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7119	USA
Interleukin-2	Teceleukin	2/5/90	Treatment of metastatic renal cell carcinoma.	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA
Interleukin-2	Teleleukin	2/6/90	Treatment of metastatic malignant melanoma.	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7119	USA
Interleukin-3 human (recombinant)	n/a	5/20/91	Promotion of erythropoiesis in Diamond-Blackfan anemia (congenital pure red cell aplasia).	Designated/Withdrawn			N/A	N/A	Immunex Corporation	51 University Street		Seattle	Washington	98101	USA
"Interleukin-3, human, recombinant"	n/a	9/30/93	For sequential administration with sargramostim to accelerate neutrophil and platelet recovery in patients undergoing autologous bone marrow transplantation for the treatment of Hodgkin's disease or non-Hodgkin's lymphoma.	Designated/Withdrawn			N/A	N/A	Sandoz Pharmaceuticals Corp.	59 Route 10		East Hanover	New Jersey	7936	USA
Intraoral fluoride releasing system	Ifrs	7/31/01	Prevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer	Designated			N/A	N/A	"Digestive Care, Inc."	1120 Win Drive		Bethlehem	Pennsylvania	18017	USA
intravenous carbamazepine	Carnexiv	6/27/13	Treatment of epilepsy patients who cannot take anything by mouth (NPO)	Designated/Approved	Approved for Orphan Indication	"Replacement therapy for oral carbamazepine formulations, when oral administration is temporarily not feasible, in adults with the following seizure types: (1) Partial seizures with complex symptomology; (2)Generalized clonic-tonic seizures; and (3) Mixed seizure patterns which include the above or other partial or generalized seizures"	10/07/2016	10/07/2023	Lundbeck LLC	Four Parkway North		Deerfield	Illinois	60015	USA
Intravenous immune globulin	Vitigam	7/26/07	Treatment of Stage IIB to IV malignant melanoma	Designated			N/A	N/A	GammaCan Ltd.	39 Jerusalem Street					Israel
Intravenous immune globulin (human) 10%	Octagam(R)	7/31/08	Treatment of stiff-person syndrome	Designated			N/A	N/A	"Octapharma USA, Inc."	121 River Street		Hoboken	New Jersey	7030	USA
intraventricular nimodipine	n/a	5/28/15	Treatment of subarachnoid hemorrhage	Designated			N/A	N/A	"Edge Therapeutics, Inc."	211 Warren Street		Newark	New Jersey	7103	USA
Iobenguane I 123	Adreview	12/1/06	For the diagnosis of pheochromocytomas	Designated/Approved	Approved for Orphan Indication	To be used in the detection of primary or metastatic pheochromocytomas or neuroblastomas as an adjunct to other diagnostic tests	09/19/2008	09/19/2015	"GE Healthcare, Inc."	101 Carnegie Center		Princeton	New Jersey	8540	USA
Iobenguane I 123	Adreview	12/1/06	For the diagnosis of neuroblastomas	Designated/Approved	Approved for Orphan Indication	To be used in the detection of primary or metastatic pheochromocytomas or neuroblastomas as an adjunct to other diagnostic tests	09/19/2008	09/19/2015	"GE Healthcare, Inc."	101 Carnegie Center		Princeton	New Jersey	8540	USA
iobenguane I 131	n/a	7/5/07	Treatment of neuroendocrine tumors	Designated			N/A	N/A	"Jubilant DraxImage, Inc."	"Div. of Draxis Specialty Pharmaceuticals, Inc."	"Kirkland, Quebec H9H 4J4"				Canada
Iobenguane I 131	Azedra Ultratrace	1/18/06	Treatment of neuroendocrine tumors	Designated			N/A	N/A	Molecular Insight Pharmaceuticals	160 Second street		Cambridge	Massachusetts	2142	USA
Iobenguane Sulfate I 131	n/a	11/14/84	For use as a diagnostic adjunct in patients with pheochromocytoma.	Designated/Approved/Withdrawn		Adjunctive diagnostic agent in the localization of primary or metastatic pheochromocytomas.	N/A	03/25/2001	University of Michigan	UH B1 H410/0028	1500 E. Medical Center Drive	Ann Arbor	Michigan	48109	USA
Iobenguane Sulfate I-123	Omaclear	10/17/05	"For scintigraphic detection, localization and staging of neuroblastoma."	Designated			N/A	N/A	"Brogan Pharmaceuticals, LLC"	312 Lacebark Street		Schererville	Indiana	46375	USA
iobenguane sulfate I-123	Omaclear	10/21/05	"For the detection, localization, and staging of pheochromocytomas."	Designated			N/A	N/A	"Brogan Pharmaceuticals, Inc."	9800 Connecticut Drive	c/o Purdue Technology Center	Crown Point	Indiana	46307	USA
Iodine 131 6B-iodomethyl-19-norcholesterol	n/a	8/1/84	For use in adrenal cortical imaging.	Designated			N/A	N/A	"David E. Kuhl, M.D."	University of Michigan Medical Center/1500 E. Med.	B1G412 /0028 University Hospital	Ann Arbor	Michigan	48109	USA
Iodine I 123 murine monoclonal antibody to alpha-fetoprotein	n/a	9/30/88	1. Detection of hepatocellular carcinoma and hepatoblastoma 2. Detection of alpha-fetoprotein producing germ cell tumors	Designated/Withdrawn			N/A	N/A	"Immunomedics, Inc."	300 American Road		Morris Plains	New Jersey	7950	USA
Iodine I 123 murine monoclonal antibody to hCG	n/a	11/7/88	Detection of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Designated			N/A	N/A	"Immunomedics, Inc."	300 American Road		Morris Plains	New Jersey	7950	USA
Iodine I 131 bis(indium-diethylenetriaminepentaacetic acid)tyrosyllysine/hMN-14 x m734 F(ab')2 bispecific monoclonal antibody	Pentacea	2/22/00	Treatment of small-cell lung cancer.	Designated			N/A	N/A	"IBC Pharmaceuticals, L.L.C."	300 American Rd.		Morris Plains	New Jersey	7950	USA
Iodine I 131 Lym-1 Monoclonal Antibody	n/a	11/2/87	Treatment of B-cell lymphoma.	Designated/Withdrawn			N/A	N/A	Lederle Laboratories Division	American Cyanamide Company	401 N. Middletown Road	Pearl River	New York	10965	USA
Iodine I 131 murine monoclonal antibody IgG2a to B cell	"Immurait, Ll-2-I-131"	9/18/89	Treatment of B-cell leukemia and B-cell lymphoma.	Designated/Withdrawn			N/A	N/A	"Immunomedics, Inc."	300 American Road		Morris Plains	New Jersey	7950	USA
Iodine I 131 murine monoclonal antibody to alpha-fetoprotein	n/a	9/30/88	1. Treatment of hepatocellular carcinoma and hepatoblastoma 2. Treatment of alpha-fetoprotein producing germ cell tumors	Designated/Withdrawn			N/A	N/A	"Immunomedics, Inc."	300 American Road		Morris Plains	New Jersey	7950	USA
Iodine I 131 murine monoclonal antibody to hCG	n/a	11/7/88	Treatment of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Designated/Withdrawn			N/A	N/A	"Immunomedics, Inc."	300 American Road		Morris Plains	New Jersey	7950	USA
Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B)	131ichtnt-1	2/12/99	Treatment of glioblastoma multiforme and anaplastic astrocytoma.	Designated			N/A	N/A	"Peregrine Pharmaceuticals, Inc."	14282 Franklin Ave.		Tustin	California	92780	USA
Ipatasertib	n/a	4/30/14	For the treatment of gastric cancer including cancer of the gastro-esophageal junction.	Designated/Withdrawn			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
ipilimumab	Yervoy	6/3/04	"Treatment of high risk Stage II, Stage III, and Stage IV melanoma"	Designated/Approved	Approved for Orphan Indication	"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy."	10/28/2015	10/28/2022	Bristol-Myers Squibb Company	P. O. Box 4000		Princeton	New Jersey	8543	USA
ipilimumab	Yervoy	6/3/04	"Treatment of high risk Stage II, Stage III, and Stage IV melanoma"	Designated/Approved	Approved for Orphan Indication	Treatment of unresectable or metastatic melanoma	03/25/2011	03/25/2018	Bristol-Myers Squibb Company	P. O. Box 4000		Princeton	New Jersey	8543	USA
irofulven	n/a	7/27/99	Treatment of renal cell carcinoma.	Designated/Withdrawn			N/A	N/A	"Eisai, Inc."	300 Tice Blvd		Woodcliff Lake	New Jersey	7677	USA
irofulven	n/a	7/6/99	Treatment of ovarian cancer.	Designated/Withdrawn			N/A	N/A	"Eisai, Inc."	300 Tice Blvd		Woodcliff Lake	New Jersey	7677	USA
iron(III)-hexacyanoferrate(II)	Radiogardase	5/1/03	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Designated/Approved	Approved for Orphan Indication	Treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination	10/02/2003	10/02/2010	"Heyl Chemisch-Pharmzeutische Fabrik GMBH & Co, KG"	Goerzallee 253	"D-14167 Berlin, Federal Republic of Germany"				Germany
isavuconazonium sulfate	n/a	10/20/14	Treatment of invasive candidiasis/candidemia	Designated			N/A	N/A	"Astellas Pharma Global Development, Inc."	1 Astellas Way		Northbrook	Illinois	60062	USA
isavuconazonium sulfate	Cresemba	10/25/13	Treatment of zygomycosis	Designated/Approved	Approved for Orphan Indication	Treatment of invasive mucormycosis in patients 18 years of age and older	03/06/2015	03/06/2022	Astellas Pharma Global Development Inc.	1 Astellas Way		Northbrook	Illinois	60062	USA
isavuconazonium sulfate	Cresemba	5/6/13	Treatment of invasive aspergillosis	Designated/Approved	Approved for Orphan Indication	Treatment of invasive aspergillosis in patienst 18 years of age and older	03/06/2015	03/06/2022	Astellas Pharma Global Development Inc.	1 Astellas Way		Northbrook	Illinois	60062	USA
Isobutyramide	Isobutyramide Oral Solution	12/18/92	Treatment of beta-hemoglobinopathies and beta-thalassemia syndromes.	Designated			N/A	N/A	"Perrine, Susan P., M.D."	Boston University	Cancer Research Center	Boston	Massachusetts	2118	USA
Isobutyramide	n/a	5/25/94	Treatment of sickle cell disease and beta thalassemia.	Designated			N/A	N/A	Alpha Therapeutic Corporation	5555 Valley Boulevard		Los Angeles	California	90032	USA
isocitrate dehydrogenase 1 (IDH1)-mutant inhibitor	n/a	6/9/15	Treatment of acute myeloid leukemia (AML)	Designated			N/A	N/A	"Agios Pharmaceuticals, Inc."	88 Sidney Street		Cambridge	Massachusetts	2139	USA
isocitrate dehydrogenase 2-mutant inhibitor	n/a	6/12/14	Treatment of acute myelogenous leukemia	Designated			N/A	N/A	Celgene Corporation	"Corporate Woods Bldg 32, Suite 900"	9225 Indian Creek Parkway	Overland Park	Kansas	66210	USA
isofagomine tartrate	n/a	1/10/06	Treatment of Gaucher disease	Designated			N/A	N/A	"Amicus Therapeutics, Inc."	6 Cedar Brook Drive		Cranbury	New Jersey	8512	USA
"Isoindolin-1,3-Di Thione"	n/a	11/21/16	Treatment of Frontotemporal dementia	Designated			N/A	N/A	"P2D, Inc."	10101 Alliance Road	Suite 105	Cincinnati	Ohio	45242	USA
isotretinoin	n/a	4/10/14	Treatment of congenital ichthyosis	Designated			N/A	N/A	"Patagonia Pharmaceuticals, LLC"	50 Tice Blvd	Suite A35	Woodcliff Lake	New Jersey	7677	USA
Itraconazole	n/a	5/19/16	Treatment of basal cell carcinoma nevus syndrome.	Designated			N/A	N/A	"HedgePath Pharmaceuticals, Inc"	324 South Hyde Park Avenue	Suite 350	Tampa	Florida	33606	USA
itraconazole inhalation powder	n/a	8/16/16	Treatment of pulmonary fungal infections in patients with cystic fibrosis	Designated			N/A	N/A	"Pulmatrix, Inc"	99 Hayden Avenue		Lexington	Massachusetts	2421	USA
Itraconazole suspension	n/a	10/30/08	Topical treatment of fungal otitis externa (otomycosis)	Designated			N/A	N/A	"Fairfield Clinical Trials, LLC"	200 Steep Hill Road		Weston	Connecticut	6883	USA
ivabradine	n/a	3/23/16	Treatment of pediatric patients (0 through 16 years of age) with dilated cardiomyopathy.	Designated			N/A	N/A	"Amgen, Inc.,"	1 Amgen Center Drive		Thousand Oaks	California	91320	USA
ivacaftor	Kalydeco	12/20/06	Treatment of patients with cystic fibrosis	Designated/Approved	Approved for Orphan Indication	Treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene.	01/31/2012	01/31/2019	"Vertex Pharmaceuticals, Inc."	130 Waverly St.		Cambridge	Massachusetts	2139	USA
ixazomib citrate	Ninlaro	2/18/11	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy	11/20/2015	11/20/2022	Millennium Pharmaceuticals	40 Landsdowne St.		Cambridge	Massachusetts	2139	USA
"Japanese encephalitis vaccine (live, attenuated)"	n/a	5/19/99	Prevention of Japanese encephalitis.	Designated			N/A	N/A	"Glovax Co., Ltd."	"Room 307, Koryo Academytel, 437-3"	"Ahyun-Dong, Mapo-Gu, Seoul 121-010"				
"Japanese encephalitis vaccine, inactivated, adsorbed"	Ixiaro	9/25/12	Prevention of Japanese encephalitis virus in pediatric patients.	Designated/Approved	Approved for Orphan Indication	"To extend the age range to include infants, children, and adolescents 2 months to less than 17 years of age for active immunization for the prevention of disease caused by Japanese encephalitis virus."	05/17/2013	05/17/2020	Intercell AG	Campus Vienna Biocenter 3	A-1030	Vienna			Austria
Ketoconazole	Nizoral	3/27/91	For use with cyclosporine A to diminish the nephrotoxicity induced by cyclosporine in organ transplantation.	Designated/Withdrawn			N/A	N/A	Pharmedic Company	28101 Ballard Road		Lake Forest	Illinois	60045	USA
ketotifen	n/a	2/25/15	Treatment of mastocytosis	Designated			N/A	N/A	"Valcrest Pharmaceuticals, LLC"	520 White Plains Road	Suite 500	Tarrytown	New York	10591	USA
Kre-Celazine	n/a	4/1/13	Treatment of juvenile rheumatoid arthritis joint and related tissue inflammation in the pediatric population	Designated			N/A	N/A	All American Pharmaceutical & Natural Foods Corpor	2376 Main Street		Billings	Montana	59105	USA
L-2-oxothiazolidine-4-carboxylic acid	Procysteine	6/14/94	Treatment of adult respiratory distress syndrome.	Designated			N/A	N/A	"Transcend Therapeutics, Inc."	"640 Memorial Drive, 3rd Floor West"		Cambridge	Massachusetts	2139	USA
L-2-oxothiazolidine-4-carboxylic acid	Procysteine	7/30/96	Treatment of amyotrophic lateral sclerosis.	Designated			N/A	N/A	"Transcend Therapeutics, Inc."	"640 Memorial Drive, 3rd Floor West"		Cambridge	Massachusetts	2139	USA
L-5 Hydroxytrytophan	n/a	11/1/84	Treatment of postanoxic intention myoclonus.	Designated			N/A	N/A	"Watson Laboratories, Inc."	33 Ralph Avenue	P.O. Box 30	Copiaque	New York	11726	USA
L-5-hydroxytryptophan	n/a	1/20/99	Treatment of tetrahydrobiopterin deficiency.	Designated			N/A	N/A	"Watson Laboratories, Inc."	311 Bonnie Circle	P.O. Box 1900	Corona	California	91718	USA
"L-amino acids, vitamins and minerals combined with omega-3 fatty acids"	n/a	1/12/11	Treatment of patients with pediatric Crohn's disease	Designated			N/A	N/A	"Immunopath Profile, Inc."	325 Dunes Blvd - Suite 403 (zip code 34110)		Naples	Florida	34110	USA
L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal	n/a	1/18/06	Treatment of Duchenne and Becker muscular dystrophy	Designated			N/A	N/A	CepTor Corporation	200 International Circle		Hunt Valley	Maryland	21030	USA
L-arginyl-L-isoleucyl-L-valyl-L-prolyl-L-alanine-amide	n/a	9/11/13	Treatment of acute radiation syndrome	Designated			N/A	N/A	"Soligenix, Inc."	29 Emmons Drive	Suite C-10	Princeton	New Jersey	8540	USA
L-asparaginase	n/a	3/27/14	Treatment of acute myeloid leukemia	Designated			N/A	N/A	ERYTECH Pharma S.A.	Batiment Adenine	"60, avenue Rockefeller"	Lyon			France
L-asparaginase encapsulated in red blood cells	Graspa	1/6/10	Treatment of acute lymphoblastic leukemia	Designated			N/A	N/A	Erytech Pharma	Batiment Adenine	"60, Avenue Rockfeller"	LYON			France
L-asparaginase encapsulated in red blood cells	Graspa	7/6/12	Treatment of pancreatic cancer.	Designated			N/A	N/A	ERYTECH Pharma	Batiment Adenine	60 Avenue Rockefeller	lyon			France
L-baclofen	Neuralgon	1/30/92	Treatment of intractable spasticity in children with cerebral palsy.	Designated			N/A	N/A	Osmotica Pharmaceutical Corp.	1205 Culbreth Drive	Suite 200	Wilmington	North Carolina	28405	USA
L-baclofen	n/a	12/17/91	Treatment of spasticity associated with spinal cord injury or multiple sclerosis.	Designated			N/A	N/A	Osmotica Pharmaceutical Corp.	1205 Culbreth Drive	Suite 200	Wilmington	North Carolina	28405	USA
L-baclofen	n/a	7/13/90	Treatment of trigeminal neuralgia.	Designated			N/A	N/A	"Fromm, Gerhard M.D."	University Of Pittsburgh School of Medicine		Pittsburgh	Pennsylvania	15261	USA
L-baclofen	n/a	1/6/98	Treatment of trigeminal neuralgia	Designated			N/A	N/A	Osmotica Pharmaceutical Corp.	1205 Culbreth Drive	Suite 200	Wilmington	North Carolina	28405	USA
L-citrulline	n/a	1/9/17	Prevention of clinical sequelae of acute lung injury induced by cardiopulmonary bypass in pediatric patients	Designated			N/A	N/A	"Asklepion Pharmaceuticals, LLC"	729 East Pratt Street	Suite 360	Baltimore	Maryland	21202	USA
L-cycloserine	n/a	8/1/89	Treatment of Gaucher's disease.	Designated			N/A	N/A	"Lev, Meir M.D."	"The City College, City University Of NY Medical Sc"	Convent Avenue at 138 Street	New York	New York	10031	USA
L-cysteine	n/a	5/16/94	For the prevention and lessening of photosensitivity in erythropoietic protoporphyria.	Designated			N/A	N/A	Brigham and Women's Hospital	Channing Laboratory	181 Longwood Ave.	Boston	Massachusetts	2115	USA
L-glutamine	n/a	8/1/01	Treatment of sickle cell disease	Designated			N/A	N/A	"Emmaus Medical, Inc."	"21250 Hawthorne Blvd., Suite 800"		Torrance	California	90503	USA
L-glutamyl-L-tryptophan	n/a	10/20/99	Treatment of AIDS-related Kaposi's sarcoma.	Designated			N/A	N/A	Implicit Bioscience Pty Ltd	P. O. Box 2072.	Toowong Business Center				Australia
L-ornithine phenylacetate	n/a	4/7/10	Treatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure or acute on chronic liver disase	Designated			N/A	N/A	"Ocera Therapeutics, Inc."	5001 South Miami Blvd	Suite 300	Durham	North Carolina	27703	USA
L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	n/a	6/13/16	Treatment to increase survival and improve functioning of pancreatic islets following transplantation	Designated			N/A	N/A	"Araim Pharmaceuticals, Inc."	580 White Plains Road	Suite 210	Tarrytown	New York	10591	USA
L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	n/a	9/13/11	Treatment of neuropathic pain in patients with sarcoidosis.	Designated			N/A	N/A	"Araim Pharmaceuticals, Inc."	712 Kitchawan Road		Ossining	New York	10562	USA
L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	n/a	9/18/09	Prevention of delayed graft function following renal transplant	Designated			N/A	N/A	"Araim Pharmaceuticals, Inc."	712 Kitchawan Road		Ossining	New York	10562	USA
L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	n/a	6/13/16	Treatment of sarcoidosis.	Designated			N/A	N/A	"Araim Pharmaceuticals, Inc."	580 White Plains Road	Suite 210	Tarrytown	New York	10591	USA
L-threonine	Threostat	2/6/89	Treatment of amyotrophic lateral sclerosis.	Designated/Withdrawn			N/A	N/A	Tyson And Associates	12832 Chadron Avenue		Hawthorne	California	90250	USA
L-threonine	n/a	7/24/92	Treatment of spasticity associated with familial spastic paraparesis.	Designated/Withdrawn			N/A	N/A	"Interneuron Pharmaceuticals, Inc."	"99 Hayden Ave., Suite 200"		Lexington	Massachusetts	2421	USA
L-threonyl-L-prolyl-L-prolyl-L-threonine	n/a	4/26/05	Treatment of neuropathic pain associated with spinal cord injury	Designated			N/A	N/A	"Nyxis Neurotherapies, Inc."	1801 Maple Avenue	Suite 4300	Evanston	Illinois	60201	USA
L-tyrosine-L-serine-L-leucine	Cms-024	9/10/04	Treatment of hepatocellular carcinoma.	Designated			N/A	N/A	CMS Peptides Patent Holding Company Limited	"Unit 2106, 21st Floor, Island Place Tower"	510 King's Rd	North Point			Hong Kong
L. reuteri	n/a	8/1/13	"Prevention of necrotizing enterocolitis in preterm infants with birth weight less than or equal to 1,500 grams"	Designated			N/A	N/A	Infant Bacterial Therapeutics	Kungsbroplan 3A	P. O. Box 3242	Stockholm			Sweden
Lactic acid	Aphthaid	6/29/99	"Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients."	Designated			N/A	N/A	"Frontier Pharmaceutical, Inc."	SUNY Farmingdale	Conklin Hall	Farmingdale	New York	11735	USA
"lactic acid bacteria (Lactobacilli, Bifidobacteria, and Steptococci)"	n/a	1/15/02	Treatment of active chronic pouchitis	Designated			N/A	N/A	"VSL Pharmaceuticals, Inc."	800 S. Frederick Ave.		Gaithersburg	Maryland	20877	USA
"lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococcus species)"	n/a	1/15/02	Prevention of disease relapse in patients with chronic pouchitis	Designated			N/A	N/A	"VSL Pharmaceuticals, Inc."	800 S. Frederick Ave.		Gaithersburg	Maryland	20877	USA
Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis	n/a	3/24/15	Prevention of necrotizing enterocolitis (NEC) in premature infants with very low birth weight less than or equal to 1500 grams	Designated			N/A	N/A	Sigma Tau Industrie Farmaceutiche Riunite S.p.A.	Via Pontina	km 30.400 - 00071	Rome			Italy
lactobacillus brevis CD2	n/a	10/4/11	Treatment Behcet's disease	Designated			N/A	N/A	"VSL Pharmaceuticals, Inc."	100 West Road		Towson	Maryland	21204	USA
lactobacillus plantarum	n/a	11/30/16	Treatment of amyotrophic lateral sclerosis (ALS)	Designated			N/A	N/A	"New Biotic, LLC"	19546 Rogan Court		Rowland Heights	California	91748	USA
Lactobin	Lactobin	9/12/90	Treatment of AIDS-associated diarrhea unresponsive to initial antidiarrheal therapy.	Designated/Withdrawn			N/A	N/A	"Roxane Laboratories, Inc."	PO Box 16532		Columbus	Ohio	43216	USA
laminin-111 (human)	n/a	7/21/11	Treatment of Duchenne Muscular Dystrophy	Designated			N/A	N/A	"Prothelia, Inc."	30 Haven Street		Milford	Massachusetts	1757	USA
Lamotrigine	Lamictal	8/23/95	Treatment of Lennox-Gastaut syndrome.	Designated/Approved	Approved for Orphan Indication	Adjunctive treatment of Lennox-Gastaut syndrome in pediatric and adult patients.	08/24/1998	08/24/2005	Glaxo Wellcome Research and Development	5 Moore Drive	P.O. Box 13398	Research Triangle Park	North Carolina	27709	USA
Lanreotide	Somatuline Depot	9/11/00	Treatment for acromegly	Designated/Approved	Approved for Orphan Indication	Long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy	08/30/2007	08/30/2014	"IPSEN, Inc."	27 Maple Street		Milford	Massachusetts	1757	USA
lanreotide acetate	n/a	9/8/11	Treatment of symptoms associated with carcinoid syndrome	Designated			N/A	N/A	"Ipsen Biopharmaceuticals, Inc."	106 Allen Road		Basking Ridge	New Jersey	7920	USA
lanreotide acetate	Somatuline Depot	8/25/11	Treatment of neuroendocrine tumors	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with unresectable,well- or moderately-differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival"	12/16/2014	12/16/2021	"Ipsen Biopharmaceuticals, Inc."	106 Allen Road		Basking Ridge	New Jersey	7920	USA
lapatinib	Tykerb	5/29/09	Treatment of ErbB2 positive gastric cancer	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Jersey	7936	USA
lapatinib ditosylate hydrochloride	Tykerb	5/29/09	Treatment of ErbB2 positive esophageal cancer	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Hampshire	7936	USA
Laromustine	Cloretazine	3/27/14	Treatment of acute myelogenous leukemia	Designated			N/A	N/A	"Nanotherapeutics, Inc."	13859 Progress Blvd	Suite 300	Alachua	Florida	32615	USA
laromustine	Onrigin	10/21/04	Treatment of acute myelogenous leukemia	Designated			N/A	N/A	"Vion Pharmaceuticals, Inc."	Four Science Park		New Haven	Connecticut	6511	USA
laronidase	Aldurazyme	9/24/97	Treatment of patients with mucopolysaccharidosis-I.	Designated/Approved	Approved for Orphan Indication	Treatment for patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms	04/30/2003	04/30/2010	"BioMarin Pharmaceutical, Inc."	105 Digital Drive		Novato	California	94949	USA
late stage human motor neutron progenitors	Motorgraft(Tm)	11/25/09	Treatment of spinal muscular atrophy	Designated/Withdrawn			N/A	N/A	Caladrius Biosciences	106 Allen Road	4th Floor	Basking Ridge	New Jersey	7920	USA
Latrodectus immune F(ab)2	Analatro	6/18/01	Treatment of black widow spider envenomations	Designated			N/A	N/A	"Instituto Bioclon, S.A. de C.V."	"Tlalpan,"	No. 4687 Colonia Toriello Guerra	Tlalpan			Mexico
lebrikizumab	n/a	3/9/15	Treatment of idiopathic pulmonary fibrosis	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
ledipasvir/sofosbuvir	Harvoni	10/12/16	Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients	Designated			N/A	N/A	"Gilead Sciences, Inc."	333 Lakeside Drive		Foster City	California	94404	USA
Leflunomide	n/a	10/18/96	Prevention of acute and chronic rejection in patients who have received solid organ transplants.	Designated			N/A	N/A	"Williams, MD, James W."	"Rush-Presbyterian-St. Luke's Medical Ctr., Dept. o"	1653 West Congress Parkway	Chicago	Illinois	60612	USA
lenalidomide	Revlimid	4/29/15	Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue	Designated			N/A	N/A	Celgene Corporation	400 Connell Drive	Suite 7000	Berkley Heights	New Jersey	7922	USA
lenalidomide	Revlimid	9/20/01	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	For use in combination with dexamethasone for the treatment of patients with multiple myeloma who have not received at least one prior therapy (first line treatment)	02/17/2015	02/17/2022	Celgene Corporation	400 Connell Drive	Suite 7000	Berkeley Heights	New Jersey	7922	USA
lenalidomide	Revlimid	1/17/07	Treatment of chronic lymphocytic leukemia	Designated			N/A	N/A	Celgene Corporation	86 Morris Avenue		Summit	New Jersey	7901	USA
lenalidomide	Revlimid	4/27/09	Treatment of mantle cell lymphoma	Designated/Approved	Approved for Orphan Indication	"Treatment of mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib."	06/05/2013	06/05/2020	Celgene Corporation	"400 Connell Dr., Suite 7000"	Connell Corporate Park	Berkeley Heights	New Jersey	7922	USA
lenalidomide	Revlimid	3/28/11	Treatment of diffuse large B-cell lymphoma	Designated			N/A	N/A	Celgene Corporation	86 Morris Avenue		Summit	New Jersey	7901	USA
lenalidomide	Revlimid	9/17/13	Treatment of follicular lymphoma	Designated			N/A	N/A	Celgene Corporation	400 Connell Drive	Suite 7000	Berkeley Heights	New Jersey	7922	USA
lenalidomide	Revlimid	9/20/01	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	For use in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy	06/29/2006	06/29/2013	Celgene Corporation	400 Connell Drive	Suite 7000	Berkeley Heights	New Jersey	7922	USA
lenalidomide	Revlimid	1/4/17	Treatment of nodal marginal zone lymphoma	Designated			N/A	N/A	Celgene Corporation	400 Connell Drive	Suite 7000	Berkley Heights	New Jersey	7922	USA
lenalidomide	n/a	1/4/17	Treatment of splenic marginal zone lymphoma	Designated			N/A	N/A	Celgene Corporation	400 Connell Drive	Suite 7000	Berkley Heights	New Jersey	7922	USA
lenalidomide	Revlimid	1/29/04	Treatment of myelodysplastic syndromes	Designated/Approved	Approved for Orphan Indication	Treatment of patients with transfusion dependant anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5 q cytogenetic abnormality with or without additional cytogenetic abnormalities	12/27/2005	12/27/2012	Celgene Corporation	86 Morris Avenue		Summit	New Jersey	7901	USA
Lentiviral vector containing the human ABCA4 gene	Stargen (Tm)	4/30/10	Treatment of Stargardt disease	Designated			N/A	N/A	"Sanofi US Services, Inc."	55 Corporate Drive	Mail Stop D225A	Bridgewater	New Jersey	8807	USA
lentiviral vector containing the human liver and erythroid pyruvate kinase gene	n/a	3/23/16	Treatment of pyruvate kinase deficiency.	Designated			N/A	N/A	Centro de Investigacion Biomedica en RED (CIBER)	Monforte de Lemos	3-5 Pabellion 11	Madrid			Spain
Lentiviral vector containing the human MY07A gene	Ushstat(Tm)	5/17/10	Treatment of retinitis pigmentosa associated with Usher syndrome 1B gene defect.	Designated			N/A	N/A	"Sanofi US Services, Inc."	55 Corporate Drive	Mail Stop 55D-220B	Bridgewater	New Jersey	8807	USA
Lentiviral vector encoded with a human beta-globin gene plasmid	Thalagen	1/11/06	Treatment of beta-thalassemia major and beta-thalassemia intermedia	Designated			N/A	N/A	Memorial Sloan-Kettering Cancer Center	1275 York Avenue	Box 65	New York	New York	10065	USA
lenvatinib	n/a	3/27/14	Treatment of hepatocellular carcinoma	Designated			N/A	N/A	"Eisai, Inc."	155 Tice Blvd		Woodcliff Lake	New Jersey	7677	USA
lenvatinib	n/a	3/26/14	Treatment of stage IIB to Stage IV melanoma	Designated			N/A	N/A	"Eisai, Inc."	155 Tice Blvd		Woodcliff Lake	New Jersey	7677	USA
lenvatinib	Lenvima	12/27/12	"Treatment of follicullar, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer"	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine refractory differentiated thyroid cancer"	02/13/2015	02/13/2022	"Eisai, Inc."	155 Tice Blvd		Woodcliff Lake	New Jersey	7677	USA
Lepirudin	Refluden	2/13/97	Treatment of heparin-associated thrombocytopenia type II.	Designated/Approved	Approved for Orphan Indication	For anticoagulation in patients with heparin-induced thrombocytopenia and associated thromboembolic disease in order to prevent further thromboembolic complications.	03/06/1998	03/06/2005	Hoechst Marion Roussel	Frankfurt am Main	P.O. Box 1140	Marburg			Germany
lestaurtinib	n/a	9/3/09	Treatment of Philadelphia-negative classic myeloproliferative disorders	Designated			N/A	N/A	"Teva Branded Pharmaceutical Products R&D, Inc."	41 Moores Road	P. O. Box 4011	Frazer	Pennsylvania	19355	USA
Lestaurtinib	n/a	3/24/06	Treatment of acute myeloid leukemia	Designated			N/A	N/A	"Teva Branded Pharmaceutical Products R&D, Inc."	41 Moores Road	P. O. Box 4011	Frazer	Pennsylvania	19355	USA
letermovir	n/a	12/12/11	Prevention of human cytomegalovirus viremia and disease in at risk populations	Designated			N/A	N/A	Merck Sharpe & Dhome Corporation	"P. O. Box 1000, UG2D-68"		North Wales	Pennsylvania	19454	USA
Leucovorin	Leucovorin Calcium	12/8/86	For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.	Designated/Approved	Approved for Orphan Indication	For use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.	12/12/1991	12/12/1998	Immunex Corporation	51 University Street		Seattle	Washington	98101	USA
Leucovorin	Leucovorin Calcium	8/17/88	For rescue use after high dose methotrexate therapy in the treatment of osteosarcoma.	Designated/Approved	Approved for Orphan Indication		08/31/1988	08/31/1995	Immunex Corporation	51 University Street		Seattle	Washington	98101	USA
Leucovorin calcium	Wellcovorin	6/23/88	For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.	Designated/Withdrawn			N/A	N/A	Glaxo Wellcome Research and Development	5 Moore Drive	PO Box 13398	Research Triangle Park	North Carolina	27709	USA
leukocyte interleukin	Multikine	5/4/07	Neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck	Designated			N/A	N/A	CEL-SCI Corporation	8229 Boone Blvd.	Suite 802	Vienna	Virginia	22182	USA
leukotriene A4 hydrolase inhibitor	n/a	1/26/15	Treatment of cystic fibrosis	Designated			N/A	N/A	"Celtaxsys, Inc."	"201 17th Street, NW"	Suite 530	Atlanta	Georgia	30363	USA
Leupeptin	n/a	9/18/90	For use as an adjunct to microsurgical peripheral nerve repair.	Designated			N/A	N/A	"Neuromuscular Adjuncts, Inc."	S.U.N.Y. at Stony Brook	H.S.C. T18-020	Stony Brook	New York	11794	USA
Leuprolide acetate	Lupron Injection	7/25/88	Treatment of central precocious puberty	Designated/Approved	Approved for Orphan Indication	Treatment of children with central precocious puberty	04/16/1993	04/16/2000	"Tap Pharmaceuticals, Inc."	2355 Waukegan Road		Deerfield	Illinois	60015	USA
levetiracetam	Keppra	4/30/10	Treatment of neonatal seizures	Designated			N/A	N/A	University of California	UCSD Medical Center 0935		La Jolla	California	92093	USA
Levocabastine HCl ophthalmic suspension 0.05%	n/a	2/29/88	Treatment of vernal keratoconjunctivitis.	Designated/Withdrawn			N/A	N/A	Iolab Pharmaceuticals	500 Iolab Drive		Claremont	California	94608	USA
Levocarnitine	Carnitor	2/28/84	Treatment of genetic carnitine deficiency.	Designated/Approved	Approved for Orphan Indication		04/10/1986	04/10/1993	"Sigma-Tau Pharmaceuticals, Inc."	9841 Washingtonian Blvd	Suite 500	Gaithersburg	Maryland	20878	USA
Levocarnitine	Carnitor	4/7/97	Treatment of zidovudine-induced mitochondrial myopathy.	Designated			N/A	N/A	"Sigma-Tau Pharmaceuticals, Inc."	9841 Washingtonian Blvd	Suite 500	Gaithersburg	Maryland	20878	USA
Levocarnitine	Carnitor	11/22/93	Treatment of pediatric cardiomyopathy.	Designated			N/A	N/A	"Sigma-Tau Pharmaceuticals, Inc."	9841 Washingtonian Blvd	Suite 500	Gaithersburg	Maryland	20878	USA
Levocarnitine	Carnitor	9/6/88	Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.	Designated/Approved	Approved for Orphan Indication	Prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis.	12/15/1999	12/15/2006	"Sigma-Tau Pharmaceuticals, Inc."	9841 Washingtonian Blvd	Suite 500	Gaithersburg	Maryland	20878	USA
Levocarnitine	Carnitor	11/24/86	Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.	Designated/Withdrawn			N/A	N/A	"Sigma-Tau Pharmaceuticals, Inc."	9841 Washingtonian Blvd	Suite 500	Gaithersburg	Maryland	20878	USA
Levocarnitine	Carnitor	7/26/84	Treatment of primary and secondary carnitine deficiency of genetic origin.	Designated/Approved	Approved for Orphan Indication	Treatment of primary systemic carnitine deficiency. (approved 12/27/85) Treatment of secondary carnitine deficiency. (approved 12/16/92)	12/16/1992	12/16/1999	"Sigma-Tau Pharmaceuticals, Inc."	9841 Washingtonian Blvd	Suite 500	Gaithersburg	Maryland	20878	USA
levocarnitine	Carnitor	11/15/89	1. Prevention of secondary carnitine deficiency in valproic acid toxicity 2. Treatment of secondary carnitine deficiency in valproic acid toxicity	Designated			N/A	N/A	"Sigma-Tau Pharmaceuticals, Inc."	9841 Washingtonian Blvd	Suite 500	Gaithersburg	Maryland	20878	USA
Levodopa and carbidopa	Duodopa	1/18/00	Treatment of late stage Parkinson's disease	Designated/Approved	Approved for Orphan Indication	Treatment of motor flucuations in patients with advanced Parkinson's disease	01/09/2015	01/09/2022	"AbbVie, Inc."	1 N. Waukegan Road		North Chicago	Illinois	60064	USA
Levofloxacin	n/a	2/27/08	Treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis patients	Designated			N/A	N/A	Horizon Orphan LLC	7 Hamilton Landing	Suite 100	Novato	California	94949	USA
levoleucovorin	Fusilev	12/18/90	For use in combination chemotherapy with the approved agent 5-fluorouracil in the palliative treatment of metastatic adenocarcinoma of the colon and rectum	Designated/Approved	Approved for Orphan Indication	For use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer	04/29/2011	04/29/2018	"Spectrum Pharmaceuticals, Inc."	157 Technology Drive		Irvine	California	92618	USA
Levoleucovorin	Fusilev	8/1/91	For use in conjunction with high-dose methotrexate in the treatment of osteosarcoma.	Designated/Approved	Approved for Orphan Indication	Levoleucovorin rescue is indicated after high-dose methotrexate therapy in osteosarcoma. Levoleucovorin is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists	03/07/2008	03/07/2015	"Spectrum Pharmaceuticals, Inc."	157 Technology Drive		Irvine	California	92618	USA
levomefolate calcium	n/a	2/10/15	Treatment of megaloblastic anemia caused by folate deficiency	Designated			N/A	N/A	Cox Biosciences LLC	"267 West 71st Street, #3F"		New York	New York	10023	USA
Levomethadyl acetate hydrochloride	Orlaam	1/24/85	Treatment of heroin addicts suitable for maintenance on opiate agonists.	Designated/Approved	Approved for Orphan Indication	For the management of opiate dependence.	07/09/1993	07/09/2000	Biodevelopment Corporation	"8180 Greensboro Drive, Suite 1000"		McLean	Virginia	22102	USA
levothyroxine sodium	n/a	4/26/11	The preservation of organ function in brain-dead organ donors.	Designated			N/A	N/A	"Fera Pharmaceuticals, LLC"	134 Birch Hill Road		Locust Valley	New York	11560	USA
liarozole	n/a	6/18/04	Treatment of congenital ichthyosis	Designated/Withdrawn			N/A	N/A	"Stiefel Laboratories, Inc."	20 T.W. Alexander Drive	P. O. Box 14910	Research Triangle Park	North Carolina	27709	USA
Lidocaine patch 5%	Lidoderm Patch	10/24/95	"For relief of allodynia (painful hypersensitivity), and chronic pain in postherpetic neuralgia."	Designated/Approved	Approved for Orphan Indication		03/19/1999	03/19/2006	"Teikoku Pharma USA, Inc."	745-D Camden Ave.		Campbell	California	95008	USA
linsitinib	n/a	3/9/12	Treatment of adrenocortical carcinoma	Designated/Withdrawn			N/A	N/A	"Astellas Pharma Global Development, Inc."	1 Astellas Way		Northbrook	Illinois	60062	USA
lintuzumab	n/a	3/20/07	Treatment of myelodysplastic syndrome	Designated/Withdrawn			N/A	N/A	"Seattle Genetics, Inc."	21823 30th Drive Southeast		Bothell	Washington	98021	USA
lintuzumab	n/a	1/30/07	Treatment of acute myeloid leukemia.	Designated/Withdrawn			N/A	N/A	"Seattle Genetics, Inc."	21823 30th Drive Southeast		Bothell	Washington	98021	USA
lintuzumab	Zamyl	9/9/02	Treatment of acute myelogenous leukemia	Designated/Withdrawn			N/A	N/A	"Protein Design Labs, Inc."	34801 Campus Drive		Fremont	California	94555	USA
Liothyronine sodium injection	Triostat	7/30/90	Treatment of myxedema coma/precoma.	Designated/Approved	Approved for Orphan Indication	Treatment of myxedema coma/precoma.	12/31/1991	12/31/1998	SmithKline Beecham Pharmaceuticals	One Franklin Plaza		Philadelphia	Pennsylvania	19101	USA
"lipase, amylase, and protease"	Theraclec-Total	1/23/02	Treatment of pancreatic insufficiency	Designated/Withdrawn by OPD			N/A	N/A	Altus Biologics Inc.	625 Putnam Avenue		Cambridge	Massachusetts	2139	USA
Lipid/DNA human cystic fibrosis gene	n/a	4/8/96	Treatment of cystic fibrosis.	Designated/Withdrawn			N/A	N/A	Genzyme Corporation	Metrowest Place	15 Pleasant St. Connector	Framingham	Massachusetts	1701	USA
liposomal amikacin	Arikace	3/9/06	Treatment of bronchopulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients	Designated			N/A	N/A	"Insmed, Inc."	Princeton Corporate Plaza	"9 Deer Park Drive, Suite C"	Monmouth Junction	New Jersey	8852	USA
liposomal amikacin	Arikace	3/25/13	Treatment infections caused by non-tuberculous mycobacteria	Designated			N/A	N/A	"Insmed, Inc."	10 Finderne Avenue	Building 10	Bridgewater	New Jersey	8817	USA
liposomal amikacin	Arikace	8/25/09	Treatment of bronchiectasis in patients with Pseudomonas aeruginosa or other susceptible microbial pathogens	Designated			N/A	N/A	"Insmed, Inc."	Princeton Corpoarate Plaza	Suite C	Monmouth Junction	New Jersey	8852	USA
Liposomal amphotericin B	Ambisome	12/10/96	Treatment of cryptococcal meningitis.	Designated/Approved	Approved for Orphan Indication	Treatment of disseminated cryptococcosis including meningitis.	08/11/1997	08/11/2004	"Fujisawa USA, Inc."	3 Parkway North Center		Deerfield	Illinois	60015	USA
Liposomal amphotericin B	Ambisome	12/6/96	Treatment of visceral leishmaniasis.	Designated/Approved	Approved for Orphan Indication	Treatment of visceral leishmaniasis.	08/11/1997	08/11/2004	"Fujisawa USA, Inc."	3 Parkway North Center		Deerfield	Illinois	60015	USA
Liposomal amphotericin B	Ambisome	12/10/96	Treatment of histoplasmosis.	Designated			N/A	N/A	"Fujisawa USA, Inc."	3 Parkway North Center		Deerfield	Illinois	60015	USA
Liposomal annamycin	n/a	6/17/05	Treatment of acute myeloid leukemia	Designated			N/A	N/A	"Callisto Pharmaceuticals, Inc."	420 Lexington Avenue		New York	New York	10170	USA
Liposomal annamycin	n/a	6/17/05	Treatment of acute lymphoblastic leukemia	Designated			N/A	N/A	"Callisto Pharmaceuticals, Inc."	420 Lexington Avenue		New York	New York	10170	USA
liposomal busulfan	Busulipo	6/24/13	For use as a conditioning regimen for patients with malignancies undergoing autologous or allogenic hematopoietic stem cell transplantation	Designated			N/A	N/A	Pharmalink AB	Engelbrekts kyrkogata 7B	SE-114 26 Stockholm				Sweden
Liposomal ciprofloxacin for inhalation	n/a	12/27/06	Management of bronchiectasis	Designated			N/A	N/A	Aradigm Corporation	3929 Point Eden Way		Hayward	California	94545	USA
Liposomal ciprofloxacin for inhalation	n/a	4/19/06	Management of cystic fibrosis	Designated			N/A	N/A	Aradigm Corporation	3929 Point Eden Way		Hayward	California	94545	USA
liposomal ciprofloxacin plus ciprofloxacin	n/a	6/1/12	For the management of cystic fibrosis	Designated			N/A	N/A	Aradigm Corporation	3929 Point Eden Way		Hayward	California	94545	USA
Liposomal cisplatin	Lipova-Pt	5/23/06	Treatment of ovarian cancer	Designated			N/A	N/A	Eleison Pharmaceuticals LLC	263 13th Avenue	Suite 375	St. Petersburg	Florida	33701	USA
Liposomal cyclosporin A	Cyclospire	4/30/98	For aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow transplantation.	Designated			N/A	N/A	"Vernon Knight, M.D."	"Baylor College of Medicine, Dept. of Molecular Phy"	One Baylor Plaza	Houston	Texas	77030	USA
liposomal cyclosporine	n/a	5/11/09	Treatment of bronchiolitis obliterans	Designated			N/A	N/A	PARI Pharma GmbH	Moosstrasse 3					Germany
liposomal cyclosporine for inhalation	n/a	6/24/08	Prevention of bronchiolitis obliterans.	Designated			N/A	N/A	PARI Pharma GmbH	Moosstrasse 3					Germany
Liposomal doxorubicin hydrochloride	Sarcodoxome	12/27/06	Treatment of soft tissue sarcomas	Designated			N/A	N/A	GP-Pharm SA	"Pol. Ind. Els Vinyets els Fogars n 2,"	Quinti de Mediona	Barcelona			Spain
liposomal encapsulated paclitaxel	n/a	1/21/15	Treatment of ovarian cancer	Designated			N/A	N/A	"Insys Development Company, Inc."	"1333 South Sprectum Blvd, Suite 100"		Chandler	Arizona	85286	USA
liposomal gadodiamide	n/a	11/12/08	Treatment of glioma.	Designated			N/A	N/A	"MedGenesis Therapeutix, Inc."	730-730 View Street	"Victoria, BC V8W 3Y7"				Canada
Liposomal Glutathione	n/a	4/30/10	Support of glutathione deficiency in individuals with inborn errors of metabolism of glutathione (IEMG)	Designated			N/A	N/A	"Your Energy Systems, LLC"	555 Bryant Street #305		Palo Alto	California	94301	USA
liposomal glutathione	n/a	5/18/16	Treatment of Dengue Virus infection.	Designated			N/A	N/A	"Your Energy Systems, LLC"	555 Bryant Street #305		Palo Alto	California	94301	USA
liposomal irinotecan	n/a	7/21/11	Treatment of pancreatic cancer	Designated/Approved	Approved for Orphan Indication	"For use in combination with 5-fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas that has progressed following gemcitabine-based therapy"	10/22/2015	10/22/2022	"Merrimack Pharmaceuticals, Inc."	1 Kendall Square		Cambridge	Massachusetts	2139	USA
Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala -gylcerolidpalmitoyl	Immther	6/10/98	Treatment of Ewing's sarcoma.	Designated			N/A	N/A	Endorex Corp.	900 North Shore Drive		Lake Bluff	Illinois	60044	USA
Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala -gylcerolidpalmitoyl	Immther	6/10/98	Treatment of osteosarcoma.	Designated			N/A	N/A	Endorex Corp.	900 North Shore Drive		Lake Bluff	Illinois	60044	USA
Liposomal nystatin	Nyotran	6/13/00	Treatment of invasive fungal infections.	Designated			N/A	N/A	The University of Texas	M.D. Anderson Cancer Center	Unit 038	Houston	Texas	77030	USA
liposomal P-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide	n/a	4/27/15	Treatment of acute myeloid leukemia	Designated			N/A	N/A	"Bio-Path Holdings, Inc."	4710 Bellaire Blvd	Suite 210	Houston	Texas	77401	USA
liposomal p-ethoxy growth receptor bound protein-2 antisense product	n/a	12/5/03	Treatment of chronic myelogenous leukemia	Designated			N/A	N/A	"Bio-Path, Inc."	"3293 Harrison Blvd., Suite 230"		Ogden	Utah	84403	USA
Liposomal prostaglandin E1 injection	n/a	4/25/96	Treatment of acute respiratory distress syndrome.	Designated/Withdrawn			N/A	N/A	"Liposome Company, Inc."	One Research Way		Princeton	New Jersey	8540	USA
liposomal topotecan hydrochloride	n/a	10/30/08	Treatment of gliomas	Designated			N/A	N/A	"MedGenesis Therapeutix, Inc."	730-730 View Street	"Victoria, BC V8W 3Y7"				Canada
liposomal vinorelbine	n/a	10/12/16	Treatment of cutaneous t-cell lymphoma (CTCL)	Designated			N/A	N/A	"Taiwan Liposome Company, Ltd."	"11F-1, No. 3, Yuanqu Street"		Taipei City			Taiwan
liposomal }-galactosylceramide	Lip. Alpha Galactosylceramide	9/28/12	Prevention of graft-versus-host disease	Designated			N/A	N/A	REGiMMUNE Corporation	320 Logue Avenue		Mountain View	California	94043	USA
"Liposomal-cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane-Pt (II)"	Aroplatin	9/1/99	Treatment of malignant mesothelioma.	Designated/Withdrawn			N/A	N/A	Antigenics Incorporated	3 Forbes Road		Lexington	Massachusetts	2421	USA
liposome encapsulated paclitaxel	n/a	12/3/14	Treatment of gastric cancer	Designated			N/A	N/A	"Insys Development Company, Inc."	"1333 South Sprectum Blvd, Suite 100"		Chandler	Arizona	85286	USA
Liposome encapsulated recombinant interleukin-2	n/a	6/20/94	Treatment of cancers of the kidney and renal pelvis	Designated			N/A	N/A	"Oncothyreon Canada, Inc."	2011 - 94th Street NW	Canada T6N 1H1				Canada
Liposome encapsulated recombinant interleukin-2	n/a	11/25/91	Treatment of brain and CNS tumors.	Designated			N/A	N/A	"Oncothyreon Canada, Inc."	"2011-94 St., NW"	Suite 200				Canada
lisinopril oral solution	n/a	1/27/15	Treatment of primary hypertension with complications and secondary hypertension in pediatric patients (ages 0 through 16 years of age)	Designated/Withdrawn by OPD			N/A	N/A	"BioRamo, LLC"	5319 NW 35th Terrace		Ft. Lauderdale	Florida	33309	USA
lisinopril oral solution	n/a	10/14/15	Treatment of hypertension in pediatric patients 0 through 16 years of age.	Designated/Withdrawn by OPD			N/A	N/A	"Silvergate Pharmaceuticals, Inc."	6251 Greenwood Plaza Blvd.	Suite 101	Greenwood Village	Colorado	80111	USA
Lisofylline	n/a	6/10/99	Treatment of patients undergoing induction therapy for acute myeloid leukemia.	Designated			N/A	N/A	"Cell Therapeutics, Inc."	501 Elliott Avenue West	Suite 400	Seattle	Washington	98119	USA
listeria monocytogenes	n/a	9/5/13	Treatment of pancreatic cancer	Designated			N/A	N/A	"Aduro BioTech, Inc."	740 Heinz Avenue		Berkeley	California	94710	USA
lisuride	n/a	1/17/13	Treatment of pulmonary arterial hypertension	Designated			N/A	N/A	Sinoxa Pharma GmbH	Thomasiusstr.13					Germany
lithium citrate tetrahydrate (in reverse micelle formulation)	n/a	12/13/10	Treatment of Huntington's disease.	Designated			N/A	N/A	Medesis Pharma	L'Oree des Mas	34 670 Baillargues				France
live attenuated bioengineered Listeria monocytogenes immunotherapy	n/a	5/21/14	Treatment of osteosarcoma.	Designated			N/A	N/A	"Advaxis, Inc."	305 College Road East		Princeton	New Jersey	8540	USA
live attenuated bioengineered Listeria monocytogenes immunotherapy	n/a	11/4/13	Treatment of human papilloma virus-associated head and neck cancer	Designated			N/A	N/A	"Advaxis, Inc."	305 College Road East		Princeton	New Jersey	8540	USA
live attenuated E. Coli expressing Beta catenin shRNA	n/a	12/20/10	Treatment of Familial Adenomatous Polyposis	Designated			N/A	N/A	Marina Biotech	One Kendall Square	"Building 400, Suite B4401"	Cambridge	Massachusetts	2139	USA
live E. coli Nissle bacterium modified to assimilate ammonia	n/a	8/22/16	Treatment of urea cycle disorders	Designated			N/A	N/A	"Synlogic, Inc."	200 Sidney Street	#320	Cambridge	Massachusetts	2139	USA
Live-attenuated Listeria monocytogenes actA/inlB/human mesothelin (hMeso) Strain hMeso38	Not Determined	3/24/15	Treatment of mesothelioma.	Designated			N/A	N/A	"Aduro BioTech, Inc."	740 Heinz Avenue		Berkeley	California	94710	USA
"LOAd703, a modified adenovirus 5/35 containing a CMV promoter-driven transgene cassette with the human transgenes for a membrane-bound CD40 ligand (TMZ-CD40L) and full length 4-1BBL"	n/a	5/4/15	Treatment of pancreatic cancer	Designated			N/A	N/A	Lokon Pharma AB	"Dag Hammarskjoldsvag 40c, 751 83"	Uppsala				Sweden
Lodoxamide tromethamine	Alomide Ophthalmic Solution	10/16/91	Treatment of vernal keratoconjunctivitis.	Designated/Approved	Approved for Orphan Indication	"Treatment of ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, vernal keratitis."	09/23/1993	09/23/2000	"Alcon Laboratories, Inc."	6201 South Freeway		Fort Worth	Texas	76134	USA
lomitapide	n/a	3/3/11	Treatment of Familial Chylomicronemia	Designated			N/A	N/A	"Aegerion Pharmaceuticals, Inc."	One Main St	Suite 800	Cambridge	Massachusetts	2142	USA
lomitapide	Juxtapid	10/23/07	Treatment of homozygous familial hypercholesterolemia	Designated/Approved	Approved for Orphan Indication	"Adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH)."	12/21/2012	12/21/2019	"Aegerion Pharmaceuticals, Inc."	"101 Main St., Suite 1850"		Cambridge	Massachusetts	2142	USA
Lonafarnib	n/a	11/19/13	Treatment of Hepatitis Delta Virus (HDV)infection	Designated			N/A	N/A	"Eiger Biopharmaceuticals, Inc."	PO Box 430		San Carlos	California	94070	USA
lonafarnib	n/a	4/18/11	Treatment of Hutchinson-Gilford progeria syndrome	Designated			N/A	N/A	"The Progeria Research Foundation, Inc."	P. O. Box 3453		Peabody	Massachusetts	1961	USA
long acting recombinantFactor VIIa-CTP3	n/a	2/27/14	Treatment and prophylaxis of bleeding episodes in patients with hemophilia A or B with inhibitors to factor VIII or factor IX	Designated			N/A	N/A	"PROLOR Biotech, Ltd"	7 Golda Meir St.	P. O. Box 4101	Nes Ziona			Israel
losartan	n/a	12/12/11	Treatment of Marfan Syndrome	Designated			N/A	N/A	National Marfan Foundation	22 Manhhasset Avenue		Port Washington	New York	11050	USA
low molecular weight dextran sulfate	Ibsolvmir(R)	7/6/11	Treatment to mobilze progenitor cells prior to stem cell transplantation	Designated			N/A	N/A	TikoMed AB	P.O. Box 81 (Karlsfaltsvagen 349)	"SE-263 03, Viken"				Sweden
low molecular weight dextran sulfate	Ibsolvmir	10/20/09	Prevention of graft rejection during pancreatic islet transplantation	Designated			N/A	N/A	TikoMed AB	Dag Hammarskjolds vag 10A					Sweden
Loxoribine	n/a	2/24/92	Treatment of common variable immunodeficiency.	Designated/Withdrawn			N/A	N/A	R. W. Johnson Pharmaceutical Research Institute	"Route 202, P.O. Box 300"		Raritan	New Jersey	8869	USA
lucerastat	n/a	10/29/15	Treatment of Fabry Disease.	Designated			N/A	N/A	Actelion Pharmaceuticals Ltd	16 Gewerbestrasse		Allschwil			Switzerland
Lucinactant	Surfaxin	7/30/96	Treatment of meconium aspiration syndrome in newborn infants	Designated/Withdrawn			N/A	N/A	"Windtree Therapeutics, Inc."	2600 Kelly Road	Suite 100	Warrington	Pennsylvania	18976	USA
Lucinactant	"Surfaxin(R), Aerosurf(R)"	10/21/10	Treatment of cystic fibrosis.	Designated			N/A	N/A	"Windtree Therapeutics, Inc."	2600 Kelly Road	Suite 100	Warrington	Pennsylvania	18976	USA
Lucinactant	Surfaxin	10/21/05	Treatment of bronchopulmonary dysplasia in premature infants.	Designated			N/A	N/A	"Windtree Therapeutics, Inc."	2600 Kelly Road	Suite 100	Warrington	Pennsylvania	18976	USA
Lucinactant	Surfaxin	7/17/95	Treatment of acute respiratory distress syndrome in adults.	Designated			N/A	N/A	"Windtree Therapeutics, Inc."	2600 Kelly Road	Suite 100	Warrington	Pennsylvania	18976	USA
Lucinactant	Surfaxin	10/18/95	Treatment of respiratory distress syndrome in premature infants.	Designated			N/A	N/A	"Windtree Therapeutics, Inc."	2600 Kelly Road	Suite 100	Warrington	Pennsylvania	18976	USA
Lucinactant	Surfaxin	5/23/06	Prevention of bronchopulmonary dysplasia in premature infants	Designated			N/A	N/A	"Windtree Therapeutics, Inc."	2600 Kelly Road	Suite 100	Warrington	Pennsylvania	18976	USA
lumacaftor/ivacaftor	Orkambi	6/30/14	Treatment of cystic fibrosis	Designated/Approved	Approved for Orphan Indication	Treatment of cystic fibrosis (CF) in patients age 6-11 year old who are homozygous for the F508del mutation in the CFTR gene	09/28/2016	09/28/2023	Vertex Pharmaceuticals Inc.	50 Northern Avenue		Boston	Massachusetts	2210	USA
lumacaftor/ivacaftor	Orkambi	6/30/14	Treatment of cystic fibrosis	Designated/Approved	Approved for Orphan Indication	Treatment of cystic fibrosis in patients age 12 years and older who are homozygous for F508del mutation in the CFTR gene	07/02/2015	07/02/2022	Vertex Pharmaceuticals Inc.	50 Northern Avenue		Boston	Massachusetts	2210	USA
lurbinectedin	n/a	8/20/12	Treatment of ovarian cancer	Designated			N/A	N/A	"PharmaMar USA, Inc."	205 East 42nd St.	Suite 15003	New York	New York	10017	USA
lutetium (177Lu)-edotreotide	n/a	5/21/15	Treatment of gastro-entero-pancreatic neuroendocrine tumors	Designated			N/A	N/A	ITG Isotope Technologies Garching GmbH	Lichtenbergstrasse 1	85748 Garching				Germany
Lysine acetylsalicylate injectable	n/a	8/1/89	Treatment of pain and fever secondary to sickle cell disease crisis.	Designated/Withdrawn			N/A	N/A	G.D. Searle & Company	4901 Searle Parkway		Skokie	Illinois	60077	USA
lyso-thermosensitive lipsomal doxorubicin	Thermodox (R)	3/17/09	Treatment of hepatocellular carcinoma	Designated			N/A	N/A	Celsion Corporation	997 Lenox Drive	Suite 100	Lawrenceville	New Jersey	8648	USA
lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase	n/a	9/10/08	Treatment of mucopolysaccharidosis Type IVA (Morquio Syndrome)	Designated			N/A	N/A	Vivendy Therapeutics LTD	Peter Merian -Strasse 45					Switzerland
MA09-hRPE cells	n/a	2/2/10	Treatment of Stargardt's macular dystrophy	Designated			N/A	N/A	Astellas Pharma Global Development Inc.	1 Astellas Parkway		Northbrook	Illinois	60062	USA
macitentan	Opsumit	9/3/09	Treatment of pulmonary arterial hypertension	Designated/Approved	Approved for Orphan Indication	"Treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). Opsumit also reduced hospitalization for PAH."	10/18/2013	10/18/2020	Actelion Pharmaceuticals Ltd	Gewerbestrasse 16		Allschwil			Switzerland
macitentan	n/a	4/14/09	Treatment of idiopathic pulmonary fibrosis.	Designated/Withdrawn			N/A	N/A	Actelion Pharmaceuticals Ltd.	Gewerbestrasse 16					Switzerland
Mafenide acetate solution	Sulfamylon Solution	7/18/90	For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.	Designated/Approved	Approved for Orphan Indication		06/05/1998	06/05/2005	"Mylan Laboratories, Inc."	781 Chestnut Ridge Road	P.O. Box 4310	Morgantown	West Virginia	26504	USA
Mafosfamide	n/a	1/21/03	Treatment of neoplastic meningitis	Designated			N/A	N/A	Baxter Healthcare Corporation	Route 120 & Wilson Road		Round Lake	Illinois	60073	USA
MAGE-A3 cancer therapeutic Trojan peptide vaccine	n/a	11/24/08	Treatment of MAGE-A3 expressing head and neck squamous cell carcinoma	Designated			N/A	N/A	"Gliknik, Inc."	801 W. Baltimore Street	Suite 501A	Baltimore	Maryland	21201	USA
magnesium lysinate bis eicosapentaenoate	n/a	12/23/15	Treatment of familial adenomatous polyposis.	Designated			N/A	N/A	Thetis Pharmaceuticals	167 Old Post Road	2nd Floor	Southport	Connecticut	6890	USA
manganese (II) chloride tetrahydrate (with L-alanine and vitamin D3 as promoters of absorption)	n/a	9/26/13	Use as a targeted contrast agent for diagnostic MRI for the detection and localization of focal liver lesions in patients where use of gadolinium based contrast agents may be medically inadvisable or where gadolinium based contrast agents cannot be administered	Designated			N/A	N/A	CMC Contrast AB	Scion DTU	DK-2800 Lyngby				Denmark
Manganese superoxide dismutase mimetic	n/a	2/27/08	Prevention of radiation- or chemotherapy-induced oral mucositis in cancer patients	Designated			N/A	N/A	"Galera Therapeutics, LLC"	4041 Forest Park Avenue		St. Louis	Missouri	63108	USA
Mannitol	Bronchitol	2/11/05	For use to facilitate clearance of mucus in patients with bronchiectasis and in patients with cystic fibrosis at risk for bronchiectasis	Designated			N/A	N/A	Pharmaxis Ltd.	10 Rodborough Rd.		NSW 2086			Australia
mannopentaose phosphate sulfate	n/a	4/27/04	"Treatment of high-risk Stage II, Stage III, and Stage IV melanoma"	Designated			N/A	N/A	Medigen Biotechnology Corp.	"14F, No. 3, Yuancyu St."	Nangang District				
maralixibat	n/a	9/4/13	Treatment of progressive familial intrahepatic cholestasis	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	300 Shire Way		Lexington	Massachusetts	2421	USA
maribavir	n/a	6/7/11	Treatment of clinically significant cytomegalovirus viremia and disease in at-risk patients.	Designated			N/A	N/A	"Shire ViroPharma, Inc."	300 Shire Way		Lexington	Massachusetts	2421	USA
maribavir	n/a	2/1/07	Prevention of cytomegalovirus viremia and disease in the populations at risk.	Designated			N/A	N/A	"Shire ViroPharma, Inc."	300 Shire Way		Lexington	Massachusetts	2421	USA
Marijuana	n/a	5/25/99	Treatment of HIV-associated wasting syndrome.	Designated			N/A	N/A	"Multidisciplinary Association for Psychedelic Studies, Inc."	3 Francis St.		Belmont	Massachusetts	2478	USA
marizomib	n/a	9/21/15	Treatment of malignant glioma.	Designated			N/A	N/A	Triphase Research & Development I Corp.	3210 Merryfield Row		San Diego	California	92121	USA
Marizomib	n/a	12/13/13	Treatment of multiple myeloma	Designated			N/A	N/A	Triphase Research and Development I Corp.	3210 Merryfield Row		San Diego	California	92121	USA
MART-1 adenoviral gene therapy for malignant melanoma	n/a	3/28/97	Treatment of metastatic melanoma.	Designated/Withdrawn			N/A	N/A	Genzyme Corporation	500 Kendall Street		Cambridge	Massachusetts	1701	USA
masitinib	n/a	7/21/09	Treatment of patients with pancreatic cancer	Designated			N/A	N/A	AB Science	"3, avenue George V"					France
masitinib	n/a	4/20/05	Treatment of malignant gastrointestinal stromal tumors	Designated			N/A	N/A	AB Science	"3, avenue George V"		Paris			France
masitinib	n/a	9/14/05	Treatment of mastocytosis	Designated			N/A	N/A	AB Science	"3, avenue George V"					France
masitinib mesylate	n/a	9/14/15	Treatment of gastric cancer including cancer of the gastroesophageal junction	Designated			N/A	N/A	AB Science	"3, avenue George V"		Paris			France
masitinib mesylate	n/a	3/18/15	Treatment of amyotrophic lateral sclerosis.	Designated			N/A	N/A	AB Science	"3, avenuve George V"	75008 Paris				France
Matrix metalloproteinase inhibitor	Galardin	12/5/91	Treatment of corneal ulcers.	Designated			N/A	N/A	"Glycomed, Inc"	860 Atlantic Avenue		Alameda	California	94501	USA
MaxAdFVIII	n/a	3/3/03	Treatment of Hemophilia A	Designated			N/A	N/A	GenStar Therapeutics Corporation	10865 Altman Row	Suite 200	San Diego	California	92121	USA
maytansinoid conjugated humanized monoclonal antibody against FOLRI	n/a	7/14/14	Treatment of ovarian cancer	Designated			N/A	N/A	"ImmunoGen, Inc."	830 Winter Street		Waltham	Massachusetts	2451	USA
Maytansinoid DM-1 Conjugated Humanized Monoclonal Antibody N901	n/a	8/17/10	Treatment of small cell lung cancer.	Designated/Withdrawn			N/A	N/A	"ImmunoGen, Inc."	830 Winter Street		Waltham	Massachusetts	2451	USA
maytansinoid DM1-conjugated humanized monoclonal antibody N901	n/a	3/2/10	Treatment of Merkel cell carcinoma	Designated/Withdrawn			N/A	N/A	"ImmunoGen, Inc."	830 Winter Street		Waltham	Massachusetts	2451	USA
maytansinoid DM1-conjugated humanized monoclonal antibody N901	n/a	11/29/10	Treatment of multiple myeloma.	Designated/Withdrawn			N/A	N/A	"ImmunoGen, Inc."	830 Winter Street		Waltham	Massachusetts	2451	USA
maytansinoid-conjugated humanized monoclonal antibody against CD37	n/a	5/12/16	Treatment of diffuse large B-cell lymphoma	Designated			N/A	N/A	"ImmunoGen, Inc."	830 Winter Street		Waltham	Massachusetts	2451	USA
mazindol	n/a	7/6/16	Treatment of narcolepsy	Designated			N/A	N/A	NLS-0 Pharma AG	10 Breitenweg	CH-6370	Stans NW			Switzerland
Mazindol	Sanorex	12/8/86	Treatment of Duchenne muscular dystrophy.	Designated			N/A	N/A	"Collipp, Platon J. M.D."	176 Memorial Dr.		Jesup	Georgia	31545	USA
MCMV5322A/MCMV3068A	n/a	11/22/11	Prevention of maternal-fetal transmission of congenital CMV in pregnant women who acquire CMV infection during pregnancy	Designated/Withdrawn			N/A	N/A	Genentech	1 DNA Way	MS#241B	South San Francisco	California	94080	USA
mebendazole	Vermox 500 Mg Chewable Tablets	9/3/14	"Treatment of single or mixed gastrointestinal infestations by Trichuris trichiura (whipworm), Ascaris lumbricoides (large roundworm), and Ancylostoma duodenale and Nectar americanus (hookworm)."	Designated/Approved	Approved for Orphan Indication	treatment of patients one year of age and older withgastrointestinal infections caused by Ascaris lumbricoides (roundworm) and Trichuris trichiura (whipworm)	10/19/2016	TBD	"Janssen Pharmaceutical Research & Development, LLC"	920 Route 202 South		Raritan	New Jersey	8869	USA
Mecamylamine	Inversine	10/14/98	Treatment of Tourette's syndrome.	Designated			N/A	N/A	"Targacept, Inc."	200 East First St.	Suite 300	Winston-Salem	North Carolina	27101	USA
Mecasermin	Increlex	12/12/95	Treatment of growth hormone insensitivity syndrome.	Designated/Approved	Approved for Orphan Indication	Long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone.	08/30/2005	08/30/2012	"Ipsen Biopharmaceuticals, Inc."	106 Allen Road		Basking Ridge	New Jersey	7920	USA
Mecasermin	Myotrophin	8/5/91	Treatment of amyotrophic lateral sclerosis.	Designated/Withdrawn			N/A	N/A	"Teva Branded Pharmaceutical Products R&D, Inc."	41 Moores Road		Frazer	Pennsylvania	19355	USA
mecasermin	Iplex	12/3/07	Treatment of myotonic dystrophy	Designated			N/A	N/A	"Insmed, Inc."	10 Finderne Avenue	Building 10	Bridgewater	New Jersey	8817	USA
mecasermin rinfabate	Iplex	7/23/12	Treatment of amyotropic lateral sclerosis	Designated			N/A	N/A	"PCUT BioPartners, Inc."	2196 Glenkirk Drive		San Jose	California	95124	USA
mecasermin rinfabate	n/a	9/20/12	Prevention of retinopathy of prematurity in premature infants born at risk for the disease	Designated			N/A	N/A	Premacure AB	Dag Hammarskjolds vag 10B	SE-751 83	Uppsala			Sweden
mecasermin rinfabate	Iplex	5/17/02	Treatment of growth hormone insensitivity syndrome (GHIS)	Designated/Approved	Approved for Orphan Indication	Treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone	12/12/2005	12/12/2012	"Insmed, Inc."	Princeton Corporate Plaza	"9 Deer Park Drive, Suite C"	Monmouth Junction	New Jersey	8852	USA
"mecasermin, recombinant human insulin-like growth factor-1"	Increlex	9/21/15	Treatment of Rett Syndrome.	Designated			N/A	N/A	Keck Graduate Institute of Applied Life Sciences	535 Watson Drive		Claremont	California	91711	USA
meclorethamine	Valchlor	8/17/04	Treatment of mycosis fungoides	Designated/Approved	Approved for Orphan Indication	Topical treatment of Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.	08/23/2013	08/23/2020	Actelion Pharmaceuticals Ltd.	Gewerberstrass16	Allschwil CH-4123				Switzerland
Medroxyprogesterone acetate	Hematrol	2/22/01	Treatment of immune thrombocytopenic purpura.	Designated			N/A	N/A	"ZaBeCor Pharmaceutical Company, LLC"	821 Westview Street		Philadelphia	Pennsylvania	19119	USA
mefloquine HCL	Lariam	4/13/88	"For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs"	Designated/Approved	Approved for Orphan Indication	Treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax	05/02/1989	05/02/1996	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA
mefloquine HCL	Lariam	4/13/88	"For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs"	Designated/Approved	Approved for Orphan Indication	Prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs	05/03/1989	05/03/1996	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA
Mefloquine HCl	Mephaquin	7/22/87	Treatment and prevention of chloroquine-resistant Falciparummalaria	Designated			N/A	N/A	Mepha AG	4143 Dornach	Aesch Basel				Switzerland
Megestrol acetate	Megace	4/13/88	"Treatment of patients with anorexia, cachexia, or significant weight loss (=/>10% of baseline body weight) and confirmed diagnosis of AIDS."	Designated/Approved	Approved for Orphan Indication	"Treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immune deficiency syndrome."	09/10/1993	09/10/2000	Bristol-Myers Squibb Pharmaceutical Research Institute	2400 West Lloyd Expressway		Evansville	Indiana	47721	USA
Melanoma autologous dendritic cell vaccine	n/a	9/6/06	Treatment of stage IIIb through IV metastatic melanoma	Designated			N/A	N/A	Caladrius Biosciences	18301 Von Karman	Suite 130	Irvine	California	92612	USA
Melanoma cell vaccine	Canvaxin	10/13/94	Treatment of invasive melanoma.	Designated			N/A	N/A	CancerVax Corporation	2110 Rutherford Road		Carlsbad	California	92008	USA
Melanoma peptide vaccine	n/a	3/29/05	"Treatment of HLA-A2+ patients with stage IIB, IIC, III, and IV malignant melanoma"	Designated			N/A	N/A	Bristol-Myers Squibb Research Inst	5 Research Parkway	P. O. Box 5100	Wallingford	Connecticut	6492	USA
Melanoma vaccine	Melacine	12/20/89	Treatment of stage III - IV melanoma.	Designated			N/A	N/A	"Ribi ImmunoChem Research, Inc."	533 Old Corvallis Road		Hamilton	Montana	59840	USA
melarsoprol-hydroxypropylbetadex	n/a	9/13/13	Treatment of human African trypanosomiasis (sleeping sickness)	Designated			N/A	N/A	"Peter Kennedy, CBE, MD, PhD, DSc, FRCP FMedSci,"	"Glasgow University, Neurology Dept., Institute of"	"Neurlogy Block, Southern General Hospital-G51 4TF"	Glasgow			United Kingdom
melatonin	n/a	11/3/16	Treatment of smith-magenis syndrome in combination with a beta-blocker	Designated			N/A	N/A	Therapicon SrL	21 Via Malachia Marchesi de Taddei		Milano			Italy
Melatonin	n/a	11/15/93	Treatment of circadian rhythm sleep disorders in blind people with no light perception.	Designated			N/A	N/A	"Sack, Robert, M.D."	Oregon Health Sciences University	3181 S.W. Sam Jackson Park Road	Portland	Oregon	97201	USA
Melatonin	Circadin	7/9/04	Treatment of non-24-hour sleep-wake disorder in blind individuals without light perception	Designated			N/A	N/A	"Neurim Pharmaceuticals, Ltd."	8 Hanechoshet St.		Tel-Aviv			Israel
melatonin	n/a	4/12/13	Treatment of neonatal hypoxic ischemic encephalopathy	Designated			N/A	N/A	Scharper S.p.A.	Viale Ortles 12		Milan			Italy
melatonin	n/a	1/25/17	Treatment of necrotizing enterocolitis	Designated			N/A	N/A	Therapicon SrL	21 Via Malachia Marchesi de Taddei		Milano			Italy
meloxicam	Mobic	11/22/02	Treatment of juvenile rheumatoid arthritis	Designated/Approved	Approved for Orphan Indication	For relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients 2 years of age or older	08/11/2005	08/11/2012	"Boehringer Ingelheim Pharmaceuticals, Inc."	900 Ridgebury Road	P. O. Box 368	Ridgefield	Connecticut	6877	USA
Melphalan	Alkeran For Injection	3/3/92	For use in hyperthermic regional limb perfusion to treat metastatic melanoma of the extremity.	Designated/Withdrawn			N/A	N/A	Glaxo Wellcome Research and Development	5 Moore Drive	PO Box 13398	Research Triangle Park	North Carolina	27709	USA
melphalan	n/a	11/19/12	Treatment of retinoblastoma	Designated			N/A	N/A	"Icon Bioscience, Inc."	1253 Reamwood Avenue		Sunnyvale	California	94089	USA
Melphalan	Alkeran For Injection	2/24/92	Treatment of patients with multiple myeloma for whom oral therapy is inappropriate.	Designated/Approved	Approved for Orphan Indication	For the palliative treatment of patients with multiple myeloma for whom oral melphalan is not appropriate.	11/18/1992	11/18/1999	Glaxo Wellcome Inc.	5 Moore Drive		Research Triangle Park	North Carolina	27709	USA
melphalan	n/a	11/19/12	Treatment of Stage IIB through IV melanoma	Designated			N/A	N/A	"OncoTx, LLC"	9 Brandeis Road		Newton	Massachusetts	2459	USA
melphalan	Evomela	11/24/08	High dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation	Designated/Approved	Approved for Orphan Indication	for high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma	03/10/2016	03/10/2023	"Spectrum Pharmaceuticals, INc."	157 Technology Drive		Irvine	California	92618	USA
melphalan	n/a	7/14/15	Treatment of cholangiocarcinoma.	Designated			N/A	N/A	"Delcath Systems, Inc."	1301 Avenue of the Americas	43rd Floor	New York	New York	10019	USA
melphalan flufenamide hydrochloride	n/a	3/16/15	"Treatment of plasma cell myeloma, also referred to as multiple myeloma"	Designated			N/A	N/A	Oncopeptides AB	Vastra Tradgardsgatan 15	111 53 Stockholm				Sweden
melphalan hydrochloride	n/a	11/12/08	Treatment of patients with cutaneous melanoma.	Designated			N/A	N/A	"Delcath Systems, Inc."	566 Queensbury Avenue		Queensbury	New York	12804	USA
melphalan hydrochloride	n/a	9/26/13	Treatment of patients with hepatocellular carcinoma	Designated			N/A	N/A	"Delcath Systems, Inc."	566 Queensbury Avenue		Queensbury	New York	12804	USA
melphalan hydrochloride	n/a	11/12/08	Treatment of patients with ocular (uveal) melanoma.	Designated			N/A	N/A	"Delcath Systems, Inc."	566 Queensbury Avenue		Queensbury	New York	12804	USA
melphalan hydrochloride	n/a	5/22/09	Treatment of neuroendocrine tumors	Designated			N/A	N/A	"Delcath Systems, Inc."	810 Seventh Avenue	35th Floor	New York	New York	10019	USA
Menadione Sodium Bisulfite	n/a	5/14/14	For the treatment of autosomal dominant polycystic kidney disease	Designated			N/A	N/A	IC-MedTech Corporation	9902 Indian Creek Lane		El Cajon	California	92021	USA
menadione sodium bisulfite	n/a	5/14/14	Treatment of autosomal dominant polycystic liver disease	Designated			N/A	N/A	IC-MedTech Corporation	9902 Indian Creek Lane		El Cajon	California	92021	USA
menaquinone	Menaquinonegold	9/4/12	Treatment of calciphylaxis	Designated			N/A	N/A	"Nu Science Trading, LLC"	428 East Thunderbird Road	Suite 510	Phoenix	Arizona	85022	USA
menatetrenone	Mk4(R)	11/2/10	Treatment of acute promyelocytic leukemia.	Designated			N/A	N/A	"NBI Pharmaceuticals, Inc."	c/o Neil & Co CPAs	"1184 N. 15th Ave., Suite 1"	Bozeman	Montana	59715	USA
menatetrenone	Mk4(R)	2/4/11	Treatment of myelodysplastic syndrome.	Designated			N/A	N/A	"NBI Pharmaceuticals, Inc."	1087 Stoneridge Drive		Bozeman	Montana	59718	USA
menatetrenone	Mk4	3/17/11	Treatment of acute myeloid leukemia	Designated			N/A	N/A	"NBI Pharmaceuticals, Inc."	1087 Stoneridge Drive		Bozeman	Montana	59718	USA
menatetrenone	Mk4(R)	11/2/10	Treatment of hepatocellular carcinoma (HCC).	Designated			N/A	N/A	"NBI Pharmaceuticals, Inc."	1087 Stoneridge Drive		Bozeman	Montana	59718	USA
menatetrenone and Vitamin D3	n/a	8/22/11	Treatment of myelodysplastic syndrome	Designated			N/A	N/A	"NBI Pharmaceuticals, Inc."	c/o Neil & Co CPAs	"1184 N. 15th Ave., Suite 1"	Bozeman	Montana	59715	USA
mepivacaine	n/a	1/8/07	Treatment of postherpetic neuralgia	Designated			N/A	N/A	"Relmada Therapeutics, Inc."	546 Fifth Avenue	14th Floor	New York	New York	10036	USA
mepivacaine	n/a	10/18/06	Treatment of painful HIV-associated neuropathy	Designated			N/A	N/A	"Relmada Therapeutics, Inc."	546 Fifth Avenue	14th Floor	New York	New York	10036	USA
mepolizumab	n/a	5/28/04	For first-line treatment in patients with hypereosinophilic syndrome	Designated			N/A	N/A	GlaxoSmithKline LLC	Corporation Service Company	Suite 400	Wilmington	Delaware	19808	USA
mepolizumab	n/a	7/14/11	Treatment of Churg-Strauss Syndrome.	Designated			N/A	N/A	GlaxoSmithKline LLC	Corporation Service Company	Suite 400	Wilmington	Delaware	19808	USA
mercaptopurine oral solution	Purixan	8/20/12	Treatment of acute lymphoblastic leukemia in pediatric patients	Designated/Approved	Approved for Orphan Indication	Treatment of patients with acute lymphoblastic leukemia as part of a combination regimen.	04/28/2014	04/28/2021	Nova Laboratories Limited	Martin House	"Wigston, Leicester LE18 4YL"	England			United Kingdom
Meropenem	Merrem Iv	4/27/00	"Management of acute pulmonary exacerbations, in cystic fibrosis patients, due to respiratory tract infection with susceptible organisms."	Designated/Withdrawn			N/A	N/A	AstraZeneca Pharmaceuticals	1800 Concord Pike	PO Box 15437	Wilmington	Delaware	19850	USA
mesalamine	Canasa	1/19/10	Treatment of pediatric ulcerative colitis	Designated			N/A	N/A	"Aptalis Pharma US, Inc."	100 Somerset corporate Blvd		Bridgewater	New Jersey	8807	USA
mesalamine and N-acetycysteine	n/a	9/10/09	Treatment of pediatric patients with ulcerative colitis (inclusive through age 16 years)	Designated			N/A	N/A	"Altheus Therapeutics, Inc."	755 Research Parkway	Suite 435	Oklahoma City	Oklahoma	73104	USA
mesalamine; 5-aminosalicylic acid	Lialda	2/27/08	Treatment of ulcerative colitis in pediatric patients (revised indication 10/21/2010).	Designated			N/A	N/A	Shire	725 Chesterbrook Blvd.		Wayne	Pennsylvania	19087	USA
"mesencephalic, astrocyte-derived neurotrophic factor"	n/a	9/10/15	Treatment of retinal artery occlusion.	Designated			N/A	N/A	"Amarantus BioScience Holdings, Inc."	655 Montgomery Street	Suite 900	San Francisco	California	94111	USA
mesenchymal stromal cells secreting neurotrophic factors	Nurown	2/4/11	Treatment of Amyotrophic Lateral Sclerosis	Designated			N/A	N/A	BrainStorm Cell Therapeutics Ltd.	"12 Bazel St., Kiryat Arie"					Israel
Mesna	n/a	12/16/87	Inhibition of the urotoxic effects induced by oxazaphosphorine compounds such as cyclophosphamide.	Designated/Withdrawn			N/A	N/A	"Asta Medica , Inc."	890 East St.		Tewksbury	Massachusetts	1876	USA
Mesna	Mesnex	11/14/85	For use as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.	Designated/Approved	Approved for Orphan Indication		12/30/1988	12/30/1995	Degussa Corporation	65 Challenger Road		Ridgefield Park	New Jersey	7660	USA
mesylate synthetic small molecule inhibitor of HDAC and PI3K	n/a	9/6/16	Treatment of nuclear protein in testis (NUT) midline carcinoma	Designated			N/A	N/A	"Curis, Inc."	4 Maguire Road		Lexington	Massachusetts	2421	USA
met-enkephalin; Met-N	n/a	2/18/11	Treatment of pancreatic cancer.	Designated			N/A	N/A	"NBI Pharmaceuticals, Inc."	c/o Neil & Co CPAs	"1184 N. 15th Ave., Suite 1"	Bozeman	Montana	59715	USA
metadoxine	n/a	12/16/13	Treatment of Fragile X Syndrome	Designated			N/A	N/A	"Alcobra, Inc."	2 Weizman Street		Tel-Aviv			Israel
"metavert, N-hydroxy-4-(5-((4-methoxyphenyl)amino)-1,3,4-oxadiazol-2-yl)benzamide"	n/a	7/6/16	Treatment of pancreatic cancer	Designated			N/A	N/A	"Avenzoar Pharmaceuticals, Inc."	662 Encinitas Blvd	Suite 248	Encinitas	California	92024	USA
metformin	n/a	5/29/14	Treatment of pediatric polycystic ovary syndrome	Designated			N/A	N/A	EffRx Pharmaceuticals SA	Wolleraustrass 41 B	8807 Freienbach (SZ)				Switzerland
methimazole and liothyronine sodium	n/a	6/2/16	Treatment of glioblastoma multiforme.	Designated			N/A	N/A	Musli Thyropeutics Ltd	6 HaGefen Street		zur Moshe			Israel
Methionine/L-methionine	n/a	8/21/96	Treatment of AIDS myelopathy.	Designated			N/A	N/A	"Genopia USA, Inc."	"90 Gold Street, 6N"		New York	New York	10038	USA
Methotrexate	Amethopterin	8/28/14	Treatment of Myasthenia Gravis	Designated			N/A	N/A	The Universtiy of Kanasa Medical Center	3901 Rainbow Blvd	MSN 2012	Kanasa City	Kansas	66160	USA
methotrexate	Rheumatrex	8/23/93	Treatment of juvenile rheumatoid arthritis.	Designated/Withdrawn			N/A	N/A	Wyeth-Ayerst Laboratories	P.O. Box 8299		Philadelphia	Pennsylvania	19101	USA
methotrexate	n/a	8/20/09	Treatment of acute lymphoblastic leukemia	Designated			N/A	N/A	Orbona Pharma Ltd	Old Chambers	93-94 West Street	England			United Kingdom
methotrexate oral liquid formulation	n/a	3/18/15	Treatment of acute lymphoblastic leukemia in pediatric patients aged 0 through 16 years.	Designated			N/A	N/A	Chesapeake Therapeutics	1498-M Reistertown Road	Suite 313	Pikesville	Maryland	21208	USA
methotrexate oral solution	n/a	8/27/15	"Treatment of oligoarticular juvenile idiopathic arthritis (persistent oligoarthritis, psoriatic juvenile idiopathic arthritis, enthesitis-related arthritis, or undifferentiated arthritis) and polyarticular juvenile idiopathic arthritis in children 0 through 16 years of age"	Designated			N/A	N/A	"Silvergate Pharmaeuticals, Inc."	6251 Greenwood Plaza Blvd	Suite 101	Greenwood Village	Colorado	80111	USA
methotrexate oral solution	n/a	5/28/15	Treatment of acute lymphoblastic leukemia in pediatric patients (0 through 16 years of age)	Designated			N/A	N/A	"Silvergate Pharmaceuticals, Inc."	6251 Greenwood Plaza Blvd.	Suite 101	Greenwood Village	Colorado	80111	USA
Methotrexate sodium	Methotrexate	10/21/85	Treatment of osteogenic sarcoma.	Designated/Approved	Approved for Orphan Indication	For the use of high dose methotrexate with leucovorin rescue in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor.	04/07/1988	04/07/1995	Lederle Laboratories	Division of American Cyanamid Company	401 N. Middletown Road	Pearl River	New York	10965	USA
Methotrexate with laurocapram	Methotrexate/Azone	10/15/90	Topical treatment of mycosis fungoides.	Designated			N/A	N/A	"Echo Therapeutics, Ltd."	8 Penn Center	1628 JFK Blvd	Philadelphia	Pennsylvania	19103	USA
methoxsalen	Uvadex	5/12/94	For the prevention of acute rejection of cardiac allografts	Designated			N/A	N/A	"Therakos, Inc."	10 North High Street	Suite 300	West Chester	Pennsylvania	19380	USA
Methoxsalen	Uvadex	10/14/98	For use in conjunction with the UVAR photopheresis system to treat graft versus host disease.	Designated			N/A	N/A	"Therakos, Inc."	1001 Route 202		Raritan	New Jersey	8869	USA
"Methyl O-4-O-[2-[2-[2-[2-[[N-[(1R)-1-[[4-(aminoiminomethyl)phenyl]methyl]-2-oxo-2-(1-piperidinyl)ethyl]-N2-[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]-L-???&?_???-aspararginyl-4-aminobutanoyl-N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno["	n/a	4/18/11	Prevention of ischemia reperfusion injury associated wth solid organ transplantation	Designated			N/A	N/A	Endotis Pharma	"102, avenue Gaston Roussel"					France
methyldopa	n/a	1/12/17	Treatment of type 1 diabetes in DQ8 positive patients with residual beta cell function	Designated			N/A	N/A	IM Therapeutics LLC	11001 West 120th Avenue	Suite 400	Broomfield	Colorado	80021	USA
methylene blue	n/a	7/24/12	Treatment of methemoglobinemia	Designated			N/A	N/A	"Fera Pharmaceuticals, LLC"	134 Birch Hill Road		Locust Valley	New York	11560	USA
methylene blue injection	n/a	8/11/12	Treatment of congenital and acquired methemoglobinemia	Designated			N/A	N/A	"Luitpold Pharmaceuticals, Inc."	One Luitpold Drive	P. O. Box 9001	Shirley	New York	11967	USA
methylene blue0.5%	Provayblue	12/18/12	Treatment of hereditary and acquired methemoglobinemia	Designated/Approved	Approved for Orphan Indication	For treatment of pediatric and adult patients with acquired methemoglobinemia.	04/08/2016	04/08/2023	Provepharm SAS	Technopote de Chateau-Combert	13013 Marseille				France
Methylnaltrexone	Relistor	6/17/96	Treatment of chronic opioid-induced constipation unresponsive to conventional therapy.	Designated/Withdrawn by OPD			N/A	N/A	"Progenics Pharmaceuticals, Inc."	765 Old Saw Mill River Rd.		Tarrytown	New York	10591	USA
methylparaben suberohydroxamic acid phenyl ester	n/a	4/15/13	Treatment of cutaneous T-cell lymphoma	Designated			N/A	N/A	Medivir AB	Box 1086		Huddinge			Sweden
methylprednisolone oral suspension	n/a	9/19/16	Treatment of adrenal insufficiency in pediatric patients	Designated			N/A	N/A	Generic Specialty Pharma	"Unit 10, Block 3"	City North Business Campus	Stamullin			Ireland
metreleptin	n/a	8/22/01	Treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy	Designated			N/A	N/A	"Aegerion Pharnaceuticals, Inc."	101 Main Street	Suite 1850	Cambridge	Massachusetts	2142	USA
metreleptin	Myalept	8/22/01	Treatment of metabolic disorders secondary to lipodystrophy	Designated/Approved	Approved for Orphan Indication	Adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.	02/24/2014	02/24/2021	"Aegerion Pharmaceuticals, Inc."	101 Main Street	Suite 1850	Cambridge	Massachusetts	2142	USA
Metronidazole	Metrogel	10/24/91	Treatment of perioral dermatitis.	Designated			N/A	N/A	"Galderma Laboratories, Inc."	P.O. Box 331329		Fort Worth	Texas	76163	USA
metronidazole	n/a	4/26/11	Treatment of pouchitis.	Designated			N/A	N/A	S.L.A. Pharma Limited (UK)	Elite House	"Watford, Hertfordshire. WD25 7SA."				United Kingdom
metronidazole	n/a	4/5/16	Treatment of clostridium difficile infection in pediatric patients (0 through 16 years of age).	Designated			N/A	N/A	"Appili Therapeutics, Inc."	1344 Summer Street	Suite 415	Halifax	Nova Scotia		Canada
metronidazole	n/a	9/17/08	Treatment of pouchitis	Designated			N/A	N/A	Avivia Project BV	Leeuwenhoekweg 12	5482 TK Schijndel				Netherlands
Metronidazole (topical)	Metrogel	10/22/87	Treatment of acne rosacea.	Designated/Approved	Approved for Orphan Indication		11/22/1988	11/22/1995	"Galderma Laboratories, Inc."	P.O. Box 331329		Fort Worth	Texas	76163	USA
Metronidazole (topical)	Flagyl	11/24/87	"Treatment of grade III and IV, anaerobically infected, decubitus ulcers."	Designated/Withdrawn			N/A	N/A	Searle	4901 Searle Parkway		Skokie	Illinois	60077	USA
Metronidazole 10% ointment	n/a	11/8/07	Topical treatment of active perianal Crohn's disease	Designated			N/A	N/A	SLA Pharma (UK) Ltd	Elite House	Hill Farm Industrial Estate	Watford WD25 7SA			United Kingdom
metyrapone	n/a	9/25/12	Treatment of Cushing's syndrome	Designated			N/A	N/A	Laboratoire HRA Pharma	"15 rue Beranger,"		Paris			France
metyrosine	Demser	7/25/08	Treatment of velocardiofacial syndrome associated psychosis.	Designated			N/A	N/A	"Cerberus Princeton, LLC"	c/o Cerberus Capital Management L.P.	875 Third Avenue	New York	New York	10022	USA
mexiletine	n/a	9/2/10	Treatment of nondystrophic myotonia	Designated			N/A	N/A	University of Rochester Medical Center	1351 Mt. Hope Ave.	Suite 203	Rochester	New York	14620	USA
mibefradil	n/a	10/16/08	Treatment of pancreatic cancer.	Designated			N/A	N/A	"Cavion, LLC"	600 E. Water Street		Charlottesville	Virginia	22902	USA
mibefradil	n/a	8/25/09	Treatment of glioblastoma multiforme.	Designated			N/A	N/A	"Cavion, LLC"	600 E. Water Street		Charlottesville	Virginia	22902	USA
mibefradil	n/a	6/15/07	Treatment of ovarian cancer	Designated			N/A	N/A	"Cavion, LLC"	600 E. Water Street		Charlottesville	Virginia	22902	USA
miconazole	n/a	5/22/14	Treatment of fungal otitis externa (otomycosis)	Designated			N/A	N/A	"Hill Dermaceuticals, Inc."	2650 S. Mellonville Ave.		Sanford	Florida	32773	USA
Microbubble contrast agent	Filmix Neurosonographic Contrast Agent	11/16/90	Intraoperative aid in the identification and localization of intracranial tumors.	Designated			N/A	N/A	"Cav-Con, Inc."	55 Knollwood Road		Farmington	Connecticut	6032	USA
Microvesiculated modified glycosylated tissue factor	n/a	10/11/07	"Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in patients with von Willebrand disease."	Designated			N/A	N/A	Thrombotargets Corp.	2530 Meridian Parkway		Durham	North Carolina	27713	USA
Microvesiculated modified glycosylated tissue factor	n/a	1/25/07	"Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in hemophiliac patients"	Designated			N/A	N/A	Thrombotargets Corp.	2530 Meridian Parkway	Suite 3023	Durham	North Carolina	27713	USA
midazolam	n/a	7/24/12	Treatment of nerve agent-induced seizures	Designated			N/A	N/A	"Meridian Medical Technologies, Inc."	A Pfizer Company	6350 Stevens Forest Road	Columbia	Maryland	21046	USA
midazolam	n/a	10/20/09	"Rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity (e.g. acute repetitive seizures, seizure clusters)"	Designated			N/A	N/A	"Upsher-Smith Laboratories, Inc."	6701 Evenstad Drive		Maple Grove	Minnesota	55369	USA
midazolam	n/a	2/18/16	Treatment of status epilepticus	Designated			N/A	N/A	Shire Development LLC	300 Shire Way		Lexington	Massachusetts	2421	USA
midazolam	n/a	2/4/16	Treatment of status epilepticus	Designated			N/A	N/A	"Meridian Medical Technologies, Inc."	A Pfizer Company	6350 Stevens Forest Road	Columbia	Maryland	21046	USA
midazolam	n/a	5/8/06	Treatment of bouts of increased seizure activity in selected refractory patients with epilepsy who are on stable regimens of anti-epileptic drugs and who require intermittent use of midazolam	Designated			N/A	N/A	"UCB, Inc"	1950 Lake Park rive		Smyrna	Georgia	30080	USA
midazolam	n/a	2/8/16	Treatment of seizures induced by organophosporous insecticide poisoning.	Designated			N/A	N/A	"Meridian Medical Technologies, Inc."	A Pfizer Company	6350 Stevens Forest Road	Columbia	Maryland	21046	USA
Midodrine HCl	Amatine	6/21/85	Treatment of patients with symptomatic orthostatic hypotension.	Designated/Approved	Approved for Orphan Indication	Treatment of symptomatic orthostatic hypotension.	09/06/1996	09/06/2003	Shire	725 Chesterbrook Blvd		Wayne	Pennsylvania	19087	USA
Midostaurin	n/a	7/7/09	Treatment of acute myeloid leukemia	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
Midostaurin	Rydapt	4/30/10	Treatment of mastocytosis	Designated			N/A	N/A	Novartis Oncology	One Health Plaza		East Hanover	New Jersey	7936	USA
mifamuritide	Junovan	6/5/01	Treatment of osteosarcoma	Designated			N/A	N/A	"Millennium Pharmaceuticals, Inc."	40 Landsdowne Street		Cambridge	Massachusetts	2139	USA
Mifepristone	n/a	2/7/05	Treatment of Cushing's syndrome secondary to ectopic ACTH secretion	Designated			N/A	N/A	HRA Pharma	"15 , rue Beranger"	75003 Paris				France
mifepristone	Korlym	1/14/16	Treatment of ovarian cancer.	Designated			N/A	N/A	"Corcept Therapeutics, Inc."	149 Commonwealth Drive		Menlo Park	California	94025	USA
mifepristone	Korlym	7/5/07	Treatment of the clinical manifestations of endogenous Cushing's syndrone	Designated/Approved	Approved for Orphan Indication	for the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.	02/17/2012	02/17/2019	"Corcept Therapeutics, Inc."	149 Commonwealth Drive		Menlo Park	California	94025	USA
migalastat hydrochloride	n/a	2/25/04	Treatment of Fabry Disease	Designated			N/A	N/A	"Amicus Therapeutics, Inc."	1 Cedarbrook Drive		Cranbury	New Jersey	8512	USA
miglustat	Zavesca	5/29/98	Treatment of Gaucher disease.	Designated/Approved	Approved for Orphan Indication	"Treatment of mild to moderate Type I Gaucher disease in adults for whom enzyme replacement therapy is not a therapeutic option (e.g., due to constraints such as allergy, hypersensitivity, or poor venous access)."	07/31/2003	07/31/2010	Actelion Pharmaceuticals Ltd	Gewerbestrasse 16	CH - 4123 Allschwi				Switzerland
miglustat	Zavesca (R)	11/12/08	"Treatment of the neurological manifestations of Niemann-Pick disease,type C."	Designated			N/A	N/A	Actelion Pharmaceuticals Ltd	Innovation Centre	"CH-4123, Allschwil"				Switzerland
milatuzumab	n/a	6/24/08	Treatment of chronic lymphocytic leukemia.	Designated			N/A	N/A	"Immunomedics, Inc."	300 The American Road		Morris Plains	New Jersey	7950	USA
milatuzumab	n/a	3/10/08	Treatment of multiple myeloma	Designated			N/A	N/A	"Immunomedics, Inc."	300 The American Road		Morris Plains	New Jersey	7950	USA
milciclib maleate	n/a	9/20/12	Treatment of thymic epithelial tumors.	Designated			N/A	N/A	Tiziana Life Sciences PLC	18 South Street	W1K 1DG	London			United Kingdom
miltefosine	Miltex/Impavido	3/18/09	Topical treatment of cutaneous lymphoma encompassing cutaneous manifestations of T-cell lymphoma and B-cell lymphoma	Designated			N/A	N/A	ExperGen Drug Development GmbH	Hernalser Haupstrasse 24/16					Austria
miltefosine	Impavido	10/10/06	Treatment of leishmaniasis.	Designated/Approved	Approved for Orphan Indication	"Treatment of visceral leishmaniasis due to Leishmania donovani; cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis; and mucosal leishmaniasis due to Leishmania braziliensis."	03/19/2014	03/19/2021	Knight Therapeutics (USA)	Corporation Trust Center	1209 Orange Street	Wilmington	Delaware	19801	USA
miltefosine	Impavido	12/6/16	Treatment of Acanthamoeba keratitis	Designated			N/A	N/A	"Profounda, Inc."	5790 Hoffner Avenue	Suite 507	Orlando	Florida	32822	USA
miltefosine	Impavido	12/6/16	Treatment of primary amebic encephalitis (PAM)	Designated			N/A	N/A	"Profounda, Inc."	5790 Hoffner Avenue	Suite 507	Orlando	Florida	32822	USA
Minnelide	Minnelide (Tm)	2/18/13	Treatment of pancreatic cancer	Designated			N/A	N/A	"Minneamrita Therapeutics, LLC"	6 Hickory Court		Rock Island	Illinois	61201	USA
Minocycline HCl	Minocin Intravenous	6/19/92	Treatment of chronic malignant pleural effusion.	Designated/Withdrawn			N/A	N/A	Lederle Laboratories Division	Division of American Cyanamid Company	401 N. Middletown Road	Pearl River	New York	10965	USA
Minocycline hydrochloride	n/a	3/28/06	Treatment of sarcoidosis	Designated			N/A	N/A	Autoimmunity Research Foundation	3423 Hill Canyon Avenue		Thousand Oaks	California	91360	USA
mipomersen	Kynamro	5/23/06	Treatment of homozygous familial hypercholesterolemia	Designated/Approved	Approved for Orphan Indication	"Adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH)."	01/29/2013	01/29/2020	"Kastle Therapeutics, LLC"	181 West Madison Street	Suite 3745	Chicago	Illinois	60602	USA
misoprostol	Gymiso	1/10/05	Treatment of intrauterine fetal death not accompanied by complete expulsion of the products of conception in the second and third trimesters of pregnancy.	Designated			N/A	N/A	"Gynuity Health Projects, LLC"	15 East 26th Street		New York	New York	10010	USA
Mitoguazone	Apep	3/18/94	"Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma."	Designated			N/A	N/A	"ILEX Oncology, Inc."	4545 Horizon Hill Blvd.		San Antonio	Texas	78229	USA
Mitolactol	n/a	1/23/89	Treatment of invasive carcinoma of the uterine cervix	Designated			N/A	N/A	"Targent, Inc.."	155 Lambert Drive		Princeton	New Jersey	8540	USA
Mitolactol	n/a	7/12/95	As adjuvant therapy in the treatment of primary brain tumors.	Designated			N/A	N/A	"Targent, Inc."	155 Lambert Drive		Princeton	New Jersey	8540	USA
mitomycin	n/a	1/13/11	Prevention of recurrence of pterygium after its surgical excision.	Designated			N/A	N/A	"Mobius Therapeutics, LLC"	4041 Forest Park Avenue		St. Louis	Missouri	63108	USA
mitomycin	n/a	6/1/11	Prevention of corneal sub-epithelial haze formation following surface ablation laser keratectomy	Designated			N/A	N/A	"Mobius Therapeutics, LLC"	1141 South 7th Street		St. Louis	Missouri	63104	USA
mitomycin	Mitogel	9/8/14	Treatment of upper tract urothelial cell cancers (transitional cell carcinoma of the renal pelvis and ureter)	Designated			N/A	N/A	"TheraCoat, Ltd."	"9 Ha'Ta'asiya St., POB 2397"	Ra'anana 4365007				Israel
Mitomycin-C	n/a	8/20/93	Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.	Designated			N/A	N/A	IOP Inc.	"3100 Airway Avenue, Suite 106"		Costa Mesa	California	92626	USA
mitomycin-C	Mitosol	1/8/08	Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.	Designated/Approved	Approved for Orphan Indication	An adjunct to ab externo glaucoma surgery.	02/07/2012	02/07/2019	"Mobius Therapeutics, LLC"	1141 South 7th Street		St. Louis	Missouri	63104	USA
Mitoxantrone	Novantrone	8/21/96	Treatment of hormone refractory prostate cancer.	Designated/Approved	Approved for Orphan Indication	In combination with corticosteroids as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer.	11/13/1996	11/13/2003	Serono	One Technology Place		Rockland	Massachusetts	2370	USA
Mitoxantrone	Novantrone	8/13/99	Treatment of progressive-relapsing multiple sclerosis.	Designated/Approved	Approved for Orphan Indication	"Reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly adnormal between relapses)."	10/13/2000	10/13/2007	"Serono, Inc."	One Technology Place		Rockland	Massachusetts	2370	USA
Mitoxantrone	Novantrone	8/13/99	Treatment of secondary-progressive multiple sclerosis.	Designated/Approved	Approved for Orphan Indication	"Reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly adnormal between relapses)."	10/13/2000	10/13/2007	"Serono, Inc."	One Technoloogy Place		Rockland	Massachusetts	2370	USA
Mitoxantrone HCl	Novantrone	7/13/87	"Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia."	Designated/Approved	Approved for Orphan Indication		12/23/1987	12/23/1994	Lederle Laboratories	Division of American Cyanamid Company	401 N. Middletown Road	Pearl River	New York	10965	USA
Mixture of 2 anti-rabies humanized monoclonal immunoglobulin (Ig)G1k antibodies	n/a	10/7/15	Post-exposure prophylaxis against rabies virus infection	Designated			N/A	N/A	"Synermore Biologics Co., Ltd"	"6F, No 5-6, Aly 22, Ln 513 Ruiguang Rd."	Neihu Dist.				Taiwan
MLN4924-Inhibitor of Nedd8-activating enzyme (NAE)	n/a	2/4/11	Treatment of Myelodysplastic syndrome	Designated			N/A	N/A	"Millennium Pharmaceuticals, Inc."	40 Landsdowne St.		Cambridge	Massachusetts	2139	USA
MLN4924-Inhibitor of Nedd8-activating enzyme (NAE)	n/a	2/4/11	Treatment of acute myelogenous leukemia.	Designated			N/A	N/A	Millennium Pharmaceuticals	40 Landsdowne St.		Cambridge	Massachusetts	2139	USA
MN14 monoclonal antibody to carcinoembryonic antigen	Cea-Cide	9/18/98	Treatment of small cell lung cancer	Designated			N/A	N/A	"Immunomedics, Inc."	300 The American Road		Morris Plains	New Jersey	7950	USA
MN14 monoclonal antibody to carcinoembryonic antigen	Cea-Cide	11/24/98	Treatment of pancreatic cancer.	Designated			N/A	N/A	"Immunomedics, Inc."	300 The American Road		Morris Plains	New Jersey	7950	USA
mocetinostat	n/a	8/7/14	Treatment of diffuse large B-cell lymphoma	Designated			N/A	N/A	"Mirati Therapeutics, Inc."	9363 Towne Centre Drive	Suite 200	San Diego	California	92121	USA
Mocetinostat	n/a	6/12/14	Treatment of myelodysplastic syndrome	Designated			N/A	N/A	"Mirati Therapeutics, Inc."	9363 Towne Centre Drive	Suite 200	San Diego	California	92121	USA
MOD-423 hGH analogue	n/a	9/29/10	Treatment of growth hormone deficiency	Designated			N/A	N/A	OPKO Biologics Ltd.	P.O.B. 4101	"Weizmann Science Park, 2nd floor"	Nes-Ziona			Israel
Modafinil	Provigil	3/15/93	Treatment of excessive daytime sleepiness in narcolepsy.	Designated/Approved	Approved for Orphan Indication	Improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy.	12/24/1998	12/24/2005	"Cephalon, Inc."	145 Brandywine Parkway		West Chester	Pennsylvania	19380	USA
modified a-cobratoxin	n/a	9/1/15	Treatment of pediatric multiple sclerosis (0 through 16 years of age).	Designated			N/A	N/A	Nutra Pharma Corporation	12502 W. Atlantic Blvd		Coral Springs	Florida	33071	USA
modified human papillomavirus capsid protein conjugated to a near infrared dye	n/a	4/8/15	Treatment of uveal melanoma	Designated			N/A	N/A	"Aura Biosciences, Inc."	85 Bolton Street		Cambridge	Massachusetts	2140	USA
"modified mRNA encoding UGT1A1 protein, formulated in lipid nanoparticles"	n/a	7/5/16	Treatment of Crigler-Najjar syndrome	Designated			N/A	N/A	Alexion Pharmaceuticals	55 Cambridge Parkway	Suite 800	Cambridge	Massachusetts	2142	USA
modified recombinant human C-type natriuretic peptide (CNP)	n/a	1/17/13	Treatment of achondroplasia	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	105 Digital Drive		Novato	California	94949	USA
modified recombinant human Factor VIIa (rFVIIa) molecule	n/a	5/30/13	Treatment of bleeding episodes in hemophilia A or B subjects with inhibitors	Designated/Withdrawn			N/A	N/A	"Bayer Healthcare Pharmaceuticals, Inc."	100 Bayer Boulevard		Whippany	New Jersey	7981	USA
modified recombinant mitochondrial transcription factor A (TFAM) containing the mitochondrial transduction domain	n/a	8/20/12	Treatment of inherited mitochondrial respiratory chain disease	Designated			N/A	N/A	Gencia Corporation	200 Garrett Street	Suite H	Charlottesville	Virginia	22902	USA
mogamulizumab	n/a	11/2/10	Treatment of patients with cutaneous T-cell lymphoma.	Designated			N/A	N/A	Kyowa Kirin Pharmaceutical Development Inc.	212 Carnegie Center # 101		Princeton	New Jersey	8540	USA
mogamulizumab	n/a	11/2/10	Treatment of peripheral T-cell lymphoma.	Designated			N/A	N/A	"Kyowa Kirin Pharmaceutical Development, Inc."	212 Carnegie Center #101		Princeton	New Jersey	8540	USA
mogamulizumab	n/a	7/14/11	Treatment of adult T-cell leukemia/lymphoma (ATLL).	Designated			N/A	N/A	"Kyowa Kirin Pharmaceutical Development, Inc."	212 Carnegie Center	Suite 101	Princeton	New Jersey	8540	USA
Molgramostim	Leucomax	1/24/89	"Treatment of AIDS patients with neutropenia due to the disease, AZTor ganciclovir."	Designated/Withdrawn			N/A	N/A	Schering Corporation	2000 Galloping Hill Road		Kenilworth	New Jersey	7033	USA
Molgramostim	Leucomax	9/25/89	Treatment of aplastic anemia.	Designated/Withdrawn			N/A	N/A	Schering Corporation	2000 Galloping Hill Road		Kenilworth	New Jersey	7033	USA
monarsen	n/a	11/14/03	Treatment of myasthenia gravis	Designated			N/A	N/A	"Bioline Rx, Ltd."	19 Hartum Street	P. O. Box 45158	Jerusalem			Israel
mongersen	n/a	7/20/15	Treatment of pediatric Crohn's disease	Designated			N/A	N/A	Celgene Corporation	86 Morris Avenue		Summit	New Jersey	7901	USA
Monoclonal Ab(murine) anti-idiotype melanoma-associated antigen	Melimmune	9/19/94	Treatment of invasive cutaneous melanoma.	Designated/Withdrawn			N/A	N/A	IDEC Pharmaceuticals Corporation	3030 Callan Road		San Diego	California	92121	USA
Monoclonal antibodies (murine or human) to B-cell lymphoma	n/a	5/6/86	Treatment of B-cell lymphoma.	Designated/Withdrawn			N/A	N/A	IDEC Pharmaceuticals Corporation	11011 Torreyana Road		San Diego	California	92121	USA
Monoclonal antibodies PM-81 and AML-2-23	n/a	3/12/90	For the exogenous depletion of CD14 and CD15 positive acute myeloid leukemic bone marrow cells from patients undergoing bone marrow transplantation.	Designated/Withdrawn			N/A	N/A	"Medarex, Inc."	519 Route 173 West		Bloomsbury	New Jersey	8804	USA
monoclonal antibody	n/a	1/21/11	Prevention of congential cytomegalovirus (CMV)infection following primary CMV infection in pregnant women.	Designated/Withdrawn			N/A	N/A	Theraclone Sciences	1124 Columbia Street		Seattle	Washington	98104	USA
monoclonal antibody 11-1F4	n/a	12/11/09	For use as a therapeutic agent for patients AL amyloidosis.	Designated			N/A	N/A	Columbia University	College of Physicians & Surgeons	Dept of Hematology/Onclogy	New York	New York	10032	USA
monoclonal antibody 11-1F4	n/a	12/7/09	For use as a radioimmaging agent in amyloidosis	Designated			N/A	N/A	Columbia University	College of Physicians & Surgeons	Dept. of Hematology/Oncology	New York	New York	10032	USA
Monoclonal antibody 17-1a	Panorex	4/4/88	Treatment of pancreatic cancer.	Designated/Withdrawn			N/A	N/A	"Centocor, Inc."	244 Great Valley Parkway		Malvern	Pennsylvania	19355	USA
monoclonal antibody 3F8	n/a	10/16/08	Treatment of neuroblastoma	Designated			N/A	N/A	United Therapeutics Corporation	55 TW Alexander Drive	P. O. Box 14186	Research Triangle Park	North Carolina	27709	USA
"monoclonal antibody consisting of three mouse/human chimeric IgG1 monoclonal antibodies (c2G4, c4G7, and c13C6) that target Ebola virus"	n/a	8/25/14	Treatment of Ebola virus infection	Designated			N/A	N/A	"LeafBio, Inc."	"6160 Lusk Blvd.,"	Suite C105	San Diego	California	90121	USA
monoclonal antibody directed at hepatitis C virus E2 glycoprotein	n/a	11/4/13	Prevention of Hepatitis C recurrence in patients receiving liver transplantation	Designated			N/A	N/A	MassBiologics-University of MA Medical School	460 Walk HIll Street		Boston	Massachusetts	2126	USA
Monoclonal antibody for immunization against lupus nephritis	n/a	1/7/93	Treatment of lupus nephritis.	Designated			N/A	N/A	"VivoRx Autoimmune, Inc."	"2825 Santa Monica Blvd., Suite 200"		Santa Monica	California	90404	USA
monoclonal antibody Hu3F8	n/a	1/10/14	Treatment of osteosarcoma	Designated			N/A	N/A	Memorial Sloan-Kettering Cancer Center	1275 York Avenue		New York	New York	10065	USA
Monoclonal antibody PM-81	n/a	6/27/91	Adjunctive treatment of acute myelogenous leukemia.	Designated/Withdrawn			N/A	N/A	"Medarex, Inc."	519 Route 173 West		Bloomsbury	New Jersey	8804	USA
monoclonal antibody targeting eotaxin-2	n/a	10/29/15	Treatment of idiopathic pulmonary fibrosis.	Designated			N/A	N/A	"ChemomAb, Ltd."	6 Hanehoset St.		Tel Aviv			Israel
monoclonal antibody targeting eotaxin-2	n/a	1/6/15	Treatment of systemic sclerosis	Designated			N/A	N/A	"ChemomAb, Ltd."	6 Hanehoset St.		Tel Aviv			Israel
Monoclonal antibody to cytomegalovirus (human)	n/a	11/15/91	Treatment of cytomegalovirus retinitis in patients with AIDS.	Designated/Withdrawn			N/A	N/A	"Protein Design Labs, Inc."	2375 Garcia Avenue		Mountain View	California	94043	USA
Monoclonal antibody to cytomegalovirus (human)	n/a	9/13/91	Prophylaxis of cytomegalovirus disease in patients undergoing solid organ transplantation.	Designated/Withdrawn			N/A	N/A	"Protein Design Labs, Inc."	2375 Garcia Avenue		Mountain View	California	94043	USA
Monoclonal antibody to hepatitis B virus (human)	n/a	6/17/91	Prophylaxis of hepatitis B reinfection in patients undergoing liver transplantation secondary to end-stage chronic hepatitis B infection.	Designated/Withdrawn			N/A	N/A	"Protein Design Labs, Inc."	34801 Campus Dr.		Fremont	California	94555	USA
Monoclonal antibody-B43.13	Ovarex Mab-B43.13	11/25/96	Treatment of epithelial ovarian cancer.	Designated			N/A	N/A	"Quest PharmaTech, Inc."	9407 20 Avenue	"Edmonton, Alberta T6N 1E5"				Canada
Monoclonal antiendotoxin antibody XMMEn-0e5	n/a	11/4/85	Treatment of patients with gram-negative sepsis which has progressed to shock.	Designated/Withdrawn			N/A	N/A	"Pfizer, Inc."	235 East 42nd Street		New York	New York	10017	USA
Monolaurin	Glylorin	4/29/93	Treatment of congenital primary ichthyosis.	Designated			N/A	N/A	Glaxo Wellcome Inc.	5 Moore Drive	PO Box 13398	Research Triangle Park	North Carolina	27709	USA
monomethyl auristatin E conjugated to a monoclonal antibody which targets guanylyl cyclase C	n/a	7/29/14	Treatment of pancreatic cancer.	Designated/Withdrawn			N/A	N/A	"Millennium Pharmaceuticals, Inc."	40 Landsdowne Street		Cambridge	Massachusetts	2139	USA
Mononuclear enriched fraction of human umbilical cord blood	U-Cord-Cell(R)	9/15/15	Treatment of amyotrophic lateral sclerosis (ALS).	Designated			N/A	N/A	"Saneron CCEL Therapeutics, Inc."	13014 North Dale Mabry Highway	Suite 266	Tampa	Florida	33618	USA
Monooctanoin	Moctanin	5/30/84	For dissolution of cholesterol gallstones retained in the common bile duct.	Designated/Approved	Approved for Orphan Indication		10/31/1985	10/31/1992	"Ethitek Pharmaceuticals, Inc."	"7855 Gross Point Road, Unit L"		Skokie	Illinois	60077	USA
"Monovalent replication-incompetent adenovirus serotype 26 (Ad26) vaccine, AD26.ZEBOV in combination with multivalent replication-defective Modified Vaccinia Ankara (MVA)-Bavarian Nordic (BN) vaccine, MVA-mBN226B"	n/a	1/11/17	Pre-exposure prophylaxis of Ebola virus disease	Designated			N/A	N/A	Crucell Holland B.V.	Archimedesweg 4-6		Leiden			Netherlands
Morphine sulfate concentrate (preservative free)	Infumorph	7/12/90	For use in microinfusion devices for intraspinal administration in the treatment of intractable chronic pain.	Designated/Approved	Approved for Orphan Indication	For intrathecal or epidural infusion in the treatment of tractable chronic pain. It was developed for use in continuous microinfusion devices and may require dilution before use as directed.	07/19/1991	07/19/1998	"Elkins-Sinn, Inc."	2 Esterbrook Lane		Cherry Hill	New Jersey	8003	USA
motexafin gadolinium	Xcytrin	1/27/03	For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors	Designated			N/A	N/A	"Pharmacyclics, LLC"	995 E. Arques Avenue		Sunnyvale	California	94085	USA
"mouse-human chimeric antibody of the IgG1 isotype, directed against human CD37"	n/a	3/24/15	Treatment of chronic lymphocytic leukemia (CLL).	Designated			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc."	"900 Ridgebury Rd., PO Box 368"		Ridgefield	Connecticut	6877	USA
mouse-human chimeric monoclonal anti-GD2 IgG1 antibody	n/a	9/20/12	Treatment of neuroblastoma.	Designated			N/A	N/A	APEIRON Biologics AG	Campus-Vienna-Biocenter 5	1030 Vienna				Austria
moxetumomab pasudotox	n/a	6/28/13	Treatment of acute lymphoblastic leukemia	Designated			N/A	N/A	"MedImmune, LLC"	One MedImmune Way		Gaithersburg	Maryland	20878	USA
moxetumomab pasudotox	n/a	11/15/07	Treatment of hairy cell leukemia	Designated			N/A	N/A	"MedImmune, LLC"	One MedImmune Way		Gaithersburg	Maryland	20878	USA
moxetumomab pasudotox	n/a	11/15/07	Treatment of CD22-positive chronic lymphocytic leukemia	Designated			N/A	N/A	"MedImmune, LLC"	One MedImmune Way		Gaithersburg	Maryland	20878	USA
moxidectin	n/a	9/29/10	Treatment of onchocerciasis volvulus in children and adults.	Designated			N/A	N/A	Medicines Development Limited	"Level 1, 18 Kevanagh Street"	Southbank VIC 3006	Melbourne			Australia
moxifloxacin hydrochloride	n/a	4/30/14	Treatment of tuberculosis	Designated/Withdrawn			N/A	N/A	"Bayer HealthCare Pharmaceuticals, Inc."	100 Bayer Boulevard	P. O. Box 915	Whippany	New Jersey	7981	USA
mPEG-r-crisantaspase	Asparec(Tm)	2/1/10	Treatment of acute lymphoblastic leukemia.	Designated			N/A	N/A	"Jazz Pharmaceuticals, Inc."	3180 Porter Drive		Palo Alto	California	94304	USA
mRNA encoding human ornithine transcarbamylase	n/a	11/23/16	Treatment of ornithine transcarbamylase deficiency	Designated			N/A	N/A	"PhaseRx, Inc."	410 West Harrison Street	Suite 300	Seattle	Washington	98119	USA
MTC-DOX for Injection	n/a	1/3/01	Treatment of hepatocellular carcinoma	Designated			N/A	N/A	FeRx Incorporated	4330 La Jolla Village Drive	Suite #250	San Diego	California	92122	USA
mTOR kinase inhibitor (CC-223)	n/a	10/16/13	Treatment of hepatocellular carcinoma	Designated			N/A	N/A	Celgene Corporation	400 Connell Drive	Suite 7000	Berkeley Heights	New Jersey	7922	USA
Mucoid exopolysaccharide Pseudomonas hyperimmune globulin	Mep Igiv	11/7/90	Prevention of pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.	Designated/Withdrawn			N/A	N/A	"North American Biologicals, Inc."	12280 Wilkins Avenue		Rockville	Maryland	20852	USA
Mucoid exopolysaccharide Pseudomonas hyperimmune globulin	Mep Igiv	1/9/91	Treatment of pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.	Designated/Withdrawn			N/A	N/A	"North American Biologicals, Inc."	12280 Wilkins Avenue		Rockville	Maryland	20852	USA
multi-epitope folate receptor alpha peptide vaccine with GM-CSF adjuvant (TPIV200)	n/a	12/7/15	Treatment of ovarian cancer.	Designated			N/A	N/A	"Tapimmune, Inc."	50 North Laura Street		Jacksonville	Florida	32202	USA
Multi-ligand somatostatin analog	n/a	7/27/04	"Treatment of patients with functional gastroenteropancreatic (GEP) neuroendocrine tumors (specifically, carcinoid, insulinoma, gastrinoma, somastatinoma, GRFoma, VIPoma and glucagonoma."	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
Multi-peptide cancer vaccine	n/a	6/23/13	Treatment of multiple myeloma	Designated			N/A	N/A	"OncoPep, Inc."	520 Boston Street		North Andover	Massachusetts	1845	USA
Multi-vitamin infusion (neonatal formula)	n/a	12/12/89	For establishment and maintenance of total parenteral nutrition in very low birth weight infants.	Designated			N/A	N/A	"Astra Pharmaceuticals, L.P."	725 Chesterbrook Blvd.		Wayne	Pennsylvania	19087	USA
multi-vitamin infusion without vitamin K	M.V.I.-12	3/8/04	Prevention of vitamin deficiency and thromboembolic complications in people receiving home parenteral nutrition and warfarin-type anticoagulant therapy	Designated/Approved	Approved for Orphan Indication	Prevention of vitamin deficiency and thrombormbolic complications in people receiving home parenteral nutrition who also receive warfarin-type anticoagulant therapy	09/09/2004	09/09/2011	Mayne Pharma (USA) Inc.	Mack-Cali Centre II	Second Floor	Paramus	New Jersey	7652	USA
Multistem(r)	n/a	9/15/10	Prophylaxis of graft vs host disease	Designated			N/A	N/A	"Athersys, Inc."	3201 Carnegie Avenue		Cleveland	Ohio	44115	USA
Murine MAb (Lym-1) and Iodine 131-I radiolabeled murine MAb (Lym-1) to human B-cell lymphoma	Oncolym	11/27/98	Treatment of B-cell non-Hodgkin's lymphoma.	Designated			N/A	N/A	"Peregrine Pharmaceuticals, Inc."	14272 Franklin Ave.	Suite 100	Tustin	California	92780	USA
"Murine MAb to polymorphic epithelial mucin, human milk fat globule 1"	Theragyn	3/22/99	Adjuvant treatment of ovarian cancer.	Designated			N/A	N/A	Antisoma plc	West Africa House	Hanger Lane Ealing	London W5 3QR			United Kingdom
murine monoclonal antibody against CD26	Begedina	2/18/11	Treatment of graft versus host disease	Designated			N/A	N/A	Adienne S.A.	"Via Zurigo, 46"	6900 Lugano				Switzerland
"MV-NB-02, its bivalent ganglioside vaccine consisting of GD2-lactone and GD3-lactone each covalently conjugated to keyhole hemocyanin"	n/a	9/23/14	Treatment of Neuroblastoma	Designated			N/A	N/A	"MabVax Therapeutics, Inc."	11588 Sorrento Road	Suite 20	San Diego	California	92121	USA
Mx-dnG1	Rexin-G	6/24/08	Treatment of osteosarcoma.	Designated			N/A	N/A	Epeius Biotechnologies Corporation	475 Huntington Drive		San Marino	California	91108	USA
Mx-dnG1	Rexin-G(R)	6/24/08	Treatment of soft tissue sarcoma	Designated			N/A	N/A	Epeius Biotechnologies Corporation	475 Huntington Drive		San Marino	California	91108	USA
Mx-dnG1 or Rexin-G retroviral vector	Rexin-G	8/15/03	Treatment of pancreatic cancer	Designated			N/A	N/A	Epeius Biotechnologies Corporation	"345 Pioneer Drive, 1803W"		Glendale	California	91203	USA
Mycobacterium avium sensitin RS-10	n/a	10/11/95	For use in the diagnosis of invasive Mycobacterium avium disease in immunocompetent individuals.	Designated			N/A	N/A	Statens Seruminstitut	5 Artillerivej	DK-2300 Copenhagen S				Sweden
mycobacterium vaccae	n/a	8/6/10	Treatment of pancreatic cancer	Designated/Withdrawn			N/A	N/A	Immodulon Therapeutics Ltd.	22 Devonshire Place	"London, W1G 6JA"				United Kingdom
mycobacterium vaccae	n/a	8/20/10	Treatment of tuberculosis	Designated			N/A	N/A	Immodulon Therapeutics Ltd	22 Devonshire Place	B2				United Kingdom
Mycophenolate mofetil	Cellcept	5/26/06	Treatment of pemphigus vulgaris	Designated/Withdrawn			N/A	N/A	"Hoffman-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA
Mycophenolate mofetil	Cellcept	12/19/05	Treatment of myasthenia gravis	Designated/Withdrawn			N/A	N/A	"Hoffman-LaRoche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA
Myelin	n/a	6/27/91	Treatment of multiple sclerosis.	Designated/Withdrawn			N/A	N/A	"AutoImmune, Inc."	128 Spring Street		Lexington	Massachusetts	2173	USA
myo-inositol	n/a	4/7/05	Prevention of retinopathy of prematurity in preterm infants at risk for developing retinopathy of prematurity	Designated			N/A	N/A	Abbott Nutrition	Abbott Laboratories	625 Cleveland Ave.	Columbus	Ohio	43215	USA
myristoylated recombinant SCR1-3 of human complement reseptor type I	Apt070	5/21/03	Prevention of delayed graft function in solid organ transplant	Designated/Withdrawn			N/A	N/A	Orexo AB	Box 303	Virdings alle 32 A				Sweden
"N'-(7-Chloroquinolin-4-yl)-N,N-diethyl-propane-1,3-diamine"	n/a	10/29/15	Treatment of malaria.	Designated			N/A	N/A	"Donald J. Krogstad, MD"	"1430 Tulane Ave., #8317"	J.B. Johnson Building	New Orleans	Louisiana	70112	USA
"N,N'-bis(2-mercaptoethyl)isophthalamide (NBMI)"	n/a	4/6/12	Treatment of mercury toxicity	Designated			N/A	N/A	CTI Science Limited	c/o Philip Lee Solicitors	7/8 Wilton Terrace	Dublin 2			Ireland
"N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide, phosphate (1:2)"	n/a	1/13/05	Treatment of gastrointestinal stromal tumors	Designated/Withdrawn			N/A	N/A	"Amgen, Inc."	One Amgen Center Drive		Thousand Oaks	California	91320	USA
"N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)ethyl)-2-hydroxybenzamide"	n/a	11/17/14	Treatment of Duchenne muscular dystrophy	Designated			N/A	N/A	"Catabasis Pharmaceuticals, Inc."	"One Kendall Square, Suite B14202"	Suite B14202	Cambridge	Massachusetts	2139	USA
N-(2-amino-2-oxoethyl)-2-(2-((4-fluorophenethyl)amino)-N-isobutylacetamido)-N-(3-(2-oxopyrrolidin-1-yl)propyl)acetamide N-({Carbamoylmethyl-[3-(2-oxo-pyrrolidin-1-yl)propyl}-carbamoyl}-methyl)-2-[2-(2-fluorophenyl)-ethylamino]-N-isobutyl-acetamide	n/a	11/17/14	Treatment of optic neuritis	Designated			N/A	N/A	Bionure Farma SL	Dalmases 27	8017	Barcelona			Spain
N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide	n/a	2/1/08	Treatment of acute myeloid leukemia	Designated			N/A	N/A	"Mirati Therapeutics, Inc."	9363 Towne Center Drive	Suite 200	San Diego	California	92121	USA
N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide	n/a	8/8/07	Treatment of Hodgkin's lymphoma	Designated			N/A	N/A	"Mirati Therapeutics, Inc."	9363 Towne Centre Drive	Suite 200	San Diego	California	92121	USA
"N-(3,4-dihydroxyphenyl)-3,4-dihydroxybenzamide"	n/a	10/15/14	Treatment of AL Amyloidosis	Designated			N/A	N/A	"ProteoTech, Inc."	"12040 115th Ave., NE"		Kirkland	Washington	98034	USA
N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl) pyridin-2-yl) Acetamide Besylate	n/a	11/26/13	Treatment of gliomas	Designated			N/A	N/A	"Kinex Pharmaceuticals, Inc."	701 Ellicott Street		Buffalo	New York	14203	USA
"N-(4-Fluoro-benzoyl)-L-arginyl-L-arginyl-[L-3-(naphthyl-alanyl]-L-cysteinyl-L-tyrosyl-L-citrullinyl-L-lysyl-D-lysyl-L-prolyl-L-trosyl-L-arginyl-L-citrullinyl-L-cysteinyl-L-aginine amide, cyclic (4-13)-disulfide"	n/a	7/6/12	For use to mobilize hematopoietic stem cells (HSCs) from the marrow to peripheral blood for collection for autologous or allogeneic transplantation	Designated			N/A	N/A	"BioLineRx, Ltd."	Modi'in Technology Park	2 HaMa'ayan Street	Modi'in			Israel
"N-(4-Methoxyphenyl)-N,2,6-trimethylfuro[2,3-d] pyrimidin-4-amine"	n/a	2/18/16	Treatment of glioma.	Designated			N/A	N/A	"Flag Therapeutics, Inc."	9168 Wooden Road		Raleigh	North Carolina	27617	USA
N-(4-{3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxy}phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine bis-mesylate dihydrate	n/a	10/21/14	Treatment of ovarian cancer	Designated			N/A	N/A	"Amgen, Inc."	One Amgen Center Drive	Mail Stop 17-2-B	Thousand Oaks	California	91320	USA
"N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy) imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt"	n/a	3/18/09	Treatment of acute myeloid leukemia	Designated			N/A	N/A	Daiichi Sankyo Pharma Development	399 Thornall Street		Edison	New Jersey	8837	USA
N-(6-2-aminophenylamino)-6-oxohexyl)-4-methylbenzamide	n/a	5/17/10	Treatment of Friedreich's ataxia.	Designated/Withdrawn			N/A	N/A	Repligen Corporation	"Building 1, Suite 100"		Waltham	Massachusetts	2453	USA
N-(9-methoxynonyl)-1-deoxynojirimycin hydrochloride	n/a	11/17/14	"Treatment of acute dengue illness (inclusive of acute dengue illness, dengue fever, dengue hemorrhagic fever, and dengue shock syndrome)"	Designated			N/A	N/A	"Emergent Virology, LLC"	400 Professional Drive		Gaithersburg	Maryland	20879	USA
N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl(phenyl]amino}pyrimidin-4-yl)benzamide	n/a	8/5/10	Treatment of myelofibrosis	Designated			N/A	N/A	"Gilead Sciences, Inc."	333 Lakeside Drive		Foster City	California	94404	USA
N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole) mesylate	n/a	10/17/05	Treatment of multiple myeloma.	Designated			N/A	N/A	AB Science	"3, avenue George V"					France
N-acetyl cysteine amide	n/a	12/31/13	Treatment of retinitis pigmentosa	Designated			N/A	N/A	"Nacuity Pharmaceuticals, Inc."	Fort Worth Club Building	306 W 17th Street	Fort Worth	Texas	76106	USA
N-acetyl-glucosamine thiazoline	n/a	2/6/06	Treatment of adult Tay-Sachs disease	Designated			N/A	N/A	ExSAR Corporation	11 Deer Park Drive		Monmouth Junction	New Jersey	8852	USA
N-acetyl-procainamide	n/a	12/10/96	Prevention of life-threatening ventricular arrhythmias in patients with documented procainamide-induced lupus.	Designated			N/A	N/A	NAPA of the Bahamas	"3560 Pennsylvania Avenue, Suite 7"		Dubuque	Iowa	52002	USA
N-acetyl-sarcosyl-glycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl_L-prolylethylaminde acetate	n/a	12/9/03	Treatment of soft tissue sarcoma	Designated/Withdrawn			N/A	N/A	"AbbVie, Inc."	1 N. Waukegan Road		North Chicago	Illinois	60064	USA
N-acetylcysteinate Lysine	Nacystelyn Dry Powder Inhaler	12/27/00	For the management of cystic fibrosis	Designated			N/A	N/A	"Galephar Pharmaceutical Research, Inc."	"Road 198, No. 100 km. 14.7"	Juncos Industrial Park	Juncos			Puerto Rico
N-acetylcysteine	n/a	7/19/12	Prevention of ototoxicity caused by platinum-based chemotherapeutic agents used to treat pediatric cancers	Designated			N/A	N/A	"Edward A. Neuwelt, MD"	Oregon Health & Science University	3181 SW Sam Jackson Park Road - Mail Code L603	Portland	Oregon	97239	USA
N-acetylcysteine	n/a	9/9/02	Treatment of acute liver failure	Designated			N/A	N/A	"Cumberland Pharmaceuticals, Inc."	2525 West End Ave.	Suite 950	Nashville	Tennessee	37203	USA
N-acetylcysteine	"Acetadote(C), Mucomist(C)"	10/21/10	Treatment of apnea of prematurity	Designated/Withdrawn			N/A	N/A	Galleon Pharmaceuticals	213 Witmer Road		Horsham	Pennsylvania	19044	USA
N-acetylcysteine and sodium thiosulfate	n/a	8/31/15	Prevention of platinum-induced toxicities in pediatric patients (0 through 16 years of age).	Designated			N/A	N/A	"Edward A. Neuwelt, MD"	Oregon Health & Science University	3181 SW Sam Jackson Park Road - Mail Code L603	Portland	Oregon	97239	USA
"N-acetylgalactosamine-4-sulfatase, recombinant human"	Naglazyme	2/17/99	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	Designated/Approved	Approved for Orphan Indication	For patients with mucopolysaccharidosis VI. Galsulfase has been shown to improve walking and stair-climbing capacity.	05/31/2005	05/31/2012	"BioMarin Pharmaceutical, Inc."	105 Digital Drive		Novato	California	94949	USA
N-Acetylmannosamine (ManNAc)	n/a	4/5/10	Treatment of GNE Myopathy (Hereditary Inclusion Body Myopathy Type 2)	Designated			N/A	N/A	"Escala Therapeutics, Inc."	2 Gansevoort Street	9th Floor	New York	New York	10014	USA
N-acetylprocainamide	Napa	3/23/90	To lower the defibrillation energy requirement sufficiently to allow automatic implantable cardioverter defibrillator therapy in those patients who could otherwise not use the device.	Designated/Withdrawn			N/A	N/A	"Medco Research, Inc."	8455 Beverly Blvd.	Suite 308	Los Angeles	California	90048	USA
N-adamantanyl-N'-Geranyl-ethylenediamine	n/a	10/16/07	Treatment of tuberculosis.	Designated			N/A	N/A	"Sequella, Inc."	9610 Medical Center Drive		Rockville	Maryland	20850	USA
N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide	n/a	1/13/12	Treatment of Schwannoma of the central nervous system	Designated			N/A	N/A	"Arno Therapeutics, Inc."	200 Route 31 North	Suite 104	Flemington	New Jersey	8822	USA
N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide	n/a	1/13/12	Treatment of meningioma	Designated			N/A	N/A	"Arno Therapeutics, Inc."	200 Route 31 North	Suite 104	Flemington	New Jersey	8822	USA
N-Methanocarbathymidine	n/a	10/15/14	Treatment of neonatal herpes	Designated			N/A	N/A	"N & N Pharmaceuticals, Inc."	2400 Research Blvd	Suite 310	Rockville	Maryland	20850	USA
N-Methyl-2-[3-[((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]benzamide	Axitinib	5/4/07	"Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer."	Designated/Withdrawn			N/A	N/A	"Pfizer, Inc."	10646 Science Center Drive		San Diego	California	92121	USA
N-methyl-4-({4-[({3-methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride	n/a	7/18/13	Treatment of mesothelioma	Designated			N/A	N/A	"Verastem, Inc."	117 Kendrick Street	Suite 500	Needham	Massachusetts	2494	USA
N-t-butylhydroxylamine	n/a	5/12/15	Treatment of infantile neuronal ceroid lipofuscinosis.	Designated			N/A	N/A	Andrew Lim	California Institute of Technology	1200 East California Blvd.	Pasadena	California	91125	USA
N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate	n/a	3/21/13	Treatment of polycythemia vera	Designated			N/A	N/A	sanofi-aventis U.S. LLC	55 Corporate Drive		Bridgewater	New Jersey	8807	USA
N-tert-butyl-3-[5-methyl-2-{[4-(2-pryyolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl-amino] benzenesulfonamide dihydrochloride monohydrate	n/a	5/18/09	Treatment of secondary and primary myelofibrosis	Designated			N/A	N/A	"Sanofi-Aventis US, LLC a Sanofi company"	55 Corporate Drive		Bridgewater	New Jersey	8807	USA
"N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino] isonicotinamide hydrochloride"	n/a	1/12/11	Treatment of acute myeloid leukemia (AML).	Designated			N/A	N/A	"EMD Serono, Inc."	1 Technology Place		Rockland	Massachusetts	2370	USA
"N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino] isonicotinamide hydrochloride"	n/a	1/29/10	Treatment of pancreatic cancer	Designated			N/A	N/A	"EMD Serono, Inc."	1 Technology Place		Rockland	Massachusetts	2370	USA
"N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt"	n/a	1/7/15	For the treatment of Cushing's Syndrome	Designated			N/A	N/A	"Millendo Therapeutics, Inc."	301 North Main St.	Suite 100	"Ann Arbor,"	Michigan	48104	USA
N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide	n/a	9/30/04	Treatment of neuroblastoma	Designated/Withdrawn			N/A	N/A	"AbbVie, Inc."	1 N. Waukegan Road		North Chicago	Illinois	60064	USA
"N-[3-(4',5'-bipyrimidin-2-ylamino)-4-methylphenyl]-4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl}-3-(trifluoromethyl)benzamide"	n/a	12/27/06	Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia.	Designated			N/A	N/A	CytRx Corporation	3030 Bunker Hill Street	Suite 101	San Diego	California	92109	USA
N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea	n/a	10/23/07	Treatment of acute myelogenous leukemia	Designated/Withdrawn			N/A	N/A	"AbbVie, Inc."	1 N Waukegan Road	AP34/RA72	North Chicago	Illinois	60064	USA
N-[4-(3-amino1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl)urea	n/a	5/23/07	Treatment of hepatocellular carcinoma	Designated/Withdrawn			N/A	N/A	"AbbVie, Inc."	1 N Waukegan Road	AP34/RA72	North Chicago	Illinois	60064	USA
"N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide"	n/a	8/13/04	Treatment of stages IIB-IV melanoma	Designated/Withdrawn			N/A	N/A	"Pfizer, Inc."	50 Pequot	6025-A3106	New London	Connecticut	6320	USA
"N-[4-(4-amino-2-ethyl-lH-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide"	n/a	3/24/06	Treatment of cutaneous T-cell lymphoma	Designated/Withdrawn			N/A	N/A	"Pfizer, Inc."	50 Pequot Avenue	6025-A3106	New London	Connecticut	6320	USA
N-[4-(trifluoromethyl)phenyl] 5 methylisoxazole-4-carboxamide	n/a	5/25/95	Treatment of malignant glioma.	Designated			N/A	N/A	"Sugen, Inc."	230 East Grand Ave.		South San Francisco	California	94080	USA
N-[4-(trifluoromethyl)phenyl]-5-methylisoxazole-4-carboxamide	n/a	3/12/96	Treatment of ovarian cancer.	Designated			N/A	N/A	"Sugen, Inc."	230 East Grand Ave.		South San Francisco	California	94080	USA
"N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]urea"	n/a	5/13/02	Treatment of sickle cell disease	Designated/Withdrawn			N/A	N/A	NeuroSearch A/S	93 Pederstrupvej	DK-2750 Ballerup				Denmark
"N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide"	n/a	2/3/15	"Treatment of TrkA-positive, TrkB-positive, TrkC-positive ROS1-positive or ALK-positive non-small cell lung cancer"	Designated			N/A	N/A	"Ignyta, Inc."	11111 Flintkote Avenue		San Diego	California	92121	USA
"N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide"	n/a	2/12/15	"Treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive, or ALK-positive colorectal cancer"	Designated			N/A	N/A	"Ignyta, Inc."	11111 Flintkote Avenue		San Diego	California	92121	USA
"N-{[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide"	n/a	2/4/11	Treatment of tuberculosis.	Designated			N/A	N/A	"Sequella, Inc."	9610 Medical Center Drive	Suite 200	Rockville	Maryland	20820	USA
"N1,N14,-diethyl-3,12,-dihydroxyhomospermine"	n/a	8/7/14	Treatment of pancreatic cancer	Designated			N/A	N/A	"Sun BioPharma, Inc."	712 Vista Blvd	Suite 305	Waconia	Minnesota	55387	USA
N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-Maystansine-Conjugated Humanized C242 Monoclonal Antibody	n/a	12/7/00	For pancreatic cancer	Designated			N/A	N/A	SmithKline Beecham Pharmaceuticals	1250 S. Collegeville Road		Collegeville	Pennsylvania	19426	USA
N2'-Deacetyl-N2'-[4-methyl-4-(oxobuthyldithio)-1-oxopentyl]-maytansine-chimerized anti-CD138 IgG4 Monoclonal Antibody	n/a	2/27/08	Treatment of multiple myeloma	Designated			N/A	N/A	Biotest Pharmaceuticals Corporation	"5800 Park of Commerce Blvd, NW"		Boca Raton	Florida	33487	USA
nabumetone	n/a	5/5/08	Treatment of pediatric juvenile rheumatoid arthritis	Designated			N/A	N/A	Cook Pharma	109 Graylyn Drive		Chapel Hill	North Carolina	27516	USA
Nafarelin acetate	Synarel Nasal Solution	7/20/88	Treatment of central precocious puberty.	Designated/Approved	Approved for Orphan Indication	Treatment of central precocious puberty (gonadotropin-dependent precocious puberty) in children of both sexes.	02/26/1992	02/26/1999	"Syntex (USA), Inc."	3401 Hillview Avenue		Palo Alto	California	94303	USA
naloxone	n/a	11/23/10	Topical treatment of pruritus associated with mycosis fungoides	Designated			N/A	N/A	"Elorac, Inc."	100 Fairway Drive		Vernon Hills	Illinois	60061	USA
naltrexone	n/a	1/19/10	Treatment of Crohn's disease in pediatric patients	Designated			N/A	N/A	"TNI BioTech, Inc."	6701 Democracy Blvd	Suite 300	Bethesda	Maryland	20817	USA
naltrexone	n/a	2/23/15	Treatment of postherpetic neuralgia	Designated			N/A	N/A	Allodynic Therapeutics LLC	1785 NE 123rd Street		North Miami	Florida	33181	USA
naltrexone	n/a	1/13/15	Treatment of autoimmune hepatitis	Designated			N/A	N/A	"TaiwanJ Pharmaceuticals Co., Ltd."	"Room 204 A, Bldg 53"	"195 Chung Hsing Rd., Sec 4"	"Chutung, Hsinchu"			Taiwan
Naltrexone HCl	Trexan	3/11/85	For blockade of the pharmacological effects of exogenously administered opioids as an adjunct to the maintenance of the opioid-free state in detoxified formerly opioid-dependent individuals.	Designated/Approved	Approved for Orphan Indication		11/30/1984	11/30/1991	DuPont Pharmaceuticals	E.I. Du Pont De Nemours & Co.		Wilmington	Delaware	19898	USA
naltrexone/clonidine combination	n/a	4/14/14	Treatment of postherpetic neuralgia	Designated			N/A	N/A	Allodynic Therapeutics LLC	1785 NE 123rd Street		North Miami	Florida	33181	USA
nano-diamino-tetraiodothyroacetic acid	n/a	7/9/15	Treatment of glioblastoma multiforme (GBM)	Designated			N/A	N/A	"NanoPharmaceuticals, LLC"	1 Discovery Place		Rensselaer	New York	12144	USA
nano-diamino-tetraiodothyroacetic acid	n/a	10/28/15	Treatment of pancreatic cancer	Designated			N/A	N/A	"NanoPharmaceuticals, LLC"	1 Discovery Place		Rensselaer	New York	12144	USA
Nanocomplex consisting of a small interfering RNA that targets the human EV11 oncogenic transcription factor and an elastin-like polypeptide drug carrier.	n/a	5/23/16	Treatment of ovarian cancer.	Designated			N/A	N/A	PeptiMed	922 Walsh Road	Suite 208	Madison	Wisconsin	53714	USA
NanoDTPA(tm)	n/a	6/17/11	"Treatment of known or suspected cases of internal contamination with plutonium, americium, or curium"	Designated			N/A	N/A	"Nanotherapeutics, Inc."	13859 Progress Blvd		Alachua	Florida	32615	USA
nanoparticles containing Zoledronic acid	Edroma	11/29/16	Treatment of Glioma	Designated			N/A	N/A	Laboratorio Italiano Biochimico Farmaceutico Lisapharma SpA	Via Licinio 11		Erba (CO)			Italy
nanoparticulate paclitaxel	Nanotax	10/6/15	Treatment of ovarian cancer	Designated			N/A	N/A	"NanOlogy, LLC"	231 Bonetti Drive		San Luis Obispo	California	93401	USA
napabucasin	n/a	6/20/16	Treatment of gastric cancer including gastroesophageal junction cancer.	Designated			N/A	N/A	"Boston Biomedical, Inc."	640 Memorial Drive		Cambridge	Massachusetts	2139	USA
napabucasin	n/a	10/25/16	Treatment of pancreatic cancer.	Designated			N/A	N/A	"Boston Biomedical, Inc."	640 Memorial Drive		Cambridge	Massachusetts	2139	USA
naproxcinod	n/a	3/16/15	Treatment of Duchenne muscular dystrophy.	Designated			N/A	N/A	Nicox SA	2105 route des Dolines	Drakkar bat D-CS 10313	Valbonne			France
Natural human lymphoblastoid interferon-alpha	n/a	1/18/00	Treatment of Behcet's disease	Designated			N/A	N/A	"Amarillo Biosciences, Inc."	4134 Business Park Drive		Amarillo	Texas	79110	USA
natural human lymphoblastoid interferon-alpha	n/a	11/18/02	Treatment of polycythemia vera	Designated			N/A	N/A	"Amarillo Biosciences, Inc."	4134 Business Park Drive		Amarillo	Texas	79110	USA
Natural human lymphoblastoid interferon-alpha	n/a	8/10/00	Treatment of papillomavirus warts in the oral cavity of HIV positive patients.	Designated			N/A	N/A	"Amarillo Biosciences, Inc."	4134 Business Park Drive		Amarillo	Texas	79110	USA
NDX-peptides	n/a	12/14/10	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	NeoDiagnostic Research Ltd	Sheraton House 1st Floor	Chorleywood	Herts WD3 5LH			United Kingdom
Nebacumab	Centoxin	10/1/86	Treatment of patients with gram-negative bacteremia which has progressed to endotoxin shock.	Designated			N/A	N/A	"Centocor, Inc."	244 Great Valley Parkway		Malvern	Pennsylvania	19355	USA
necitumumab	n/a	11/20/15	Treatment of squamous non-small cell lung cancer	Designated/Approved	Approved for Orphan Indication	"Use in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic, squamous, non-small cell lung cancer. PORTRAZZA is not indicated for treatment of non-squamous, non-small cell lung cancer"	11/24/2015	11/24/2022	Eli Lilly and Company	33 ImClone Drive		Branchburg	New Jersey	8876	USA
nelarabine	n/a	9/2/99	Treatment of chronic lymphocytic leukemia.	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Jersey	7936	USA
nelarabine	Arranon	8/10/04	Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens	10/28/2005	10/28/2012	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Jersey	7936	USA
neostigmine	n/a	3/18/13	Treatment of acute colonic pseudo-obstruction	Designated			N/A	N/A	"Luitpold Pharmaceuticals, Inc."	One Luitpold Drive	P. O. Box 9001	Shirley	New York	11967	USA
neostigmine methylsulfate	n/a	2/17/12	Treatment of Myasthenia Gravis	Designated			N/A	N/A	"Luitpold Pharmaceuticals, Inc."	One Luitpold Drive	P. O. Box 9001	Shirley	New York	11967	USA
neridronate	n/a	3/25/13	"Treatment of complex regional pain syndrome (CRPS-1, CRPS-II, CRPS-NOS)"	Designated			N/A	N/A	"Grunenthal USA, Inc."	One Pluckemin Way		Bedminster	New Jersey	7921	USA
Neurotrophin-1	n/a	9/13/94	Treatment of motor neuron disease/amyotrophic lateral sclerosis.	Designated			N/A	N/A	"Ericsson, Arthur Dale, M.D."	Institute of Biologic Research	"6560 Fannin, Suite 720"	Houston	Texas	77030	USA
Neutrophil-endothelial interaction inhibitor	Cylexin	12/22/93	Treatment of post-ischemic pulmonary reperfusion edema following surgical treatment for chronic thromboembolic pulmonary hypertension.	Designated			N/A	N/A	Cytel Corporation	3525 John Hopkins Court		San Diego	California	92121	USA
nevirapine	n/a	11/25/09	Prevention of HIV infection in pediatric patients under the age of 16 years	Designated			N/A	N/A	Auritec Pharmaceuticals	1434 6th Street		Santa Monica	California	90401	USA
NiCord (cord blood-derived exvivo expanded CD34+ cells and the non-expanded cell fraction of the same cord blood unit)	n/a	11/9/16	Treatment of chronic myelogenous leukemia (CML)	Designated			N/A	N/A	Gamida Cell Ltd.	P. O. Box 34670		Jerusalem			Israel
nicotinamide riboside	Niasun	1/25/17	"Treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome (MELAS)"	Designated			N/A	N/A	Rejuvenation Therapeutics	774 Mays Boulevard	10-509 PMB	Incline Village	Nevada	89451	USA
Nifedipine	n/a	6/13/91	Treatment of interstitial cystitis.	Designated			N/A	N/A	"Fleischmann, Jonathan M.D."	MetroHealth Medical Center	3395 Scranton Road	Cleveland	Ohio	44109	USA
nifurtimox	Lampit	8/5/10	Treatment of Chagas disease (American Typanosomiasis)caused by T. cruzi	Designated			N/A	N/A	"Bayer HealthCare Pharmaceuticals, Inc."	P. O. Box 1000		Montville	New Jersey	7045	USA
nifurtimox	n/a	12/31/13	Treatment of Chagas disease	Designated			N/A	N/A	"MetronomX Therapeutics, LLC"	7000 Fannin Street	Suite 1960	Houston	Texas	77030	USA
Nikkomycin Z	n/a	2/14/06	Treatment of coccidioidomycosis	Designated			N/A	N/A	Valley Fever Center for Excellence (1-111 INF)	University of Arizona		Tucson	Arizona	85723	USA
nilotinib	Tasigna	4/27/06	Treatment of chronic myelogenous leukemia	Designated/Approved	Approved for Orphan Indication	For the use for chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior therapy that included imatinib.	10/29/2007	10/29/2014	Novartis Pharmaceutical Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
nilotinib	Tasigna	3/20/07	Treatment of gastrointestinal stromal tumors.	Designated/Withdrawn			N/A	N/A	Novartis Pharmaeuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
nimodipine	Nymalize	9/16/11	Treatment of subarachnoid hemorrhage.	Designated/Approved	Approved for Orphan Indication	"Improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V)."	05/10/2013	05/10/2020	"Arbor Pharmaceuticals, Inc."	6 Concourse Parkway	Suite 1800	Atlanta	Georgia	30328	USA
Nimotuzumab	n/a	11/17/04	Treatment of glioma	Designated			N/A	N/A	InnoKeys PTE Ltd.	26 Bukit Batok East Avenue 2 #03-10					Singapore
nimotuzumab	n/a	9/8/15	Treatment of pancreatic cancer.	Designated			N/A	N/A	InnoCIMab Pte Ltd	21 Bukit Batok Crescent	WCEGA Tower #14-78				Singapore
Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/04	Treatment of acute myelogenous leukemia	Designated			N/A	N/A	The Vaccine Company	P. O. Box 93921		Carmel	California	93921	USA
Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/04	Treatment of chronic myelogenous leukemia.	Designated			N/A	N/A	The Vaccine Company	P. O. Box 93921		Carmel	California	93921	USA
Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/04	Treatment of myelodysplastic syndromes requiring therapy	Designated			N/A	N/A	The Vaccine Company	P. O. Box 93921		Carmel	California	93921	USA
nintedanib	Ofev	6/29/11	Treatment of patients with idiopathic pulmonary fibrosis.	Designated/Approved	Approved for Orphan Indication	Treatment of idiopathic pulmonary fibrosis	10/15/2014	10/15/2021	"Boehringer Ingelheim Pharmaceuticals, Inc."	900 Ridgebury Rd.	PO Box 368	Ridgefield	Connecticut	6877	USA
nintedanib	n/a	7/6/16	Treatment of systemic sclerosis (including the associated interstitial lung disease).	Designated			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc."	900 Ridgebury Road	Box 368	Ridgefield	Connecticut	6877	USA
Nintedanib	n/a	12/12/16	Treatment of mesothelioma	Designated			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc."	900 Ridgebury Road	P. O. Box 368	Ridgefield	Connecticut	6877	USA
niprisan	Hemoxin	8/15/03	Treatment of sickle cell disease	Designated			N/A	N/A	"Xechem International, Inc."	379 Thornall Street		Edison	New Jersey	8837	USA
niraparib	n/a	4/30/10	Treatment of ovarian cancer	Designated			N/A	N/A	"TESARO, Inc."	1000 Winter St.	Suite 300	Waltham	Massachusetts	2451	USA
Nitazoxanide	Alinia	12/12/96	Treatment of cryptosporidiosis.	Designated/Approved	Approved for Orphan Indication	Treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia	11/22/2002	11/22/2009	"Romark Laboratories, L.C."	6200 Courtney Campbell Causeway	Suite 880	Tampa	Florida	33607	USA
nitazoxanide	Cryptaz	10/23/01	Treatment for intestinal amebiasis	Designated			N/A	N/A	"Romark Laboratories, L.C."	6200 Courtney Campbell Causeway	Suite 880	Tampa	Florida	33607	USA
nitazoxanide	Alinia	2/14/02	Treatment of intestinal giardiasis	Designated/Approved	Approved for Orphan Indication	Treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia	11/22/2002	11/22/2009	"Romark Laboratories, L.C."	6200 Courtney Campbell Causeway	Suite 880	Tampa	Florida	33607	USA
Nitisinone	Orfadin	5/16/95	Treatment of tyrosinemia type 1.	Designated/Approved	Approved for Orphan Indication	Adjunctive therapy to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1	01/18/2002	01/18/2009	Swedish Orphan Biovitrum AB	"890 Winter Street, Suite 115"		Waltham	Massachusetts	2451	USA
Nitisinone	Orfadin	10/19/01	Treatment of alkaptonuria	Designated			N/A	N/A	Swedish Orphan AB	"Kungsgatan 37, 7th Floor"	SE-111 56				Sweden
Nitisinone	Orfadin	5/16/95	Treatment of tyrosinemia type 1.	Designated/Approved	Approved for Orphan Indication	Treatment of hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.	04/22/2016	04/22/2023	Swedish Orphan Biovitrum AB	"890 Winter Street, Suite 115"		Waltham	Massachusetts	2451	USA
nitric oxide	n/a	1/31/17	Treatment of idiopathic pulmonary fibrosis	Designated			N/A	N/A	"GeNo, LLC"	2941 Oxbow Circle		Cocoa	Florida	32926	USA
nitric oxide	Inomax	12/28/11	Treatment of pulmonary arterial hypertension	Designated			N/A	N/A	Bellerophon Therapeutics	53 Frontage Road	Suite 301	Hampton	New Jersey	8827	USA
Nitric oxide	n/a	7/10/95	Treatment of acute respiratory distress syndrome in adults.	Designated			N/A	N/A	"INO Therapeutics, Inc."	Perryville III Corporate Park	"53 Frontage RD, 3rd Floor"	Hampton	New Jersey	8827	USA
nitric oxide	Inomax (R)	9/5/08	Use in combination with a drug delivery device for acute treatment of sickle cell vaso-occlusive crisis (pain crises)	Designated			N/A	N/A	INO Therapeutics	Perryville III Corporate Park	"53 Frontage Rd, 3rd Floor"	Hampton	New Jersey	8827	USA
Nitric oxide	n/a	2/16/05	Diagnosis of sarcoidosis	Designated			N/A	N/A	SensorMedics Corporation	22705 Savi Ranch Parkway		Yorba Linda	California	92887	USA
Nitric oxide	Inomax	6/22/93	Treatment of persistent pulmonary hypertension in the newborn.	Designated/Approved	Approved for Orphan Indication	"In conjunction with ventilatory support and other appropriate agents, in the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation."	12/23/1999	12/23/2006	"INO Therapeutics, Inc."	Perryville III Corporate Park	"53 Frontage RD, 3rd Floor"	Hampton	New Jersey	8827	USA
nitric oxide	n/a	1/25/17	Treatment of pulmonary arterial hypertension excluding persistent pulmonary hypertension of the newborn	Designated			N/A	N/A	"GeNo, LLC"	2941 Oxbow Circle		Cocoa	Florida	32926	USA
Nitric oxide	n/a	9/11/13	Treatment of cystic fibrosis	Designated			N/A	N/A	"Novoteris, LLC"	7245 Garden Grove Blvd.	Suite C	Garden Grove	California	92841	USA
Nitric oxide	Inomax	9/27/04	To reduce the risk of chronic lung disease in premature neonates	Designated			N/A	N/A	INO Therapeutics	Perryville III Corporate Park	53 Frontage Rd. 3rd Floor	Hampton	New Jersey	8827	USA
nitric oxide	n/a	9/23/14	Treatment of cystic fibrosis	Designated			N/A	N/A	Advanced Inhalation Therapies Ltd.	2 Derech Meir Weisgal	7632605				Israel
nitric oxide	n/a	6/18/12	Treatment of persistent pulmonary hypertension in newborns	Designated			N/A	N/A	"GeNO, LLC"	2941 Oxbox Circle		Cocoa	Florida	32926	USA
Nitroprusside	n/a	2/21/01	Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.	Designated			N/A	N/A	"Thomas, MD, Jeffrey Evan"	Thomas Jefferson University and Wills Neurosensory	"834 Walnut Street, Suite 650"	Philadelphia	Pennsylvania	19107	USA
nivolumab	Opdivo	8/7/14	Treatment of Hodgkin lymphoma	Designated/Approved	Approved for Orphan Indication	Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation brentuximab vedotin	05/17/2016	05/17/2023	Bristol-Myers Squibb Co.	Route 206 & Province Line Road		Princeton	New Jersey	8543	USA
nivolumab	Opdivo	12/20/16	Treatment of gastric cancer and gastro-esophageal junction cancer.	Designated			N/A	N/A	Bristol-Myers Squibb Co.	5 Research Parkway		Wallingford	Connecticut	6492	USA
nivolumab	n/a	1/23/13	Treatment of Stage IIb to IV melanoma	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor"	12/22/2014	12/22/2021	Bristol-Myers Squibb Co.	Route 206 & Province Line Road		Princeton	New Jersey	8540	USA
nivolumab	Opdivo(R)	9/2/15	Treatment of hepatocellular carcinoma.	Designated			N/A	N/A	Bristol-Myers Squibb Company	P. O. Box 4000		Princeton	New Jersey	8543	USA
nivolumab	Opdivo	8/22/16	Treatment of esophageal cancer	Designated			N/A	N/A	Bristol-Myers Squibb Co.	5 Research Parkway		Wallingford	Connecticut	6492	USA
nivolumab	n/a	9/15/15	Treatment of small cell lung cancer.	Designated			N/A	N/A	Bristol-Myers Squibb Company	Route 206 & Province Line Road	Mail Stop D32-07	Princeton	New Jersey	8543	USA
nivolumab	n/a	8/27/15	Treatment of glioblastoma	Designated			N/A	N/A	Bristol-Myers Squibb Co	P. O. Box 4000		Princeton	New Jersey	8543	USA
Nivolumab and Ipilimumab	n/a	12/20/16	Treatment of gastric cancer and gastric-esophageal junction cancer.	Designated			N/A	N/A	Bristol-Myers Squibb Co.	5 Research Parkway		Wallingford	Connecticut	6492	USA
nolatrexed	Thymitaq	10/18/01	Treatment of hepatocellular carcinoma	Designated/Withdrawn			N/A	N/A	EXIMIAS Pharmaceutical Corporation	1055 Westlakes Drive	Suite 200	Berwyn	Pennsylvania	19312	USA
non-peptide small molecule orally available agonist of the parathyroid hormone receptor type I	n/a	12/15/14	Treatment of hypoparathyroidism	Designated			N/A	N/A	"Chugai Pharma USA, LLC"	300 Connell Drive	Suite 300	Berkeley Heights	New Jersey	7922	USA
"non-replicating adeno-associated viral vector, serotype 8, expressing human myotubularin gene"	At001	12/3/14	Treatment of x-linked myotubular myopathy	Designated			N/A	N/A	"Audentes Therapeutics, Inc."	"101 Montgomery St., #2650"		San Francisco	California	94104	USA
Non-replicating recombinant adeno-associated viral vector expressing the human acid alpha-glucosidase gene	n/a	1/11/17	Treatment of Pompe disease	Designated			N/A	N/A	Duke University Medical Center	Box 103856		Durham	North Carolina	27710	USA
"non-replicating recombinant adeno-associated viral vector, serotype 8, expressing the 1A1 isoform of the bilirubin-uridine diphosphate glucuronosyltransferase gene"	n/a	5/24/16	Treatment of Crigler Najjar syndrome.	Designated			N/A	N/A	"Audentes Therapeutics, Inc."	600 California Street	17th Floor	San Francisco	California	94109	USA
non-replicating recombinant adeno-associated virus (AAV) vector of serotype 9 expressing human iduronate-2-sulfatase	n/a	12/8/15	Treatment of Mucopolysaccharidosis Type II	Designated			N/A	N/A	"REGENXBIO, Inc."	9712 Medical Center Drive	Suite 100	Rockville	Maryland	20850	USA
non-replicating recombinant adeno-associated virus vector containing a fragment of the gene encoding channelrhodopsin-2 protein	n/a	10/20/14	Treatment of retinitis pigmentosa	Designated			N/A	N/A	"RetroSense Therapeutics, LLC"	"330 East Liberty Street, LL"		Ann Arbor	Michigan	48104	USA
NorLeu3-Angiontensin(1-7)) [NorLeu3-A(1-7)]	n/a	12/31/13	Treatment of leakage from the surgical site following penetrating keratoplasty	Designated			N/A	N/A	"US Biotest, Inc."	"231 Bonetti Dr.,"	Suite 240	San Luis Obispo	California	93401	USA
NorLeu3-Angiotensin(1-7) [NorLeu3-A(1-7)]	n/a	1/31/14	Treatment of dermal injury due to nuclear/radiation incident	Designated			N/A	N/A	"US Biotest, Inc."	"231 Bonetti Dr.,"	Suite 240	San Luis Obispo	California	93401	USA
noscapine	n/a	12/29/15	Treatment of amyotrophic lateral sclerosis.	Designated			N/A	N/A	KineMed Inc.	5980 Horton Street	Suite 470	Emeryville	California	94608	USA
Novel Acting Thrombolytic (NAT)	n/a	1/26/01	Treatment of peripheral arterial occlusion (PAO)	Designated/Withdrawn			N/A	N/A	"Nuvelo, Inc. Inc."	201 Industrial Road	Suite 310	San Carlos	California	94070	USA
Nucleic acid aptamer binding to tumor cell nucleolin	n/a	8/17/04	Treatment of pancreatic cancer	Designated			N/A	N/A	Antisoma Research Ltd.	Hanger Lane	London				United Kingdom
Nucleic acid aptamer binding to tumor cell nucleolin	n/a	9/10/09	Treatment of acute myeloid leukemia	Designated			N/A	N/A	"Antisoma, Inc."	300 Technology Square		Cambridge	Massachusetts	2139	USA
Nucleic acid aptamer binding to tumor cell nucleon	n/a	7/28/05	Treatment of renal cell carcinoma	Designated			N/A	N/A	Antisoma Inc.	300 Technology Square		Cambridge	Massachusetts		USA
nusinersen	Spinraza	4/18/11	Treatment of spinal muscular atrophy	Designated/Approved	Approved for Orphan Indication	Treatment of spinal muscular atrophy in pediatric and adult patients	12/23/2016	12/23/2023	"Biogen, Inc"	225 Binney Street		Cambridge	Massachusetts	2142	USA
O-(3-piperidino-2-hydroxyl-1-propyl)-nicotinic acid amidoxime hydrochloride	n/a	1/15/13	Treatment of Duchenne Muscular Dystrophy	Designated			N/A	N/A	Vudbenk Life Sciences	Tancsics Mihaly utca 18	5900 Oroshaza				Hungary
"O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate"	n/a	3/16/12	Treatment of acute myeloid leukemia	Designated			N/A	N/A	"JSK Therapeutics, Inc."	85 Fort Douglas Boulevard	P. O. Box 58986	Salt Lake City	Utah	84158	USA
"O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1yl]diazen-1-ium-1,2-diolate"	n/a	12/13/13	Treatment of multiple myeloma	Designated			N/A	N/A	"JSK Therapeutics, Inc."	85 Fort Douglas Boulevard	P.O. Box 58986	Salt Lake City	Utah	84158	USA
Obatoclax mesylate	n/a	11/6/06	Treatment of myelodysplastic syndrome	Designated/Withdrawn			N/A	N/A	"Gemin X, Inc."	400 Chesterfield Parkway	Suite 100	Malvern	Pennsylvania	19355	USA
obatoclax mesylate	n/a	10/8/04	Treatment of chronic lymphocytic leukemia	Designated/Withdrawn			N/A	N/A	"Teva Branded Pharmaceutical Products R&D, Inc."	41 Moores Road	P. O. Box 4011	Frazer	Pennsylvania	19355	USA
Obatoclax mesylate	n/a	12/1/06	Treatment of myelofibrosis	Designated/Withdrawn			N/A	N/A	"Gemin X Pharmaceuticals US, Inc."	400 Chesterfield Pkwy.	Suite 100	Malvern	Pennsylvania	19355	USA
obeticholic acid	Ocaliva	4/9/08	Treatment of primary biliary cirrhosis	Designated/Approved	Approved for Orphan Indication	"Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA"	05/27/2016	05/27/2023	"Intercept Pharmaceuticals, Inc."	4760 Eastgate Mall		San Diego	California	92122	USA
obiltoxaximab	Anthim	6/9/06	Treatment of exposure to B. anthracis spores	Designated/Approved	Approved for Orphan Indication	Treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.	03/18/2016	03/18/2023	"Elusys Therapeutics, Inc."	25 Riverside Drive	P.O. Box 102	Pine Brook	New Jersey	7058	USA
obinutuzumab	n/a	2/17/12	Treatment of diffuse large B cell lymphoma	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
obinutuzumab	Gazyva	6/11/15	Treatment of splenic marginal zone lymphoma	Designated/Withdrawn			N/A	N/A	"Genentech, Inc."	1 DNA Way	MS# 214A	South San Francisco	California	94080	USA
obinutuzumab	Gazyva	2/17/12	Treatment of chronic lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of patients with previously untreated chronic lymphocytic leukemia in combination with chlorambucil.	11/01/2013	11/01/2020	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
obinutuzumab	Gazyva	4/15/15	Treatment of follicular lymphoma	Designated/Approved	Approved for Orphan Indication	"Indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen"	02/26/2016	02/26/2023	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
oblimersen	Genasense	7/31/00	"Treatment of advanced malignant melanoma (Stages II,III, IV)."	Designated			N/A	N/A	"Genta, Inc."	200 Connell Drive		Berkeley Heights	New Jersey	7922	USA
oblimersen	Genasense	8/28/01	Treatment of multiple myeloma	Designated			N/A	N/A	"Genta, Inc."	200 Connell Drive		Berkeley Heights	New Jersey	7922	USA
oblimersen	Genasense	8/28/01	Treatment of acute myelocytic leukemia	Designated			N/A	N/A	"Genta, Inc."	200 Connell Drive		Berkeley Heights	New Jersey	7922	USA
oblimersen	Genasense	8/28/01	Treatment of chronic lymphocytic leukemia	Designated			N/A	N/A	"Genta, Inc."	200 Connell Drive		Berkeley Heights	New Jersey	7922	USA
octavalent Psuedomonas aeruginosa O-polysaccaharide-toxin A conjugate	Aerugen	5/16/02	Prevention of Psuedomonas aeruginosa infections in patients with cystic fibrosis	Designated/Withdrawn			N/A	N/A	Berna Biotech Ltd.	Rehhagstrass 79	CH-3018	Berna			Switzerland
Octreotide	Sandostatin Lar	8/24/98	Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).	Designated/Approved	Approved for Orphan Indication	Treatment of profuse watery diarrhea associated with VIPoma.	11/25/1998	11/25/2005	Novartis Pharmaceuticals Corporation	59 Route 10		East Hanover	New Jersey	7936	USA
octreotide	Sandostatin Lar	8/5/10	Treatment of neuroendocrine tumors	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	One Health laza		East Hanover	New Jersey	7936	USA
Octreotide	Sandostatin Lar	8/24/98	Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.	Designated/Approved	Approved for Orphan Indication	Supression of severe diarrhea and flushing associated with malignant carcinoid syndrome.	11/25/1998	11/25/2005	Novartis Pharmaceuticals Corporation	59 Route 10		East Hanover	New Jersey	7936	USA
Octreotide	Sandostatin Lar	8/24/98	Treatment of acromegaly.	Designated/Approved	Approved for Orphan Indication	Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly.	11/25/1998	11/25/2005	Novartis Pharmaceuticals Corporation	59 Route 10		East Hanover	New Jersey	7936	USA
octreotide (oral)	Octreolin(Tm)	6/17/10	For the oral treatment of acromegaly	Designated			N/A	N/A	"Chiasma, Inc."	831 Beacon Street	Suite 3B	Newton Centre	Massachusetts	2459	USA
octreotide acetate subcutaneous implant	n/a	12/7/09	Treatment of acromegaly	Designated			N/A	N/A	"Endo Pharmaceuticals Solutions, Inc."	100 Endo Blvd		Chadds Ford	Pennsylvania	19317	USA
ofatumumab	Arzerra	3/10/09	Treatment of chronic lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	Arzerra in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL).	08/30/2016	08/30/2023	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
ofatumumab	Arzerra	3/10/09	Treatment of chronic lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	"Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate."	04/17/2014	04/17/2021	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
ofatumumab	Arzerra	3/10/09	Treatment of chronic lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.	01/19/2016	01/19/2023	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
ofatumumab	Arzerra	3/10/09	Treatment of chronic lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine	10/26/2009	10/26/2016	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
Ofloxacin	Ocuflox Ophthalmic Solution	4/18/91	Treatment of bacterial corneal ulcers.	Designated/Approved	Approved for Orphan Indication	Treatment of bacterial corneal ulcers.	05/22/1996	05/22/2003	"Allergan, Inc."	2525 Dupont Drive	P.O. Box 19534	Irvine	California	92713	USA
oglufanide disodium	n/a	9/24/01	Treatment of ovarian cancer	Designated			N/A	N/A	Implicit Bioscience Pty Ltd	P. O. Box 2072	Toowong Business Center				Australia
olaparib	Lynparza	10/16/13	Treatment of ovarian cancer	Designated/Approved	Approved for Orphan Indication	Use of as monotherapy for patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy	12/19/2014	12/19/2021	AstraZeneca Pharmaceuticals LP	1800 Concord Pike	P. O. Box 8355	Wilmington	Delaware	19803	USA
olaptesed pegol	n/a	8/19/14	Treatment of glioblastoma in conjunction with radiotherapy.	Designated			N/A	N/A	Noxxon Pharma AG	Max-Dohrn0Strasse 8-10		Berlin			Germany
olaratumab	Lartruvo	10/9/14	Treatment of soft tissue sarcoma	Designated/Approved	Approved for Orphan Indication	"In combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery."	10/19/2016	10/19/2023	Eli Lilly and Company	"Lilly Corporate Center, Drop Code 2543"		Indianapolis	Indiana	46285	USA
oleylphosphocholine	n/a	10/25/13	Treatment of leishmaniasis	Designated			N/A	N/A	Dafra Pharma International nv	Slachthuisstraat 30 b7					Belgium
oligodendrocyte progenitor cells	n/a	2/2/16	Treatment of acute spinal cord injury	Designated			N/A	N/A	Asterias Biotherapeutics	6300 Dumbarton Circle		Fremont	California	94555	USA
oligopeptide containing 6 amino acids (H-Phe-Ser-Arg-Tyr-Ala-Arg-OH)	n/a	2/27/14	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	"Genervon Biopharmaceuticals, LLC"	1055 E. Colorado Blvd	Suite 500	Pasadena	California	91106	USA
olipudase alfa	n/a	8/3/00	Treatment of acid sphingomyelinase deficiency (Niemann-Pick disease)	Designated			N/A	N/A	Genzyme Corporation	500 Kendall Street		Cambridge	Massachusetts	2142	USA
omacetaine mepesuccinate	n/a	1/12/09	Treatment of myelodysplastic syndromes	Designated			N/A	N/A	IVAX International GmbH	Alpenstrasse 2	8640 Rapperswil				Switzerland
omacetaxine mepesuccinate	Synribo	3/10/06	Treatment of chronic myelogenous leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI)	10/26/2012	10/26/2019	IVAX International GmbH	Alpenstrasse 2	8640 Rapperswil	Frazer			Switzerland
Ombitasvir/Paritaprevir/Ritonavir	Technivie Tablets	2/24/16	Treatment of pediatric patients with chronic hepatitis C virus infection	Designated			N/A	N/A	AbbVie Inc.	1 North Waukegan Road		North Chicago	Illinois	60064	USA
ombitasvir/paritaprevir/ritonavir and dasabuvir	Viekira Pak	7/16/15	Treatment of pediatric patients with hepatitis C virus infection (0 through 16 years of age)	Designated			N/A	N/A	"Abbvie, Inc."	1 North Waukegan Road		North Chicago	Illinois	60064	USA
"ombrabulin; N-{2-methoxy-5-[(Z)-2-(3,4,5-trimethozyphenyl)vinyl]phenyl}-L-serinamide hydrochloride"	n/a	3/3/11	Treatment of soft tissue sarcoma	Designated			N/A	N/A	"Sanofi-Aventis U.S., Inc."	55 Corporate Drive		Bridgewater	New Jersey	8807	USA
Omega-3 (n-3) polyunsaturated fatty acid with all double bonds in the cis configuration	n/a	11/22/95	Prevention of organ graft rejection.	Designated			N/A	N/A	Research Triangle Pharmaceuticals	4364 South Alston Avenue		Durham	North Carolina	27713	USA
Omega-3 (n-3) polyunsaturated fatty acids	Omacor	5/4/00	Treatment of IgA nephropathy.	Designated			N/A	N/A	"Pronova Biocare, AS"	PO Box 420	1327 Lysaker				Norway
Omegaven emulsion	Omegaven	2/27/08	Treatment of parenteral nutrition-associated liver disease	Designated			N/A	N/A	Fresenius Kabi Deutschland GmbH	Daimlerstrasse 16					Germany
omeprazole-lansoprazole with buffer	n/a	2/10/15	Treatment of esophageal ulcers	Designated			N/A	N/A	"Effexus Pharmaceuticals, LLC"	10901 Granada Lane	Suite 101	Leawood	Kansas	66211	USA
omigapil	n/a	6/24/08	Treatment of congenital muscular dystrophy.	Designated			N/A	N/A	Santhera Pharmaceuticals Limited	Hammerstrasse 7	Liestal				Switzerland
onartuzumab	n/a	1/23/13	Treatment of gastric cancer including gastroesophageal cancer	Designated/Withdrawn			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
onartuzumab (MetMab)	n/a	12/16/13	Treatment of hepatocellular carcinoma	Designated/Withdrawn			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
Oncolytic adenovirus coding for granulocyte macrophage colony stimulating factor (ONCOS-102)	n/a	12/22/14	Treatment of malignant mesothelioma	Designated			N/A	N/A	Oncos Therapeutics	Saukonpaadenranta 2		Helsinki			Finland
oncophage	n/a	4/14/09	Treatment of glioma	Designated			N/A	N/A	"Agenus, Inc."	3 Forbes Road		Lexington	Massachusetts	2421	USA
ondansetron inhalation powder	n/a	10/14/15	Prevention of chemotherapy-induced nausea and vomiting due to highly emetogenic chemotherapy in pediatric patients (0 through 16 years of age) .	Designated			N/A	N/A	"Luxena Pharmaceuticals, Inc."	1400 Coleman Avenue	Suite D27	Santa Clara	California	95050	USA
opioid growth factor	n/a	4/16/13	Treatment of liver and intrahepatic bile duct cancer	Designated			N/A	N/A	"Primocure Pharma, Inc."	1521 Concord Pike	#303	New Castle	Delaware	19803	USA
opium tincture	n/a	12/2/11	Treatment of chronic diarrhea in short bowel syndrome patients with an inadequate response to anti-diarrheal treatment	Designated			N/A	N/A	"Valeant Pharmaceuticals International, Inc."	400 Somerset Corporate Blvd		Bridgewater	New Jersey	8807	USA
Oprelvekin	Neumega	12/17/96	Prevention of severe chemotherapy-induced thrombocytopenia.	Designated/Approved	Approved for Orphan Indication		11/25/1997	11/25/2004	"Genetics Institute, Inc."	87 Cambridge Park Drive		Cambridge	Massachusetts	2140	USA
oprozomib	n/a	8/25/14	Treatment of Waldenstrom's macroglobulinemia	Designated			N/A	N/A	"Onyx Therapeutics, Inc."	249 E. Grand Avenue		South San Francisco	California	94080	USA
oprozomib	n/a	10/28/14	Treatment of multiple myeloma	Designated			N/A	N/A	"Onyx Therapeutics, Inc."	249 E. Grand Avenue		South San Francisco	California	94080	USA
optically pure phenylalanine derivative	n/a	8/20/12	Treatment of narcolepsy	Designated			N/A	N/A	Jazz Pharmaceuticals International III Limited	3180 Porter Drive		Palo Alto	California	94304	USA
oral potent and selective antagonist	n/a	2/18/11	Treatment of patients with chondrosarcoma.	Designated/Withdrawn			N/A	N/A	"Infinity Pharmaceuticals, Inc."	780 Memorial Drive		Cambridge	Massachusetts	2139	USA
oral testosterone	n/a	6/2/16	Treatment of constitutional delay of growth and puberty in adolescent boys 14 to 17 years of age.	Designated			N/A	N/A	"TesoRx Pharma, LLC"	3670 West Temple Avenue	Suite 270	Pomona	California	91768	USA
oral unfractionated heparin	n/a	1/29/04	Treatment of sickle cell disease	Designated			N/A	N/A	"TRF Technologies, Inc."	"863 Mitten Road, Suite 101"		Burlingame	California	94010	USA
Orgotein for injection	n/a	12/22/94	"Treatment of familial amyotrophic lateral sclerosis associated with a mutation of the gene (on chromosome 21q) for copper, zinc superoxide dismutase."	Designated/Withdrawn			N/A	N/A	"Oxis International, Inc."	"6040 N. Cutter Circle, Suite 317"		Portland	Oregon	97217	USA
osilodrostat	n/a	9/13/13	Treatment of Cushing's disease	Designated			N/A	N/A	Novartis Pharmaceuticals corporation	One Health Plaza	Bldg 104	East Hanover	New Jersey	7936	USA
osimertinib	Tagrisso	9/4/14	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer	Designated/Approved	Approved for Orphan Indication	"For treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy"	11/13/2015	11/13/2022	AstraZeneca Pharmaceuticals LP	P. O. Box 8355	1800 Concord Pike	Wilmington	Delaware	19803	USA
otelixizumab	n/a	2/6/06	Treatment of new-onset type I diabetes mellitus	Designated			N/A	N/A	GlaxoSmithKline	2301 Renaissance Blvd (RN0420)	P. O. Box 61540	King of Prussia	Pennsylvania	19406	USA
OTL38; conjugate of pteroi acid and S0456 near infrared dye	n/a	12/23/14	Detecting folic receptor alpha positive lesions in ovarian cancer patients (diagnostic for the management of ovarian cancer)	Designated			N/A	N/A	"On Target Laboratories, LLC"	1282 Win Hentschel Blvd		West Lafayette	Indiana	47906	USA
Oxaliplatin	n/a	10/6/92	Treatment of ovarian cancer.	Designated			N/A	N/A	Debio Pharm S.A.	Rue des Terreaux 17	CH-1000				Switzerland
oxaloacetate	n/a	7/24/12	Treatment of gliomas	Designated			N/A	N/A	Terra Biological LLC	3830 Valley Centre Drive	Suite 705-561	San Diego	California	92130	USA
Oxaloacetic acid	n/a	11/18/15	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	Terra Biological LLC	3830 Valley Centre Drive	Suite 705-561	San Diego	California	92130	USA
Oxalobacter formigenes	n/a	3/29/06	Treatment of primary hyperoxaluria	Designated			N/A	N/A	"OxThera, Inc."	13709 Progress Blvd. #17		Alachua	Florida	32615	USA
Oxandrolone	n/a	10/5/90	Treatment of constitutional delay of growth and puberty.	Designated/Withdrawn			N/A	N/A	Bio-Technology General Corp.	"70 Wood Avenue, South"		Iselin	New Jersey	8830	USA
Oxandrolone	Hepandrin	3/18/94	Treatment of moderate/severe acute alcoholic hepatitis in the presence of moderate protein calorie malnutrition.	Designated/Withdrawn			N/A	N/A	Bio-Technology General Corp.	70 Wood Avenue South		Iselin	New Jersey	8830	USA
Oxandrolone	Oxandrin	4/22/97	Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.	Designated			N/A	N/A	"Savient Pharmaceuticals, Inc."	"One Tower Center Boulevard, 12th floor"		East Brunswick	New Jersey	8816	USA
Oxandrolone	Oxandrin	7/5/90	Treatment of short stature associated with Turner's syndrome.	Designated/Withdrawn			N/A	N/A	Bio-Technology General Corp.	"70 Wood Avenue, South"		Iselin	New Jersey	8830	USA
Oxandrolone	Oxandrin	9/6/91	Adjunctive therapy for AIDS patients suffering from HIV-wasting syndrome.	Designated			N/A	N/A	Bio-Technology General Corp.	70 Wood Avenue South		Iselin	New Jersey	8830	USA
oxfendazole	n/a	7/14/14	Treatment of cysticercosis (including neurocysticercosis)	Designated			N/A	N/A	"Robert H. Gilman, MD, DTMH and"	Johns Hopkins School of Public Health	"615 N. Wolfe St, Room W5515"	Baltimore	Maryland	21205	USA
oxybate	Xyrem	11/7/94	Treatment of narcolepsy.	Designated/Approved	Approved for Orphan Indication	Treatment of cataplexy associated with narcolepsy	07/17/2002	07/17/2009	Jazz Pharmaceuticals	3180 Porter Drive		Palo Alto	California	94304	USA
oxybate	Xyrem	11/7/94	Treatment of narcolepsy.	Designated/Approved	Approved for Orphan Indication	Treatment of excessive daytime sleepiness in patients with narcolepsy	11/18/2005	11/18/2012	Jazz Pharmaceuticals	3180 Porter Drive		Palo Alto	California	94304	USA
Oxymorphone	Numorphan H.P.	3/19/85	For relief of severe intractable pain in narcotic-tolerant patients.	Designated			N/A	N/A	DuPont Merck Pharmaceutical Company	P.O. Box 80027		Wilmington	Delaware	19880	USA
Oxypurinol	n/a	11/9/98	Treatment of hyperuricemia in patients intolerant to allopurinol.	Designated			N/A	N/A	Cardiome Pharma Corp.	3650 Westbrook Mall	"Vancouver, B.C."				Canada
oxytocin	n/a	11/24/14	Treatment of Prader-Willi syndrome	Designated			N/A	N/A	Pr Maithe Tauber	Hospital des enfants	TSA70034 31059	Toulouse			France
ozanimod	n/a	12/29/15	Treatment of pediatric (0 through 16 years of age) ulcerative colitis	Designated			N/A	N/A	"Receptos Services, LLC"	3033 Science Park Road	Suite 300	San Diego	California	92121	USA
"P1, P4-Di(uridine 5'-tetraphosphate), tetrasodium salt"	n/a	10/27/98	Treatment of cystic fibrosis.	Designated/Withdrawn			N/A	N/A	"Inspire Pharmaceuticals, Inc."	"4222 Emperor Blvd., Suite 470"		Durham	North Carolina	27703	USA
"p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium salt"	n/a	3/7/01	For the treatment of cystic fibrosis	Designated/Withdrawn			N/A	N/A	"Inspire Pharmaceuticals, Inc."	4222 Emperor Blvd.	Suite 200	Durham	North Carolina	27703	USA
P140K MGMT transduced human CD34 cells	n/a	1/9/13	For bone marrow protection in the treatment of glioblastoma multiforme	Designated			N/A	N/A	Lentigen Corporation	910 Clopper Road	Suite 200 South Building	Gaithersburg	Maryland	20878	USA
p38 mitogen-activated kinase inhibitor	n/a	5/27/14	"Treatment of dilated cardiomyopathy, including dilated cardiomyopathy secondary to lamin A/C gene mutations"	Designated			N/A	N/A	"Array BioPharma, Inc."	3200 Walnut Street		Boulder	Colorado	80301	USA
paclitaxel	n/a	5/1/09	Treatment of pancreatic cancer	Designated			N/A	N/A	"SynCore Biotechnology Co., Ltd."	No. 84 Chung Shan Rd	Tung-Shan Shine I-Lan 269				Taiwan
paclitaxel	Tocosol	12/22/04	Treatment of non-superficial urothelial cancer	Designated/Withdrawn			N/A	N/A	"Sonus Pharmaceuticals, Inc."	22026 20th Avenue SE		Bothell	Washington	98021	USA
Paclitaxel	Taxol	3/25/97	Treatment of AIDS-related Kaposi's sarcoma.	Designated/Approved	Approved for Orphan Indication	For the second line treatment of AIDS-related Kaposi's sarcoma.	08/04/1997	08/04/2004	Bristol-Myers Squibb Pharmaceutical Research Institute	5 Research Parkway	P.O. Box 5100	Wallingford	Connecticut	6492	USA
Paclitaxel	Paxene	4/15/97	Treatment of AIDS-related Kaposi's sarcoma.	Designated			N/A	N/A	"Baker Norton Pharmaceuticals, Inc."	4400 Biscayne Boulevard		Miami	Florida	33137	USA
paclitaxel aqueous gel	Oncogel(Tm)	2/1/08	Treatment of esophageal cancer	Designated			N/A	N/A	"BTG International, Inc."	5214 Maryland Way	Suite 405	Brentwood	Tennessee	37027	USA
paclitaxel aqueous gel	Oncogel (Tm)	12/23/08	Treatment of brain cancer.	Designated			N/A	N/A	BTG International Inc.	5214 Maryland Way	Suite 405	Brentwood	Tennessee	37027	USA
paclitaxel nanoparticles	n/a	1/2/13	Treatment of pancreatic cancer	Designated			N/A	N/A	"CIRJ Co., Ltd."	1800 Loma Vista Street		Pasadena	California	91104	USA
paclitaxel poliglumex	Opaxio	9/20/12	Treatment of glioblastoma multiforme	Designated			N/A	N/A	CTI BioPharma Corporation	3101 Western Ave	Suite 600	Seattle	Washington	98119	USA
paclitaxel protein-bound particles	Abraxane	9/3/09	Treatment of pancreatic cancer.	Designated/Approved	Approved for Orphan Indication	"Treatment of metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine."	09/06/2013	09/06/2020	"Abraxis BioScience, LLC"	"9225 Indian Creek Parkway, Suite 900"		Overland Park	Kansas	66210	USA
Paclitaxel protein-bound particles for injection suspension	Abraxane	10/1/09	Treatment of stage IIb to IV melanoma	Designated/Withdrawn			N/A	N/A	Celgene Corporation	400 Connell Drive	Suite 7000	Berkeley Heights	New Jersey	7922	USA
"paclitaxel, micellar"	Paclical	4/3/09	Treatment of ovarian cancer	Designated			N/A	N/A	Oasmia Pharmaceutical AB	Vallongatan	Uppsala				Sweden
paclitaxel-coated buttress	n/a	7/15/14	For use as local administration at the time of curative surgery in the treatment of stage 0 to III non-small cell lung cancer.	Designated			N/A	N/A	"AcuityBio, Inc."	200 Upland Road		Newton	Massachusetts	2460	USA
pacritinib	n/a	3/13/08	"Treatment of primary myelofibrosis (MF), post-polycythemia vera MF, and post-essential thrombocythemia MF"	Designated			N/A	N/A	CTI BioPharma Corporation	3101 Western Avenue	Suite 600	Seattle	Washington	98121	USA
pafuramidine maleate	n/a	11/17/06	Treatment of pneumocystis jiroveci pneumonia	Designated			N/A	N/A	"Immtech Pharmaceuticals, Inc."	150 Fairway Drive		Vernon Hills	Illinois	60061	USA
Pafuramidine maleate	n/a	8/31/07	Treatment of human African trypanosomiasis (sleeping sickness)	Designated			N/A	N/A	"Immtech Pharmaceuticals, Inc."	150 Fairway Drive		Vernon Hills	Illinois	60061	USA
Pafuramidine maleate	n/a	5/14/07	Treatment of malaria	Designated			N/A	N/A	"Immtech Pharmaceuticsl, Inc."	150 Fairway Drive		Vernon Hills	Illinois	60061	USA
Palifosfamide	n/a	5/5/08	Treatment of soft tissue sarcomas	Designated/Withdrawn			N/A	N/A	"ZIOPHARM Oncology, Inc."	"One First Avenue, Parris Building #34"	Navy Yard Plaza	Boston	Massachusetts	2129	USA
palovarotene	n/a	7/21/14	Treatment of fibrodysplasia ossificans progressiva	Designated			N/A	N/A	"Clementia Pharmaceuticals, Inc."	1375 TransCanada Highway	"Dorval, Quebec H9P 2W8"				Canada
panobinostat	Farydak	8/20/12	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent"	02/23/2015	02/23/2022	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
Panobinostat	Faridak	9/26/07	Treatment of cutaneous T-cell lymphoma	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
panobinostat	Faridak	9/18/09	Treatment of Hodgkin's lymphoma	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceuticals Corporation	"One Health Plaza, 105/3W038"		East Hanover	New Jersey	7936	USA
pantothenate phosphate	n/a	5/4/15	Treatment of pantothenate kinase associated neurodegeneration (PKAN).	Designated			N/A	N/A	"Retrophin, Inc."	777 Third Avenue	22nd Floor	New York	New York	10017	USA
"Papain, trypsin, and chymotrypsin"	Wobe-Mugos	12/21/98	Treatment of multiple myeloma.	Designated			N/A	N/A	"Marlyn Nutraceuticals, Inc."	14851 N. Scottsdale Rd.		Scottsdale	Arizona	85254	USA
Papaverine topical gel	n/a	2/6/92	Treatment of sexual dysfunction in spinal cord injury patients.	Designated/Withdrawn by OPD			N/A	N/A	Pharmedic Company	417 Harvester Court		Wheeling	Illinois	60090	USA
paquinimod	n/a	1/17/14	Treatment of systemic sclerosis	Designated			N/A	N/A	Active Biotech AB	Scheelevagen 22	SE-220 07	LUND			Sweden
Para-toluenesulfonamide	n/a	1/30/17	Treatment of adenoid cystic carcinoma	Designated			N/A	N/A	PTS International Inc.	2211 Newoak Park		San Antonio	Texas	78230	USA
parathyroid hormone	Natpara	8/31/07	Treatment of hypoparathyroidism	Designated/Approved	Approved for Orphan Indication	An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism	01/23/2015	01/23/2022	"Shire-NPS Pharmaceuticals, Inc."	300 Shire Way		Lexington	Massachusetts	2421	USA
paricalcitol	Zemplar	10/27/15	Treatment of pediatric hyperparathyroidism	Designated/Approved	Approved for Orphan Indication	Indicated in pediatric patients 10 years and older for the prevention and treatment of secondary hyperparathyroidism associated with Chronic kidney disease (CKD) Stages 3 and 4 and CKD Stage 5 in patients on hemodialysis or peritoneal dialysis	10/18/2016	10/18/2023	"Abbvie, inc."	1 North Waukegan Road		North Chicago	Illinois	60064	USA
paromomycin	n/a	2/11/15	Treatment of cutaneous leishmaniasis (Old World and New World)	Designated			N/A	N/A	"The Surgeon General, Dept. of the Army"	USAMRMC	504 Scott Street	Ft. Detrick	Maryland	21702	USA
paromomycin sulfate/gentamicin sulfate	n/a	1/18/08	Treatment of all uncomplicated cutaneous leishmaniasis (both New World and Old World)	Designated			N/A	N/A	Office of the Surgeon General	Department of the Army	1430 Veteran's Drive	Ft. Detrick	Maryland	21702	USA
Partial agonist at the opioid receptor-like 1 receptor with amino acid sequence Ac-Arg-Tyr-Tyr-Arg-Trp-Lys-Lys-Lys-Lys-Lys-Lys-Lys-NH2	n/a	10/19/16	Treatment of pulmonary arterial hypertension	Designated			N/A	N/A	Serodus ASA	Gaustadallen 21		Oslo			Norway
Parvovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine	Medi-491	5/7/99	Prevention of transient aplastic crisis in patients with sickle cell anemia.	Designated			N/A	N/A	"MedImmune, Inc."	35 West Watkins Mill Rd.		Gaithersburg	Maryland	20878	USA
pasireotide	Signifor	7/24/09	Treatment of Cushing's disease	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative	12/14/2012	12/14/2019	Novartis Pharmaceuticals Corporation	One Health Plaza	"Bldg 104, 3K28"	East Hanover	New Jersey	7936	USA
pasireotide	n/a	8/25/09	Treatment of acromegaly	Designated/Approved	Approved for Orphan Indication	Treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option	12/15/2014	12/15/2021	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
patupilone	n/a	2/2/10	Treatment of primary pertitoneal cancer.	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
Patupilone	n/a	10/4/05	Treatment of ovarian cancer.	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceutical Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
patupilone	n/a	2/2/10	Treatment of primary fallopian tube cancer.	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
pazopanib	n/a	5/6/13	Treatment of ovarian cancer.	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Jersey	7936	USA
pazopanib	Votrient	10/20/09	Treatment of soft tissue sarcomas	Designated/Approved	Approved for Orphan Indication	Advanced soft tissue sarcoma (STS) who have received prior chemotherapy	04/26/2012	04/26/2019	Novartis Pharmaceuticals Corp	1 Health Plaza		East Hanover	New Jersey	7936	USA
"PEG-b-PLA micelles containing (1) paclitaxel, (2) sirolimus (rapamycin) and (3) tanespimycin (17-AAG)(also known as: triolimus)"	n/a	4/2/15	Treatment of angiosarcoma	Designated			N/A	N/A	"Co-D Therapeutics, Inc."	1625 Kings Mill Way	Suite 205	Madison	Wisconsin	53718	USA
PEG-glucocerebrosidase	Lysodase	12/9/92	For use as chronic enzyme replacement therapy in patients with Gaucher's disease who are deficient in glucocerebrosidase.	Designated			N/A	N/A	"National Institute of Mental Health, NIH"	49 Convent Dr. MSC4405	"Bldg. 49, Room B1EE16"	Bethesda	Maryland	20892	USA
PEG-interleukin-2	n/a	2/1/90	Treatment of primary immunodeficiencies associated with T-cell defects.	Designated			N/A	N/A	Chiron Corporation	4560 Horton Street		Emeryville	California	94608	USA
Pegademase bovine	Adagen	5/29/84	For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.	Designated/Approved	Approved for Orphan Indication		03/21/1990	03/21/1997	"Sigma-tau Pharmaceuticals, Inc."	9841 Washingtonian Blvd	Suite 500	Gaithersburg	Maryland	20878	USA
pegargiminase	n/a	7/21/14	Treatment of mesothelioma.	Designated			N/A	N/A	Polaris Group	"Polaris Pharmaceuticals, Inc."	"9373 Town Centre Dr., Suite 150"	San Diego	California	92121	USA
Pegaspargase	Oncaspar	10/20/89	Treatment of acute lymphocytic leukemia.	Designated/Approved	Approved for Orphan Indication	Combination chemotherapy for the treatment of patients with acute lymphoblastic leukemia who are hypersensitive to native forms of L-asparaginase.	02/01/1994	02/01/2001	"Baxalta US, Inc."	650 Kendall Street		Cambridge	Massachusetts	2142	USA
Pegfilgrastim	Neulasta	11/20/13	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	Designated/Approved	Approved for Orphan Indication	To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome)	11/13/2015	11/13/2022	"Amgen, Inc."	One Amgen Center Drive	M/S 17-1-C	Thousand Oaks	California	91320	USA
Peginterferon alfa-2a	Pegasys	7/13/98	Treatment of renal cell carcinoma.	Designated			N/A	N/A	Hoffman-La Roche Inc.	340 Kingsland St.		Nutley	New Jersey	7110	USA
Peginterferon alfa-2a	Pegasys	9/30/99	Treatment of chronic myelogenous leukemia.	Designated			N/A	N/A	Hoffman-La Roche Inc.	340 Kingsland St.		Nutley	New Jersey	7110	USA
peginterferon alfa-2b	Sylatron	4/9/08	Treatment of malignant melanoma stages IIb through IV.	Designated/Approved	Approved for Orphan Indication	Adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy	03/29/2011	N/A	Schering-Plough Corporation	2000 Galloping Hill Road		Kenilworth	New Jersey	7933	USA
pegloticase	Krystexxa	2/21/01	To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.	Designated/Approved	Approved for Orphan Indication	Treatment of chronic gout in adult patients refractory to conventional treatment	09/14/2010	09/14/2017	"Horizon Pharma Rheumatology, LLC"	150 S. Saunders RoadDrive	Suite 400	Lake Forest	Illinois	60045	USA
pegsitacase	Uricase-Peg 20	12/3/09	Treatment of Lesch-Nyhan syndrome.	Designated			N/A	N/A	"EnzymeRx, LLC"	17 Arcadian Avenue		Paramus	New Jersey	7652	USA
Pegvisomant	Somavert	6/24/97	Treatment of acromegaly.	Designated/Approved	Approved for Orphan Indication	"Treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate"	03/25/2003	03/25/2010	Sensus Corporation	"Suite 430,"	98 San Jacinto Boulevard	Austin	Texas	78701	USA
Pegylated arginine deiminase	Melanocid	4/12/99	Treatment of invasive malignant melanoma.	Designated			N/A	N/A	"Polaris Pharmaceuticals, Inc."	A Polaris Group Company	Suite 106	San Diego	California	92121	USA
pegylated arginine deiminase	Hepacid	3/26/99	Treatment of hepatocellular carcinoma	Designated			N/A	N/A	"Polaris Pharmaceuticals, Inc."	A Polaris Group Company	6370 Nancy Ridge Drive	San Diego	California	92121	USA
pegylated carboxyhemoglobin	n/a	10/21/10	Treatment of acute painful sickling crises in patients with sickle cell disease	Designated			N/A	N/A	"Sangart, Inc."	6175 Lusk Blvd		San Diego	California	92121	USA
pegylated carboxyhemoglobin bovine	Sanguinate	1/15/15	Treatment of the comorbidities associated with Sickle Cell Disease	Designated			N/A	N/A	"Prolong Pharmaceuticals, LLC"	300 B Corporate Court		South Plainfield	New Jersey	7080	USA
pegylated granulocyte colony stimulating factor	n/a	4/30/14	Treatment of patients at risk of developing myelosuppression following a radiological or nuclear incident	Designated			N/A	N/A	PharmaEssentia	"13 F, No.3, YuanQu Street"	Taipei 115				Taiwan
pegylated human recombinant arginase I	n/a	3/16/15	Treatment of arginase I deficiency (hyperargininemia).	Designated			N/A	N/A	"AERase, Inc."	815-A Brazos Street	Suite 101	Austin	Texas	78701	USA
pegylated proline interferon alpha-2b	n/a	4/11/14	Treatment of essential thrombocythemia	Designated			N/A	N/A	"PharmaEssentia, Corporation"	"13F, No 3, YuanQu Street"	Taipei 115				Taiwan
pegylated proline interferon alpha-2b	n/a	4/10/14	Treatment of myelofibrosis	Designated			N/A	N/A	"PharmaEssentia, Corporation"	"13F, No 3, YuanQu Street"	Taipei 115				Taiwan
pegylated proline-interferon alpha-2b; PEG-P-IFNa-2b	n/a	4/2/12	Treatment of polycythemia vera	Designated			N/A	N/A	PharmaEssentia Corporation	"13F, No. 3 YuanQu St."	Nankang Dist.	Taipei 115			Taiwan
PEGylated recombinant anti-Pseudomonas aeruginosa PcrV Fab' antibody	n/a	10/25/13	Treatment of cystic fibrosis patients with Pseudomonas aeruginosa lung infections	Designated			N/A	N/A	"KaloBios Pharmaceuticals, Inc."	442 Littlefield Avenue		South San Francisco	California	94080	USA
PEGylated recombinant human hyaluronidase PH20	n/a	10/1/14	Treatment of pancreatic cancer	Designated			N/A	N/A	"Halozyme Therapeutics, Inc."	11388 Sorrento Valley Road		San Diego	California	92121	USA
Pegylated recombinant human interleukin-10	n/a	7/18/16	Treatment of pancreatic cancer	Designated			N/A	N/A	"ARMO BioSciences, Inc."	575 Chesapeake Drive		Redwood City	California	94063	USA
Pegylated recombinant human megakaryocyte growth and development factor	Megagen	10/20/97	For reducing the period of thrombocytopenia in patients undergoing hematopoietic stem cell transplantation.	Designated/Withdrawn			N/A	N/A	"Amgen, Inc."	One Amgen Center Dr.		Thousand Oaks	California	91320	USA
pelareorep	Reolysin	2/24/15	Treatment of fallopian tube cancer	Designated			N/A	N/A	"Oncolytics Biotech, Inc."	"210, 1167 Kensington Crescent NW"	Calgary AB T2N1X7				Canada
pelareorep	Reolysin	5/4/15	Treatment of gastric cancer	Designated			N/A	N/A	"Oncolytics Biotech, Inc."	"210, 1167 Kensington Crescent NW"	T2N 1X7				Canada
pelareorep	Reolysin	4/15/15	Treatment of malignant glioma	Designated			N/A	N/A	"Oncolytics Biotech, Inc."	"210, 1167 Kensington Crescent NW"	T2N 1X7				Canada
pelareorep	Reolysin(R)	2/24/15	Treatment of primary peritoneal cancer	Designated			N/A	N/A	"Oncolytics Biotech, Inc."	"210, 1167 Kensington Crescent NW"	Calgary AB T2N1X7				Canada
pelareorep	Reolysin(R)	2/10/15	Treatment of ovarian cancer	Designated			N/A	N/A	"Oncolytics Biotech, Inc."	"210, 1167 Kensington Crescent NW"	T2N 1X7				Canada
pelareorep	Reolysin(R)	2/11/15	Treatment of pancreatic cancer	Designated			N/A	N/A	"Oncolytics Biotech, Inc."	"210, 1167 Kensington Crescent NW"	T2N 1X7				Canada
Peldesine	n/a	10/5/93	Treatment of cutaneous T-cell lymphoma.	Designated			N/A	N/A	"BioCryst Pharmaceuticals, Inc."	2190 Parkway Lake Drive		Birmingham	Alabama	35244	USA
pembrolizumab	Keytruda	12/30/15	Treatment of Hodgkin lymphoma.	Designated			N/A	N/A	"Merck, Sharp & Dohme Corp."	One Merck Drive		Whitehouse Station	New Jersey	8889	USA
pembrolizumab	Keytruda	10/11/16	Treatment of nasopharyngeal carcinoma	Designated			N/A	N/A	"Merck, Sharp & Dohme Corp., a subsidiary of Merck & Co."	1 Merck Drive			New Jersey	8889	USA
pembrolizumab	Keytruda	2/17/16	Treatment of multiple myeloma.	Designated			N/A	N/A	"Merck, Sharp & Dohme Corp."	One Merck Drive		Whitehouse Station	New Jersey	8889	USA
pembrolizumab	Keytruda	11/19/12	Treatment of Stage IIB through IV malignant melanoma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with unresectable or metastatic melanoma.	12/18/2015	12/18/2022	"Merck, Sharp & Dohme Corp."	351 North Sumneytown Pike	UG2CDS-015	North Wales	Pennsylvania	19454	USA
pembrolizumab	Keytruda	11/19/12	Treatment of Stage IIB through IV malignant melanoma	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor."	09/04/2014	09/04/2021	"Merck, Sharp & Dohme Corp."	351 North Sumneytown Pike	UG2CDS-015	North Wales	Pennsylvania	19454	USA
pembrolizumab	Ketruda	1/14/16	Treatment of primary mediastinal B cell lymphoma.	Designated			N/A	N/A	"Merck, Sharp & Dohme Corp."	One Merck Drive		Whitehouse Station	New Jersey	8889	USA
pembrolizumab	Keytruda	6/16/15	"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma"	Designated			N/A	N/A	"Merck, Sharp & Dohme"	"a subsidiary of Merck & Co., INc."	One Merck Drive	Whitehouse Station	New Jersey	8889	USA
pembrolizumab	Keytruda	12/28/16	Treatment of Merkel cell carcinoma	Designated			N/A	N/A	"Merck, Sharp, and Dohme Corp."	1 Merck Access Road			New Jersey	8889	USA
pemetrexed disodium	Alimta	8/28/01	Treatment of malignant pleural mesothelioma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery	02/04/2004	02/04/2011	Eli Lilly and Company	Lilly Corporate Center		Indianapolis	Indiana	46285	USA
pentagastrin	n/a	5/29/09	To aid in the diagnosis of medullary thyroid carcinoma	Designated			N/A	N/A	"Medical Defense Technologies, LLC"	717 Pinehurst Drive		Chapel Hill	North Carolina	27517	USA
pentamidine	n/a	8/12/13	Treatment of liver and intrahepatic bile duct cancer	Designated/Withdrawn			N/A	N/A	"Verlyx Pharma, Inc."	"555 Rene-Levesque West, 9th Floor"	"Montreal, Quebec H2Z 1B1"				Canada
pentamidine	n/a	9/13/10	Treatment of pancreatic cancer.	Designated/Withdrawn			N/A	N/A	"Oncozyme Pharma, Inc."	555 Rene-Levesque West - 9th Floor					Canada
pentamidine	n/a	8/12/13	Treatment of ovarian cancer	Designated/Withdrawn			N/A	N/A	"Oncozyme Pharma, Inc."	555 Rene-Levesque West	"Montreal, Quebec H2Z 1B1"				Canada
Pentamidine isethionate	n/a	10/29/84	Treatment of Pneumocystis carinii pneumonia.	Designated			N/A	N/A	Aventis Behring L.L.C.	1020 First Avenue	PO Box 61501	King of Prussia	Pennsylvania	19406	USA
Pentamidine isethionate	Pentam 300	2/28/84	Treatment of Pneumocystis carinii pneumonia.	Designated/Approved	Approved for Orphan Indication		10/16/1984	10/16/1991	"Fujisawa USA, Inc."	3 Parkway North Center		Deerfield	Illinois	60015	USA
Pentamidine isethionate	Nebupent	1/12/88	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.	Designated/Approved	Approved for Orphan Indication		06/15/1989	06/15/1996	"Fujisawa USA, Inc."	3 Parkway North Center		Deerfield	Illinois	60015	USA
Pentamidine isethionate (inhalation)	Pneumopent	10/5/87	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease	Designated			N/A	N/A	Fisons Corporation	"755 Jefferson Rd., P.O. Box 1710"		Rochester	New York	14603	USA
pentapeptide with sequence Ac-VSRRR-NH2	n/a	1/13/15	Treatment of intracerebral hemorrhage	Designated			N/A	N/A	"CereNOva, LLC"	3105 Cone Manor Lane	Suite B	Raleigh	North Carolina	27613	USA
"Pentasaccharide ethyl glycoside consisting of one alpha-D-sialylosyl residue as a sodium salt, two beta-D-galactopyranosyl residues, one 2-acetamido-beta-D-glucopyranosyl unit, and one alpha-L-fucopyranosyl unit"	Cylexin	7/18/97	Treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.	Designated			N/A	N/A	Cytel Corporation	3525 John Hopkins Court		San Diego	California	92121	USA
Pentastarch	Pentaspan	8/28/85	As an adjunct in leukapheresis to improve the harvesting and increase the yield of leukocytes by centrifugal means.	Designated/Approved	Approved for Orphan Indication		05/19/1987	05/19/1994	DuPont Pharmaceuticals	E.I. Du Pont De Nemours & Co.		Wilmington	Delaware	19898	USA
pentetate trisodium	Diethylenetriaminepentaacetate	4/12/04	"Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium."	Designated			N/A	N/A	Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co. KG	Goerzallee 253	Fedderal of Republic of Germany				Germany
pentetrazol	n/a	9/9/15	Treatment of idiopathic hypersomnia.	Designated			N/A	N/A	"Balance Therapeutics, Inc."	1250 Bayhill	Ste 125	San Bruno	California	94066	USA
Pentosan polysulfate sodium	Elmiron	8/7/85	Treatment of interstitial cystitis.	Designated/Approved	Approved for Orphan Indication	Relief of bladder pain or discomfort associated with interstitial cystitis.	09/26/1996	09/26/2003	Alza Corporation	950 Page Mill Rd.	PO Box 10950	Palo Alto	California	94303	USA
pentosan polysulfate sodium	Lysosan (Tm)	1/5/15	Treatment of mucopolysaccharidosis (MPS) type VI	Designated			N/A	N/A	"Plexcera Therapeutics, LLC"	4445 North Highway A1A	Suite 241	Vero Beach	Florida	32963	USA
pentosan polysulfate sodium	n/a	9/16/11	Treatment of sickle cell disease.	Designated			N/A	N/A	"Vanguard Therapeutics, Inc."	108 Eagle Trace Drive		Half Moon Bay	California	94019	USA
pentosan polysulfate sodium	n/a	11/21/08	Treatment of sickle cell disease.	Designated			N/A	N/A	"TRF Pharma, Inc."	863 Mitten Road		Burlingame	California	94010	USA
Pentostatin	Nipent	11/24/99	Treatment of peripheral T-cell lymphomas.	Designated			N/A	N/A	"SuperGen, Inc."	4140 Dublin Blvd.	Suite 200	Dublin	California	94568	USA
Pentostatin	Nipent	1/29/91	Treatment of patients with chronic lymphocytic leukemia.	Designated			N/A	N/A	"SuperGen, Inc."	"Two Annabel Lane, Suite 220"		San Ramon	California	94583	USA
Pentostatin	Nipent	3/27/98	Treatment of cutaneous T-cell lymphoma.	Designated			N/A	N/A	"SuperGen, Inc."	4140 Dublin Blvd.	Suite 200	Dublin	California	94568	USA
Pentostatin for injection	Nipent	9/10/87	Treatment of hairy cell leukemia.	Designated/Approved	Approved for Orphan Indication	Single agent treatment for adult patients with alpha-interferon-refractory hairy cell leukemia.	10/11/1991	10/11/1998	"SuperGen, Inc."	"Two Annabel Lane, Suite 220"		San Ramon	California	94583	USA
pentoxifylline	n/a	6/14/12	Treatment of Behcet's disease	Designated			N/A	N/A	Keck Graduate Institute of Applied Life Sciences	535 Watson Drive		Claremont	California	91711	USA
Peptide 144 TGF beta-1 inhibitor	n/a	4/27/06	Treatment of systemic sclerosis	Designated			N/A	N/A	"Digna Biotech, S.L."	Calloe ORENSE No. 85	Edificio Lexington	Madrid			Spain
Peptide 144 TGF beta-1-inhibitor	n/a	4/26/06	Treatment of localized scleroderma	Designated			N/A	N/A	"Digna Biotech, S.L."	Avenida Pio XII 22	Pamplona (Navarra)				Spain
Peptide consisting of L-amino acids with the sequence H-lys-glu-phe-leu-his-pro-ser-lys-val-asp-leu-pro-arg-OH	n/a	6/29/16	Treatment of pancreatic cancer.	Designated			N/A	N/A	"Soricimed Biopharma, Inc."	18 Botsford Street	Suite 201	Moncton	New Brunswick		Canada
Peptide that inhibits mechanosensitive ion channel (MSC) activity	n/a	9/15/10	Treatment of Duchenne Muscular Dystrophy (DMD.)	Designated			N/A	N/A	Rose Pharmaceuticals	8210 Godlen Oak Circle		Williamsville	New York	14221	USA
peptide YY	n/a	4/18/11	Treatment of hepatocellular carcinoma.	Designated			N/A	N/A	Mondobiotech Laboratories AG	Herrengasse 21	Furstentum Liechtenstein				Switzerland
peptide-based vaccine targeting telomerase reverse transcriptase	n/a	2/20/09	Treatment of telomerase reverse transcriptase (TERT) positive non-small cell lung cancer in HLA-A*0201 positive patients	Designated			N/A	N/A	VAXON-Biotech	3-5 impasse Reille					France
peptide-conjugated phosporodiamidate morpholino oligomer (PPMO)	n/a	9/3/09	"Treatment of Duchenne muscular dystrophy in patients with a deletion, duplication or frame shift mutation correctable by skipping of exon 50 of the dystrophin gene to allow restoration of the reading frame (including mutations within exons 51, 51-53, or 51-55)."	Designated			N/A	N/A	"Sarepta Therapeutics, Inc."	215 First Street	Suite 415	Cambridge	Massachusetts	2142	USA
peptides mimicking antigen receptors on autoimmune B cells and autoimmune T cells associated with myasthenia gravis	n/a	2/4/11	Treatment of myasthenia gravis	Designated			N/A	N/A	CuraVac Europe SPRL	Avenue de Villefranche 80					Belgium
Peptidomimetic analog of hexarelin	n/a	5/14/07	Diagnosis of growth hormone deficiency	Designated			N/A	N/A	Aeterna Zentaris GmbH	Weissmullerstrasse 50	D-63014 Franfurt AM Main				Germany
perampanel	Fycompa	12/7/12	Treatment of Lennox-Gastaut Syndrome	Designated			N/A	N/A	"Eisai, Inc."	155 Tice Blvd		Woodcliff	New Jersey	7677	USA
peretinoin	n/a	9/23/11	Treatment of hepatocellular carcinoma.	Designated			N/A	N/A	Kowa Pharmaceutical Europe Co. Ltd.	105 Wharfedale Road	RG41 5RB	Wokingham			United Kingdom
Perflubron	Liquivent(Tm)	4/26/01	Treatment of acute respiratory distress disease (ARDS) in adults	Designated			N/A	N/A	PFC Development/New Alliance Pharmaceutical	15021 Venture Blvd		Sherman Oaks	California	91403	USA
Perfosfamide	Pergamid	12/4/89	"For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia."	Designated/Withdrawn			N/A	N/A	"Scios Nova, Inc."	2450 Bayshore Parkway		Mountain View	California	94043	USA
Pergolide	Permax	11/20/97	Treatment of Tourette's syndrome.	Designated/Withdrawn			N/A	N/A	"Sallee, Floyd R. M.D., Ph.D."	Cincinnati Children's Hospital Medical Center	3333 Burnet Ave.	Cincinnati	Ohio	45229	USA
perhexiline maleate	n/a	6/14/12	Treatment of moderate to severe symptomatic hypertrophic cardiomyopathy	Designated			N/A	N/A	"Heart Metabolics, Limited."	88 Harcourt Street	Dublin 2				Ireland
perifosine	n/a	9/3/09	Treatment of multiple myeloma.	Designated/Withdrawn			N/A	N/A	Aeterna Zentaris GmbH	Weismuellerstrasse 50	D-60314 Frankfurt Am Main				Germany
perifosine	n/a	7/9/10	Treatment of neuroblastoma	Designated			N/A	N/A	Aeterna Zentaris GmbH	Weismuellerstrasse 50	D-60314 Frankfurt Am Main				Germany
perillyl alcohol	n/a	4/18/11	Treatment of glioma	Designated			N/A	N/A	"NeOnc Technologies, Inc."	10524 South La Cienega Blvd.		Inglewood	California	90304	USA
pertuzumab	n/a	6/8/09	Treatment of ovarian cancer	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way	MS # 355C	South San Francisco	California	94080	USA
pertuzumab	n/a	7/12/13	"Treatment of gastric cancer, including gastroesophageal junction cancer"	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
pexastimogene devacirepvec	n/a	5/6/13	Treatment of hepatocellular carcinoma	Designated			N/A	N/A	"SillaJen Biotherapeutics, Inc."	450 Sansome Street	Suite 200	San Francisco	California	94111	USA
PG2 (Astragalus polysaccharides extracted and purified from the dry root of Astragalus membranaceus)	n/a	7/5/12	Treatment of idiopathic thrombocytopenic purpura	Designated			N/A	N/A	PhytoHealth Corporation	Fl. 5 No. 167	"Taipei City, 105"	Taipei ROC			Taiwan
PGC-C12E-terlipressin	n/a	12/27/12	Treatment of ascites due to all etiologies except for cancer	Designated			N/A	N/A	PharmaIN Corporation	19805 N. Creek Pkwy	Suite 200	Bothell	Washington	98011	USA
phenobarbitol sodium injection	n/a	10/23/13	Treatment of hypoxic-ischemic encephalopathy to prevent siezures in neonates	Designated			N/A	N/A	"Fera Pharmaceuticals, LLC"	134 Birch Hill Road		Locust Valley	New York	11560	USA
"phenol, 4-[2-(aminomethyl)-4-thiazolyl]-2,6-bis (1,1-dimethyethyl) monohydrochloride"	n/a	3/16/15	Treatment of Huntington's disease.	Designated			N/A	N/A	"Ipsen Biopharmaceuticals, Inc."	106 Allen Road	3rd Floor	Basking Ridge	New Jersey	7920	USA
Phenylacetate	n/a	3/6/98	"For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma."	Designated			N/A	N/A	"Elan Drug Delivery, Inc."	1300 Gould Dr.		Gainesville	Georgia	30504	USA
Phenylalanine ammonia-lyase	Phenylase. Ravpal-Peg	3/8/95	Treatment of hyperphenylalaninemia	Designated			N/A	N/A	BioMarin Pharmaceutical	105 Digital Drive		Novato	California	94949	USA
Phenylbutyrate	n/a	1/19/00	Treatment of acute promyelocytic leukemia.	Designated			N/A	N/A	"Elan Drug Delivery, Inc."	1300 Gould Dr.		Gainesville	Georgia	30504	USA
phenylephrine	n/a	2/14/02	Treatment of ileal pouch anal anastomosis related fecal incontinence	Designated			N/A	N/A	S.L.A. Pharma	"Unit 3, Hill Farm Industrial Estate"	"Leavesden, Watford"				United Kingdom
phenylephrine	n/a	1/31/12	Treatment of Tetralogy of Fallot	Designated			N/A	N/A	"Luitpold Pharmaceuticals, Inc."	One Luitpold Drive	P. O. Box 9001	Shirley	New York	11967	USA
"Phosphatidylinositol 3-Kinase ""PI3K"" Inhibitor"	n/a	11/2/10	Treatment of chronic lymphocytic leukemia (CLL)	Designated			N/A	N/A	Semafore Pharmaceuticals	17338 Westfield Park Road	Suite 3	Westfield	Indiana	46074	USA
Phosphocysteamine	n/a	9/12/88	Treatment of cystinosis.	Designated/Withdrawn			N/A	N/A	Medea Research Laboratories	Port Jefferson Business Center	"200 Wilson Street, Building D-6"	Port Jefferson	New York	11776	USA
phosphoinositide-3-kinase delta inhibitor	n/a	8/23/16	Treatment of chronic lymphocytic leukemia	Designated			N/A	N/A	"TG Therapeutics, Inc."	3 Columbus Circle	15th Floor	New York	New York	10019	USA
phosphorothioate antisense olignucleotide against EWS-Fli-1	n/a	9/22/08	Treatment of Ewing's sarcoma	Designated			N/A	N/A	The Cure Our Children Foundation	1730 Michael Lane		Pacific Palisades	California	90272	USA
phosphorothioate oligonucleotide	n/a	11/9/07	Treatment of amyotrophic lateral sclerosis	Designated/Withdrawn			N/A	N/A	"Isis Pharmaceuticals, Inc."	2855 Gazelle Court		Carlsbad	California	92010	USA
phoxilium	n/a	2/14/14	For use as a replacement solution in patients undergoing continuous renal replacement therapy	Designated/Approved	Approved for Orphan Indication	As a replacement solution in Continuous Renal Replacement Therapy (CRRT) and in case of drug poisoning when CRRT is used to remove dialzable substances	01/13/2015	01/13/2022	"Gambro Renal Products, Inc."	1845 Mason Avenue		Daytona Beach	Florida	32117	USA
physostigmine salicylatephysostigmine salicylate	n/a	1/16/85	Treatment of Friedreich's and other inherited ataxias.	Designated/Withdrawn			N/A	N/A	Forest Pharmaceuticals.3-.3-.30 6	150 East 58th Street		New York	New York	10155	USA
picibanil	n/a	3/17/11	Treatment of lymphatic malformations	Designated			N/A	N/A	"Richard Smith, M.D."	University of Iowa Hospitals & Clinics	21151-PFP	Iowa City	Iowa	52242	USA
picibanil	n/a	5/15/09	Treatment of patients with lymphatic malformations	Designated			N/A	N/A	"Royds Pharmaceuticals, Inc."	4365 Route 1 South		Princeton	New Jersey	8540	USA
Picoplatin	n/a	11/2/05	Treatment of small cell lung cancer	Designated			N/A	N/A	Poniard Pharmaceuticals	300 Elliott Avenue West		Seattle	Washington	98119	USA
Pilocarpine	Salagen	9/24/90	Treatment of xerostomia induced by radiation therapy for head and neck cancer.	Designated/Approved	Approved for Orphan Indication	Treatment of symptoms of xerostomia from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck.	03/22/1994	03/22/2001	"MGI Pharma, Inc."	5775 West Old Shakopee Rd.	Suite 100	Bloomington	Minnesota	55437	USA
Pilocarpine HCl	Salagen	2/28/92	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	Designated/Approved	Approved for Orphan Indication	Treatment of dry mouth in patients with Sjogren's syndrome.	02/11/1998	02/11/2005	"MGI Pharma, Inc."	5775 West Old Shakopee Rd.	Suite 100	Bloomington	Minnesota	55437	USA
Piracetam	Nootropil	10/2/87	Treatment of myoclonus.	Designated/Withdrawn			N/A	N/A	"UCB Pharma, Inc."	1950 Lake Park Drive		Smyrna	Georgia	30080	USA
pirfenidone	Esbriet	3/5/04	Treatment of idiopathic pulmonary fibrosis	Designated/Approved	Approved for Orphan Indication	Treatment of idiopathic pulmonary fibrosis	10/15/2014	10/15/2021	Genentech	1 DNA Way		South San Francisco	California	94080	USA
pirfenidone	n/a	7/31/14	Treatment of idiopathic pulmonary fibrosis	Designated			N/A	N/A	"Genoa Pharmaceuticals, Inc."	c/o Latham & Watkins LLP	12670 High Bluff Drive	San Diego	California	92130	USA
pirfenidone	n/a	11/19/13	Treatment of systemic sclerosis (including the associated interstitial lung disease)	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
Piritrexim isethionate	n/a	6/13/88	"Treatment of infections caused by Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium-intracellulare."	Designated/Withdrawn			N/A	N/A	Burroughs Wellcome Company	3030 Cornwallis Road	P.O. Box 12700	Research Triangle Park	North Carolina	27709	USA
plasmid DNA encoding the human cystic fibrosis transmembrane conductance regulator gene complexed with a nonviral cationic lipid based gene transfer agent	n/a	6/30/14	Treatment of cystic fibrosis	Designated			N/A	N/A	Imperial Innovations Limited	52 Princess Gate	"London, SW7 2PG"				United Kingdom
Plasmid DNA vector expressing cystic fibrosis transmembrane gene	n/a	3/29/05	Treatment of cystic fibrosis	Designated			N/A	N/A	"Copernicus Therapeutics, Inc."	11000 Cedar Avenue		Cleveland	Ohio	44106	USA
plasmin (human)	n/a	3/30/09	Treatment of acute peripheral arterial occlusion	Designated			N/A	N/A	"Grifols Therapeutics, Inc."	8368 US 70 Business Hwy West		Clayton	North Carolina	27520	USA
plasminogen (human)	n/a	3/5/13	"Treatment of hypoplasminogenemia, or type I plasminogen deficiency"	Designated			N/A	N/A	"ProMetic BioTherapeutics, Inc"	1330 Piccard Drive	Suite 201	Rockville	Maryland	20850	USA
pleconaril	n/a	12/22/14	Treatment of symptomatic enteroviral infection in the neonate	Designated			N/A	N/A	"AntiVirus Therapeutics, Inc."	7 Ardsley Ct.		Princeton	New Jersey	8550	USA
plerixafor	Mozobil (R)	7/10/03	For use to improve the yield of progentor cells in the apheresis product for subsequest stem cell transplantation following myelosuppressive or myeloablative chemotherapy	Designated/Approved	Approved for Orphan Indication	To enhance mobilization of hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma	12/15/2008	12/15/2015	Genzyme Corporation	500 Kendall Street		Cambridge	Massachusetts	2142	USA
plerixafor	Mozobil (R)	7/28/11	Treatment of acute myeloid leukemia	Designated/Withdrawn			N/A	N/A	Genzyme Corporation	500 Kendall Street		Cambridge	Massachusetts	2142	USA
Plevitrexed	Plevitrexed	5/14/07	Treatment of ovarian cancer	Designated/Withdrawn			N/A	N/A	BTG International Ltd	10 Fleet Place	London EC4M 7SB				United Kingdom
Plevitrexed	Plevitrexed	5/29/07	Treatment of gastric (stomach cancer	Designated/Withdrawn			N/A	N/A	BTG International Ltd	10 Fleet Place	London EC4M 7SB				United Kingdom
Plitidepsin	Aplidin	9/30/04	Treatment of multiple myeloma	Designated			N/A	N/A	"PharmaMar USA, Inc."	205 East 42nd St.	Suite 15003	New York	New York	10017	USA
Plitidepsin	Aplidin	6/18/04	Treatment of acute lymphoblastic leukemia	Designated/Withdrawn			N/A	N/A	"PharmaMar USA, Inc"	University Park at M.I.T.	Sidney Street	Cambridge	Massachusetts	2139	USA
Polatuzumab vedotin	n/a	12/12/16	Treatment of diffuse large B-cell lymphoma	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way	MS# 355E	South San Francisco	California	94080	USA
polidocanol	n/a	2/19/15	Treatment of congenital venous malformations	Designated			N/A	N/A	Provensis Ltd	5 Fleet Place	London EC4M 7RD				United Kingdom
polifeprosan 20 with carmustine	Gliadel	12/13/89	Treatment of malignant glioma.	Designated/Approved	Approved for Orphan Indication	As an adjunct to surgery to prolong survival in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated	09/23/1996	09/23/2003	"Guilford Pharmaceuticals, Inc."	6611 Tributary Street		Baltimore	Maryland	21224	USA
polifeprosan 20 with carmustine	Gliadel	12/13/89	Treatment of malignant glioma.	Designated/Approved	Approved for Orphan Indication	Expanding the indication to include patients with malignant glioma undergoing primary surgical resection.	02/25/2003	02/25/2010	"Guilford Pharmaceuticals, Inc."	6611 Tributary Street		Baltimore	Maryland	21224	USA
poloxamer 188	n/a	11/8/13	Treatment of Acute Limb Ischemia	Designated			N/A	N/A	Mast Therapeutics Inc.	12390 El Camino Real	Suite 150	San Diego	California	92130	USA
Poloxamer 188	Florcor	2/22/90	Treatment of severe burns requiring hospitalization.	Designated			N/A	N/A	CytRx Corporation	154 Technology Parkway		Norcross	Georgia	30092	USA
Poloxamer 188	n/a	8/5/97	Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.	Designated			N/A	N/A	CytRx Corporation	154 Technology Parkway		Norcross	Georgia	30092	USA
poloxamer 188 (purified)	n/a	6/27/89	Treatment of sickle cell disease (this includes the treatment and prevention of complications of sickle cell disease)	Designated			N/A	N/A	Mast Therapeutics Inc.	12390 El Camino Real	Suite 150	San Diego	California	92130	USA
Poloxamer 331	Protox	3/21/91	Initial therapy of toxoplasmosis in patients with AIDS.	Designated			N/A	N/A	CytRx Corporation	154 Technology Parkway		Norcross	Georgia	30092	USA
poloxamer-188 NF	n/a	1/19/10	Treatment of Duchenne muscular dystrophy	Designated			N/A	N/A	"Phrixus Pharmaceuticals, Inc."	300 N. Fifth Avenue		Ann Arbor	Michigan	48104	USA
Poly I: poly C12U	Ampligen	12/9/93	Treatment of chronic fatigue syndrome	Designated			N/A	N/A	"Hemispherx Biopharma, Inc."	One Penn Center	1617 JFK Boulevard	Philadelphia	Pennsylvania	19103	USA
Poly I: poly C12U	Ampligen	5/20/91	Treatment of renal cell carcinoma.	Designated			N/A	N/A	"Hemispherx Biopharma, Inc."	1617 JFK Boulvard	Suite 500	Philadelphia	Pennsylvania	19103	USA
Poly I: poly C12U	Ampligen	12/9/93	"Treatment of invasive metastatic melanoma (stage IIb, III, IV)."	Designated			N/A	N/A	"Hemispherx Biopharma, Inc."	One Penn Center	1617 JFK Boulevard	Philadelphia	Pennsylvania	19103	USA
poly(lactide-co-glycolide) carboxylated microparticle	n/a	9/13/16	Treatment of malaria	Designated			N/A	N/A	"Cour Pharmaceutical Development Company, Inc."	428 S. Hillside Avenue		Elmhurst	Illinois	60126	USA
poly(lactide-co-glycolide) carboxylated microparticle	n/a	10/25/13	Treatment of acute encephalitis syndrome	Designated			N/A	N/A	"Cour Pharmaceutical Development Company, Inc."	428 S. Hillside Avenue		Elmhurst	Illinois	60126	USA
poly-CD-PEG-camptothecin	n/a	5/21/15	Treatment of ovarian cancer.	Designated			N/A	N/A	"Cerulean Pharma, Inc."	35 Gatehouse Drive		Waltham	Massachusetts	2451	USA
Poly-ICLC	Hiltonol	3/17/97	Treatment of primary brain tumors.	Designated			N/A	N/A	Oncovir	3202 Cleveland Avenue N.W.		Washington	District of Columbia	20008	USA
"poly-N,N'-hexamethyleneguanidine-poly-N1,N4-hexamethyleneaminoguanidine"	n/a	4/5/16	"Treatment of pulmonary infections in patients with cystic fibrosis including infections due to pseudomonas aeruginosa,Burkholderia cepacia and other bacteria"	Designated			N/A	N/A	"TGV-Inhalonix, Inc."	303 5th Avenue	Suite 2012	New York	New York	10016	USA
polyethylene glycol modified recombinant C-terminal truncate of human cystathionine beta-synthase	n/a	3/17/15	Treatment of homocystinuria	Designated			N/A	N/A	Orphan Technologies Limited	P. O. Box 662	Tortola				
Polyethylene glycol-modified uricase	n/a	6/6/05	Treatment of hyperuricemia in patients with gout refractory to conventional therapy or in whom conventional therapy is contraindicated	Designated			N/A	N/A	"EnzymeRx, LLC"	17 Arcadian Avenue	Suite 104	Paramus	New Jersey	7652	USA
Polyethylene glycol-modified uricase	Zurase	9/14/99	Prophylaxis of hyperuricemia in cancer patients prone to develop tumor lysis syndrome during chemotherapy.	Designated			N/A	N/A	"EnzymeRx, LLC"	17 Arcadian Avenue	Suite 104	Paramus	New Jersey	7652	USA
Polyethylene glycol-modified uricase	Zurase	12/21/98	Treatment of tumor lysis syndrome in cancer patients undergoing chemotherapy.	Designated			N/A	N/A	"EnzymeRx, LLC"	17 Arcadian Avenue	Suite 104	Paramus	New Jersey	7652	USA
polyinosinic-polycytidilic acid	Poly-Iclc	3/3/03	"Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses"	Designated			N/A	N/A	Oncovir	"3203 Cleveland Ave., NW"		Washington	District of Columbia	20008	USA
polyinosinic-polycytidilic acid	Poly-Iclc	8/2/02	As an adjuvant to smallpox vaccination	Designated			N/A	N/A	Oncovir	"3203 Cleveland Ave., NW"		Washington	District of Columbia	20008	USA
polyinosinic-polycytidilic acid (Poly-ICLC)	Hiltonol	11/19/02	Treatment for orthopox virus infections	Designated			N/A	N/A	Oncovir	"3203 Cleveland Ave., NW"		Washington	District of Columbia	20008	USA
Polymeric oxygen	n/a	3/25/92	Treatment of sickle cell anemia.	Designated			N/A	N/A	Capmed USA	P.O. Box 14		Bryn Mawr	Pennsylvania	19010	USA
polyphenon E	n/a	7/17/08	Treatment of chronic lymphocytic leukemia	Designated			N/A	N/A	"Mitsui Norin Co., Ltd"	223-1 Miyabara	426-0133				Japan
Polyribonucleotide; Polyribo-inosinic/-cyclidylic/-uridylic acid	Ampligen	7/19/88	Treatment of AIDS	Designated			N/A	N/A	"Hemispherx Biopharma, Inc."	One Penn Center	1617 JFK Boulevard	Philadelphia	Pennsylvania	19103	USA
"Polyvalent, shed-antigen melanoma vaccine"	n/a	6/9/06	Treatment of stage IIb to stage IV melanoma	Designated			N/A	N/A	Polynoma LLC	11622 El Camino Real #100		San Diego	California	92130	USA
pomalidomide	n/a	9/21/10	Treatment of persons with myeloproliferative neoplasm-associated myelofibrosis and anemia who are red blood cell tranfusion dependent.	Designated/Withdrawn			N/A	N/A	Celgene Corporation	86 Morris Avenue		Summit	New Jersey	7901	USA
pomalidomide	Pomalyst	1/15/03	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.	02/08/2013	02/08/2020	Celgene Corporation	400 Connell Drive	Suite 7000	Berkeley Heights	New Jersey	7922	USA
pomalidomide	n/a	8/22/13	Treatment of systemic sclerosis	Designated/Withdrawn			N/A	N/A	Celgene Corporation	86 Morris Avenue		Summit	New Jersey	7901	USA
ponatinib	Iclusig	11/20/09	Treatment of chronic myeloid leukemia	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy."	12/14/2012	12/14/2019	ARIAD Pharmaceuticals Inc.	26 Landsdowne Street		Cambridge	Massachusetts	2139	USA
ponatinib	Iclusig	11/20/09	Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.	12/14/2012	12/14/2019	ARIAD Pharmaceuticals Inc.	26 Landsdowne Street		Cambridge	Massachusetts	2139	USA
ponatinib	Iclusig(R)	3/12/15	Treatment of gastrointestinal stromal tumors (GIST).	Designated			N/A	N/A	"ARIAD Pharmaceuticals, Inc."	26 Landsdowne Street		Cambridge	Massachusetts	2339	USA
Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation	Neurocell-Pd	12/17/96	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Designated			N/A	N/A	Diacrin/Genzyme LLC	One Kendall Square		Cambridge	Massachusetts	2129	USA
Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared for intracerebral implantation.	Neurocell-Pd	12/17/96	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Designated			N/A	N/A	Diacrin/Genzyme LLC	One Kendall Square		Cambridge	Massachusetts	2139	USA
Porcine fetal neural gabaergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation	Neurocell-Hd	12/10/96	Treatment of Huntington's disease.	Designated			N/A	N/A	Diacrin/Genzyme LLC	One Kendall Square		Cambridge	Massachusetts	2129	USA
Porcine fetal neural gabaergic cells and/or precursors aseptically prepared for intracerebral implantation for Huntington's disease.	Neurocell-Hd	12/10/96	Treatment of Huntington's disease.	Designated			N/A	N/A	Diacrin/Genzyme LLC	One Kendall Square		Cambridge	Massachusetts	2139	USA
porcine GM1 ganglioside	n/a	12/3/12	Treatment of acute spinal cord injury	Designated			N/A	N/A	TRB Chemedica International S.A.	Rue Michel-Servet 12	CH-1211	Geneva 12			Switzerland
Porcine Sertoli cells aseptically prepared for intracerebral co-implantation with fetal neural tissue	N-Graft	6/24/97	Treatment of Hoehn and Yahr stage four and five Parkinson's disease.	Designated			N/A	N/A	"Titan Pharmaceuticals, Inc."	Post Office Plaza	"50 Division Street, Suite 503"	Somerville	New Jersey	8876	USA
porfimer	Photofrin	10/19/01	For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy	Designated/Approved	Approved for Orphan Indication	For the ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy	08/01/2003	08/01/2010	Axcan Scandipharm Inc.	22 Inverness Parkway	Suite 310	Birmingham	Alabama	35242	USA
Porfimer sodium	Photofrin	11/18/04	Treatment of cholangiocarcinoma	Designated			N/A	N/A	"Concordia Laboratories, Inc."	Canewood Business Centre	"St. Michael, Barbados BB"				
Porfimer sodium	Photofrin	11/15/89	For the photodynamic therapy of patients with transitional cell carcinoma in situ of the urinary bladder.	Designated			N/A	N/A	"QLT Phototherapeutics, Inc."	Lederle Laboratories	401 North Middletown Road	Pearl River	New York	10965	USA
Porfimer sodium	Photofrin	6/6/89	For the photodynamic therapy of patients with primary or recurrent obstructing (either partially or completely) esophageal carcinoma.	Designated/Approved	Approved for Orphan Indication	"Photodynamic therapy with PHOTOFRIN for the palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who cannot be satisfactorily treated with Nd:YAG laser therapy."	12/27/1995	12/27/2002	"QLT Phototherapeutics, Inc."	Lederle Laboratories	401 North Middletown Road	Pearl River	New York	10965	USA
Porfiromycin	Promycin	9/19/95	Treatment of head and neck cancer.	Designated			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc."	900 Ridgebury Road	PO Box 368	Ridgefield	Connecticut	6877	USA
Porfiromycin	Promycin	3/13/97	Treatment of cervical cancer.	Designated			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc."	900 Ridgebury Road	PO Box 368	Ridgefield	Connecticut	6877	USA
Posaconazole	Posoril	7/16/04	Treatment of zygomycosis	Designated			N/A	N/A	Schering-Plough Corporation	2000 Galloping Hill Road		Kenilwortoh	New Jersey	7033	USA
Posaconazole	Noxafil	10/4/16	Treatment of invasive aspergillosis	Designated			N/A	N/A	"Merck, Sharp & Dohme Corp."	1 Merck Drive		Whitehouse Station	New Jersey	8889	USA
Potassium citrate	Urocit-K	11/1/84	Prevention of uric acid nephrolithiasis.	Designated/Approved	Approved for Orphan Indication		08/30/1985	08/30/1992	University of Texas Health Science Center at Dallas	5323 Harry Hines Blvd		Dallas	Texas	75235	USA
Potassium citrate	Urocit-K	11/1/84	1. Prevention of calcium renal stones in patients with hypocitraturia 2. For avoidance of the complication of calcium stone formation in patients with uric lithiasis.	Designated/Approved	Approved for Orphan Indication	Prevention of recurring calcium conating stines associated with a deficiency in the urine.	08/07/1985	08/07/1992	University of Texas Health Science Center at Dallas	5323 Harry Hines Blvd		Dallas	Texas	75235	USA
Potassium citrate and citric acid	n/a	2/14/86	For the dissolution and control of uric acid and cysteine calculi in the urinary tract.	Designated/Withdrawn			N/A	N/A	Willen Drug Company						
Potassium Iodide Oral Solution	Thyroshield	11/17/04	For use as a thyroid blocking agent in pediatric patients exposed to radiactive iodine	Designated/Approved	Approved for Orphan Indication	For use as a thyroid blocking agent in pediatric patients exposed to radiactive iodine	01/12/2005	N/A	"Fleming & Company, Pharmaceuticals"	1733 Gilsinn Lane		Fenton	Missouri	63026	USA
potassium sodium aluminosilicate	n/a	1/8/07	For treatment of poisoning by or exposure to cesium.	Designated			N/A	N/A	"Castle Creek Pharmaceuticals, LLC"	1033 Skokie Blvd	Suite 600	Northbrook	Illinois	60062	USA
Pr-122 (redox-phenytoin)	n/a	7/5/90	"For the emergency rescue treatment of status epilepticus, grand mal type."	Designated/Withdrawn			N/A	N/A	Pharmos	2 Innovation Drive		Alachua	Florida	32615	USA
PR-225 (redox-acyclovir)	n/a	5/29/90	Treatment of herpes simplex encephalitis in individuals afflicted with AIDS.	Designated/Withdrawn			N/A	N/A	Pharmos	2 Innovation Drive		Alachua	Florida	32615	USA
PR-239 (redox penicillin G)	n/a	5/23/90	Treatment of AIDS associated neurosyphilis.	Designated/Withdrawn			N/A	N/A	Pharmos	2 Innovation Drive		Alachua	Florida	32615	USA
Pr-320 (molecusol-carbamazepine)	n/a	7/20/90	"For the emergency rescue treatment of status epilepticus, grand mal type."	Designated/Withdrawn			N/A	N/A	Pharmos	2 Innovation Drive		Alachua	Florida	32615	USA
pracinostat	n/a	2/27/14	Treatment of acute myeloid leulemia	Designated			N/A	N/A	MEI Pharma Inc.	"11975 El Camino Real, Suite 101"		San Diego	California	92130	USA
pralatrexate	Folotyn	7/20/06	Treatment of T-cell lymphoma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with relapsed or refractory peripheral T-cell lymphoma	09/25/2009	09/25/2016	"Allos Therapeutics, Inc."	"11080 Circle Point Road, Suite 200"		Westminister	Colorado	80020	USA
pralatrexate	n/a	5/3/10	Treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder	Designated			N/A	N/A	"Allos Therapeutics, Inc."	"11080 Circle Point Road, Suite 200"		Westminister	Colorado	80020	USA
pralatrexate	n/a	10/20/08	Treatment of diffuse large B-cell lymphoma	Designated			N/A	N/A	"Allos Therapeutics, Inc."	"11080 Circle Point Road, Suite 200"		Westminister	Colorado	80020	USA
pralatrexate	n/a	10/20/08	Treatment of follicular lymphoma	Designated			N/A	N/A	"Allos Therapeutics, Inc."	"11080 Circle Point Road, Suite 200"		Westminister	Colorado	80020	USA
pralmorelin hydrochloride	n/a	10/18/12	As a diagnostic agent for the detection of growth hormone deficiency	Designated			N/A	N/A	"Sella Pharmaceuticals, Inc."	412 Wister Road		Wynnewood	Pennsylvania	19096	USA
pramipexole	Mirapex	1/31/08	Treatment of Tourette's syndrome in pediatric patients	Designated			N/A	N/A	"Boehringer-Ingelheim Pharmaceuticals, Inc."	900 Ridgebury Road		Ridgefield	Connecticut	6877	USA
Pramiracetam Sulfate	n/a	11/4/91	For the management of cognitive dysfunction and enhancement of antidepressant activity associated with electroconvulsive therapy.	Designated/Withdrawn			N/A	N/A	"Cambridge Neuroscience, Inc."	"1 Kendall Square, Bldg. 700"		Cambridge	Massachusetts	2139	USA
prasugrel hydrochloride	Effient	5/26/15	Treatment of sickle cell disease	Designated			N/A	N/A	Eli Lilly	Lilly Corporate Center		Indianapolis	Indiana	46285	USA
Praziquantel	n/a	4/18/88	Treatment of neurocysticercosis.	Designated/Withdrawn			N/A	N/A	"EM Pharmaceuticals, Inc."						
Prednimustine	Sterecyt	6/17/85	Treatment of malignant non-Hodgkin's lymphomas.	Designated/Withdrawn			N/A	N/A	Pharmacia Inc.	P.O. Box 16529		Columbus	Ohio	43216	USA
Primaquine phosphate	n/a	7/23/93	For use in combination with clindamycin hydrochloride in the treatment of Pneumocystis carinii pneumonia associated with AIDS.	Designated			N/A	N/A	"Sanofi Winthrop, Inc."	90 Park Avenue		New York	New York	10016	USA
pritumumab	n/a	4/6/16	Treatment of pancreatic cancer.	Designated			N/A	N/A	"Nascent Biotech, Inc."	8400 Miramar Road	Suite 247	San Diego	California	92126	USA
pritumumab	n/a	10/28/14	Treatment of glioma	Designated			N/A	N/A	"Nascent Biotech, Inc."	10246 Parkdale Avenue		San Diego	California	92126	USA
Procarbazine HCl	Matulane	8/8/06	Treatment of malignant glioma	Designated			N/A	N/A	"Sigma-Tau Pharmaceuticals, Inc."	9841 Washingtonian Blvd	Suite 500	Gaithersburg	Maryland	20878	USA
procaspase-activating compound 1	n/a	7/23/15	Treatment of malignant glioma	Designated			N/A	N/A	"Vanquish Oncology, Inc."	2001 S. First Street	Suite 201	Champaign	Illinois	61820	USA
profimer sodium	Photofrin(R)	12/2/11	Treatment of malignant mesothelioma	Designated			N/A	N/A	"Concordia Laboratories, Inc."	Canewood Business Centre	"St. Michael, Barbados BB"				
progesterone	n/a	12/22/94	Establishment and maintenance of pregnancy in women undergoing in vitro fertilization or embryo transfer procedures.	Designated			N/A	N/A	"Watson Laboratories, Inc."	311 Bonnie Circle		Corona	California	91720	USA
progesterone	n/a	9/3/09	For early intervention in the treatment of moderate to severe closed-head traumatic brain injury	Designated/Withdrawn			N/A	N/A	"BHR Pharma, LLC"	607 Herndon Parkway	Suite 110	Herndon	Virginia	20170	USA
prolactin receptor antagonist	Prolanta	4/15/13	Treatment of ovarian cancer	Designated			N/A	N/A	"Oncolix, Inc."	14405 Walters Road	Suite 780	Houston	Texas	77014	USA
propagermanium and irbesartan	n/a	12/9/15	Treatment of focal segmental glomerulosclerosis.	Designated			N/A	N/A	Dimerix Bioscience Ltd.	"Level 2, 25 Flinders Lane"		Melbourne			Australia
Propamidine isethionate 0.1% ophthalmic solution	Brolene	3/10/88	Treatment of acanthamoeba keratitis.	Designated/Withdrawn			N/A	N/A	Bausch & Lomb	Pharmaceuticals Division	8500 Hidden River Parkway	Tampa	Florida	33637	USA
"Propanoic acid, 2,2-dimethyl-,1,1'-[[[[4-[[4-hydroxy-3-(phenylmethyl)phenyl]methyl]-3,5-dimethylphenoxy]methyl]phosphinylidene]bis(oxymethylene)] ester"	n/a	12/5/16	Treatment of X-linked adrenoleukodystrophy.	Designated			N/A	N/A	"Viking Therapeutics, Inc."	12340 El Camino Real	Suite 250	San Diego	California	92130	USA
propofol hemisuccinate	n/a	8/19/16	Treatment of acute repetitive seizures	Designated			N/A	N/A	EpaleX Corporation	305 Lytton Avenue		Palo Alto	California	94301	USA
propranolol	Hemangeol	9/5/08	Treatment of proliferating infantile hemangiomas requiring systemic therapy	Designated/Approved	Approved for Orphan Indication	Treatment of proliferating infantile hemangioma requiring systemic therapy.	03/14/2014	03/14/2021	Pierre Fabre Dermatologie	"8 Campus Drive, 2nd Floor"		Parsippany	New Jersey	7054	USA
propranolol and etodolac	n/a	7/8/15	Treatment of malignant glioma.	Designated			N/A	N/A	"Vicus Therapeutics, LLC"	55 Madison Avenue	Suite 400	Morristown	New Jersey	7960	USA
propranolol and etodolac	n/a	4/27/15	Treatment of pancreatic cancer.	Designated			N/A	N/A	"Vicus Therapeutics, LLC"	55 Madison Avenue	Suite 400	Morristown	New Jersey	7960	USA
propranolol hydrochloride and etodolac	n/a	2/24/15	Treatment of hepatocellular carcinoma	Designated			N/A	N/A	"Vicus Therapeutics, LLC"	55 Madison Avenue	Suite 400	Morristown	New Jersey	7960	USA
Prostaglandin E1 enol ester (AS-013)	Circulase	6/12/98	Treatment of Fontaine Stage IV chronic critical limb ischemia.	Designated			N/A	N/A	"LTT Baio-Pharma Co., Ltd"	Research & Development Division	"2-5-1 Atago, Minato-ku, Tokyo"				Japan
Prostaglandin E1 in lipid emulsion	Lipo-Pge1	9/10/96	Treatment of ischemic ulceration of the lower limbs due to peripheral arterial disease.	Designated/Withdrawn			N/A	N/A	Alpha Therapeutic Corporation	5555 Valley Boulevard		Los Angeles	California	90032	USA
Protaxel	n/a	5/21/03	Treatment of ovarian cancer	Designated			N/A	N/A	"Biophysica, Inc."	2159 Avenida de la Playa	Suite B	La Jolla	California	92037	USA
Protein C concentrate	"Protein C Concentrate (Human) Vapor Heated, Immuno"	4/22/93	For use in the prevention and treatment of purpura fulminans in meningococcemia.	Designated/Withdrawn			N/A	N/A	Immuno Clinical Research Corp.	"750 Lexington Avenue, 19th Floor"		New York	New York	10022	USA
Protein C concentrate	Ceprotin	6/23/92	"For replacement therapy in congenital protein C deficiency for the prevention and treatment of thrombosis, pulmonary emboli, and purpura fulminans."	Designated/Approved	Approved for Orphan Indication	Prevention and treatment of venous thrombosis and purpura fulminans	03/30/2007	03/30/2014	"Baxalta US, Inc."	One Baxter Way		West Lake Village	California	91362	USA
Protein C concentrate	"Protein C Concentrate (Human) Vapor Heated, Immuno"	6/19/92	For replacement therapy in patients with congenital or acquired protein C deficiency for the prevention and treatment of warfarin-induced skin necrosis during oral anticoagulation.	Designated			N/A	N/A	Immuno Clinical Research Corp.	750 Lexington Avenue		New York	New York	10022	USA
prothrombin complex concentrate (human)	Kcentra	12/27/12	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	Designated/Approved	Approved for Orphan Indication	"Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding."	04/29/2013	04/29/2020	CSL Behring	P. O. Box 61501	1020 First Avenue	King of Prussia	Pennsylvania	19406	USA
prothrombin complex concentrate (human)	Kcentra	12/27/12	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	Designated/Approved	Approved for Orphan Indication	"Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy (VKA, e.g., warfarin) in adult patients with the need for urgent surgery/invasive procedure."	12/13/2013	12/13/2020	CSL Behring	P. O. Box 61501	1020 First Avenue	King of Prussia	Pennsylvania	19406	USA
Protirelin	n/a	8/24/93	Prevention of infant respiratory distress syndrome associated with prematurity.	Designated/Withdrawn			N/A	N/A	"UCB Pharma, Inc."	1950 Lake Park Drive		Smyrna	Georgia	30080	USA
Protirelin injection	n/a	1/10/85	Treatment of amyotrophic lateral sclerosis.	Designated/Withdrawn			N/A	N/A	Abbott Laboratories	200 Abbott Park Road		Abbott Park	Illinois		USA
ProTmune (ex vivo Programmed Mobilized Peripheral Blood)	n/a	9/19/16	Prevention of graft-versus-host disease in patients undergoing allogenic hematopoietic cell transplantation	Designated			N/A	N/A	Fate Therapeutics	3535 General Atomics Court	Suite 200	San Diego	California	92121	USA
"protoplasmic protein matrix, omega-3 fatty oils, vitamins, minerals and trace elements, cell membrane matrix phospholipid, entracellular matrix, lipids, medium chain triglycerides, longer chain triglycerides, carbohydrates, probiotic, and phytonutrients"	n/a	1/11/17	Treatment of juvenile rheumatoid arthritis.	Designated			N/A	N/A	"Leonard S. Girsh, MD"	"Immunopath Profile, Ind."	P. O. Box 770805	Naples	Florida	34107	USA
Pulmonary surfactant replacement	n/a	12/5/88	Prevention and treatment of infant respiratory distress syndrome.	Designated/Withdrawn			N/A	N/A	"Scios Nova, Inc."	2450 Bayshore Parkway		Mountain View	California	94043	USA
"Pulmonary surfactant replacement, porcine"	Curosurf	8/2/93	For the treatment and prevention of respiratory distress syndrome in premature infants.	Designated/Approved	Approved for Orphan Indication	Treatment (rescue) of respiratory distress syndrome in premature infants.	11/18/1999	N/A	"Chiesi USA, Inc."	1255 Crescent Green Drive	Suite 250	Cary	North Carolina	27518	USA
purified autologous type 1 regulatory T lymphocytes specific for human type II collagen	n/a	9/1/15	Treatment of chronic non-infectious uveitis	Designated			N/A	N/A	TxCell SA	Allee de la Nertiere	06560 Valbonne - Sophia-Antipolis				France
purified bovine type collagen	n/a	4/27/09	Treatment of idiopathic pulmonary fibrosis	Designated			N/A	N/A	"ImmuneWorks, Inc."	351 West 10th Street		Indianapolis	Indiana	46202	USA
Purified extract of Pseudomonas aeruginosa	Immudyn	9/22/97	Treatment of immune thrombocytopenia purpura where it is required to increase platelet counts.	Designated			N/A	N/A	"Able Laboratories, Inc."	200 Highland Avenue	Suite 30	Needham	Massachusetts	2494	USA
Purified type II collagen	Colloral	2/9/95	Treatment of juvenile rheumatoid arthritis.	Designated			N/A	N/A	"AutoImmune, Inc."	128 Spring Street		Lexington	Massachusetts	2421	USA
pVGI.1(VEGF2)	n/a	11/9/99	Treatment of thromboangiitis obliterans.	Designated/Withdrawn			N/A	N/A	"Corautus Genetics, Inc."	"75 Fifth St., NW"	Suite 700	Atlanta	Georgia	30308	USA
PyNTTTTGT class of oligodeoxynucleotide with a 24-base single chain composed of nucleotide sequence 5'TCATCATTTTGTCATTTTGTCATT 3'	Imt504	11/24/14	Treatment of rabies virus infections	Designated			N/A	N/A	"Mid-Atlantic BioTherapeutics, Inc."	3805 Old Easton Rd.		Doylestown	Pennsylvania	18902	USA
pyridopyrimidinone SMN2 splicing modifier	n/a	1/4/17	Treatment of spinal muscular atrophy	Designated			N/A	N/A	"Hoffmann-La Roche, Inc."	"c/o Genentech, Inc."	1 DNA Way	South San Francisco	California	94080	USA
pyridoxal-5 phosphate monohydrate (P5P)	n/a	1/4/17	Treatment of seizures associated with pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency	Designated			N/A	N/A	Medicure International Inc.	2-1250 Waverley Street		Winnipeg	Manitoba		Canada
pyridoxine; vitamin B6	n/a	3/3/11	Treatment of pyridoxine dependent seizures.	Designated			N/A	N/A	"NBI Pharmaceuticals, Inc."	c/o Neil & Co CPAs	"1184 N. 15th Ave., Suite 1"	Bozeman	Montana	59715	USA
pyrimethamine	n/a	8/16/11	Treatment of GM-2 gangliosidoses (Tay-Sachs disease and Sandhoff disease).	Designated			N/A	N/A	ExSAR Corporation	11 Deer Park Drive		Monmouth Junction	New Jersey	8852	USA
Pyruvate	n/a	2/21/01	Treatment of interstitial lung disease.	Designated			N/A	N/A	"Cellular Sciences, Inc"	84 park Avenue	P.O. Box 968	Flemington	New Jersey	8822	USA
pyrvinium	n/a	1/5/15	Treatment of familial adenomatous polyposis	Designated			N/A	N/A	"StemSynergy Therapeutics, Inc."	1951 NW 7th Avenue	Suite 300	Miami	Florida	33136	USA
quinacrine	n/a	9/28/12	Treatment of hepatocellular carcinoma	Designated			N/A	N/A	"Cleveland BioLabs, Inc & Incuron, LLC Joint Ventur"	73 High Street		Buffalo	New York	14203	USA
Quinacrine hydrochloride	n/a	10/17/84	For prevention of recurrence of pneumothorax in patients at high risk of recurrence.	Designated/Withdrawn			N/A	N/A	"Lyphomed, Inc."						
quinine sulfate	n/a	12/2/08	Treatment of malaria excluding Plasmodium faliparum	Designated			N/A	N/A	"Zydus Pharmaceuticals, Inc."	210 Carnegie Center		Princeton	New Jersey	8540	USA
quinine Sulfate	n/a	6/3/04	Treatment of malaria	Designated/Approved	Approved for Orphan Indication	Treatment of uncomplicated Plasmodium falciparum malaria	08/12/2005	08/12/2012	"AR Holding Company, Inc."	1100 Orthodox Street		Philadelphia	Pennsylvania	19124	USA
R-(-)-gossypol	n/a	10/24/06	Treatment of chronic lymphocytic leukemia.	Designated			N/A	N/A	"Ascenta Therapeutics, Inc."	101 Lindenwood Drive	Suite 405	Malvern	Pennsylvania	19355	USA
"R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1 H -1,4-benzodiazepine -3-yl]-3-(3-methylaminophenyl)urea"	n/a	9/10/09	Treatment of gastric carcinoids	Designated			N/A	N/A	Trio Medicines Ltd.	Pavillion View	Brighton BN1 1EY				United Kingdom
R-4-amino-3-(4-chlorophenyl)butanoic acid	n/a	11/28/08	Treatment of the behavorial abnormalities associated with fragile X syndrome	Designated			N/A	N/A	"Seaside Therapeutics, Inc."	840 Memorial Drive		Cambridge	Massachusetts	2139	USA
R-etodolac	n/a	12/9/02	Treatment of chronic lymphocytic leukemia	Designated/Withdrawn			N/A	N/A	"Cephalon, Inc."	41 Moores Road		Frazer	Pennsylvania	19355	USA
rAAV2-CB-hRPE65	n/a	2/11/05	Treatment of type II Leber's Congential Amaurosis	Designated			N/A	N/A	Applied Genetic Technologies Corp.	11801 Research Drive	Suite D	Alachua	Florida	32615	USA
Rabbit anti-human thymocyte globulin (rATG)	Thymoglobulin	9/26/06	Induction treatment to prevent rejection and to minimize maintenance immunosupression in pediatric liver transplant recipients	Designated			N/A	N/A	Children's Hospital of Pittsburgh	University of Pittsburgh		Pittsburgh	Pennsylvania	15213	USA
radiolabeled somastatin analog	Galiomedix(Tm)	12/31/13	Diagnostic for the management of neuroendocrine tumors	Designated			N/A	N/A	"RadioMedix, Inc."	9701 Richmond Avenue	Suite 222	Houston	Texas	77042	USA
raloxifene	Evista	7/14/05	Reduction of the risk of breast cancer in postmenopausal women	Designated/Approved	Approved for Orphan Indication	Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer	09/13/2007	09/13/2014	Eli Lilly and Company	Lilly Corporate Center	Drop Code 1853	Indianapolis	Indiana	46285	USA
raloxifene hydrochloride	Evista	8/20/10	Treatment of hereditary hemorrhagic telangiectasia	Designated			N/A	N/A	Consejo Superior de Investigaciones Cientificas	C/ Serrano 142		Madrid			
ramucirumab	n/a	11/4/11	Treatment of hepatocellular carcinoma	Designated			N/A	N/A	Eli Lilly and Company	ImClone Systems LLC-Lilly Subsdiary	33 ImClone Drive	Branchburg	New Jersey	8876	USA
ramucirumab	Cyramza	2/16/12	Treatment of gastric cancer	Designated/Approved	Approved for Orphan Indication	"Treatment of advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single-agent after prior fluoropyrimidine-or platinum-containing therapy."	04/21/2014	04/21/2021	Eli Lilly and Company	33 ImClone Drive		Branchburg	New Jersey	8876	USA
ramucirumab	Cyramza	2/16/12	Treatment of gastric cancer	Designated/Approved	Approved for Orphan Indication	"Treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, as a single agent or in combination with paclitaxel, after prior fluoropyrimidine- or platinium-containing chemotherapy."	11/05/2014	11/05/2021	Eli Lilly and Company	33 ImClone Drive		Branchburg	New Jersey	8876	USA
ranagengliotucel-L	Glionix(Tm)	5/29/09	Treatment of astrocytic tumors	Designated			N/A	N/A	NovaRx Corporation	6828 Nancy Ridge Drive		San Diego	California	92121	USA
ranprinase	Onconase	1/25/07	Treatment of malignant mesothelioma	Designated			N/A	N/A	Alfacell Corporation	225 Belleville Ave.		Bloomfield	New Jersey	7003	USA
Rapamycin	n/a	3/20/07	Treatment of tuberous sclerosis complex	Designated			N/A	N/A	"OncoImmune, Inc."	333 Parkland Plaza	Suite 1000	Ann Arbor	Michigan	48103	USA
rapamycin	n/a	2/24/16	Treatment of facial angiofibromas (FA) associated with tuberous sclerosis complex (TSC).	Designated			N/A	N/A	DSLP	129 Hurstmere Road	"Level 1, Nielsen Building"	Auckland			New Zealand
rapamycin	n/a	10/20/16	Treatment of pulmonary arterial hypertention	Designated			N/A	N/A	Lam Therapeutics	530 Old Whitfield Street		Guilford	Connecticut	6437	USA
Rapamycin (mTOR) inhibitor	n/a	8/9/05	Treatment of bone sarcoma.	Designated/Withdrawn			N/A	N/A	Merck Sharp & Dohme Corp.	"S Merck & Co., Inc. Subsidiary"	"P. O. Box 1000, UG-2C50"	North Wales	Pennsylvania	19454	USA
rasburicase	Elitek	10/11/00	Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.	Designated/Approved	Approved for Orphan Indication	"Initial management of plasma uric acid levels in pediatric patients with leukemia,lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid."	07/12/2002	07/12/2009	Sanofi-Synthelabo Research	9 Great Valley Parkway		Malvern	Pennsylvania	19355	USA
raxibacumab	Abthraxtm	11/12/03	Treatment of anthrax	Designated/Approved	Approved for Orphan Indication	"Treatment of inhalation anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs,"	12/14/2012	12/14/2019	"Human Genome Sciences, Inc."	14200 Shady Grove Road		Rockville	Maryland	20850	USA
Re188 P2045 somatostatin analog	n/a	2/6/14	Treatment of small cell lung cancer	Designated			N/A	N/A	Andarix Pharmaceuticals	"141 Powderhouse Blvd, Suite 1"		Somerville	Massachusetts	2144	USA
Re188 P2045 somatostatin peptide analogue	n/a	6/19/14	Treatment of pancreatic cancer.	Designated			N/A	N/A	"Andarix Pharmaceuticals, Inc."	141 Powderhouse Blvd	Suite 1	Somerville	Massachusetts	2144	USA
recilisib sodium	Ex-Rad(R)	9/4/12	Treatment of acute radiation syndrome	Designated			N/A	N/A	"Onconova Therapeutics, Inc."	375 Pheasant Run		Newton	Pennsylvania	18940	USA
recilisib sodium	Ex-Rad(R)	6/1/12	Prevention of acute radiation syndrome	Designated			N/A	N/A	"Onconova Therapeutics, Inc."	375 Pheasant Run		Newtown	Pennsylvania	18940	USA
Recombinant AAV9 expressing human alpha-N-acetylglucosaminidase	n/a	4/30/14	Mucopolysaccharidosis III-B (Sanfilippo Syndrome Type B)	Designated			N/A	N/A	Abeona Therapeutics LLC	10000 Cedar Avenue		Cleveland	Ohio	44106	USA
recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase	n/a	4/29/14	Treatment of mucopolysaccharidosis type III-A (Sanfilippo Syndrome Type A)	Designated			N/A	N/A	Abeona Therapeutics	6555 Carnegie Blvd	Suite 401	Cleveland	Ohio	44103	USA
recombinant activated Factor X variant	n/a	3/3/15	Treatment of intracerebral hemorrhage	Designated			N/A	N/A	"Pfizer, Inc."	500 Arcola Road		Collegeville	Pennsylvania	19426	USA
recombinant adeno- associated virus vector AAV2/rh8 expressing human B-hexosaminidase A and B subunits	n/a	3/25/13	For the treatment of Sandhoff disease	Designated			N/A	N/A	Nat'l Tay-Sachs & Allied Diseases Association	2001 Beacon Street	Suite 204	Boston	Massachusetts	2135	USA
Recombinant adeno-associated virus (serotype 2) (rAAV2) gene transfer agent expressing RPE65	n/a	5/11/09	Treatment of Leber's congential amaurosis	Designated			N/A	N/A	AmpliPhi Biosciences Corporation	601 Union St.	Suite 4200	Seattle	Washington	98111	USA
recombinant adeno-associated virus alpha 1-antitrypsin vector	Raav-Aat	1/27/03	Treatment of alpha1-antitrypsin deficiency	Designated			N/A	N/A	Applied Genetic Technologies Corp.	11801 Research Drive	Suite D	Alachua	Florida	32615	USA
recombinant adeno-associated virus encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP)	n/a	8/25/09	Treatment of Huntington's disease.	Designated			N/A	N/A	"Neurologix, Inc."	"One Bridge Plaza, North"		Fort Lee	New Jersey	7024	USA
Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2	n/a	6/24/08	Treatment of Leber congenital amaurosis due to RPE65 mutations.	Designated			N/A	N/A	"Spark Therapeutics, Inc."	3737 Market Street	Suite 1300	Philadelphia	Pennsylvania	19104	USA
recombinant adeno-associated virus serotype 8 vector encoding human glucose-6-phosphatase-alpha (G6Pase or G6PC)	n/a	9/28/16	Treatment of glycogen storage disease type Ia (von Gierke Disease)	Designated			N/A	N/A	Dimension Therapeutics	840 Memorial Drive		Cambridge	Massachusetts	2139	USA
recombinant adeno-associated virus serotype 9 vector containing the transgene UBE3A encoding for ubiquitin protein ligase E3A/E6-AP	n/a	10/29/15	Treatment of Angelman Syndrome.	Designated			N/A	N/A	"Agilis Biotherapeutics, LLC"	245 First Street	Suite 1800	Cambridge	Massachusetts	2142	USA
recombinant adeno-associated virus serotype AAV8 vector encoding human ornithine transcarbamylase	n/a	12/29/15	Treatment of ornithine transcarbamylase deficiency	Designated			N/A	N/A	Dimension Therapeutics	840 Memorial Drive		Cambridge	Massachusetts	2139	USA
"recombinant adeno-associated virus serotype rhesus 74 (rh74) expressing the human CT GalNac transferase (GALGT2) gene, also called the Sda or Cad GAlNac transferase or b4Galnt2, under control of the muscle creatine kinase (MCK) promoter"	n/a	6/16/15	Treatment of Duchenne muscular dystrophy	Designated			N/A	N/A	Nationwide Children's Hospital	700 Children's Drive	Rm WA2025	Columbus	Ohio	43205	USA
recombinant adeno-associated virus serotype rhesus 74 expressing the human dysferin gene (AAVrh74.MHCK7.DYSF.DV)	n/a	9/19/16	Treatment of Limb Girdle Muscular Dystrophy Type 2B	Designated			N/A	N/A	Nationwide Children's Hospital	700 Children's Drive	Rm WA2025	Columbus	Ohio	43205	USA
recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel alpha subunit (CNGA3)	n/a	11/16/15	Treatment of achromatopsia caused by mutations in the CNGA3 gene	Designated			N/A	N/A	Applied Genetic Technologies Corp.	11801 Research Drive	Suite D	Alachua	Florida	32615	USA
recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel beta subunit (rAAV-CNGB3)	n/a	2/4/11	Treatment of achromatopsia caused by mutations in the CNGB3 gene.	Designated			N/A	N/A	Applied Genetic Technologies Corporation	11801 Research Drive	Suite D	Alachua	Florida	32615	USA
recombinant adeno-associated virus vector serotype 9 expressing human iduronate-2-sulfatase	n/a	9/1/16	"Treatment of mucopolysaccharidosis II, also called Hunter syndrome A."	Designated			N/A	N/A	Research Institute at Nationwide Children's Hospital	Center for Gene Therapy	700 Childrens Drive	Columbus	Ohio	43205	USA
recombinant adeno-associated virus vector serotype 9 expressing human N-Sulfoglucosamine Sulfohydrolase	n/a	9/1/16	"Treatment of mucopolysaccharidosis type III A, also called Sanfilippo syndrome A"	Designated			N/A	N/A	Research Institute at Nationwide Children's Hospital	Center for Gene Therapy	700 Childrens Drive	Columbus	Ohio	43205	USA
recombinant adenovirus vector AAV2/rh8 expressing human B-hexosaminidase A & B subunits	n/a	3/25/13	Treatment of Tay-Sachs disease	Designated			N/A	N/A	Na't Tay-Sachs & Allied Diseases Association	2001 Beacon Street	Suite 204	Boston	Massachusetts	2135	USA
Recombinant anti-CD-40 monoclonal antibody	n/a	1/25/06	Treatment of multiple myeloma	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceutical Corporation	Oncology Business Unit	"One Health Plaza, Bldg 104"	East Hanover	New Jersey	7936	USA
Recombinant anti-CD40 monoclonal antibody	n/a	8/12/05	Treatment of chronic lymphocytic leukemia	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceutical Corporation	Oncology Business Unit	"One Health Plaza, Bldg 104"	East Hanover	New Jersey	7936	USA
Recombinant antibody construct against human CD30 and CD16A	n/a	8/20/09	Treatment of Hodgkin lymphoma	Designated			N/A	N/A	Affimed GmbH	Technologie Park	"Heidelberg,"				Germany
Recombinant bactericidal/permeability-increasing protein	Neuprex	6/22/98	Treatment of severe meningococcal disease.	Designated/Withdrawn			N/A	N/A	Xoma (US) LLC	2910 Seventh Street		Berkeley	California	94710	USA
Recombinant coagulation factor VIIa	n/a	4/26/06	Treatment of diffuse alveolar hemorrhage	Designated			N/A	N/A	Savara Inc.	900 S. Capital Texas Highway	Suite 150	Austin	Texas	78746	USA
recombinant deriative of C3 transferase	Cethrin	11/18/05	Treatment of acute spinal cord injury	Designated			N/A	N/A	"Vertex Pharmaceuticals, Inc."	50 Northern Avenue		Boston	Massachusetts	2210	USA
Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs	n/a	7/29/08	"Prevention of thrombotic thrombocytopenic purpura including its congential, acquired idiopathic and secondary forms."	Designated			N/A	N/A	Baxalta US Inc.	1 Baxter Way		Westlake Village	California	91362	USA
Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs	n/a	7/29/08	"Treatment of thrombotic thrombocytopenic purpura including its congential, acquired idiopathic, and secondary forms."	Designated			N/A	N/A	Baxalta US Inc.	1 Baxter Way		Westlake Village	California	91362	USA
recombinant DNA plasmid	n/a	1/31/14	"Treatment of stage IIb, IIc, III and IV melanoma."	Designated			N/A	N/A	Scancell Ltd.	Dept of Clinical Oncology - City Hospital	NG5 1 PB	Nottingham			United Kingdom
recombinant elafin	n/a	3/18/13	Prevention of inflammatory complications of transthoracic esophagectomy	Designated			N/A	N/A	Proteo Biotech AG	Am Kiel Kanal 44	D-24106 Kiel				Germany
Recombinant Epstein-Barr virus gp350 glycoprotein vaccine	n/a	8/18/05	Prevention of post-transplantation lymphoproliferative disorders in pediatric recipients of solid-organ transplantation	Designated			N/A	N/A	Henogen S.A.	"Rue des Professeurs Jenner et Brachet, 12"	B-6041-Gosselies				Belgium
Recombinant fully human monoclonal antibody to anthrax protective antigen	Valortim	2/16/06	Treatment of anthrax infection	Designated			N/A	N/A	"PharmAthene, Inc."	One Park Place	Suite 450	Annapolis	Maryland	21401	USA
Recombinant Fusion Protein	n/a	7/24/12	Treatment of Myelodysplastic Syndrome	Designated			N/A	N/A	Apogenix GmbH	Im Neuenheimer Feld 584	69120	Heidelberg			Germany
recombinant fusion protein comprising exenatide and XTEN	n/a	10/7/15	Treatment of short bowel syndrome.	Designated			N/A	N/A	"NAIA Pharmaceuticals, Inc."	215 McAllister Avenue		Kentfield	California	94904	USA
recombinant fusion protein consisiting of a modified form of extracellular domain of human Activin receptor IIB	n/a	3/18/13	Treatment of myelodysplastic syndrome	Designated			N/A	N/A	Celgene Corporation	"Corporate Woods Bldg 32, Suite 900"	9225 Indian Creek Parkway	Overland Park	Kansas	66210	USA
recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB (ActRIIB) linked to a human IgG1 Fc domain	n/a	3/11/13	Treatment of B-thalassemia	Designated			N/A	N/A	Celgene Corporation	"Corporate Woods Bldg 32, Suite 900"	9225 Indian Creek Parkway	Overland Park	Kansas	66210	USA
recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)	Idelvion	4/27/12	Treatment of patients with congenital factor IX deficiency (hemophilia B).	Designated/Approved	Approved for Orphan Indication	"Indicated for the (1) on-demand control and prevention of bleeding episodes, (2) perioperative management of bleeding, and (3) routine prophylaxis to prevent or reduce the frequency of bleeding episodes."	03/04/2016	03/04/2023	"CSL Behring, LLC"	1020 First Avenue	P.O. Box 61501	King of Prussia	Pennsylvania	19406	USA
recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)	n/a	5/6/13	Treatment of congenital factor VII deficiency which includes treatment and prophylaxis of bleeding episodes in patients with congenital factor VII deficiency	Designated			N/A	N/A	CSL Behring	P. O. Box 61501	1020 First Avenue	King of Prussia	Pennsylvania	19406	USA
Recombinant fusion protein of Mycobacterium bovis BCG Hsp65 and HPV16 E7	n/a	3/19/01	Treatment of recurrent respiratory papillomatosis (RRP)	Designated			N/A	N/A	"StressGen Biotechnologies, Inc. is now Nventa"	Nventa Biopharmaceuticals Corporation	6055 Lusk Boulevard	San Diego	California	19426	USA
recombinant fusion protein with a truncated form of the cytotoxic protein Pseudomonas exotoxin	Proxinium	1/28/05	Treatment of Ep-CAM-positive squamous cell carcinoma of the head and neck	Designated			N/A	N/A	"Viventia Biotech, Inc."	7895 Tranmere Drive	"Mississauga,"	Ontario L55 1V9			Canada
Recombinant fusion protein-extracellular portion of CD95 fused to the Fc part of human IgG1	n/a	10/13/09	Treatment of glioblastoma multiforme	Designated			N/A	N/A	Apogenix GmbH	Im Meuenheimer Feld 584					Germany
recombinant glycosylated independent lysosomal targeting (GILT) tagged human acid alpha glucosidase	n/a	8/20/10	Treatment of Pompe disease.	Designated			N/A	N/A	"BioMarin Pharmaceutical, Inc."	105 Digital Drive		Novato	California	94949	USA
recombinant growth hormone fused to hyFc	n/a	11/9/16	Treatment of growth hormone deficiency.	Designated			N/A	N/A	"Genexine, Inc."	700 Daewangpangyo-ro	"Korea Bio Pk Bldg B, Bundang-gu"	Gyeonggi-do			"Korea, Republic of"
Recombinant human acid alpha-glucosidase; alglucosidase alfa	1. Myozyme 2. Lumizyme	8/19/97	Treatment of glycogen storage disease type II.	Designated/Approved	Approved for Orphan Indication	(Lumizyme) Patients with Pompe disease (acid alpha-glucosidase (GAA deficiency)).	08/01/2014	08/01/2021	Genzyme Corporation	500 Kendall Street		Cambridge	Massachusetts	2142	USA
Recombinant human acid alpha-glucosidase; alglucosidase alfa	1. Myozyme 2. Lumizyme	8/19/97	Treatment of glycogen storage disease type II.	Designated/Approved	Approved for Orphan Indication	"Myozyme for use in patients with Pompe disease (GAA deficiency). Alglucosidase alfa has been shown to improve ventilator-free survival in patients with infantile onset Pompe disease as compared to an untreated historical control, whereas use of Alphaglucosidase in patients with other forms of Pompe disease has not been adequately studied to assure safety and efficacy."	04/28/2006	04/28/2013	Genzyme Corporation	500 Kendall Street		Cambridge	Massachusetts	2142	USA
Recombinant human acid alpha-glucosidase; alglucosidase alfa	1. Myozyme 2. Lumizyme	8/19/97	Treatment of glycogen storage disease type II.	Designated/Approved	Approved for Orphan Indication	"Lumizyme for patients 8 years and older with late (non-infantile) onset Pompe disease (GAA deficiency) who do not have evidence of cardiac hypertrophy. The safety and efficacy of Lumizyme (alglucosidase alfa) have not been evaluated in controlled clinical trials in infantile-onset patients, or in late (non-infantile) onset patients less than 8 years of age"	05/24/2010	05/24/2017	Genzyme Corporation	500 Kendall Street		Cambridge	Massachusetts	2142	USA
recombinant human acid ceramidase	Plexcerase(Tm)	12/24/13	Treatment of Faber disease	Designated			N/A	N/A	Enzyvant Sciences Ltd.	Clarendon House	2 Church Street	Hamilton HM11			Bermuda
recombinant human alkaline phosphatase	n/a	5/13/15	Treatment of hypophosphatasia.	Designated			N/A	N/A	AM-Pharma BV	Rumpsterweg 6	3891 AK Bunnik				Netherlands
Recombinant human alpha 1-antitrypsin	n/a	4/28/05	Prevention of bronchopulmonary dysplasia	Designated			N/A	N/A	"Arriva Pharmaceuticals, Inc."	1010 Atlantic Avenue		Alameda	California	94501	USA
recombinant human alpha 1-antitrypsin (rAAT)	n/a	11/20/01	Treatment of cystic fibrosis	Designated			N/A	N/A	AiroMedica LLC	6114 LaSalle Avenue	Suite 141	Alameda	California	94611	USA
recombinant human alpha-1 antitrypsin	n/a	3/6/98	Treatment of cystic fibrosis.	Designated			N/A	N/A	PPL Therapeutics (Scotland) Limited	"Roslin, Edinburgh"	EH259PP Scotland				United Kingdom
recombinant human alpha-1 antitrypsin (rAAT)	n/a	8/28/01	To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis	Designated			N/A	N/A	AiroMedica LLC	6114 LaSalle Avenue	Suite 141	Alameda	California	94611	USA
Recombinant Human Alpha-Fetoprotein (rhAFP)	n/a	2/22/01	Treatment of myasthenia gravis	Designated			N/A	N/A	"Alpha Cancer Technologies, Inc."	"MaRS Discovery District, South Tower"	200-101 College St.	Toronto	Ontario		Canada
recombinant human alpha-glucosidase conjugated with synthetic bis-mannose-6-phosphate-Man6 glycan	n/a	11/19/13	Treatment of Pompe Disease	Designated			N/A	N/A	"Genzyme, a Sanofi Company"	500 Kendall Street		Cambridge	Massachusetts	2142	USA
Recombinant human alpha-mannosidase	n/a	2/2/06	Treatment of alpha-mannosidosis	Designated			N/A	N/A	"Chiesi USA, Inc."	1255 Crescent Green	Suite 250	Cary	North Carolina	27518	USA
recombinant human alpha-N-acetylglucosaminidase	n/a	4/15/13	Treatment of mucopolysaccharidosis IIIB (Sanfilippo B syndrome)	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	100 College Street		Hew Haven	Connecticut	6510	USA
Recombinant human anti-GDF-8 (growth and differentiation factor-8) antibody	n/a	2/16/05	Treatment of Duchenne and Becker muscular dystrophies	Designated/Withdrawn			N/A	N/A	"Wyeth Pharmaceuticals, Inc."	P. O. Box 8299		Philadelphia	Pennsylvania	19101	USA
recombinant human anti-GDF-8 monoclonal antibody	n/a	7/24/12	Treatment of Duchenne Muscular Dystrophy.	Designated			N/A	N/A	"Pfizer, Inc."	500 Arcola Road		Collegeville	Pennsylvania	19426	USA
recombinant human antithrombin	Atryn	12/7/07	"Treatment of congenital antithrombin deficiency to prevent the occurrence of serious, potentially life-threatening venous thromboembolisms which may develop as a result of surgical or obstetrical procedures"	Designated/Approved	Approved for Orphan Indication	"Prevention of peri-operative and peri-partum thromboembolic events, in hereditary antithrombin deficient patients."	02/06/2009	02/06/2016	"GTC Biotherapeutics, Inc."	175 Crossing Blvd		Framingham	Massachusetts	1702	USA
Recombinant human antithrombin III	n/a	4/6/00	Treatment of antithrombin III dependent heparin resistance requiring anticoagulation.	Designated			N/A	N/A	AT III LLC	c/o Genzyme Corporation	"15 Pleasant St. Connector, P.O. Box 9322"	Framingham	Massachusetts	1701	USA
recombinant human arylsulphatase A	n/a	4/11/08	Treatment of metachromatic leukodystrophy (MLD).	Designated/Withdrawn			N/A	N/A	Shire Human Genetic Therapies	300 Patriot Way		Lexington	Massachusetts	2421	USA
recombinant human beta-glucuronidase	n/a	2/16/12	"Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)"	Designated			N/A	N/A	"Ultragenyx Pharmaceutical, Inc."	60 Leveroni Court		Novato	California	94949	USA
recombinant human biglycan	n/a	7/13/16	Treatment of Duchenne Muscular Dystrophy	Designated			N/A	N/A	"Tivorsan Pharmaceuticals, Inc."	3 Davol Square	A340	Providence	Rhode Island	2903	USA
Recombinant human C1 inhibitor	n/a	6/9/06	Prevention and/or treatment of delayed graft function after solid organ transplantation	Designated			N/A	N/A	Pharming Group N.V.	Darwinweg 24	2333 CR Leiden				Netherlands
Recombinant human C1 inhibitor	n/a	6/9/06	Treatment of capillary leakage syndrome	Designated			N/A	N/A	Pharming Technologies B.V.	Archimedesweg 4					Netherlands
Recombinant human C1-esterase inhibitor	n/a	2/23/99	Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Designated			N/A	N/A	Pharming Group N.V.	P. O. Box 451 Darwinweg 24	2300 Al Leiden				Netherlands
recombinant human CD24FcIg (humanized fusion protein consisting of the extracellular domain of CD24 linked to IgG1 Fc domain	n/a	6/9/15	Prevention of graft-versus-host disease	Designated			N/A	N/A	"OncoImmune, Inc."	"502 E Street, NE"		Washington	District of Columbia	20002	USA
Recombinant human CD4 immunoglobulin G	n/a	8/30/90	Treatment of AIDS resulting from infection with HIV-1.	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
recombinant human cerebral dopamine neurotrophic factor	n/a	6/8/16	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	Herantis Pharma Plc	4 Viikinkaari		Helsinki			Finland
Recombinant human Clara Cell 10kDa protein	n/a	7/13/98	Prevention of neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome.	Designated			N/A	N/A	"Therabron Therapeutics, Inc."	9430 Key West Avenue	Suite 150	Rockville	Maryland	20850	USA
recombinant human collagen alpha-1 (VII) chain homo-trimer (rC7)	n/a	3/17/14	Treatment of dystrophic epidermolysis bullosa	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	100 Hayden Avenue		Lexington	Massachusetts	2421	USA
recombinant human deoxyribonuclease I	n/a	8/18/14	Treatment of graft-vs-host disease	Designated			N/A	N/A	SciVac Ltd.	13 Gad Feinstei Road	Rehovot 7610303				Israel
recombinant human deoxyribonuclease I (DNase I)	n/a	8/18/14	Prevention of graft-vs-host disease	Designated			N/A	N/A	SciVac Ltd.	13 Gad Feinstei Road	Rehovot 7610303				Israel
recombinant human endostatin protein	n/a	2/21/02	Treatment of metastatic melanoma	Designated			N/A	N/A	"EntreMed, Inc."	9640 Medical Center Drive		Rockville	Maryland	20850	USA
Recombinant human endostatin protein	n/a	8/13/01	Treatment of neuroendocrine tumors	Designated			N/A	N/A	"EntreMed, Inc."	9640 Medical Center Drive		Rockville	Maryland	20850	USA
recombinant human erythropoietin (rHuEPO)	n/a	5/26/11	Treatment of mutliple myeloma	Designated			N/A	N/A	"XTL Biopharmaceuticals, Ltd"	85 Medinat Hayehudim St.		Herzliya Pituach 46766			Israel
Recombinant Human Factor VIIa Variant	n/a	11/30/12	Routine prophylaxis to prevent bleeding episodes in patients with hemophilia A and B patients with inhibitors	Designated			N/A	N/A	"Pfizer, Inc."	500 Arcola Road		Collegeville	Pennsylvania	19426	USA
Recombinant human fibrinogen	n/a	10/4/07	Treatment of bleeding in patients deficient in fibrinogen	Designated			N/A	N/A	Pharming Technologies B.V.	Archimedesweg 4					Netherlands
recombinant human fibroblast growth factor-20	n/a	1/29/04	Treatment of radiation induced oral mucositis	Designated/Withdrawn			N/A	N/A	CuraGen Corporation	322 East Main Street		Branford	Connecticut	6405	USA
recombinant human fucosyltransferase VI [ FTVI ] + GDP-fucose	n/a	1/27/15	To increase the activity of regulatory T-cells (Tregs) used in the prevention of graft versus host disease in patients undergoing hematopoietic stem cell transplantation	Designated			N/A	N/A	"TargaZyme, Inc."	2100 Palomar Airport Road	Suite 214-219	Carlsbad	California	92011	USA
recombinant human galactocerebrosidase (rhGALC);	Galaczym	12/12/11	Treatment of globoid cell leukodystrophy (Krabbe Disease)	Designated			N/A	N/A	ACE BioSciences A/S	Roskildevej 12C	DK-3400 Hillerod				Denmark
Recombinant human gelsolin	n/a	3/6/95	Treatment of acute and chronic respiratory symptoms of bronchiectasis.	Designated			N/A	N/A	"BioAgeis, Therapeutics, Inc."	6 East Cove Lane		Morristown	New Jersey	7960	USA
Recombinant human gelsolin	n/a	1/12/94	Treatment of the respiratory symptoms of cystic fibrosis.	Designated			N/A	N/A	"BioAegis Therapeutics, Inc."	6 East Cove Lane		Morristown	New Jersey	7960	USA
Recombinant human glutamic acid decarboxylase 65KDa isoform	n/a	3/22/10	Treatment of Type I diabetes with residual beta cell function	Designated			N/A	N/A	Diamyd Therapeutics AB	Linnegatan 89B					Sweden
"recombinant human GM-CSF, molgramostim"	n/a	10/31/12	Treatment of pulmonary alveolar proteinosis	Designated			N/A	N/A	Savara Inc.	900 S. Capitol of Texas Highway	Suite 150	Austin	Texas	78746	USA
recombinant human gowth hormone in an ocular delivery system	n/a	12/3/12	Treatment of persistent corneal epithelial defects	Designated			N/A	N/A	Jade Therapeutics LLC	7585 Ranch Club Trail		Park City	Utah	84098	USA
Recombinant human granulocyte colony stimulating factor	n/a	7/24/06	Prevention of implantation failure and unexplained recurrent miscarriage	Designated/Withdrawn			N/A	N/A	"Nora Therapeutics, Inc."	530 Lytton Avenue	2nd Floor	Palo Alto	California	94301	USA
Recombinant human highly phosphorylated acid alpha-glucosidase	Tbd	9/20/00	"For enzyme replacement therapy in patients with all subtypes of glycogen storage disease type II (GSDII, Pompe Disease)"	Designated			N/A	N/A	"Novazyme Pharmaceuticals, Inc."	800 Research Parkway	Suite 200	Oklahoma City	Oklahoma	73104	USA
Recombinant human highly phosphorylated alpha-L-iduronidase (rhHP-IDUA)	n/a	4/11/01	Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I.	Designated			N/A	N/A	"Novazyme Pharmaceuticals, Inc."	800 Research Parkway	Suite 200	Oklahoma City	Oklahoma	73104	USA
recombinant human histidyl tRNA synthetase	n/a	4/22/15	Treatment of facioscapulohumeral muscular dystrophy	Designated			N/A	N/A	"aTyr Pharma, Inc."	3545 John Hopkins Court	Suite 250	San Diego	California	92121	USA
recombinant human histone H1.3; recombinant human N-bis-met-histone H1.3	Oncohist	10/20/08	Treatment of acute myeloid leukemia	Designated			N/A	N/A	Xenetic Biosciences Plc	London Bioscience Innovation Centre	2 Royal College Street	London			United Kingdom
recombinant human IgG1 monoclonal antibody	n/a	12/14/09	Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets)	Designated			N/A	N/A	"Ultragenyx Pharmaceutical, Inc."	60 Leveroni Court	Suite 200	Novato	California	94949	USA
Recombinant human insulin-like growth factor 1	Igf-1	6/7/95	Treatment of antibody-mediated growth hormone resistance in patients with isolated growth hormone deficiency Ia.	Designated/Withdrawn			N/A	N/A	Pharmacia & Upjohn	7000 Portage Road		Kalamazoo	Michigan	49001	USA
Recombinant human insulin-like growth factor 1	Igf-1	6/7/95	Treatment of growth hormone receptor deficiency.	Designated/Withdrawn			N/A	N/A	Pharmacia & Upjohn	7000 Portage Road		Kalamazoo	Michigan	49001	USA
Recombinant human insulin-like growth factor-I	Pv802	2/16/00	Treatment of short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines.	Designated			N/A	N/A	GroPep Pty Ltd.	"Gate 11, Victoria Dr."	Adelaide SA 5000				Australia
Recombinant human insulin-like growth factor-I	n/a	10/13/95	Treatment of post-poliomyelitis syndrome.	Designated/Withdrawn			N/A	N/A	"Teva Branded Pharmaceutical Product R&D, Inc."	41 Moores Road		Frazer	Pennsylvania	19355	USA
Recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3	n/a	6/15/99	Treatment of major burns that require hospitalization.	Designated			N/A	N/A	"Insmed, Inc."	Princeton Corporate Plaza	"9 Deer Park Drive, Suite C"	Monmouth Junction	New Jersey	8852	USA
Recombinant human interleukin-12	n/a	10/20/97	Treatment of renal cell carcinoma.	Designated			N/A	N/A	"Genetics Institute, Inc."	87 Cambridge Park Drive		Cambridge	Massachusetts	2140	USA
recombinant human interleukin-12	Hemamax	8/22/16	Treatment of acute radiation syndrome	Designated			N/A	N/A	"Neumedicines, Inc."	133 Altadena Drive	Suite 133	Pasadena	California	91107	USA
Recombinant Human Interleukin-21 (rIL-21)	n/a	10/4/05	"Treatment of stage II (T4), III or IV malignant melanoma."	Designated			N/A	N/A	"Zymo Genetics, Inc"	1201 Eastlake Avenue East		Seattle	Washington	98102	USA
Recombinant human keratinocyte growth factor	n/a	12/20/99	Reducing the incidence and severity of radiation-induced xerostomia.	Designated			N/A	N/A	Swedish Orphan Biovitrum AB (publ) (SOBI)	SE-112 76		Stockholm			Sweden
recombinant human lecithin:cholesterol acyltransferase (rhLCAT)	n/a	9/2/10	Treatment of LCAT deficiency syndromes	Designated			N/A	N/A	"AlphaCore Pharma, LLC"	333 Parkland Plaza #5		Ann Arbor	Michigan	48103	USA
Recombinant human luteinizing hormone	Luveris	10/7/94	For use in association with recombinant human follicle stimulating hormone for the treatment of women with chronic anovulation due to hypogonadotropic hypogonadism.	Designated/Approved	Approved for Orphan Indication	"Luveris (lutropin alfa for injection), concomitantly administered with Gonal-f (follitropin alfa for injection), is indicated for stimulation of follicular development in infertile hypogonadotropic hypogonadal women with profound LH deficiency (LH (less than) 1.2 IU/L)."	10/08/2004	10/08/2011	"EMD Serono, Inc."	One Technology Place		Rockland	Massachusetts	2370	USA
Recombinant human lysosomal acid lipase or cholesteryl ester hydrolase	Cholestrase	7/14/05	"Treatment of lipase deficiencies, including Wolman Disease and cholesteryl ester storage disease"	Designated			N/A	N/A	"Lysosomal Acid Lipase, LLC"	"Subsidiary of Kentucky BioProcessing, LLC"	3700 Airpark Drive	Owensboro	Kentucky	42301	USA
Recombinant human microplasmin	n/a	1/23/06	Treatment of peripheral arterial occlusion	Designated			N/A	N/A	ThromboGenics Ltd	"Unit 14, Bridgecourt Office Park"		Dublin			Ireland
recombinant human minibody against complement component	Mubodina(R)	6/7/11	Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system.	Designated			N/A	N/A	Adienne S.A	Via Zurigo 46	6900 Lugano				Switzerland
recombinant human minibody against complement component C5	Mubodina	2/4/09	Treatment of primary membranoproliferative glomerulonephritis	Designated			N/A	N/A	Adienne S.A.	Via Zurigo 46	6900 Lugno				Switzerland
recombinant human minibody against complement component C5 fused with RGD-motif	n/a	2/4/09	Prevention of ischemia/reperfusion injury associated with solid organ transplantation.	Designated			N/A	N/A	Adienne S.A.	Via Zurigo 46	6900 Lugno				Switzerland
recombinant human monoclonal antibody against activin receptors type II	n/a	6/18/12	Treatment of inclusion body myositis	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Jersey	7936	USA
Recombinant human monoclonal antibody against human complement component C5a	n/a	10/6/16	Treatment of acute graft versus host disease	Designated			N/A	N/A	"Alexion Pharmaceuticals, Inc."	100 College Street		New Haven	Connecticut	6510	USA
recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor	n/a	8/19/14	"Treatment of pigmented villonodular synovitis, including giant cell tumor of the tendon sheath"	Designated			N/A	N/A	Novartis Pharmaceuticals Corp	One Health Plaza		East Hanover	New Jersey	7936	USA
recombinant human monoclonal antibody of the IgG1 kappa class against prostate stem cell antigen	n/a	12/3/12	Treatment of pancreatic cancer	Designated/Withdrawn			N/A	N/A	"Astellas Pharma Global Development, Inc."	1 Astellas Way		Northbrook	Illinois	60062	USA
recombinant human monoclonal antibody to hsp90	Mycograb	9/16/02	Treatment of invasive candidiasis	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Jersey		United Kingdom
recombinant human monoclonal IgG1 antibody against programmed death ligand-1 (anti-PD-L1)	n/a	9/21/15	Treatment of merkel cell carcinoma.	Designated			N/A	N/A	"EMD Serono, Inc."	45 Middlesex Turnpike		Billerica	Massachusetts	1821	USA
recombinant human monoclonal IgM antibody targeting glucose regulated protein 78	n/a	10/25/13	Treatment of multiple myeloma	Designated			N/A	N/A	Patrys Ltd.	"Suite 614, Level 6"	"Melbourne, Victoria 3000"				Australia
recombinant human Naglu- insulin-like growth factor II	n/a	3/5/13	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B)	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	300 Shire Way		Lexington	Massachusetts	2421	USA
recombinant human nerve growth factor	n/a	8/8/13	Treatment of retinitis pigmentosa	Designated			N/A	N/A	Dompe s.p.a.	"Via S. Martino 12-12/A, 20122"		Milan			Italy
Recombinant human nerve growth factor	n/a	4/16/99	Treatment of HIV-associated sensory neuropathy.	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
recombinant human nerve growth factor	n/a	6/23/14	Treatment of neurotrophic keratitis	Designated			N/A	N/A	Dompe s.p.a.	Via S. Martino 12-12/A		Milan			Italy
recombinant human neutrophil inhibitor (hNE)	n/a	12/9/03	Treatment of cystic fibrosis	Designated			N/A	N/A	Dyax Corporation	300 Technology Square		Cambridge	Massachusetts	2139	USA
recombinant human Pentraxin-2	n/a	8/26/14	Treatment of myelofibrosis	Designated			N/A	N/A	"Promedior, Inc."	101 Hartwell Avenue		Lexington	Massachusetts	2421	USA
recombinant human Pentraxin-2; recombinant human Serum Amyloid P	n/a	2/17/12	Treatment of idiopathic pulmonary fibrosis.	Designated			N/A	N/A	"Promedior, Inc."	101 Hartwell Avenue		Lexington	Massachusetts	19355	USA
Recombinant human platelet derived growth factor BB	n/a	2/1/07	Treatment of osteonecrosis of the jaws	Designated			N/A	N/A	"Luitpold Pharmaceuticals, Inc."	800 Adams Avenue	Suite 100	Norristown	Pennsylvania	19403	USA
recombinant human platelet derived growth factor-BB	n/a	8/6/10	Treatment of osteochondritis dissecans	Designated/Withdrawn			N/A	N/A	"Biomimetic Therapeutics, Inc."	389-A Nichol Mill Lane		Franklin	Tennessee	37067	USA
recombinant human porphobilinogen deaminase	Porphozyme	9/9/02	Treatment of acute intermittent porphyria attacks	Designated			N/A	N/A	Zymenex A/S	Roskildevej 12C	3400 Hillerod				Denmark
"recombinant human porphobilinogen deaminase, erythropoetic form"	n/a	7/11/02	Treatment of acute intermittent porphyria preventing attacks	Designated			N/A	N/A	Zymenex A/S	Roskildevej 12C	3400 Hillerod				Denmark
recombinant human proinsulin (Including rhPI-Methionine)	n/a	12/10/08	Treatment of retinitis pigmentosa	Designated			N/A	N/A	"ProRetina Therapeutics, S.L."	Pza. CEIN	31110 Noain (Navarra)				Spain
Recombinant human relaxin	n/a	11/3/95	Treatment of progressive systemic sclerosis.	Designated/Withdrawn			N/A	N/A	Connetics Corporation	3400 West Bayshore Road		Palo Alto	California	94303	USA
recombinant human rod-derived cone viability factor	n/a	1/7/08	Treatment of retinitis pigmentosa	Designated/Withdrawn			N/A	N/A	Fovea Pharmaceuticals	12 Rue Jean Antoine de Baif		Paris			France
recombinant human serum albumin human growth hormone	n/a	1/13/16	Treatment of growth hormone deficiency	Designated			N/A	N/A	"TEVA Branded Pharmaceutical Products R&D, Inc."	41 Moores Road	P. O. Box 4011	Frazer	Pennsylvania	19355	USA
Recombinant Human soluble Fc-gamma Receptor IIb	n/a	3/22/10	Treatment of idiopathic thrombocytopenic purpura	Designated			N/A	N/A	SuppreMol GmbH	Am Klopferspitz 19	Munich				Germany
Recombinant human superoxide dismutase	Oxsodrol	4/18/91	Prevention of bronchopulmonary dysplasia in premature neonates weighing less than 1500 grams.	Designated/Withdrawn			N/A	N/A	"Savient Pharmaceuticals, Inc."	"One Tower Center Boulevard, 12th floor"		East Brunswick	New Jersey	8816	USA
recombinant human surfactant protein D	n/a	6/23/14	Prevention of bronchopulmonary dysplasia	Designated			N/A	N/A	Airway Therapeutics LLC	c/o Triathlon Medical Ventures	Suite 200	Cincinnati	Ohio	45219	USA
Recombinant human thrombopoietin	n/a	9/29/97	For use in accelerating platelet recovery in patients undergoing hematopoietic stem cell transplantation.	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
recombinant human type I pancreatic elastase	n/a	4/3/09	Prevention of arteriovenous fistula and arteriovenous graft failure in patients with chronic kidney disease (CKD) who are receiving hemodialysis or preparing for hemodialysis	Designated			N/A	N/A	"Proteon Therapeutics, Inc."	200 West Street		Waltham	Massachusetts	2451	USA
recombinant human type VII collagen	n/a	6/18/08	Treatment of hereditary dystrophic epidermolysis bullosa (DEB)	Designated			N/A	N/A	"David T. Woodley, MD and Mei Chen, MD"	"USC Department of Dermatology, Cancer Research Lab"	1303 North Mission Road	Los Angeles	California	90033	USA
recombinant human vascular endothelial growth factor	n/a	6/7/10	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	NeuroNova AB	Fiskartorpsvagen 15 A-D	Stockholm				Sweden
recombinant humanized anti-interleukin 13 (IL-13) monoclonal antibody	n/a	2/11/15	Treatment of eosinophilic esophagitis	Designated			N/A	N/A	"Receptos Services, LLC"	3033 SciencePark Road	Suite 300	San Diego	California	92121	USA
Recombinant humanized anti-LOXL2 monoclonal antibody	n/a	4/18/11	Treatment of idiopathic pulmonary fibrosis	Designated/Withdrawn			N/A	N/A	"Gilead Sciences, Inc."	199 East Blaine St.		Seattle	Washington	98102	USA
"recombinant humanized anti-LOXL2 monoclonal antibody, IgG4(S241P)"	n/a	5/17/11	Treatment of pancreatic cancer.	Designated/Withdrawn			N/A	N/A	"Gilead Sciences, Inc."	199 E. Blaine St.		Seattle	Washington	98102	USA
"Recombinant humanized anti-LOXL2 monoclonal antibody, IgG4(S241P)"	n/a	6/1/11	Treatment of myelofibrosis.	Designated/Withdrawn			N/A	N/A	"Gilead Sciences, Inc."	199 E. Blaine St.		Seattle	Washington	98102	USA
recombinant humanized anti-matrix metalloprotein 9 (MMP9) monoclonal antibody IgG4	n/a	7/16/15	Treatment of gastric cancer	Designated			N/A	N/A	"Gilead Sciences, Inc."	199 E. Blaine St.		Seattle	Washington	98102	USA
recombinant humanized anti-tau antibody	n/a	1/22/15	Treatment of progressive supranuclear palsy	Designated			N/A	N/A	"AbbVie, Inc."	1 North Waukegan Road		North Chicago	Illinois	60064	USA
recombinant humanized IgG1k monoclonal antibody to human invariant T cell receptor (iTCR)	n/a	4/12/13	Treatment of sickle cell disease	Designated			N/A	N/A	"NKT Therapeutics, Inc."	880 Winter Street	Suite 350	Waltham	Massachusetts	2451	USA
recombinant humanized IgG4 monoclonal antibody that binds human colony stimulating factor 1 receptor	n/a	1/11/16	Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor	Designated			N/A	N/A	"Five Prime Therapeutics, Inc."	2 Corporate Drive		South San Francisco	California	94080	USA
Recombinant humanized MAb 5c8	n/a	3/22/99	Prevention of rejection of solid organ transplants.	Designated			N/A	N/A	"Biogen, Inc."	14 Cambridge Center		Cambridge	Massachusetts	2142	USA
Recombinant humanized MAb 5c8	n/a	3/22/99	Prevention of rejection of pancreatic islet cell transplants.	Designated			N/A	N/A	"Biogen, Inc."	14 Cambridge Center		Cambridge	Massachusetts	2142	USA
Recombinant humanized MAb 5c8	n/a	10/14/98	Prevention and treatment of Factor VIII/Factor IX inhibitors in patients with hemophilia A or B.	Designated			N/A	N/A	"Biogen, Inc."	14 Cambridge Center		Cambridge	Massachusetts	2142	USA
Recombinant humanized monclonal antibody 5c8	n/a	2/3/98	Treatment of immune thrombocytopenic purpura.	Designated			N/A	N/A	"Biogen, Inc."	14 Cambridge Center		Cambridge	Massachusetts	2142	USA
Recombinant humanized monoclonal antibody 5c8	n/a	2/18/98	Treatment of systemic lupus erythematosus.	Designated			N/A	N/A	"Biogen, Inc."	14 Cambridge Center		Cambridge	Massachusetts	2142	USA
Recombinant humanized monoclonal antibody directed against an epidermal growth factor receptor	n/a	2/17/12	Treatment of glioblastoma multiforme	Designated/Withdrawn			N/A	N/A	"AbbVie, Inc."	1 N. Waukegan Road		North Chicago	Illinois	60064	USA
recombinant humanized monoclonal antibody of the immunoglobulin G1 subclass directed against colony stimulating factor-1 receptor expressed on macrophages	n/a	5/14/14	Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
recombinant IgA protease of bacterium Heamophilus influenzae	n/a	4/18/11	"Treatment of immunoglobulin A nephropathy (IgAN, Berger's disease)."	Designated			N/A	N/A	Shire Human Genetics Therapies	300 Shire Way		Lexington	Massachusetts	2421	USA
Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin	n/a	2/11/02	Treatment of epithelial ovarian cancer	Designated			N/A	N/A	National Institutes of Health	Cancer Therapy Evaluation Program	"6130 Executive Blvd, Suite 7111"	Rockville	Maryland	20852	USA
Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin	n/a	2/11/02	Treatment of malignant mesothelioma	Designated			N/A	N/A	National Institutes of Health	Cancer Therapy Evaluation Program	"6130 Executive Blvd, Suite 7111"	Rockville	Maryland	20852	USA
recombinant kallikrein inhibitor	n/a	11/23/10	Treatment of Netherton Syndrome.	Designated			N/A	N/A	Dermadis SA	Batiment Le Forum	74160 Archamps				France
recombinant lens epithelium derived growth factor 1-326	n/a	5/19/14	Treatment of retinitis pigmentosa	Designated			N/A	N/A	"Ocugen, Inc."	Bioscience Park Center	Suite 100	Aurora	Colorado	80045	USA
Recombinant methionyl brain-derived neurotrophic factor	n/a	11/28/94	Treatment of amyotrophic lateral sclerosis.	Designated			N/A	N/A	"Amgen, Inc."	One Amgen Center Dr.	M/S: 17-2-B	Thousand Oaks	California	91320	USA
Recombinant methionyl human stem cell factor	n/a	11/22/95	Treatment of primary bone marrow failure.	Designated/Withdrawn			N/A	N/A	"Amgen, Inc."	One Amgen Center Drive		Thousand Oaks	California	91320	USA
recombinant monoclonal antibody to human serum amyloid P component	n/a	2/10/15	Treatment of AL amyloidosis	Designated			N/A	N/A	"Glaxo Group Limited, England d/b/a GlaxoSmithKline"	980 Great West Road	"Middlesex, TW8, 9GS"				United Kingdom
recombinant multimerized human IgG1 Fc	n/a	7/14/15	Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).	Designated			N/A	N/A	"Pfizer, Inc."	500 Arcola Road		Collegeville	Pennsylvania	19426	USA
recombinant nematode anticoagulant protein c2 (rNAPc2)	n/a	12/8/14	Treatment of viral hemorrhagic fever post-exposure to Ebola virus (treatment of Ebola)	Designated			N/A	N/A	"ARCA Biopharma, Inc."	11080 Circle Point Rd.	Suite 140	Westminster	Colorado	80020	USA
recombinant neuroglobin (rNgb) containing mutations H64Q/C46G/C55S/C120S	n/a	11/17/14	Treatment of patients with carbon monoxide poisoning	Designated			N/A	N/A	University of Pittsburgh	4200 Fifth Ave.		Pittsburgh	Pennsylvania	15260	USA
recombinant NY-ESO-1 protein mixed with glucopyranosyl lipid A	n/a	1/6/16	Treatment of soft tissue sarcoma.	Designated			N/A	N/A	Immune Design Corp.	1616 Eastlake Ave. E	Suite 310	Seattle	Washington	98102	USA
recombinant ovine interferon tau	Tauferon	1/25/05	Treatment of pediatric multiple sclerosis	Designated			N/A	N/A	PEPGEN Corporation	1301 Harbor Bay Parkway		Alameda	California	94502	USA
Recombinant P-Selectin glycoprotein ligand	n/a	3/29/06	Prevention of delayed graft function in renal transplant patients	Designated			N/A	N/A	"Y's Therapeutics, Inc."	1111 Bayhill Drive	Suite 405	San Bruno	California	94066	USA
Recombinant P-selectin glycoprotein ligand-immunoglobulin Ig	n/a	7/26/07	Prevention of ischemia reperfusion injury in all solid organ transplants	Designated			N/A	N/A	"Y's Therapeutics, Inc."	1539 Granger Way		Redwood City	California	94061	USA
Recombinant protein inhibitor of complement factor 5	n/a	5/10/16	Treatment of Guillain-Barre Syndrome.	Designated			N/A	N/A	Akari Therapeutics Plc	24 West 40th Street	8th Floor	New York	New York	10018	USA
Recombinant replication deficient adenovirus vector carrying human p53 gene	n/a	4/12/99	Treatment of primary ovarian cancer.	Designated			N/A	N/A	Schering Corporation	2000 Galloping Hill Rd.		Kenilworth	New Jersey	7033	USA
Recombinant retroviral vector - glucocerebrosidase	n/a	11/15/93	"For use as enzyme replacement therapy for patients with types I, II, or III Gaucher disease."	Designated			N/A	N/A	"Genetic Therapy, Inc."	938 Clopper Road		Gaithersburg	Maryland	20878	USA
Recombinant secretory leucocyte protease inhibitor	n/a	3/29/91	Treatment of cystic fibrosis.	Designated			N/A	N/A	"Amgen, Inc."	3200 Walnut Street		Boulder	Colorado	80301	USA
Recombinant secretory leucocyte protease inhibitor	n/a	3/29/91	Treatment of congenital alpha-1 antitrypsin deficiency.	Designated/Withdrawn			N/A	N/A	Amgen Inc.	3200 Walnut Street		Boulder	Colorado	80301	USA
Recombinant soluble human CD4	Receptin	11/20/89	Treatment of acquired immunodeficiency syndrome.	Designated/Withdrawn			N/A	N/A	"Biogen, Inc."	14 Cambridge Center		Cambridge	Massachusetts	2142	USA
Recombinant soluble human CD4 (rCD4)	n/a	3/23/89	Treatment of AIDS in patients infected with HIV virus.	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
Recombinant T-cell receptor ligand	n/a	5/2/03	Treatment of multiple sclerosis patients who are both HLA-DR2 positive and autoreactive to myelin oligodendrocyte glycoprotein residues 35-55	Designated			N/A	N/A	"Artielle ImmunoTherapeutics, Inc."	9020 SW Washington Square Road	Suite 450	"Tigard,"	Oregon	97223	USA
recombinant thymidine phosphorylase encapsulated with autologous erythrocytes	n/a	12/13/10	Treatment of mitochondrial neurogastrointestinal encephalomyopathydue to thymidine phosphorylase deficiency.	Designated			N/A	N/A	St. George's University of London	Joint Research Office	London SW17 ORE				United Kingdom
Recombinant truncated SPINT2 protease inhibitor	n/a	6/24/05	Treatment of cystic fibrosis	Designated			N/A	N/A	"Aerovance, Inc."	2929 Seventh Street		Berkeley	California	94710	USA
Recombinant urate oxidase	n/a	10/11/00	Prophylaxis of chemotherapy-induced hyperuricemia.	Designated			N/A	N/A	Sanofi-Synthelabo Research	9 Great Valley Parkway		Malvern	Pennsylvania	19355	USA
Recombinant vaccinia (human papillomavirus)	Ta-Hpv	8/24/94	Treatment of cervical cancer.	Designated/Withdrawn			N/A	N/A	Xenova Research Limited	310 Cambridge Science Park	Cambridge CB4 OWG				USA
recombinant von Willebrand factor (rhVWF)	n/a	11/23/10	Treatment of von Willebrand disease.	Designated/Approved	Approved for Orphan Indication	Indicated for on-demand treatment and control of bleeding episodes in adults diagnosed with von Willebrand disease (VWD)	12/08/2015	12/08/2022	"Baxalta US, Inc."	One Baxter Way		Westlake Village	California	91362	USA
"recombinant, adeno-associated virus serotype 2 vector carrying linear single-stranded AADC mRNA cDNA"	n/a	6/8/16	Treatment of aromatic L-amino acid decarboxylase deficiency.	Designated			N/A	N/A	"Agilis Biotherapeutics, LLC"	Kendall Square	245 First Street	Cambridge	Massachusetts	2142	USA
"recombinant, adeno-associated virus serotype 5 vector, containing the transgene, which encodes for the human protein, frataxin"	n/a	7/25/16	Treatment of Friedreich's Ataxia	Designated			N/A	N/A	"Agilis Biotherapeuties, LLC"	245 First Street	Suite 1800	Cambridge	Massachusetts	2142	USA
"recombinant, fully-human, IgG4 immunoglobulin with antigen-binding specificity for human vascular adhesion protein-1 (VAP-1)"	n/a	8/25/16	Treatment of primary sclerosing cholangitis.	Designated			N/A	N/A	"Acorda Therapeutics, Inc."	420 Saw Mill River Road		Ardsley	New York	10502	USA
"recombinant, glycoenfineered humanized IgG1 kappa monoclonal antibody directed against Fibroblast Growth Factor Receptor 2b"	n/a	6/29/16	Treatment of gastric cancer including cancer of the gastroesophageal junction.	Designated			N/A	N/A	"Five Prime Therapeutics, Inc."	2 Corporate Drive		South San Francisco	California	94080	USA
"recombinant, non-pathogenic poliovirus:rhinovirus chimera that consists of the genome of the live attenuated poliovirus serotype 1 vaccine with its cognate IRES element replaced with that of HRV2"	n/a	5/26/16	Treatment of glioma	Designated			N/A	N/A	"Darell D. Bigner, MD, PhD"	Duke University Medical Center	Oreuss Laboratory -Brain Tumor Research	Durham	North Carolina	27710	USA
Reduced L-glutathione	Cachexon	2/14/94	Treatment of AIDS-associated cachexia.	Designated			N/A	N/A	Telluride Pharmaceutical Corporation	146 Flanders Drive		Hillsborough	New Jersey	8876	USA
refanalin	n/a	5/25/10	To improve renal function and prevent delayed graft function following renal transplantation	Designated			N/A	N/A	Angion Biomedica Corporation	1050 Stewart Avenue		Garden City	New York	11530	USA
regorafenib	Stivarga	1/12/11	Treatment gastrointestinal stromal tumors	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate."	02/25/2013	02/25/2020	"Bayer HealthCare Pharmaceuticals, Inc."	100 Bayer Blvd	P. O. Box 915	Whippany	New Jersey	7981	USA
regorafenib	Stivarga	6/4/15	Treatment of hepatocellular carcinoma.	Designated			N/A	N/A	"Bayer HealthCare Pharmaceuticals, Inc."	100 Bayer Blvd	P. O. Box 915	Whippany	New Jersey	7981	USA
Remacemide	Ecovia	3/6/00	Treatment of Huntington's disease.	Designated/Withdrawn			N/A	N/A	AstraZeneca LP	725 Chesterbrook Blvd.		Wayne	Pennsylvania	19087	USA
REMUNE HIV 1	n/a	2/14/14	Treatment of pediatric HIV/AIDS (age through 16 years)	Designated			N/A	N/A	"Immune Response BioPharma, Inc."	1801 Atlantic Avenue	Suite 8352	Atlantic City	New Jersey	8401	USA
reparixin	n/a	9/25/12	Prevention of graft loss in pancreatic islet transplantation	Designated			N/A	N/A	Dompe S.p.A.	Via Campo di Pile		L'Aquila			Italy
reparixin	n/a	1/27/03	Prevention of delayed graft function in solid organ transplant	Designated			N/A	N/A	Dompe S.p.A.	Via Campo di Pile	67100 - L'Aquila				Italy
Replication defective recombinant adenovirus serotype 5 vector carrying the p53 gene in its E1 deleted region	Advexin	1/27/03	Treatment of head and neck cancer	Designated			N/A	N/A	"Introgen Therapeutics, Inc."		2250 Holcombe Blvd	Houston	Texas	77030	USA
replication-deficient recombinant serotype 2 adeno-associated viral vector containing hAQP1 cDNA	n/a	5/3/13	Treatment of symptoms of Grade 2 and Grade 3 late xerostomia from parotid gland hypofunction caused by radiotherapy for cancer of the oral cavity.	Designated			N/A	N/A	"MeiraGTx, LLC"	450 East 29th Street	15th Floor	New York	New York	10016	USA
Replication-incompetent GM-CSF-expressing gene-modified allogeneic acute myeloid leukemia cancer cell lines	Gvax Acute Myeloid Leukemia	3/2/10	Treatment of acute myeloid leukemia	Designated			N/A	N/A	"Aduro BioTech, Inc."	740 Heinz Avenue		Berkeley	California	94710	USA
Replication-incompetent GM-CSF-expressing gene-modified allogeneic chronic myeloid leukemia cancer cell lines	Gvax Chronic Myeloid Leukemia	4/30/10	Treatment of chronic myeloid leukemia	Designated			N/A	N/A	"Aduro BioTech, Inc."	740 Heinz Avenue		Berkeley	California	94710	USA
Replication-incompetent GM-CSF-expressing gene-modified allogeneic pancreatic cancer cell lines	Gvax Pancreas	3/1/10	Treatment of pancreatic cancer.	Designated			N/A	N/A	"Aduro BioTech, Inc."	740 Heinz Avenue		Berkeley	California	94710	USA
repository corticortropin injection	H.P. Acthar Gel	6/28/13	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	"Mallinckrodt Pharmaceuticals, Inc."	Perryville III Corporate Park	P. O. Box 9001	Hampton	New Jersey	8827	USA
repository corticotropin or adrenocorticotropic hormone	H.P. Acthar Gel	5/21/03	Treatment of infantile spasms	Designated/Approved	Approved for Orphan Indication	To treat infantile spasms	10/15/2010	10/15/2017	"Questcor Pharmaceuticals, Inc."	26118 Research Road		Hayward	California	94545	USA
resiniferatoxin	n/a	5/13/03	Treatment of intractable pain at end-stage disease	Designated			N/A	N/A	"Sorrento Theraeputics, Inc."	9380 Judicial Drive		San Diego	California	92121	USA
reslizumab	n/a	12/19/07	Treatment of children with eosinophilic esophagitis	Designated			N/A	N/A	"Teva Respiratory, LLC"	41 Moores Road	P. O. Box 4011	Frazer	Pennsylvania	19335	USA
reslizumab	Cinquil	1/12/11	Treatment of hypereosinophilic syndrome	Designated			N/A	N/A	"Teva Pharmaceuticals, Inc."	41 Moores Road	P. O. Box 4011	Frazer	Pennsylvania	19355	USA
resminostat	n/a	9/16/11	Treatment of Hodgkin's lymphoma.	Designated			N/A	N/A	4SC AG	Am Klopferspitz 19a	82152 Martinsried				Germany
resminostat	n/a	6/29/11	Treatment of hepatocellular carcinoma	Designated			N/A	N/A	4SC AG	Am Klopferspitz 19a	82152 Martinsried				Germany
Respiratory syncytial virus immune globulin (Human)	Respigam	9/27/90	Prophylaxis of respiratory syncytial virus lower respiratory tract infections in infants and young children at high risk of RSV disease.	Designated/Approved	Approved for Orphan Indication	For the prevention of serious lower respiratory tract infections caused by RSV in children less than 24 months of age with bronchopulmonary dysplasia or a history of prematurity (less than or equal to 35 weeks gestation).	01/18/1996	01/18/2003	MedImmune & Massachussetts Public Health Biologics Labs.	35 West Watkins Mill Road		Gaithersburg	Maryland	20878	USA
Respiratory Syncytial Virus Immune Globulin (human)	Hypermune Rsv	9/27/90	Treatment of respiratory syncytial virus lower respiratory tract infections in hospitalized infants and young children.	Designated			N/A	N/A	"MedImmune, Inc."	35 West Watkins Mill Road		Gaithersburg	Maryland	20878	USA
retaspimycin	n/a	8/31/07	Treatment for gastrointestinal stromal tumor	Designated/Withdrawn			N/A	N/A	"Infinity Pharmaceuticals, Inc."	780 Memorial Drive		Cambridge	Massachusetts	2139	USA
retaspimycin hydrochloride	n/a	6/24/08	Treatment of melanoma stages IIb through IV.	Designated/Withdrawn			N/A	N/A	AstraZeneca Pharmaceuticals LP	P. O. Box 8355	1800 Concord Pike	Wilmington	Delaware	19803	USA
Retinol palmitate	n/a	8/8/16	Prevention of bronchopulmonary dysplasia.	Designated			N/A	N/A	"Phillipp Heinrich Novak, DVM, MSc"	41 Peter-Rosegger-Strae		Ried im Innkreis			Austria
retroviral gamma-c cDNA containing vector	n/a	4/29/02	Treatment of X linked severe combined immune deficiency disease	Designated			N/A	N/A	"AVAX technologies, Inc."	9200 Indian Creek Parkway	"Building 9, Suite 200"	Overland Park	Kansas	66210	USA
"Retroviral vector, R-GC and GC gene 1750"	n/a	5/6/97	Treatment of Gaucher disease.	Designated/Withdrawn			N/A	N/A	Genzyme Corporation	500 Kendall Street		Cambridge	Massachusetts	1701	USA
Reversal agent linked to chloroquine-like moiety	n/a	3/26/10	Treatment of malaria	Designated			N/A	N/A	DesignMedix	2828 SW Corbett Avenue		Portland	Oregon	97201	USA
Revimmune	n/a	2/18/11	Treatment of autoimmune hemolytic anemia.	Designated			N/A	N/A	Accentia Biopharmaceuticals	324 South Hyde Park Avenue #350		Tampa	Florida	33606	USA
Reviparin sodium	Clivarine	6/18/01	Long-term treatment of acute deep vein trombosis with or without pulmonary embolism in pregnant patients	Designated			N/A	N/A	Abbott	"Abbott Laboratories, Dept. 389, Bldg. J-45"	200 Abbott Park Rd.	Abbott Park	Illinois	60064	USA
Reviparin sodium	Clivarine	6/18/01	Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients	Designated			N/A	N/A	Abbott	"Abbott Laboratories, Dept. 389, Bldg. J-45"	200 Abbott Park Rd.	Abbott Park	Illinois	60064	USA
revusiran	n/a	5/18/15	Treatment of transthyretin amyloidosis	Designated			N/A	N/A	"Alnylam Pharmaceuticals, Inc."	300 Third Street		Cambridge	Massachusetts	2142	USA
"RGG0853, E1A lipid complex"	n/a	9/15/95	Treatment of ovarian cancer.	Designated/Withdrawn			N/A	N/A	Targeted Genetics Corporation	"1100 Olive Way, Suite 100"		Seattle	Washington	98101	USA
"rh-microplasmin, ocriplasmin"	Jetrea	3/16/04	Adjunct to surgery in cases of pediatric vitrectomy	Designated			N/A	N/A	ThromboGenics Inc.	Unit 14	Walkinstown Avenue	Dublin 12			Ireland
rhIGF-I/rhIGFBP-3	Somatokine	12/9/03	"Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)"	Designated			N/A	N/A	"Insmed, Inc."	Princeton Corporate Plaza	"9 Deer Park Drive, Suite C"	Monmouth Junction	New Jersey	8852	USA
Rho (D) immune globulin intravenous (human)	Winrho Sd	11/9/93	Treatment of immune thrombocytopenic purpura.	Designated/Approved	Approved for Orphan Indication	Treatment of adults and children with chronic and acute immune thrombocytopenic purpura.	03/24/1995	03/24/2002	"Rh Pharmaceuticals, Inc."	104 Chancellor Matheson Road	R3T 2N2				Canada
ribavirin	Virazole	4/12/91	Treatment of hemorrhagic fever with renal syndrome	Designated			N/A	N/A	Valeant Pharmaceuticals International	3300 Hyland Avenue		Costa Mesa	California	92626	USA
ribavirin	Rebetol	4/4/03	Treatment of chronic hepatitis C in pediatric patients	Designated/Approved	Approved for Orphan Indication	Treatment of chronic hepatitis C among previously untreated pediatric patients at least three years of age or older.	07/29/2003	07/29/2010	Schering Corporation	2000 Galloping Hill Road		Kenilworth	New Jersey	7033	USA
ribavirin elaidate	n/a	9/2/11	"Treatment of follicular, medullary, and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer"	Designated			N/A	N/A	"Translational Therapeutics, Inc."	163 Scituate Street		Arlington	Massachusetts	2476	USA
riboflavin ophthalmic solution & ultraviolet A	Photrexa Viscous	9/2/11	Treatment of keratoconus	Designated/Approved	Approved for Orphan Indication	Treatment of progressive keratoconus	04/15/2016	04/15/2023	"Avedro, Inc."	230 Third Avenue		Waltham	Massachusetts	2451	USA
riboflavin ophthalmic solution ultraviolet-A (UVA) irradiation	Photrexa Viscous	12/2/11	Treatment of corneal ectasia following refractive surgery	Designated/Approved	Approved for Orphan Indication	Treatment of corneal ectasia following refractive surgery	07/15/2016	07/15/2023	"Avedro, Inc."	230 Third Avenue		Waltham	Massachusetts	2451	USA
riboflavin-vitamin E-TPGS topical solution	Ribocross	11/8/16	Treatment of keratoconus in patients undergoing crosslinking procedure	Designated			N/A	N/A	Institute of Refractive & Ophthalmic Surgery	"Via Andrea D'Isernia 31,"		Napoli			Italy
Ricin (blocked) conjugated murine mca (anti-b4)	n/a	1/24/91	For the ex-vivo purging of leukemic cells from the bone marrow of non-T cell acute lymphocytic leukemia patients who are in complete remission.	Designated/Withdrawn			N/A	N/A	"ImmunoGen, Inc."	830 Winter Street		Waltham	Massachusetts	2451	USA
Ricin (blocked) conjugated murine MCA (anti-B4)	n/a	11/17/88	Treatment of B-cell leukemia and B-cell lymphoma.	Designated/Withdrawn			N/A	N/A	"ImmunoGen, Inc."	148 Sidney Street		Cambridge	Massachusetts	2139	USA
Ricin (blocked) conjugated murine MCA (anti-my9)	n/a	2/1/90	For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia.	Designated/Withdrawn			N/A	N/A	"ImmunoGen, Inc."	830 Winter Street		Waltham	Massachusetts	2451	USA
Ricin (blocked) conjugated murine MCA (anti-my9)	n/a	8/3/89	"Treatment of myeloid leukemia, including AML, and blast crisis of CML."	Designated/Withdrawn			N/A	N/A	"ImmunoGen, Inc."	830 Winter Street		Waltham	Massachusetts	2451	USA
Ricin (blocked) conjugated murine MCA (n901)	n/a	1/25/91	Treatment of small cell lung cancer	Designated/Withdrawn			N/A	N/A	"ImmunoGen, Inc."	830 Winter Street		Waltham	Massachusetts	2451	USA
Ricin (blocked) conjugated murine monoclonal antibody (CD6)	n/a	9/6/94	"Treatment of cutaneous T-cell lymphomas, acute T-cell leukemia-lymphoma, and related mature T-cell malignancies."	Designated/Withdrawn			N/A	N/A	"ImmunoGen, Inc."	830 Winter Street		Waltham	Massachusetts	2451	USA
ricin vaccine	Rivax(R)	1/7/11	Prevention of ricin intoxication.	Designated			N/A	N/A	"Soligenix, Inc."	29 Emmons Drive	Suite C-10	Princeton	New Jersey	8540	USA
ridaforolimus	n/a	8/12/05	Treatment of soft tissue sarcoma	Designated/Withdrawn			N/A	N/A	Merck Sharp & Dohme Corp.	"Merck & Co., Inc. Subsidiary"	"P. Box 1000, UG-2C50"	North Wales	Oregon	19454	USA
Rifabutin	Mycobutin	12/18/89	Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.	Designated/Approved	Approved for Orphan Indication	Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections.	12/23/1992	12/23/1999	"Adria Laboratories, Inc."	P.O. Box 16529		Columbus	Ohio	43216	USA
Rifabutin	n/a	12/18/89	Treatment of disseminated Mycobacterium avium complex disease.	Designated			N/A	N/A	Pfizer Inc.	235 East 42nd Street		New York	New York	10017	USA
Rifalazil	n/a	4/13/99	Treatment of pulmonary tuberculosis.	Designated			N/A	N/A	PathoGenesis Corporation	201 Elliott Avenue West	Suite 150	Seattle	Washington	98119	USA
Rifampin	Rifadin I.V.	12/9/85	For antituberculosis treatment where use of the oral form of the drug is not feasible.	Designated/Approved	Approved for Orphan Indication		05/25/1989	05/25/1996	Hoechst Marion Roussel	P.O. Box 9627		Kansas City	Missouri	64134	USA
"Rifampin, isoniazid, pyrazinamide"	Rifater	9/12/85	For the short-course treatment of tuberculosis.	Designated/Approved	Approved for Orphan Indication	Short-course treatment of tuberculosis.	05/31/1994	05/31/2001	Hoechst Marion Roussel	P.O. Box 9627		Kansas City	Missouri	64134	USA
Rifapentine	Priftin	6/9/95	Treatment of pulmonary tuberculosis.	Designated/Approved	Approved for Orphan Indication		06/22/1998	06/22/2005	Hoechst Marion Roussel	P.O. Box 9627	Mail Station: H3-M2516	Kansas City	Missouri	64134	USA
Rifapentine	Priftin	3/12/96	Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.	Designated			N/A	N/A	"Hoechst Marion Roussel, Inc."	P.O. Box 9627	Mail Station: H3-M2516	Kansas City	Missouri	64134	USA
Rifapentine	Priftin	6/9/95	Treatment of Mycobacterium avium complex in patients with AIDS.	Designated			N/A	N/A	"Hoechst Marion Roussel , Inc."	P.O. Box 9627	Mail Station: H3-M2516	Kansas City	Missouri	64134	USA
rifaximin	Normix	2/10/98	Treatment of hepatic encephalopathy	Designated/Approved	Approved for Orphan Indication	Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age	03/24/2010	03/24/2017	"Salix Pharmaceuticals, Inc."	400 Somerset Corporate Blvd		Somerset	New Jersey	8807	USA
rigosertib	n/a	3/18/11	Treatment of pancreatic cancer.	Designated			N/A	N/A	"Onconova Therapeutics, Inc"	375 Pheasant Run		Newtown	Pennsylvania	18940	USA
rigosertib	n/a	3/16/12	Treatment of ovarian cancer	Designated			N/A	N/A	"Onconova Therapeutics, Inc."	375 Pheasant Run		Newton	Pennsylvania	18940	USA
rigosertib	n/a	9/3/09	Treatment of myelodysplastic syndromes	Designated			N/A	N/A	"Onconova Therapeutics, Inc."	375 Pheasant Run		Newtown	Pennsylvania	18940	USA
RII retinamide	n/a	5/6/93	Treatment of myelodysplastic syndromes.	Designated			N/A	N/A	"Sparta Pharmaceuticals, Inc."	111 Rock Road		Horsham	Pennsylvania	19044	USA
rilonacept	Arcalyst	1/9/13	Treatment of familial Mediterranean fever	Designated			N/A	N/A	"Philip J Hashkes, MD, MSc."	"Head, Section of Pediatric Rheumatology"	9500 Euclid Avenue	Cleveland	Ohio	44195	USA
Rilonacept	Arcalyst	12/20/04	Treatment of CIAS1-Associated Periodic Syndromes	Designated/Approved	Approved for Orphan Indication	Treatment of Cryopyrin-Assisted Periodic Syndromes (CAPS)	02/27/2008	02/27/2015	"Regeneron Pharmaceuticals, Inc."	777 Old Saw Mill River Road		Tarrytown	New York	10591	USA
rilotumumab	n/a	6/18/12	Treatment of gastric cancer including gastroesophageal junction adenocarcinoma	Designated/Withdrawn			N/A	N/A	"Amgen, Inc."	One Amgen Center Drive	M/S 17-2-B	Thousand Oaks	California	91320	USA
Riluzole	Rilutek	3/16/93	Treatment of amyotrophic lateral sclerosis.	Designated/Approved	Approved for Orphan Indication	Treatment of patients with amyotrophic lateral sclerosis. Riluzole extends survival and/or time to tracheostomy.	12/12/1995	12/12/2002	"Rhone-Poulenc Rorer Pharmaceuticals, Inc."	"500 Arcola Road, P.O. Box 1200"		Collegeville	Pennsylvania	19426	USA
riluzole	n/a	2/23/16	Treatment of spinocereballar ataxia.	Designated			N/A	N/A	"Biohaven Pharmaceutical Holding Company, Ltd."	234 Church Street	Suite 304	New Haven	Connecticut	6511	USA
Riluzole	Rilutek	10/15/96	Treatment of Huntington's disease.	Designated			N/A	N/A	"Rhone-Poulenc Rorer Pharmaceuticals, Inc."	500 Arcola Road	PO Box 5096	Collegeville	Pennsylvania	19426	USA
riluzole oral suspension	Teglutik	9/15/16	Treatment of amyotrophic lateral sclerosis (ALS).	Designated			N/A	N/A	Italfarmaco SpA	54 Via dei Lavoratori		Cinisello Balsamo			Italy
riluzole orally disolving tablet	n/a	11/30/16	Treatment of amyotrophic lateral sclerosis (ALS)	Designated			N/A	N/A	"Biohaven Pharmaceutical Holding Company, Ltd"	234 Church Street	Suite 304	New Haven	Connecticut	6511	USA
rindopepimut	n/a	11/19/07	Treatment of EGFRvIII-expressing glioblastoma multiforme	Designated			N/A	N/A	"Celldex Therapeutics, Inc."	119 Fourth Avenue		Needham	Massachusetts	2494	USA
riociguat	Adempas	9/19/13	Treatment of chronic thromboembolic pulmonary hypertension	Designated/Approved	Approved for Orphan Indication	"Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) WHO Group 4, after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class"	10/08/2013	10/08/2020	"Bayer HealthCare Pharmaceuticals, Inc."	100 Bayer Blvd.		Whippany	New Jersey	7981	USA
riociguat	Adempas	9/19/13	Treatment of pulmonary arterial hypertension.	Designated/Approved	Approved for Orphan Indication	"Treatment of adults with pulmonary arterial hypertension (PAH) WHO Group 1, to improve exercise capacity, WHO functional class and to delay clinical worsening."	10/08/2013	10/08/2020	"Bayer HealthCare Pharmaceuticals, Inc."	100 Bayer Blvd.		Whippany	New Jersey	7981	USA
riociguat	Adempas	7/24/14	Treatment of systemic sclerosis	Designated			N/A	N/A	Bayer HealthCare Pharmaceuticals	100 Bayer Blvd	P. O. Box 915	Whippany	New Jersey	7981	USA
risankizumab	n/a	11/29/16	Treatment of pediatric Crohn's disease	Designated			N/A	N/A	AbbVie Inc.	Regulatory Affair	1 North Waukegan Road	North Chicago	Illinois	60044	USA
risedronate sodium	Actonel	12/18/06	Treatment of patients with osteogenesis imperfecta.	Designated/Withdrawn			N/A	N/A	Warner Chilcott Pharmaceuticals	100 Enterprise Drive		Roakaway	New Jersey	7866	USA
Ritonavir powder for oral suspension	Norvir Powder For Oral Suspension	1/11/17	Use with other antiretroviral agents for the treatment of pediatric HIV-1 infection	Designated			N/A	N/A	AbbVie Inc.	Regulatory Affairs	1 Waukegan Road	North Chicago	Illinois	60044	USA
rituximab	Rituxan(R); Mabthera(R)	2/23/15	Treatment of pemphigus vulgaris.	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California		United States Minor Outlying Islands
rituximab	Rituxan	6/13/94	Treatment of non-Hodgkin's B-cell lymphoma	Designated/Approved	Approved for Orphan Indication		11/26/1997	11/26/2004	"Genentech, Inc."	"1 DNA Way, MS 242"		South San Francisco	California	94080	USA
rituximab	n/a	11/9/16	Treatment of Rasmussen's encephalitis	Designated			N/A	N/A	Keck Graduate Institute of Applied Life Sciences	535 Watson Drive		Claremont	California	91711	USA
rituximab	Rituxan	2/14/06	"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)"	Designated/Approved	Approved for Orphan Indication	For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). )	04/19/2011	04/19/2018	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
rituximab	Rituxan	1/29/04	Treatment of chronic lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide	02/18/2010	02/18/2017	"Genentech, Inc."	1DNA Way	MS 241A	South San Francisco	California	94080	USA
rituximab	Rituxan	3/12/02	Treatment of immune thrombocytopenic purpura	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
rituximab and recombinant human hyaluronidase	Rituxin Sc	8/22/16	Treatment of chronic lymphocytic leukemia (CLL)	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
rituximab and recombinant human hyaluronidase	n/a	8/22/16	Treatment of follicular lymphoma	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
Rituximab/hyaluronidase	Rituxan	9/7/16	Treatment of diffuse large B-cell lymphoma	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
rociletinib	n/a	5/14/13	Treatment of non-small cell lung cancer and mutations in the epidermal growth factor receptor	Designated			N/A	N/A	"Clovis Oncology, Inc."	5500 Flatiron Parkway	Suite 100	Boulder	Colorado	80301	USA
rofecoxib	Vioxx	3/16/04	Treatment of juvenile rheumatoid arthritis	Designated			N/A	N/A	"MERCK & Co., Inc."	126 East Lincoln Ave.		Rahway	New Jersey	7065	USA
romidepsin	Istodax	9/30/04	Treatment of non-Hodgkin T-cell lymphomas	Designated/Approved	Approved for Orphan Indication	Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy	06/16/2011	06/16/2018	Celgene Corporation	One Broadway	14th Floor	Cambridge	Massachusetts	2142	USA
romidepsin	Istodax	9/30/04	Treatment of non-Hodgkin T-cell lymphomas	Designated/Approved	Approved for Orphan Indication	Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy	11/05/2009	11/05/2016	Celgene Corporation	One Broadway	14th Floor	Cambridge	Massachusetts	2142	USA
romiplostim	n/a	10/31/07	Treatment of thrombocytopenia associated with myelodysplasia syndrome	Designated			N/A	N/A	Amgen Inc.	One Amgen Center Drive	Mail Stop 17-2-B	Thousand Oaks	California	91320	USA
romiplostim	Nplate	3/27/03	Treatment of immune thrombocytopenic purpura	Designated/Approved	Approved for Orphan Indication	"Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy"	08/22/2008	08/22/2015	"Amgen, Inc."	One Amgen Center Drive		Thousand Oaks			
roneparstat	n/a	3/19/15	Treatment of multiple myeloma	Designated			N/A	N/A	Sigma-Tau Research Switerland S.A.	Via Motta 2	CH-6850 Mendrisio				Switzerland
ropidoxuridine (5-iodo-2-pyrimidinone-2'-deoxyribose)	n/a	5/19/16	Radiosensitizer to be used during radiation treatment of glioblastoma multiforme.	Designated			N/A	N/A	"EMEK, Inc."	196 Channel View		Warwick	Rhode Island	2889	USA
Roquinimex	Linomide	7/1/93	To prolong time to relapse in leukemia patients who have undergone autologous bone marrow transplantation.	Designated/Withdrawn			N/A	N/A	Pharmacia & Upjohn	7000 Portage Road		Kalamazoo	Michigan	49001	USA
Rose Bengal Disodium	n/a	12/21/06	Treatment of metastatic melanoma	Designated			N/A	N/A	"Provectus Pharmaceuticals, Inc."	7327 Oak Ridge Highway		Knoxville	Tennessee	37931	USA
Roseburia hominis	Rosburix	8/4/14	Treatment of ulcerative colitis in pediatric patients age 0 through 16 years	Designated			N/A	N/A	4D Pharma Research Ltd	Life Sciences Innovation Bldg	Cornhill Road				United Kingdom
Rosomidnar	n/a	3/10/16	Treatment of diffuse large B-cell lymphoma.	Designated/Withdrawn			N/A	N/A	"ProNAi Therapeutics, Inc."	46701 Commerce Center Drive		Plymouth	Michigan	48170	USA
rosuvastatin	Crestor	2/14/14	For the treatment of pediatric homozygous familial hypercholesterolemia	Designated/Approved	Approved for Orphan Indication	"An adjunct to diet to reduce LDL-C, Total-C, nonHDL-C and ApoB in children and adolescents 7 to 17 years of age with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments (e.g., LDL apheresis)."	05/27/2016	05/27/2023	"iPR Pharmaceuticals, Inc."	1 MedImmune Way		Gaithersburg	Maryland	20878	USA
rovalpituzumab tesirine	n/a	12/22/15	Treatment of small cell lung cancer	Designated			N/A	N/A	AbbVie Inc.	"Dept. PA77, Bldg. AP30-1"	1 Waukegan Road	Lake Bluff	Illinois	60044	USA
rozrolimupab	n/a	9/13/10	Treatment of primary immune thrombocytopenia.	Designated			N/A	N/A	Symphogen A/S	"Elektrovey, Building 375"					Denmark
rsATP7A cDNA	n/a	1/10/14	Treatment of Menkes disease	Designated			N/A	N/A	"Stephen G. Kaler, MD"	"Translational Neuroscience, Molecular Med. Program"	"10 Center Drive, MSC 1853"	Bethesda	Maryland	20892	USA
rSP-C lung surfactant	Venticute	4/3/00	Treatment of adult respiratory distress syndrome.	Designated			N/A	N/A	Byk Gulden Pharmaceuticals	Byk-Gulden StraBe 2	78467 Konstanz				Germany
rSP-C surfactant	Venticute	9/18/06	"For use in patients with pneumonia or aspiration of gastric contents leading to intubation, mechanical ventilation, and severe oxygen impairment"	Designated			N/A	N/A	Altana Pharma	220 Park avenue		Florham Park	New Jersey	7932	USA
rt-PA	Activase	10/20/14	Treatment of plastic bronchitis	Designated			N/A	N/A	"Kathleen A Stringer, PharmD, FCCP - Professor"	University of MI	428 Church St.	Ann Arbor	Michigan	48109	USA
rubitecan	n/a	7/17/02	Treatment of pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndrome	Designated			N/A	N/A	"SuperGen, Inc."	4140 Dublin Blvd.	Suite 200	Dublin	California	94568	USA
rucaparib	Rubraca	7/31/12	Treatment of ovarian cancer	Designated/Approved	Approved for Orphan Indication	As monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies	12/19/2016	12/19/2023	"Clovis Oncology, Inc."	5500 Flatiron Parkway	Suite 100	Boulder	Colorado	80301	USA
rufinamide	Banzel	10/8/04	Treatment of Lennox-Gastaut Syndrome.	Designated/Approved	Approved for Orphan Indication	Adjunctive therapy of seizures associated with Lennox-Gastaut syndrome.	11/14/2008	11/14/2015	"Eisai, Inc."	300 Tice Blvd		Woodcliff Lake	New Jersey	7677	USA
Ruxolitinib	n/a	7/18/16	Treatment of acute lymphoblastic leukemia.	Designated			N/A	N/A	Incyte Corporation	1801 Augustine Cut-off		Wilmington	Delaware	19803	USA
ruxolitinib	Jakafi	11/3/16	Treatment of graft versus host disease	Designated			N/A	N/A	Incyte Corporation	1801 Augustine Cut-Off		Wilmington	Delaware	19803	USA
ruxolitinib	Jakafi	8/16/13	Treatment of pancreatic cancer	Designated			N/A	N/A	Incyte Corporation	Experimental Station	"Bldg 400, Rm 6220A"	Wilmington	Delaware	19880	USA
ruxolitinib	Jakafi	3/26/10	Treatment of polycythemia vera	Designated/Approved	Approved for Orphan Indication	Treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.	12/04/2014	12/04/2021	Incyte Corporation	1801 Augustine Cut-Off		Wilmington	Delaware	19803	USA
ruxolitinib phosphate	Jakafi	3/22/10	Treatment of essential thrombocythemia	Designated			N/A	N/A	Incyte Corporation	1801 Augustine Cut-Off		Wilmington	Delaware	19803	USA
ruxolitinib phosphate	Jakafi	9/5/08	Treatment of myelofibrosis	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis"	11/16/2011	11/16/2018	Incyte Corporation	1801 Augustine Cut-Off		Wilmington	Delaware	19803	USA
rVIIa-FP	n/a	12/22/11	Treatment and prophyllaxis of bleeding episodes in patients with congenital hemophilia and inhibitors to coagulation factor VIII or IX	Designated			N/A	N/A	CSL Behring	1020 First Avenue	P. O. Box 61501	King of Prussia	Pennsylvania	19406	USA
S(-)-3-[3-amino-phthalimido]-glutaramide	n/a	3/14/02	Treatment of multiple myeloma	Designated			N/A	N/A	EntreMed Incorporated	9640 Medical Center Dr.		Rockville	Maryland	20850	USA
S-59 treated FFP (plasma treated with amotosalen hydrochloride & ultraviolet A light	Intercept Blood System For	2/14/11	Treatment of thrombotic thrombocytopenic purpura	Designated			N/A	N/A	Cerus Corporation	2550 Stanwell Drive		Concord	California	94520	USA
S-adenosylmethionine	n/a	4/30/98	Treatment of AIDS-myelopathy.	Designated			N/A	N/A	"Genopia USA, Inc."	"90 Gold Street, 6N"		New York	New York	10038	USA
S-ethylisothiourea diethylphosphate	n/a	8/29/16	"Treatment of symptomatic intradialytic hypotension, including symptomatic hypotension in the immediate post-dialytic period."	Designated			N/A	N/A	"TrioxBio, Inc."	P. O. Box 1000		Wilmington	Delaware	19801	USA
S-nitrosoglutathione	n/a	5/12/09	Management of cystic fibrosis patients to improve airway clearance and to improve or stabilize pulmonary function	Designated			N/A	N/A	"N30 PHARMAceuticals, LLC"	3122 Sterling Circle		Boulder	Colorado	80301	USA
S-nitrosoglutathione	n/a	12/28/12	Treatment of severe preeclampsia	Designated			N/A	N/A	Salupont Consulting Ltd	"The Old Quarters, Hazells Hall"	"Everton Road, Sandy"	Bedfordshire SG19 2DD			United Kingdom
"S-[2,3-bispalmitoyloxy-(2R)-propyl]-cysteinly-GNNDESNISFKEK"	n/a	10/20/09	Treatment of pancreatic cancer	Designated			N/A	N/A	MBiotec GmBH	"Hohenweg 13, D-82229 Seefeld"					Germany
"S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide"	n/a	11/16/15	Treatment of C3 glomerulopathy.	Designated			N/A	N/A	Amyndas Pharmaceuticals	N.Zerva 28		Glyfada			Greece
"S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)"	n/a	10/9/14	Treatment of paroxysmal nocturnal hemoglobinuria (PNH)	Designated			N/A	N/A	Amyndas Pharmaceuticals	N.Zerva 28		Glyfada			Greece
sacituzumab govitecan	n/a	5/29/14	Treatment of pancreatic cancer.	Designated			N/A	N/A	"Immunomedics, Inc."	300 The American Road		Morris Plains	New Jersey	7950	USA
sacituzumab govitecan	n/a	11/27/13	Treatment of small cell lung cancer	Designated			N/A	N/A	"Immunomedics, Inc."	300 The American Road		Morris Plains	New Jersey	7950	USA
Sacrosidase	Sucraid	12/10/93	Treatment of congenital sucrase-isomaltase deficiency	Designated/Approved	Approved for Orphan Indication	"Oral replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrease-isomaltase deficiency."	04/09/1998	04/09/2005	"QOL Medical, LLC"	4445 North Highway	"A1A, 241"	Vero Beach	Florida	32963	USA
salicylic acid 6%	n/a	2/17/12	Treatment of rare congenital ichthyoses.	Designated			N/A	N/A	"Orenova Group, LLC"	10 New King Street	Suite 106	White Plains	New York	10604	USA
salirasib	n/a	12/18/06	Treatment of pancreatic cancer.	Designated			N/A	N/A	"Kadmon Corporation, LLC"	450 East 29th Street	5th Floor	New York	New York	10016	USA
salmeterol xinafoate/fluticasone propionate	n/a	10/29/09	Treatment of symptomatic exophthalmos associated with thyroid related eye disease	Designated			N/A	N/A	"Lithera, Inc."	9191 Towne Center Drive		San Diego	California	92122	USA
saposin C	n/a	2/3/15	Treatment of glioblastoma multiforme	Designated			N/A	N/A	"Bexion Pharmaceuticals, LLC"	632 Russell St.		Covington	Kentucky	41011	USA
sapropterin	Kuvan	1/29/04	Treatment of hyperphenylalaninemia	Designated/Approved	Approved for Orphan Indication	Indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet.	12/13/2007	12/13/2014	"BioMarin Pharmaceutical, Inc."	105 Digital Drive		Novato	California	94949	USA
"Sar9, Met(O2)11-Substance P"	Homspera	3/16/11	Treatment of idiopathic pulmonary fibrosis	Designated			N/A	N/A	"ImmuneRegen BioSciences, Inc."	"IR Biosciences Holdings, Inc"		Scottsdale	Arizona	85258	USA
sarcosine	n/a	10/12/11	Treatment of obsessive compulsive disorder in pediatric patients (0 to 16 years of age)	Designated			N/A	N/A	"Guochuan Emil Tsai, MD, PhD"	"David Geffen School of Medicine, UCLA"	"1000 W., Carson St."	Torrance	California	90502	USA
Sargramostim	Leukine	3/6/95	To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.	Designated/Approved	Approved for Orphan Indication	Following induction chemotherapy in older adult patients with acute myelogenous leukemia to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death.	09/15/1995	09/15/2002	Immunex Corporation	51 University Street		Seattle	Washington	98101	USA
sargramostim	Leukine	11/9/16	Treatment of individuals acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome)	Designated			N/A	N/A	Sanofi Genzyme	500 Kendall Street		Cambridge	Massachusetts	2142	USA
Sargramostim	Leukine	5/3/90	"Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment."	Designated/Approved	Approved for Orphan Indication		03/05/1991	03/05/1998	Immunex Corporation	51 University Street		Seattle	Washington	98101	USA
sarizotan	n/a	7/7/15	Treatment of Rett syndrome.	Designated			N/A	N/A	"Newron Pharmaceuticals US, Inc."	89 Headquarter Plaza North	Suite 1438	Morristown	New Jersey	7960	USA
sarsasapogenin	n/a	6/18/04	Treatment of amyotrophic lateral sclerosis (ALS)	Designated/Withdrawn			N/A	N/A	Phytopharm plc	Corpus Christi House	"Godmanchester, Cambridgeshire PE29 2HY"				United Kingdom
Satumomab pendetide	Oncoscint Cr/Ov	9/25/89	Detection of ovarian carcinoma.	Designated/Approved	Approved for Orphan Indication	For determining the extent and location of extraphepatic malignant disease in patients with known colorectal and ovarian cancer.	12/29/1992	12/29/1999	Cytogen Corporation	600 College Road East		Princeton	New Jersey	8540	USA
SC-1 monoclonal antibody	n/a	11/12/03	Treatment of patients with CD55 (sc-1) positive gastric tumors	Designated			N/A	N/A	Patrys Limited	"Suite 614, Level 6, Equitable House"	"Melbourne, Victoria 3000"				Australia
SDF-1 (108) Lysine Dlmer	n/a	7/7/05	Treatment of osteogenic sarcoma	Designated			N/A	N/A	Chemokine Therapeutics Corporation	190 Agronomy Road (UBC)	Suite 405	"Vancouver, BC V6T 1Z3"			Canada
sdTD-K6a.513a.12; small interfering RNA composed of 2 strands of hybridized RNAs	n/a	4/15/13	Treatment of pachyonychia congenita	Designated			N/A	N/A	"TransDerm, Inc."	2161 Delaware Avenue		Santa Cruz		95060	USA
sebelipase alfa	Kanuma	7/1/10	Treatment of lysosomal acid lipase deficiency	Designated/Approved	Approved for Orphan Indication	Indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency	12/08/2015	12/08/2022	Alexion Pharmaceuticals	100 College Street		New Haven	Connecticut	6510	USA
Secalciferol	Osteo-D	7/26/93	Treatment of familial hypophosphatemic rickets.	Designated			N/A	N/A	Teva Pharmaceuticals USA	1090 Horsham Road		North Wales	Pennsylvania	19454	USA
Secretory leukocyte protease inhibitor	n/a	6/30/92	Treatment of bronchopulmonary dysplasia.	Designated			N/A	N/A	"Synergen, Inc."	1885 33rd Street		Boulder	Colorado	80301	USA
secukinumab	n/a	3/26/10	Adjunctive treatment of chronic non-infectious uveitis requiring systemic immunosuppression	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceutical Corporation	One Health Plaza	Bldg 404/470	East Hanover	New Jersey	7936	USA
selective antagonist of the chemokine receptor type 4	n/a	9/5/13	Treatment of acute myeloid leukemia	Designated			N/A	N/A	"BioLineRx, Ltd."	Modi'in Technology Park	2 HaMa'ayan Street	Modi'in			Israel
selective deacylglycerol acyltransferase 1 inhibitor	n/a	3/28/11	"Treatment of hypertriglyceridemia in te setting of Type I hyperlipoproteinemia, also known as Familial Chylomicronemia Syndrome"	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
selective inhibitor of fungal CYP51	n/a	3/3/16	Treatment of coccidioidomycosis.	Designated			N/A	N/A	"Viamet Pharmaceuticals, Inc."	4505 Emperor Boulevard	Suite 300	Durham	North Carolina	27703	USA
selective inhibitor of fungal lanosterol demethylase	n/a	8/19/14	Treatment of cryptococcal meningitis	Designated			N/A	N/A	"Viamet Pharmaceuticals, Inc."	4505 Emperor Blvd	Suit 300	Durham	North Carolina	27703	USA
Selective inhibitor of polymorphonuclear leukocyte (PMN) elastase	n/a	6/4/96	Therapeutic management of patients with lung disease attributable to cystic fibrosis.	Designated			N/A	N/A	DuPont Pharmaceuticals Company	"Chestnut Run, Maple Run"	Centre Rd.	Wilmington	Delaware	19805	USA
Selegiline HCl	Eldepryl	11/7/84	"As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism."	Designated/Approved	Approved for Orphan Indication		06/05/1989	06/05/1996	"Somerset Pharmaceuticals, Inc."	"400 Morris Ave., Suite 7s"		Denville	New Jersey	7834	USA
selexipag	Uptravi	4/30/10	Treatment of pulmonary arterial hypertension	Designated/Approved	Approved for Orphan Indication	"For use of Uptravi (Selexipag) Tablets, 200, 400, 600, 800, 1000, 1200, 1400, and 1600 mcg for treatment of pulmonary arterial hypertension (PAH, WHO Group I) to reduce the risks of disease progression and hospitalization for PAH"	12/21/2015	12/21/2022	Actelion Ltd	Gewerbestrasse 16		Allschwil CH-4123			Switzerland
"self-complimentary adeno-associated virus vector, serotype 9, packaging the full lenght GAN gene in the viral capsid"	n/a	9/27/13	Treatment of Giant Axonal Neuropathy	Designated			N/A	N/A	Hannah's Hope Fund	19 Blue Jay Way		Rexford	New York	12148	USA
selinexor	n/a	1/5/15	Treatment of multiple myeloma	Designated			N/A	N/A	"Karyopharm Therapeutics, Inc."	85 Wells Avenue		Newton	Maryland	2459	USA
selinexor	n/a	7/7/16	Treatment of soft tissue sarcoma	Designated			N/A	N/A	"Karyopharm Therapeutics, Inc."	85 Wells Avenue		Newton	Maryland	2459	USA
"Selinexor; (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide"	n/a	5/14/14	Treatment of acute myeloid leukemia	Designated			N/A	N/A	"Karyopharm Therapeutics, Inc."	2 Mercer Road		Natick	Massachusetts	1760	USA
selisistat	n/a	12/7/09	Treatment of Huntington's disease	Designated			N/A	N/A	Siena Biotech SpA	"35, Strada del Petriccio e Belriguardo"					Italy
selumetinib	n/a	4/15/15	Treatment of uveal melanoma.	Designated/Withdrawn			N/A	N/A	AstraZeneca Pharmaceuticals LP	1800 Concord Pike	P. O. Box 8355	Wilmington	Delaware	19803	USA
selumetinib	n/a	5/10/16	Adjuvant treatment of patients with stage III or stage IV differentiated thyroid cancer.	Designated			N/A	N/A	AstraZeneca Pharmaceuticals LP	1800 Concord Pike	P. O. Box 8355	Wilmington	Delaware	19803	USA
Seneca Valley virus	n/a	8/22/08	Treatment of neuroendocrine tumors	Designated			N/A	N/A	"Neotropix, Inc."	351 Phoenixville Pike		Malvern	Pennsylvania	19355	USA
Sermorelin acetate	Geref	2/13/90	Adjunct to gonadotropin therapy in the induction of ovulation in women with anovulatory or oligo-ovulatory infertility who fail to ovulate in response to adequate treatment with clomiphene citrate alone and gonadotropin therapy alone.	Designated/Withdrawn			N/A	N/A	"EMD Serono, Inc."	One Technology Place		Rockland	Massachusetts	2370	USA
Sermorelin acetate	Geref	12/5/91	Treatment of AIDS-associated catabolism/weight loss.	Designated/Withdrawn			N/A	N/A	"EMD Serono, Inc."	One Technology Place		Rockland	Massachusetts	2370	USA
Sermorelin acetate	Geref	9/14/88	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	Designated/Approved	Approved for Orphan Indication		09/26/1997	09/26/2004	"EMD Serono, Inc."	One Technology Place		Roackland	Massachusetts	2370	USA
Serratia marcescens extract (polyribosomes)	Imuvert	9/7/88	Treatment of primary brain malignancies.	Designated			N/A	N/A	"Cell Technology, Inc."	1668 Valtec Lane		Boulder	Colorado	80306	USA
setmelanotide	n/a	4/4/16	Treatment of pro-opiomelanocortin (POMC) deficiency due to mutations in the POMC gene	Designated			N/A	N/A	"Rhythm Pharmaceuticals, Inc."	855 Boylston Street	11th Floor	Boston	Massachusetts	2116	USA
setmelanotide	n/a	9/21/15	Treatment of Prader-Willi Syndrome.	Designated			N/A	N/A	"Rhythm Metabolics, Inc."	855 Boylston Street	11th Floor	Boston	Massachusetts	2116	USA
sevuparin	n/a	3/17/15	Treatment of sickle cell disease	Designated			N/A	N/A	Dilaforette AB	Retzius vag 8	SE-171 Solna				Sweden
Short chain fatty acid enema	Colomed	8/19/97	Treatment of chronic radiation proctitis.	Designated			N/A	N/A	"Richard I. Breuer, M.D."	"1000 Central Street, Suite 615"		Evanston	Illinois	60201	USA
Short chain fatty acid solution	Colomed	5/29/90	Treatment of the active phase of ulcerative colitis with involvement restricted to the left side of the colon.	Designated			N/A	N/A	Richard I. Breuer	"1000 Central Street, Suite 615"		Evanston	Illinois	60201	USA
sildenafil	Revatio	7/28/11	Treatment of pediatric (defined as children less than 17 years of age) pulmonary arterial hypertension	Designated			N/A	N/A	"Pfizer, Inc."	Worldwide Regulatory strategy		New York	New York	10017	USA
"silibinin-C-2',3-dihydrogensuccinate, disodium salt"	Legalon(R) Sil	9/11/14	"Treatment of amatoxin poisoning, which includes the prevention and treatment of amatoxin induced hepatic failure"	Designated			N/A	N/A	"Meda Pharmaceuticals, Inc."	265 Davidson Avenue		Somerset	New Jersey	8873	USA
"Silibinin-C-2',3-dihydrogensuccinate, disodium salt"	Legalon Sil	2/17/12	Prevention of recurrent hepatitis C in liver transplant patients	Designated			N/A	N/A	Meda AB	"Pipers Vg 2A,"	Box 906	Solna			Sweden
Silmitasertib	n/a	12/22/16	Treatment of cholangiocarcinoma	Designated			N/A	N/A	"Senhwa Biosciences, Inc."	"No. 205-1, Peihsin Road"	Section 3	New Taipei City			Taiwan
siltuximab	n/a	10/11/05	Treatment of multiple myeloma	Designated/Withdrawn			N/A	N/A	"Janssen Research & Development, LLC"	920 Route 202 South		Raritan	New Jersey	8869	USA
siltuximab	Sylvant	5/26/06	Treatment of Castleman's disease	Designated/Approved	Approved for Orphan Indication	Treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.	04/23/2014	04/23/2021	"Janssen Biotech, Inc."	920 Route 202 South	PO Box 300	Raritan	New Jersey	8869	USA
Silver sulfadiazine and cerium nitrate	Flammacerium	11/17/99	Treatment of patients with severe dermal burns	Designated			N/A	N/A	Alliance Pharmaceuticals Ltd	Avonbridge House	"Bath Road, Chippenham"	"Wiltshire, SN15 2BB"			United Kingdom
simtuzumab	n/a	1/5/15	Treatment of primary sclerosing cholangitis	Designated			N/A	N/A	"Gilead Sciences, Inc."	333 Lakeside Drive		Foster City	California	94404	USA
"single stranded, chemically modified oligonucleotide that binds to and inhibits the function of micro RNA-21"	n/a	7/17/14	Treatment of Alport syndrome	Designated			N/A	N/A	"Regulus Therapeutics, Inc."	3545 John Hopkins Court	Suite 210	San Diego		92121	USA
siplizumab	n/a	7/15/03	Treatment of T-cell lymphomas	Designated/Withdrawn			N/A	N/A	"MedImmune, LLC"	One MedImmune Way		Gaithersburg		20878	USA
siponimod	n/a	7/10/14	Treatment of dermatomyositis	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
Siponimod	n/a	11/26/13	Treatment of polymyositis	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA
sirolimus	n/a	6/25/14	Treatment of lymphangioleiomyomatosis	Designated			N/A	N/A	"LAM Therapeutics, Inc."	530 Old Whitfield Street		Guilford	Connecticut		USA
sirolimus	n/a	3/18/13	Treatment of pachyonychia congenita	Designated			N/A	N/A	Palvella Therapeutics LLC	515 Red Fox Lane	Suite B	Wayne	Pennsylvania	19087	USA
sirolimus	Rapamune	10/31/12	Treatment of lymphangioleiomyomatosis	Designated/Approved	Approved for Orphan Indication	Treatment of lymphangioleiomyomatosis (LAM)	05/28/2015	05/28/2022	"Pfizer, Inc."	500 Arcola Road		Collegeville	Pennsylvania	19426	USA
sirolimus	n/a	6/21/16	Treatment of beta-thalassemia.	Designated			N/A	N/A	Rare Partners srl Impresa Sociale	31 Corso Magenta		Milano			Italy
sirolimus	n/a	11/17/11	Treatment of lymphangioleiomyomatosis	Designated			N/A	N/A	"Cote Orphan Consulting, LLC"	"8630 Fenton St., #222"		Silver Spring	Maryland	20910	USA
sirolimus	n/a	11/4/11	"Treatment of chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, noninfectious panuveitis and non-infectious, uveitis affecting the posterior of the eye (NICUPS)."	Designated			N/A	N/A	Santen Inc.	"2100 Powell St., 16th Floor"		Emeryville	California	94608	USA
sirolimus in an implantable collagen matrix	"Coll-R, Sirogen"	5/10/12	"Prevention of arteriovenous(AV) fistula or AV graft failure in patients with end stage renal disease, receiving hemodialysis or preparing for hemodialysis"	Designated			N/A	N/A	"Vascular Therapies, LLC"	105 Union Avenue		Cresskill	New Jersey	7626	USA
Sitaxsentan Sodium	n/a	11/2/04	For the treatment of pulmonary arterial hypertension in the absence of chronic obstructive pulmonary disease or congestive heart failure.	Designated			N/A	N/A	Pfizer Global Research and Development	50 Pequot Avenue 6025-B4137		New London	Connecticut	6320	USA
sitimagene ceradenovec	Cerepro	7/31/01	Use with gancyclovir in the treatment of malignant glioma	Designated			N/A	N/A	"Gliotherapy, Ltd."	Sanderum House	Oakley Road	London			United Kingdom
skin tissue	Stratagraft	5/21/12	Treatment of hospitalized patients with complex skin defects resulting from partial and full thickness skin burns requiring excision and grafting	Designated			N/A	N/A	Stratatech Corporation	505 S. Rosa Road	Suite 169	Madison	Wisconsin	53719	USA
Small molecule Ewing Sarcoma breakpoint region 1/Friend leukemia virus integration 1 fusion protein inhibitor	n/a	6/30/16	Treatment of Ewing sarcoma	Designated			N/A	N/A	"Tokalas, Inc."	P. O. Box 1269		Rancho Santa Fe	California	92067	USA
small molecule FGFR4 inhibitor	n/a	9/14/15	Treatment of hepatocellular cancer (HCC).	Designated			N/A	N/A	Blueprint Medicines Corporation	38 Sidney Street	Suite 200	Cambridge	Massachusetts	2139	USA
small molecule inhibitor of Exon 17 Mutant KIT	n/a	1/21/16	Treatment of mastocytosis	Designated			N/A	N/A	Blueprint Medicines Corporation	38 Sidney Street	Suite 200	Cambridge	Massachusetts	2139	USA
Small Molecule Inhibitor of Exon 17 mutant KIT	n/a	1/6/16	Treatment of gastrointestinal stromal tumors (GIST).	Designated			N/A	N/A	Blueprint Medicines Corporation	38 Sidney Street	Suite 200	Cambridge	Massachusetts	2139	USA
small molecule inhibitor of histone methyltransferase DOT1L	n/a	8/8/13	Treatment of acute lymphoblastic leukemia (ALL)	Designated			N/A	N/A	Epizyme Inc.	"400 Technology Square, 4th Floor"		Cambridge	Massachusetts	2139	USA
small molecule inhibitor of histone methyltransferase DOT1L	n/a	8/15/13	Treatment of Acute Myeloid Leukemia	Designated			N/A	N/A	Epizyme Inc.	"400 Technology Square, 4th Floor"		Cambridge	Massachusetts	2139	USA
small molecule inhibitor of phosphodiesterase 10	n/a	9/26/13	Treatment of Huntington's disease	Designated			N/A	N/A	Omeros Corporation	201 Elliott Avenue West		Seattle	Washington	98119	USA
small molecule normalizing the p53 function	n/a	6/12/14	Treatment of ovarian cancer	Designated			N/A	N/A	"Critical Outcome Technologies, Inc."	700 Collip Circle - Suite 213	"London, ON N6G 4X8"	London			Canada
smilagenin	Cogane	7/21/11	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	"Junaxo, Inc."	First Canadian Place	Suite 5600				Canada
sobetirome	n/a	4/29/11	Treatment of X-linked adrenoleukodystrophy	Designated			N/A	N/A	"NeuroVia, Inc."	332 Broadway	Suite 1	Cambridge	Massachusetts	2139	USA
"sodium 2, 2 dimethylbutyrate"	n/a	7/25/08	Treatment of sickle cell disease.	Designated			N/A	N/A	"HemaQuest Pharmaceuticals, Inc."	1001 Fourth Avenue	Suite 3317	Seattle	Washington	98154	USA
sodium 2-hydroxylinoleate	n/a	8/25/15	Treatment of neuroblastoma.	Designated			N/A	N/A	"Ability Pharmaceuticals, SL"	Edifici Eureka	Campus de la UAB	Bellaterra			Spain
sodium 2-hydroxylinoleate	n/a	11/23/16	Treatment of pancreatic cancer.	Designated			N/A	N/A	"Ability Pharmaceuticals, SL"	Edifici Eureka	Campus de la UAB	Bellaterra			Spain
sodium 4-phenylbutyrate	n/a	10/18/11	Treatment of spinal muscular atrophy	Designated			N/A	N/A	GMP-Orphan SAS	"7, rue du Pasteur Wagner"	F-75011	Paris			France
"sodium 4-{ [9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-d] [2] benzazepin-2-yl]-2-methoxybenzoate"	n/a	4/3/09	Treatment of ovarian cancer	Designated/Withdrawn			N/A	N/A	"Millennium Pharmaceuticals, Inc."	40 Landsdowne Street		Cambridge	Massachusetts	2139	USA
sodium alginate oligosaccharide	n/a	2/24/16	Treatment of cystic fibrosis.	Designated			N/A	N/A	AlgiPharma AS	Industriveien 33	N-1337	Sandvika			Norway
Sodium aluminosilicate	n/a	3/4/05	Treatment of chronic hepatic encephalopathy	Designated			N/A	N/A	Castle Creek Pharmaceuticals LLC	1033 Skokie Blvd	Suite 600	Northbrook	Illinois	60062	USA
Sodium ascorbate and menadione sodium bisulfite	Apatone	7/31/07	Treatment of metastatic or locally advanced inoperable transitional cell carcinoma of the urothelium (stage III and IV bladder cancer)	Designated			N/A	N/A	IC-MedTech Corporation	9902 Indian Creek Lane		San Diego	California	92021	USA
sodium ascorbate and menadione sodium bisulfite	Apatone	4/15/13	Treatment of autosomal dominant polycystic liver disease	Designated			N/A	N/A	IC-Medtech Corporation	9902 Indian Creek Lane		El Cajon	California	92021	USA
sodium ascorbate and menadione sodium bisulfite	Apatone	4/15/13	Treatment of autosomal dominant polycystic kidney disease	Designated			N/A	N/A	IC-MedTech Corporation	9902 Indian Creek Lane		El Cajon	California	92021	USA
sodium ascorbate and menadione sodium bisulfite	Apatone	4/9/15	Treatment of noninfected painful total joint without mechanical complication	Designated			N/A	N/A	IC-MedTech Corporation	9902 Indian Creek Lane		El Cajon	California	92021	USA
sodium benzoate and clozapine	n/a	12/22/11	Treatment of treatment-resistant schizophrenia	Designated			N/A	N/A	SyneuRx International Corp.	"20F-9 99 Section 1, Xintaiwu Road"	Xizhi District				Taiwan
sodium chlorite	n/a	8/22/11	For slowing the progression of amyotrophic lateral sclerosis.	Designated			N/A	N/A	"Neuraltus Pharmaceuticals, Inc."	2483 E. Bayshore Road	Suite 212	Palo Alto	California	94303	USA
Sodium dichloroacetate	n/a	12/31/97	Treatment of congenital lactic acidosis.	Designated/Withdrawn			N/A	N/A	"Questcor Pharmaceuticals, Inc."	3260 Whipple Rd.		Union City	California	94587	USA
Sodium dichloroacetate	Ceresine	6/14/99	Treatment of severe head injury.	Designated/Withdrawn			N/A	N/A	"Questcor Pharmaceuticals, Inc."	3260 Whipple Rd.		Union City	California	94587	USA
Sodium dichloroacetate	n/a	6/11/90	Treatment of homozygous familial hypercholesterolemia.	Designated			N/A	N/A	"Stacpoole, Peter W. M.D., Ph.D."	University of Florida	P.O. Box 100277	Gainesville	Florida	32610	USA
sodium dichloroacetate	n/a	11/29/10	For pulmonary arterial hypertension.	Designated			N/A	N/A	"Peter W. Stackpoole, PhD, MD"	University of FL College of Medicine	P. O. Box 100226	Gainesville	Florida	32611	USA
Sodium dichloroacetate	n/a	6/11/90	Treatment of congenital lactic acidosis	Designated			N/A	N/A	"Stacpoole, Peter W. M.D., Ph.D."	University of Florida	P.O. Box 100277	Gainesville	Florida	32610	USA
sodium dichloroacetate	n/a	7/3/03	Use as an antidote in the management of systemic monochloroacetic acid poisoning	Designated			N/A	N/A	EBD Group	2032 Corte del Nogal	Suite 120	Carlsbad	California	92011	USA
Sodium dichloroacetate	n/a	11/10/94	Treatment of lactic acidosis in patients with severe malaria.	Designated			N/A	N/A	"Stacpoole, Peter W. M.D., Ph.D."	University of Florida	P.O. Box 100277	Gainesville	Florida	32610	USA
sodium fusidate	n/a	10/23/13	Treatment of patients with prosthetic joint infections	Designated			N/A	N/A	"Cempra Pharmaceuticals, Inc."	6340 Quadrangle Drive	Suite 100	Chapel Hill	North Carolina	27517	USA
Sodium monomercaptoundecahydro-closo-dodecaborate	n/a	12/18/84	For use in conjunction with a thermal or epithermal neutron beam in boron nuclear capture therapy of glioblastoma multiforme.	Designated/Withdrawn			N/A	N/A	Theragenics Corporation						
Sodium Monomercaptoundecahydro-closo-dodecaborate	Borocell	4/15/92	For use in boron neutron capture therapy (BNCT) in the treatment of glioblastoma multiforme.	Designated			N/A	N/A	Neutron Technology Corp.& Neutron R&D Partner	"877 Main Street, Suite 402"		Boise	Idaho	83702	USA
Sodium nitrite	n/a	1/17/07	Prevention of vasospasm associated with subarachnoid hemorrhage	Designated			N/A	N/A	Hope Pharmaceuticals	16416 N. 92nd Street		Scottsdale	Arizona	85260	USA
sodium nitrite	n/a	1/9/12	Treatment of chlorine gas poisoning	Designated			N/A	N/A	Hope Pharmaceuticals	16416 N. 92nd Street		Scottsdale	Arizona	85260	USA
sodium nitrite	n/a	9/3/09	Prevention of ischemia reperfusion injury to donor organ tissue associated with solid organ transplantation	Designated			N/A	N/A	Hope Pharmaceuticals	16416 N. 92nd Street		Scottsdale	Arizona	85260	USA
sodium nitrite	n/a	7/8/08	Treatment of pulmonary arterial hypertension	Designated			N/A	N/A	"Airess Pharmaceuticals, Inc."	"(subsidiary of Mast Therapeutics, Inc)"	3611 Valley Centre Drive	San Diego	California	92130	USA
Sodium nitrite	n/a	4/18/07	Treatment of cyanide poisoning	Designated			N/A	N/A	Hope Pharmaceuticals	16416 N. 92nd Street		Scottsdale	Arizona	85260	USA
Sodium nitrite	n/a	4/2/07	Treatment of vaso-occlusive crisis associated with sickle cell disease	Designated			N/A	N/A	Hope Pharmaceuticals	16416 N. 92nd Street		Scottsdale	Arizona	85260	USA
sodium nitrite and EDTA	n/a	11/10/15	Treatment of Pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis	Designated			N/A	N/A	"Arch Biopartners, Inc."	27 Saint Clair Avenue East	P. O. Box 305	Toronto	Ontario		Canada
sodium nitrite and sodium thiosulfate	Nithiodote	4/9/08	Treatment of known or suspected cyanide poisoning	Designated/Approved	Approved for Orphan Indication	For sequential use for the treatment of cyanide poisoning that is judged to be life-threatening	01/14/2011	01/14/2018	Hope Pharmaceuticals	16416 N. 92nd Street		Scottsdale	Arizona	85260	USA
Sodium nitrite/sodium thiosulfate	Cyanide Antidote Package	3/23/07	Treatment of cyanide poisoning	Designated			N/A	N/A	"Keystone Pharmaceuticals, Inc."	26072 Merit Circle		Laguna Hills	California	92653	USA
Sodium phenylacetate/sodium benzoate 10%/10% Injection	Ammonul(R)	6/3/05	Treatment of grade III and IV hepatic encephalopathy	Designated			N/A	N/A	"Ucyclyd Pharma, Inc."	7720 N. Dobson Road		Scottsdale	Arizona	85256	USA
sodium phenylbutyrate	n/a	8/19/14	Treatment of maple syrup urine disease	Designated			N/A	N/A	"Acer Therapeutics, Inc."	222 Third Street	Suite 2240	Cambridge	Massachusetts	2142	USA
Sodium phenylbutyrate	n/a	3/20/07	Treatment of spinal muscular atrophy	Designated			N/A	N/A	"Tikvah Therapeutics, Inc."	"75 5th Street, NW."		Atlanta	Georgia	30308	USA
sodium phenylbutyrate	Pheburane	6/6/13	Treatment of urea cycle disorders	Designated			N/A	N/A	Lucane Pharma SA	172 rue de Charonne		Paris			France
Sodium phenylbutyrate	Buphenyl	1/25/07	Treatment of spinal muscular atrophy	Designated			N/A	N/A	"OrphaMed, Inc."	7720 N. Dobson Road	subsidiary of Medicis Pharmaceutical Corp.	Scottsdale	Arizona	85256	USA
sodium phenylbutyrate	n/a	1/19/10	Treatment of urea cycle disorder.	Designated			N/A	N/A	Navinta LLC	1499 Lower Ferry Road		Ewing	New Jersey	8618	USA
sodium phenylbutyrate	n/a	7/2/92	"Treatment for sickling disorders, which include S-S hemoglobinopathy, S-C hemoglobinopathy, and S-thalassemia hemoglobinopathy."	Designated			N/A	N/A	Medicis Pharmaceutical Corp.	8125 N. Hayden Road		Scottsdale	Arizona	85258	USA
Sodium phenylbutyrate	n/a	4/24/98	"For use as an adjuct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma."	Designated			N/A	N/A	"Elan Drug Delivery, Inc."	1300 Gould Dr.		Gainesville	Georgia	30504	USA
sodium phenylbutyrate	Buphenyl	11/22/93	"Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency."	Designated/Approved	Approved for Orphan Indication	"Adjunctive therapy in the chronic managment of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase."	04/30/1996	04/30/2003	Medicis Pharmaceutical Corp.	8125 N. Hayden Road		Scottsdale	Arizona	85258	USA
Sodium pyruvate	n/a	3/31/03	Treatment of cystic fibrosis	Designated			N/A	N/A	"Cellular Sciences, Inc"	84 park Avenue	P.O. Box 968	Flemington	New Jersey	8822	USA
sodium stibogluconate	n/a	10/28/09	Treatment of cutaneous leishmaniasis	Designated			N/A	N/A	Surgeon General of the US Army	US Army Medical Research & Materiel Command	1430 Veterans Drive	Ft. Detrick	Maryland	21702	USA
Sodium stibogluconate	n/a	6/16/06	Treatment of cutaneous leishmaniasis	Designated			N/A	N/A	"VioQuest Pharmaceuticals, Inc."	180 Mt. Airy Road	Suite 102	Basking Ridge	New Jersey	7920	USA
"sodium sulfate, potassium sulfate, and magnesium sulfate"	Suprep	10/31/12	For cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in children and adolescents	Designated			N/A	N/A	"Braintree Laboratories, Inc."	60 Cloumbian Street West	PO Box 850929	Braintree	Massachusetts	2185	USA
"sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride"	Suclear	9/4/13	For use in cleansing of the colon in preparation for colonoscopy in children and adolescents	Designated			N/A	N/A	"Braintree Laboratories, Inc."	60 Columbian Street West	P.O. Box 850929	Braintree	Massachusetts	2185	USA
Sodium tetradecyl sulfate	Sotradecol	6/10/86	Treatment of bleeding esophageal varices.	Designated			N/A	N/A	"Elkins-Sinn, Inc."	2 Esterbrook Lane		Cherry Hill	New Jersey	8003	USA
sodium thiosulfate	n/a	3/3/11	Treatment of sulfur mustard poisoning	Designated			N/A	N/A	Hope Pharmaceuticals	16416 N. 92nd Street		Scottsdale	Arizona	85260	USA
Sodium thiosulfate	n/a	3/17/04	Prevention of platinum-induced ototoxicity in pediatric patients	Designated			N/A	N/A	"Fennec Pharmaceuticals, Inc."	PO Box 13628	68 T.W. Alexander Drive	Research Triangle Park	North Carolina	27709	USA
sodium thiosulfate	n/a	10/13/11	Prevention of platinum-induced ototoxicity in pediatric patients	Designated			N/A	N/A	Hope Pharmaceuticals	16416 N. 92nd Street		Scottsdale	Arizona	85260	USA
sodium thiosulfate	n/a	10/28/14	Treatment of dermatomyositis	Designated			N/A	N/A	Hope Pharmaceuticals	16416 N. 92nd Street		Scottsdale	Arizona	85260	USA
sodium thiosulfate	n/a	11/19/12	Treatment of calciphylaxis	Designated			N/A	N/A	Edinburg BioQuarter	University Medical School 47	EH16 4TJ	Edinburgh			United Kingdom
sodium thiosulfate	n/a	11/9/11	Treatment of uremic and non-uremic calciphylaxis	Designated			N/A	N/A	Hope Pharmaceuticals	16416 N. 92nd Street		Scottsdale	Arizona	85260	USA
sodium thiosulfate	n/a	12/2/10	Treatment of extravasation of meclorethamine hydrochloride into subcutaneous tissues.	Designated			N/A	N/A	Hope Pharmaceuticals	16416 N. 92nd Street		Scottsdale	Arizona	85260	USA
Sodium Thiosulfate	n/a	2/16/12	Treatment of uremic and non-uremic calciphylaxis	Designated			N/A	N/A	"Luitpold Pharmaceuticals, Inc."	800 Adams Avenue	Suite 100	Norristown	Pennsylvania	19403	USA
Sodium thiosulfate and sodium nitrite	n/a	12/18/06	Treatment of cyanide poisoning	Designated			N/A	N/A	"Akorn, Inc."	2500 Millbrook Drive		Buffalo Grove	Illinois	60089	USA
"Sodium thiosulfate, sodium nitrite, amyl nitrite"	Cyanide Antidote Package	6/16/06	Treatment of cyanide poisoning	Designated			N/A	N/A	"Keystone Pharmaceuticals, Inc."	26072 Merit Circle		Laguna Hills	California	92653	USA
sodium valproate	n/a	8/5/15	Treatment of Wolfram syndrome	Designated			N/A	N/A	The University of Birmingham	Birmingham Research Park - Vincent Drive	Birmingham B15 2SQ				United Kingdom
sofosbuvir	Sovaldi	10/25/16	Treatment of pediatric chronic hepatitis C virus infection	Designated			N/A	N/A	"Gilead Sciences, Inc."	333 Lakeside Drive		Foster City	California	94404	USA
Solasonine and solamargine	Coramsine	2/6/06	"Treaatment of high risk stage II, stage III and stage IV melanoma"	Designated			N/A	N/A	Solbec Pharmaceuticals Limited	P. O. Box 2142	"Osbourne Park, Western Australia 6017"				Australia
Solasonine and solamargine	Coramsine	11/2/05	Treatment of renal cell carcinoma	Designated			N/A	N/A	Solbec Pharmaceuticals Limited	P. O. Box 2142	WA 6018				Australia
solnatide	n/a	2/8/16	Treatment of generalized systemic pseudohypoaldosteronism type 1 (also known as autosomal recessive PHA-I or PHA-IB)	Designated			N/A	N/A	Apeptico Forschung und Entwicklung GmbH	Mariahilferstrabe 136	Top 1150	Vienna			Austria
solnatide	n/a	2/4/16	Treatment of primary graft dysfunction following lung transplantation	Designated			N/A	N/A	Apeptico Forschung und Entwicklung GmbH	c/o mingo bueros	1150	Vienna			Austria
Soluble complement receptor type 1	n/a	3/6/00	Prevention of post-cardiopulmonary bypass syndrome in children undergoing cardiopulmonary bypass.	Designated			N/A	N/A	"Avant Immunotherapeutics, Inc."	119 Fourth Ave.		Needham	Massachusetts	2494	USA
Soluble recombinant human complement receptor type 1	n/a	11/21/94	Prevention or reduction of adult respiratory distress syndrome.	Designated			N/A	N/A	"T Cell Sciences, Inc."	119 Fourth Avenue		Needham Heights	Massachusetts	2194	USA
solvent/detergent treated non-blood-group specific human coagulation active plasma	Uniplas	12/12/05	Treatment of thrombotic thrombocytopenic purpura	Designated			N/A	N/A	"Octapharma USA, Inc."	121 River Street	12th Floor	Hoboken	New Jersey	7030	USA
"somatic cell therapy product containing hematopoietic progenitor cells (HPC), Facilitating Cells (FC), and alpha beta T cells."	n/a	2/4/16	Prevention of organ rejection in living donor kidney transplant recipients	Designated			N/A	N/A	Regenerex LLC	570 South Preston Street	Suite 404	Louisville	Kentucky	40202	USA
somatorelin	Somatrel	8/8/89	Diagnostic measure of the capacity of the pituitary gland to release growth hormone.	Designated			N/A	N/A	"Ferring Laboratories, Inc."	"400 Rella Boulevard, Suite 201"		Suffern	New York	10901	USA
Somatostatin	Zecnil	6/20/88	"Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas."	Designated			N/A	N/A	"Ferring Laboratories, Inc."	"400 Rella Boulevard, Suite 201"		Suffern	New York	10901	USA
Somatostatin	n/a	12/22/94	Treatment of bleeding esophageal varices.	Designated			N/A	N/A	Eumedica Pharmaceuticals A.G. (Schweiz)	Arnold Bocklin-Strasse 1	CH-4051	BASEL			Switzerland
Somatrem for injection	Protropin	12/9/85	"1. Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion (prevalence 15,000) 2. Treatment of short stature associated with Turner's syndrome (prevalence 8000)."	Designated/Approved	Approved for Orphan Indication		10/17/1985	10/17/1992	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
Somatropin	Serostim	3/16/04	Treatment of patients with HIV-associated adipose redistribution syndrome	Designated			N/A	N/A	"EMD Serono, Inc."	One Technology Place		Rockland	Massachusetts	2370	USA
Somatropin	Nutropin	3/6/87	For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Designated/Approved	Approved for Orphan Indication		10/17/1985	10/17/1992	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
Somatropin	Norditropin	8/9/06	Treatment of short stature in patients with Noonan syndrome	Designated/Approved	Approved for Orphan Indication	Treatment of short stature in patients with Noonan syndrome	05/31/2007	05/31/2014	Novo Nordisk Inc.	100 College Road West		Princeton	New Jersey	8540	USA
Somatropin	Biotropin	2/12/93	Treatment of cachexia associated with AIDS.	Designated/Withdrawn			N/A	N/A	Bio-Technology General Corp.	"70 Wood Avenue, South"		Iselin	New Jersey	8830	USA
Somatropin	Norditropin	9/1/87	"Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization procedures."	Designated/Withdrawn			N/A	N/A	Novo Nordisk Pharmaceuticals	100 Overlook Center	Suite 200	Princeton	New Jersey	8540	USA
Somatropin	Genotropin	9/6/94	Treatment of adults with growth hormone deficiency.	Designated/Approved	Approved for Orphan Indication		10/31/1997	10/31/2004	Pharmacia & Upjohn	7000 Portage Road		Kalamazoo	Michigan	49001	USA
Somatropin	Humatrope	5/8/90	Treatment of short stature associated with Turner syndrome.	Designated/Approved	Approved for Orphan Indication	Treatment of short stature associated with Turner syndrome in patients whose epiphyses are not closed.	12/30/1996	12/30/2003	Eli Lilly and Company	Lilly Corporate Center		Indianapolis	Indiana	46285	USA
Somatropin	Humatrope	12/15/05	Treatment of short stature in pediatric patients with short stature homeobox-containing gene (SHOX) deficiency	Designated/Approved	Approved for Orphan Indication	Treatment of short stature or growth failure in children with SHOX (short stature homeobox-containing gene) deficiency whose epiphyses are not closed	11/01/2006	11/01/2013	Eli Lilly and Company	Lilly Corporate Center		Indianapolis	Indiana	46285	USA
Somatropin (rDNA)	Saizen	5/3/89	For the enhancement of nitrogen retention in hospitalized patients suffering from severe burns.	Designated			N/A	N/A	"EMD Serono, Inc."	One Technology Place		Rockland	Massachusetts	2370	USA
Somatropin (r-DNA)	Zorbtive	3/6/95	For use alone or in combination with glutamine in the treatment of short bowel syndrome.	Designated/Approved	Approved for Orphan Indication	Treatment of short bowel syndrome in patients receiving specialized nutritional support	12/01/2003	12/01/2010	"EMD Serono, Inc."	One Technology Place		Roackland	Massachusetts	2370	USA
Somatropin (r-DNA) for injection	Serostim	3/26/96	Treatment of children with AIDS-associated failure-to-thrive including AIDS-associated wasting.	Designated			N/A	N/A	"EMD Serono, Inc."	One Technology Place		Roackland	Massachusetts	2370	USA
Somatropin (rDNA origin)	Nutropin Depot	10/28/99	Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Designated/Approved	Approved for Orphan Indication	Long-term treatment of growth failure due to a lack of adequate endogenous growth hormone secetion for once- or twice-a-month administration.	12/22/1999	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
Somatropin (rDNA origin)	Saizen	3/6/87	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	Designated/Approved	Approved for Orphan Indication	Long term treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.	10/08/1996	N/A	"EMD Serono, Inc."	One Technology Place		Roackland	Massachusetts	2370	USA
Somatropin (rDNA origin) injection	Norditropin	7/10/87	1. Treatment of growth failure in children due to inadequate growth hormone secretion 2. Treatment of short stature associated with Turner's syndrome	Designated/Approved	Approved for Orphan Indication	Long-term treatment of children who have growth failure due to inadequate secretion of endogenous growth hormone.	06/20/2000	N/A	Novo Nordisk Pharmaceuticals	100 Overlook Center	Suite 200	Princeton	New Jersey	8540	USA
Somatropin for injection	Nutropin	11/18/96	As replacement therapy for growth hormone deficiency in adults after epiphyseal closure.	Designated/Approved	Approved for Orphan Indication		12/15/1997	12/15/2004	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
Somatropin for injection	Serostim	11/15/91	Treatment of AIDS-associated catabolism/weight loss.	Designated/Approved	Approved for Orphan Indication	Treatment of AIDS wasting or cachexia.	08/23/1996	08/23/2003	"EMD Serono, Inc."	One Technology Place		Roackland	Massachusetts	2370	USA
Somatropin for injection	Nutropin	8/4/89	Treatment of growth retardation associated with chronic renal failure.	Designated/Approved	Approved for Orphan Indication	Treatment of children with growth failure associated with chronic renal insufficency.	11/17/1993	11/17/2000	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
Somatropin for injection	Humatrope	6/12/86	For the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.	Designated/Approved	Approved for Orphan Indication		03/08/1987	03/08/1994	Eli Lilly and Company	Lilly Corporate Center		Indianapolis	Indiana	46285	USA
Somatropin for injection	Nutropin	3/23/89	Treatment of short stature associated with Turner's syndrome.	Designated/Approved	Approved for Orphan Indication	Treatment of growth failure associated with Turner syndrome.	12/30/1996	12/30/2003	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
somatropin [rDNA]	Genotropin	12/27/00	Treatment of growth failure in children who were born small for gestational age.	Designated/Approved	Approved for Orphan Indication	For long-term treatment of growth failure in children born small for gestational age who fail to manifest catch-up growth by two years of age.	07/25/2001	07/25/2008	Pharmacia and Upjohn Company	7000 Portage Road		Kalamazoo	Michigan	49001	USA
Somatropin [rDNA]	Genotropin	7/6/99	Treatment of short stature in patients with Prader-Willi syndrome.	Designated/Approved	Approved for Orphan Indication	Long-term treatment of pediatric patients who have growth failure due to Prader-Willi syndrome (PWS).	06/20/2000	06/20/2007	Pharmacia & Upjohn	7000 Portage Rd.	0633-298-113	Kalamazoo	Michigan	49001	USA
sonidegib	n/a	3/23/15	Treatment of medulloblastoma	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Jersey	7936	USA
Sorafenib	Nexavar	4/20/06	Treatment of hepatocellular carcinoma	Designated/Approved	Approved for Orphan Indication	Treatment of unresectable hepatocellular carcinoma	11/16/2007	11/16/2014	Bayer Pharmaceuticals Corporation	400 Morgan Lane		West Haven	Connecticut	6516	USA
Sorafenib	Nexavar	10/8/04	Treatment of renal cell carcinoma.	Designated/Approved	Approved for Orphan Indication	Treatment of patients with advanced renal cell carcinoma	12/20/2005	12/20/2012	Bayer Pharmaceutical Corporation	400 Morgan Lane		West Haven	Connecticut	6516	USA
Sorafenib	Nexavar	9/29/06	Treatment of stage IIB through stage IV melanoma	Designated/Withdrawn			N/A	N/A	Bayer Pharmaceuticals Corp.	100 Bayer Blvd	P. O. Box 915	Whippany	New Jersey	7981	USA
sorafenib	Nexavar	12/12/11	"Treatment of medullary thyroid cancer, anaplastic thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer"	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DCT) that is refractory to radioactive iodine treatment."	11/22/2013	11/22/2020	"Bayer HealthCare Pharmaceuticals, Inc."	100 Bayer Blvd.	PO Box 915	Whippany	New Jersey	7981	USA
Sorivudine	Bravavir	11/9/95	Treatment of herpes zoster (shingles) in immunocompromised patients	Designated/Withdrawn			N/A	N/A	Bristol-Myers Squibb	5 Research Parkway	P.O. Box 5100	Wallingford	Connecticut	6492	USA
sotalol (IV)	So-Aqueous	7/25/08	"For ventricular tachycardia, ventricular fibrillation, or the maintenance of sinus rhythm in patients converted from atrial fibrillation or atrial flutter when oral administration is not possible."	Designated/Approved	Approved for Orphan Indication	"For use as a substitute for oral sotalol in patients who are unable to take sotalol orally [oral sotalol is indicated for maintenance of normal sinus rhythm in patients with history of highly symptomatic atrial fibrillation /flutter, and for treatment of documented life-threatening ventricular arrhythmias]"	07/02/2009	07/02/2016	Academic Pharmaceuticals	21 N. Skokie Hwy		Lake Bluff	Illinois	60044	USA
Sotalol HCl	Betapace	9/23/88	1. Treatment of life-threatening ventricular tachyarrhythmias 2. Prevention of life treatening ventricular tachyarrhythmias	Designated/Approved	Approved for Orphan Indication	Treatment of life-threatening ventricular tachyarrhythmias	10/30/1992	10/30/1999	"Berlex Laboratories, Inc."	300 Fairfield Road		Wayne	New Jersey	7470	USA
sotalol hydrochloride	Sotylize	2/10/14	Treatment of life-threatening ventricular arrhythmias in pediatric patients	Designated			N/A	N/A	"Arbor Pharmaceuticals, LLC"	980 Hammond Drive	"Bldg Two, Suite 1250"	Atlanta	Georgia	30328	USA
sotatercept	n/a	4/28/14	Treatment of anemias associated with myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasms.	Designated			N/A	N/A	Celgene Corporation	86 Morris Avenue		Summit	New Jersey	7901	USA
sotatercept	n/a	12/5/13	Treatment of beta-thalassemia intermedia and major	Designated			N/A	N/A	Celgene Corporation	86 Morris Avenue		Summit	New Jersey	7901	USA
sparsentan	n/a	1/5/15	Treatment of Focal Segmental Glomerulosclerosis	Designated			N/A	N/A	"Retrophin, LLC"	330 Madison Avenue	6th Floor	New York	New York	10031	USA
Sperm Protein-17 oral microparticle vaccine	n/a	6/21/16	Treatment of ovarian cancer	Designated			N/A	N/A	"Kiromic, LLC"	2707 Fannin Street	Fannin St. Professional Building	Houston	Texas	77002	USA
spherical carbon adsorbent	n/a	12/19/07	Treatment of chronic pouchitis	Designated			N/A	N/A	"Ocera Therapeutics, Inc."	12651 High Bluff Drive		San Diego	California	92130	USA
Spiramycin	Rovamycine	10/17/84	For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.	Designated/Withdrawn			N/A	N/A	Rhone-Poulenc Rorer Pharmaceuticals	500 Arcola Road		Collegeville	Pennsylvania	19426	USA
spironolactone	Aldactone	5/22/14	Use in pediatric patients with primary hyperaldosteronism	Designated			N/A	N/A	"CMP Pharma, Inc."	PO Box 147	8026 US Highway 264A	Farmville	North Carolina	27828	USA
squalamine lactate	n/a	5/11/01	Treatment of ovarian cancer refractory or resistant to standard chemotherapy	Designated			N/A	N/A	Genaera Corporation	5110 Campus Drive		Plymouth Meeting	Pennsylvania	19462	USA
ST1-RTA immunotoxin (SR 44163)	n/a	8/12/87	1. Prevention of acute graft versus host disease in allogenic bone marrow transplantation 2. Treatment of patients with B-chronic lymphocytic leukemia	Designated/Withdrawn			N/A	N/A	"Sanofi Winthrop, Inc."	9 Great Valley Parkway		Malvern	Pennsylvania	19355	USA
stabilized sulforaphane	n/a	8/22/16	Treatment of subarachnoid hemorrhage	Designated			N/A	N/A	Evgen Pharma PLC	146 Brownlow Hill		Liverpool			United Kingdom
staphylococcal aureus protein A	n/a	6/10/15	Treatment of immune thrombocytopenic purpura	Designated			N/A	N/A	"Protalex, Inc."	131 Columbia Turnpike	Suite 1	Florham Park	New Jersey	7932	USA
Staphylococcal immunoglobulin (human)	Veronate	6/13/01	Reduction (prevention) of nosocomial bacteremia caused by staphylococci in very low birth weight infants.	Designated/Withdrawn			N/A	N/A	"Inhibitex, Inc."	8995 Westside Parkway	Suite 150	Alpharetta	Georgia	30004	USA
Staphylococcus aureus Immune Globulin (Human)	Altastaph	1/29/04	Prophylaxis against Staphylococcus aureus infections in low birth weight neonates	Designated			N/A	N/A	Biotest Pharmaceuticals Corporation	"5800 Park of Commerce Blvd, NW"		Boca Raton	Florida	33487	USA
Stem and progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood	Stemex	3/4/05	For use as hematopoietic support in patients with relapsed or refractory hematologic malignancies who are receiving high-dose therapy	Designated/Withdrawn			N/A	N/A	Gamida Cell Ltd - Teva Joint Venture	"5, Nahum Hafzadi St."	P. O. Box 34670	Jerusalem			Israel
stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells	Nicord(R)	11/13/14	Treatment of Hodgkin lymphoma.	Designated			N/A	N/A	Gamida Cell Ltd.	P. O. Box 34670		Jerusalem			Israel
stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells	Nicord(R)	11/13/14	Treatment of acute lymphoblastic leukemia.	Designated			N/A	N/A	Gamida Cell Ltd.	P. O. Box 34670		Jerusalem			Israel
stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells	Nicord(R)	11/13/14	Treatment of myelodysplastic syndrome.	Designated			N/A	N/A	Gamida Cell Ltd.	P. O. Box 34670		Jerusalem			Israel
stemchymal	n/a	12/16/15	Treatment of polyqlutamine spinocerebellar ataxia	Designated			N/A	N/A	"Steminent Biotherapeutics, Inc."	No. 16 Wenhu Street	Neihu Dist.				Taiwan
"Sterile Bicarbonate Infusate, Hemofiltration, Hemodiafiltration, and Hemopdialysis Solution"	Accusol	5/29/09	For use as a replacement solution in adults and children during Continous Renal Replacement Therapy	Designated			N/A	N/A	"Nikkiso America, Inc."	5910 Pacific Center Blvd	Suite 110	San Diego	California	92121	USA
Sterile talc	Steritalc	12/8/97	Treatment of pneumothorax.	Designated			N/A	N/A	Novatech SA	Z. I. Athelia III	"1058, Voie Antiope"				France
Sterile talc	Steritalc	12/8/97	Treatment of malignant pleural effusion.	Designated			N/A	N/A	Novatech SA	Z. I. Athelia III	"1058, Voie Antiope"				France
Sterile talc powder	Sclerosol Intrapleural Aerosol	9/18/95	Treatment of malignant pleural effusion.	Designated/Approved	Approved for Orphan Indication	Prevention of recurrence of malignant pleural effusions in symptomatic patients.	12/24/1997	12/24/2004	Bryan Corporation	4 Plympton Street		Woburn	Massachusetts	1801	USA
stiripentol	Diacomit	10/30/08	Treatment of Dravet syndrome	Designated			N/A	N/A	Biocodex	"7, avenue Gallieni"	94250 Gentilly				France
substituted benzaldehyde that binds to the oxy-conformation of Hb between amino terminal residues of the alpha-subunits	n/a	10/23/87	Treatment of sickle cell disease.	Designated/Withdrawn			N/A	N/A	Burroughs Wellcome Company	3030 Cornwallis Road	P.O. Box 12700	Research Triangle Pk	North Carolina	27709	USA
Substituted imidazopyridine amide	n/a	12/22/15	Treatment of active tuberculosis (TB).	Designated			N/A	N/A	"Qurient Co., Ltd."	"C-dong 8th floor, 242 Pangyo-ro"	"Bundang-gu, Seongnam-si"	Gyeonggi-do			"Korea, Republic of"
Succimer	Chemet	3/22/91	Treatment of mercury intoxication.	Designated			N/A	N/A	"Sanofi Winthrop, Inc."	90 Park Avenue		New York	New York	10016	USA
Succimer	Chemet	11/5/90	Prevention of cystine kidney stone formation in patients with homozygous cystinuria who are prone to stone development.	Designated			N/A	N/A	"Sanofi Winthrop, Inc."	90 Park Avenue		New York	New York	10016	USA
Succimer	Chemet Capsules	5/9/84	Treatment of lead poisoning in children.	Designated/Approved	Approved for Orphan Indication		01/30/1991	01/30/1998	Bock Pharmacal Company	P.O. Box 419056		Saint Louis	Missouri	63141	USA
Sucralfate	n/a	7/15/93	Treatment of oral mucositis and stomatitis following radiation therapy for head and neck cancer.	Designated/Withdrawn			N/A	N/A	"Fuisz Technologies, Ltd."	14555 Avion at Lakeside		Chantilly	Virginia	20151	USA
Sucralfate suspension	n/a	3/4/91	Treatment of oral ulcerations and dysphagia in patients with epidermolysis bullosa.	Designated			N/A	N/A	"Darby Pharmaceuticals, Inc."	100 Banks Avenue		Rockville Centre	New York	11570	USA
Sucralfate suspension	n/a	3/12/90	Treatment of oral complications of chemotherapy in bone marrow transplant patients.	Designated			N/A	N/A	"Darby Pharmaceuticals, Inc."	100 Banks Avenue		Rockville Centre	New York	11570	USA
Sulfadiazine	n/a	3/14/94	For use in combination with pyrimethamine for the treatment of Toxoplasma gondii encephalitis in patients with and without AIDS.	Designated/Approved	Approved for Orphan Indication	"Toxoplasmosis, as adjunctive with pyrimethamine"	07/29/1994	07/29/2001	"Eon Labs Manufacturing, Inc."	227-15 North Conduit Avenue		Laurelton	New York	11413	USA
sulfamidase	n/a	5/22/08	For treatment of Sanfilippo Syndrome (MPS IIIA)	Designated			N/A	N/A	"Shire Human Genetic Therapies, Inc."	300 Shire Way		Lexington	Massachusetts	2421	USA
Sulfapyridine	n/a	9/10/90	Treatment of dermatitis herpetiformis.	Designated			N/A	N/A	Jacobus Pharmaceutical Company	37 Cleveland Avenue	P.O. Box 5290	Princeton	New Jersey	8540	USA
sulfonated monophosphorylated mannose oligosaccharide	n/a	2/17/12	Treatment of hepatocellular carcinoma	Designated			N/A	N/A	Medigen Biotechnology Corporation	"14F, No. 3, Yuancyu Street"	Nangang District	Taipei City			Taiwan
sulthiame	n/a	7/25/13	Treatment of patients with benign epilepsy of childhood with centrotemporal spikes (BECTS) also known as rolandic epilepsy	Designated			N/A	N/A	"Marathon Pharmaceuticals, LLC"	"1033 Skokie Blvd.,"	Suite 600	Northbrook	Illinois	60062	USA
Superoxide dismutase (human)	n/a	3/6/85	"For protection of donor organ tissue from damage or injury mediated by oxygen-derived free radicals that are generated during the necessary periods of ischemia (hypoxia, anoxia), and especially reperfusion, associated with the operative procedure."	Designated			N/A	N/A	Pharmacia-Chiron Partnership	4560 Horton Street		Emeryville	California	94608	USA
Superoxide dismutase (recombinant human)	Oxsodrol	5/17/88	Prevention of reperfusion injury to donor organ tissue.	Designated/Withdrawn			N/A	N/A	Bio-Technology General Corp.	"70 Wood Avenue, South"		Iselin	New Jersey	8830	USA
"superoxide dismutase, gliadin"	Etr019	4/30/10	Treatment of amyotrophic lateral sclerosis	Designated			N/A	N/A	Verius Limited	Chartwell House	"Cambridge, CB5 8LP, UK"				United Kingdom
Suramin	Metaret	5/6/97	Treatment of hormone-refractory prostate cancer.	Designated			N/A	N/A	Warner-Lambert Company	Parke-Davis Pharmaceutical Research Division	2800 Plymouth Road	Ann Arbor	Michigan	48105	USA
Surfactant (human) (amniotic fluid derived)	Human Surf	3/25/87	Prevention and treatment of neonatal respiratory distress syndrome.	Designated/Withdrawn			N/A	N/A	"Merritt, T. Allen M.D."	2516 Stockton Boulevard		Sacramento	California	95817	USA
Synsorb Pk	n/a	7/17/95	Treatment of verocytotoxogenic E. coli infections.	Designated			N/A	N/A	Synsorb Biotech Inc.	"201, 1204 Kensington Road, N.W."	"Calgary, Alberta"				Canada
Synthesized peptide of the L-amino acids with the sequence H-Lys-Glu-Phe-Leu-His-Pro-Ser-Lys-Val-Asp-Leu-Pro-Arg-OH	n/a	2/4/16	Treatment of ovarian cancer.	Designated			N/A	N/A	Soricimed Biopharma Inc.	18 Botsford Street	Suite 201	Moncton	New Brunswick		Canada
synthetic 14-mer phosphorothioate antisense oligonucleotide directed against TGF-beta2 mRNA	n/a	6/4/14	Prevention of scarring post glaucoma filtration surgery	Designated			N/A	N/A	Isarna Therapeutics GmbH	Leopoldstrasse 254-256	D-80807 Munich				Germany
"Synthetic 47 amino acid-long N-terminally myristoylated, HBV-L-protein derived lipopeptide"	n/a	3/31/15	Treatment of hepatitis D virus infection.	Designated			N/A	N/A	MYR GmbH	Weinbergsweg 66	61348 Bad Homburg				Germany
"Synthetic derivative of 16-hydroxy-9Z, 12Z, 14E-octadecatrienoic acid"	Drepanol	10/24/91	Prophylactic treatment of sickle cell disease.	Designated			N/A	N/A	"Omex International, Inc."	"6001 Savoy, Suite 110"		Houston	Texas	77036	USA
synthetic double-stranded (hybridized duplex) ribonucleic acid oligonucleotide specific to hydroxyacid oxidase 1 gene	n/a	4/22/15	Treatment of primary hyperoxaluria type 1	Designated			N/A	N/A	"Dicerna Pharmaceuticals, Inc."	87 Cambridgepark Drive		Cambridge	Massachusetts	2140	USA
synthetic double-stranded siRNA oligonucleotide against antithrombin (AT) mRNA	n/a	8/16/13	Treatment of hemophilia A	Designated			N/A	N/A	Alnylam Pharmaceuticals	300 Third Street		Cambridge	Massachusetts	2142	USA
synthetic double-stranded siRNA oligonucleotide against antithrombin mRNA	n/a	8/12/13	Treatment of hemophilia B	Designated			N/A	N/A	Alnylam Pharmaceuticals	300 Third Street		Cambridge	Massachusetts	2142	USA
Synthetic double-stranded siRNA oligonucleotide against caspase 2 mRNA	n/a	9/25/12	Treatment of ischemic optic neuropathy	Designated			N/A	N/A	"Quark Pharmaceuticals, Inc."	6501 Dumbarton Circle		Fremont	California	94555	USA
synthetic double-stranded siRNA oligonucleotide against p53 mRNA	n/a	12/23/09	Prophylaxis of delayed graft function in renal transplant patients	Designated			N/A	N/A	"Quark Pharmaceuticals, Inc."	6501 Dumbarton Circle		Fremont	California	94555	USA
synthetic double-stranded siRNA oligonucleotide against transthyretin (TTR) mRNA	n/a	6/14/12	Treatment of familial amyloidotic polyneuropathy	Designated			N/A	N/A	"Alnylam Pharmaceuticals, Inc."	300 Third Street		Cambridge	Maryland	2142	USA
synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 (HAO1) mRNA	n/a	2/8/16	Treatment of primary hyperoxaluria type 1	Designated			N/A	N/A	"Alnylam Pharmaceuticals, Inc."	300 Third Street		Cambridge	Massachusetts	2142	USA
Synthetic double-stranded small interfering RNA (siRNA) oligonucleotide targeting delta-aminoevulinic acid synthase 1	n/a	8/29/16	Treatment of acute hepatic porphyria	Designated			N/A	N/A	Alnylam Pharmaceuticals	300 Third Street		Cambridge	Massachusetts	2142	USA
Synthetic Human Parathyroid Hormone 1-34	n/a	1/26/01	Treatment of hypoparathyroidism	Designated/Withdrawn			N/A	N/A	"Rare Disease Therapeutics, Inc."	2550 Meridian Blvd		Nashville	Tennessee	37217	USA
Synthetic human secretin	n/a	6/16/99	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	Designated			N/A	N/A	"ChiRhoClin, Inc."	1550 Gallaudet Ave.		Silver Spring	Maryland	20905	USA
Synthetic human secretin	n/a	6/16/99	For use in the evaluation of exocrine pancreas function.	Designated			N/A	N/A	"ChiRhoClin, Inc."	1550 Gallaudet Ave.		Silver Spring	Maryland	20905	USA
Synthetic human secretin	n/a	3/7/00	"For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion."	Designated			N/A	N/A	"ChiRhoClin, Inc."	15500 Gallaudet Ave.		Silver Spring	Maryland	20905	USA
Synthetic human secretin	n/a	9/18/06	For use in conjunction with diagnostic procedures (excluding ERCP) for pancreatic disorders to increase pancreatic fluid secretion	Designated			N/A	N/A	"Innovate Biopharmaceuticals, Inc."	8601 Six Forks Road	Suite 400	Raleigh	North Carolina	27615	USA
Synthetic human secretin	Chirostim	6/16/99	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	Designated/Approved	Approved for Orphan Indication	"Stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction, stimulation of gastrin secretion to aid in the diagnosis of gastrinoma, and stimulation of pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography"	04/09/2004	N/A	"ChiRhoClin, Inc."	1550 Gallaudet Ave.		Silver Spring	Maryland	20905	USA
synthetic oligomer of 16 nucleotides	n/a	1/13/15	Treatment of myotonic dystrophy Type I	Designated			N/A	N/A	"Ionis Pharmaceuticals, Inc."	2855 Gazelle Ct.		Carlsbad	California	92010	USA
synthetic peptide H-D-Ala-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-D-Ala-OH	n/a	10/12/11	Treatment of necrotizing soft tissue infections (NSTI)	Designated			N/A	N/A	"Atox Bio, Inc."	3 Golda Meir St.		Ness Ziona			Israel
synthetic peptide; cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-ALA-Lys-Pro-Trp-Tyr-Cys	n/a	1/16/13	Treatment of high altitude pulmonary edema	Designated			N/A	N/A	Apeptico Forschung und Entwicklung GmbH	c/o mingo bueros	1150	Vienna			Austria
Synthetic porcine secretin	Secreflo	6/18/99	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	Designated/Approved	Approved for Orphan Indication	Use in secretin stimulation testing for stimulation of gastrin secretion to aid in the diagnosis of gastrinoma	04/04/2002	04/04/2009	"ChiRhoClin, Inc."	1550 Gallaudet Ave.		Silver Spring	Maryland	20905	USA
Synthetic porcine secretin	Secreflo	6/18/99	For use in the evaluation of exocrine pancreas function.	Designated/Approved	Approved for Orphan Indication	For use in secretin stimulation testing for: Stimulation of pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangio-pancreatography (ERCP)	11/01/2002	11/01/2009	"ChiRhoClin, Inc."	1550 Gallaudet Ave.		Silver Spring	Maryland	20905	USA
Synthetic porcine secretin	Secreflo	3/7/00	"For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion."	Designated/Approved	Approved for Orphan Indication	"Use in secretin stimulation testing for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction"	04/04/2002	04/04/2009	"ChiRhoClin, Inc."	15500 Gallaudet Ave.		Silver Spring	Maryland	20905	USA
Synthetic porcine secretin	n/a	6/18/99	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	Designated			N/A	N/A	"ChiRhoClin, Inc."	1550 Gallaudet Ave.		Silver Spring	Maryland	20905	USA
synthetic signal peptide of human mucin-1 (amino acids 1-21)	n/a	6/16/15	Treatment of multiple myeloma.	Designated			N/A	N/A	Vaxil Bio Therapeutics Ltd.	"13 Einstein St., Building 13A"	Nes-Ziona 7414001				Israel
"synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue"	n/a	3/16/12	Treatment of preterm neonatal respiratory distress syndrome	Designated			N/A	N/A	"Chiesi USA, Inc."	1255 Crescent Green Drivve	Suite 250	Cary	North Carolina	27518	USA
"T cell receptor (TCR) peptide (BV5S2, BV6S5, BV13S1) vaccine"	Neurovax	2/6/14	Treatment of Pediatric Multiple Sclerosis	Designated			N/A	N/A	"Immune Response BioPharma, Inc."	244 5th Avenue	Suite 1727	New York		10001	USA
T-cell depleted stem cell enriched cellular product from peripheal b lood stem cells	n/a	11/1/01	Treatment of chronic granulomatous disease	Designated			N/A	N/A	Nexell Therapeutics Inc.	9 Parker		Irvine	California	92618	USA
"T4 endonuclease V, liposome encapsulated"	n/a	6/27/89	To prevent cutaneous neoplasms and other skin abnormalities in xeroderma pigmentosum.	Designated			N/A	N/A	AGI Dermatics	205 Buffalo Avenue		Freeport	New York	11520	USA
tabalumab	n/a	11/19/12	Treatment of multiple myeloma	Designated/Withdrawn			N/A	N/A	Eli Lilly and Company	Lilly Corporate Center		Indianapolis	Indiana	46285	USA
taberminogene vadenovec	Trinam	10/24/00	Prevention of complications due to neointimal hyperplasia disease in certain vascular anastomoses.	Designated			N/A	N/A	"Finvector Vision Therapies, Ltd."	1 Fitzroy Mews	London				United Kingdom
tacrolimus	n/a	5/4/15	Treatment of pulmonary arterial hypertension	Designated			N/A	N/A	Stanford University School of Medicine	300 Pasteur Drive	Room H3143	Stanford	California	94305	USA
tacrolimus	n/a	3/16/15	Treatment of pulmonary arterial hypertension.	Designated			N/A	N/A	"VIVUS, Inc."	900 East Hamilton Avenue	Suite 550	Campbell	California	95008	USA
tacrolimus	n/a	7/6/12	Treatment of hemorrhagic cystitis	Designated			N/A	N/A	Lipella Pharmaceuticals Inc.	"400 N. Lexington Ave, LL105"		Pittsburgh	Pennsylvania	15208	USA
tacrolimus	Envarsus Xr	12/20/13	Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant	Designated/Approved	Approved for Orphan Indication	Prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants	07/10/2015	07/10/2022	"Veloxis Pharmaceuticals, Inc."	499 Thornall Street	3rd Floor	Edison	New Jersey	8837	USA
Tacrolimus	Prograf	6/6/05	Prophylaxis of organ rejection in patients receiving heart transplants.	Designated/Approved	Approved for Orphan Indication	Prophylaxis of organ rejection in patients receiving allogenic heart transplants.	03/29/2006	03/29/2013	"Astellas Pharma US, Inc."	Three Parkway North		Deerfield	Illinois	60015	USA
Tacrolimus	Prograf	4/6/98	Prophylaxis of graft-versus-host-disease.	Designated			N/A	N/A	"Fujisawa USA, Inc."	3 Parkway North Center		Deerfield	Illinois	60015	USA
Tacrolimus granules for oral suspension	n/a	10/4/16	"Prevention of rejection in kidney, liver or heart transplant in pediatric patients."	Designated			N/A	N/A	"Astellas Pharma Global Development, Inc."	1 Astellas Way		Northbrook	Illinois	60062	USA
tadalafil	Adcirca	12/18/06	Treatment of pulmonary arterial hypertension	Designated/Approved	Approved for Orphan Indication	Treatment of pulmonary arterial hypertension (WHO Group I) to improve exercise ability	05/22/2009	05/22/2016	Eli Lilly and Company	Lilly Corporate Center		Indianapolis	Indiana	46285	USA
tadalafil	Cialis(R); Adcirca(R)	5/4/15	Treatment of Duchenne Muscular Dystrophy (DMD)	Designated			N/A	N/A	Eli Lilly and Company	Lilly Corporate Center		Indianapolis	Indiana	46285	USA
tadekinig alfa	n/a	1/12/17	Treatment of hemophagocytic lymphohistiocytosis.	Designated			N/A	N/A	AB2 Bio Ltd	EPFL Innovation Park	Building B	Lausanne			Switzerland
tafamidis	n/a	5/23/06	Treatment of familial amyloid polyneuropathy	Designated			N/A	N/A	"Pfizer, Inc."	P. O. Box 8299		Philadelphia	Pennsylvania	19101	USA
tafamidis meglumine	n/a	2/17/12	Treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy.	Designated			N/A	N/A	"Pfizer, Inc."	500 Arcola Road		Collegeville	Pennsylvania	19426	USA
tafenoquine	n/a	1/15/13	Treatment of malaria	Designated			N/A	N/A	"Glaxo Group Limited, England"	Glaxo Wellcome House	"Greenford, Middlesex, UB6 0NN"				United Kingdom
Talactoferrin alfa	n/a	8/8/07	Treatment of stage III/IV non-small cell lung cancer	Designated/Withdrawn			N/A	N/A	"Agennix, Inc."	8 Greenway Plaza	Suite 910	Houston	Texas	77046	USA
talactoferrin alfa	n/a	8/20/03	For the treatment of graft versus host disease	Designated			N/A	N/A	"Agennix, Inc."	Greenway Plaza	Suite 910	Houston	Texas	77046	USA
talactoferrin alfa	n/a	9/29/06	Treatment of renal cell carcinoma	Designated/Withdrawn			N/A	N/A	"Agennix, Inc."	8 Greenway Plaza	Suite 910	Houston	Texas	77046	USA
talactoferrin alfa	n/a	8/20/03	For the prevention of graft-versus-host disease	Designated			N/A	N/A	"Agennix, Inc."	Greenway Plaza	Suite 910	Houston	Texas	77046	USA
talampanel	n/a	3/24/08	Treatment of amyotrophic lateral sclerosis	Designated/Withdrawn			N/A	N/A	TEVA Neuroscience	P. O. Box 1005	425 Privet Road	Horsham	Pennsylvania	19044	USA
talampanel	n/a	2/17/09	Treatment of glioma	Designated/Withdrawn			N/A	N/A	"TEVA Neuroscience, Inc."	425 Privet Road		Horsham	Pennsylvania	19044	USA
talarazole	n/a	3/16/12	Treatment of congenital ichthyosis	Designated/Withdrawn			N/A	N/A	"Stiefel Laboratories, Inc."	20 T.W. Alexander Drive		Research Triangle Park	North Carolina	27709	USA
Taliglucerase alfa	Elelyso For Injection	9/3/09	Treatment of Gaucher's disease	Designated/Approved	Approved for Orphan Indication	Use as long-term enzyme replacement therapy in patients with Type 1 Gaucher disease	05/01/2012	N/A	"Pfizer, Inc."	235 East 42nd Street		New York	New York	10017	USA
talimogene laherparepvec	Imlygic	3/14/11	Treatment of stage IIb-stage IV melanoma	Designated/Approved	Approved for Orphan Indication	"Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery"	10/27/2015	10/27/2022	"BioVex, Inc. (subsidiary of Amgen)"	Amgen	Mail Stop 17-2-B	Thousand Oaks	California	91320	USA
Talotrexin	n/a	5/8/06	Treatment of acute lymphoblastic leukemia	Designated/Withdrawn			N/A	N/A	"Hana Biosciences, Inc."	7000 Shoreline Court	Suite 370	South San Francisco	California	94080	USA
Tamibarotene	n/a	10/11/07	Treatment of acute promyelocytic leukemia (APL).	Designated			N/A	N/A	CytRx Corporation	3030 Bunker Hill Road	Suite 101	San Diego	California	92109	USA
Tanespimycin	n/a	9/9/04	Treatment of multiple myeloma	Designated			N/A	N/A	Bristol-Myers Squibb	Research and Development	5 Research Parkway	Wallingford	Connecticut	6492	USA
tarextumab	n/a	1/26/15	Treatment of pancreatic cancer	Designated			N/A	N/A	"OncoMed Pharmaceuticals, Inc."	800 Chesapeake Drive		Redwood City	California	94063	USA
tarextumab	n/a	1/26/15	Treatment of small cell lung cancer	Designated			N/A	N/A	"OncoMed Pharmaceuticals, Inc."	800 Chesapeake Drive		Redwood City	California	94063	USA
Targeted Gastrin 17 Complexed Peptide	n/a	5/14/14	Treatment of pancreatic cancer	Designated			N/A	N/A	Tyg Oncology Ltd	"Synergy House, 7 Acorn Business Park"	Nottinghamshire NG18 1 EX				United Kingdom
tasimelteon	n/a	4/30/10	Treatment of sleep-wake disorder in Smith-Magenis syndrome associated with diurnal melatonin secretion	Designated			N/A	N/A	"Vanda Pharmaceuticals, Inc."	9605 Medical Center Drive		Rockville	Maryland	20850	USA
tasimelteon	Hetlioz	1/19/10	Non-24-hour sleepwake disorder in blind individuals without light perception	Designated/Approved	Approved for Orphan Indication	Treatment of non-24-hour sleep-wake disorder	01/31/2014	01/31/2021	"Vanda Pharmaceuticals, Inc."	"2200 Penn. Ave., NW"	Suite 300 E	Washington	District of Columbia	20037	USA
tasisulam sodium	n/a	9/3/09	Treatment of melanoma stages IIB through IV	Designated/Withdrawn			N/A	N/A	Eli Lilly and Company	Lilly Corporate Center		Indianapolis	Indiana	46285	USA
taurine	n/a	3/22/10	Treatment of cystathionine beta-synthase deficient homocystinuria	Designated			N/A	N/A	"Johan L. Van Hove, MD, PhD"	Department of Pediatrics/University of Colorado De	"13121 E. 17th Ave., P. O. Box 6508"	Aurora	Colorado	80045	USA
taurolidine	n/a	5/16/16	Treatment of pancreatic cancer.	Designated			N/A	N/A	"Geistlich Pharma NA, Inc."	202 Carnegie Center Drive		Princeton	New Jersey	8540	USA
Taxol isolated from Taxus brevifolia	n/a	10/15/90	Treatment of ovarian cancer.	Designated/Withdrawn			N/A	N/A	Bristol-Myers Squibb	5 Research Parkway		Wallingford	Connecticut	6492	USA
tazemetostat	n/a	2/4/16	Treatment of malignant rhabdoid tumors (MRTs)	Designated			N/A	N/A	Epizyme Inc.	400 Technology Square	4th Floor	Cambridge	Massachusetts	2139	USA
TD-K6a.513a.12	Reveker	6/15/06	Treatment of pachyonychia congenita	Designated			N/A	N/A	"TransDerm, Inc."	2161 Delaware Aenue		Santa Cruz	California	95060	USA
technetium Tc 99m tilmanocept	Lymphoseek	9/17/14	"Use in sentinel lymph node detection (SLN) with a hand-held gamma-counter, with scintigraphic imaging, in patients with cancer of the head and neck"	Designated/Approved	Approved for Orphan Indication	"Guiding sentinel lymph node biopsy, using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity."	06/13/2014	06/13/2021	Navidea Biopharmaceuticals	"5600 Blazer Parkway, Suite 200"		Dublin	Ohio	43017	USA
Technetium Tc99m anti-melanoma murine monoclonal antibody	Oncotrac Melanoma Imaging Kit	6/2/87	"For use in detecting, by imaging, metastases of malignant melanoma."	Designated/Withdrawn			N/A	N/A	NeoRx Corporation	410 West Harrison		Seattle	Washington	98119	USA
Technetium Tc99m murine monoclonal antibody (IgG2a) to B cell	Lymphoscan	4/7/92	"Diagnostic imaging in the evaluation of the extent of disease in patients with histologically confirmed diagnosis of non-Hodgkin's B-cell lymphoma, acute B-cell lymphoblastic leukemia (in children and adults), and chronic B-cell lymphocytic leukemia."	Designated			N/A	N/A	"Immunomedics, Inc."	300 The American Road		Morris Plains	New Jersey	7950	USA
Technetium Tc99m murine monoclonal antibody to hCG	"Immuraid, Hcg-Tc-99m"	8/7/89	Detection of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Designated/Withdrawn			N/A	N/A	"Immunomedics, Inc."	300 American Road		Morris Plains	New Jersey	7950	USA
Technetium Tc99m murine monoclonal antibody to human AFP	Afp-Scan	8/1/89	Detection of alpha-fetoprotein producing germ cell tumors.	Designated/Withdrawn			N/A	N/A	"Immunomedics, Inc."	300 American Road		Morris Plains	New Jersey	7950	USA
Technetium Tc99m murine monoclonal antibody to human alpha-fetoprotein	"Immuraid, Afp-Scan"	8/1/89	Detection of hepatocellular carcinoma and hepatoblastoma.	Designated/Withdrawn			N/A	N/A	"Immunomedics, Inc."	300 American Road		Morris Plains	New Jersey	7950	USA
Technetium Tc99m rh-Annexin V	Apomate	11/3/00	"Diagnosis or assessment of rejection status in heart, heart-lung, single lung, or bilateral lung transplants."	Designated			N/A	N/A	Theseus Imaging Corporation	124 Mount Auburn Street	Suite 200 North	Cambridge	Massachusetts	2138	USA
"Technetium Tc99m sulfur colloid injection, lyophilized"	Technetium Tc99m Sulfur Colloi	3/17/09	For localization of sentinel lymph nodes in patients with melanoma.	Designated/Approved	Approved for Orphan Indication	Localization of lymph nodes draining a primary tumor in patients with melanoma when used with a hand-held gamma counter	08/13/2012	08/13/2019	"Pharmalucence, Inc."	10 DeAngelo Drive		Bedford	Massachusetts	1730	USA
tecovirimat	n/a	12/27/06	Treatment of smallpox.	Designated			N/A	N/A	"SIGA Technologies, Inc."	4575 SW Research Way	Suite 230	Corvallis	Oregon	97333	USA
tecovirimat	n/a	12/18/06	post exposure prophylaxis against smallpox	Designated			N/A	N/A	"SIGA Technologies, Inc."	4575 SW Research Way	Suite 230	Corvallis	Oregon	97333	USA
tecovirimat	n/a	9/29/10	Treatment of orthopoxvirus infections.	Designated			N/A	N/A	"SIGA Technologies, Inc."	4575 SW Research Way		Corvallis	Oregon	97333	USA
teduglutide [rDNA origin]	Gattex	6/29/00	Treatment of short bowel syndrome.	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support	12/21/2012	12/21/2019	"NPS Pharmaceuticals, Inc."	550 Hills Drive	Third Floor	Bedminster	New Jersey	7921	USA
Tegafur/gimeracil/oteracil	n/a	7/20/06	Treatment of gastric cancer	Designated			N/A	N/A	"Taiho Pharma USA, Inc."	210 Carnegie Center		Princeton	New Jersey	8540	USA
telatinib	n/a	5/17/10	Treatment of gastric cancer	Designated			N/A	N/A	ACT Biotech Inc.	717 market St #650	Suite 650	San Francisco	California	94103	USA
telotristat etiprate	n/a	3/9/12	Treatment of carcinoid syndrome in patients with neuroendocrine tumors	Designated			N/A	N/A	"Lexicon Pharmaceuticals, Inc."	8800 Technology Forest Drive		The Woodlands	Texas	77381	USA
temocillin sodium	Negaban	4/21/04	Treatment of pulmonary infections caused by Burkholderia cepacia	Designated			N/A	N/A	Belpharma S.A.	"127, rue of Munlenbach"	L-2168	Luxembourg			Germany
Temoporfin	Foscan	10/28/99	"Palliative treatment of recurrent, refractory or second primary squamous cell carcinomas of the head and neck in patients considered to be incurable with surgery or radiotherapy."	Designated			N/A	N/A	Biolitec Pharma Ireland Ltd.	United Drug House	Dublin				Ireland
Temozolomide	Temodal	10/14/98	Treatment of advanced metastatic melanoma.	Designated			N/A	N/A	Schering-Plough Research Institute	2000 Galloping Hill Rd.		Kenilworth	New Jersey	7033	USA
temozolomide	Temodar	10/5/98	Treatment of recurrent malignant glioma.	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with refractory anaplastic astrocytoma, i.e., patients at first relapse who have experienced disease progression on a drug regimen containing a nitrosourea and procarbazine"	08/11/1999	08/11/2006	Schering-Plough Research Institute	2000 Galloping Hill Rd.		Kenilworth	New Jersey	7033	USA
Temozolomide	Temodal	10/18/04	Treatment of newly diagnosed high grade glioma	Designated			N/A	N/A	Schering-Plough Research Institute	2000 Galloping Hill Road		Kenilworth	New Jersey	7033	USA
temozolomide	n/a	11/25/15	Treatment glioblastoma multiforme in pediatric patients	Designated			N/A	N/A	"AmpliPharm Pharmaceuticals, LLC"	970 Peachtree Industrial Boulevard	Suite 100	Suwanee	Georgia	30024	USA
temozolomide	Temodar	10/5/98	Treatment of recurrent malignant glioma.	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with newly diagnosed glioblastoma multiforme concomitatly with radiotherapy and then as maintenance treatment	03/15/2005	03/15/2012	Schering-Plough Research Institute	2000 Galloping Hill Rd.		Kenilworth	New Jersey	7033	USA
Temsirolimus	Torisel	12/16/04	Treatment of renal cell carcinoma	Designated/Approved	Approved for Orphan Indication	Treatment of advanced renal cell carcinoma	05/30/2007	05/30/2014	"Wyeth Pharmaceuticals, Inc."	P. O. Box 8299		Philadelphia	Pennsylvania	19101	USA
tenecteplase	n/a	5/15/09	Restore function to hemodialysis catheters	Designated/Withdrawn			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
Teniposide	Vumon For Injection	11/1/84	Treatment of refractory childhood acute lymphocytic leukemia.	Designated/Approved	Approved for Orphan Indication	Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents.	07/14/1992	07/14/1999	Bristol-Myers Squibb Pharmaceutical Research Institute	5 Research Parkway	P.O. Box 5100	Wallingford	Connecticut	6492	USA
tenofovir	Viread	3/17/09	Treatment of pediatric HIV infection.	Designated/Approved	Approved for Orphan Indication	Treatment of HIV infection in combination with other antiretroviral agents in patients 12 to less than 18 years of age	03/24/2010	03/24/2017	"Gilead Sciences, Inc."	333 Lakeside Drive		Foster city	California	94404	USA
tenofovir disoproxil fumarate	Viread	9/27/16	Prevention of mother to child transmission of hepatitis B virus	Designated			N/A	N/A	"Gilead Sciences, Inc."	333 Lakeside Drive		Foster City	California	94404	USA
teprotumumab	n/a	5/6/13	Treatment of active (dynamic) phase Grave's orbitopathy	Designated			N/A	N/A	"River Vision, Inc."	One Rockefeller Plaza	Suite 1204	New York	New York	10020	USA
terguride	n/a	5/2/08	Treatment of pulmonary arterial hypertension	Designated/Withdrawn			N/A	N/A	ErgoNex Pharma GmbH	Ruetistr. 20	CH-9050 Appenzell				Switzerland
terguride	"Mysalfon, Teluron"	5/17/13	Treatment of systemic sclerosis	Designated			N/A	N/A	Medac GmbH	TheaterstraBe 6+		Wedel			Germany
Teriparatide	Parathar	10/28/99	Treatment of idiopathic osteoporosis.	Designated			N/A	N/A	"Biomeasure, Inc."	27 Maple St.		Milford	Massachusetts	1757	USA
Teriparatide	Parathar	1/9/87	Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism.	Designated/Approved	Approved for Orphan Indication		12/23/1987	12/23/1994	"Rhone-Poulenc Rorer Pharmaceuticals, Inc."	500 Arcola Road		Collegeville	Pennsylvania	19426	USA
teriparatide	Forteo	4/18/14	Treatment of hypoparathyroidism	Designated			N/A	N/A	"Entera Bio, Ltd."	"Kiryat Hadassah Minrav Bldg, 5th Floor"	P. O. Box 12117	Jeusalem			Israel
Terlipressin	Glypressin	3/6/86	Treatment of bleeding esophageal varices.	Designated			N/A	N/A	"Ferring Laboratories, Inc."	"400 Rella Boulevard, Suite 201"		Suffern	New York	10901	USA
terlipressin	n/a	9/8/16	Treatment of ascites due to all etiologies except cancer	Designated			N/A	N/A	Bio Vie Inc.	100 Cummings Center	Suite 247-C	Beverly	Massachusetts	1915	USA
terlipressin	n/a	10/29/04	Treatment of Hepatorenal Syndrome	Designated			N/A	N/A	Ikaria (INO Therapeutics)	Perryville III Corporate Park	"53 Frontage Road, Third Floor"	Hampton	New Jersey	8827	USA
tesetaxel	n/a	11/21/08	"Treatment of stages IIB, IIC, III, and stage IV melanoma"	Designated			N/A	N/A	"Genta, Inc."	200 Connell Drive		Berkley Heights	New Jersey	7922	USA
tesetaxel	n/a	12/22/08	Treatment of gastric cancer	Designated			N/A	N/A	Genta Inc.	200 Connell Drive		Berkeley Heights	New Jersey	7922	USA
Tesevatinib	n/a	3/1/16	Treatment of patients with autosomal recessive polycystic kidney disease (ARPKD)	Designated			N/A	N/A	"Kadmon Corporation, LLC"	450 East 29th Street		New York	New York	10016	USA
Testosterone	Androgel	2/5/96	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Designated/Withdrawn			N/A	N/A	"Unimed Pharmaceuticals, Inc."	901 Sawyer Rd.		Marietta	Georgia	30062	USA
Testosterone	Theraderm Testosterone Transdermal System	9/22/97	For use as physiologic testosterone replacement in androgen deficient HIV+ patients with an associated weight loss.	Designated			N/A	N/A	Watson Laboratories	Research Park	417 Wakara Way	Salt Lake City	Utah	84108	USA
Testosterone propionate ointment 2%	n/a	7/31/91	Treatment of vulvar dystrophies.	Designated			N/A	N/A	"Star Pharmaceuticals, Inc."	1990 N.W. 44th Street		Pompano Beach	Florida	33064	USA
Testosterone sublingual	n/a	1/16/91	Treatment of constitutional delay of growth and puberty in boys.	Designated/Withdrawn			N/A	N/A	Bio-Technology General Corp.	"70 Wood Avenue, South"		Iselin	New Jersey	8830	USA
testosterone undecanoate (oral)	n/a	2/13/13	Treatment of constitutional delay in growth and puberty in adolescent boys (14-17 yrs of age)	Designated			N/A	N/A	"SOV Therapeutics, Inc."	101 Guymon Court		Morrisville	North Carolina	27560	USA
tetra substituted prophyrin derivative containing manganese (III)	n/a	1/17/14	For use in patients exposed to radiation following a nuclear accident or detonation in order to treat or mitigate acute radiation syndrome.	Designated			N/A	N/A	"Aeolus Pharmaceuticals, Inc."	26361 Crown Valley Parkway	Suite 150	Mission Viejo	California	92691	USA
tetra-substituted porphyrin derivative containing manganese (III)	n/a	3/16/15	Treatment of idiopathic pulmonary fibrosis	Designated			N/A	N/A	Aeolus Pharmaceuticals	26361 Crown Valley Parkway	Suite 150	Mission Viejo	California	92691	USA
Tetrabenazine	n/a	5/12/98	Treatment of moderate/severe tardive dyskinesia.	Designated			N/A	N/A	"Prestwick Pharmaceuticals, Inc."	"1825 K Street, NW"	Suite 1475	Washington	District of Columbia	20006	USA
Tetrabenazine	Xenazine	12/11/97	Treatment of Huntington's disease	Designated/Approved	Approved for Orphan Indication	Treatment of chorea associated with Huntington's disease	08/15/2008	08/15/2015	"Prestwick Pharmaceuticals, Inc"	1825 K Street NW	Suite 1475	Washington	District of Columbia	20006	USA
tetrabenazine	n/a	7/1/09	"Treatment of Tourette's Syndrome in school-age children, ages 5-16"	Designated			N/A	N/A	Valeant International (Barbados) SRL	Welches Christ Church	"Barbados, BB17154"				Barbados
tetracosactide hexaacetate (beta 1-24-corticotrophin)	"Synacthen Depot, S. Retard"	10/31/12	Treatment of infantile spasms	Designated			N/A	N/A	"Cerium Pharmaceuticals, Inc."	817-B Linsdale Street		Gaithersburg	Maryland	20878	USA
"tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride"	n/a	6/20/16	Treatment of infantile spasms	Designated			N/A	N/A	Anavex Life Sciences Corp.	51 West 52nd Street	7th Floor	New York	New York	10019	USA
Tetraiodothyroacetic acid	n/a	5/1/00	Suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.	Designated			N/A	N/A	"Danforth, Jr., MD, Elliot"	University of Vermont	84 Beartown Rd.	Underhill	Vermont	5489	USA
tetrandrine	n/a	5/19/16	Treatment of chronic myeloid leukemia.	Designated			N/A	N/A	"Escend Pharmaceuticals, Inc."	3475 Edison Way	Suite R	Menlo Park	California	94025	USA
tetrandrine	n/a	12/13/16	Treatment of acute myeloid leukemia.	Designated			N/A	N/A	"Escend Pharmaceuticals, Inc."	3475 Edison Way	Suite R	Menlo Park	California	94025	USA
Tezacitabine	n/a	1/27/03	Treatment of adenocarcinoma of the esophagus and stomach	Designated			N/A	N/A	"Sanofi-Aventis US, Inc."	9 Great valley Parkway		Malvern	Pennsylvania	19355	USA
Thalidomide	n/a	1/12/93	Treatment of the clinical manifestations of mycobacterial infection caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria.	Designated			N/A	N/A	Celgene Corporation	7 Powder Horn Dr.		Warren			
Thalidomide	n/a	11/15/88	Treatment and maintenance of reactional lepromatous leprosy.	Designated			N/A	N/A	"Pediatric Pharmaceuticals, Inc."	718 Bradford Avenue		Westfield	New Jersey	7090	USA
Thalidomide	n/a	5/1/95	"Treatment of severe recurrent aphthous stomatitis in severely, terminally immunocompromised patients."	Designated			N/A	N/A	Celgene Corporation	7 Powder Horn Dr.		Warren			
Thalidomide	n/a	7/29/98	Treatment of Kaposi's sarcoma.	Designated			N/A	N/A	Celgene Corporation	7 Powder Horn Dr.		Warren			
Thalidomide	Thalomid	4/6/99	Treatment of Crohn's disease.	Designated			N/A	N/A	Celgene Corporation	7 Powder Horn Dr.		Warren			
Thalidomide	n/a	3/5/90	Treatment of graft versus host disease.	Designated			N/A	N/A	Andrulis Research Corporation	"11800 Baltimore Avenue, Suite 113"		Beltsville	Maryland	20705	USA
Thalidomide	Thalomid	7/26/95	Treatment of erythema nodosum leprosum.	Designated/Approved	Approved for Orphan Indication	Acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) and as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrences.	07/16/1998	07/16/2005	Celgene Corporation	86 Morris Avenue		Summit	New Jersey	7901	USA
thalidomide	n/a	9/19/88	1. Treatment of graft versus host disease in patients receiving bone marrow transplantation 2. Prevention of graft versus host disease in patients receiving bone marrow transplantation	Designated			N/A	N/A	"Pediatric Pharmaceuticals, Inc."	718 Bradford Avenue		Westfield	New Jersey	7090	USA
Thalidomide	n/a	3/5/90	Prevention of graft versus host disease.	Designated			N/A	N/A	Andrulis Research Corporation	"11800 Baltimore Avenue, Suite 113"		Beltsville	Maryland	20705	USA
Thalidomide	n/a	2/27/98	Treatment of primary brain malignancies.	Designated			N/A	N/A	Celgene Corporation	7 Powder Horn Dr.		Warren			
Thalidomide	Thalomid	10/14/98	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with newly diagnosed multiple myeloma	05/25/2006	05/25/2013	Celgene Corporation	7 Powder Horn Dr.		Warren			
Thalidomide	Synovir	3/11/96	Treatment of HIV-associated wasting syndrome.	Designated			N/A	N/A	Celgene Corporation	7 Powder Horn Dr.		Warren			
Thalidomide	n/a	5/15/95	"Treatment and prevention of recurrent aphthous ulcers in severely, terminally immunocompromised patients."	Designated			N/A	N/A	Andrulis Research Corporation	"11800 Baltimore Avenue, Suite 113"		Beltsville	Maryland	20705	USA
Thalidomide	Thalomid	9/27/04	Treatment of myelodysplastic syndrome	Designated			N/A	N/A	Celgene Corporation	86 Morris Avenue		Summit	New Jersey	7901	USA
Thawed donor matched banked umbilical cord blood enriched by cell sorting to produce a subpopulation expressing high levels of intracellular aldehyde dehydrogenase	n/a	10/23/08	To improve patient outcomes by decreasing time to platlet and neutrophil engraftment in patients with inherited metabolic diseases (IMD) undergoing umbilical cord blood transplantation.	Designated			N/A	N/A	"Aldagen, Inc."	2810 Meridian Parkway		Durham	North Carolina	27713	USA
Theranost 68 Ga RGD	n/a	10/1/14	A Diagnostic for the management of Moyamoya disease (MMD)	Designated			N/A	N/A	"Advanced Imaging Projects, LLC (AIP)"	3651 FAU Blvd.		Boca Raton	Florida	33467	USA
Theranost 68Ga RGD	n/a	1/26/15	Diagnostic for the clinical management of patients with tuberculosis	Designated			N/A	N/A	"Advanced Imaging Projects, LLC"	FL ATlantic University Research Park	3651 FAU Blvd	Boca Raton	Florida	33431	USA
theranost 68Ga-RGD	n/a	12/8/14	Diagnostic for clinical management of patients with neuroblastoma	Designated			N/A	N/A	"Advanced Imaging Projects, LLC"	Florida Atlantic University Research Park	3651 FAU Blvd	Boca Raton	Florida	33431	USA
Thiotepa	Tepadina	4/2/07	Conditioning treatment prior to hematopoietic stem cell transplantation	Designated/Approved	Approved for Orphan Indication	Indicated for reducing the risk of graft rejection when used in conjunction with	01/26/2017	TBD	Adienne S.A.	"Via Zurigo, 46"	6900 Lugano				Switzerland
thioureidobutyronitrile	Kevetrin	1/20/16	Treatment of pancreatic cancer.	Designated			N/A	N/A	Cellceutix Corporation	100 Cummings Center	Suite 151-B	Beverly	Massachusetts	1915	USA
thioureidobutyronitrile	Kevetrin	7/14/15	Treatment of ovarian cancer	Designated			N/A	N/A	Cellceutix Corporation	100 Cummings Center	Suite 151-B	Beverly	Massachusetts	1915	USA
thioureidobutyronitrile	Kevetrin	11/17/15	Treatment of retinoblastoma.	Designated			N/A	N/A	Cellceutix Corporation	100 Cummings Center	Suite 151-B	Beverly	Massachusetts	1915	USA
"three human IgG1 mAbs (REGN3470, REGN3471, and REGN3479) directed against different epitopes on Ebola virus glycoprotein"	n/a	7/14/16	Treatment of ebola virus infection	Designated			N/A	N/A	"Regeneron Pharmaceuticals, Inc."	777 Old Saw Mill River Road		Tarrytown	New York	10591	USA
Thymalfasin	Zadaxin	3/6/00	Treatment of hepatocellular carcinoma.	Designated			N/A	N/A	"SciClone Pharmaceuticals, Inc."	950 Tower Lane	Suite 900	Foster city	California	94404	USA
Thymalfasin	Zadaxin	1/8/98	Treatment of DiGeorge anomaly with immune defects.	Designated			N/A	N/A	"SciClone Pharmaceuticals, Inc."	901 Mariner's Island Blvd.		San Mateo	California	94404	USA
Thymalfasin	Zadaxin	3/13/06	Treatment of stage IIb through Stage IV malignant melanoma	Designated			N/A	N/A	"SciClone Pharmaceuticals, Inc."	950 Tower Lane	Suite 900	Foster City	California	94404	USA
Thymalfasin	Zadaxin	5/3/91	Treatment of chronic active hepatitis B.	Designated			N/A	N/A	"SciClone Pharmaceuticals, Inc."	950 Tower Lane	Suite 900	Foster City	California	94404	USA
thymopentin	n/a	2/4/11	Treatment of sarcoidosis.	Designated			N/A	N/A	Mondobiotech Laboratories AG	Herrengasse 21	Furstentum Liechtenstein				Switzerland
thymosin beta 4	n/a	12/31/13	Treatment of patients with neurotrophic keratopathy	Designated			N/A	N/A	"ReGenTree, LLC"	116 Village Blvd	Suite 200	Princeton	New Jersey	8540	USA
Thymosin beta 4	n/a	5/28/04	Treatment of epidermolysis bullosa.	Designated			N/A	N/A	"GtreeBNT Co., Ltd"	"22nd Fl, Parkview Tower"	"248 Jungjail-ro, Bundang-gu"	Gyeonggi-do			"Korea, Republic of"
Thymoxamine HCl	n/a	11/16/87	Reversal of phenylephrine-induced mydriasis in patients who have narrow anterior angles and are at risk of developing an acute attack of angle-closure glaucoma following mydriasis.	Designated/Withdrawn			N/A	N/A	Iolab Pharmaceuticals	500 Iolab Drive		Claremont	California	94608	USA
Thyrotropin alfa	Thyrogen	8/3/01	"Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid"	Designated/Approved	Approved for Orphan Indication	For use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of metastatic thyroid cancer	12/14/2007	12/14/2014	Genzyme Corporation	One Kendall Square		Cambridge	Massachusetts	2139	USA
Thyrotropin alpha	Thyrogen	2/24/92	As an adjunct in the diagnosis of thyroid cancer.	Designated/Approved	Approved for Orphan Indication	As an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with thyroid cancer.	11/30/1998	11/30/2005	Genzyme Corporation	One Kendall Square		Cambridge	Massachusetts	2139	USA
Tiapride	n/a	4/21/98	Treatment of Tourette's syndrome.	Designated/Withdrawn			N/A	N/A	"Sanofi-Synthelabo, Inc."	9 Great Valley Parkway	PO Box 3026	Malvern	Pennsylvania	19355	USA
Tiazofurin (2-Beta-D-ribofuranosyl-4-thiazolecarboxamide)	n/a	12/27/00	Chronic myelogenous leukemia (CML)	Designated			N/A	N/A	Valeant Pharmaceuticals North America	3300 Hyland Avenue		Costa Mesa	California	92626	USA
tigecycline	n/a	10/23/13	Treatment of acute myeloid leukemia.	Designated			N/A	N/A	"Trillium Therapeutics, Inc."	96 Skyway Avenue	"Toronto, ON M9W 4Y9"				Canada
Tilarginine acetate	n/a	4/11/05	Treatment of cardiogenic shock	Designated			N/A	N/A	"Arginox Pharmceuticals, Inc."	120 Constitution Drive		Menlo Park	California	94025	USA
tin ethyl etiopurpurin	n/a	11/4/03	Prevention of access graft disease in hemodialysis patients	Designated			N/A	N/A	Miravant Medical Technologies	336 Bollay Drive		Goleta	California	93117	USA
tinidazole	Tindamax	4/18/02	Treatment of giardiasis	Designated/Approved	Approved for Orphan Indication	Treatment of giardiasis caused by G. duodenalis (also termed G. lamblia) in both adults and pediatric patients older than three years of age	05/17/2004	05/17/2011	"Presutti Laboratories, Inc."	1607 N. Douglas Avenue		Arlington Heights	Illinois	60004	USA
Tinidazole	Tindamax	8/20/03	Treatment of amebiasis	Designated/Approved	Approved for Orphan Indication	Treatment of intestinal amebiasis and amebic liver abcess caused by E. histolytica in both adults and pediatric patients older than three years of age. It is not indicated for the treatment of asymptomatic cyst passage.	05/17/2004	05/17/2011	"Presutti Laboratories, Inc."	1607 N. Douglas Avenue		Arlington Heights	Illinois	60004	USA
Tiopronin	Thiola	1/17/86	Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.	Designated/Approved	Approved for Orphan Indication		08/11/1988	08/11/1995	"Pak, Charles Y.C. M.D."	The University of Texas Health Scienc Center at Da	5323 Harry Hines Boulevard	Dallas	Texas	75235	USA
Tiotropium bromide	Spiriva	1/8/08	To improve pulmonary function in conjunction with standard therapy in the management of patients with cystic fibrosis	Designated			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc."	P. O. Box 368	900 Ridgebury Road	Ridgefield	Connecticut	6877	USA
tipelukast	n/a	10/20/14	Treatment of idiopathic pulmonary fibrosis	Designated			N/A	N/A	"MediciNova, Inc."	4275 Executive Square	Suite 650	La Jolla	California	92037	USA
Tipifarnib	Zarnestra	7/6/04	Treatment of acute myeloid leukemia	Designated			N/A	N/A	Johnson & Johnson Pharmaceutical Research & Dev.	920 U.S. Highway 202		Raritan	New Jersey	8869	USA
tiprelestat	Elafin	12/28/12	Treatment of pulmonary arterial hypertension	Designated			N/A	N/A	Proteo Biotech AG	Am Kiel-Kanal 44					Germany
tirapazamine	n/a	10/23/02	Treatment of head and neck cancer	Designated			N/A	N/A	"Sanofi-Aventis US, Inc."	11 Great Valley Parkway	P. O. Box 3026	Malvern	Pennsylvania	19355	USA
tirapazamine	n/a	11/30/15	Treatment of hepatocellular carcinoma	Designated			N/A	N/A	Teclison Limited	28 Baltusrol Way		Short Hills	New Jersey	7078	USA
tirasemtiv	n/a	3/2/10	Treatment of amyotrophic lateral sclerosis (ALS)	Designated			N/A	N/A	Cytokinetics Inc.	280 East Grand Avenue		South San Francisco	California	94080	USA
Tiratricol	Triacana	8/13/91	For use in combination with levo-thyroxine to suppress thyroid stimulating hormone in patients with well-differentiated thyroid cancer who are intolerant to adequate doses of levo-thyroxine alone.	Designated			N/A	N/A	Laphal Laboratoires	"48 Bis, Rue des Belles-Feuilles"	75116 Paris				France
tisagenlecleucel-T	n/a	2/3/15	Treatment of diffuse large B-cell lymphoma	Designated			N/A	N/A	Novartis Pharmaceuticals Corporation	"One Health Plaza,"	Bldg 315 - Room 3450B	East Hanover	New Jersey	7936	USA
Tissue Plasminogen activator	n/a	4/18/11	Treatment of acute ischemic stroke (AIS) in children age 16 years and younger.	Designated			N/A	N/A	"Catherine Amlie-Lefond, MD"	University of Washington	4800 Sand Point Way NE - M/S B5552	Seattle	Washington	98105	USA
Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system	n/a	3/13/06	Treatment of osteonecrosis.	Designated			N/A	N/A	"Aastrom Biosciences, Inc."	"Domino's Farms, Lobby K"	24 Frank Lloyd Wright Drive	Ann Arbor	Michigan	48105	USA
Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system	n/a	1/25/07	Treatment of dilated cardiomyopathy	Designated			N/A	N/A	Vericel Corporation.	"Domino's Farms, Lobby L"	24 Frank Lloyd Wright Drive	Ann Arbor	Michigan	48105	USA
Titanium dioxide and bisoctrizole	n/a	5/25/05	"For the secondary prevention (prevention of lesional induction) of disorders with UV-A and visible light-induced photosensitivity, specifically Actinic prurigo, Hydroa vacciniforme, Solar urticara (SU), Chronic Actinic Dermatitis (CAD), the cutaneous prophyrias, Smith-Lemli-Optiz Syndrome, and Hartnup's Disease."	Designated/Withdrawn			N/A	N/A	Orfagen	CRDPF - LANGLADE	31035 Toulouse Cedex				France
tivantinib	n/a	10/16/13	Treatment of hepatocelular carcinoma	Designated			N/A	N/A	Daiichi Sankyo Pharma Development	399 Thornall Street		Edison	New Jersey	8837	USA
Tizanidine HCl	Zanaflex	1/31/94	Treatment of spasticity associated with multiple sclerosis and spinal cord injury.	Designated			N/A	N/A	"Athena Neurosciences, Inc."	800 Gateway Boulevard		South San Francisco	California	94080	USA
Tobramycin	Tobi	6/18/99	Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.	Designated			N/A	N/A	Novartis Pharmaceuticals Corp.	"Bldg 100, Room 130"	One Health Plaza	East Hanover	New Jersey	7936	USA
Tobramycin for inhalation	Tobi	10/13/94	Treatment of bronchopulmonary infections of Pseudomonas aeruginosa in cystic fibrosis patients.	Designated/Approved	Approved for Orphan Indication	Management of cystic fibrosis patients with P.aeruginosa.	12/22/1997	12/22/2004	Novartis Pharmaceuticals Corp	Drug Regulatory Affairs	One Health Plaza	East Hanover	New Jersey	7936	USA
tobramycin liposomal	Fluidosoes(Tm)-Tobramycin	5/11/09	Treatment of pulmonary infection due to Burkholderia cepacia complex pathogens in cystic fibrosis patients	Designated/Withdrawn			N/A	N/A	Axentis Pharma AG	138 Limmatquai	Zurich				Switzerland
tobramycin liposomal for inhalation	Fluidosomes	4/14/09	Treatment of chronic pulmonary infection due to P. aeruginosa in cystic fibrosis patients	Designated/Withdrawn			N/A	N/A	Axentis Pharma AG	138 Limmatquai	CH-8001	Zurich			Switzerland
tocilizumab	Actemra	4/17/13	Treatment of systemic sclerosis	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
tocilizumab	Actemra	7/31/12	Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis	Designated/Approved	Approved for Orphan Indication	Treatment of active polyarticular juvenile idiopathic arthritis in patients 2 through 16 years of age.	04/29/2013	04/29/2020	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
Tocophersolan oral solution (vitamin E-tpgs)	n/a	4/15/88	Treatment of vitamin E deficiency resulting from malabsorption due to prolonged cholestatic hepatobiliary disease.	Designated/Withdrawn			N/A	N/A	Sterling Winthrop	9 Great Valley Parkway		Malvern	Pennsylvania	19355	USA
Tolcapone	n/a	12/24/13	Treatment of transthyretin amyloidosis	Designated			N/A	N/A	"Corino Therapeutics, Inc."	57 West 57th Street	18th Floor	New York	New York	10019	USA
tolerogen	n/a	2/5/15	Treatment of myasthenia gravis	Designated			N/A	N/A	Toleranzia AB	Arvid Wallgrens backe 20	SE-413 46 Goteborg				Sweden
tolfenamic acid	n/a	7/13/16	Treatment of Frontotemporal Dementia	Designated			N/A	N/A	Nasser H. Zawia	83 Castle Rocks Road		Warwick	Rhode Island	2886	USA
tolfenamic acid	n/a	7/13/16	Treatment of progressive supranuclear palsy	Designated			N/A	N/A	Nasser H. Zawia	83 Castle Rocks Road		Warwick	Rhode Island	2886	USA
tolvaptan	Samsca	4/6/12	Treatment of autosomal dominant polycystic kidney disease	Designated			N/A	N/A	"Otsuka Pharmaceuticals Co., Ltd."	"2-9, Kanda-Tsukasamachi"	101-8535	Tokyo			Japan
Topiramate	Topamax	11/25/92	Treatment of Lennox-Gastaut syndrome.	Designated/Approved	Approved for Orphan Indication	As adjunctive therapy in patients two years and older with siezures associated with Lennox-Gastaut syndrome.	08/28/2001	08/28/2008	"Johnson & Johnson Pharmaceutical R & D, LLC"	"Route 202, P.O. Box 300"		Raritan	New Jersey	8869	USA
topiramate injection	n/a	7/24/13	Treatment of partial onset or primary generalized tonic-clonic seizures for hospitalized epilepsy patients or epilepsy patients being treated in an emergency care setting who are unable to take oral topiramate	Designated			N/A	N/A	"CURx Pharmaceuticals, Inc."	3210 Merryfield Row		San Diego	California	92121	USA
toralizumab	n/a	3/14/02	Treatment of immune thrombocytopenic purpura	Designated/Withdrawn			N/A	N/A	Biogen IDEC Inc.	3030 Callan Road		San Diego	California	92121	USA
Toremifene	n/a	8/17/93	Treatment of desmoid tumors.	Designated			N/A	N/A	Orion Corporation	Orionintie 1	0FI-02200 ESPOO				Finland
Toremifene	Fareston	9/19/91	Hormonal therapy of metastatic carcinoma of the breast.	Designated/Approved	Approved for Orphan Indication	Treatment of metastatic breast cancer in postmenopausal women with estrogen positive or receptor unknown tumors.	05/29/1997	05/29/2004	Orion Corporation	Orionintie 1	0FI-02200 ESPOO				Finland
Tosedostat	n/a	12/10/08	Treatment of acute myeloid leukemia	Designated			N/A	N/A	CTI BioPharma Corporation	3101 Western Avenue	Suite 600	Seattle	Washington	98121	USA
Tositumomab and iodine I 131 tositumomab	Bexxar	5/16/94	Treatment of non-Hodgkin's B-cell lymphoma.	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy"	06/27/2003	06/27/2010	GlaxoSmithKline LLC	Corporation Service Company	"2711 Centerville Road, Suite 400"	Wilmington	Delaware	19808	USA
trabectedin	Yondelis	9/30/04	Treatment of soft tissue sarcoma	Designated/Approved	Approved for Orphan Indication	For the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen	10/23/2015	10/23/2022	"Janssen Research & Development, LLC"	920 US Highway 202	P. O. Box 300	Raritan	New Jersey	8869	USA
trabectedin	Yondelis	3/29/05	Treatment of patients with ovarian cancer	Designated			N/A	N/A	"Janssen Research & Development, LLC"	920 US Highway 202	P. O. Box 300	Raritan	New Jersey	8869	USA
trabedersen	n/a	8/22/11	Treatment of Stage IIB through Stage IV malignant melanoma.	Designated			N/A	N/A	"Oncotelic, Inc."	29397 Agoura Road	Suite 107	Agoura Hills	California	91301	USA
trabedersen	n/a	7/21/09	Treatment of pancreatic cancer.	Designated			N/A	N/A	"Oncotelic, Inc."	29397 Agoura Road	Suite 107	Agoura Hills	California	91301	USA
trabedersen	Oncomun	6/5/02	Treatment of malignant glioma	Designated			N/A	N/A	Oncotelic Inc.	29397 Agoura Road	Suite 107	Agoura Hills	California	91301	USA
tralokinumab	n/a	7/24/12	Treatment of idiopathic pulmonary fibrosis	Designated/Withdrawn			N/A	N/A	MedImmune Ltd.	Milstein Building	Granta Park	Cambridge CB21 6GH			United Kingdom
Tramadol hydrochloride	n/a	1/28/05	Treatment of painful HIV-associated neuropathy	Designated			N/A	N/A	"TheraQuest Biosciences, LLC"	146 Medinah Drive		Blue Bell	Pennsylvania	19422	USA
Tramadol hydrochloride	n/a	4/26/05	Management of postherpetic neuralgia	Designated			N/A	N/A	"TheraQuest Biosciences, LLC"	146 Medinah Drive		Blue Bell	Pennsylvania	19422	USA
trametinib	Mekinist	12/20/10	Treatment of Stage IIb through Stage IV melanoma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test.	05/29/2013	05/29/2020	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Jersey	7936	USA
trametinib and dabrafenib	Mekinist And Tafinlar	9/20/12	Treatment of Stage IIb through IV melanoma.	Designated/Approved	Approved for Orphan Indication	TAFINLAR (dabrafenib) in combination with trametinib for treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. This indication is based on the demonstration of durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated for TAFINLAR in combination with trametinib.	01/09/2014	01/09/2021	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Jersey	7936	USA
trametinib and dabrafenib	Mekinist And Tafinlar	9/20/12	Treatment of Stage IIb through IV melanoma.	Designated/Approved	Approved for Orphan Indication	MEKINIST (trametinib) in combination with dabrafenib for treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. This indication is based on the demonstration of durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated for MEKINIST in combination with dabrafenib.	01/08/2014	01/08/2021	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Jersey	7936	USA
tranexamic acid	Cyklokapron	9/9/85	Treatment of hereditary angioneurotic edema	Designated/Approved/Withdrawn		Treatment of patients with hemophilia for short term use (2 to 8 days) before and after tooth extraction to reduce or prevent hemorrhage abd reduce the need for replacement therapy	N/A	12/30/1993	Pharmacia Inc.	P.O. Box 16529		Columbus	Ohio	43216	USA
tranilast	Rizaben	12/23/10	Prevention of scarring following glaucoma filtration surgery	Designated			N/A	N/A	Altacor Ltd	St. John's Innovation Centre		Cambridge CB4 0WS			United Kingdom
Tranilast	Rizaben	12/2/03	For the treatment of maligant glioma	Designated			N/A	N/A	"Angiogen Pharmaceuticals, Pty. Ltd."	"Level 31, ABN AMRO Tower"	"88 Phillip Street Sydney, N.S.W. 2000"				Australia
trans sodium crocetinate	n/a	7/21/11	Treatment of glioblastoma in conjunction with radiotherapy	Designated			N/A	N/A	"Diffusion Pharmaceuticals, LLC"	2020 Avon Court	Suite 4	Charlottesville	Virginia	22902	USA
trans sodium crocetinate	n/a	12/3/12	Treatment of brain metastasis	Designated			N/A	N/A	"Diffusion Pharmaceuticals, LLC"	2020 Avon Court #4		Charlottesville	Virginia	22902	USA
Transforming growth factor-beta 2	n/a	12/18/92	Treatment of full thickness macular holes.	Designated			N/A	N/A	"Celtrix Pharmaceuticals, Inc."	3055 Patrick Henry Drive		Santa Clara	California	95054	USA
transforming growth factor-beta receptor 1 kinase inhibitor	n/a	3/11/13	Treatment of glioma	Designated			N/A	N/A	Eli Lilly and Company	Lilly Corporate Center		Indianapolis	Indiana	46285	USA
transforming growth factor-beta receptor 1 kinase inhibitor	n/a	4/1/13	Treatment of hepatocellular carcinoma	Designated			N/A	N/A	Eli Lilly and Company	Lilly Corporate Center		Indianapolis	Indiana	46285	USA
Transgenic human alpha 1 antitrypsin	n/a	5/19/99	Treatment of emphysema secondary to alpha 1 antitrypsin deficiency.	Designated			N/A	N/A	PPL Therapeutics (Scotland) Limited	"Roslin, Edinburgh"	EH259PP Scotland				United Kingdom
trastuzumab	Herceptin	12/14/99	Treatment of patients with pancreatic cancer that overexpress p185HER2.	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
trastuzumab	Herceptin	10/13/09	"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction"	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease"	10/20/2010	10/20/2017	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
trastuzumab emtansine	Kadcyla 	10/25/13	For the treatment of gastric cancer including gastroesophageal junction cancer.	Designated/Withdrawn			N/A	N/A	"Genethech, Inc."	1 DNA Way		south San Francisco	California	94080	USA
trebananib	n/a	8/30/13	Treatment of ovarian cancer	Designated			N/A	N/A	"Amgen, Inc."	One Amgen Center Drive		Thousand Oaks	California	91320	USA
trehalose	n/a	11/17/14	Treatment of spinal cerebellar ataxia type 3 (also known as SCA3 or Machado Joseph disease)	Designated			N/A	N/A	BioBlast Pharma Ltd	157 Church Street		New Haven	Connecticut	6510	USA
trehalose	Cabaletta	10/25/13	Treatment of occulopharyngeal muscular dystrophy	Designated			N/A	N/A	"BioBlast Pharma, Ltd."	157 Church St.		New Haven	Connecticut	6510	USA
tremelimumab	n/a	3/18/15	Treatment of malignant mesothelioma	Designated			N/A	N/A	"MedImmune, LLC"	One MedImmune Way		Gaithersburg	Maryland	20878	USA
tremelimumab	n/a	9/18/06	Treatment of stage IIb to stage IV metastatic melanoma	Designated			N/A	N/A	MedImmune	One Medimmune Way		Gaithersburg	Maryland	20878	USA
Treosulfan	Ovastat	5/16/94	Treatment of ovarian cancer.	Designated			N/A	N/A	Medac GmbH	Fehlandtstrasse 3	D-20354 Hamburg				Germany
treosulfan	n/a	4/8/15	Conditioning treatment prior to hematopoietic stem cell transplantation (HSCT) in malignant and non-malignant diseases in adults and pediatric patients.	Designated			N/A	N/A	Medac GmbH	TheaterstraBe 6	22880 Wedel				Germany
treprostinil	Remodulin	6/4/97	Treatment of pulmonary arterial hypertension.	Designated/Approved	Approved for Orphan Indication	Treatment of pulmonary arterial hypertension.	05/21/2002	05/21/2009	United Therapeutics Corp.	55 T.W. Alexander Dr.		Research Triangle Park	North Carolina	27709	USA
treprostinil (inhalational)	Tyvaso	6/17/10	Treatment of pulmonary arterial hypertension	Designated/Approved	Approved for Orphan Indication	"Treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III symptoms, to increase walk distance"	07/30/2009	07/30/2016	"LungRx, Inc."	A Subsidary of United Therapeutics Corp.	1077 Highway A1A	Satellite Beach	Florida	32937	USA
"treprostinil sodium solution enclosed within a pre-filled, pre-programmed, single-use, electronically-controlled infusion pump"	n/a	12/29/15	Treatment of pulmonary arterial hypertension	Designated			N/A	N/A	SteadyMed Therapeutics	2603 Camino Ramon	Suite 350	San Ramon	California	94583	USA
Tretinoin	Atra-Iv	1/14/93	Treatment of acute and chronic leukemia.	Designated			N/A	N/A	"Antigenics, Inc."	3 Forbes Road		Lexington	Massachusetts	2421	USA
Tretinoin	Atra-Iv	4/11/03	Treatment of T-cell non-Hodgkin's lymphoma	Designated			N/A	N/A	"Antigenics, Inc."	3 Forbes Road		Lexington	Massachusetts	2421	USA
Tretinoin	n/a	4/15/85	Treatment of squamous metaplasia of the ocular surface epithelia (conjunctiva and/or cornea) with mucous deficiency and keratinization.	Designated			N/A	N/A	"Hannan Ophthalmic Marketing Services, Inc"	34 Sherrill Rd.		Marshfield	Massachusetts	2050	USA
Tretinoin	Vesanoid	10/24/90	Treatment of acute promyelocytic leukemia.	Designated/Approved	Approved for Orphan Indication	Induction of remission in patients with acute promyelocytic leukemia who are refractory to or unable to tolerate anthracycline based cytotoxic chemotherapeutic regimens.	11/22/1995	11/22/2002	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA
tri-antennary glycotripeptide derivative of 5-fluorodeoxyuridine monophosphate	n/a	11/23/01	Treatment for hepatocellular carcinoma	Designated			N/A	N/A	Cell Works Inc.	6200 Seaforth Street		Baltimore	Maryland	21224	USA
triciribine	n/a	2/1/08	Treatment of multiple myeloma	Designated			N/A	N/A	"VioQuest Pharmaceuticals, Inc."	180 Mt. Airy Road		Basking Ridge	New Jersey	7920	USA
triclabendazole	Triclathera(Tm)	6/27/16	Treatment of fascioliasis.	Designated			N/A	N/A	"Tropicalis Pharmaceuticals, LLC"	22345 Bracketts Road		Excelsior	Minnesota	55331	USA
Trientine HCl	Syprine	12/24/84	"Treatment of patients with Wilson's disease who are intolerant, or inadequately responsive to penicillamine."	Designated/Approved	Approved for Orphan Indication		11/08/1985	11/08/1992	Merck Sharp & Dohme Research	Division Of Merck And Company		West Point	Pennsylvania	19486	USA
trientine hydrochloride	Syprine(R)	11/2/10	Treatment of manganism.	Designated			N/A	N/A	"Cerberus Princeton, LLC"	c/o Cerberus Capital Management L.P.	875 Third Avenue	New York	New York	10022	USA
trientine tetrahydrochloride	n/a	3/10/16	treatment of Wilsons disease	Designated			N/A	N/A	GMP-Orphan SAS	"Voisin Consulting, Inc."	"222 Third Street, Suite 3121"	Cambridge	Massachusetts	2142	USA
trifarotene	n/a	6/6/14	Treatment of congenital ichthyosis	Designated			N/A	N/A	"Galderma R&D, LLC"	5 Cedar Brook Drive	Suite 1	Cranbury	New Jersey	8512	USA
Triheptanoin	Triheptanoim-Sasol Special Oil	5/26/06	Treatment of fatty acid disorders	Designated			N/A	N/A	Baylor Research Institute	Institute of Metabolic Disease	3812 Elm Street	Dallas	Texas	75226	USA
triheptanoin	n/a	10/21/14	Treatment of glucose transporter type-1 deficiency syndrome	Designated			N/A	N/A	"Ultragenyx Pharmaceutical, Inc."	60 Leveroni Court		Novato	California	94949	USA
Triheptanoin	Triheptanoin-Sasol Special Oil	2/1/08	Treatment of glycogen storage disorder II (Pompe disease)	Designated			N/A	N/A	Baylor Research Institute	3330 Live Oak Blvd		Dallas	Texas	75204	USA
triheptanoin	n/a	4/15/15	Treatment of fatty acid oxidation disorders	Designated			N/A	N/A	"Ultragenyx Pharmaceutical, Inc."	60 Leveroni Court		Novato	California	94949	USA
Trimetrexate	Neutrexin	8/10/00	Treatment of metastatic osteogenic sarcoma.	Designated/Withdrawn			N/A	N/A	"Medimmune Oncology, Inc."	One MedImmune Way		Gaithersburg	Maryland	20878	USA
Trimetrexate glucuronate	n/a	7/25/85	Treatment of pancreatic adenocarcinoma.	Designated/Withdrawn			N/A	N/A	"Medimmune Oncology, Inc."	One MedImmune Way		Gaithersburg	Maryland	20878	USA
Trimetrexate glucuronate	n/a	1/13/88	Treatment of patients with advanced non-small cell carcinoma of the lung.	Designated/Withdrawn			N/A	N/A	"Medimmune Oncology, Inc."	One MedImmune Way		Gaithersburg	Maryland	20878	USA
Trimetrexate glucuronate	Neutrexin	5/15/86	Treatment of Pneumocystis carinii pneumonia in AIDS patients.	Designated/Approved	Approved for Orphan Indication	"Concurrent leucovorin administration as an alternative therapy for the treatment of moderate to severe PCP in immunocompromised patients who are intolerant of, or are refractory to, trimethoprim sulfamethoxazole."	12/17/1993	12/17/2000	"Medimmune Oncology, Inc."	One Tower Bridge	"100 Front St., Suite 400"	West Conshohocken	Pennsylvania	19428	USA
triptorelin pamoate	n/a	8/20/12	Treatment of central precocious puberty	Designated			N/A	N/A	"Arbor Pharmaceuticals, LLC"	6 Concourse Parkway	Suite 1800	Atlanta	Georgia	30328	USA
Triptorelin pamoate	Decapeptyl Injection	8/10/90	For use in the palliative treatment of advanced ovarian carcinoma of epithelial origin.	Designated/Withdrawn			N/A	N/A	Debio R.A. Inc.	"7929 Westpark Drive, Suite 400"		Mclean	Virginia	22102	USA
Trisaccharides A and B	Biosynject	4/12/87	Treatment of moderate to severe clinical forms of hemolytic disease of the newborn arising from placental transfer of antibodies against blood group substances A and B.	Designated			N/A	N/A	"Chembiomed, Ltd."	P.O. Box 8050	T6H 4NP				Canada
Trisaccharides A and B	Biosynject	4/15/88	Prevention of ABO medical hemolytic reactions arising from ABO-incompatible bone marrow transplantation.	Designated			N/A	N/A	"Chembiomed, Ltd."	P.O. Box 8050	T6H 4NP				Canada
Trisaccharides A and B	Biosynject	4/20/87	"For use in ABO-incompatible solid organ transplantation, including kidney, heart, liver and pancreas."	Designated			N/A	N/A	"Chembiomed, Ltd."	P.O. Box 8050	T6H 4NP				Canada
Trisaccharides A and B	n/a	8/3/87	"Treatment of moderate to very severe clinical forms of transfusion reactions arising from ABO incompatible transfusions of blood, blood products, and blood derivatives."	Designated/Withdrawn			N/A	N/A	"Chembiomed, Ltd."	P.O. Box 8050	T6H 4NP				Canada
Trisodium citrate concentration	Hemocitrate	6/15/95	For use in leukapheresis procedures.	Designated			N/A	N/A	"Hemotec Medical Products, Inc."	Box 19255		Johnston	Rhode Island	2919	USA
Trisodium zinc Diethylenetriaminepentaacetate	n/a	2/27/04	"Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rate of elimination."	Designated			N/A	N/A	CustomCare Pharmacy	5710 Hoover Blvd		Tampa	Florida	33634	USA
triterpenoid saponin	n/a	7/23/14	Treatment of mantle cell lymphoma	Designated			N/A	N/A	"Avicin Therapeutics, Ltd."	Westpark Corporate Center	4364 S. Alston Avenue	Durham	North Carolina	27713	USA
Troleandomycin	n/a	9/21/89	Treatment of severe steroid-requiring asthma.	Designated/Withdrawn			N/A	N/A	"Szefler, Stanley M. M.D."	National Jewish Center for Immunology and Respirat	1400 Jackson Street	Denver	Colorado	80206	USA
Troxacitabine	Troxatyl	4/4/05	Treatment of acute myeloid leukemia	Designated/Withdrawn			N/A	N/A	"Structural GenomiX, Inc. (SGX)"	10505 Roselle Street		San Diego	California	92121	USA
Trypan blue	Membraneblue	8/2/06	Selectively staining epiretinal membranes during ophthalmic surgical vitrectomy procedures	Designated/Approved	Approved for Orphan Indication	"For use as an aid in ophthalmic surgery by staining the epiretinal membranes during ophthalmic surgical vitrectomy procedures, facilitating removal of the tissue"	02/20/2009	02/20/2016	Dutch Ophthalmic Research Center Int'l BV	Scheijdelveweg 2	P.O. Box 43 3214ZG Zuidland				Netherlands
Tumor necrosis factor-binding protein 1	n/a	1/6/93	Treatment of symptomatic patients with AIDS including all patients with CD4 counts less than 200 cells per mm3.	Designated			N/A	N/A	"EMD Serono, Inc."	One Technology Place		Roackland	Massachusetts	2370	USA
Tumor necrosis factor-binding protein II	n/a	1/6/93	Treatment of symptomatic patients with the AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.	Designated			N/A	N/A	"EMD Serono, Inc."	One Technology Place		Roackland	Massachusetts	2370	USA
tumor-inflitrating lymphocytes; LN-144	n/a	6/9/15	Treatment of malignant melanoma Stages IIb to IV	Designated			N/A	N/A	"Lion Biotechnologies, Inc."	21900 Burbank Blvd	3rd Floor	Woodland Hills	California	91367	USA
TXA127	n/a	10/25/13	Treament of acute radiation syndrome	Designated			N/A	N/A	"US Biotest, Inc."	"231 Bonetti Dr.,"	Suite 240	San Luis Obispo	California	93401	USA
Tyloxapol	Supervent	3/8/95	Treatment of cystic fibrosis.	Designated			N/A	N/A	"Kennedy & Hoidal, M.D.'s"	University of Utah Health Sciences Center	"50 North Medical Drive, Room 4R240"	Salt Lake City	Utah	84132	USA
Type 1 native bovine skin collagen	n/a	2/1/08	Treatment of diffuse systemic sclerosis	Designated			N/A	N/A	"arGentis Pharmaceuticals, LLC"	20 South Dudley Street		Memphis	Tennessee	38139	USA
ubenimex	n/a	11/19/15	Treatment of pulmonary arterial hypertension.	Designated			N/A	N/A	"Eiger BioPharmaceuticals, Inc."	350 Cambridge Avenue	Suite 350	Palo Alto	California	94306	USA
ubiquinol	"Ubi-Q-Nol, Li-Q-Nol"	4/12/04	Treatment of Huntington's Disease	Designated			N/A	N/A	"Gel-Tec, Division of Tishcon Corp."	30 New York Avenue	P. O. Box 331	Westbury	New York	11590	USA
"Ubiquinol, coenzyme Q10, ubiquinone"	Ubi-Q-Nol	4/12/04	Treatment of pediatric congestive heart failure	Designated			N/A	N/A	"Gel-Tec, Division of Tishcon Corporation"	30 New York Avenue	P. O. Box 331	Westbury	New York	11590	USA
Ubiquinone	Ubi-Q-Gel	12/14/99	Treatment of mitochondrial cytopathies.	Designated			N/A	N/A	"Gel-Tec, Division of Tishcon Corp."	30 New York Avenue	P. O. Box 331	Westbury	New York	11590	USA
ublituximab	n/a	8/6/10	Treatment of chronic lymphocytic leukemia	Designated			N/A	N/A	"TG Therapeutics, Inc."	787 Seventh Avenue	48th Floor	New York	New York	10019	USA
ublituximab	n/a	9/5/13	"Treatment of Extranodal marginal zone lymphoma (mucosa-associated lymphatic tissue, MALT)"	Designated			N/A	N/A	"TG Therapeutics, Inc."	"787 Seventh Avenue, 48th Floor"		New York	New York	10019	USA
ublituximab	n/a	9/5/13	Treatment of Nodal marginal zone lymphoma	Designated			N/A	N/A	"TG Therapeutics, Inc."	"787 Seventh Avenue, 48th Floor"		New York	New York	10019	USA
ublituximab	n/a	8/25/16	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	Designated			N/A	N/A	"TG Therapeutics, Inc."	3 Columbus Circle	15th Floor	New York	New York	10019	USA
Ublituximab and phosphoinositide-3-kinase delta inhibitor	n/a	1/5/17	Treatment of chronic lymphocytic leukemia	Designated			N/A	N/A	"TG Therapeutics, Inc."	2 Gansevoort Street	9th Floor	New York	New York	10014	USA
Ublituximab in combination with phosphoinositide-3-kinase (PI3K) delta inhibitor	n/a	1/19/17	Treatment of diffuse large B-cell lymphoma	Designated			N/A	N/A	"TG Therapeutics, Inc."	2 Gansevoort Street	9th Floor	New York	New York	10014	USA
udenafil	n/a	8/31/15	Treatment of single ventricle congenital heart disease with Fontan physiology	Designated			N/A	N/A	Mezzion Pharma Co. Ltd.	3rd Floor C & H Building	Gangnam-gu 135-879	Seoul			"Korea, Republic of"
ulocuplumab	n/a	1/12/15	Treatment of acute myeloid leukemia	Designated			N/A	N/A	Bristol-Myers Squibb Company	5 Research Parkway		Wallingford	Connecticut	6492	USA
unoprostone isopropyl	Rescula	9/16/10	Treatment of retinitis pigmentosa	Designated/Withdrawn			N/A	N/A	"R-Tech Ueno, Ltd."	"Kobe Hybrid Business Center, 3F"	"Chuo-ku, Kobe City, Hyogo 650-0047"				Japan
urea	n/a	11/7/11	"Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis)."	Designated			N/A	N/A	"Orenova Group, LLC"	10 New King Street	Suite 106	White Plains	New York	10604	USA
Urea for intravitreal injection	Neurosolve	12/14/05	Treatment of retinitis pigmentosa	Designated			N/A	N/A	"Vitreo Retinal Techologies, Inc"	2 Venture Plaza		Irvine	California	92618	USA
Uridine 5'-triphosphate	n/a	12/4/95	Treatment of cystic fibrosis.	Designated/Withdrawn			N/A	N/A	"Inspire Pharmaceuticals, Inc."	"4222 Emperor Boulevard, Suite 470"		Durham	North Carolina	27703	USA
Uridine 5'-triphosphate	n/a	6/26/96	To facilitate the removal of lung secretions in the treatment of patients with primary ciliary dyskinesia.	Designated/Withdrawn			N/A	N/A	"Inspire Pharmaceuticals, Inc."	"4222 Emperor Boulevard, Suite 470"		Durham	North Carolina	27703	USA
uridine triacetate	n/a	5/1/09	An antidote in the treatment of 5-fluorouracil or capecitabine poisoning	Designated/Approved	Approved for Orphan Indication	"For the emergency treatment of adult and pediatric patients following a fluorouracil or capecitabine overdose regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration"	12/11/2015	12/11/2022	Wellstat Therapeutics Corp.	930 Clopper Road		Gaithersburg	Maryland	20878	USA
uridine triacetate	n/a	8/9/13	Treatment of hereditary orotic aciduria	Designated/Approved	Approved for Orphan Indication	Treatment of hereditary orotic aciduria	09/04/2015	09/04/2022	"Wellstat Therapeutics, Inc."	930 Clopper Road		Gaithersburg	Maryland	20878	USA
uridine triacetate	n/a	9/3/09	Treatment of mitchondrial disease	Designated			N/A	N/A	Wellstat Therapeutics Corporation	930 Clopper Road		Gaithersburg	Maryland	20878	USA
Urofollitropin	Metrodin	11/25/87	For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.	Designated/Approved	Approved for Orphan Indication		09/18/1986	09/18/1993	"EMD Serono, Inc."	One Technology Place		Roackland	Massachusetts	2370	USA
Urofollitropin	Fertinex	12/5/97	"For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism."	Designated/Withdrawn			N/A	N/A	"EMD Serono, Inc."	One Technology Place		Rockland	Massachusetts	2370	USA
Urogastrone	n/a	11/1/84	For acceleration of corneal epithelial regeneration and healing of stromal incisions from corneal transplant surgery.	Designated			N/A	N/A	Chiron Vision	500 Iolab Drive		Claremont	California	91711	USA
Ursodiol	Urso 250	6/20/91	Treatment of patients with primary biliary cirrhosis	Designated/Approved	Approved for Orphan Indication		12/10/1997	12/10/2004	"Aptalis Pharma US, Inc."	100 Somerset corporate Blvd		Bridgewater	New Jersey	8807	USA
Ursodiol	Actigall	2/19/91	Management of the clinical signs and symptoms associated with primary biliary cirrhosis.	Designated/Withdrawn			N/A	N/A	Novartis Pharmaceuticals Corporation	59 Route 10		East Hanover	New Jersey	7936	USA
ursodiol	Ursofalk Suspension	10/23/07	Treatment of cystic fibrosis liver disease	Designated			N/A	N/A	"Asklepion Pharmaceuticals, LLC"	5200 Maryland Way		Brentwood	Tennessee	37027	USA
ustekinumab	Stelara	12/28/11	Treatment of chronic sarcoidosis	Designated/Withdrawn			N/A	N/A	"Janssen Biotech, Inc."	800 & 850 Ridgeview Drive		Horsham	Pennsylvania	19044	USA
ustekinumab	Stelara	5/18/16	Treatment of pediatric Crohn's disease (0 through 16 years of age)	Designated			N/A	N/A	"Janssen Research & Development, LLC"	P. O. Box 776	1400 McKean Road	Spring House	Pennsylvania	19477	USA
ustekinumab	Stelara	11/29/10	Treatment of type 1 diabetes mellitus patients with residual beta-cell function.	Designated			N/A	N/A	Johnson & Johnson Pharmaceutical & Development LLC	902 Route 202 South	Room 1654	Raritan	New Jersey	8869	USA
ustekinumab; human monocloncal antibody to interkeukin 12p40	Stelara	12/22/11	Treatment of primary biliary cirrhosis	Designated/Withdrawn			N/A	N/A	"Janssen Biotech, Inc."	200 Great Valley Parkway		Malvern	Pennsylvania	19355	USA
Vaccinia Immune Globulin (Human) Intravenous	n/a	6/18/04	Treatment of severe complications from the smallpox vaccine	Designated/Approved	Approved for Orphan Indication	"Treatment and modification of aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in cases of isolated keratitis), mouth, or other areas where vaccinia infection would constitute a special hazard; eczema vaccinatum; progressive vaccinia; severe generalized vaccinia, and vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions"	02/18/2005	02/18/2012	DynPort Vaccine Company LLC	64 Thomas Johnson Drive		Frederick	Maryland	21702	USA
Vaccinia Immune Globulin (Human) Intravenous	Cnj-016	6/18/04	Treatment of complications of vaccinia vaccination	Designated/Approved	Approved for Orphan Indication	"treatment and/or modification of the following conditions, which are complications resulting from smallpox vaccination: Eczema vaccinatum Progressive vaccinia Severe generalized vaccinia Vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions Aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in cases of isolated keratitis), mouth, or other areas where vaccinia infection would constitute a special hazard."	05/02/2005	N/A	Cangene Corporation	104 Chancellor Matheson Road		"Winnipeg, ManitobaR3T 5Y3"			Canada
vadastuximab talirine	n/a	11/10/15	Treatment of acute myeloid leukemia.	Designated			N/A	N/A	"Seattle Genetics, Inc."	21823 30th Drive Southeast		Bothell	Washington	98021	USA
"Valine, isoleucine and leucine"	Vil	1/5/96	Treatment of hyperphenylalaninemia	Designated			N/A	N/A	Leas Research Products	78 Fallon Drive		North Haven	Connecticut	6473	USA
valine-valine-ganciclovir	n/a	5/21/07	Treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HSV1 and HSV2.	Designated			N/A	N/A	"Verenta Pharmaceuticals, Inc."	10901 Granada Lane	Suite 101	Leawood	Kansas	66211	USA
Valproate	n/a	5/5/08	Treatment of fragile X syndrome	Designated			N/A	N/A	"Neuropharm Ltd,"	Fetcham Park House	Surrey KT22 9HD				United Kingdom
"Valproic acid, sodium"	Peac(R)	6/24/05	Treatment of familial adenomatous polyposis	Designated/Withdrawn			N/A	N/A	Topotarget A/S	Fruebjergvej 3	DK-2100	Copenhagen			Denmark
Valrubicin	Valstar	5/23/94	Treatment of carcinoma in situ of the urinary bladder.	Designated/Approved	Approved for Orphan Indication	For intravesical therapy of BCG-refractory carcinoma in situ of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.	09/25/1998	09/25/2005	"Anthra Pharmaceuticals, Inc."	"103 Carnegie Center, Suite 102"		Princeton	New Jersey	8540	USA
valsartan oral solution	n/a	10/28/15	Treatment of hypertension in pediatric patients 0 through 16 years of age	Designated/Withdrawn by OPD			N/A	N/A	Carmel Biosciences	5673 Peachtree Dunwoody Road	Suite 440	Atlanta	Georgia	30342	USA
vamorolone	n/a	12/2/11	Treatment of Duchenne muscular dystrophy	Designated			N/A	N/A	ReveraGen Biopharma	"155 Gibbs Road, Suite 433"		Rockville	Maryland	20850	USA
vancomycin	n/a	12/27/12	Treatment of endophthalmitis	Designated			N/A	N/A	"Fera Pharmaceuticals, LLC"	134 Birch Hill Road		Locust Valley	New York	11560	USA
Vancomycin HCL and Tobramycin sulfate multi-pack component of the Joint Purification Systems X7 Spacer	n/a	1/9/17	Treatment of periprosthetic joint infection	Designated			N/A	N/A	Joint Purification Systems LLC	c/o Cor Medical Ventures LLC	215 S. Highway 101	Solana Beach	California	92075	USA
vancomycin hydrochloride (inhalational)	n/a	9/20/12	Treatment of persistent methicillin-resistant S. aureus lung infection in patients with cystic fibrosis	Designated			N/A	N/A	"Savara Pharmaceuticals, Inc."	5900 Shepherd Mountasin Cove	Suite 2-205	Austin	Texas	78730	USA
vandetanib	Caprelsa(R)	10/21/05	"Treatment of patients with follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, and locally advanced and metastatic papillary thyroid carcinoma"	Designated/Approved	Approved for Orphan Indication	Treatment of asymptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease	04/06/2011	04/06/2018	Genzyme Corporation	500 Kendall Street		Cambridge	Massachusetts	2142	USA
Vapreotide	Sanvar	4/6/04	Treatment of symptomatic carcinoid tumors	Designated			N/A	N/A	"H3 Pharma, Inc."	666 Sherbrooke Street West Suite 1400	"Montreal, Quebec,"				Canada
vapreotide	Sanvar	1/10/00	Treatment of esophageal variceal hemorrhage patients with portal hypertension.	Designated			N/A	N/A	"Debiovision, Inc."	666 Sherbrooke Street West	Suite 1400	"Montreal, Quebec H3A 1E7"			Canada
vapreotide	Octastatin	1/10/00	Treatment of gastrointestinal and pancreatic fistulas.	Designated			N/A	N/A	Debiopharm S.A.	17 rue des Terreaux	CH-1000 Lausanne 9				Switzerland
vapreotide	Octastatin	3/6/00	Prevention of early postoperative complications following pancreatic resection.	Designated			N/A	N/A	Debiopharm S.A.	17 rue des Terreaux	CH-1000 Lausanne 9				Switzerland
vapreotide	Sanvar	11/4/03	Treatment of acromegaly	Designated			N/A	N/A	"H3 Pharma, Inc."	"666 Sherbrooke Street West, Suite 1400"	"Montreal, Quebec"				USA
Varbulin	Azixa	11/5/09	Treatment of glioblastoma multiforme.	Designated			N/A	N/A	"Myrexis, Inc."	305 Chipeta Way		Salt Lake City	Utah	84108	USA
varespladib sodium	n/a	11/19/07	Prevention of acute chest syndrome in at-risk patients with sickle cell disease	Designated/Withdrawn			N/A	N/A	"Anthera Pharmaceuticals, Inc."	25801 Industrial Blvd.	Suite B	Hayward	California	94545	USA
Varicella Zoster Immune Globulin (Human)	Varizig	11/7/06	"Passive immunization for the treatment of exposed, susceptible individuals who are at risk of complications from varicella"	Designated/Approved	Approved for Orphan Indication	Post exposure prophylaxis of varicella in high risk individuals to reduce the severity of varicella	12/20/2012	12/20/2019	"Cangene bioPharma, Inc."	155 Innovation Drive	Winnipeg	Manitoba R3T5Y3			Canada
Varlitinib	n/a	8/5/15	Treatment of cholangiocarcinoma.	Designated			N/A	N/A	ASLAN Pharmaceuticals	"10A Bukit Pasoh Road, 089824"					Singapore
varlitinib	n/a	6/20/16	Treatment of gastric cancer.	Designated			N/A	N/A	ASLAN Pharmaceuticals	10A Bukit Pasoh Road					Singapore
vascular endothelial growth factor 165b	n/a	6/24/08	Treatment of advanced melanoma stages IIb through IV.	Designated			N/A	N/A	"PhiloGene, Inc."	174 Summit Avenue		Summit	New Jersey	7901	USA
Vasoactive intestinal peptide	n/a	3/9/01	Treatment of Acute Respiratory Distress Syndrome.	Designated			N/A	N/A	mondoBIOTECH	Europark	FL - 9490 Vaduz				USA
vasoactive intestinal peptide (VIP)-elastin-like peptide (ELP) fusion protein	n/a	5/13/14	"Treatment of pulmonary arterial hypertension, WHO Group 1"	Designated			N/A	N/A	"PhaseBio Pharmaceuticals, Inc."	1 Great Valley Parkway	Suite 30	Malvern	Pennsylvania	19355	USA
Vasoactive intestinal polypeptide	n/a	6/23/93	Treatment of acute esophageal food impaction.	Designated			N/A	N/A	Research Triangle Pharmaceuticals	200 Westpark Corporate Center	4364 South Alston Avenue	Durham	North Carolina	27713	USA
Vasomera	n/a	11/19/15	"Treatment of cardiomyopathy associated with dystrophinopathies; Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy BMD), and X-linked dilated cardiomyopathy (XL-dCMP)."	Designated			N/A	N/A	"PhaseBio Pharmaceuticals, Inc."	1 Great Valley Parkway	Suite 30	Malvern	Pennsylvania	19355	USA
vatiquinone	Vincerinone	1/31/14	Treatment of Friedreich's ataxia	Designated			N/A	N/A	"Edison pharmaceuticals, Inc."	350 N. Bernardo Ave.		Mountain View	California	94043	USA
vatiquinone	Vincerinone	6/4/14	Treatment of Leigh Syndrome	Designated			N/A	N/A	"Edison Pharmaceuticals, Inc."	350 North Bernardo Ave.		Mountain View	California	94043	USA
vatiquinone	Vincerinone	11/17/14	Treatment of Rett syndrome	Designated			N/A	N/A	"Edison pharmaceuticals, Inc."	350 N. Bernardo Ave.		Mountain View	California	94043	USA
vedolizumab	n/a	8/4/16	Prevention of graft versus host disease.	Designated			N/A	N/A	"Millennium Pharmaceuticals, Inc."	40 Landsdowne Street		Cambridge	Massachusetts	2139	USA
velaglucerase-alfa	Vpriv	6/8/09	Treatment of Gaucher disease	Designated/Approved	Approved for Orphan Indication	Treatment of Type I Gaucher Disease	02/26/2010	N/A	"Shire Human Genetics Therapies, Inc."	700 Main Street		Cambridge	Massachusetts	2139	USA
veliparib	n/a	11/20/09	Treatment of hepatocellular carcinoma in combination with DNA-damaging agents	Designated			N/A	N/A	"AbbVie, Inc."	1 N. Waukegan Road		North Chicago	Illinois	60064	USA
veliparib	n/a	5/9/08	Treatment of glioblastoma multiforme when used in combination with DNA-damaging agents	Designated			N/A	N/A	"AbbVie, Inc."	1 N. Waukegan Road		North Chicago	Illinois	60064	USA
veliparib	n/a	12/17/14	Treatment of brain metastases when used in combination with DNA-damaging agents	Designated			N/A	N/A	AbbVie Inc.	1 North Waukegan Road		North Chicago	Illinois	60064	USA
veliparib	n/a	9/3/09	Treatment of epithelial ovarian cancer in combination with DNA-damaging agents	Designated			N/A	N/A	"AbbVie, Inc."	1 N. Waukegan Road		North Chicago	Illinois	60064	USA
veliparib	n/a	11/3/16	Treatment of squamous non-small cell lung cancer	Designated			N/A	N/A	AbbVie Inc.	1 North Waukegan Road		North Chicago	Illinois	60064	USA
veltuzumab	n/a	7/28/15	Treatment of immune thrombocytopenic purpura.	Designated			N/A	N/A	"Immunomedics, Inc."	300 The American Road		Morris Plains	New Jersey	7950	USA
veltuzumab	n/a	11/17/14	Treatment of pemphigus	Designated			N/A	N/A	"Immunomedics, Inc."	300 The American Rd.		Morris Plains	New Jersey	7950	USA
veltuzumab	n/a	8/28/08	Treatment of chronic lymphocytic leukemia	Designated			N/A	N/A	"Immunomedics, Inc."	300 The American Road		Morris Plains	New Jersey	7950	USA
vemurafenib	Zelboraf	12/20/10	Treatment of patients with IIb to Stage IV melanoma positive for the BRAF(v600) mutation	Designated/Approved	Approved for Orphan Indication	Treatment of unresectable or metastatic melanoma with the BRAFV600E mutation as detected by an FDA-approved test.	08/17/2011	08/17/2018	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA
vemurafenib	Zelboral	8/2/16	Treatment of Erdheim-Chester Disease	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
vemurafenib	Zelboraf	8/26/14	Treatment of hairy cell leukemia (HCL).	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way	MS 241b	South San Francisco	California	94080	USA
vemurafenib	Zelboraf	11/26/13	Treatment of anaplastic thyroid carcinoma and advanced papillary thyroid cancer whose tumors harbor a BRAF V600 mutation	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way	MS 241b	South San Francisco	California	94080	USA
vemurafenib	Zelboraf	9/8/14	Treatment of patients with non-small cell lung cancer (NSCLC) with BRAF V600 mutation	Designated			N/A	N/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA
venetoclax	Venclexta	9/20/12	Treatment of chronic lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy"	04/11/2016	04/11/2023	"AbbVie, Inc"	1 North Waukegan Road	"Dept. PA77, Bldg. AP30-1"	North Chicago	Illinois	60064	USA
Venetoclax	n/a	8/29/16	Treatment of multiple myeloma	Designated			N/A	N/A	AbbVie Inc.	Regualtory Affairs	1 North Waukegan Road	North Chicago	Illinois	60064	USA
venetoclax	n/a	2/4/16	Treatment of acute myeloid leukemia.	Designated			N/A	N/A	AbbVie Inc.	1 Waukegan Road	"Dept PA77, Bldg. AP30"	North Chicago	Illinois	60044	USA
verteporfin	Visudyne(R)	3/9/12	Treatment of chronic or recurrent central serous chorioretinopathy	Designated			N/A	N/A	Valeant Pharmaceuticals North America LLC	700 Route 202/206 North		Bridgewater	New Jersey	8807	USA
Vibrio alginolyticus collagenase	n/a	10/12/16	Treatment of advanced Dupuytren's disease (Dupuytren's contracture)	Designated			N/A	N/A	Fidia Farmaceutici S.p.A.	"Via Ponte della Fabbrica, 3/A"		Abano Terme PD			Italy
vibriolysin	Vibrilase	6/16/06	"Debridement of severe, deep dermal burns in hospitalized patients"	Designated			N/A	N/A	BioMarin Pharmaceutical Inc.	105 Digital Drive		Novato	California	94949	USA
vigabatrin	Sabril	6/12/00	Treatment of infantile spasms.	Designated/Approved	Approved for Orphan Indication	For infantile spasms (IS) - 1 month to 2 years of age.	08/21/2009	08/21/2016	H. Lundbeck A/S	Four Parkway North		Deerfield	Illinois	60015	USA
viloxazine HCL	Catatrol	6/11/84	Treatment of cataplexy and narcolepsy	Designated/Withdrawn			N/A	N/A	Stuart Pharmaceuticals	Division of ICI Americas		Wilmington	Delaware	19897	USA
vinCRIStine sulfate LIPOSOME injection	Marqibo	1/8/07	Treatment of acute lymphoblastic leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.	08/09/2012	08/09/2019	"Talon Therapeutics, Inc."	400 Oyster Point Blvd	Suite 200	South San Francisco	California	94080	USA
vincristine sulfate liposomes	Marqibo	6/24/08	Treatment of metastatic uveal melanoma.	Designated			N/A	N/A	Talon Therapeutics	400 Oyster Point Blvd	Suite 200	South San Francisco	California	94080	USA
vintafolide	n/a	12/16/13	Treatment of ovarian cancer	Designated			N/A	N/A	"Endocyte, Inc."	3000 Kent Avenue	Suite A1-100	West Lafayette	Indiana	47906	USA
Virulizin	Virulizin	2/1/01	Treatment of pancreatic cancer.	Designated			N/A	N/A	"ZOR Pharmaceuticals, LLC"	100-A Eastwood Center Drive	Suite 118	Wilmington	North Carolina	28403	USA
vitamin A palmitate	n/a	7/14/15	Prevention of bronchopulmonary dysplasia.	Designated			N/A	N/A	"Advent Therapeutics, Inc."	6500 Old Carversville Road		Lumberville	Pennsylvania	18933	USA
"volanesorsen sodium, apolipotrotein C-III antisense oligonucleotide"	n/a	6/23/15	treatment of familial chylomicronemia syndrome	Designated			N/A	N/A	"Ionis Pharmaceuticals, Inc."	2855 Gazelle Court		Carlsbad	California	92010	USA
volasertib	n/a	4/14/14	Treatment of acute myeloid leukemia	Designated			N/A	N/A	"Boehringer Ingelheim Pharmaceuticals, Inc."	900 Ridgebury Road	P. O. Box 368	Ridgefield	Connecticut	6877	USA
von Willebrand Factor Human Concentrate	Wilfactin	5/29/14	Treatment of Von Willebrand Disease	Designated			N/A	N/A	"rEVO Biologics, Inc."	175 Crossing Blvd		Framingham	Massachusetts	1702	USA
vorinostat	n/a	3/17/04	Treatment of mesothelioma	Designated/Withdrawn			N/A	N/A	"Merck & Co., Inc."	"P. O. Box 2000, RY 32-605"		Rahway	New Jersey	7065	USA
vorinostat	Zolinza	3/16/04	Treatment of T-cell non-Hodgkin's lymphoma	Designated/Approved	Approved for Orphan Indication	"Treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistant or recurrent disease on or following two systemic therapies."	10/06/2006	10/06/2013	"Merck & Co., Inc."	"P. O. Box 2000, RY 32-605"		Rahway	New Jersey	7065	USA
vorinostat	n/a	10/13/16	"Treatment of advanced melanoma (stages IIb, IIc, III, and IV)"	Designated			N/A	N/A	Qameleon Therapeutics	Moslaan 32	1433 WJ	Kudelstaart			Netherlands
vorinostat	n/a	6/12/03	Treatment of multiple myeloma	Designated/Withdrawn			N/A	N/A	Merck Research Laboratories	"Merck & Co., Inc."	"P. O. Box 2000, RY 32-605"	Rahway	New Jersey	7065	USA
vosaroxin	n/a	10/28/09	Treatment of acute myeloid leukemia	Designated			N/A	N/A	"Sunesis Pharmaceuticals, Inc."	395 Oyster Point Blvd	Suite 400	South San Francisco	California	94080	USA
Water-miscible vitamin A palmitate	Aquasol A Parenteral	3/26/10	Prevention of bronchopulmonary dysplasia.	Designated			N/A	N/A	"Fox Pharma, Inc."	6097 Hidden Valley Drive		Doylestown	Pennsylvania	18902	USA
Wharton's jelly mesenchymal stem cells	n/a	9/27/16	Treatment of graft-versus-host disease	Designated			N/A	N/A	Midwest Stem Cell Therapy Center	University of Kansas Medical Center	3901 Rainbow Boulevard	Kansas City	Kansas	66160	USA
Xenogeneic hepatocytes	Hepatassist Liver Assist System	11/27/98	Treatment of severe liver failure.	Designated			N/A	N/A	"Circe Biomedical, Inc."	99 Hayden Ave.		Lexington	Massachusetts	2421	USA
xenon gas	n/a	12/3/14	Treatment of hypoxic ischemic encephalopathy	Designated			N/A	N/A	Neuroprotexeon	Imperial Innovations	London SW7 2PG				United Kingdom
xenon gas	n/a	5/18/15	To improve neurological outcome in hospitalized cardiac arrest patients.	Designated			N/A	N/A	Neuroprotexeon	Imperial Innovations	London SW7 2PG				United Kingdom
Yersinia pestis plague recombinant antigen (rF1V; F1 capsular protein fused to V antigen; E. coli) vaccine with aluminum hydroxide	n/a	11/30/16	Prevention of plague (Yersinia pestis)	Designated			N/A	N/A	"DynPort Vaccine Company, LLC, a CSRA Comapny"	64 Thomas Johnson Drive		Frederick	Maryland	21702	USA
Yttrium (90Y) antiferritin polyclonal antibodies	Ferritarg P	9/18/06	Treatment of Hodgkin's disease.	Designated			N/A	N/A	"Alissa Pharma, LLC"	341 North Woodland St.		Englewood	New Jersey	7631	USA
Yttrium(90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10	n/a	12/3/12	Treatment of soft tissue sarcoma	Designated			N/A	N/A	"OncoTherapy Science, Inc."	Kanagawa Science Park R & D D-6F	"Kawasaki-shi, Kanagawa, 213-0012"				Japan
Yttrium-90 radiolabeled humanized monoclonal anti-carcinoembroyonic antigen IgG antibody	Cea-Cide	8/3/99	Treatment of ovarian carcinoma.	Designated			N/A	N/A	"Immunomedics, Inc."	300 The American Road		Morris Plains	New Jersey	7950	USA
Zalcitabine	Hivid	6/28/88	Treatment of AIDS.	Designated/Approved	Approved for Orphan Indication	Combination therapy with zidovudine is indicated for the treatment of adult patients with advanced HIV infection (CD4 count < 300) who have demonstrated malignant clinical or immunologic deterioration.	06/19/1992	06/19/1999	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA
Zalcitabine	n/a	12/9/86	Treatment of AIDS.	Designated			N/A	N/A	"National Cancer Institute, DCT"	"NIH, Executive Plaza North, Room 7-18"		Bethesda	Maryland	20892	USA
zidovudine	Retrovir	7/17/85	Treatment of AIDS	Designated/Approved	Approved for Orphan Indication	Management of certain adult patients with symptomatic HIV infection (AIDS and advanced ARC) who have a history of cytologically confirmed Pneumocytis carinii pneumonia (PCP) or an absolute CD4 (T4 helper/induccer) lymphocyte count of less than 200/mm in the peripheral blood before therapy is begun	03/19/1987	03/19/1994	Glaxo Wellcome Inc.	5 Moore Drive		Research Triangle Park	North Carolina	27709	USA
Zinc acetate	Galzin	11/6/85	Treatment of Wilson's disease.	Designated/Approved	Approved for Orphan Indication	For maintenance treatment of patients with Wilson's disease who have been initially treated with a chelating agent.	01/28/1997	01/28/2004	Lemmon Company	1510 Delp Drive		Kulpsville	Pennsylvania	19443	USA
Zoledronate	"Zometa, Zabel"	8/18/00	Treatment of tumor induced hypercalcemia.	Designated/Approved	Approved for Orphan Indication	Treatment of hypercalcemia of malignancy.	08/20/2001	08/20/2008	Novartis Pharmaceuticals Corp.	59 Route 10		East Hanover	New Jersey	7936	USA
"zoledronate D,L-lysine monohydrate (ZLM)"	n/a	4/15/15	Treatment of complex regional pain syndrome (CRPS)	Designated			N/A	N/A	Thar Pharmaceuticals	150 Gamma Drive		Pittsburgh	Pennsylvania	15238	USA
zoledronic acid	"Zometa, Reclast, Aclasta"	5/6/13	Treatment of complex regional pain syndrome (CRPS).	Designated			N/A	N/A	"Axsome Therapeutics, Inc."	45 Rockefeller Plaza	Suite 2000	New York	New York	10111	USA
Zosuquidar trihydrochloride	n/a	12/15/05	Treatment of acute myeloid leukemia	Designated			N/A	N/A	"Kanisa Pharmaceuticals, Inc."	12264 El Camino Real		San Diego	California	2130	USA
[131I]-N-(2-(diethylamino) ethyl-4-(4 flurobenzamido)-5-(iodo)-2-methoxybenzamide	n/a	9/17/08	"Treatment of metastatic melanoma, stages IIB, IIC, III and IV"	Designated			N/A	N/A	"Molecular Insight Pharmaceuticals, Inc. (Progenics Subsidiary)"	777 Old Saw Mill River Road		Tarrytown	New York	10591	USA
"[5,10,15,20-tetrakis(1,3-diethylimidazolium-2-yl)porphyrinato] manganese(III)pentachloride"	n/a	11/4/03	Treatment of Amyotrophic Lateral Sclerosis	Designated			N/A	N/A	"Aeolus Pharmaceuticals, Inc."	PO Box 14287; 79 T.W. Alexander Dr.	Suite 200	Research Triangle Park	North Carolina	27709	USA
"[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride salt"	n/a	2/14/14	Treatment of pigmented villonodular synovitis/giant cell tumor of the tendon sheath	Designated			N/A	N/A	"Daiichi Sankyo, Inc."	399 Thornall Street		Edison	New Jersey	8837	USA
"[5-Amino-1-(4-fluoro-phenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxy-propoxy)-phenyl]-methanone"	n/a	10/20/14	Treatment of pancreatic cancer	Designated			N/A	N/A	Synovo GmbH	Paul-Ehrlich-Str. 15	D-72076 Tubingen				Germany
[a-N-(2'succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr	n/a	5/14/14	Treatment of glioblastoma multiforme	Designated			N/A	N/A	"Angiochem, Inc."	201 President-Kennedy Avenue	MOntreal QCH2X 3Y7				Canada
[AC3-yCD2(V)] and Flucytosine (5-FC XR)	n/a	1/12/11	Treatment of glioblastoma multiforme	Designated			N/A	N/A	"Tocagen, Inc."	3030 Bunker Hill St.		San Diego	California	92109	USA
[F18] florilglutamic acid	n/a	7/13/16	Diagnostic for the management of hepatocellular carcinoma	Designated			N/A	N/A	Piramal Imaging S.A.	13 Route de l'Ecole		Matran			Switzerland
[F18] florilglutamic acid	n/a	7/13/16	For the diagnosis of hepatocellular carcinoma	Designated			N/A	N/A	Piramal Imaging S.A.	13 Route de l'Ecole		Matran			Switzerland
[Lu-177]-DOTA-Tyr3-Octreotate	n/a	1/12/09	Treatment of gastro-entero-pancreatic neuroendocrine tumors	Designated			N/A	N/A	Advanced Accelerator Applications	20 rue Diesel	01630 Saint Genis Pouilly				France
[met5]-enkephalin	Opioid Growth Factor	1/24/13	Treatment of pancreatic cancer	Designated			N/A	N/A	"TNI BioTech, Inc."	6701 Democracy Blvd	Suite 300	Bethesda	Maryland	20817	USA
[N-(2succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[N-(2succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[N-(2succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr	n/a	4/15/15	Treatment of breast cancer patients with brain metastases	Designated			N/A	N/A	"Angiochem, Inc."	201 President Kennedy	"Montreal, Quebec H2X 3Y7"				Canada
"{2-amino-8-[4-(pyrrolidinylcarbonyl)phenyl](3H-benzo[f]azepin-4-yl)}-N,N-dipropycarboxamide"	n/a	4/10/14	Treatment of ovarian cancer	Designated			N/A	N/A	"VentiRx Pharmaceuticals, Inc."	1191 Second Avenue	Suite 1105	Seattle	Washington	98101	USA
	Nicord	4/28/14	For the treatment of acute myeloid leukemia	Designated			N/A	N/A	Gamida Cell Ltd	PO Box 34670		Jerusalem			Israel
	Dysport(R)	12/5/91	Treatment of essential blepharospasm.	Designated			N/A	N/A	"Ipsen Biopharmaceuticals, Inc."	106 Allen Road	3rd Floor	Basking Ridge	New Jersey	7920	USA